covid-19-trials.geojson 2.6 MB
Newer Older
1
{"features": [{"geometry": {"coordinates": [113.290203, 23.131424], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "lipipi007@163.com;", "contactPhone": "020- 36052117;", "dateEnrollment": "January 28, 2020", "description": "The Efficacy of Lopinavir Plus Ritonavir and Arbidol Against Novel Coronavirus Infection", "name": "NCT04252885", "primaryOutcome": "The rate of virus inhibition", "study_type": "Interventional", "time": "2020-01-30", "weburl": "https://clinicaltrials.gov/show/NCT04252885"}, "type": "Feature"}, {"geometry": {"coordinates": [117.017829, 36.655591], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "panda.how@sdu.edu.cn", "contactPhone": "86-18560086593", "dateEnrollment": "January 20, 2020", "description": "2019-nCoV Outbreak and Cardiovascular Diseases", "name": "NCT04255940", "primaryOutcome": "Cardiovascular Death", "study_type": "Observational", "time": "2020-02-03", "weburl": "https://clinicaltrials.gov/show/NCT04255940"}, "type": "Feature"}, {"geometry": {"coordinates": [114.273531, 30.583868], "type": "Point"}, "properties": {"classification": "Other", "contactEmail": "eier_dai@163.com;eier_dai@163.com", "contactPhone": "+86 13476229575;+86 13476229575", "dateEnrollment": "February 3, 2020", "description": "A Survey of Psychological Status of Medical Workers and Residents in the Context of 2019 Novel Coronavirus Pneumonia", "name": "NCT04260308", "primaryOutcome": "GHQ-12(general health questionnaire-12)", "study_type": "Observational", "time": "2020-02-03", "weburl": "https://clinicaltrials.gov/show/NCT04260308"}, "type": "Feature"}, {"geometry": {"coordinates": [121.468684, 31.22015], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "", "contactPhone": "", "dateEnrollment": "February 7, 2020", "description": "Clinical Study of Arbidol Hydrochloride Tablets in the Treatment of Pneumonia Caused by Novel Coronavirus", "name": "NCT04260594", "primaryOutcome": "Virus negative conversion rate in the first week", "study_type": "Interventional", "time": "2020-02-06", "weburl": "https://clinicaltrials.gov/show/NCT04260594"}, "type": "Feature"}, {"geometry": {"coordinates": [116.414237, 39.912829], "type": "Point"}, "properties": {"classification": "Advanced therapy medicinal products", "contactEmail": "litsh@263.net", "contactPhone": "010-69155086", "dateEnrollment": "February 10, 2020", "description": "The Efficacy of Intravenous Immunoglobulin Therapy for Severe 2019-nCoV Infected Pneumonia", "name": "NCT04261426", "primaryOutcome": "Clinical improvement based on the 7-point scale;Lower Murray lung injury score;Lower Murray lung injury score", "study_type": "Interventional", "time": "2020-02-06", "weburl": "https://clinicaltrials.gov/show/NCT04261426"}, "type": "Feature"}, {"geometry": {"coordinates": [120.17848, 30.255805], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": ";xxw69@126.com", "contactPhone": ";+86 13605708066", "dateEnrollment": "February 7, 2020", "description": "Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Novel Coronavirus Infection", "name": "NCT04261907", "primaryOutcome": "The incidence of composite adverse outcome", "study_type": "Interventional", "time": "2020-02-06", "weburl": "https://clinicaltrials.gov/show/NCT04261907"}, "type": "Feature"}, {"geometry": {"coordinates": [114.129895, 30.340085], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "doctoryanzhao@whu.edu.cn", "contactPhone": "+86 13995577963", "dateEnrollment": "2020-02-01", "description": "Construction and Analysis of Prognostic Predictive Model of Novel Coronavirus Pneumonia (COVID-19)", "name": "ChiCTR2000029953", "primaryOutcome": "duration of in hospital;in hospital mortality;the 28s day' mortality after admission;duration of ICU stay;", "study_type": "Observational study", "time": "2020-02-17", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49217"}, "type": "Feature"}, {"geometry": {"coordinates": [114.11445, 30.356522], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "doctoryanzhao@whu.edu.cn", "contactPhone": "+86 13995577963", "dateEnrollment": "2020-02-16", "description": "A Medical Records Based Study for the Effectiveness of Extracorporeal Membrane Oxygenation in Patients with Severe Novel Coronavirus Pneumonia (COVID-19)", "name": "ChiCTR2000029949", "primaryOutcome": "inhospital length;inhospital mortality;ECMO treatment length;28th day mortality after admission;", "study_type": "Observational study", "time": "2020-02-16", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49181"}, "type": "Feature"}, {"geometry": {"coordinates": [121.430329, 31.187514], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "tcmdoctorlu@163.com", "contactPhone": "+86 13817729859", "dateEnrollment": "2020-03-01", "description": "A Randomized Controlled Trial for Qingyi No. 4 Compound in the treatment of Convalescence Patients of Novel Coronavirus Pneumonia (COVID-19)", "name": "ChiCTR2000029947", "primaryOutcome": "Lung function;", "study_type": "Interventional study", "time": "2020-02-16", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49599"}, "type": "Feature"}, {"geometry": {"coordinates": [121.414884, 31.203951], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "tcmdoctorlu@163.com", "contactPhone": "+86 13817729859", "dateEnrollment": "2020-03-01", "description": "A randomized controlled trial for Traditional Chinese Medicine in the treatment for Novel Coronavirus Pneumonia (COVID-19)", "name": "ChiCTR2000029941", "primaryOutcome": " Number of worsening events;", "study_type": "Interventional study", "time": "2020-02-16", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49596"}, "type": "Feature"}, {"geometry": {"coordinates": [121.55358, 29.866086], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "caiting@ucas.ac.cn", "contactPhone": "+86 13738498188", "dateEnrollment": "2020-02-10", "description": "A Single-blind, Randomized, Controlled Clinical Trial for Chloroquine Phosphate in the treatment of Novel Coronavirus Pneumonia 2019 (COVID-19)", "name": "ChiCTR2000029939", "primaryOutcome": "Length of hospital stay;", "study_type": "Interventional study", "time": "2020-02-16", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49612"}, "type": "Feature"}, {"geometry": {"coordinates": [121.538135, 29.882523], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "caiting@ucas.ac.cn", "contactPhone": "+86 13738498188", "dateEnrollment": "2020-02-06", "description": "A Single-arm Clinical Trial for Chloroquine Phosphate in the treatment of Novel Coronavirus Pneumonia 2019 (COVID-19)", "name": "ChiCTR2000029935", "primaryOutcome": "Length of hospital stay;", "study_type": "Interventional study", "time": "2020-02-16", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49607"}, "type": "Feature"}, {"geometry": {"coordinates": [104.068396, 30.653616], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "1037070596@qq.com", "contactPhone": "+86 18980601415", "dateEnrollment": "2020-02-16", "description": "Study for construction and assessment of early warning score of the clinical risk of novel coronavirus (COVID-19) infected patients", "name": "ChiCTR2000029907", "primaryOutcome": "clinical features and risk factors;validity and reliability of the model;", "study_type": "Observational study", "time": "2020-02-16", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49587"}, "type": "Feature"}, {"geometry": {"coordinates": [114.345692, 30.555553], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "doctoryanzhao@whu.edu.cn", "contactPhone": "+86 13995577963", "dateEnrollment": "2020-02-10", "description": "A medical records based study of novel coronavirus pneumonia (COVID-19) and influenza virus co-infection", "name": "ChiCTR2000029905", "primaryOutcome": "Incidence of co-infection;", "study_type": "Observational study", "time": "2020-02-16", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49595"}, "type": "Feature"}, {"geometry": {"coordinates": [125.302998, 43.860391], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "Wangtan215@sina.com", "contactPhone": "+86 13756858523", "dateEnrollment": "2020-01-31", "description": "Evaluate the effectiveness of Traditional Chinese medicine in the treatment of novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000029896", "primaryOutcome": "Conversion rate of mild and common type patients to severe type;Mortality Rate;", "study_type": "Observational study", "time": "2020-02-16", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49432"}, "type": "Feature"}, {"geometry": {"coordinates": [114.599317, 30.580326], "type": "Point"}, "properties": {"classification": "Diagnosis", "contactEmail": "sxu@hust.edu.cn", "contactPhone": "+86 13517248539", "dateEnrollment": "2020-02-17", "description": "A comparative study on the sensitivity of nasopharyngeal and oropharyngeal swabbing for the detection of SARS-CoV-2 by real-time PCR", "name": "ChiCTR2000029883", "primaryOutcome": "detection of SARS-CoV-2 nucleic acid;SEN;", "study_type": "Diagnostic test", "time": "2020-02-16", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49549"}, "type": "Feature"}, {"geometry": {"coordinates": [120.282065, 31.550428], "type": "Point"}, "properties": {"classification": "Diagnosis", "contactEmail": "caojuncn@hotmail.com", "contactPhone": "+86 0510-68781007", "dateEnrollment": "2020-02-15", "description": "Evaluation of Rapid Diagnostic Kit (IgM/IgG) for Novel Coronavirus Pneumonia (COVID-19)", "name": "ChiCTR2000029870", "primaryOutcome": "Positive/Negtive;SEN, SPE, ACC, AUC of ROC;", "study_type": "Diagnostic test", "time": "2020-02-15", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49563"}, "type": "Feature"}, {"geometry": {"coordinates": [115.054184, 30.244847], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "fangbji@163.com", "contactPhone": "+86 0714-6224162", "dateEnrollment": "2020-02-10", "description": "A multicenter, randomized, controlled trial for integrated Chinese and western medicine in the treatment of ordinary novel coronavirus pneumonia (COVID-19) based on the ' Internal and External Relieving -Truncated Torsion' strategy", "name": "ChiCTR2000029869", "primaryOutcome": "14 day outcome of the subjects, including: recovery, improvement, turning critical, death.;lung CT;", "study_type": "Interventional study", "time": "2020-02-15", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49486"}, "type": "Feature"}, {"geometry": {"coordinates": [116.28263, 39.874805], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "dinghuiguo@medmail.com.cn", "contactPhone": "+86 13811611118", "dateEnrollment": "2020-02-15", "description": "The efficacy and safety of carrimycin treatment in patients with novel coronavirus pneumonia (COVID-19): a multicenter, randomized, open-label, controlled trial", "name": "ChiCTR2000029867", "primaryOutcome": "Body temperature returns to normal time;Pulmonary inflammation resolution time (HRCT);Mouthwash (pharyngeal swab) at the end of treatment COVID-19 RNA negative rate;", "study_type": "Interventional study", "time": "2020-02-15", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49514"}, "type": "Feature"}, {"geometry": {"coordinates": [121.191675, 30.163335], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "wuguolin28@163.com", "contactPhone": "+86 13136150848", "dateEnrollment": "2020-02-15", "description": "A randomized, open and controlled clinical trial for traditional Chinese medicine in the treatment of novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000029855", "primaryOutcome": "TCM symptom score;Antifebrile time;The time and rate of transition of new coronavirus to Yin;", "study_type": "Interventional study", "time": "2020-02-15", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49543"}, "type": "Feature"}, {"geometry": {"coordinates": [114.906648, 32.014973], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "503818505@qq.com", "contactPhone": "+86 13839708181", "dateEnrollment": "2020-02-16", "description": "A randomized, open-label, controlled clinical trial for azvudine in the treatment of novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000029853", "primaryOutcome": "time and rate of temperature return to normal;;time and rate of improvement of respiratory symptoms and signs (lung rhones, cough, sputum, sore throat, etc.);time and rate of improvement of diarrhea, myalgia, fatigue and other symptoms;time and rate of pulmonary imaging improvement;time and rate of change to negative COVID-19 nucleic acid test;time and rate of improvement of oxygenation measurement;improvement time and rate of CD4 count;rate of mild/modorate type to severe type, rate of severe type to critical type;length of hospitalization;mortality;", "study_type": "Interventional study", "time": "2020-02-15", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49532"}, "type": "Feature"}, {"geometry": {"coordinates": [121.17623, 30.179772], "type": "Point"}, "properties": {"classification": "Advanced therapy medicinal products", "contactEmail": "xxw69@126.com", "contactPhone": "+86 13605708066", "dateEnrollment": "2020-02-15", "description": "Study on convalescent plasma treatment for severe patients with novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000029850", "primaryOutcome": "Fatality rate;", "study_type": "Interventional study", "time": "2020-02-15", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49533"}, "type": "Feature"}, {"geometry": {"coordinates": [113.67907, 34.786016], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "wanghuaqi2004@126.com", "contactPhone": "+86 15890689220", "dateEnrollment": "2020-02-01", "description": "Application of Regulating Intestinal Flora in the Treatment of Severe Novel Coronavirus Pneumonia (COVID-19)", "name": "ChiCTR2000029849", "primaryOutcome": "Length of admission;mortality rate;", "study_type": "Interventional study", "time": "2020-02-15", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49530"}, "type": "Feature"}, {"geometry": {"coordinates": [121.570725, 29.882051], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "caocdoctor@163.com", "contactPhone": "+86 574-87089878", "dateEnrollment": "2020-02-10", "description": "An observational study on the clinical characteristics, treatment and outcome of novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000029839", "primaryOutcome": "Time to clinical recovery;", "study_type": "Observational study", "time": "2020-02-15", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49439"}, "type": "Feature"}, {"geometry": {"coordinates": [118.709669, 31.86612], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "ian0126@126.com", "contactPhone": "+86 13338628626", "dateEnrollment": "2020-02-07", "description": "A randomized controlled trial for honeysuckle decoction in the treatment of patients with novel coronavirus (COVID-19) infection", "name": "ChiCTR2000029822", "primaryOutcome": "rate of cure;", "study_type": "Interventional study", "time": "2020-02-14", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49502"}, "type": "Feature"}, {"geometry": {"coordinates": [104.40212, 31.13469], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "973007530@qq.com", "contactPhone": "+86 13881070630", "dateEnrollment": "2020-02-14", "description": "Based on Delphi Method to Preliminarily Construct a Recommended Protocol for the Prevention of Novel Coronavirus Pneumonia (COVID-19) in Deyang Area by Using Chinese Medicine Technology and its Clinical Application Evaluation", "name": "ChiCTR2000029821", "primaryOutcome": "CD4+;CD3+;HAMA;HAMD;STAI;", "study_type": "Prevention", "time": "2020-02-14", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49306"}, "type": "Feature"}, {"geometry": {"coordinates": [120.213994, 30.255631], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "yingsrrsh@163.com", "contactPhone": "+86 13588706900", "dateEnrollment": "2020-02-11", "description": "Ba-Bao-Dan in the adjuvant therapy of novel coronavirus pneumonia (COVID-19) patients", "name": "ChiCTR2000029819", "primaryOutcome": "Clinical and laboratory indicators;Viral load;chest CT;serum cell factor;", "study_type": "Interventional study", "time": "2020-02-14", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49490"}, "type": "Feature"}, {"geometry": {"coordinates": [113.25266, 23.120313], "type": "Point"}, "properties": {"classification": "Impact on helpers", "contactEmail": "zhanjie34@126.com", "contactPhone": "+86 15818136908", "dateEnrollment": "2020-02-01", "description": "Psychological survey of frontline medical staff in various regions of China during the epidemic of novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000029815", "primaryOutcome": "Self-rating depression scale, SDS;Self-Rating Anxiety Scale, SAS;", "study_type": "Observational study", "time": "2020-02-14", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49346"}, "type": "Feature"}, {"geometry": {"coordinates": [121.558226, 31.090574], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "zhaixiaowendy@163.com", "contactPhone": "+86 64931902", "dateEnrollment": "2020-02-14", "description": "Clinical Trial for Integrated Chinese and Western Medicine in the Treatment of Children with Novel Coronavirus Pneumonia (COVID-19)", "name": "ChiCTR2000029814", "primaryOutcome": "Time fo fever reduction;Time of nucleic acid negative;Severe conversion rate;Improvement time of respiratory symptoms;", "study_type": "Interventional study", "time": "2020-02-14", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49387"}, "type": "Feature"}, {"geometry": {"coordinates": [120.91209, 31.94961], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "luhongzhou@fudan.edu.cn", "contactPhone": "+86 18930810088", "dateEnrollment": "2020-02-14", "description": "Clinical Trial for Tanreqing Capsules in the Treatment of Novel Coronavirus Pneumonia (COVID-19)", "name": "ChiCTR2000029813", "primaryOutcome": "Time of viral nucleic acid turns negative;Antipyretic time;", "study_type": "Interventional study", "time": "2020-02-14", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49425"}, "type": "Feature"}, {"geometry": {"coordinates": [113.413247, 23.113511], "type": "Point"}, "properties": {"classification": "Other", "contactEmail": "164972769@qq.com", "contactPhone": "+86 15018720816", "dateEnrollment": "2020-02-20", "description": "Clinical Study for Anti-aging Active Freeze-dried Powder Granules in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19)", "name": "ChiCTR2000029811", "primaryOutcome": "Time to disease recovery;", "study_type": "Interventional study", "time": "2020-02-14", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49355"}, "type": "Feature"}, {"geometry": {"coordinates": [114.242065, 22.649365], "type": "Point"}, "properties": {"classification": "Diagnosis", "contactEmail": "pony8980@163.com", "contactPhone": "+86 13923781386", "dateEnrollment": "2020-02-16", "description": "Clinical study of a novel high sensitivity nucleic acid assay for novel coronavirus pneumonia (COVID-19) based on CRISPR-cas protein", "name": "ChiCTR2000029810", "primaryOutcome": "SEN, SPE, ACC, AUC of ROC;", "study_type": "Diagnostic test", "time": "2020-02-14", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49407"}, "type": "Feature"}, {"geometry": {"coordinates": [114.13166, 30.61702], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "3131862959@qq.com", "contactPhone": "+86 13871120171", "dateEnrollment": "2020-02-12", "description": "Immunomodulatory Therapy for Severe Novel Coronavirus Pneumonia (COVID-19)", "name": "ChiCTR2000029806", "primaryOutcome": "Proportion of patients with a lung injury score reduction of 1-point or more 7 days after randomization;", "study_type": "Interventional study", "time": "2020-02-14", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49161"}, "type": "Feature"}, {"geometry": {"coordinates": [114.116215, 30.633456], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "88071718@qq.com", "contactPhone": "+86 13397192695", "dateEnrollment": "2020-02-12", "description": "Analysis of clinical characteristics of severe novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000029805", "primaryOutcome": "28-day mortality and 90-day mortality.;", "study_type": "Observational study", "time": "2020-02-14", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49188"}, "type": "Feature"}, {"geometry": {"coordinates": [114.116215, 30.633456], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "1346801465@qq.com", "contactPhone": "+86 13397192695", "dateEnrollment": "2020-02-12", "description": "Clinical Application of ECMO in the Treatment of Patients with Very Serious Respiratory Failure due to novel Coronavirus Pneumonia (COVID-19)", "name": "ChiCTR2000029804", "primaryOutcome": "Inpatient mortality;", "study_type": "Prognosis study", "time": "2020-02-14", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49178"}, "type": "Feature"}, {"geometry": {"coordinates": [121.505543, 31.305357], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "wlx1126@hotmail.com", "contactPhone": "+86 18917962300", "dateEnrollment": "2020-02-17", "description": "Clinical study for the integration of traditional Chinese and western medicine in the treatment of novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000029790", "primaryOutcome": "TCM symptoms efficacy;", "study_type": "Interventional study", "time": "2020-02-13", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49453"}, "type": "Feature"}, {"geometry": {"coordinates": [113.785639, 34.675497], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "li_js8@163.com", "contactPhone": "+86 371-65676568", "dateEnrollment": "2020-02-15", "description": "Randomized controlled trial for TCM syndrome differentiation treatment impacting quality of life of post-discharge patients with novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000029789", "primaryOutcome": "St. George's Respiratory Questionnaire;", "study_type": "Interventional study", "time": "2020-02-13", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49348"}, "type": "Feature"}, {"geometry": {"coordinates": [116.418388, 39.932714], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "zysjsgzs@163.com", "contactPhone": "+86 18134048843", "dateEnrollment": "2020-03-01", "description": "Traditional Chinese medicine cooperative therapy for patients with novel coronavirus pneumonia (COVID-19): a randomized controlled trial", "name": "ChiCTR2000029788", "primaryOutcome": "Antipyretic time;Pharyngeal swab nucleic acid negative time;Blood gas analysis;Traditional Chinese medicine syndrome score;", "study_type": "Interventional study", "time": "2020-02-13", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49452"}, "type": "Feature"}, {"geometry": {"coordinates": [118.93172, 28.73485], "type": "Point"}, "properties": {"classification": "Impact on helpers", "contactEmail": "jiayongshi@medmail.com.cn", "contactPhone": "+86 13605813177", "dateEnrollment": "2020-01-30", "description": "Clinical study for the changes in mental state of medical staff in the department of radiotherapy in a comprehensive tertiary hospital in Zhejiang Province during the epidemic of novel coronavirus infection (COVID-19)", "name": "ChiCTR2000029782", "primaryOutcome": "PSQI;", "study_type": "Observational study", "time": "2020-02-13", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49445"}, "type": "Feature"}, {"geometry": {"coordinates": [120.298751, 31.55958], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "xiangming_fang@njmu.edu.cn", "contactPhone": "+86 13861779030", "dateEnrollment": "2020-02-14", "description": "Study for the key issues of the diagnosis and treatment of novel coronavirus pneumonia (COVID-19) based on the medical imaging", "name": "ChiCTR2000029779", "primaryOutcome": "Chest CT findings;Epidemiological history;Laboratory examination;Pulmonary function test;SEN, SPE, ACC, AUC of ROC;", "study_type": "Diagnostic test", "time": "2020-02-13", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49378"}, "type": "Feature"}, {"geometry": {"coordinates": [121.483669, 31.246879], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "zhangw1190@sina.com", "contactPhone": "+86 13601733045", "dateEnrollment": "2020-02-14", "description": "Clinical Study for Traditional Chinese Medicine Combined With Western Medicine in Treatment of Novel Coronavirus Pneumonia (COVID-19)", "name": "ChiCTR2000029778", "primaryOutcome": "Length of hospital stay;fever clearance time;", "study_type": "Interventional study", "time": "2020-02-13", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49422"}, "type": "Feature"}, {"geometry": {"coordinates": [115.160743, 30.134317], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "fangbji@163.com", "contactPhone": "+86 0714-6224162", "dateEnrollment": "2020-02-05", "description": "A multicenter, randomized, controlled trial for integrated chinese and western medicine in the treatment of novel coronavirus pneumonia (COVID-19) based on the 'Truncated Torsion' strategy", "name": "ChiCTR2000029777", "primaryOutcome": "14 day outcome of the subjects, including: recovery, improvement, turning critical, death.;lung CT;", "study_type": "Interventional study", "time": "2020-02-13", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49380"}, "type": "Feature"}, {"geometry": {"coordinates": [120.696115, 27.939977], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "zjwzhxy@126.com", "contactPhone": "+86 13819711719", "dateEnrollment": "2020-02-11", "description": "A randomized, open-label, blank-controlled, multicenter trial for Polyinosinic-Polycytidylic Acid Injection in the treatment of novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000029776", "primaryOutcome": "Time to Clinical recovery;", "study_type": "Interventional study", "time": "2020-02-13", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49342"}, "type": "Feature"}, {"geometry": {"coordinates": [121.250615, 28.656856], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "lvdq@enzemed.com", "contactPhone": "+86 13867622009", "dateEnrollment": "2020-02-15", "description": "Babaodan Capsule used for the adjuvant treatment of severe novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000029769", "primaryOutcome": "28-day survival;Inflammatory factor levels;", "study_type": "Interventional study", "time": "2020-02-13", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49415"}, "type": "Feature"}, {"geometry": {"coordinates": [114.236454, 30.229555], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "wdznyy@126.com", "contactPhone": "+86 13971156723", "dateEnrollment": "2020-02-12", "description": "A randomized, open, controlled trial for diammonium glycyrrhizinate enteric-coated capsules combined with vitamin C tablets in the treatment of common novel coronavirus pneumonia (COVID-19) in the basic of clinical standard antiviral treatment to evaluate the safety and efficiency", "name": "ChiCTR2000029768", "primaryOutcome": "Time to Clinical recovery;", "study_type": "Interventional study", "time": "2020-02-13", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49131"}, "type": "Feature"}, {"geometry": {"coordinates": [115.53393, 30.52833], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "xxlahh08@163.com", "contactPhone": "+86 18963789002", "dateEnrollment": "2020-02-10", "description": "A multicenter, randomized controlled trial for the efficacy and safety of tocilizumab in the treatment of new coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000029765", "primaryOutcome": "cure rate;", "study_type": "Interventional study", "time": "2020-02-13", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49409"}, "type": "Feature"}, {"geometry": {"coordinates": [106.63382, 33.16597], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "songlab_radiology@163.com", "contactPhone": "86 28 85423680", "dateEnrollment": "2020-02-16", "description": "Imaging Features and Mechanisms of Novel Coronavirus Pneumonia (COVID-19): a Multicenter Study", "name": "ChiCTR2000029764", "primaryOutcome": "imaging feature;", "study_type": "Observational study", "time": "2020-02-13", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49388"}, "type": "Feature"}, {"geometry": {"coordinates": [116.524909, 39.822121], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "huangluqi01@126.com", "contactPhone": "+86 010-64089801", "dateEnrollment": "2020-02-13", "description": "The efficacy of traditional chinese medicine on Novel Coronavirus Pneumonia (COVID-19) patients treated in square cabin hospital: a prospective, randomized controlled trial", "name": "ChiCTR2000029763", "primaryOutcome": "Rate of conversion to severe or critical illness;", "study_type": "Interventional study", "time": "2020-02-12", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49408"}, "type": "Feature"}, {"geometry": {"coordinates": [106.618374, 33.182406], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "Kangyan@scu.edu.cn", "contactPhone": "+86 18980601566", "dateEnrollment": "2020-02-03", "description": "Cohort Study of Novel Coronavirus Pneumonia (COVID-19) Critical Ill Patients", "name": "ChiCTR2000029758", "primaryOutcome": "length of stay;length of stay in ICU;Antibiotic use;Hospital costs;Organ function support measures;Organ function;", "study_type": "Observational study", "time": "2020-02-12", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49295"}, "type": "Feature"}, {"geometry": {"coordinates": [114.147061, 30.356048], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "doctorzhang2003@163.com", "contactPhone": "+86 18062567610", "dateEnrollment": "2020-02-15", "description": "Clinical study of nebulized Xiyanping injection in the treatment of novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000029756", "primaryOutcome": "vital signs (Body temperature, blood pressure, heart rate, breathing rate);Respiratory symptoms and signs (Lung sounds, cough, sputum);Etiology and laboratory testing;PaO2/SPO2;Liquid balance;Ventilator condition;Imaging changes;", "study_type": "Interventional study", "time": "2020-02-12", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49222"}, "type": "Feature"}, {"geometry": {"coordinates": [104.061699, 30.641376], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "leilei_25@126.com", "contactPhone": "+86 18980605819", "dateEnrollment": "2020-02-10", "description": "Study for the Effect of Novel Coronavirus Pneumonia (COVID-19) on the Health of Different People", "name": "ChiCTR2000029754", "primaryOutcome": "Physical and mental health;", "study_type": "Observational study", "time": "2020-02-12", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49370"}, "type": "Feature"}, {"geometry": {"coordinates": [121.298234, 30.052805], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "maoweilw@163.com", "contactPhone": "+86 0571-87068001", "dateEnrollment": "2020-02-01", "description": "Clinical Study for Traditional Chinese Medicine in the Prevention and Treatment of Novel Coronavirus Pneumonia (COVID-19)", "name": "ChiCTR2000029751", "primaryOutcome": "blood routine examination;CRP;PCT;Chest CT;Liver and kidney function;Etiology test;", "study_type": "Observational study", "time": "2020-02-12", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49354"}, "type": "Feature"}, {"geometry": {"coordinates": [117.256275, 31.855782], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "13505615645@163.com", "contactPhone": "+86 13505615645", "dateEnrollment": "2020-02-11", "description": "Effect evaluation and prognosis of Chinese medicine based on Novel Coronavirus Pneumonia (COVID-19)", "name": "ChiCTR2000029747", "primaryOutcome": "Chest CT;Routine blood test;liver and renal function;TCM syndrome;", "study_type": "Interventional study", "time": "2020-02-11", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49287"}, "type": "Feature"}, {"geometry": {"coordinates": [114.583872, 30.596762], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "31531955@qq.com", "contactPhone": "+86 27 83662688", "dateEnrollment": "2020-02-10", "description": "A randomized, parallel controlled trial for the efficacy and safety of Sodium Aescinate Injection in the treatment of patients with pneumonia (COVID-19)", "name": "ChiCTR2000029742", "primaryOutcome": "Chest imaging (CT);", "study_type": "Interventional study", "time": "2020-02-11", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49297"}, "type": "Feature"}, {"geometry": {"coordinates": [113.574792, 22.2972], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "xiajinyu@mail.sysu.edu.cn", "contactPhone": "+86 13823078064", "dateEnrollment": "2020-02-12", "description": "Efficacy of Chloroquine and Lopinavir/ Ritonavir in mild/general novel coronavirus (CoVID-19) infections: a prospective, open-label, multicenter randomized controlled clinical study", "name": "ChiCTR2000029741", "primaryOutcome": "Length of stay;Length of severe;oxygenation index during treatment;all-cause mortality in 28 days;Peripheral blood cell count (including white blood cells, lymphocytes, neutrophils, etc.);procalcitonin;C-reactive protein;Inflammatory factors (including IL-6, IL-10, TNF-a, etc.);Lymphocyte subsets and complement;Coagulation indicators (prothrombin time, activated partial prothrombin time, fibrinogen, D-dimer, platelet count);Virus nucleic acid;", "study_type": "Interventional study", "time": "2020-02-11", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49263"}, "type": "Feature"}, {"geometry": {"coordinates": [113.396794, 23.003845], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "zheng862080@139.com", "contactPhone": "+86 18928868242", "dateEnrollment": "2020-02-12", "description": "A Multicenter, Randomized, Parallel Controlled Clinical Study of Hydrogen-Oxygen Nebulizer to Improve the Symptoms of Patients With Novel Coronavirus Pneumonia (COVID-19)", "name": "ChiCTR2000029739", "primaryOutcome": "the condition worsens and develops into severe or critical condition;the condition improves significantly and reaches the discharge standard;The overall treatment time is no longer than 14 days;", "study_type": "Interventional study", "time": "2020-02-11", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49283"}, "type": "Feature"}, {"geometry": {"coordinates": [114.452086, 30.448476], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "xie_m@126.com", "contactPhone": "+86 18602724678", "dateEnrollment": "2020-01-26", "description": "Risks of Death and Severe cases in Patients with 2019 Novel Coronavirus Pneumonia (COVID-19)", "name": "ChiCTR2000029735", "primaryOutcome": "incidence;mortality;", "study_type": "Observational study", "time": "2020-02-10", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49279"}, "type": "Feature"}, {"geometry": {"coordinates": [109.95917, 27.54944], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "qiuchengfeng0721@163.com", "contactPhone": "+86 14786531725", "dateEnrollment": "2020-02-08", "description": "Epidemiological investigation and clinical characteristics analysis of novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000029734", "primaryOutcome": "Epidemiological history;haematological;First symptom;blood glucose;blood glucose;prognosis;Blood gas analysis;complication;", "study_type": "Observational study", "time": "2020-02-10", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=48868"}, "type": "Feature"}, {"geometry": {"coordinates": [106.618374, 33.182406], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "guojun@wchscu.cn", "contactPhone": "+86 15388178461", "dateEnrollment": "2020-02-10", "description": "Impact of vitamin D deficiency on prognosis of patients with novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000029732", "primaryOutcome": "ROX index;", "study_type": "Observational study", "time": "2020-02-10", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49302"}, "type": "Feature"}, {"geometry": {"coordinates": [114.26326, 22.72289], "type": "Point"}, "properties": {"classification": "Diagnosis", "contactEmail": "jxxk1035@yeah.net", "contactPhone": "+86 13530027001", "dateEnrollment": "2020-03-01", "description": "Early Detection of Novel Coronavirus Pneumonia (COVID-19) Based on a Novel High-Throughput Mass Spectrometry Analysis With Exhaled Breath", "name": "ChiCTR2000029695", "primaryOutcome": "Sensitivity of detection of NCP;Specificity of detection of NCP;", "study_type": "Diagnostic test", "time": "2020-02-10", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49219"}, "type": "Feature"}, {"geometry": {"coordinates": [114.492994, 29.547003], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "bluesearh006@sina.com", "contactPhone": "+86 15337110926", "dateEnrollment": "2020-02-14", "description": "A randomized, open-label study to evaluate the efficacy and safety of low-dose corticosteroids in hospitalized patients with novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000029656", "primaryOutcome": "ECG;Chest imaging;Complications;vital signs;NEWS2 score;", "study_type": "Interventional study", "time": "2020-02-09", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49086"}, "type": "Feature"}, {"geometry": {"coordinates": [113.557715, 22.313772], "type": "Point"}, "properties": {"classification": "Impact on helpers", "contactEmail": "wenshl@mail.sysu.edu.cn", "contactPhone": "+86 13312883618", "dateEnrollment": "2020-02-10", "description": "Study for Mental health and psychological status of doctors, nurses and patients in novel coronavirus pneumonia (COVID-19) designated hospital and effect of interventions", "name": "ChiCTR2000029639", "primaryOutcome": "Physical examination;Nucleic acid;Oxygenation index;GAD-7;PHQ-9;SASRQ;PSQI;Lymphocyte subsets;", "study_type": "Interventional study", "time": "2020-02-08", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49187"}, "type": "Feature"}, {"geometry": {"coordinates": [113.237215, 23.136749], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "doctorzzd99@163.com", "contactPhone": "+86 13903076359", "dateEnrollment": "2020-02-07", "description": "An observational study for Xin-Guan-1 formula  in the treatment of novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000029637", "primaryOutcome": "Completely antipyretic time: completely antipyretic was defined as the body temperature return to normal for over 24 hours.;Time to remission/disappearance of primary symptoms: defined as the number of days when the three main symptoms of fever, cough, and shortness of breath are all relieved / disappeared;", "study_type": "Observational study", "time": "2020-02-08", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49127"}, "type": "Feature"}, {"geometry": {"coordinates": [114.433339, 30.431406], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "hubo@mail.hust.edu.cn", "contactPhone": "+86 13707114863", "dateEnrollment": "2020-02-09", "description": "Efficacy and safety of aerosol inhalation of vMIP in the treatment of novel coronavirus pneumonia (COVID-19): a single arm clinical trial", "name": "ChiCTR2000029636", "primaryOutcome": "2019-nCoV nucleic acid turning negative time (from respiratory secretion), or the time to release isolation;", "study_type": "Interventional study", "time": "2020-02-08", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49215"}, "type": "Feature"}, {"geometry": {"coordinates": [113.237215, 23.136749], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "doctorzzd99@163.com", "contactPhone": "+86 13903076359", "dateEnrollment": "2020-02-07", "description": "A clinical observational study for Xin-Guan-2 formula in the treatment of suspected novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000029628", "primaryOutcome": "Time to completely antipyretic time:completely antipyretic was defined as the body temperature return to normal for over 24 hours.;Main symptom relief/disappearance time: defined as the days when the three main symptoms of fever, cough and shortness of breath all remission/disappear.;", "study_type": "Observational study", "time": "2020-02-07", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49155"}, "type": "Feature"}, {"geometry": {"coordinates": [120.161675, 30.260665], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "13588867114@163.com", "contactPhone": "+86 13588867114", "dateEnrollment": "2020-02-17", "description": "Immune Repertoire (TCR & BCR) Evaluation and Immunotherapy Research in Peripheral Blood of Novel Coronavirus Pneumonia (COVID-19)", "name": "ChiCTR2000029626", "primaryOutcome": "TCR sequencing;BCR sequencing;HLA sequencing;", "study_type": "Basic Science", "time": "2020-02-07", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49170"}, "type": "Feature"}, {"geometry": {"coordinates": [120.28483, 30.165682], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "caiicu@163.com", "contactPhone": "+86 13505811696", "dateEnrollment": "2020-02-17", "description": "Construction of Early Warning and Prediction System for Patients with Severe / Critical Novel Coronavirus Pneumonia (COVID-19)", "name": "ChiCTR2000029625", "primaryOutcome": "Lymphocyte subpopulation analysis;Cytokine detection;Single cell sequencing of bronchial lavage fluid cells;", "study_type": "Diagnostic test", "time": "2020-02-07", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49177"}, "type": "Feature"}, {"geometry": {"coordinates": [121.018659, 31.839091], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "Luhongzhou@shphc.org.cn", "contactPhone": "+86 18930810088", "dateEnrollment": "2020-02-08", "description": "A real world study for traditional Chinese Medicine in the treatment of novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000029624", "primaryOutcome": "Time for body temperature recovery;Chest CT absorption;Time of nucleic acid test turning negative;", "study_type": "Observational study", "time": "2020-02-07", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49132"}, "type": "Feature"}, {"geometry": {"coordinates": [121.474855, 31.232517], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "jmqu0906@163.com", "contactPhone": "+86 21 64370045", "dateEnrollment": "2020-02-07", "description": "Clinical study of arbidol hydrochloride tablets in the treatment of novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000029621", "primaryOutcome": "Virus negative conversion rate in the first week;", "study_type": "Interventional study", "time": "2020-02-07", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49165"}, "type": "Feature"}, {"geometry": {"coordinates": [113.557715, 22.313772], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "shanhong@mail.sysu.edu.cn", "contactPhone": "+86 0756 2528573", "dateEnrollment": "2020-02-10", "description": "A prospective, open-label, multiple-center study for the efficacy of chloroquine phosphate in patients with novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000029609", "primaryOutcome": "virus nucleic acid negative-transforming time;", "study_type": "Interventional study", "time": "2020-02-06", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49145"}, "type": "Feature"}, {"geometry": {"coordinates": [120.269385, 30.182118], "type": "Point"}, "properties": {"classification": "Advanced therapy medicinal products", "contactEmail": "ljli@zju.edu.cn", "contactPhone": "+86 0571-87236426", "dateEnrollment": "2020-01-25", "description": "Clinical Study for Human Menstrual Blood-Derived Stem Cells in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19)", "name": "ChiCTR2000029606", "primaryOutcome": "Mortality in patients;", "study_type": "Interventional study", "time": "2020-02-07", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49146"}, "type": "Feature"}, {"geometry": {"coordinates": [120.269385, 30.182118], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "qiuyq@zju.edu.cn", "contactPhone": "+86 13588189339", "dateEnrollment": "2020-02-06", "description": "A Randomized, Open-Label, Multi-Centre Clinical Trial Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Confirmed Cases of Novel Coronavirus Pneumonia (COVID-19)", "name": "ChiCTR2000029603", "primaryOutcome": "The incidence of composite adverse outcome within 14 days after admission: Defined as (one of them) SPO2<= 93% without oxygen supplementation, PaO2/FiO2 <= 300mmHg or RR <=30 breaths per minute.;", "study_type": "Interventional study", "time": "2020-02-06", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49075"}, "type": "Feature"}, {"geometry": {"coordinates": [115.650098, 30.770064], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "Xiaolintong66@sina.com", "contactPhone": "+86 13910662116", "dateEnrollment": "2020-02-01", "description": "Clinical study for community based prevention and control strategy of novel coronavirus pneumonia (COVID-19) in the isolate suspected and confirmed population", "name": "ChiCTR2000029602", "primaryOutcome": "Incidence of onset at home / designated isolation population who progressed to designated isolation treatment or were diagnosed with novel coronavirus-infected pneumonia;days of onset at home / designated isolation population who progressed to designated isolation treatment or were diagnosed with novel coronavirus-infected pneumonia;", "study_type": "Interventional study", "time": "2020-02-06", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=48985"}, "type": "Feature"}, {"geometry": {"coordinates": [115.634653, 30.786501], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "252417083@qq.com", "contactPhone": "+86 18908628577", "dateEnrollment": "2020-02-01", "description": "Community based prevention and control for Chinese medicine in the treatment of novel coronavirus pneumonia (COVID-19) in the isolate suspected and confirmed population", "name": "ChiCTR2000029601", "primaryOutcome": "the negative conversion ratio;the proportion of general patients with advanced severe disease;confirmed rate of suspected cases;", "study_type": "Interventional study", "time": "2020-02-06", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=48988"}, "type": "Feature"}, {"geometry": {"coordinates": [114.247815, 22.739326], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "yingxialiu@hotmail.com", "contactPhone": "+86 755 61238922", "dateEnrollment": "2020-01-30", "description": "Clinical study for safety and efficacy of Favipiravir in the treatment of novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000029600", "primaryOutcome": "Declining speed of Novel Coronavirus by PCR;Negative Time of Novel Coronavirus by PCR;Incidentce rate of chest imaging;Incidence rate of liver enzymes;Incidence rate of kidney damage;", "study_type": "Interventional study", "time": "2020-02-06", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49042"}, "type": "Feature"}, {"geometry": {"coordinates": [120.144338, 30.178144], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "wengcp@163.com", "contactPhone": "+86 571 86613587", "dateEnrollment": "2020-02-06", "description": "Chinese medicine prevention and treatment program for novel coronavirus pneumonia (COVID-19): a perspective, sing-arm trial", "name": "ChiCTR2000029578", "primaryOutcome": "Cure rate;The cure time;The rate and time at which the normal type progresses to the heavy type;Rate and time of progression from heavy to critical type and even death;", "study_type": "Interventional study", "time": "2020-02-05", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49080"}, "type": "Feature"}, {"geometry": {"coordinates": [112.146577, 32.040674], "type": "Point"}, "properties": {"classification": "Advanced therapy medicinal products", "contactEmail": "xyxzyxzh@163.com", "contactPhone": "+86 18995678520", "dateEnrollment": "2020-02-05", "description": "Safety and efficacy of umbilical cord blood mononuclear cells in the treatment of severe and critically novel coronavirus pneumonia(COVID-19): a randomized controlled clinical trial", "name": "ChiCTR2000029572", "primaryOutcome": "PSI;", "study_type": "Interventional study", "time": "2020-02-05", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=41760"}, "type": "Feature"}, {"geometry": {"coordinates": [112.131132, 32.057111], "type": "Point"}, "properties": {"classification": "Advanced therapy medicinal products", "contactEmail": "xyxzyxzh@163.com", "contactPhone": "+86 18995678520", "dateEnrollment": "2020-02-05", "description": "Safety and efficacy of umbilical cord blood mononuclear cells conditioned medium in the treatment of severe and critically novel coronavirus pneumonia (COVID-19): a randomized controlled trial", "name": "ChiCTR2000029569", "primaryOutcome": "PSI;", "study_type": "Interventional study", "time": "2020-02-04", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49062"}, "type": "Feature"}, {"geometry": {"coordinates": [114.253603, 30.245525], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "doctorzhang2003@163.com", "contactPhone": "+86 18962567610", "dateEnrollment": "2020-01-31", "description": "Therapeutic effect of hydroxychloroquine on novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000029559", "primaryOutcome": "The time when the nucleic acid of the novel coronavirus turns negative;T cell recovery time;", "study_type": "Interventional study", "time": "2020-02-04", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=48880"}, "type": "Feature"}, {"geometry": {"coordinates": [104.054895, 30.725905], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "xcg718@aliyun.com", "contactPhone": "+86 18980880132", "dateEnrollment": "2020-01-29", "description": "Recommendations of Integrated Traditional Chinese and Western Medicine for Diagnosis and Treatment of Novel Coronavirus Pneumonia (COVID-19) in Sichuan Province", "name": "ChiCTR2000029558", "primaryOutcome": "blood routine;urine routines;CRP;PCT;ESR;creatase;troponin;myoglobin;D-Dimer;arterial blood gas analysis;Nucleic acid test for 2019-nCoV ;chest CT;Biochemical complete set;", "study_type": "Interventional study", "time": "2020-02-04", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=48792"}, "type": "Feature"}, {"geometry": {"coordinates": [120.269385, 30.182118], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "qiuyq@zju.edu.cn", "contactPhone": "+86 13588189339", "dateEnrollment": "2020-02-04", "description": "Randomized, open-label, controlled trial for evaluating of the efficacy and safety of Baloxavir Marboxil, Favipiravir, and Lopinavir-Ritonavir in the treatment of novel coronavirus pneumonia (COVID-19) patients", "name": "ChiCTR2000029548", "primaryOutcome": "Time to viral negativityby RT-PCR;Time to clinical improvement: Time from start of study drug to hospital discharge or to NEWS2<2 for 24 hours.;", "study_type": "Interventional study", "time": "2020-02-04", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49015"}, "type": "Feature"}, {"geometry": {"coordinates": [120.269385, 30.182118], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "qiuyq@zju.edu.cn", "contactPhone": "+86 13588189339", "dateEnrollment": "2020-02-04", "description": "A randomized controlled trial for the efficacy and safety of Baloxavir Marboxil, Favipiravir tablets in novel coronavirus pneumonia (COVID-19) patients who are still positive on virus detection under the current antiviral therapy", "name": "ChiCTR2000029544", "primaryOutcome": "Time to viral negativity by RT-PCR;Time to clinical improvement;", "study_type": "Interventional study", "time": "2020-02-03", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49013"}, "type": "Feature"}, {"geometry": {"coordinates": [113.41342, 23.018178], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "shanpingjiang@126.com", "contactPhone": "+86 13922738892", "dateEnrollment": "2020-02-03", "description": "Study for the efficacy of chloroquine in patients with novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000029542", "primaryOutcome": "viral negative-transforming time;30-day cause-specific mortality;", "study_type": "Interventional study", "time": "2020-02-03", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=48968"}, "type": "Feature"}, {"geometry": {"coordinates": [114.11445, 30.356522], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "wangxinghuan@whu.edu.cn", "contactPhone": "+86 18971387168/+86 15729577635", "dateEnrollment": "2020-02-10", "description": "A randomised, open, controlled trial for darunavir/cobicistat or Lopinavir/ritonavir combined with thymosin a1 in the treatment of novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000029541", "primaryOutcome": "Time to conversion of 2019-nCoV RNA result from RI sample;", "study_type": "Interventional study", "time": "2020-02-03", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=48992"}, "type": "Feature"}, {"geometry": {"coordinates": [114.433536, 30.464924], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "zhaojp@tjh.tjmu.edu.cn", "contactPhone": "+86 13507138234", "dateEnrollment": "2020-02-04", "description": "A randomized, open-label study to evaluate the efficacy and safety of Lopinavir-Ritonavir in patients with mild novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000029539", "primaryOutcome": "The incidence of adverse outcome within 14 days after admission: Patients with conscious dyspnea, SpO2 = 94% or respiratory frequency = 24 times / min in the state of resting without oxygen inhalation;", "study_type": "Interventional study", "time": "2020-02-03", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=48991"}, "type": "Feature"}, {"geometry": {"coordinates": [120.250896, 30.067613], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "wengcp@163.com", "contactPhone": "+86 13906514781", "dateEnrollment": "2020-02-04", "description": "Chinese medicine prevention and treatment program for novel coronavirus pneumonia (COVID-19): a perspective, double-blind, placebo, randomised controlled trial", "name": "ChiCTR2000029518", "primaryOutcome": "Recovery time;Ratio and time for the general type to progress to heavy;Ratio and time of severe progression to critical or even death;", "study_type": "Interventional study", "time": "2020-02-03", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=48860"}, "type": "Feature"}, {"geometry": {"coordinates": [120.128892, 30.19458], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "wengcp@163.com", "contactPhone": "+86 13601331063", "dateEnrollment": "2020-02-04", "description": "Chinese medicine prevention and treatment program for suspected novel coronavirus pneumonia (COVID-19): a perspective, double-blind, placebo, randomised controlled trial", "name": "ChiCTR2000029517", "primaryOutcome": "Relief of clinical symptoms and duration;", "study_type": "Interventional study", "time": "2020-02-03", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=48861"}, "type": "Feature"}, {"geometry": {"coordinates": [114.436667, 30.464892], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "1025823309@qq.com", "contactPhone": "+86 13307161995", "dateEnrollment": "2020-02-03", "description": "Traditional Chinese Medicine, Psychological Intervention and Investigation of Mental Health for Patients With Novel Coronavirus Pneumonia (COVID-19) in Convalescent Period", "name": "ChiCTR2000029495", "primaryOutcome": "Self-rating depression scale, SDS;Self-Rating Anxiety Scale, SAS;ocial support rate scale, SSRS;", "study_type": "Interventional study", "time": "2020-02-02", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=48971"}, "type": "Feature"}, {"geometry": {"coordinates": [114.436667, 30.464892], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "jxzhang1607@163.com", "contactPhone": "+86 13377897297", "dateEnrollment": "2020-02-03", "description": "Traditional Chinese Medicine for Pulmonary Fibrosis, Pulmonary Function and Quality of Life in Patients With Novel Coronavirus Pneumonia (COVID-19) in Convalescent Period: a Randomized Controlled Trial", "name": "ChiCTR2000029493", "primaryOutcome": "pulmonary function;St Georges respiratory questionnaire, SGRQ;Modified Barthel Index, MBI;", "study_type": "Interventional study", "time": "2020-02-02", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=48931"}, "type": "Feature"}, {"geometry": {"coordinates": [114.599252, 29.436806], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "784404524@qq.com", "contactPhone": "+86 13659897175", "dateEnrollment": "2020-02-10", "description": "Clinical Study for Gu-Biao Jie-Du-Ling in Preventing of Novel Coronavirus Pneumonia (COVID-19) in Children", "name": "ChiCTR2000029487", "primaryOutcome": "body temperature;Whole blood count and five classifications;C-reactive protein;", "study_type": "Prevention", "time": "2020-02-02", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=48965"}, "type": "Feature"}, {"geometry": {"coordinates": [104.085022, 30.667943], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "cdjianghua@qq.com", "contactPhone": "+86 028 87393881", "dateEnrollment": "2020-02-01", "description": "A real-world  study for lopinavir/ritonavir (LPV/r) and emtritabine (FTC) / Tenofovir alafenamide Fumarate tablets (TAF) regimen in the treatment of novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000029468", "primaryOutcome": "Patient survival rate;", "study_type": "Interventional study", "time": "2020-02-02", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=48919"}, "type": "Feature"}, {"geometry": {"coordinates": [113.804557, 34.777628], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "li_js8@163.com", "contactPhone": "+86 371 65676568", "dateEnrollment": "2020-02-01", "description": "Study for clinical characteristics and distribution of TCM syndrome of novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000029462", "primaryOutcome": "Clinical characteristics;TCM syndrome;", "study_type": "Observational study", "time": "2020-02-02", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=48922"}, "type": "Feature"}, {"geometry": {"coordinates": [114.436667, 30.464892], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "docxwg@163.com", "contactPhone": "+86 13377897278", "dateEnrollment": "2020-02-03", "description": "A Randomized Controlled Trial for Integrated Traditional Chinese Medicine and Western Medicine in the Treatment of Common Type Novel Coronavirus Pneumonia (COVID-19)", "name": "ChiCTR2000029461", "primaryOutcome": "pulmonary function;Antipyretic time;Time of virus turning negative;", "study_type": "Interventional study", "time": "2020-02-02", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=48927"}, "type": "Feature"}, {"geometry": {"coordinates": [114.436667, 30.464892], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "chanjuanzheng@163.com", "contactPhone": "+86 18971317115", "dateEnrollment": "2020-02-02", "description": "The effect of shadowboxing for pulmonary function and quality of life in patients with novel coronavirus pneumonia (COVID-19) in rehabilitation period", "name": "ChiCTR2000029460", "primaryOutcome": "pulmonary function;St Georges respiratory questionnaire, SGRQ;Modified Barthel Index, MBI;Incidence of adverse events;", "study_type": "Interventional study", "time": "2020-02-02", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=48930"}, "type": "Feature"}, {"geometry": {"coordinates": [114.436667, 30.464892], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "docxwg@163.com", "contactPhone": "+86 13377897278", "dateEnrollment": "2020-02-03", "description": "The effect of pulmonary rehabilitation for pulmonary function and quality of life in patients with novel coronavirus pneumonia (COVID-19) in rehabilitation period", "name": "ChiCTR2000029459", "primaryOutcome": "pulmonary function;St Georges respiratory questionnaire, SGRQ;", "study_type": "Interventional study", "time": "2020-02-02", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=48929"}, "type": "Feature"}, {"geometry": {"coordinates": [116.410039, 39.926901], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "ZJHTCM@FOXMAIL.COM", "contactPhone": "+86 13902020873", "dateEnrollment": "2020-02-02", "description": "Combination of traditional Chinese medicine and western medicine in the treatment of common type novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000029439", "primaryOutcome": "Antipyretic time;Time of virus turning negative;", "study_type": "Interventional study", "time": "2020-02-01", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=48904"}, "type": "Feature"}, {"geometry": {"coordinates": [116.524161, 39.827448], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "ZJHTCM@FOXMAIL.COM", "contactPhone": "+86 13902020873", "dateEnrollment": "2020-02-04", "description": "A randomized controlled trial of integrated TCM and Western Medicine in the treatment of severe novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000029438", "primaryOutcome": "CURB-65;PSI score;Mechanical ventilation time;Length of stay in hospital;", "study_type": "Interventional study", "time": "2020-02-01", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=48911"}, "type": "Feature"}, {"geometry": {"coordinates": [114.436667, 30.464892], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "DOCXWG@16.COM", "contactPhone": "+86 13902020873", "dateEnrollment": "2020-02-03", "description": "A single arm study for combination of traditional Chinese and Western Medicine in the treatment of novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000029437", "primaryOutcome": "all available outcome;", "study_type": "Observational study", "time": "2020-02-01", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=48913"}, "type": "Feature"}, {"geometry": {"coordinates": [113.802548, 34.801986], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "lisuyun2000@126.com", "contactPhone": "+86 371 66248624", "dateEnrollment": "2020-02-01", "description": "A single arm study for evaluation of integrated traditional Chinese and western medicine in the treatment of novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000029436", "primaryOutcome": "Duration of PCR normalization;Clinical symptom score;", "study_type": "Interventional study", "time": "2020-02-01", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=48884"}, "type": "Feature"}, {"geometry": {"coordinates": [114.583807, 29.453242], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "whsdyyykjc@126.com", "contactPhone": "+86 13163283819", "dateEnrollment": "2020-02-01", "description": "Randomized controlled trial for traditional Chinese medicine in the prevention of novel coronavirus pneumonia (COVID-19) in high risk population", "name": "ChiCTR2000029435", "primaryOutcome": "Viral nucleic acid detection;CT Scan of the Lungs;Blood routine examination;Temperature;Height;Weight;", "study_type": "Interventional study", "time": "2020-02-01", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=48827"}, "type": "Feature"}, {"geometry": {"coordinates": [113.381295, 23.064331], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "yang_zhongqi@163.com", "contactPhone": "+86 13688867618", "dateEnrollment": "2020-02-01", "description": "A Real World Study for the Efficacy and Safety of Large Dose Tanreqing Injection in the Treatment of Patients with Novel Coronavirus Pneumonia (COVID-19)", "name": "ChiCTR2000029432", "primaryOutcome": "Time for body temperature recovery;Chest X-ray absorption;", "study_type": "Interventional study", "time": "2020-02-01", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=48881"}, "type": "Feature"}, {"geometry": {"coordinates": [121.641576, 38.917483], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "zhaodewei2016@163.com", "contactPhone": "+86 0411-62893509", "dateEnrollment": "2020-01-29", "description": "Clinical study for the remedy of M1 macrophages target in the treatment of novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000029431", "primaryOutcome": "CT of lung;CT and MRI of hip;", "study_type": "Interventional study", "time": "2020-02-01", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=48907"}, "type": "Feature"}, {"geometry": {"coordinates": [116.92699, 38.93373], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "ZJHTCM@FOXMAIL.COM", "contactPhone": "+86 13902020873", "dateEnrollment": "2020-02-03", "description": "Study for the TCM syndrome characteristics of novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000029430", "primaryOutcome": "TCM syndroms;", "study_type": "Observational study", "time": "2020-02-01", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=48902"}, "type": "Feature"}, {"geometry": {"coordinates": [116.43549, 39.94861], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "shanghongcai@126.com", "contactPhone": "+86 010 84012510", "dateEnrollment": "2020-02-03", "description": "Chinese Herbal medicine for Severe nevel coronavirus pneumonia (COVID-19): a Randomized Controlled Trial", "name": "ChiCTR2000029418", "primaryOutcome": "Critically ill patients (%);", "study_type": "Interventional study", "time": "2020-01-30", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=48886"}, "type": "Feature"}, {"geometry": {"coordinates": [116.509464, 39.838557], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "huangluqi01@126.com", "contactPhone": "+86 010-64089801", "dateEnrollment": "2020-01-29", "description": "Clinical Controlled Trial for Traditional Chinese Medicine in the treatment of Novel Coronavirus Pneumonia (COVID-19)", "name": "ChiCTR2000029400", "primaryOutcome": "the rate of remission;", "study_type": "Interventional study", "time": "2020-01-29", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=48824"}, "type": "Feature"}, {"geometry": {"coordinates": [113.397887, 23.035742], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "ylsong70@163.com", "contactPhone": "+86 020 34294311", "dateEnrollment": "2020-01-24", "description": "A prospective comparative study for Xue-Bi-Jing injection in the treatment of novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000029381", "primaryOutcome": "pneumonia severity index (PSI);", "study_type": "Interventional study", "time": "2020-01-27", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=48768"}, "type": "Feature"}, {"geometry": {"coordinates": [118.819773, 31.886165], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "", "contactPhone": "", "dateEnrollment": "February 10, 2020", "description": "Immunoregulatory Therapy for 2019-nCoV", "name": "NCT04268537", "primaryOutcome": "lung injury score", "study_type": "Interventional", "time": "2020-02-08", "weburl": "https://clinicaltrials.gov/show/NCT04268537"}, "type": "Feature"}, {"geometry": {"coordinates": [114.33954, 30.575135], "type": "Point"}, "properties": {"classification": "Advanced therapy medicinal products", "contactEmail": ";znyylcsy@126.com;", "contactPhone": ";18971387168;", "dateEnrollment": "February 6, 2020", "description": "Umbilical Cord(UC)-Derived Mesenchymal Stem Cells(MSCs) Treatment for the 2019-novel Coronavirus(nCOV) Pneumonia", "name": "NCT04269525", "primaryOutcome": "Oxygenation index", "study_type": "Interventional", "time": "2020-02-07", "weburl": "https://clinicaltrials.gov/show/NCT04269525"}, "type": "Feature"}, {"geometry": {"coordinates": [113.573787, 22.247427], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "13600001163@139.com", "contactPhone": "+86 0756-3325892", "dateEnrollment": "2020-02-15", "description": "Clinical Study on Syndrome Differentiation of TCM in Treating Severe and Critical novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030188", "primaryOutcome": "TCM symptom score;Becomes negative time of COVID-19;Cure / mortality rate;", "study_type": "Interventional study", "time": "2020-02-24", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50025"}, "type": "Feature"}, {"geometry": {"coordinates": [106.618374, 33.182406], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "doctorwhy@126.com", "contactPhone": "+86 13518106758", "dateEnrollment": "2020-02-24", "description": "The Value of Critical Care Ultrasound in Rapid Screening, Diagnosis, Evaluation of Effectiveness and Intensive Prevention of Novel Coronavirus Pneumonia (COVID-19)", "name": "ChiCTR2000030185", "primaryOutcome": "28day mortality;", "study_type": "Diagnostic test", "time": "2020-02-24", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50058"}, "type": "Feature"}, {"geometry": {"coordinates": [115.900712, 28.677222], "type": "Point"}, "properties": {"classification": "Advanced therapy medicinal products", "contactEmail": "leaiping@126.com", "contactPhone": "+86 13707089009", "dateEnrollment": "2020-02-24", "description": "Experimental study of novel coronavirus pneumonia rehabilitation plasma therapy severe novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030179", "primaryOutcome": "Cure rate;Mortality;", "study_type": "Interventional study", "time": "2020-02-24", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50059"}, "type": "Feature"}, {"geometry": {"coordinates": [112.973378, 28.186618], "type": "Point"}, "properties": {"classification": "Advanced therapy medicinal products", "contactEmail": "xuezg@tongji.edu.cn", "contactPhone": "+86 15000285942", "dateEnrollment": "2020-02-17", "description": "Key techniques of umbilical cord mesenchymal stem cells for the treatment of novel coronavirus pneumonia (COVID-19) and clinical application demonstration", "name": "ChiCTR2000030173", "primaryOutcome": "pulmonary function;Novel coronavirus pneumonic nucleic acid test;", "study_type": "Interventional study", "time": "2020-02-24", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49229"}, "type": "Feature"}, {"geometry": {"coordinates": [121.003214, 31.855527], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "luhongzhou@shphc.org.cn", "contactPhone": "+86 18930810088", "dateEnrollment": "2020-02-15", "description": "Study for safety and efficacy of Jakotinib hydrochloride tablets in the treatment severe and acute exacerbation patients of novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030170", "primaryOutcome": "Severe NCP group: Time to clinical improvement (TTCI) [time window: 28 days];Acute exacerbation NCP group: Time to clinical recovery [time window: 28 days] and the ratio of common to severe and critically severe.;", "study_type": "Interventional study", "time": "2020-02-24", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50017"}, "type": "Feature"}, {"geometry": {"coordinates": [114.238041, 30.262132], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "chenqx666@whu.edu.cn", "contactPhone": "+86 027-88041911-82237", "dateEnrollment": "2020-03-02", "description": "Clinical Trial for Recombinant Human Interleukin-2 in the Treatment of Novel Coronavirus Pneumonia (COVID-19)", "name": "ChiCTR2000030167", "primaryOutcome": "CD8+ T cells numbers;CD4+ T cell numbers;NK cell numbers;Fatality rate;Clinical recovery time;Critical (severe or critical) conversion rate;", "study_type": "Interventional study", "time": "2020-02-24", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49567"}, "type": "Feature"}, {"geometry": {"coordinates": [116.389189, 39.764275], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "zhaoyl2855@126.com", "contactPhone": "+86 13681208998", "dateEnrollment": "2020-02-25", "description": "Randomized, parallel control, open trial for Qing-Wen Bai-Du-Yin combined with antiviral therapy in the treatment of novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030166", "primaryOutcome": "CT scan of the lungs;Nucleic acid detection of throat secretion;", "study_type": "Interventional study", "time": "2020-02-24", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49696"}, "type": "Feature"}, {"geometry": {"coordinates": [117.18523, 39.107429], "type": "Point"}, "properties": {"classification": "Other", "contactEmail": "ykb@tju.edu.cn", "contactPhone": "+86 22 58830026", "dateEnrollment": "2020-02-24", "description": "Clinical study for ozonated autohemotherapy in the treatment of Novel Coronavirus Pneumonia (COVID-19)", "name": "ChiCTR2000030165", "primaryOutcome": "Chest CT;Whole blood cell analysis;Recovery rate;Oxygenation index;Inflammatory response index;", "study_type": "Interventional study", "time": "2020-02-24", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49947"}, "type": "Feature"}, {"geometry": {"coordinates": [114.417893, 30.447842], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "you_shang@126.com", "contactPhone": "+86 15972127819", "dateEnrollment": "2020-02-24", "description": "A cross-sectional study of novel coronavirus pneumonia (COVID-19) patients in ICU", "name": "ChiCTR2000030164", "primaryOutcome": "the daily treatment intensity;", "study_type": "Observational study", "time": "2020-02-24", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49983"}, "type": "Feature"}, {"geometry": {"coordinates": [116.293653, 39.967509], "type": "Point"}, "properties": {"classification": "Advanced therapy medicinal products", "contactEmail": "boj301@sina.com", "contactPhone": "+86 13801257802", "dateEnrollment": "2020-02-24", "description": "Clinical Trial for Human Mesenchymal Stem Cells in the Treatment of Severe Novel Coronavirus Pneumonia (COVID-19)", "name": "ChiCTR2000030138", "primaryOutcome": "Clinical index;", "study_type": "Interventional study", "time": "2020-02-24", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50004"}, "type": "Feature"}, {"geometry": {"coordinates": [108.950405, 34.271425], "type": "Point"}, "properties": {"classification": "Impact on helpers", "contactEmail": "shpingg@126.com", "contactPhone": "+86 13709206398", "dateEnrollment": "2020-02-24", "description": "Humanistic Care in Healthcare Workers in Novel Coronavirus Pneumonia (COVID-19)", "name": "ChiCTR2000030137", "primaryOutcome": "Self-rating depression scale;", "study_type": "Observational study", "time": "2020-02-24", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50007"}, "type": "Feature"}, {"geometry": {"coordinates": [108.93496, 34.287861], "type": "Point"}, "properties": {"classification": "Impact on helpers", "contactEmail": "shpingg@126.com", "contactPhone": "+86 13709206398", "dateEnrollment": "2020-02-24", "description": "Humanistic Care in Patients With Novel Coronavirus Pneumonia (COVID-19)", "name": "ChiCTR2000030136", "primaryOutcome": "recovery time;", "study_type": "Interventional study", "time": "2020-02-24", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50005"}, "type": "Feature"}, {"geometry": {"coordinates": [114.04575, 22.544759], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "64699629@qq.com", "contactPhone": "+86 18664556429", "dateEnrollment": "2020-02-24", "description": "A clinical study for ''Huo-Shen'' particles in the treatment of novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030118", "primaryOutcome": "Chest CT scan;Nucleic acid of novel coronavirus;Routine blood test;Routine urine test;Stool routine test;", "study_type": "Interventional study", "time": "2020-02-23", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49594"}, "type": "Feature"}, {"geometry": {"coordinates": [116.54107, 39.842634], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "luhongzhou@shphc.org.cn", "contactPhone": "+86 21-37990333", "dateEnrollment": "2020-02-15", "description": "A multicenter, randomized, open, parallel controlled trial for the evaluation of the effectiveness and safety of Xiyanping injection in the treatment of common type novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030117", "primaryOutcome": "Clinical recovery time;", "study_type": "Interventional study", "time": "2020-02-23", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49762"}, "type": "Feature"}, {"geometry": {"coordinates": [115.3602, 27.7153], "type": "Point"}, "properties": {"classification": "Advanced therapy medicinal products", "contactEmail": "zhangweiliuxin@163.com", "contactPhone": "+86 13707089183", "dateEnrollment": "2020-02-01", "description": "Safety and effectiveness of human umbilical cord mesenchymal stem cells in the treatment of acute respiratory distress syndrome of severe novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030116", "primaryOutcome": "Time to leave ventilator on day 28 after receiving MSCs infusion;", "study_type": "Interventional study", "time": "2020-02-23", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49901"}, "type": "Feature"}, {"geometry": {"coordinates": [114.436641, 30.464912], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "lingqing1985@163.com", "contactPhone": "+86 15827257012", "dateEnrollment": "2020-02-27", "description": "A clinical research for the changes of Blood cortisol ACTH level and adrenal morphology in blood cortisol to guide the application of individualized hormone in severe novel coronavirus pneumonia (COVID-19) patients", "name": "ChiCTR2000030115", "primaryOutcome": "Cortisol;ACTH;Form of Adrenal tissue;", "study_type": "Observational study", "time": "2020-02-23", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49964"}, "type": "Feature"}, {"geometry": {"coordinates": [113.930539, 22.551224], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "yingxialiu@hotmail.com", "contactPhone": "+86 755 61238922", "dateEnrollment": "2020-02-22", "description": "Randomized controlled trial for safety and efficacy of Favipiravir in the treatment of novel coronavirus pneumonia (COVID-19) with poorly responsive ritonavir/ritonavir", "name": "ChiCTR2000030113", "primaryOutcome": "Blood routine tests, Liver function examination, Renal function examination, Blood gas analysis, Chest CT examination;", "study_type": "Interventional study", "time": "2020-02-23", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49988"}, "type": "Feature"}, {"geometry": {"coordinates": [117.291746, 38.99683], "type": "Point"}, "properties": {"classification": "Other", "contactEmail": "Tongxg@yahoo.com", "contactPhone": "+86 13820088121", "dateEnrollment": "2020-02-24", "description": "A multicenter randomized controlled trial for ozone autohemotherapy in the treatment of novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030102", "primaryOutcome": "Chest imaging;RNA test of COVID-19;Time to remission/disappearance of primary symptoms: defined as the number of days when the three main symptoms of fever, cough, and shortness of breath are all relieved / disappeared;Completely antipyretic time: completely antipyretic was defined as the body temperature return to normal for over 24 hours.;Blood oxygen saturation;Time to 2019-nCoV RT-PCR negativity: defined as the last test time for two consecutive negative respiratory viral nucleic acid tests (sampling interval of at least 1 day);Liver, renal  and heart  function;", "study_type": "Interventional study", "time": "2020-02-23", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49747"}, "type": "Feature"}, {"geometry": {"coordinates": [116.347211, 39.914978], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "zhaohong_pufh@bjmu.edu.cn", "contactPhone": "+86 13810765943", "dateEnrollment": "2020-02-17", "description": "Study for establishment of correlation between virological dynamics and clinical features in noveal coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030096", "primaryOutcome": "SARS-CoV2 Nucleic Acid Quantification;", "study_type": "Observational study", "time": "2020-02-23", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49794"}, "type": "Feature"}, {"geometry": {"coordinates": [104.114564, 30.615375], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "1924238034@qq.com", "contactPhone": "+86 18980880525", "dateEnrollment": "2020-03-01", "description": "Effects of novel coronavirus pneumonia (COVID-19) on menstruation, TCM body construction and psychological state for female at different ages", "name": "ChiCTR2000030094", "primaryOutcome": "menstruation changes;TCM body constitution score;", "study_type": "Observational study", "time": "2020-02-23", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49970"}, "type": "Feature"}, {"geometry": {"coordinates": [112.567202, 37.862844], "type": "Point"}, "properties": {"classification": "Impact on helpers", "contactEmail": "tflook@163.com", "contactPhone": "+86 13934570253", "dateEnrollment": "2020-03-01", "description": "Study for application of simplified cognitive-behavioral therapy for related emergency psychological stress reaction of medical providers working in the position of treatment and control of novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030093", "primaryOutcome": "State anxiety;", "study_type": "Interventional study", "time": "2020-02-23", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49932"}, "type": "Feature"}, {"geometry": {"coordinates": [114.417893, 30.447842], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "xiemx@hust.edu.cn", "contactPhone": "+86 13607108938", "dateEnrollment": "2020-02-12", "description": "Assessment of cardiac function in patients with Novel Coronavirus Pneumonia (COVID-19) by echocardiography and its new techniques", "name": "ChiCTR2000030092", "primaryOutcome": "M mode echocardiography;two-dimensional echocardiography;Doppler ultrasound;two-dimensional speckle tracking;three-dimensional echocardiography;", "study_type": "Observational study", "time": "2020-02-23", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49880"}, "type": "Feature"}, {"geometry": {"coordinates": [104.174977, 30.54307], "type": "Point"}, "properties": {"classification": "Other", "contactEmail": "luyibingli@163.com", "contactPhone": "+86 18328737998", "dateEnrollment": "2020-02-22", "description": "A Prospective Randomized Controlled Trial for Home Exercise Prescription Intervention During Epidemic of Novel Coronary Pneumonia (COVID-19) in College Students", "name": "ChiCTR2000030090", "primaryOutcome": "Mood index;", "study_type": "Interventional study", "time": "2020-02-22", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49910"}, "type": "Feature"}, {"geometry": {"coordinates": [121.581437, 31.121984], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "xuhuji@smmu.edu.cn", "contactPhone": "+86 13671609764", "dateEnrollment": "2020-02-28", "description": "A clinical study for the efficacy and safety of Adalimumab Injection in the treatment of patients with severe novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030089", "primaryOutcome": "TTCI (Time to Clinical Improvement);", "study_type": "Interventional study", "time": "2020-02-22", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49889"}, "type": "Feature"}, {"geometry": {"coordinates": [116.400499, 39.857844], "type": "Point"}, "properties": {"classification": "Advanced therapy medicinal products", "contactEmail": "lianru666@163.com", "contactPhone": "+86 18600310121", "dateEnrollment": "2020-03-01", "description": "Umbilical cord Wharton's Jelly derived mesenchymal stem cells in the treatment of severe novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030088", "primaryOutcome": "The nucleic acid of the novel coronavirus is negative;CT scan of ground glass shadow disappeared;", "study_type": "Interventional study", "time": "2020-02-22", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49902"}, "type": "Feature"}, {"geometry": {"coordinates": [114.436774, 30.464884], "type": "Point"}, "properties": {"classification": "Diagnosis", "contactEmail": "xiemx@hust.edu.cn", "contactPhone": "+86 13607108938", "dateEnrollment": "2020-02-12", "description": "Clinical study for the diagnostic value of pulmonary ultrasound for novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030087", "primaryOutcome": "Three-dimensional ultrasound;Two-dimensional ultrasound;Respiration related parameters;Doppler ultrasound;", "study_type": "Observational study", "time": "2020-02-22", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49919"}, "type": "Feature"}, {"geometry": {"coordinates": [114.436682, 30.464901], "type": "Point"}, "properties": {"classification": "Impact on helpers", "contactEmail": "xiangdongchen2013@163.com", "contactPhone": "+86 15071096621", "dateEnrollment": "2020-02-24", "description": "Study for the effects on medical providers' infection rate and mental health after performing different anesthesia schemes in cesarean section for novel coronavirus pneumonia (COVID-19) puerperae", "name": "ChiCTR2000030086", "primaryOutcome": "CT image of lung of close contact medical staff;Human body temperature of close contact medical staff;Anxiety Scale of of close contact medical staff;", "study_type": "Observational study", "time": "2020-02-22", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49934"}, "type": "Feature"}, {"geometry": {"coordinates": [112.673771, 37.752325], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "xuyongsmu@vip.163.com", "contactPhone": "+86 18234016125", "dateEnrollment": "2020-02-24", "description": "A multicenter study for efficacy of intelligent psychosomatic adjustment system intervention in the treatment of novel coronavirus pneumonia (COVID-19) patients with mild to moderate anxiety and depression", "name": "ChiCTR2000030084", "primaryOutcome": "the score of Hamilton depression scale;the score of Hamilton anxiety scale;the score of Self-Rating Depression Scale;the score of Self-Rating Anxiety Scale;the score of Athens Insomnia Scale;", "study_type": "Interventional study", "time": "2020-02-22", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49952"}, "type": "Feature"}, {"geometry": {"coordinates": [114.131616, 30.372484], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "hukejx@163.com", "contactPhone": "+86 18971035988", "dateEnrollment": "2020-03-10", "description": "A multicenter, randomized, double-blind, controlled clinical trial for leflunomide in the treatment of novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030058", "primaryOutcome": "The days from positive to negative for viral nucleic acid testing;", "study_type": "Interventional study", "time": "2020-02-22", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49831"}, "type": "Feature"}, {"geometry": {"coordinates": [114.436682, 30.464901], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "wqp1968@163.com", "contactPhone": "+86 13971605283", "dateEnrollment": "2020-02-23", "description": "Study for the effect of early endotracheal intubation on the outcome of novel coronavirus pneumonia (COVID-19) patients", "name": "ChiCTR2000030056", "primaryOutcome": "ICU hospitalization days;Death rate;", "study_type": "Observational study", "time": "2020-02-22", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49904"}, "type": "Feature"}, {"geometry": {"coordinates": [118.103838, 24.48995], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "Yinzy@xmu.edu.cn", "contactPhone": "+86 13950120518", "dateEnrollment": "2020-02-22", "description": "A prospective, open label, randomized, control trial for chloroquine or hydroxychloroquine in patients with mild and common novel coronavirus pulmonary (COVIP-19)", "name": "ChiCTR2000030054", "primaryOutcome": "Clinical recovery time;", "study_type": "Interventional study", "time": "2020-02-22", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49869"}, "type": "Feature"}, {"geometry": {"coordinates": [114.345292, 30.554816], "type": "Point"}, "properties": {"classification": "Advanced therapy medicinal products", "contactEmail": "liubende99@outlook.com", "contactPhone": "+86 13907191851", "dateEnrollment": "2020-02-07", "description": "A single arm trial to evaluate the efficacy and safety of anti-2019-nCoV inactivated convalescent plasma in the treatment of novel coronavirus pneumonia patient (COVID-19)", "name": "ChiCTR2000030046", "primaryOutcome": "The changes of clinical symptom, laboratory and radiological data ;Oxyhemoglobin saturation.;dyspnea;Body temperature;Radiological characteristic sign;Blood routine;C-reaction protein;lymphocyte count;Liver function: TBIL(total bilirubin), AST(alanine aminotransferase) and ALT(aspartate aminotransferase);Neutralization antibody level;", "study_type": "Interventional study", "time": "2020-02-21", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49861"}, "type": "Feature"}, {"geometry": {"coordinates": [116.415415, 39.874365], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "mapenglin1@163.com", "contactPhone": "+86 13810339898", "dateEnrollment": "2020-02-21", "description": "Shen-Fu injection in the treatment of severe novel coronavirus pneumonia (COVID-19): a multicenter, randomized, open-label, controlled trial", "name": "ChiCTR2000030043", "primaryOutcome": "pneumonia severity index (PSI);Incidence of new organ dysfunction;", "study_type": "Interventional study", "time": "2020-02-21", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49866"}, "type": "Feature"}, {"geometry": {"coordinates": [114.330247, 30.57199], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "chzs1990@163.com", "contactPhone": "+86 02767812787", "dateEnrollment": "2020-02-25", "description": "A single-arm, single-center clinical trial for Azivudine tablets in the treatment of adult novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030041", "primaryOutcome": "The novel coronavirus nucleic acid negative rate;", "study_type": "Interventional study", "time": "2020-02-21", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49891"}, "type": "Feature"}, {"geometry": {"coordinates": [116.431005, 33.949705], "type": "Point"}, "properties": {"classification": "Advanced therapy medicinal products", "contactEmail": "yxbxuzhou@126.com", "contactPhone": "+86 15205215685", "dateEnrollment": "2020-05-31", "description": "Clinical study for infusing convalescent plasma to treat patients with new coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030039", "primaryOutcome": "SARS-CoV-2 DNA;SARS-CoV-2  antibody levels;thoracic spiral CT;", "study_type": "Interventional study", "time": "2020-02-21", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49544"}, "type": "Feature"}, {"geometry": {"coordinates": [120.118875, 30.241645], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "ckqmzygzs@163.com", "contactPhone": "+86 13906503739", "dateEnrollment": "2020-02-07", "description": "Traditional Chinese Medicine in the treatment of novel coronavirus pneumonia (COVID-19): a multicentre, randomized controlled trial", "name": "ChiCTR2000030034", "primaryOutcome": "Body temperature;TCM syndrome integral;Murray lung injury score;The transition time of novel coronavirus nucleic acid;MuLBSTA score;", "study_type": "Interventional study", "time": "2020-02-21", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49647"}, "type": "Feature"}, {"geometry": {"coordinates": [113.304482, 23.036874], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "412475734@qq.com", "contactPhone": "+86 13710801606", "dateEnrollment": "2020-02-24", "description": "A study for the intervention of Xiangxue antiviral oral solution and Wu-Zhi-Fang-Guan-Fang on close contacts of novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030033", "primaryOutcome": "Proportion of COVID-19 close contacts who have developed as confirmed cases;", "study_type": "Interventional study", "time": "2020-02-21", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49703"}, "type": "Feature"}, {"geometry": {"coordinates": [108.630496, 34.040526], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "huang-yi-1980@163.com", "contactPhone": "+86 13319184133", "dateEnrollment": "2020-02-10", "description": "Study on ultrasonographic manifestations of new type of novel coronavirus pneumonia (covid-19) in non-critical stage of pulmonary lesions", "name": "ChiCTR2000030032", "primaryOutcome": "Distribution of 'B' line around lungs of both lungs;Whether there is peripulmonary focus;", "study_type": "Observational study", "time": "2020-02-21", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49816"}, "type": "Feature"}, {"geometry": {"coordinates": [114.583872, 30.596762], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "xugang@tjh.tjmu.edu.cn", "contactPhone": "+86 13507181312", "dateEnrollment": "2020-02-20", "description": "A medical records based study for acute kidney injury in novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030030", "primaryOutcome": "Acute kidney injury;", "study_type": "Observational study", "time": "2020-02-20", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49841"}, "type": "Feature"}, {"geometry": {"coordinates": [120.269385, 30.182118], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "stjz@zju.edu.cn", "contactPhone": "13957111817", "dateEnrollment": "2020-02-20", "description": "A multi-center study on the efficacy and safety of suramin sodium in adult patients with novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030029", "primaryOutcome": "clinical cure rate;Incidence of mechanical ventilation by day28;All-cause mortality by day28;Incidence of ICU admission by day28;", "study_type": "Interventional study", "time": "2020-02-21", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49824"}, "type": "Feature"}, {"geometry": {"coordinates": [116.402943, 39.949151], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "ysz3129@163.com", "contactPhone": "+86 18610329658", "dateEnrollment": "2020-02-20", "description": "Traditional Chinese medicine cooperative therapy for patients with Novel coronavirus pneumonia (COVID-19) and its effect on spermatogenesis: a randomized controlled trial", "name": "ChiCTR2000030027", "primaryOutcome": "Release rate of discharge standards for isolation;Change in Critical Illness;Traditional Chinese medicine syndrome score;", "study_type": "Interventional study", "time": "2020-02-20", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49852"}, "type": "Feature"}, {"geometry": {"coordinates": [114.583872, 30.596762], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "minzhou@tjh.tjmu.edu.cn", "contactPhone": "+86 15002749377", "dateEnrollment": "2020-02-20", "description": "A medical records based analysis for the clinical characteristics of novel coronavirus pneumonia (COVID-19) in immunocompromised patients", "name": "ChiCTR2000030021", "primaryOutcome": "Clinical characteristics;", "study_type": "Observational study", "time": "2020-02-20", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49690"}, "type": "Feature"}, {"geometry": {"coordinates": [112.584781, 26.896463], "type": "Point"}, "properties": {"classification": "Advanced therapy medicinal products", "contactEmail": "706885399@qq.com", "contactPhone": "+86 13907342350", "dateEnrollment": "2020-02-06", "description": "The clinical application and basic research related to mesenchymal stem cells to treat novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030020", "primaryOutcome": "Coronavirus nucleic acid markers negative rate;Symptoms improved after 4 treatments;Inflammation (CT of the chest);", "study_type": "Interventional study", "time": "2020-02-20", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49812"}, "type": "Feature"}, {"geometry": {"coordinates": [121.536888, 31.076984], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "bai.chunxue@zs-hospital.sh.cn", "contactPhone": "+86 18621170011", "dateEnrollment": "2020-02-28", "description": "The COVID-19 Mobile Health Study (CMHS), a large-scale clinical observational registration study using nCapp", "name": "ChiCTR2000030019", "primaryOutcome": "Accuracy;", "study_type": "Observational study", "time": "2020-02-20", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49768"}, "type": "Feature"}, {"geometry": {"coordinates": [114.331215, 30.573185], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "qingzhou.wh.edu@hotmail.com", "contactPhone": "+86 13971358226", "dateEnrollment": "2020-02-17", "description": "Feature of Multiple Organs in Ultrasound Investigation for Clinical Management and Prognostic Evaluation of Novel Coronavirus Pneumonia (COVID-19)", "name": "ChiCTR2000030017", "primaryOutcome": "Death;Recovered;Discharged;", "study_type": "Observational study", "time": "2020-02-20", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49798"}, "type": "Feature"}, {"geometry": {"coordinates": [108.316216, 22.81669], "type": "Point"}, "properties": {"classification": "Other", "contactEmail": "2534776680@qq.com", "contactPhone": "+86 13807887867", "dateEnrollment": "2020-02-04", "description": "Basic and clinical study of inhalation of inactivated mycobacterium vaccine in the treatment of Novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030016", "primaryOutcome": "viral negative-transforming time;30-day cause-specific mortality;30-day cause-adverse events;30-day all-cause mortality;co-infections;Time from severe and critical patients to clinical improvement;Others (liver function, kidney function, myocardial enzyme);", "study_type": "Interventional study", "time": "2020-02-19", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49799"}, "type": "Feature"}, {"geometry": {"coordinates": [114.436641, 30.464912], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "sxwang@tjh.tjmu.edu.cn", "contactPhone": "+86 027-83663078", "dateEnrollment": "2020-02-19", "description": "Study for the correlation between the incidence and outcome of novel coronary pneumonia (COVID-2019) and ovarian function in women", "name": "ChiCTR2000030015", "primaryOutcome": "menstruation changes;", "study_type": "Basic Science", "time": "2020-02-20", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49800"}, "type": "Feature"}, {"geometry": {"coordinates": [112.590446, 26.89909], "type": "Point"}, "properties": {"classification": "Advanced therapy medicinal products", "contactEmail": "quxiaowang@163.com", "contactPhone": "+86 15526272595", "dateEnrollment": "2020-02-19", "description": "Development of anti-2019-nCoV therapeutic antibody from the recovered novel coronavirus pneumonia patients (COVID-19)", "name": "ChiCTR2000030012", "primaryOutcome": "NA;", "study_type": "Treatment study", "time": "2020-02-19", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49718"}, "type": "Feature"}, {"geometry": {"coordinates": [114.116215, 30.633456], "type": "Point"}, "properties": {"classification": "Advanced therapy medicinal products", "contactEmail": "1813886398@qq.com", "contactPhone": "+86 13507117929", "dateEnrollment": "2020-02-19", "description": "A randomized, double-blind, parallel-controlled, trial to evaluate the efficacy and safety of anti-SARS-CoV-2 virus inactivated plasma in the treatment of severe novel coronavirus pneumonia patients (COVID-19)", "name": "ChiCTR2000030010", "primaryOutcome": "Improvement of clinical symptoms (Clinical improvement is defined as a reduction of 2 points on the 6-point scale of the patient's admission status or discharge from the hospital);", "study_type": "Interventional study", "time": "2020-02-19", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49777"}, "type": "Feature"}, {"geometry": {"coordinates": [113.591279, 22.313912], "type": "Point"}, "properties": {"classification": "Impact on helpers", "contactEmail": "liujing25@mail.sysu.edu.cn", "contactPhone": "+86 13844021812", "dateEnrollment": "2020-02-12", "description": "Correalation between anxiety as well as depression and gut microbiome among staff of hospital during the novel coronavirus pneumonia (COVID-19) outbreak", "name": "ChiCTR2000030008", "primaryOutcome": "psychological scale;Intestinal flora abundance, etc;Upper respiratory flora abundance, etc;", "study_type": "Observational study", "time": "2020-02-19", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49426"}, "type": "Feature"}, {"geometry": {"coordinates": [113.411051, 22.926355], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "linling@gird.cn", "contactPhone": "+86 13902233092", "dateEnrollment": "2020-02-03", "description": "Multicenter randomized controlled trial for rhG-CSF in the treatment of novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030007", "primaryOutcome": "Clinical symptoms;Blood routine;the viral load of 2019-nCOV of throat swab;TBNK cell subsets;TH1/TH2 Cytokine;Chest CT;", "study_type": "Interventional study", "time": "2020-02-19", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49619"}, "type": "Feature"}, {"geometry": {"coordinates": [114.436774, 30.464884], "type": "Point"}, "properties": {"classification": "Other", "contactEmail": "xiangdongchen2013@163.com", "contactPhone": "+86 15071096621", "dateEnrollment": "2020-02-19", "description": "A randomized controlled trial for the efficacy of ozonated autohemotherapy in the treatment of Novel Coronavirus Pneumonia (COVID-19)", "name": "ChiCTR2000030006", "primaryOutcome": "Recovery rate;", "study_type": "Interventional study", "time": "2020-02-19", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49737"}, "type": "Feature"}, {"geometry": {"coordinates": [106.723234, 33.039475], "type": "Point"}, "properties": {"classification": "Impact on helpers", "contactEmail": "xuntao26@hotmail.com", "contactPhone": "+86 18980601817", "dateEnrollment": "2020-02-20", "description": "Effect of Novel Coronavirus Pneumonia (COVID-19) on the Mental Health of College Students", "name": "ChiCTR2000030004", "primaryOutcome": "Mental health status;", "study_type": "Observational study", "time": "2020-02-19", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49783"}, "type": "Feature"}, {"geometry": {"coordinates": [104.03945, 30.742342], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "tangjianyuan163@163.com", "contactPhone": "+86 13910768464", "dateEnrollment": "2020-02-19", "description": "Optimization Protocal of Integrated Traditional Chinese and Western Medicine in the Treatment for Novel Coronavirus Pneumonia (COVID-19)", "name": "ChiCTR2000030003", "primaryOutcome": "hospital stay;Discharge rate;Site-specific hospital metastasis rate or severe conversion rate;Body temperature normalization time;Clinical symptoms disappearance rate;", "study_type": "Interventional study", "time": "2020-02-19", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49770"}, "type": "Feature"}, {"geometry": {"coordinates": [115.518485, 30.544766], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "44271370@qq.com", "contactPhone": "+86 15956927046", "dateEnrollment": "2020-02-15", "description": "Clinical study of novel NLRP Inflammasome inhibitor (Tranilast) in the treatment of novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030002", "primaryOutcome": "cure rate;", "study_type": "Interventional study", "time": "2020-02-19", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49738"}, "type": "Feature"}, {"geometry": {"coordinates": [126.624467, 45.747647], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "yangbf@ems.hrbmu.edu.cn", "contactPhone": "+86 133 0451 2381", "dateEnrollment": "2020-02-15", "description": "The efficacy and safety of Triazavirin for 2019 novel coronary pneumonia (COVID-19): a multicenter, randomized, double blinded, placebo-controlled trial", "name": "ChiCTR2000030001", "primaryOutcome": "Time to Clinical recovery;", "study_type": "Interventional study", "time": "2020-02-19", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49723"}, "type": "Feature"}, {"geometry": {"coordinates": [116.007228, 28.566623], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "Chenhongyi8660@163.com", "contactPhone": "+86 13807088660", "dateEnrollment": "2020-02-16", "description": "An open, controlled clinical trial for evaluation of ganovo combined with ritonavir and integrated traditional Chinese and Western medicine in the treatment of novel coronavirus infection (COVID-19)", "name": "ChiCTR2000030000", "primaryOutcome": "Rate of composite advers outcomes:SpO2,PaO2/FiO2, respiratory rate;", "study_type": "Interventional study", "time": "2020-02-19", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49748"}, "type": "Feature"}, {"geometry": {"coordinates": [121.500256, 31.26115], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "18917683122@189.cn", "contactPhone": "+86 18917683122", "dateEnrollment": "2020-02-20", "description": "A clinical study for probiotics in the regulation of intestinal function and microflora structure of novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000029999", "primaryOutcome": "gut microbiome;Fecal metabolomics;Blood routine;albumin;serum potassium;CRP;ALT;AST;urea;Cr;urea nitrogen;D-Dimer;ESR;IgG;IgM;IgA;hepatitis B surface antigen;ß2-microglobulin;IFN-gama;IL-6;TNF-beta;IL-10;IL-2;IL-4;IL-13;IL-12;chest CT;abdominal CT;ECG;Weight;height;body temperature;respiratory rate;Heart Rate;Blood Pressure;Defecate frequency;Bristol grading;", "study_type": "Interventional study", "time": "2020-02-19", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49717"}, "type": "Feature"}, {"geometry": {"coordinates": [116.453539, 39.911452], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "13910930309@163.com", "contactPhone": "+86 13910930309", "dateEnrollment": "2020-02-20", "description": "A randomized, open-label, controlled trial for the efficacy and safety of Farpiravir Tablets in the treatment of patients with novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000029996", "primaryOutcome": "Time to Clinical Recovery;", "study_type": "Interventional study", "time": "2020-02-20", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49510"}, "type": "Feature"}, {"geometry": {"coordinates": [121.338171, 31.088858], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "jhong.pku@163.com", "contactPhone": "+86 15301655562", "dateEnrollment": "2020-02-20", "description": "Study on anxiety of different populations under novel coronavirus (COVID-19) infection", "name": "ChiCTR2000029995", "primaryOutcome": "Self-Rating Anxiety Scale;Self-Rating Depression Scale;Posttraumatic stress disorder checklist,;Questionnaire for Simple Responses;", "study_type": "Observational study", "time": "2020-02-19", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49418"}, "type": "Feature"}, {"geometry": {"coordinates": [121.835116, 31.051518], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "fanglei586@126.com", "contactPhone": "+86 021-51323092", "dateEnrollment": "2020-02-19", "description": "Liu-Zi-Jue Qigong and Acupressure Therapy for Pulmonary Function and Quality of Life in Patient with Severe novel coronavirus pneumonia (COVID-19): A Randomized Controlled Trial", "name": "ChiCTR2000029994", "primaryOutcome": "lung function;ADL;6min walk;", "study_type": "Interventional study", "time": "2020-02-18", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49309"}, "type": "Feature"}, {"geometry": {"coordinates": [118.210397, 24.37942], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "Yinzy@xmu.edu.cn", "contactPhone": "+86 13950120518", "dateEnrollment": "2020-02-17", "description": "A prospective, randomized, open label, controlled trial for chloroquine and hydroxychloroquine in patients with severe novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000029992", "primaryOutcome": "Clinical recovery time;Clinical recovery time;Changes in viral load of upper and lower respiratory tract samples compared with the baseline;", "study_type": "Interventional study", "time": "2020-02-18", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49574"}, "type": "Feature"}, {"geometry": {"coordinates": [116.422301, 39.908804], "type": "Point"}, "properties": {"classification": "Advanced therapy medicinal products", "contactEmail": "zhaochunhua@vip.163.com", "contactPhone": "+86 010-65125311", "dateEnrollment": "2020-01-30", "description": "Clinical trials of mesenchymal stem cells for the treatment of pneumonitis caused by novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000029990", "primaryOutcome": "Improved respiratory system function (blood oxygen saturation) recovery time;", "study_type": "Interventional study", "time": "2020-02-18", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49674"}, "type": "Feature"}, {"geometry": {"coordinates": [116.401667, 39.88862], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "fengcao8828@163.com", "contactPhone": "+86 13911798280", "dateEnrollment": "2020-02-20", "description": "A randomized controlled Trial for therapeutic efficacy of Recombinant Human Interferon alpha 1b Eye Drops in the treatment of elderly with novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000029989", "primaryOutcome": "Arterial Blood Oxygen Saturation;TTCR,Time to Clinical recovery;temperature;respiratory rate;Lung CT;", "study_type": "Interventional study", "time": "2020-02-18", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49720"}, "type": "Feature"}, {"geometry": {"coordinates": [114.330247, 30.57199], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "doctoryanzhao@whu.edu.cn", "contactPhone": "+86 13995577963", "dateEnrollment": "2020-02-13", "description": "Clinical Study of Chloroquine Phosphate in the Treatment of Severe Novel Coronavirus Pneumonia (COVID-19)", "name": "ChiCTR2000029988", "primaryOutcome": "Time to Clinical Recovery;", "study_type": "Interventional study", "time": "2020-02-18", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49218"}, "type": "Feature"}, {"geometry": {"coordinates": [104.18988, 30.559594], "type": "Point"}, "properties": {"classification": "Impact on helpers", "contactEmail": "8999578@qq.com", "contactPhone": "+86 13699093647", "dateEnrollment": "2020-02-10", "description": "Study for mental health status and influencing factors of nurses during epidemic prevention of novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000029985", "primaryOutcome": "HSCS;SCSQ;GHQ-12;", "study_type": "Observational study", "time": "2020-02-18", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49711"}, "type": "Feature"}, {"geometry": {"coordinates": [114.436641, 30.464912], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "sxwang@tjh.tjmu.edu.cn", "contactPhone": "+86 02783663078", "dateEnrollment": "2020-02-18", "description": "Study for nucleic acid detection of novel coronavirus pneumonia (COVID-2019) in female vaginal secretions", "name": "ChiCTR2000029981", "primaryOutcome": "SARS-COV-2 nucleic acid;SEN, SPE, ACC, AUC of ROC;", "study_type": "Diagnostic test", "time": "2020-02-18", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49692"}, "type": "Feature"}, {"geometry": {"coordinates": [121.486092, 31.279422], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "fangmin19650510@163.com", "contactPhone": "+86 18930568005", "dateEnrollment": "2020-02-21", "description": "A randomized controlled trial for the efficacy of Dao-Yin in the prevention and controlling novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000029978", "primaryOutcome": "Length of hospital stay;", "study_type": "Interventional study", "time": "2020-02-18", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49702"}, "type": "Feature"}, {"geometry": {"coordinates": [120.20694, 36.0375], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "dl5506@126.com", "contactPhone": "+86 18560082787", "dateEnrollment": "2020-02-09", "description": "A prospective, multicenter, open-label, randomized, parallel-controlled trial for probiotics to evaluate efficacy and safety in patients infected with 2019 novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000029974", "primaryOutcome": "Time to Clinical recovery;Butyrate in feces;", "study_type": "Interventional study", "time": "2020-02-18", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49321"}, "type": "Feature"}, {"geometry": {"coordinates": [114.583872, 30.596762], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "chenhong1129@hotmail.com", "contactPhone": "+86 13296508243", "dateEnrollment": "2020-02-17", "description": "A randomized controlled trial for the Efficacy of Ultra Short Wave Electrotherapy in the treatment of Novel Coronavirus Pneumonia (COVID-19)", "name": "ChiCTR2000029972", "primaryOutcome": "the rate of Coronary virus nucleic acid negative at 7 days, 14 days, 21 days, and 28 days after Ultra Short Wave Electrotherapy;Symptom recovery at 7 days, 14 days, 21 days, and 28 days after Ultra Short Wave Electrotherapy;", "study_type": "Interventional study", "time": "2020-02-17", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49664"}, "type": "Feature"}, {"geometry": {"coordinates": [103.10988, 26.96854], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "chenxinyuchen@163.com", "contactPhone": "+86 13807312410", "dateEnrollment": "2020-02-28", "description": "Comparative study for integrate Chinese and conventional medicine the the treatment of novel coronavirus pneumonia (COVID-19) in Hu'nan province", "name": "ChiCTR2000029960", "primaryOutcome": "TCM syndrome;", "study_type": "Interventional study", "time": "2020-02-17", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49639"}, "type": "Feature"}, {"geometry": {"coordinates": [104.176098, 30.573785], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "tj1234753@sina.com", "contactPhone": "+86 18180609287", "dateEnrollment": "2020-01-25", "description": "Clinical observation and research of  Severe acute respiratory syndrome coronavirus 2(COVID-19) infection in perinatal newborns", "name": "ChiCTR2000029959", "primaryOutcome": "CoVID-19 Perinatal Outcomes;", "study_type": "Observational study", "time": "2020-02-17", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49636"}, "type": "Feature"}, {"geometry": {"coordinates": [104.03945, 30.742342], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "tangjianyuan163@163.com", "contactPhone": "+86 13910768464", "dateEnrollment": "2020-02-18", "description": "Chinese Medicine Promotes Rehabilitation Recommendations after 2019 Novel Coronavirus Infection (COVID-19)", "name": "ChiCTR2000029956", "primaryOutcome": "Quality of life;Anxiety assessment;Depression assessment;Major symptoms improved;", "study_type": "Interventional study", "time": "2020-02-17", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49618"}, "type": "Feature"}, {"geometry": {"coordinates": [114.417554, 30.5567], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "153267742@qq.com", "contactPhone": "+86 18971163518", "dateEnrollment": "2020-04-30", "description": "Efficacy and safety of honeysuckle oral liquid in the treatment of novel coronavirus pneumonia (COVID-19): a multicenter, randomized, controlled, open clinical trial", "name": "ChiCTR2000029954", "primaryOutcome": "Recovery time;Pneumonia psi score;", "study_type": "Interventional study", "time": "2020-02-17", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49402"}, "type": "Feature"}, {"geometry": {"coordinates": [121.357174, 28.546326], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "lvdq@enzemed.com", "contactPhone": "+86 13867622009", "dateEnrollment": "2020-02-17", "description": "Early warning prediction of patients with severe novel coronavirus pneumonia (COVID-19) based on multiomics", "name": "ChiCTR2000029866", "primaryOutcome": "Cytokine detection;Lymphocyte subpopulation analysis ;SEN, SPE, ACC, AUC of ROC;", "study_type": "Diagnostic test", "time": "2020-02-15", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49519"}, "type": "Feature"}, {"geometry": {"coordinates": [114.436774, 30.464884], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "am-penicillin@163.com", "contactPhone": "+86 13886157176", "dateEnrollment": "2020-02-20", "description": "Descriptive study on the clinical characteristics and outcomes of novel coronavirus pneumonia (COVID-19) in cardiovascular patients", "name": "ChiCTR2000029865", "primaryOutcome": "blood cell count;C-reactive protein (CRP);arterial blood-gas analysis;markers of myocardial injury;coagulation profile;serum biochemical test;brain natriuretic peptide(BNP);blood lipid;fibrinogen(FIB), D-Dimer.;", "study_type": "Observational study", "time": "2020-02-15", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49545"}, "type": "Feature"}, {"geometry": {"coordinates": [121.521443, 31.09342], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "jbge@zs-hospital.sh.cn", "contactPhone": "+86-21-64041990", "dateEnrollment": "2020-02-19", "description": "A multicenter, randomized controlled trial for the efficacy and safety of Alpha lipoic acid (iv) in the treatment of patients of severe novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000029851", "primaryOutcome": "SOFA;", "study_type": "Interventional study", "time": "2020-02-15", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49534"}, "type": "Feature"}, {"geometry": {"coordinates": [114.131616, 30.372484], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "doctorzhang2003@163.com", "contactPhone": "+86 18062567610", "dateEnrollment": "2020-02-20", "description": "A prospective, randomized, open-label, controlled clinical study to evaluate the preventive effect of hydroxychloroquine on close contacts after exposure to the Novel Coronavirus Pneumonia (COVID-19)", "name": "ChiCTR2000029803", "primaryOutcome": "Number of patients who have progressed to suspected or confirmed within 24 days of exposure to new coronavirus;", "study_type": "Interventional study", "time": "2020-02-14", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49428"}, "type": "Feature"}, {"geometry": {"coordinates": [114.436674, 30.464892], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "Xin11@hotmail.com", "contactPhone": "+86 18602724981", "dateEnrollment": "2020-02-14", "description": "A multicenter, randomized, open and controlled trial for the efficacy and safety of Kang-Bing-Du granules in the treatment of novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000029781", "primaryOutcome": "Disappearance rate of fever symptoms;", "study_type": "Interventional study", "time": "2020-02-13", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49138"}, "type": "Feature"}, {"geometry": {"coordinates": [114.436774, 30.464884], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "Xin11@hotmail.com", "contactPhone": "+86 18602724981", "dateEnrollment": "2020-02-14", "description": "A multicenter, randomized, open, controlled trial for the efficacy and safety of Shen-Qi Fu-Zheng injection in the treatment of novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000029780", "primaryOutcome": "Recovery time;", "study_type": "Interventional study", "time": "2020-02-13", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49220"}, "type": "Feature"}, {"geometry": {"coordinates": [116.373663, 39.926388], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "zhuoli.zhang@126.com", "contactPhone": "+86 13901094780", "dateEnrollment": "2020-02-11", "description": "Efficacy of therapeutic effects of hydroxycholoroquine in novel coronavirus pneumonia (COVID-19) patients(randomized open-label control clinical trial)", "name": "ChiCTR2000029740", "primaryOutcome": "oxygen index;max respiratory rate;lung radiography;count of lymphocyte;temperature;other infection;time when the nuleic acid of the novel coronavirus turns negative;prognosis;", "study_type": "Interventional study", "time": "2020-02-11", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49317"}, "type": "Feature"}, {"geometry": {"coordinates": [116.355068, 39.913123], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": ";;;xubaopingbch@163.com;", "contactPhone": ";;;861059616308;", "dateEnrollment": "February 15, 2020", "description": "Clinical Characteristics and Long-term Prognosis of 2019-nCoV Infection in Children", "name": "NCT04270383", "primaryOutcome": "The cure rate of 2019-nCoV.;The improvement rate of 2019-nCoV.;The incidence of long-term adverse outcomes.", "study_type": "Observational", "time": "2020-02-11", "weburl": "https://clinicaltrials.gov/show/NCT04270383"}, "type": "Feature"}, {"geometry": {"coordinates": [120.680453, 27.956226], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": ";xiajinglin@fudan.edu.cn", "contactPhone": ";0577-55578166", "dateEnrollment": "February 20, 2020", "description": "The Efficacy and Safety of Thalidomide in the Adjuvant Treatment of Moderate New Coronavirus (COVID-19) Pneumonia", "name": "NCT04273529", "primaryOutcome": "Time to Clinical recoveryTime to Clinical Recovery (TTCR)", "study_type": "Interventional", "time": "2020-02-14", "weburl": "https://clinicaltrials.gov/show/NCT04273529"}, "type": "Feature"}, {"geometry": {"coordinates": [120.680453, 27.956226], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": ";xiajinglin@fudan.edu.cn", "contactPhone": ";0577-55578166", "dateEnrollment": "February 18, 2020", "description": "The Efficacy and Safety of Thalidomide Combined With Low-dose Hormones in the Treatment of Severe COVID-19", "name": "NCT04273581", "primaryOutcome": "Time to Clinical Improvement (TTCI)", "study_type": "Interventional", "time": "2020-02-14", "weburl": "https://clinicaltrials.gov/show/NCT04273581"}, "type": "Feature"}, {"geometry": {"coordinates": [109.062083, 34.287357], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "liangjq@fmmu.edu.cn;", "contactPhone": "+86-13571892829;+86-029-84777631", "dateEnrollment": "February 3, 2020", "description": "Clinical Study of Anti-CD147 Humanized Meplazumab for Injection to Treat With 2019-nCoV Pneumonia", "name": "NCT04275245", "primaryOutcome": "2019 nCoV nucleic acid detection", "study_type": "Interventional", "time": "2020-02-06", "weburl": "https://clinicaltrials.gov/show/NCT04275245"}, "type": "Feature"}, {"geometry": {"coordinates": [114.299536, 36.001485], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": ";bai.chunxue@zs-hospital.sh.cn;", "contactPhone": ";+8618621170011?;", "dateEnrollment": "February 14, 2020", "description": "The COVID-19 Mobile Health Study (CMHS)", "name": "NCT04275947", "primaryOutcome": "Accuracy of nCapp COVID-19 risk diagnostic model", "study_type": "Observational", "time": "2020-02-17", "weburl": "https://clinicaltrials.gov/show/NCT04275947"}, "type": "Feature"}, {"geometry": {"coordinates": [121.478669, 31.223211], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "chenghailiu@hotmail.com;", "contactPhone": "8621-20256521;", "dateEnrollment": "February 15, 2020", "description": "Treatment of Pulmonary Fibrosis Due to 2019-nCoV Pneumonia With Fuzheng Huayu", "name": "NCT04279197", "primaryOutcome": "High-resolution computed tomography (HRCT) score;Lung function including FVC, FVC as a percentage of projected value and DLco", "study_type": "Interventional", "time": "2020-02-15", "weburl": "https://clinicaltrials.gov/show/NCT04279197"}, "type": "Feature"}, {"geometry": {"coordinates": [113.341284, 23.135415], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": ";xwx1983@163.com;pzp33@hotmail.com", "contactPhone": ";+8613760783281;+8613533978874", "dateEnrollment": "January 20, 2020", "description": "Clinical Features of Suspected and Confirmed Patients of 2019 Novel Coronavirus Infection", "name": "NCT04279782", "primaryOutcome": "Survival rate", "study_type": "Observational", "time": "2020-02-15", "weburl": "https://clinicaltrials.gov/show/NCT04279782"}, "type": "Feature"}, {"geometry": {"coordinates": [113.325839, 23.151851], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": ";xwx1983@163.com;pzp33@hotmail.com", "contactPhone": ";+8613760783281;+8613533978874", "dateEnrollment": "January 20, 2020", "description": "Detection of 2019 Novel Coronavirus in Multiple Organ System and Its Relationship With Clinical Manifestations", "name": "NCT04279795", "primaryOutcome": "Positive rate of 2019 Novel Coronavirus RNA", "study_type": "Observational", "time": "2020-02-19", "weburl": "https://clinicaltrials.gov/show/NCT04279795"}, "type": "Feature"}, {"geometry": {"coordinates": [121.395286, 31.139514], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "", "contactPhone": "", "dateEnrollment": "February 1, 2020", "description": "The Investigation of the Neonates With or With Risk of COVID-19", "name": "NCT04279899", "primaryOutcome": "The death of newborns with COVID-19;The SARS-CoV-2 infection of neonates born to mothers with COVID-19", "study_type": "Observational", "time": "2020-02-18", "weburl": "https://clinicaltrials.gov/show/NCT04279899"}, "type": "Feature"}, {"geometry": {"coordinates": [119.301965, 26.069742], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "fuying1995@163.com;wanjinchen75@fjmu.edu.cn", "contactPhone": "+86;+1386061359", "dateEnrollment": "February 22, 2020", "description": "Fingolimod in COVID-19", "name": "NCT04280588", "primaryOutcome": "The change of pneumonia severity on X-ray images", "study_type": "Interventional", "time": "2020-02-20", "weburl": "https://clinicaltrials.gov/show/NCT04280588"}, "type": "Feature"}, {"geometry": {"coordinates": [108.93496, 34.287861], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "maxr0910@163.com", "contactPhone": "+86 13992856156", "dateEnrollment": "2020-03-05", "description": "Combination of Tocilizumab, IVIG and CRRT in severe patients with novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030442", "primaryOutcome": "Inhospital time;", "study_type": "Interventional study", "time": "2020-03-02", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50380"}, "type": "Feature"}, {"geometry": {"coordinates": [119.88632, 26.70753], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "nijun1000@126.com", "contactPhone": "+86 19890572216", "dateEnrollment": "2020-03-01", "description": "Application of Rehabilitation and Lung Eight-segment Exercise in Home Rehabilitation of Survivors from novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030433", "primaryOutcome": "PCL;HRQL;IPAQ;PASE;", "study_type": "Interventional study", "time": "2020-03-01", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50273"}, "type": "Feature"}, {"geometry": {"coordinates": [119.870875, 26.723966], "type": "Point"}, "properties": {"classification": "Impact on helpers", "contactEmail": "nplrj@126.com", "contactPhone": "+86 13809508580", "dateEnrollment": "2020-03-02", "description": "Application of rehabilitation and Lung eight-segment exercise in front-line nurses in the prevention of novel coronavirus pneumonia (COVID-19) epidemic", "name": "ChiCTR2000030432", "primaryOutcome": "PCL;PSQI;FSI;", "study_type": "Interventional study", "time": "2020-03-01", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50268"}, "type": "Feature"}, {"geometry": {"coordinates": [118.768178, 24.952704], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "guyuesunny@163.com", "contactPhone": "+86 15037167775", "dateEnrollment": "2020-03-02", "description": "A single-center, single-arm clinical trial for azvudine in the treatment of novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030424", "primaryOutcome": "Sputum/nasal swab/pharyngeal swab/lower respiratory tract secretions were used to detect the negative conversion rate of the new coronavirus nucleic acid (tested daily after two days starting the azvudine tablets) and the negative conversion time.;", "study_type": "Interventional study", "time": "2020-03-01", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50174"}, "type": "Feature"}, {"geometry": {"coordinates": [121.593039, 38.910638], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "shangdongdalian@163.com", "contactPhone": "+86 18098875933", "dateEnrollment": "2020-03-01", "description": "A Clinical Trial Study for the Influence of TCM Psychotherapy on Negative Emotion of Patients with Novel Coronavirus Pneumonia (COVID-19) Based on Network Platform", "name": "ChiCTR2000030420", "primaryOutcome": "Psychological status;Treatment compliance;To evaluate the difference in isolation and rehabilitation of patients after discharge;", "study_type": "Interventional study", "time": "2020-03-01", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50286"}, "type": "Feature"}, {"geometry": {"coordinates": [119.302849, 26.083184], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "nijun1000@126.com", "contactPhone": "+86 19890572216", "dateEnrollment": "2020-03-01", "description": "Application of rehabilitation lung exercise eight-segment exercise in patients with novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030418", "primaryOutcome": "Post-traumatic stress disorder checklist;Clinical prognostic outcome;Il-6;Health-related quality of life inventory;", "study_type": "Interventional study", "time": "2020-03-01", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50341"}, "type": "Feature"}, {"geometry": {"coordinates": [114.116215, 30.633456], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "1813886398@qq.com", "contactPhone": "+86 13507117929", "dateEnrollment": "2020-02-27", "description": "A randomized, double-blind, placebo-controlled trial for evaluation of  the efficacy and safety of bismuth potassium citrate capsules in the treatment of patients with novel coronavirus pneumonia (COVID-19).", "name": "ChiCTR2000030398", "primaryOutcome": "Pharynx swabs, lower respiratory tract samples (sputum/endotracheal aspiration/alveolar lavage), and anal swabs rt-pcr of novel coronavirus nucleic acid negative conversion rate.;", "study_type": "Interventional study", "time": "2020-03-01", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50173"}, "type": "Feature"}, {"geometry": {"coordinates": [119.926146, 28.450673], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "scx1818@126.com", "contactPhone": "+86 0578 2285102", "dateEnrollment": "2020-03-01", "description": "A medical records based analysis for antiviral therapy effect on novel coronavirus pneumonia COVID-19 patients", "name": "ChiCTR2000030391", "primaryOutcome": "cure rate;virus negative rate;time of virus negative;", "study_type": "Observational study", "time": "2020-03-01", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=30796"}, "type": "Feature"}, {"geometry": {"coordinates": [116.401667, 39.88862], "type": "Point"}, "properties": {"classification": "Diagnosis", "contactEmail": "hekl301@aliyun.com", "contactPhone": "+86 010 66939107", "dateEnrollment": "2020-01-01", "description": "Research and Development of Diagnostic Assistance Decision Support System for novel coronavirus pneumonia (COVID-19) Based on Big Data Technology", "name": "ChiCTR2000030390", "primaryOutcome": "CT;SEN, SPE, ACC, AUC of ROC;", "study_type": "Diagnostic test", "time": "2020-03-01", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50224"}, "type": "Feature"}, {"geometry": {"coordinates": [114.402108, 30.573136], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "ljzwd@163.com", "contactPhone": "+86 13307173928", "dateEnrollment": "2020-02-29", "description": "A Comparative Study for the Effectiveness of ''triple energizer treatment'' Method in Repairing Lung Injury in Patients with Novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030389", "primaryOutcome": "Lung CT;TCM symptoms;", "study_type": "Observational study", "time": "2020-03-01", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50278"}, "type": "Feature"}, {"geometry": {"coordinates": [121.3897, 31.251], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "zzq1419@126.com", "contactPhone": "+86 18721335536", "dateEnrollment": "2020-03-01", "description": "Clinical observation and research of multiple organs injury in severe patients with novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030387", "primaryOutcome": "Epidemiological and clinical characteristics;", "study_type": "Observational study", "time": "2020-03-01", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50329"}, "type": "Feature"}, {"geometry": {"coordinates": [113.07999, 28.076167], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "xrchang1956@163.com", "contactPhone": "+86 0731 88458187", "dateEnrollment": "2020-03-01", "description": "Study for moxibustion in the preventing of novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030386", "primaryOutcome": "mood assessment;", "study_type": "Interventional study", "time": "2020-02-18", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50323"}, "type": "Feature"}, {"geometry": {"coordinates": [126.638388, 45.753168], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "2209447940@qq.com", "contactPhone": "+86 18672308659", "dateEnrollment": "2020-03-01", "description": "Construction and application of non-contact doctor-patient interactive diagnosis and treatment mode of moxibustion therapy for novel coronary pneumonia (COVID-19) based on mobile internet", "name": "ChiCTR2000030382", "primaryOutcome": "pulmonary iconography;", "study_type": "Observational study", "time": "2020-02-17", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50325"}, "type": "Feature"}, {"geometry": {"coordinates": [114.583872, 30.596762], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "haoyaner@163.com", "contactPhone": "+86 13971679960", "dateEnrollment": "2020-02-23", "description": "Novel Coronavirus Infected Disease (COVID-19) in children: epidemiology, clinical features and treatment outcome", "name": "ChiCTR2000030363", "primaryOutcome": "Epidemiological characteristics;clinical features;Treatment outcome;", "study_type": "Observational study", "time": "2020-02-29", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49984"}, "type": "Feature"}, {"geometry": {"coordinates": [118.694224, 31.882556], "type": "Point"}, "properties": {"classification": "Diagnosis", "contactEmail": "ian0126@126.com", "contactPhone": "+86 13338628626", "dateEnrollment": "2020-02-19", "description": "microRNA as a marker for early diagnosis of novel coronavirus infection (COVID-19)", "name": "ChiCTR2000030334", "primaryOutcome": "SEN, SPE, ACC, AUC of ROC;", "study_type": "Diagnostic test", "time": "2020-02-28", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49491"}, "type": "Feature"}, {"geometry": {"coordinates": [114.436641, 30.464912], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "huillanz_76@163.com", "contactPhone": "+86 15391532171", "dateEnrollment": "2020-03-04", "description": "A randomized, open-label controlled trial for the efficacy and safety of Pirfenidone in patients with severe and critical novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030333", "primaryOutcome": "K-bld questionnaire survey;Refers to the pulse oxygen;chest CT;blood gas;", "study_type": "Interventional study", "time": "2020-02-28", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=48801"}, "type": "Feature"}, {"geometry": {"coordinates": [117.262606, 31.843799], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "zzh1974cn@163.com", "contactPhone": "+86 13215510411", "dateEnrollment": "2020-01-21", "description": "Analysis of clinical characteristics of novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030327", "primaryOutcome": "Blood Routine;Liver function;Blood electrolyte;Anticoagulation index;Lung CT;Viral RNA;", "study_type": "Observational study", "time": "2020-02-28", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50214"}, "type": "Feature"}, {"geometry": {"coordinates": [112.253136, 31.930144], "type": "Point"}, "properties": {"classification": "Impact on helpers", "contactEmail": "55815147@qq.com", "contactPhone": "+86 13797625096", "dateEnrollment": "2020-02-28", "description": "A survey of mental health of first-line medical service providers and construction of crisis intervention model for novel coronavirus pneumonia (COVID-19) in Xiangyang", "name": "ChiCTR2000030325", "primaryOutcome": "Psychological questionnaire;", "study_type": "Observational study", "time": "2020-02-28", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50227"}, "type": "Feature"}, {"geometry": {"coordinates": [111.91778, 31.93667], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "55815147@qq.com", "contactPhone": "+86 13797625096", "dateEnrollment": "2020-02-28", "description": "Traditional Chinese Medicine 'Zang-Fu Point-pressing' massage for children with novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030324", "primaryOutcome": "Temperature;Respiratory symptoms;", "study_type": "Interventional study", "time": "2020-02-28", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50231"}, "type": "Feature"}, {"geometry": {"coordinates": [107.486, 31.0564], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "luyb6810@163.com", "contactPhone": "+86 13937642780", "dateEnrollment": "2020-02-01", "description": "Identification and Clinical Treatment of Severe novel coronavirus pneumonia (COVID-19) Patients", "name": "ChiCTR2000030322", "primaryOutcome": "Epidemiological and clinical characteristics;", "study_type": "Observational study", "time": "2020-02-28", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50240"}, "type": "Feature"}, {"geometry": {"coordinates": [106.740388, 33.055451], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "hubingnj@163.com", "contactPhone": "+86 18980601278", "dateEnrollment": "2020-03-01", "description": "Clinical study for a new type of Gastroscope isolation mask for preventing and controlling the novel coronavirus pneumonia (COVID-19) Epidemic period", "name": "ChiCTR2000030317", "primaryOutcome": "During the operation, the patient's volume of local exhaled air from the mouth and nose, the patient's heart rate, respiratory rate and blood oxygen saturation;", "study_type": "Interventional study", "time": "2020-02-28", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50247"}, "type": "Feature"}, {"geometry": {"coordinates": [126.3, 44.56667], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "Wangtan215@sina.com", "contactPhone": "+86 13756858523", "dateEnrollment": "2020-01-01", "description": "Clinical Study for Traditional Chinese Medicine in the Prevention and Treatment of Novel Coronavirus Pneumonia (COVID-19)", "name": "ChiCTR2000030315", "primaryOutcome": "Critically ill patients (%);Mortality Rate;", "study_type": "Observational study", "time": "2020-02-28", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50255"}, "type": "Feature"}, {"geometry": {"coordinates": [112.237691, 31.94658], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "55815147@qq.com", "contactPhone": "+86 13986394739", "dateEnrollment": "2020-02-28", "description": "Traditional Chinese medicine Ma-Xing-Shi-Gan-Tang and Sheng-Jiang-San in the treatment of children with novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030314", "primaryOutcome": "temperature;respiratory symptoms;", "study_type": "Interventional study", "time": "2020-02-28", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50248"}, "type": "Feature"}, {"geometry": {"coordinates": [120.080971, 29.320419], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "li_caixia@zju.edu.cn", "contactPhone": "+86 15268118258", "dateEnrollment": "2020-03-09", "description": "Multiomics study and emergency plan optimization of spleen strengthening clearing damp and stomach therapy combined with antiviral therapy for novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030305", "primaryOutcome": "blood RNA;", "study_type": "Observational study", "time": "2020-02-28", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50223"}, "type": "Feature"}, {"geometry": {"coordinates": [121.003214, 31.855527], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "dr_lif08@126.com", "contactPhone": "+86 18121150282", "dateEnrollment": "2020-03-01", "description": "Clinical observation and research plan of novel coronavirus pneumonia (COVID-19) patients", "name": "ChiCTR2000030293", "primaryOutcome": "Clinical indicators;", "study_type": "Observational study", "time": "2020-02-27", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50195"}, "type": "Feature"}, {"geometry": {"coordinates": [118.098294, 24.441766], "type": "Point"}, "properties": {"classification": "Impact on helpers", "contactEmail": "jieminzhu@xmu.edu.cn", "contactPhone": "+86 15960212649", "dateEnrollment": "2020-02-11", "description": "Health related quality of life and its influencing factors among front line nurses caring patients with new coronavirus pneumonia (COVID-19) from two hospitals in China", "name": "ChiCTR2000030290", "primaryOutcome": "Quality of Life;Epidemic Prevention Medical Protective Equipment related Skin Lesion and Management Scale;", "study_type": "Observational study", "time": "2020-02-27", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50175"}, "type": "Feature"}, {"geometry": {"coordinates": [114.21667, 29.88333], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "2066255602@qq.com", "contactPhone": "+86 13508649926", "dateEnrollment": "2020-02-27", "description": "Correlation between imaging characteristics and laboratory tests of new coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030283", "primaryOutcome": "imaging feature;", "study_type": "Observational study", "time": "2020-02-27", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50119"}, "type": "Feature"}, {"geometry": {"coordinates": [126.641955, 45.76309], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "drkaijiang@163.com", "contactPhone": "+86 13303608899", "dateEnrollment": "2020-02-24", "description": "Study for continuous renal replacement therapy with adsorption filter in the treatment of the novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030265", "primaryOutcome": "Inflammation factor;", "study_type": "Interventional study", "time": "2020-02-26", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49691"}, "type": "Feature"}, {"geometry": {"coordinates": [114.11445, 30.356522], "type": "Point"}, "properties": {"classification": "Impact on helpers", "contactEmail": "wangjing9279@163.com", "contactPhone": "+86 18186161668", "dateEnrollment": "2020-02-28", "description": "ICU healthcare personnel burnout investigation during the fight against novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030264", "primaryOutcome": "no;", "study_type": "Observational study", "time": "2020-02-26", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50161"}, "type": "Feature"}, {"geometry": {"coordinates": [116.399678, 39.889944], "type": "Point"}, "properties": {"classification": "Impact on helpers", "contactEmail": "lvjihui@139.com", "contactPhone": "+86 010 62402842", "dateEnrollment": "2020-02-20", "description": "Investigation and analysis of psychological status of hospital staff during the novel coronavirus pneumonia (COVID-19) epidemic", "name": "ChiCTR2000030263", "primaryOutcome": "GHQ-20;", "study_type": "Epidemilogical research", "time": "2020-02-26", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50140"}, "type": "Feature"}, {"geometry": {"coordinates": [120.388634, 31.439909], "type": "Point"}, "properties": {"classification": "Advanced therapy medicinal products", "contactEmail": "chump1981@163.com", "contactPhone": "+86 15052103816", "dateEnrollment": "2020-03-01", "description": "A study for the key technology of mesenchymal stem cells exosomes atomization in the treatment of novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030261", "primaryOutcome": "Lung CT;", "study_type": "Interventional study", "time": "2020-02-26", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49963"}, "type": "Feature"}, {"geometry": {"coordinates": [102.066899, 30.05127], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "27216302@qq.com", "contactPhone": "+86 17723451376", "dateEnrollment": "2020-02-27", "description": "Clinical study for individualized nutritional assessment and supportive treatment of novel coronavirus pneumonia (COVID-19) patients in Tibetan Plateau", "name": "ChiCTR2000030260", "primaryOutcome": "NRS 2002 score;BMI;triceps skinfold thickness (TSF);prealbumin;total albumin;leucocyte count;CRP;lymphocyte percentage;TNF- alpha;IL-6;", "study_type": "Interventional study", "time": "2020-02-26", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50130"}, "type": "Feature"}, {"geometry": {"coordinates": [121.565991, 31.138421], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "docd1@sina.com", "contactPhone": "+86 18917387623", "dateEnrollment": "2020-02-22", "description": "Evaluation Danorevir sodium tablets combined with ritonavir in the treatment of novel coronavirus pneumonia (COVID-19): a randomized, open and controlled trial", "name": "ChiCTR2000030259", "primaryOutcome": "Rate of composite advers outcomes: SpO2, PaO2/FiO2, respiratory rate;", "study_type": "Interventional study", "time": "2020-02-26", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49918"}, "type": "Feature"}, {"geometry": {"coordinates": [126.731049, 45.637114], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "hydyangwei@tom.com", "contactPhone": "+86 13845099775", "dateEnrollment": "2020-02-21", "description": "A multicenter, randomized, controlled trial for efficacy and safety of hydrogen inhalation in the treatment of novel coronavirus pneumonia (COVID-19) patients", "name": "ChiCTR2000030258", "primaryOutcome": "temperature;respiratory rate;Blood oxygen saturation;Cough symptom;Lung CT;Fatality rate;", "study_type": "Treatment study", "time": "2020-02-26", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49887"}, "type": "Feature"}, {"geometry": {"coordinates": [114.451838, 30.444299], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "1078404424@qq.com", "contactPhone": "+86 18602764053", "dateEnrollment": "2020-03-09", "description": "The coagulation function of novel coronavirus pneumonia (COVID-19) patients", "name": "ChiCTR2000030257", "primaryOutcome": "INR;PT;TT;APTT;FIB;DD;", "study_type": "Observational study", "time": "2020-02-26", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50006"}, "type": "Feature"}, {"geometry": {"coordinates": [121.619056, 31.199979], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "yyliuhua@126.com", "contactPhone": "+86 18930568010", "dateEnrollment": "2020-03-01", "description": "Efficacy and Safety of Jing-Yin Granule in the treatment of novel coronavirus pneumonia (COVID-19) wind-heat syndrome", "name": "ChiCTR2000030255", "primaryOutcome": "Clearance rate and time of main symptoms (fever, fatigue, cough);", "study_type": "Interventional study", "time": "2020-02-26", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50089"}, "type": "Feature"}, {"geometry": {"coordinates": [102.051454, 30.067706], "type": "Point"}, "properties": {"classification": "Diagnosis", "contactEmail": "27216302@qq.com", "contactPhone": "+86 17723451376", "dateEnrollment": "2020-02-27", "description": "Exploration and Research for a new method for detection of novel coronavirus (COVID-19) nucleic acid", "name": "ChiCTR2000030253", "primaryOutcome": "SEN, SPE, ACC, AUC of ROC;", "study_type": "Diagnostic test", "time": "2020-02-26", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50143"}, "type": "Feature"}, {"geometry": {"coordinates": [115.71841, 38.23665], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "syicu@vip.sina.com", "contactPhone": "+86 13933856908", "dateEnrollment": "2020-02-01", "description": "The treatment status and risk factors related to prognosis of hospitalized patients with novel coronavirus pneumonia (COVID-19) in intensive care unit, Hebei, China: a descriptive study", "name": "ChiCTR2000030226", "primaryOutcome": "Clinical characteristics;", "study_type": "Observational study", "time": "2020-02-26", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49855"}, "type": "Feature"}, {"geometry": {"coordinates": [121.486092, 31.279422], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "pdzhoujia@163.com", "contactPhone": "+86 18017306677", "dateEnrollment": "2020-02-22", "description": "Clinical Reseach of Acupuncture in the treatment of Novel Coronavirus Pneumonia (COVID-19)", "name": "ChiCTR2000030225", "primaryOutcome": "Length of hospital stay;Discharge time of general type;Discharge time of severe type;", "study_type": "Interventional study", "time": "2020-02-26", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49945"}, "type": "Feature"}, {"geometry": {"coordinates": [114.203072, 22.379167], "type": "Point"}, "properties": {"classification": "Other", "contactEmail": "zhangdxdaisy@cuhk.edu.hk", "contactPhone": "+852 22528451", "dateEnrollment": "2020-02-20", "description": "Quality of life among Chinese residents during and after novel coronavirus pneumonia (COVID19) outbreak: an online survey", "name": "ChiCTR2000030223", "primaryOutcome": "Quality of life;Socio-demographcis and others;", "study_type": "Health services reaserch", "time": "2020-02-26", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50026"}, "type": "Feature"}, {"geometry": {"coordinates": [106.360341, 29.436043], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "406302524@qq.com", "contactPhone": "+86 13678494357", "dateEnrollment": "2020-02-21", "description": "Cancelled due to lack of participants                                        Study for the Impact of Novel Coronavirus Pneumonia (COVID-19) to the Health of the elderly People", "name": "ChiCTR2000030222", "primaryOutcome": "health status;Mental health status;", "study_type": "Observational study", "time": "2020-02-25", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50048"}, "type": "Feature"}, {"geometry": {"coordinates": [117.308294, 39.012303], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "yingfei1981@163.com", "contactPhone": "+86 13920648942", "dateEnrollment": "2020-01-21", "description": "Study for evaluation of integrated traditional Chinese and Western Medicine in the treatment of Novel Coronavirus Pneumonia (COVID-19)", "name": "ChiCTR2000030219", "primaryOutcome": "Clinical symptoms;TCM syndrome;Lung imaging;Time of nucleic acid turning negative;", "study_type": "Interventional study", "time": "2020-02-25", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50110"}, "type": "Feature"}, {"geometry": {"coordinates": [114.950145, 25.851135], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "2590410004@qq.com", "contactPhone": "+86 13707077997", "dateEnrollment": "2020-01-22", "description": "Study of Pinavir / Ritonavir Tablets (Trade Name: Kelizhi) Combined with Xiyanping Injection for Novel Coronavirus Pneumonia (COVID-19)", "name": "ChiCTR2000030218", "primaryOutcome": "Clinical recovery time;Pneumonia Severity Index (PSI) score;", "study_type": "Interventional study", "time": "2020-02-25", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50115"}, "type": "Feature"}, {"geometry": {"coordinates": [115.344755, 27.731736], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "freebee99@163.com", "contactPhone": "+86 13576955700", "dateEnrollment": "2020-02-26", "description": "Study for the efficacy of Kangguan No. 1-3 prescription in the treatment of novel coronavirus pneumonia (COVID19)", "name": "ChiCTR2000030215", "primaryOutcome": "Routine physical examination;Vital signs: breathing, body temperature (armpit temperature);Blood routine;C-reactive protein;Liver and kidney function test;Myocardial enzyme content;ESR;T cell subsets;Cytokine;Liver, gallbladder, thyroid, and lymph node imaging;Chest CT;Infectious disease test;", "study_type": "Interventional study", "time": "2020-02-25", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50107"}, "type": "Feature"}, {"geometry": {"coordinates": [114.11445, 30.356522], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "Pengzy5@hotmail.com", "contactPhone": "+86 18672396028", "dateEnrollment": "2020-02-20", "description": "A multicenter, single arm, open label trial for the efficacy and safety of CMAB806 in the treatment of cytokine release syndrome of novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030196", "primaryOutcome": "the relive of CRS;", "study_type": "Interventional study", "time": "2020-02-25", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49883"}, "type": "Feature"}, {"geometry": {"coordinates": [104.171816, 30.546415], "type": "Point"}, "properties": {"classification": "Impact on helpers", "contactEmail": "luyibingli@163.com", "contactPhone": "+86 18328737998", "dateEnrollment": "2020-02-22", "description": "A prospective randomized controlled trial for the home exercise prescription intervention in nursing students during epidemic of novel coronary pneumonia (COVID-19)", "name": "ChiCTR2000030091", "primaryOutcome": "Mood index;", "study_type": "Interventional study", "time": "2020-02-23", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49914"}, "type": "Feature"}, {"geometry": {"coordinates": [106.548522, 29.565867], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "1041863309@qq.com", "contactPhone": "+86 023 61103649", "dateEnrollment": "2020-02-21", "description": "Cancelled due to lack of patient                                                                A Medical Records Based Study for Construction and Analysis of Diagnosis Predictive&", "name": "ChiCTR2000030042", "primaryOutcome": "ROC;calibration curve;", "study_type": "Observational study", "time": "2020-02-21", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49899"}, "type": "Feature"}, {"geometry": {"coordinates": [117.262767, 31.847597], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "ahmusld@163.com", "contactPhone": "+86 13856985045", "dateEnrollment": "2020-02-22", "description": "A parallel, randomized controlled clinical trial for the efficacy and safety of Pediatric Huatanzhike granules (containing ipecacuanha tincture) in the treatment of mild and moderate novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030022", "primaryOutcome": "COVID-19 nucleic acid detection time from positive to negative (respiratory secretion) or (3,5,7,10 days from positive to negative rate);;Lung CT observation of inflammation absorption;;Proportion of cases with progressive disease;", "study_type": "Interventional study", "time": "2020-02-20", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49797"}, "type": "Feature"}, {"geometry": {"coordinates": [116.401667, 39.88862], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "fengcao8828@163.com", "contactPhone": "+86 13911798280", "dateEnrollment": "2020-02-20", "description": "A prospective clinical study for recombinant human interferon alpha 1b spray in the prevention of novel coronavirus (COVID-19) infection in highly exposed medical staffs.", "name": "ChiCTR2000030013", "primaryOutcome": "Blood routine examination;Chest CT;Arterial Blood Oxygen Saturation;", "study_type": "Interventional study", "time": "2020-02-19", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49796"}, "type": "Feature"}, {"geometry": {"coordinates": [116.022157, 28.583145], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "zhangweiliuxin@163.com", "contactPhone": "+86 0791-88693401", "dateEnrollment": "2020-02-18", "description": "A randomized, open-label, controlled trial for the safety and efficiency of Kesuting syrup and Keqing capsule in the treatment of mild and moderate novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000029991", "primaryOutcome": "cough;", "study_type": "Interventional study", "time": "2020-02-18", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49666"}, "type": "Feature"}, {"geometry": {"coordinates": [125.309144, 43.853493], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "shuchenghua@126.com", "contactPhone": "+86 13756661209", "dateEnrollment": "2020-02-24", "description": "Single arm study for exploration of chloroquine phosphate aerosol inhalation in the treatment of novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000029975", "primaryOutcome": "viral negative-transforming time;30-day cause-specific mortality;co-infections;Time from severe and critical patients to clinical improvement;", "study_type": "Interventional study", "time": "2020-02-18", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49592"}, "type": "Feature"}, {"geometry": {"coordinates": [108.40202, 30.70576], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "xiaokh1@163.com", "contactPhone": "+86 19923204040", "dateEnrollment": "2020-02-17", "description": "Cancelled due to lack of patient                         Medical records based study for epidemiological and clinical characteristics of 2019 novel coronavirus pneumonia (COVID-19) in Chongqing", "name": "ChiCTR2000029952", "primaryOutcome": "Clinical symptoms;Test result;Examination result;", "study_type": "Observational study", "time": "2020-02-17", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49630"}, "type": "Feature"}, {"geometry": {"coordinates": [114.237851, 30.262307], "type": "Point"}, "properties": {"classification": "Impact on helpers", "contactEmail": "yogaqq116@whu.edu.cn", "contactPhone": "+86 18062586860", "dateEnrollment": "2020-02-17", "description": "Research for Risks Associated with Novel Coronavirus Pneumonia (COVID-19) in the Hospital Workers and Nosocomial  Prevention and Control Strategy", "name": "ChiCTR2000029900", "primaryOutcome": "exposed factors;latent period;preventive measures;", "study_type": "Observational study", "time": "2020-02-16", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49377"}, "type": "Feature"}, {"geometry": {"coordinates": [116.414204, 39.876292], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "shenning1972@126.com", "contactPhone": "+86 15611908958", "dateEnrollment": "2020-02-17", "description": "Evaluation the Efficacy and Safety of Hydroxychloroquine Sulfate in Comparison with Phosphate Chloroquine in Mild and Commen Patients with Novel Coronavirus Pneumonia (COVID-19): a Randomized, Open-label, Parallel, Controlled Trial", "name": "ChiCTR2000029899", "primaryOutcome": "Time to Clinical Recovery, TTCR;", "study_type": "Interventional study", "time": "2020-02-16", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49536"}, "type": "Feature"}, {"geometry": {"coordinates": [116.398759, 39.892728], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "shenning1972@126.com", "contactPhone": "+86 15611908958", "dateEnrollment": "2020-02-17", "description": "Evaluation the Efficacy and Safety of Hydroxychloroquine Sulfate in Comparison with Phosphate Chloroquine in Severe Patients with Novel Coronavirus Pneumonia (COVID-19): a Randomized, Open-Label, Parallel, Controlled Trial", "name": "ChiCTR2000029898", "primaryOutcome": "TTCI (Time to Clinical Improvement);", "study_type": "Interventional study", "time": "2020-02-16", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49482"}, "type": "Feature"}, {"geometry": {"coordinates": [108.508589, 30.595241], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "wangjinlong2007666@163.com", "contactPhone": "+86 15923859880", "dateEnrollment": "2020-02-15", "description": "Cancelled due to lack of patient                                 Medical records based study for Heart-type fatty acid-binding protein on prognosis of novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000029829", "primaryOutcome": "Worsening condition;Death;Heart fatty acid binding protein;", "study_type": "Observational study", "time": "2020-02-15", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49520"}, "type": "Feature"}, {"geometry": {"coordinates": [106.565122, 29.580125], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "wenxiang_huang@163.com", "contactPhone": "+86 13883533808", "dateEnrollment": "2020-02-12", "description": "Cancelled due to lack of patient                                                                              Clinical study for the effect and", "name": "ChiCTR2000029762", "primaryOutcome": "Negative conversion rate of COVID-19 nucleic acid;Lung inflammation absorption ratio;", "study_type": "Interventional study", "time": "2020-02-12", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49404"}, "type": "Feature"}, {"geometry": {"coordinates": [106.654802, 29.45449], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "wenxiang_huang@163.com", "contactPhone": "+86 13883533808", "dateEnrollment": "2020-02-13", "description": "Cancelled due to lack of patient                Clinical study on the safety and effectiveness of Hydroxychloroquine Sulfate tablets in the treatment of patients with novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000029761", "primaryOutcome": "Negative conversion rate of 2019-nCoV nucleic acid ;Lung inflammation absorption ratio;", "study_type": "Interventional study", "time": "2020-02-12", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49400"}, "type": "Feature"}, {"geometry": {"coordinates": [106.65509, 29.455349], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "maohwei@qq.com", "contactPhone": "+86 13928459556", "dateEnrollment": "2020-02-12", "description": "Cancelled due to lack of patient                              A study for the efficacy of hydroxychloroquine for mild and moderate COVID-19 infectious diseases", "name": "ChiCTR2000029760", "primaryOutcome": "Time to clinical recovery;", "study_type": "Interventional study", "time": "2020-02-12", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49369"}, "type": "Feature"}, {"geometry": {"coordinates": [106.654978, 29.455501], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "hp_cq@163.com", "contactPhone": "+86 13608338064", "dateEnrollment": "2020-02-15", "description": "Retracted due to lack of patient                               A multicenter, randomized, open label, controlled trial for the efficacy and safety of ASC09/ Ritonavir compound tablets and Lopinavir/ Ritonavir (Kaletra) and Arbidol tablets in the treatm", "name": "ChiCTR2000029759", "primaryOutcome": "time to recovery.;", "study_type": "Interventional study", "time": "2020-02-12", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49352"}, "type": "Feature"}, {"geometry": {"coordinates": [114.433536, 30.464924], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "ld_2069@163.com", "contactPhone": "+86 13507183749", "dateEnrollment": "2020-02-15", "description": "A randomized, open, parallel-controlled clinical trial on the efficacy and safety of Jingyebaidu granules in treating novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000029755", "primaryOutcome": "Validity observation index;", "study_type": "Interventional study", "time": "2020-02-12", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49301"}, "type": "Feature"}, {"geometry": {"coordinates": [114.436641, 30.464912], "type": "Point"}, "properties": {"classification": "Impact on helpers", "contactEmail": "ld_2069@163.com", "contactPhone": "+86 13507183749", "dateEnrollment": "2020-02-15", "description": "A Retrospective Study for Preventive Medication in Tongji Hospital During the Epidemic of Novel Coronavirus Pneumonia (COVID-19)", "name": "ChiCTR2000029728", "primaryOutcome": "The proportion of patients diagnosed with 2019-ncov viral pneumonia;", "study_type": "Observational study", "time": "2020-02-10", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49250"}, "type": "Feature"}, {"geometry": {"coordinates": [109.40029, 29.550338], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "yaokaichen@hotmail.com", "contactPhone": "+86 023-65481658", "dateEnrollment": "2020-01-25", "description": "Comparative effectiveness and safety of ribavirin plus interferon-alpha, lopinavir/ritonavir plus interferon-alpha and ribavirin plus lopinavir/ritonavir plus interferon-alphain in patients with mild to moderate novel coronavirus pneumonia", "name": "ChiCTR2000029387", "primaryOutcome": "The time to 2019-nCoV RNA negativity in patients;", "study_type": "Interventional study", "time": "2020-01-29", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=48782"}, "type": "Feature"}, {"geometry": {"coordinates": [109.384845, 29.566774], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "yaokaichen@hotmail.com", "contactPhone": "+86 13638352995", "dateEnrollment": "2020-01-29", "description": "Effectiveness of glucocorticoid therapy in patients with severe novel coronavirus pneumonia: a randomized controlled trial", "name": "ChiCTR2000029386", "primaryOutcome": "SOFA score;", "study_type": "Interventional study", "time": "2020-01-29", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=48777"}, "type": "Feature"}, {"geometry": {"coordinates": [121.467361, 31.21062], "type": "Point"}, "properties": {"classification": "Advanced therapy medicinal products", "contactEmail": ";jmqu0906@163.com", "contactPhone": ";+86-21-64370045", "dateEnrollment": "February 15, 2020", "description": "A Pilot Clinical Study on Inhalation of Mesenchymal Stem Cells Exosomes Treating Severe Novel Coronavirus Pneumonia", "name": "NCT04276987", "primaryOutcome": "Adverse reaction (AE) and severe adverse reaction (SAE);Time to clinical improvement (TTIC)", "study_type": "Interventional", "time": "2020-02-16", "weburl": "https://clinicaltrials.gov/show/NCT04276987"}, "type": "Feature"}, {"geometry": {"coordinates": [116.276303, 39.904478], "type": "Point"}, "properties": {"classification": "Diagnosis", "contactEmail": ";xiaotian-sun@hotmail.com;13911798288@163.com", "contactPhone": ";+86-01066823480;010-66947473", "dateEnrollment": "February 2020", "description": "A New Screening Strategy for 2019 Novel Coronavirus Infection", "name": "NCT04281693", "primaryOutcome": "Screening accuracy", "study_type": "Interventional", "time": "2020-02-20", "weburl": "https://clinicaltrials.gov/show/NCT04281693"}, "type": "Feature"}, {"geometry": {"coordinates": [114.258309, 30.580213], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "huilanz_76@163.com;", "contactPhone": "15391532171;", "dateEnrollment": "February 4, 2020", "description": "A Study to Evaluate the Efficacy and Safety of Pirfenidone With Novel Coronavirus Infection", "name": "NCT04282902", "primaryOutcome": "chest CT;Finger pulse oxygen;blood gas;K-BILD", "study_type": "Interventional", "time": "2020-02-10", "weburl": "https://clinicaltrials.gov/show/NCT04282902"}, "type": "Feature"}, {"geometry": {"coordinates": [114.409596, 30.498842], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "", "contactPhone": "", "dateEnrollment": "January 31, 2020", "description": "CT Scores Predict Mortality in 2019-nCoV Pneumonia", "name": "NCT04284046", "primaryOutcome": "7-day mortality", "study_type": "Observational", "time": "2020-02-22", "weburl": "https://clinicaltrials.gov/show/NCT04284046"}, "type": "Feature"}, {"geometry": {"coordinates": [115.400848, 39.373391], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": ";dinghuiguo@medmail.com.cn", "contactPhone": ";+86-13911683832", "dateEnrollment": "February 23, 2020", "description": "The Clinical Study of Carrimycin on Treatment Patients With COVID-19", "name": "NCT04286503", "primaryOutcome": "Fever to normal time (day);Pulmonary inflammation resolution time (HRCT) (day);Negative conversion (%) of 2019-nCOVRNA in gargle (throat swabs) at the end of treatment", "study_type": "Interventional", "time": "2020-02-25", "weburl": "https://clinicaltrials.gov/show/NCT04286503"}, "type": "Feature"}, {"geometry": {"coordinates": [113.663625, 34.802452], "type": "Point"}, "properties": {"classification": "Advanced therapy medicinal products", "contactEmail": "zlgj-001@126.com", "contactPhone": "+86 13673665268", "dateEnrollment": "2020-02-01", "description": "Study for using the healed novel coronavirus pneumonia (COVID-19) patients plasma in the treatment of severe critical cases", "name": "ChiCTR2000030627", "primaryOutcome": "Tempreture;Virus nucleic acid detection;", "study_type": "Interventional study", "time": "2020-03-08", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50727"}, "type": "Feature"}, {"geometry": {"coordinates": [121.17623, 30.179772], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "luxiaoyang@zju.edu.cn", "contactPhone": "+86 13605715886", "dateEnrollment": "2020-03-10", "description": "Novel coronavirus pneumonia (COVID-19) antiviral related liver dysfunction: a multicenter, retrospective, observational study", "name": "ChiCTR2000030593", "primaryOutcome": "ALT;", "study_type": "Observational study", "time": "2020-03-08", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50228"}, "type": "Feature"}, {"geometry": {"coordinates": [106.618374, 33.182406], "type": "Point"}, "properties": {"classification": "Impact on helpers", "contactEmail": "zuoyunxiahxa@qq.com", "contactPhone": "+86 18980601541", "dateEnrollment": "2020-02-02", "description": "The immediate psychological impact of novel coronavirus pneumonia (COVID-19) outbreak on medical students in anesthesiology and how the cope", "name": "ChiCTR2000030581", "primaryOutcome": "intrusion;avoidance;", "study_type": "Observational study", "time": "2020-03-08", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50394"}, "type": "Feature"}, {"geometry": {"coordinates": [116.995219, 36.647335], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "docjiangshujuan@163.com", "contactPhone": "+86 15168887199", "dateEnrollment": "2020-02-15", "description": "Risk Factors for Outcomes of Novel Coronavirus Pneumonia (COVID-19)", "name": "ChiCTR2000030579", "primaryOutcome": "clinic outcome;", "study_type": "Observational study", "time": "2020-03-08", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50692"}, "type": "Feature"}, {"geometry": {"coordinates": [117.012369, 36.663305], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "15168888626@163.com", "contactPhone": "+86 18660117915", "dateEnrollment": "2020-03-07", "description": "Clinical Prediction and Intervention of Pulmonary Function Impairment in Patients with Novel Coronavirus Pneumonia (COVID-19)", "name": "ChiCTR2000030578", "primaryOutcome": "Pulmonary function;6 minutes walking distance;The Short Form -36 Healthy Survey;", "study_type": "Interventional study", "time": "2020-03-08", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50690"}, "type": "Feature"}, {"geometry": {"coordinates": [114.43665, 30.464893], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "hmei@hust.edu.cn", "contactPhone": "+86 13886160811", "dateEnrollment": "2020-03-08", "description": "Research on peripheral immunity function monitoring and its clinical application in patients with novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030574", "primaryOutcome": "Immunity function;cytokines;viral load;", "study_type": "Observational study", "time": "2020-03-07", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49953"}, "type": "Feature"}, {"geometry": {"coordinates": [114.583872, 30.596762], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "haoyaner@163.com", "contactPhone": "+86 13971679960", "dateEnrollment": "2020-03-15", "description": "Psychological Intervention of Children with Novel Coronavirus Disease (COVID-19)", "name": "ChiCTR2000030564", "primaryOutcome": "Child Stress Disorders Checklist evaluation;Achenbach children's behavior checklist evaluation;children's severe emotional disorder and psychological crisis during inpatient treatment;", "study_type": "Observational study", "time": "2020-03-07", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50653"}, "type": "Feature"}, {"geometry": {"coordinates": [121.17623, 30.179772], "type": "Point"}, "properties": {"classification": "Advanced therapy medicinal products", "contactEmail": "zhanghuafen@zju.edu.cn", "contactPhone": "+86 13757120681", "dateEnrollment": "2020-03-07", "description": "A medical records based study for the safety of artificial liver cluster nursing in critically ill patients with novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030559", "primaryOutcome": "Unplanned shutdowns;", "study_type": "Observational study", "time": "2020-03-07", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50583"}, "type": "Feature"}, {"geometry": {"coordinates": [121.523258, 31.311702], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "hywangk@vip.sina.com", "contactPhone": "+86 13801955367", "dateEnrollment": "2020-03-10", "description": "A retrospective study on virus typing, Hematological Immunology and case Review of novel coronavirus infected and convalescent patients (COVID-19)", "name": "ChiCTR2000030557", "primaryOutcome": "viral load;virus genotyping;Classification of lymphocytes;", "study_type": "Observational study", "time": "2020-03-07", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50667"}, "type": "Feature"}, {"geometry": {"coordinates": [117.369165, 31.733269], "type": "Point"}, "properties": {"classification": "Diagnosis", "contactEmail": "drliuhu@gmail.com", "contactPhone": "+86 13866175691", "dateEnrollment": "2020-03-15", "description": "Clinical study of nano-nose and its extended technology in diagnosis of novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030556", "primaryOutcome": "Volatile organic compounds, VOCs;SEN, SPE, ACC, AUC of ROC;", "study_type": "Diagnostic test", "time": "2020-03-07", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50672"}, "type": "Feature"}, {"geometry": {"coordinates": [114.436675, 30.464902], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "shushengli16@sina.com", "contactPhone": "+86 13971086498", "dateEnrollment": "2020-03-08", "description": "Critical ultrasound in evaluating cardiopulmonary function in critical patients infected with 2019 novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030552", "primaryOutcome": "Lung ultrasound index;Right ventricular function ultrasound index;Left ventricular function ultrasound index;", "study_type": "Observational study", "time": "2020-03-07", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49708"}, "type": "Feature"}, {"geometry": {"coordinates": [114.436641, 30.464912], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "Fangmh@tjh.tjmu.edu.cn", "contactPhone": "+86 15071157405", "dateEnrollment": "2020-02-24", "description": "Study for the risk factors of critically ill patients with novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030544", "primaryOutcome": "in-ICU mortality;mortality of 28 days;", "study_type": "Observational study", "time": "2020-03-06", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50134"}, "type": "Feature"}, {"geometry": {"coordinates": [114.2348, 30.231819], "type": "Point"}, "properties": {"classification": "Diagnosis", "contactEmail": "cxfn817@163.com", "contactPhone": "+86 13986156712", "dateEnrollment": "2020-02-14", "description": "Detection of coronavirus in simultaneously collecting tears and throat swab samples collected from the patients with novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030543", "primaryOutcome": "A cycle threshold value (Ct-value);", "study_type": "Observational study", "time": "2020-03-06", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50541"}, "type": "Feature"}, {"geometry": {"coordinates": [106.618374, 33.182406], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "binwuying@126.com", "contactPhone": "+86 18980601655", "dateEnrollment": "2020-03-09", "description": "A clinical study about the diagnosis and prognosis evaluation of novel coronacirus pneumonia (COVID-19) based on viral genome, host genomic sequencing, relative cytokines and other laboratory indexes.", "name": "ChiCTR2000030542", "primaryOutcome": "Pulmonary image findings;Relevant clinical manifestations of COVID-19;Oxygen saturation in resting state;Arterial partial pressure of oxygen/ Oxygen absorption concentration;Length of hospital stay;Viral genome information;Host genome information;Expression level of host cytokines;Conventional laboratory testing index;", "study_type": "Observational study", "time": "2020-03-06", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50608"}, "type": "Feature"}, {"geometry": {"coordinates": [118.09559, 24.56048], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "417433835@qq.com", "contactPhone": "+86 13806086169", "dateEnrollment": "2020-03-06", "description": "Novel coronavirus pneumonia (COVID-19) epidemic survey of medical students in various provinces and municipalities throughout the country", "name": "ChiCTR2000030541", "primaryOutcome": "PSS-14;", "study_type": "Observational study", "time": "2020-03-06", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50623"}, "type": "Feature"}, {"geometry": {"coordinates": [114.436641, 30.464912], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "shushengli16@sina.com", "contactPhone": "+86 13971086498", "dateEnrollment": "2020-03-08", "description": "Research for the mechanism of improvement of novel coronavirus pneumonia (COVID-19) patients' pulmonary exudation by continuous renal replacement therapy", "name": "ChiCTR2000030540", "primaryOutcome": "Chest imaging;Oxygenation index;Extravascular pulmonary water;pulmonary vascular permeability index, PVPI;Inflammatory factors;Tissue kallikrein;", "study_type": "Interventional study", "time": "2020-03-06", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50658"}, "type": "Feature"}, {"geometry": {"coordinates": [104.753119, 31.45752], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "1121733818@qq.com", "contactPhone": "+86 18508160990", "dateEnrollment": "2020-02-20", "description": "Multi-Center Clinical Study on the Treatment of Patients with Novel Coronavirus Pneumonia (COVID-19) by Ebastine", "name": "ChiCTR2000030535", "primaryOutcome": "Clinical therapeutic course;Pathogenic detectio;Chest CT;Laboratory indicators (blood routine, myocardial enzyme spectrum, inflammatory cytokines, etc.);", "study_type": "Interventional study", "time": "2020-03-06", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49790"}, "type": "Feature"}, {"geometry": {"coordinates": [104.174969, 30.576736], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "1035788783@qq.com", "contactPhone": "+86 13880336152", "dateEnrollment": "2020-03-09", "description": "Efficacy and safety of Ma-Xing-Gan-Shi decoction in the treatment of novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030522", "primaryOutcome": "Time to Clinical Recovery (TTCR);", "study_type": "Interventional study", "time": "2020-03-06", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=44213"}, "type": "Feature"}, {"geometry": {"coordinates": [120.680436, 28.012744], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "13968888872@163.com", "contactPhone": "+86 13857715778", "dateEnrollment": "2020-02-29", "description": "Zedoary Turmeric Oil for Injection in the treatment of Novel Coronavirus Pneumonia (COVID-19): a randomized, open, controlled trial", "name": "ChiCTR2000030518", "primaryOutcome": "Real-time fluorescent RT-PCR detection of pharyngeal swab were used to detect the negative conversion rate of the new coronavirus nucleic acid (tested after the end of medication) and the negative conversion time(measured every other day after the start of medication, determined according to clinical needs);Time to clinical improvement;Change in size of lesion area by chest CT;Time to fever subsidence, defined as the time at which a subject with fever at enrollment has returned to normal temperature for at least 72 hours;", "study_type": "Interventional study", "time": "2020-03-05", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50586"}, "type": "Feature"}, {"geometry": {"coordinates": [121.17623, 30.179772], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "xxw69@126.com", "contactPhone": "+86 13605708066", "dateEnrollment": "2020-01-20", "description": "Extracorporeal blood purification therapy using Li's Artifical Liver System for patients with severe novel coronavirus pneumonia (COVID19) patient", "name": "ChiCTR2000030503", "primaryOutcome": "Mortality;", "study_type": "Interventional study", "time": "2020-03-05", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49632"}, "type": "Feature"}, {"geometry": {"coordinates": [114.23598, 30.262582], "type": "Point"}, "properties": {"classification": "Other", "contactEmail": "wenqin-1987@163.com", "contactPhone": "+86 13808628560", "dateEnrollment": "2020-03-04", "description": "Survey for sleep, anxiety and depression status of Chinese residents during the outbreak of novel coronavirus infected disases (COVID-19)", "name": "ChiCTR2000030493", "primaryOutcome": "Pittsburgh sleep quality index;", "study_type": "Observational study", "time": "2020-03-04", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50547"}, "type": "Feature"}, {"geometry": {"coordinates": [103.094435, 26.984976], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "chenxinyuchen@163.com", "contactPhone": "+86 13807312410", "dateEnrollment": "2020-03-04", "description": "Retrospective study for integrate Chinese and conventional medicine  treatment of novel coronavirus pneumonia (COVID-19) in Hu'nan province", "name": "ChiCTR2000030492", "primaryOutcome": "TCM syndrome;", "study_type": "Observational study", "time": "2020-03-04", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50549"}, "type": "Feature"}, {"geometry": {"coordinates": [106.618374, 33.182406], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "Kangyan@scu.edu.cn", "contactPhone": "+86 18980601566", "dateEnrollment": "2020-03-03", "description": "A medical records based study for Comparing Differences of Clinical Features and Outcomes of Novel Coronavirus Pneumonia (COVID-19) Patients between Sichuan Province and Wuhan City", "name": "ChiCTR2000030491", "primaryOutcome": "length of stay;length of stay in ICU;Hospital costs;Hospital costs;Antibiotic use;Organ function support measures;", "study_type": "Observational study", "time": "2020-03-04", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50552"}, "type": "Feature"}, {"geometry": {"coordinates": [114.102245, 30.574634], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "wanghaohh@vip.126.com", "contactPhone": "+86 13901883868", "dateEnrollment": "2020-02-01", "description": "To evaluate the efficacy and safety of diammonium glycyrrhizinate enteric-coated capsules combined with hydrogen-rich water in the treatment of novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030490", "primaryOutcome": "Cure rate;", "study_type": "Interventional study", "time": "2020-03-04", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50487"}, "type": "Feature"}, {"geometry": {"coordinates": [114.583872, 30.596762], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "s_1862777@163.com", "contactPhone": "+86 18627770651", "dateEnrollment": "2020-02-01", "description": "Study for the route of ocular surface transmission of novel coronavirus pneumonia (COVID-19) infection and related eye diseases", "name": "ChiCTR2000030489", "primaryOutcome": "Nuclei acid test of SARS-CoV-2 of conjunctival swab;Nuclei acid test of SARS-CoV-2 of throat swab;Nuclei acid test of SARS-CoV-2 of peripheral blood sample;Eye symptoms;Clinical symptoms;", "study_type": "Epidemilogical research", "time": "2020-03-04", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50490"}, "type": "Feature"}, {"geometry": {"coordinates": [113.787102, 34.818422], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "38797527@qq.com", "contactPhone": "13938415502", "dateEnrollment": "2020-03-04", "description": "A single-center, single-arm clinical trial for azvudine in the treatment of novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030487", "primaryOutcome": "Sputum/nasal swab/pharyngeal swab/lower respiratory tract secretions were used to detect the negative conversion rate of the new coronavirus nucleic acid (tested daily after two days starting the azvudine tablets) and the negative conversion time;", "study_type": "Interventional study", "time": "2020-03-04", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50507"}, "type": "Feature"}, {"geometry": {"coordinates": [114.583872, 30.596762], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "shushengli16@sina.com", "contactPhone": "+86 13971086498", "dateEnrollment": "2020-03-03", "description": "Study for timing of mechanical ventilation for critically ill patients with novel coronavirus pneumonia (COVID-19): A medical records based retrospective Cohort study", "name": "ChiCTR2000030485", "primaryOutcome": "28-day mortality;ICU 14-day mortality;", "study_type": "Observational study", "time": "2020-03-03", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50459"}, "type": "Feature"}, {"geometry": {"coordinates": [110.778673, 32.646778], "type": "Point"}, "properties": {"classification": "Advanced therapy medicinal products", "contactEmail": "182190248@qq.com", "contactPhone": "+86 0719 8801713", "dateEnrollment": "2020-02-02", "description": "HUMSCs and Exosomes Treating Patients with Lung Injury following Novel Coronavirus Pneumonia (COVID-19)", "name": "ChiCTR2000030484", "primaryOutcome": "PaO2 / FiO2 or respiratory rate (without oxygen);Frequency of respiratory exacerbation;Observe physical signs and symptoms and record clinical recovery time;The number and range of lesions indicated by CT and X-ray of lung;Time for cough to become mild or absent;Time for dyspnea to become mild or no dyspnea;Frequency of oxygen inhalation or noninvasive ventilation, frequency of mechanical ventilation;Inflammatory cytokines (CRP / PCT / SAA, etc.);Frequency of serious adverse events;", "study_type": "Interventional study", "time": "2020-03-03", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50263"}, "type": "Feature"}, {"geometry": {"coordinates": [116.434746, 39.953943], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "drhuoyong@163.com", "contactPhone": "+86 13901333060", "dateEnrollment": "2020-03-06", "description": "A Multicenter, Long- term Follow-up and Registration Study for Myocardial Injury and Prognosis of Novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030482", "primaryOutcome": "Cardiac injury;Death in hospital and/or Endotracheal Intubation Deaths during hospitalization;Admitted to the ICU;Composite end points of cardiovascular events( nonfatal heart failure, nonfatal myocardial infarction, nonfatal stroke or cardiovascular death);Stroke;Heart failure;Myocardial infarction;Other cardiovascular health related endpoints;", "study_type": "Observational study", "time": "2020-03-03", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50353"}, "type": "Feature"}, {"geometry": {"coordinates": [114.11445, 30.356522], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "chzs1990@163.com", "contactPhone": "+86 13627288300", "dateEnrollment": "2020-03-01", "description": "The clinical value of corticosteroid therapy timing in the treatment of novel coronavirus pneumonia (COVID-19): a prospective randomized controlled trial", "name": "ChiCTR2000030481", "primaryOutcome": "The time of duration of COVID-19 nucleic acid RT-PCR test results of respiratory specimens (such as throat swabs) or blood specimens change to negative.;", "study_type": "Interventional study", "time": "2020-03-03", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50453"}, "type": "Feature"}, {"geometry": {"coordinates": [114.583872, 30.596762], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "huilanz_76@163.com", "contactPhone": "+86 15391532171", "dateEnrollment": "2020-03-03", "description": "Randomized, open, blank controlled trial for the efficacy and safety of recombinant human interferon alpha 1beta in the treatment of Wuhan patients with novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030480", "primaryOutcome": "Incidence of side effects;", "study_type": "Interventional study", "time": "2020-03-03", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50470"}, "type": "Feature"}, {"geometry": {"coordinates": [118.88016, 31.934447], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "fangzjnj@hotmail.com", "contactPhone": "+86 13372018676", "dateEnrollment": "2020-02-26", "description": "Study for the Effectiveness and Safety of Yi-Qi Hua-shi Jie-Du-Fang in the Treatment of the Novel Coronavirus Pneumonia (COVID-19)", "name": "ChiCTR2000030479", "primaryOutcome": "lasting time of fever;lasting time of novel coronavirus pneumonia virus nucleic acid detected by RT-PCR and negative result rate of the novel coronavirus disease nucleic acid;", "study_type": "Interventional study", "time": "2020-03-03", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50450"}, "type": "Feature"}, {"geometry": {"coordinates": [116.398333, 39.929164], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "lixmpumch@126.com", "contactPhone": "+86 13911467356", "dateEnrollment": "2020-03-04", "description": "oXiris Membrane in Treating Critically Ill Hospitalized Adult Patients with novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030477", "primaryOutcome": "28 day mortality;", "study_type": "Interventional study", "time": "2020-03-03", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50458"}, "type": "Feature"}, {"geometry": {"coordinates": [116.524383, 39.855067], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "lixmpumch@126.com", "contactPhone": "+86 13911467356", "dateEnrollment": "2020-03-04", "description": "Cytosorb in Treating Critically Ill Hospitalized Adult Patients with novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030475", "primaryOutcome": "28 day mortality;", "study_type": "Interventional study", "time": "2020-03-03", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50452"}, "type": "Feature"}, {"geometry": {"coordinates": [123.426898, 41.800541], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "sylykjk@163.com", "contactPhone": "+86 18502468189", "dateEnrollment": "2020-02-25", "description": "An open and controlled clinical study to evaluate the efficacy and safety of Ganovo combined with ritonavir in the treatment of novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030472", "primaryOutcome": "Rate of composite advers outcomes: SPO2, PaO2/FiO2 and respiratory rate;", "study_type": "Interventional study", "time": "2020-03-03", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49753"}, "type": "Feature"}, {"geometry": {"coordinates": [110.84607, 21.93924], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "gghicu@163.com", "contactPhone": "+86 13922745788", "dateEnrollment": "2020-03-02", "description": "Efficacy and safety of lipoic acid injection in reducing the risk of progression in common patients with novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030471", "primaryOutcome": "Progression rate from mild to critical/severe;", "study_type": "Interventional study", "time": "2020-03-02", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50421"}, "type": "Feature"}, {"geometry": {"coordinates": [121.589997, 31.135576], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "Xiumingsong@sina.com", "contactPhone": "+86 13817525012", "dateEnrollment": "2020-02-27", "description": "A randomized parallel controlled trial for LIUSHENWAN in Treatment of Novel Coronavirus Pneumonia (COVID-19)", "name": "ChiCTR2000030469", "primaryOutcome": "fever clearance time;Effective rate of TCM symptoms;", "study_type": "Interventional study", "time": "2020-03-02", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50082"}, "type": "Feature"}, {"geometry": {"coordinates": [117.102071, 36.537669], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "zhagnweijinan@126.com", "contactPhone": "+86 13505319899", "dateEnrollment": "2020-02-28", "description": "Study for the key technique of integrative therapy of Novel Coronavirus Pneumonia (COVID-19): the TCM symptoms and treatment regulation", "name": "ChiCTR2000030468", "primaryOutcome": "disease incidence;Duration of PCR normalization;Distribution pattern of TCM syndromes;", "study_type": "Observational study", "time": "2020-03-02", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50390"}, "type": "Feature"}, {"geometry": {"coordinates": [121.577594, 38.927074], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "411484335@qq.com", "contactPhone": "+86 17709877386", "dateEnrollment": "2020-03-01", "description": "A Randomized  Controlled Trial  for the Influence of TCM Psychotherapy on Negative Emotion of Patients with Novel Coronavirus Pneumonia (COVID-19) Based on Network Platform", "name": "ChiCTR2000030467", "primaryOutcome": "Psychological status;", "study_type": "Interventional study", "time": "2020-03-02", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50378"}, "type": "Feature"}, {"geometry": {"coordinates": [113.258231, 23.159457], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "wucaineng861010@163.com", "contactPhone": "+86 13580315308", "dateEnrollment": "2020-03-02", "description": "Cancelled by the investigator                        Influence of nasal high-fow preoxygenation on video laryngoscope for emergency intubation in patients with critical novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030465", "primaryOutcome": "SpO2 during intubation;the total time of intubation;Mask ventilation for SpO2 < 90%;", "study_type": "Interventional study", "time": "2020-03-02", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50388"}, "type": "Feature"}, {"geometry": {"coordinates": [113.094884, 28.092601], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "gchxyy@163.com", "contactPhone": "+86 0731-88618338", "dateEnrollment": "2020-03-03", "description": "Study for the clinical characteristics of novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030464", "primaryOutcome": "Clinical characteristics;", "study_type": "Epidemilogical research", "time": "2020-03-02", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50382"}, "type": "Feature"}, {"geometry": {"coordinates": [120.802674, 27.829447], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "akidney_doctor@hotmail.com", "contactPhone": "+86 0577 55579261", "dateEnrollment": "2020-03-02", "description": "Clinical study for the effects of ACEIs/ARBs on the infection of novel coronavirus pneumonia (CoVID-19)", "name": "ChiCTR2000030453", "primaryOutcome": "ratio of severe cases;", "study_type": "Observational study", "time": "2020-03-02", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50381"}, "type": "Feature"}, {"geometry": {"coordinates": [121.420641, 31.181195], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "zhoujian@sjtu.edu.cn", "contactPhone": "+86 18930172033", "dateEnrollment": "2020-03-06", "description": "Application of flash glucose monitoring to evaluate the effect of blood glucose changes on prognosis in patients with novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030436", "primaryOutcome": "time in range;", "study_type": "Observational study", "time": "2020-03-01", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50297"}, "type": "Feature"}, {"geometry": {"coordinates": [114.329847, 30.571252], "type": "Point"}, "properties": {"classification": "Advanced therapy medicinal products", "contactEmail": "liubende99@outlook.com", "contactPhone": "+86 13907191851", "dateEnrollment": "2020-02-29", "description": "Cancelled, due to modify the protocol                                          A single-center, open-label and single arm trial to evaluate the efficacy and safety of anti-SARS-CoV-2 inactivated convalescent plasma in the treatment&", "name": "ChiCTR2000030312", "primaryOutcome": "Clinical symptom improvement rate: improvement rate of clinical symptoms = number of cases with clinical symptom improvement /number of enrolling cases * 100%;", "study_type": "Interventional study", "time": "2020-02-28", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50258"}, "type": "Feature"}, {"geometry": {"coordinates": [113.304412, 23.137034], "type": "Point"}, "properties": {"classification": "Impact on helpers", "contactEmail": "pangi88@126.com", "contactPhone": "+86 15626235237", "dateEnrollment": "2020-03-10", "description": "Protective factors of mental resilience in first-line nurses with novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030304", "primaryOutcome": "Mental status;Social support;", "study_type": "Observational study", "time": "2020-02-28", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49653"}, "type": "Feature"}, {"geometry": {"coordinates": [121.486092, 31.279422], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "18930568129@163.com", "contactPhone": "+86 18930568129", "dateEnrollment": "2020-02-25", "description": "A Medical Based Retrospective Real World Study for Assessment of Effectiveness of Comprehensive Traditional Chinese Medicine in the treatment of Novel Coronavirus Pneumonia (COVID-19)", "name": "ChiCTR2000030163", "primaryOutcome": "cure rate;duration of hospitalization;days of treatment;", "study_type": "Observational study", "time": "2020-02-24", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50031"}, "type": "Feature"}, {"geometry": {"coordinates": [114.599436, 30.564826], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "caiy_kf@163.com", "contactPhone": "+86 18702745799", "dateEnrollment": "2020-02-19", "description": "Cancelled due to lack of patient                               Effect of early pulmonary training on lung function and quality of life for novel coronavirus pneumonia (COVID-19) patients", "name": "ChiCTR2000030014", "primaryOutcome": "MRC breathlessness scale;6MWD;", "study_type": "Interventional study", "time": "2020-02-20", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49802"}, "type": "Feature"}, {"geometry": {"coordinates": [113.397887, 23.035742], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "yefeng@gird.cn", "contactPhone": "+86 13710494278; +86 13622273918", "dateEnrollment": "2020-02-20", "description": "A pilot study for Integrated Chinese and Western Medicine in the treatment of non-critical novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000029993", "primaryOutcome": "Main symptom relief time;", "study_type": "Interventional study", "time": "2020-02-18", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49435"}, "type": "Feature"}, {"geometry": {"coordinates": [114.330247, 30.57199], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "zhangzz@whu.edu.cn", "contactPhone": "+86 13971687403", "dateEnrollment": "2020-02-17", "description": "A medical records based study for the clinical characteristics of anesthesia novel coronavirus pneumonia (COVID-19) patients during perioperative period and assessment of infection and mental health of Anesthesiology Department", "name": "ChiCTR2000029958", "primaryOutcome": "CT image of lung;", "study_type": "Observational study", "time": "2020-02-17", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49635"}, "type": "Feature"}, {"geometry": {"coordinates": [116.525537, 39.860198], "type": "Point"}, "properties": {"classification": "Advanced therapy medicinal products", "contactEmail": "caobin_ben@163.com", "contactPhone": "13911318339", "dateEnrollment": "2020-02-14", "description": "Convalescent plasma for the treatment of severe and critical novel coronavirus pneumonia (COVID-19): a prospective randomized controlled trial", "name": "ChiCTR2000029757", "primaryOutcome": "the number of days between randomised grouping and clinical improvement;", "study_type": "Interventional study", "time": "2020-02-12", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49081"}, "type": "Feature"}, {"geometry": {"coordinates": [114.583872, 30.596762], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "zhougene@medmail.com.cn", "contactPhone": "+86 027 83665506", "dateEnrollment": "2020-01-31", "description": "Severe novel coronavirus pneumonia (COVID-19) patients treated with ruxolitinib in combination with mesenchymal stem cells: a prospective, single blind, randomized controlled clinical trial", "name": "ChiCTR2000029580", "primaryOutcome": "Safety;", "study_type": "Interventional study", "time": "2020-02-05", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49088"}, "type": "Feature"}, {"geometry": {"coordinates": [114.583872, 30.596762], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "zhougene@medmail.com.cn", "contactPhone": "+86 027-83665506", "dateEnrollment": "2020-01-31", "description": "The investigation of cytokine expression profile of novel coronavirus pneumonia (COVID-19) and its clinical significance", "name": "ChiCTR2000029579", "primaryOutcome": "Cytokines;", "study_type": "Observational study", "time": "2020-02-05", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49045"}, "type": "Feature"}, {"geometry": {"coordinates": [104.03945, 30.742342], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "xcg718@aliyun.com", "contactPhone": "+86 18980880132", "dateEnrollment": "2020-01-29", "description": "Recommendations for Diagnosis and Treatment of Influenza Patients in the Hospital of Chengdu University of Traditional Chinese Medicine Under the Raging of Novel Coronavirus Pneumonia (COVID-19)", "name": "ChiCTR2000029550", "primaryOutcome": "CRP;ESR;PCT;Tn;Mb;D-Dimer;blood routine examination;chest CT;creatase;", "study_type": "Interventional study", "time": "2020-02-04", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=48775"}, "type": "Feature"}, {"geometry": {"coordinates": [104.03945, 30.742342], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "xcg718@aliyun.com", "contactPhone": "+86 18980880132", "dateEnrollment": "2020-02-03", "description": "Recommendations of Integrated Traditional Chinese and Western Medicine for Novel Coronavirus Pneumonia (COVID-19)", "name": "ChiCTR2000029549", "primaryOutcome": "Severe conversion rate;Oxygenation index;2019-nCoV nucleic acid test;Chest CT;", "study_type": "Interventional study", "time": "2020-02-04", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49014"}, "type": "Feature"}, {"geometry": {"coordinates": [114.116215, 30.633456], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "1813886398@qq.com", "contactPhone": "13507117929", "dateEnrollment": "2020-01-10", "description": "A randomized, controlled open-label trial to evaluate the efficacy and safety of lopinavir-ritonavir in hospitalized patients with novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000029308", "primaryOutcome": "Clinical improvement time of 28 days after randomization;The 7-point scale;7 points: death;6 points: admission to ECMO and / or mechanical ventilation;5 points: Hospitalized for non-invasive ventilation and / or high-flow oxygen therapy;4 points: hospitalization for oxygen therapy;3 points: Hospitalization does not require oxygen therapy;2 points: discharged but not restored to normal functional status;1 point: discharged to normal function;", "study_type": "Interventional study", "time": "2020-01-23", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=48684"}, "type": "Feature"}, {"geometry": {"coordinates": [119.306501, 26.087529], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "", "contactPhone": "", "dateEnrollment": "January 1, 2020", "description": "Clinical Progressive Characteristics and Treatment Effects of 2019-novel Coronavirus", "name": "NCT04292327", "primaryOutcome": "Mortality;The time interval of Nucleic acid detection become negative", "study_type": "Observational", "time": "2020-02-23", "weburl": "https://clinicaltrials.gov/show/NCT04292327"}, "type": "Feature"}, {"geometry": {"coordinates": [121.341379, 30.791749], "type": "Point"}, "properties": {"classification": "Advanced therapy medicinal products", "contactEmail": ";luhongzhou@fudan.edu.cn;", "contactPhone": ";+86-021-37990333;008602137990333", "dateEnrollment": "February 1, 2020", "description": "Anti-SARS-CoV-2 Inactivated Convalescent Plasma in the Treatment of COVID-19", "name": "NCT04292340", "primaryOutcome": "The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 1;The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 3;The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 7;Numbers of participants with different Clinical outcomes", "study_type": "Observational", "time": "2020-02-25", "weburl": "https://clinicaltrials.gov/show/NCT04292340"}, "type": "Feature"}, {"geometry": {"coordinates": [114.242864, 30.596649], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "Zhaojp88@126.com", "contactPhone": "13507138234", "dateEnrollment": "March 1, 2020", "description": "Efficacy and Safety of IFN-a2ß in the Treatment of Novel Coronavirus Patients", "name": "NCT04293887", "primaryOutcome": "The incidence of side effects;The incidence of side effects;The incidence of side effects", "study_type": "Interventional", "time": "2020-02-15", "weburl": "https://clinicaltrials.gov/show/NCT04293887"}, "type": "Feature"}, {"geometry": {"coordinates": [114.974723, 25.824843], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "", "contactPhone": "", "dateEnrollment": "March 14, 2020", "description": "Multicenter Clinical Study on the Efficacy and Safety of Xiyanping Injection in the Treatment of New Coronavirus Infection Pneumonia (General and Severe)", "name": "NCT04295551", "primaryOutcome": "Clinical recovery time", "study_type": "Interventional", "time": "2020-03-03", "weburl": "https://clinicaltrials.gov/show/NCT04295551"}, "type": "Feature"}, {"geometry": {"coordinates": [-79.919225, 43.260879], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": ";loebm@mcmaster.ca", "contactPhone": ";9053340010", "dateEnrollment": "April 1, 2020", "description": "Medical Masks vs N95 Respirators for COVID-19", "name": "NCT04296643", "primaryOutcome": "RT-PCR confirmed COVID-19 infection", "study_type": "Interventional", "time": "2020-03-03", "weburl": "https://clinicaltrials.gov/show/NCT04296643"}, "type": "Feature"}, {"geometry": {"coordinates": [114.242864, 30.596649], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "", "contactPhone": "", "dateEnrollment": "March 7, 2020", "description": "Safety Related Factors of Endotracheal Intubation in Patients With Severe Covid-19 Pneumonia", "name": "NCT04298814", "primaryOutcome": "Success rate of intubation;Infection rate of Anesthesiologist", "study_type": "Observational", "time": "2020-02-26", "weburl": "https://clinicaltrials.gov/show/NCT04298814"}, "type": "Feature"}, {"geometry": {"coordinates": [113.545779, 22.130002], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "", "contactPhone": "", "dateEnrollment": "October 15, 2020", "description": "Mental Health and Its Correlates Among Chinese Adolescents Exposed to the Novel Coronavirus Disease 2019", "name": "NCT04299711", "primaryOutcome": "The prevalence and incidence changes of common mental disorders", "study_type": "Observational", "time": "2020-03-04", "weburl": "https://clinicaltrials.gov/show/NCT04299711"}, "type": "Feature"}, {"geometry": {"coordinates": [112.24472, 30.30722], "type": "Point"}, "properties": {"classification": "Other", "contactEmail": "49637569@qq.com", "contactPhone": "+86 13872250922", "dateEnrollment": "2020-02-10", "description": "Analysis for the mental health status of residents in Jingzhou during the outbreak of the novel coronavirus pneumonia (COVID-19) and corresponding influencing factors", "name": "ChiCTR2000030902", "primaryOutcome": "mental health status and influence factors;", "study_type": "Observational study", "time": "2020-03-16", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51130"}, "type": "Feature"}, {"geometry": {"coordinates": [114.187, 22.394766], "type": "Point"}, "properties": {"classification": "Other", "contactEmail": "chris.kclai@cuhk.edu.hk", "contactPhone": "+852 3505 3333", "dateEnrollment": "2020-03-09", "description": "Retrospective analysis of epidemiology and transmission dynamics of patients confirmed with Coronavirus Disease (COVID-19) in Hong Kong", "name": "ChiCTR2000030901", "primaryOutcome": "Transmission dynamics of COVID-19 in Hong Kong;Characteristics of super-spreading events;Effectiveness of public health measures;", "study_type": "Observational study", "time": "2020-03-16", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51064"}, "type": "Feature"}, {"geometry": {"coordinates": [125.287553, 43.876827], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "Wangtan215@sina.com", "contactPhone": "+86 13756858523", "dateEnrollment": "2020-01-27", "description": "Evaluation on the effect of Chushifangyi prescription in preventing novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030898", "primaryOutcome": "Confirmed 2019-ncov pneumonia;", "study_type": "Observational study", "time": "2020-03-16", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50780"}, "type": "Feature"}, {"geometry": {"coordinates": [121.547125, 29.858033], "type": "Point"}, "properties": {"classification": "Other", "contactEmail": "yehonghua@medmail.com.cn", "contactPhone": "+86 13505743664", "dateEnrollment": "2020-02-10", "description": "Evaluation of the effect of taking Newgen beta-gluten probiotic composite powder to nutrition intervention of patients with novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030897", "primaryOutcome": "serum albumin;siderophilin;prealbumin;lung CT scanning result;", "study_type": "Interventional study", "time": "2020-03-16", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50462"}, "type": "Feature"}, {"geometry": {"coordinates": [118.874699, 24.842111], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "13803818341@163.com", "contactPhone": "+86 13803818341", "dateEnrollment": "2020-02-06", "description": "Clinical Application and Theoretical Discussion of Fu-Zheng Qing-Fei Thought in Treating Non-Critical Novel Coronavirus Pneumonia (COVID-19)", "name": "ChiCTR2000030896", "primaryOutcome": "Improvement of symptoms;", "study_type": "Interventional study", "time": "2020-03-16", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51028"}, "type": "Feature"}, {"geometry": {"coordinates": [114.436641, 30.464912], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "majingzhi2002@163.com", "contactPhone": "+86 13871257728", "dateEnrollment": "2020-03-14", "description": "Retrospective and Prospective Study for Nosocomial infection in Stomatology Department under the Background of novel coronavirus pneumonia (COVID-19) epidemic period", "name": "ChiCTR2000030895", "primaryOutcome": "nosocomial infection ratio of SARS-Cov-2;", "study_type": "Observational study", "time": "2020-03-16", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51034"}, "type": "Feature"}, {"geometry": {"coordinates": [116.453818, 39.804522], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "john131212@126.com", "contactPhone": "+86 13911405123", "dateEnrollment": "2020-03-01", "description": "Favipiravir Combined With Tocilizumab in the Treatment of novel coronavirus pneumonia (COVID-19) - A Multicenter, Randomized, Controlled Trial", "name": "ChiCTR2000030894", "primaryOutcome": "Clinical cure rate;", "study_type": "Interventional study", "time": "2020-03-16", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51126"}, "type": "Feature"}, {"geometry": {"coordinates": [118.859254, 24.858547], "type": "Point"}, "properties": {"classification": "Impact on helpers", "contactEmail": "WH9400@163.com", "contactPhone": "+86 15937129400", "dateEnrollment": "2020-03-19", "description": "Study for effects of crisis intervention based on positive psychology for medical staffs working in the novel coronavirus pneumonia (COVID-19) field", "name": "ChiCTR2000030893", "primaryOutcome": "Symptom Checklist 90;", "study_type": "Observational study", "time": "2020-03-16", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51073"}, "type": "Feature"}, {"geometry": {"coordinates": [113.397887, 23.035742], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "luoqunx@163.com", "contactPhone": "+86 13710658121", "dateEnrollment": "2020-03-06", "description": "Efficacy and Safety of Pirfenidone in the Treatment of Severe Post-Novel Coronavirus Pneumonia (COVID-19) Fibrosis: a prospective exploratory experimental medical study", "name": "ChiCTR2000030892", "primaryOutcome": "HRCT pulmonary fibrosis score;", "study_type": "Interventional study", "time": "2020-03-16", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51118"}, "type": "Feature"}, {"geometry": {"coordinates": [105.425241, 28.894928], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "lykyk3160823@126.com", "contactPhone": "+86 15228218357", "dateEnrollment": "2020-02-18", "description": "Clinical research and preparation development of qingfei detoxification decoction (mixture) for prevention and treatment of novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030883", "primaryOutcome": "temperature;Systemic symptom;Respiratory symptoms;Chest imaging changes;Detection of novel coronavirus nucleic acid two consecutive negative time;", "study_type": "Observational study", "time": "2020-03-16", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50960"}, "type": "Feature"}, {"geometry": {"coordinates": [109.69133, 35.99219], "type": "Point"}, "properties": {"classification": "Advanced therapy medicinal products", "contactEmail": "1286779459@qq.com", "contactPhone": "+86 13975137399", "dateEnrollment": "2020-02-01", "description": "Open-label, observational study of human umbilical cord derived mesenchymal stem cells in the treatment of severe and critical patients with novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030866", "primaryOutcome": "Oxygenation index (arterial oxygen partial pressure (PaO2) / oxygen concentration (FiO2));Conversion rate from serious to critical patients;Conversion rate and conversion time from critical to serious patients;Mortality in serious and critical patients;", "study_type": "Observational study", "time": "2020-03-16", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50299"}, "type": "Feature"}, {"geometry": {"coordinates": [114.583872, 30.596762], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "xpluo@tjh.tjmu.edu.cn", "contactPhone": "+86 027-83662684", "dateEnrollment": "2020-02-01", "description": "Establishment of an early warning model for maternal and child vertical transmission of COVID-19 infection", "name": "ChiCTR2000030865", "primaryOutcome": "Maternal and neonatal morbidity;", "study_type": "Observational study", "time": "2020-03-16", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49933"}, "type": "Feature"}, {"geometry": {"coordinates": [112.269727, 31.945686], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "274770142@qq.com", "contactPhone": "+86 13995789500", "dateEnrollment": "2020-02-01", "description": "Traditional Chinese Medicine for novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030864", "primaryOutcome": "2019-ncov-RNA;Chest CT;Routine blood test;Blood biochemistry;TCM symptom;", "study_type": "Interventional study", "time": "2020-03-16", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50662"}, "type": "Feature"}, {"geometry": {"coordinates": [118.778518, 32.043882], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "cjr.luguangming@vip.163.com", "contactPhone": "+86 13951608346", "dateEnrollment": "2020-01-22", "description": "Clinical and CT imaging Characteristics of novel coronavirus pneumonia (COVID-19): An Multicenter Cohort Study", "name": "ChiCTR2000030863", "primaryOutcome": "chest CT images;", "study_type": "Observational study", "time": "2020-03-16", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50767"}, "type": "Feature"}, {"geometry": {"coordinates": [114.583872, 30.596762], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "13971587381@163.com", "contactPhone": "+86 13971587381", "dateEnrollment": "2020-01-24", "description": "Correlation analysis of blood eosinophil cell levels and clinical type category of novel coronavirus pneumonia (COVID-19): a medical records based retrospective study", "name": "ChiCTR2000030862", "primaryOutcome": "Laboratory inspection index;Oxygen therapy case;Film degree exam;", "study_type": "Observational study", "time": "2020-03-16", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51107"}, "type": "Feature"}, {"geometry": {"coordinates": [113.397887, 23.035742], "type": "Point"}, "properties": {"classification": "Diagnosis", "contactEmail": "lishiyue@188.com", "contactPhone": "+86 13902233925", "dateEnrollment": "2019-02-27", "description": "Development and application of a new intelligent robot for novel coronavirus (2019-nCOV) oropharygeal sampling", "name": "ChiCTR2000030861", "primaryOutcome": "CT;", "study_type": "Health services reaserch", "time": "2020-03-16", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51103"}, "type": "Feature"}, {"geometry": {"coordinates": [114.583872, 30.596762], "type": "Point"}, "properties": {"classification": "Diagnosis", "contactEmail": "aloof3737@126.com", "contactPhone": "+86 18971201115", "dateEnrollment": "2020-03-16", "description": "A medical records based study for investigation of dynamic profile of RT-PCR test for SARS-CoV-2 nucleic acid of novel coronavirus pneumonia (COVID-19) patients", "name": "ChiCTR2000030860", "primaryOutcome": "RT-PCR test for SARS-CoV-2;", "study_type": "Observational study", "time": "2020-03-16", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51102"}, "type": "Feature"}, {"geometry": {"coordinates": [114.235018, 30.265298], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "707986890@qq.com", "contactPhone": "+86 18971163158", "dateEnrollment": "2020-03-01", "description": "A medical based analysis for influencing factors of death of novel coronavirus pneumonia (COVID-19) patients in Wuhan third hospital", "name": "ChiCTR2000030859", "primaryOutcome": "Mortality rate;", "study_type": "Observational study", "time": "2020-03-16", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51025"}, "type": "Feature"}, {"geometry": {"coordinates": [114.43677, 30.464751], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "tiejunwanghp@163.com", "contactPhone": "+86 13277914596", "dateEnrollment": "2020-02-06", "description": "Clinical characteristics and outcomes of 483 mild patients with novel coronavirus pneumonia (COVID-19) in Wuhan, China during the outbreak: A single-center, retrospective study from the mobile cabin hospital", "name": "ChiCTR2000030858", "primaryOutcome": "Discharge rate;", "study_type": "Observational study", "time": "2020-03-16", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51097"}, "type": "Feature"}, {"geometry": {"coordinates": [114.583872, 30.596762], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "Shushengli16@sina.com", "contactPhone": "+86 13971086498", "dateEnrollment": "2020-03-01", "description": "Clinical study for bronchoscopic alveolar lavage in the treatment of critically trachea intubation patients with new coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030857", "primaryOutcome": "cytology;proteomics;chest X-ray;Oxygenation index;", "study_type": "Observational study", "time": "2020-03-16", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51040"}, "type": "Feature"}, {"geometry": {"coordinates": [114.583872, 30.596762], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "Lmxia@tjh.tjmu.edu.cn", "contactPhone": "+86 13607176908", "dateEnrollment": "2020-02-15", "description": "An artificial intelligence assistant system for suspected novel coronavirus pneumonia (COVID-19) based on chest CT", "name": "ChiCTR2000030856", "primaryOutcome": "sensitivity;SPE;", "study_type": "Diagnostic test", "time": "2020-03-16", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51091"}, "type": "Feature"}, {"geometry": {"coordinates": [106.908193, 27.704295], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "zywenjianli@163.com", "contactPhone": "+86 15186660001", "dateEnrollment": "2020-02-01", "description": "Study for the effect of external diaphragmatic pacing assisted invasive ventilation and weaning in patients with severe novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030855", "primaryOutcome": "Length of stay in ICU;Diaphragm movement;", "study_type": "Interventional study", "time": "2020-03-16", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51090"}, "type": "Feature"}, {"geometry": {"coordinates": [121.17623, 30.179772], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "ljli@zju.edu.cn", "contactPhone": "+86 13906514210", "dateEnrollment": "2020-01-22", "description": "A clinical multicenter study for the occurrence, development and prognosis of novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030854", "primaryOutcome": "white blood cell;lymphocyte;creatinine;CRP;", "study_type": "Observational study", "time": "2020-03-16", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51083"}, "type": "Feature"}, {"geometry": {"coordinates": [106.892748, 27.720731], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "zywenjianli@163.com", "contactPhone": "+86 15186660001", "dateEnrollment": "2020-02-01", "description": "Evaluation of the protective effect of dexmedetomidine on patients with severe novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030853", "primaryOutcome": "CK-MB;CTnI;neuron-specific enolase,NSE;BUN;scr.;lactic acid;", "study_type": "Interventional study", "time": "2020-03-16", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51081"}, "type": "Feature"}, {"geometry": {"coordinates": [116.470357, 39.926495], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "frank782008@aliyun.com", "contactPhone": "+86 13161985564", "dateEnrollment": "2020-01-27", "description": "Factors associated with death in patients with novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030852", "primaryOutcome": "Death;", "study_type": "Observational study", "time": "2020-03-16", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51077"}, "type": "Feature"}, {"geometry": {"coordinates": [113.36585, 23.080767], "type": "Point"}, "properties": {"classification": "Impact on helpers", "contactEmail": "liufb163@163.com", "contactPhone": "+86 020-36591782", "dateEnrollment": "2020-03-15", "description": "Study for the physical and mental health status of medical workers under the novel coronavirus pneumonia (COVID-19) epidemic", "name": "ChiCTR2000030850", "primaryOutcome": "Chinese health status scale;Self-rating Anxiety Scale;Self-rating Depression Scale;", "study_type": "Observational study", "time": "2020-03-15", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51056"}, "type": "Feature"}, {"geometry": {"coordinates": [118.859254, 24.858547], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "haoyibin0506@126.com", "contactPhone": "+86 15903715671", "dateEnrollment": "2020-03-16", "description": "Investigation on psychological status of novel coronavirus pneumonia (COVID-19) rehabilitation patients in Zhengzhou City and research on coping strategies", "name": "ChiCTR2000030849", "primaryOutcome": "SCL-90 scale;", "study_type": "Interventional study", "time": "2020-03-15", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51086"}, "type": "Feature"}, {"geometry": {"coordinates": [114.417893, 30.447842], "type": "Point"}, "properties": {"classification": "Advanced therapy medicinal products", "contactEmail": "nathancx@hust.edu.cn", "contactPhone": "+86 15972061080", "dateEnrollment": "2020-02-17", "description": "Exploratory study for Immunoglobulin From Cured COVID-19 Patients in the Treatment of Acute Severe novel coronavirus pneuvirus (COVID-19)", "name": "ChiCTR2000030841", "primaryOutcome": "Time to Clinical Improvement (TTCI);", "study_type": "Interventional study", "time": "2020-03-15", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51072"}, "type": "Feature"}, {"geometry": {"coordinates": [121.400128, 31.207382], "type": "Point"}, "properties": {"classification": "Diagnosis", "contactEmail": "SP2082@shtrhospital.com", "contactPhone": "+86 18121225835", "dateEnrollment": "2020-03-01", "description": "Preliminary screening of novel coronavirus pneumonia (COVID-19) by special laboratory examination and CT imaging before surgery", "name": "ChiCTR2000030839", "primaryOutcome": "SAA;Detection of respiratory pathogen serotype;Lymphocyte subgroup detection;IgM and IgG detection;Pulmonary CT;", "study_type": "Screening", "time": "2020-03-15", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50904"}, "type": "Feature"}, {"geometry": {"coordinates": [114.11445, 30.356522], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "xuhaibo1120@hotmail.com", "contactPhone": "+86 13545009416", "dateEnrollment": "2020-01-20", "description": "Development of warning system with clinical differential diagnosis and prediction for severe type of novel coronavirus pneumonia (COVID-19) patients based on artificial intelligence and CT images", "name": "ChiCTR2000030838", "primaryOutcome": "Precision;SEN, SPE, ACC, AUC of ROC;", "study_type": "Diagnostic test", "time": "2020-03-15", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51071"}, "type": "Feature"}, {"geometry": {"coordinates": [121.414884, 31.203951], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "fangbji@163.com", "contactPhone": "+86 18917763257", "dateEnrollment": "2020-02-01", "description": "Novel coronavirus pneumonia (COVID-19) combined with Chinese and Western medicine based on ''Internal and External Relieving -Truncated Torsion'' strategy", "name": "ChiCTR2000030836", "primaryOutcome": "14 day outcome of the subjects, including: recovery, improvement, turning critical, death. ;Lung CT;", "study_type": "Interventional study", "time": "2020-03-15", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51054"}, "type": "Feature"}, {"geometry": {"coordinates": [112.46077, 33.78483], "type": "Point"}, "properties": {"classification": "Advanced therapy medicinal products", "contactEmail": "douqifeng@126.com", "contactPhone": "+86 13503735556", "dateEnrollment": "2020-02-14", "description": "Clinical study for the efficacy of Mesenchymal stem cells (MSC) in the treatment of severe novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030835", "primaryOutcome": "", "study_type": "Interventional study", "time": "2020-03-15", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51050"}, "type": "Feature"}, {"geometry": {"coordinates": [114.583824, 29.452049], "type": "Point"}, "properties": {"classification": "Impact on helpers", "contactEmail": "haoyaner@163.com", "contactPhone": "+86 13971679960", "dateEnrollment": "2020-03-16", "description": "Epidemiological Characteristics and Antibody Levels of novel coronavirus pneumonia (COVID-19) of Pediatric Medical Staff working in Quarantine Area", "name": "ChiCTR2000030834", "primaryOutcome": "Epidemiological characteristics;SARS-CoV-2 IgM, IgG antibody titer test result;", "study_type": "Observational study", "time": "2020-03-15", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51047"}, "type": "Feature"}, {"geometry": {"coordinates": [114.436637, 30.464899], "type": "Point"}, "properties": {"classification": "Diagnosis", "contactEmail": "qning@vip.sina.com", "contactPhone": "+86 027-83662391", "dateEnrollment": "2020-03-22", "description": "Clinical validation and application of high-throughput novel coronavirus (2019-nCoV) screening detection kit", "name": "ChiCTR2000030833", "primaryOutcome": "RNA of 2019-nCov;SPE, SEN, ACC, AUC of ROC;", "study_type": "Diagnostic test", "time": "2020-03-15", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51035"}, "type": "Feature"}, {"geometry": {"coordinates": [114.583872, 30.596762], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "yuanyang70@hotmail.com", "contactPhone": "+86 13995561816", "dateEnrollment": "2020-03-16", "description": "Study for the pathogenesis and effective intervention of mood disorders caused by the novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030832", "primaryOutcome": "PHQ-9;GAD-7;PHQ-15;PSS-14;ISI;SHARPS;ACTH;cortisol;24-hour ECG;Magnetic resonance spectroscopy;", "study_type": "Interventional study", "time": "2020-03-15", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51044"}, "type": "Feature"}, {"geometry": {"coordinates": [114.583872, 30.596762], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "whtuye@163.com", "contactPhone": "+86 18986152706", "dateEnrollment": "2020-01-01", "description": "The analysis of related factors on improving oxygenation status by endotracheal intubation ventilation in severe patients suffered from novel coronavirus pneumonia (COVID-19): a single center and descriptive study in Wuhan", "name": "ChiCTR2000030831", "primaryOutcome": "Laboratory inspection index;Imaging examination results(chest CT);performance of intubation;therapeutic schedule;prognosis;", "study_type": "Observational study", "time": "2020-03-15", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51036"}, "type": "Feature"}, {"geometry": {"coordinates": [121.519342, 29.864413], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "jingfengzhang73@163.com", "contactPhone": "+86 15706855886", "dateEnrollment": "2020-01-01", "description": "Development and application of novel coronavirus pneumonia (COVID-19) intelligent image classification system based on deep learning", "name": "ChiCTR2000030830", "primaryOutcome": "Abnormalities on chest CT;Exposure to source of transmission within past 14 days;", "study_type": "Observational study", "time": "2020-03-15", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51009"}, "type": "Feature"}, {"geometry": {"coordinates": [114.235018, 30.265298], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "hcwy100@163.com", "contactPhone": "+86 13871480868", "dateEnrollment": "2020-03-01", "description": "Retrospective analysis of digestive system symptoms in 600 cases of novel coronavirus pneumonia (COVID-19) in Guanggu district, Wuhan", "name": "ChiCTR2000030819", "primaryOutcome": "Liver function;", "study_type": "Observational study", "time": "2020-03-15", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51039"}, "type": "Feature"}, {"geometry": {"coordinates": [118.891237, 24.857572], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "maozhengrong1971@163.com", "contactPhone": "+86 18695808321", "dateEnrollment": "2020-01-31", "description": "A medical records based study for the value of Lymphocyte subsets in the diagnose and treatment of novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030818", "primaryOutcome": "ymphocyte subsets;", "study_type": "Observational study", "time": "2020-03-15", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51037"}, "type": "Feature"}, {"geometry": {"coordinates": [114.583872, 30.596762], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "bianyi2526@163.com", "contactPhone": "+86 15102710366", "dateEnrollment": "2020-02-24", "description": "Nutritional risk assessment and outcome prediction of critically ill novel coronavirus pneumonia (COVID-19) patients", "name": "ChiCTR2000030816", "primaryOutcome": "Mortality of ICU 28-day;", "study_type": "Observational study", "time": "2020-03-15", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51048"}, "type": "Feature"}, {"geometry": {"coordinates": [114.583872, 30.596762], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "eyedrwjm@163.com", "contactPhone": "+86 13886169836", "dateEnrollment": "2020-02-20", "description": "A medical records based analysis of clinical evidence of human-to-human transmission of 2019 novel coronavirus pneumonia (COVID-19) by conjunctival route", "name": "ChiCTR2000030814", "primaryOutcome": "Ocular  Symptoms;", "study_type": "Observational study", "time": "2020-03-15", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51042"}, "type": "Feature"}, {"geometry": {"coordinates": [121.362461, 31.357599], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "dr.xu@aliyun.com", "contactPhone": "+86 13501722091", "dateEnrollment": "2020-01-31", "description": "Study for the virus molecular evolution which driven the immune-pathological responses and the protection mechanisms of novel coronavirus pneumonia (COVID-19) patients", "name": "ChiCTR2000030812", "primaryOutcome": "Single cell sequencing;", "study_type": "Observational study", "time": "2020-03-15", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50947"}, "type": "Feature"}, {"geometry": {"coordinates": [115.756619, 30.659471], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "spine672@163.com", "contactPhone": "+86 13807172756", "dateEnrollment": "2020-02-23", "description": "Clinical observation and evaluation of traditional Chinese medicine in the treatment of novel coronavirus pneumonia (COVID-19) in Hubei 672 Orthopaedics Hospital of Integrated Chinese&Western Medicine", "name": "ChiCTR2000030810", "primaryOutcome": "Average discharge time;WBC;ALT, AST, gama-GT, BUN, Cr, CK-MB;turn serious/crisis ratio;", "study_type": "Interventional study", "time": "2020-03-15", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50986"}, "type": "Feature"}, {"geometry": {"coordinates": [114.583872, 30.596762], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "sxu@hust.edu.cn", "contactPhone": "+86 13517248539", "dateEnrollment": "2020-02-22", "description": "A medical records based study for clinical outcomes and follow-up of novel coronavirus pneumonia (COVID-19) patients", "name": "ChiCTR2000030809", "primaryOutcome": "Clinical outcomes after discharge;", "study_type": "Observational study", "time": "2020-03-15", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51015"}, "type": "Feature"}, {"geometry": {"coordinates": [114.583872, 30.596762], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "zhwang_hust@hotmail.com", "contactPhone": "+86 13607195518", "dateEnrollment": "2020-02-15", "description": "Clinical characteristics and prognosis of cancer patients with novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030807", "primaryOutcome": "lynphocyte;cytokine;cancer history;order of severity;", "study_type": "Observational study", "time": "2020-03-15", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51019"}, "type": "Feature"}, {"geometry": {"coordinates": [115.77335, 30.67475], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "137585260@qq.com", "contactPhone": "+86 13907105212", "dateEnrollment": "2020-02-01", "description": "Retrospective study for the efficacy of ulinastatin combined with ''clear lung detoxification soup'' in the treatment of novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030806", "primaryOutcome": "blood RT;ABG;blood clotting function;liver and kidney function;", "study_type": "Observational study", "time": "2020-03-15", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51029"}, "type": "Feature"}, {"geometry": {"coordinates": [114.583872, 30.596762], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "wang6@tjh.tjmu.edu.cn", "contactPhone": "+86 13971625289", "dateEnrollment": "2020-02-15", "description": "Quantitative CT characteristic estimate the severity of novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030805", "primaryOutcome": "Quantitative CT characteristic;", "study_type": "Observational study", "time": "2020-03-15", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51026"}, "type": "Feature"}, {"geometry": {"coordinates": [110.830625, 21.955676], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "hulinhui@live.cn", "contactPhone": "+86 13580013426", "dateEnrollment": "2020-02-01", "description": "Exocarpium Citri Grandis Relieves Symptoms of Novel Coronavirus Pneunomia (COVID-19): a Randomized Controlled Clinical Trial", "name": "ChiCTR2000030804", "primaryOutcome": "Cough Score;Expectoration score;", "study_type": "Interventional study", "time": "2020-03-15", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51018"}, "type": "Feature"}, {"geometry": {"coordinates": [114.436774, 30.464884], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "314440820@qq.com", "contactPhone": "+86 13797062903", "dateEnrollment": "2020-01-31", "description": "Collection and analysis of clinical data in severe and critically ill patients with novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030803", "primaryOutcome": "age;sex;comorbidities;chest-CT examination;standard blood counts;albumin;pre-albumin;hemoglobin;alanine transaminase;aspartate transaminase;creatinine;glucose;lipids;procalcitonin;C-reactive protein;coagulation function;nutritional risk screening;body weight;body height;prognosis;", "study_type": "Observational study", "time": "2020-03-15", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51007"}, "type": "Feature"}, {"geometry": {"coordinates": [114.583872, 30.596762], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "ld_2069@163.com", "contactPhone": "+86 13507183749", "dateEnrollment": "2020-01-27", "description": "A retrospective study of clinical drug therapy in patients with novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030802", "primaryOutcome": "time  and rate of cure; proportion and time of patients who progressed to severe disease;", "study_type": "Observational study", "time": "2020-03-15", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51004"}, "type": "Feature"}, {"geometry": {"coordinates": [114.236748, 30.264066], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "541163409@qq.com", "contactPhone": "+86 18627151212", "dateEnrollment": "2020-01-23", "description": "Analysis of risk factors affecting prognosis of elderly patients infected with novel coronavirus pneumonia (COVID-19): a single-center retrospective observational study", "name": "ChiCTR2000030801", "primaryOutcome": "discharg time;", "study_type": "Observational study", "time": "2020-03-15", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50998"}, "type": "Feature"}, {"geometry": {"coordinates": [106.937117, 27.709545], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "kiphoonwu@126.com", "contactPhone": "+86 13788989286", "dateEnrollment": "2020-02-01", "description": "Cancelled by the investigator                Study on levels of inflammatory factors in peripheral blood of patients with novel coronavirus pneumonia (COVID-19) and their diagnostic and prognostic value", "name": "ChiCTR2000030800", "primaryOutcome": "", "study_type": "Diagnostic test", "time": "2020-03-15", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50997"}, "type": "Feature"}, {"geometry": {"coordinates": [114.436641, 30.464912], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "wt7636@126.com", "contactPhone": "+86 13971477320", "dateEnrollment": "2020-01-20", "description": "Establishment and validation of Premonitory model of deterioration of the 2019 novel corona virus pneumonia (COVID-19)", "name": "ChiCTR2000030799", "primaryOutcome": "cure rate;propotion of progression;SEN, SPE, ACC, AUC of ROC;", "study_type": "Diagnostic test", "time": "2020-03-15", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50995"}, "type": "Feature"}, {"geometry": {"coordinates": [114.235018, 30.265298], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "273225540@qq.com", "contactPhone": "+86 15377628125", "dateEnrollment": "2020-02-10", "description": "A medical records based study for clinical characteristics of novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030798", "primaryOutcome": "blood biochemistry;", "study_type": "Observational study", "time": "2020-03-15", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50994"}, "type": "Feature"}, {"geometry": {"coordinates": [121.401457, 31.008176], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "xuyingjia@5thhospital.com", "contactPhone": "+86 18017321696", "dateEnrollment": "2020-03-07", "description": "clinical study for hemodynamics and cardiac arrhythmia of novel coronavirus pneumonia (COVID-19) patients", "name": "ChiCTR2000030797", "primaryOutcome": "all-cause death;fatal arrhythmias;", "study_type": "Observational study", "time": "2020-03-15", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50988"}, "type": "Feature"}, {"geometry": {"coordinates": [114.492935, 38.035112], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "yuanyd1108@163.com", "contactPhone": "+86 15833119392", "dateEnrollment": "2020-01-29", "description": "Clinical characteristics and treatment of novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030796", "primaryOutcome": "mortality;effective rate;", "study_type": "Observational study", "time": "2020-03-15", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50991"}, "type": "Feature"}, {"geometry": {"coordinates": [114.583872, 30.596762], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "tjhdongll@163.com", "contactPhone": "+86 18672912727", "dateEnrollment": "2020-03-20", "description": "A multicenter retrospective study of rheumatic  patients with novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030795", "primaryOutcome": "Clinical features;", "study_type": "Observational study", "time": "2020-03-15", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50982"}, "type": "Feature"}, {"geometry": {"coordinates": [108.328009, 22.803234], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "zhangguogx@hotmail.com", "contactPhone": "+86 13978839646", "dateEnrollment": "2020-01-17", "description": "A study for clinical characteristics of novel coronavirus pneumonia (COVID-19) patients follow-up in Guangxi", "name": "ChiCTR2000030784", "primaryOutcome": "Epidemiological characteristics;clinical features;Treatment outcome;", "study_type": "Observational study", "time": "2020-03-14", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50307"}, "type": "Feature"}, {"geometry": {"coordinates": [116.864324, 38.317421], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "849614995@qq.com", "contactPhone": "+86 13832102657", "dateEnrollment": "2020-02-01", "description": "The value of CD4 / CD8 cells, CRP / ALB and APCHEII in novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030782", "primaryOutcome": "28-day prognosis;", "study_type": "Observational study", "time": "2020-03-14", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50976"}, "type": "Feature"}, {"geometry": {"coordinates": [121.565991, 31.138421], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "linzhaofen@sina.com", "contactPhone": "+86 13601605100, 13301833859, 13701682806", "dateEnrollment": "2020-03-16", "description": "A clinical trial for Ulinastatin Injection in the treatment of patients with severe novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030779", "primaryOutcome": "blood gas;SOFA score;", "study_type": "Interventional study", "time": "2020-03-14", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50973"}, "type": "Feature"}, {"geometry": {"coordinates": [121.563269, 29.882308], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "guoqing.qian@foxmail.com", "contactPhone": "+86 15888193663", "dateEnrollment": "2020-01-20", "description": "A medical records based study for epidemic and clinical features of novel coronavirus pneumonia (COVID-19) in Ningbo First Hospital", "name": "ChiCTR2000030778", "primaryOutcome": "Epidemiological features;", "study_type": "Observational study", "time": "2020-03-14", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50987"}, "type": "Feature"}, {"geometry": {"coordinates": [121.604885, 31.152031], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "money_0921@163.com", "contactPhone": "+86 13816108686", "dateEnrollment": "2020-02-12", "description": "Application of blood purification in the treatment of novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030773", "primaryOutcome": "death;Number of failure organs;Length of hospital stay;", "study_type": "Interventional study", "time": "2020-03-14", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50934"}, "type": "Feature"}, {"geometry": {"coordinates": [114.11445, 30.356522], "type": "Point"}, "properties": {"classification": "Impact on helpers", "contactEmail": "zn_chenxiong@126.com", "contactPhone": "+86 13995599373", "dateEnrollment": "2020-02-01", "description": "Study for the Psychological Status of Medical Staff of Otolaryngology Head and Neck Surgery in Hubei Province under the Epidemic of novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030768", "primaryOutcome": "anxiety;", "study_type": "Epidemilogical research", "time": "2020-03-14", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50968"}, "type": "Feature"}, {"geometry": {"coordinates": [116.30185, 39.979566], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "970236538@qq.com", "contactPhone": "+86 13699207252", "dateEnrollment": "2020-03-07", "description": "Research for the influence of epidemic of novel coronavirus pneumonia (COVID-19) on sleep, psychological and chronic diseases among different populations", "name": "ChiCTR2000030764", "primaryOutcome": "PSQI;PPHQ-9;GAD-7;PTSDChecklist-Civilian Version,PCL-C;", "study_type": "Observational study", "time": "2020-03-13", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50852"}, "type": "Feature"}, {"geometry": {"coordinates": [117.118667, 36.55192], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "xkyylfl@163.com", "contactPhone": "+86 13953116564", "dateEnrollment": "2020-02-01", "description": "A Medical Records Based analysis for Risk Factors for Outcomes After Respiratory Support in Patients with ARDS Due to Novel Coronavirus Pneumonia (COVID-19)", "name": "ChiCTR2000030763", "primaryOutcome": "Pulmonary function;Cardiac function;neural function;", "study_type": "Observational study", "time": "2020-03-13", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50921"}, "type": "Feature"}, {"geometry": {"coordinates": [106.618022, 26.643861], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "ant000999@126.com", "contactPhone": "+86 13985004689", "dateEnrollment": "2019-12-01", "description": "Diagnosis and treatment of novel coronavirus pneumonia (COVID-19) in common and severe cases based on the theory of ''Shi-Du-Yi (damp and plague)''", "name": "ChiCTR2000030762", "primaryOutcome": "Clinical characteristics according to TCM;", "study_type": "Epidemilogical research", "time": "2020-03-13", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50950"}, "type": "Feature"}, {"geometry": {"coordinates": [121.820235, 30.941067], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "qinwang_1975@126.com", "contactPhone": "+86 13621964604", "dateEnrollment": "2020-05-31", "description": "Continuous renal replacement therapy (CRRT) alleviating inflammatory response in severe patients with novel coronavirus pneumonia (COVID-19) associated with renal injury: A Prospective study", "name": "ChiCTR2000030761", "primaryOutcome": "CRP;IL-6;TNF-alpha;IL-8;", "study_type": "Interventional study", "time": "2020-03-13", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50956"}, "type": "Feature"}, {"geometry": {"coordinates": [120.225434, 30.131115], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "hongwang71@yahoo.com", "contactPhone": "+86 0571 87377780", "dateEnrollment": "2020-03-13", "description": "A medical records based study for clinical characteristics of 2019 novel coronavirus pneumonia (COVID-19) in Zhejiang province, China", "name": "ChiCTR2000030760", "primaryOutcome": "the clinical, laboratory and the radiologic characteristics;", "study_type": "Observational study", "time": "2020-03-13", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50955"}, "type": "Feature"}, {"geometry": {"coordinates": [120.71201, 27.925373], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "wzwsjcjg@126.com", "contactPhone": "+86 13857797188", "dateEnrollment": "2020-02-15", "description": "Study for the therapeutic effect and mechanism of traditional Chinese medicine in the treatment of novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030759", "primaryOutcome": "The time for the positive nucleic acid of the novel coronavirus to turn negative;Incidence of deterioration;The defervescence time;Chest CT;Primary symptom remission rate;", "study_type": "Interventional study", "time": "2020-03-13", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49284"}, "type": "Feature"}, {"geometry": {"coordinates": [114.583872, 30.596762], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "1097685807@qq.com", "contactPhone": "+86 18827001384", "dateEnrollment": "2020-03-10", "description": "A medical records based study for sedation and Analgesia Usage in critically ill patients with novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030758", "primaryOutcome": "Dose of analgesic and sedative drugs;28-day mortality rate;", "study_type": "Observational study", "time": "2020-03-13", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50590"}, "type": "Feature"}, {"geometry": {"coordinates": [114.049251, 22.555937], "type": "Point"}, "properties": {"classification": "Impact on helpers", "contactEmail": "zyzy1933@163.com", "contactPhone": "+86 18823361933", "dateEnrollment": "2020-03-13", "description": "Impact of Novel Coronavirus Pneumonia (COVID-19) Epidemic Period on the Management of investigator-initiated clinical trial and the resilience of medical service providers", "name": "ChiCTR2000030757", "primaryOutcome": "Psychological assessment;", "study_type": "Observational study", "time": "2020-03-13", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50648"}, "type": "Feature"}, {"geometry": {"coordinates": [112.38667, 24.91722], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "zhengqingyou@163.com", "contactPhone": "+86 18601085226", "dateEnrollment": "2020-02-20", "description": "Detection of SARS-CoV-2 in EPS / semen of patients with novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030756", "primaryOutcome": "SARS-CoV-2;", "study_type": "Observational study", "time": "2020-03-13", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50705"}, "type": "Feature"}, {"geometry": {"coordinates": [114.583872, 30.596762], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "ctzhang0425@163.com", "contactPhone": "+86 15927668408", "dateEnrollment": "2020-03-15", "description": "A medical records based study for characteristics, prognosis of ederly patients with Novel Coronavirus Pneumonia (COVID-19) in Wuhan area", "name": "ChiCTR2000030755", "primaryOutcome": "Critical illness ratio;", "study_type": "Observational study", "time": "2020-03-13", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50945"}, "type": "Feature"}, {"geometry": {"coordinates": [113.288967, 23.15347], "type": "Point"}, "properties": {"classification": "Diagnosis", "contactEmail": "zhanlianh@163.com", "contactPhone": "+86 13580584031", "dateEnrollment": "2020-03-11", "description": "Medical records based study for the accuracy of SARS-CoV-2 IgM antibody screening for diagnosis of novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030754", "primaryOutcome": "false positive rate of SARS-CoV-2 IgM antibody;SEN, SPE, ACC, AUC of ROC;", "study_type": "Diagnostic test", "time": "2020-03-13", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50824"}, "type": "Feature"}, {"geometry": {"coordinates": [117.101309, 36.569837], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "xkyylfl@163.com", "contactPhone": "+86 13953116564", "dateEnrollment": "2020-02-01", "description": "A medical records based analysis of the Incidence and Risk Factors of Ventilator-associated Pneumonia in ARDS Patients with Novel Coronavirus Pneumonia (COVID-19)", "name": "ChiCTR2000030753", "primaryOutcome": "ICU hospitalization days;The recurrence rate of infection;", "study_type": "Observational study", "time": "2020-03-13", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50901"}, "type": "Feature"}, {"geometry": {"coordinates": [117.103221, 36.568356], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "xkyylfl@163.com", "contactPhone": "+86 13953116564", "dateEnrollment": "2020-02-01", "description": "A medical records based analysis for risk factors for death in patients with Novel Coronavirus Pneumonia (COVID-19)", "name": "ChiCTR2000030752", "primaryOutcome": "Outcome;", "study_type": "Observational study", "time": "2020-03-13", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50925"}, "type": "Feature"}, {"geometry": {"coordinates": [122.25586, 43.612217], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "nmbrbt8989@163.com", "contactPhone": "+86 18804758989", "dateEnrollment": "2020-01-25", "description": "Clinical Research for Traditional Mongolian Medicine in the treatment of novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030751", "primaryOutcome": "nucleic acids probing;blood routine;blood biochemistry;Urine Routine;Blood Gas Analysis;CT;", "study_type": "Interventional study", "time": "2020-03-13", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50941"}, "type": "Feature"}, {"geometry": {"coordinates": [115.634653, 30.786501], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "lixiaodong555@126.com", "contactPhone": "+86 13908658127", "dateEnrollment": "2020-02-22", "description": "A prospective cohort  study for comprehensive treatment of Chinese medicine in the treatment of convalescent patients of novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030747", "primaryOutcome": "CT Scan-Chest;", "study_type": "Observational study", "time": "2020-03-13", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50000"}, "type": "Feature"}, {"geometry": {"coordinates": [117.103221, 36.568356], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "xkyylfl@163.com", "contactPhone": "+86 13953116564", "dateEnrollment": "2020-02-01", "description": "Clinical Application of ECMO(or Ultra-Protective Lung Mechanical Ventilation) in the Treatment of Patients with ARDS due to novel Coronavirus Pneumonia (COVID-19)", "name": "ChiCTR2000030744", "primaryOutcome": "Inpatient mortality;ICU hospital stay;", "study_type": "Interventional study", "time": "2020-03-13", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50910"}, "type": "Feature"}, {"geometry": {"coordinates": [114.583872, 30.596762], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "hygao@tjh.tjmu.edu.cn", "contactPhone": "+86 13886188018", "dateEnrollment": "2020-03-15", "description": "Characteristics, prognosis, and treatments effectiveness of critically ill patients with Novel Coronavirus Pneumonia (COVID-19)", "name": "ChiCTR2000030742", "primaryOutcome": "in-ICU mortality;", "study_type": "Observational study", "time": "2020-03-13", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50857"}, "type": "Feature"}, {"geometry": {"coordinates": [117.103221, 36.568356], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "xkyylfl@163.com", "contactPhone": "+86 13953116564", "dateEnrollment": "2020-02-01", "description": "Observational Study for Prone Position Ventilation and Conventional Respiratory Support in ARDS Patients with  Novel Coronavirus Pneumonia (COVID-19)", "name": "ChiCTR2000030741", "primaryOutcome": "PaO2;PaCO2;", "study_type": "Observational study", "time": "2020-03-13", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50907"}, "type": "Feature"}, {"geometry": {"coordinates": [117.103221, 36.568356], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "xkyylfl@163.com", "contactPhone": "+86 13953116564", "dateEnrollment": "2020-02-01", "description": "Analysis of the incidence and risk factors of ARDS in patients with Novel Coronavirus Pneumonia (COVID-19).", "name": "ChiCTR2000030740", "primaryOutcome": "mortality;ICU hospital stay;mechanical ventilation time;mortality of 28 days;", "study_type": "Observational study", "time": "2020-03-13", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50900"}, "type": "Feature"}, {"geometry": {"coordinates": [117.103221, 36.568356], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "xkyylfl@163.com", "contactPhone": "+86 13953116564", "dateEnrollment": "2020-02-01", "description": "Exploration of the Clinical Characteristics of Patients with Novel Coronavirus Pneumonia (COVID-19) and Its Differences from Patients with Severe Influenza A and MERS", "name": "ChiCTR2000030739", "primaryOutcome": "Tempreture;cough;dyspnea;Blood Routine;Aterial Blood Gas;Chest CT Scan;", "study_type": "Observational study", "time": "2020-03-13", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50896"}, "type": "Feature"}, {"geometry": {"coordinates": [121.484683, 31.255045], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "16683890@qq.com", "contactPhone": "+86 13621759762", "dateEnrollment": "2020-03-09", "description": "Auscultatory characteristics of novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030722", "primaryOutcome": "ascultation;", "study_type": "Observational study", "time": "2020-03-12", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50338"}, "type": "Feature"}, {"geometry": {"coordinates": [110.406792, 21.191661], "type": "Point"}, "properties": {"classification": "Diagnosis", "contactEmail": "huanqinhan@126.com", "contactPhone": "+86 13828291023", "dateEnrollment": "2020-03-16", "description": "A comparative study for the sensitivity of induced sputum and throat swabs for the detection of SARS-CoV-2 by real-time PCR in patients with novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030721", "primaryOutcome": "detection of SARS-CoV-2 RNA;SEN, SPE, ACC, AUC of ROC;", "study_type": "Diagnostic test", "time": "2020-03-12", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50759"}, "type": "Feature"}, {"geometry": {"coordinates": [115.634653, 30.786501], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "lixiaodong555@126.com", "contactPhone": "+86 13908658127", "dateEnrollment": "2020-03-01", "description": "Prognosis Investigation and Intervention Study on Patients with novel coronavirus pneumonia (COVID-19) in recovery period Based on Community Health Management", "name": "ChiCTR2000030720", "primaryOutcome": "Medical imaging improvement rate in patients during recovery period;", "study_type": "Interventional study", "time": "2020-03-11", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50793"}, "type": "Feature"}, {"geometry": {"coordinates": [114.583807, 29.453242], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "784404524@qq.com", "contactPhone": "+86 18995598097", "dateEnrollment": "2020-03-01", "description": "A retrospective cohort study for integrated traditional Chinese and western medicine in the treatment of 1071 patients with novel coronavirus pneumonia (COVID-19) in Wuhan", "name": "ChiCTR2000030719", "primaryOutcome": "Mortality rate;Common-severe conversion rate;Length of hospital stay.;", "study_type": "Observational study", "time": "2020-03-11", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50867"}, "type": "Feature"}, {"geometry": {"coordinates": [114.330247, 30.57199], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "doctoryanzhao@whu.edu.cn", "contactPhone": "+86 13995577963", "dateEnrollment": "2020-02-12", "description": "Randomized controlled trial for Chloroquine Phosphate in the Treatment of novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030718", "primaryOutcome": "Time to Clinical Recovery;", "study_type": "Interventional study", "time": "2020-03-11", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50843"}, "type": "Feature"}, {"geometry": {"coordinates": [114.436665, 30.464908], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "fangmh@tjh.tjmu.edu.cn", "contactPhone": "+86 15071157405", "dateEnrollment": "2020-04-01", "description": "A medical records based study for risk assessment and treatment timing of invasive fungal infection in novel coronavirus pneumonia (COVID-19) critical patients", "name": "ChiCTR2000030717", "primaryOutcome": "14-days mortality;28-days mortality;", "study_type": "Observational study", "time": "2020-03-11", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50860"}, "type": "Feature"}, {"geometry": {"coordinates": [114.582166, 29.4543], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "lhgyx@hotmail.com", "contactPhone": "+86 13871402927", "dateEnrollment": "2020-03-05", "description": "Shedding of SARS-CoV-2 in human semen and evaluation of reproductive health of novel coronavirus pneumonia (COVID-19) male patients", "name": "ChiCTR2000030716", "primaryOutcome": "SARS-CoV-2 virus;sex hormones;sperm quality;", "study_type": "Observational study", "time": "2020-03-11", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50850"}, "type": "Feature"}, {"geometry": {"coordinates": [106.618374, 33.182406], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "zhonghui39@126.com", "contactPhone": "+86 18980601215", "dateEnrollment": "2020-03-10", "description": "Cross sectional study of dialysis treatment and mental status under the outbreak of novel coronavirus pneumonia (COVID-2019) in China", "name": "ChiCTR2000030708", "primaryOutcome": "Levels of anxiety, stress and depression;", "study_type": "Observational study", "time": "2020-03-11", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50083"}, "type": "Feature"}, {"geometry": {"coordinates": [102.051454, 30.067706], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "27216302@qq.com", "contactPhone": "+86 17723451376", "dateEnrollment": "2020-03-20", "description": "Retrospective study on novel coronavirus pneumonia (COVID-19) in Tibetan Plateau", "name": "ChiCTR2000030707", "primaryOutcome": "Blood oxygen saturation;", "study_type": "Observational study", "time": "2020-03-11", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50160"}, "type": "Feature"}, {"geometry": {"coordinates": [106.958064, 27.725512], "type": "Point"}, "properties": {"classification": "Diagnosis", "contactEmail": "haitao3140@sina.com", "contactPhone": "+86 18085287828", "dateEnrollment": "2020-02-09", "description": "Cancelled by the investigator                       Application of cas13a-mediated RNA detection in the assay of novel coronavirus nucleic acid (COVID-19)", "name": "ChiCTR2000030706", "primaryOutcome": "Sensitivity, specificity and accuracy;", "study_type": "Diagnostic test", "time": "2020-03-11", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50001"}, "type": "Feature"}, {"geometry": {"coordinates": [109.797899, 35.881671], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "pinhuapan668@126.com", "contactPhone": "+86 13574171102", "dateEnrollment": "2020-03-10", "description": "A randomized, blinded, controlled, multicenter clinical trial to evaluate the efficacy and safety of Ixekizumab combined with conventional antiviral drugs in patients with novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030703", "primaryOutcome": "Lung CT;", "study_type": "Interventional study", "time": "2020-03-10", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50251"}, "type": "Feature"}, {"geometry": {"coordinates": [116.56006, 39.800859], "type": "Point"}, "properties": {"classification": "Advanced therapy medicinal products", "contactEmail": "caobin_ben@163.com", "contactPhone": "+86 13911318339", "dateEnrollment": "2020-02-15", "description": "Plasma of the convalescent in the treatment of novel coronavirus pneumonia (COVID-19) common patient: a prospective clinical trial", "name": "ChiCTR2000030702", "primaryOutcome": "Time to clinical recovery after randomization;", "study_type": "Interventional study", "time": "2020-03-10", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50537"}, "type": "Feature"}, {"geometry": {"coordinates": [114.247815, 22.739326], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "41180423@qq.com", "contactPhone": "+86 13760857996", "dateEnrollment": "2020-03-10", "description": "A randomized, parallel controlled open-label trial for the efficacy and safety of Prolongin (Enoxaparin Sodium Injection) in the treatment of adult patients with novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030701", "primaryOutcome": "Time to Virus Eradication;", "study_type": "Interventional study", "time": "2020-03-10", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50795"}, "type": "Feature"}, {"geometry": {"coordinates": [114.417893, 30.447842], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "whxhzy@163.com", "contactPhone": "+86 13971292838", "dateEnrollment": "2020-03-09", "description": "Study for the efficacy and safety of Prolongin (Enoxaparin Sodium Injection) in treatment of novel coronavirus pneumonia (COVID-19) adult common patients", "name": "ChiCTR2000030700", "primaryOutcome": "Time to Virus Eradication;", "study_type": "Interventional study", "time": "2020-03-10", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50786"}, "type": "Feature"}, {"geometry": {"coordinates": [121.544494, 29.868505], "type": "Point"}, "properties": {"classification": "Impact on helpers", "contactEmail": "lorenzo_87@163.com", "contactPhone": "+86 0574-87085111", "dateEnrollment": "2020-03-10", "description": "A multi-center, open-label observation study for psychological status and intervention efficacy of doctors, nurses, patients and their families in novel coronavirus pneumonia (COVID-19) designated hospitals", "name": "ChiCTR2000030697", "primaryOutcome": "SDS;SAS;PSQI;", "study_type": "Observational study", "time": "2020-03-10", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50781"}, "type": "Feature"}, {"geometry": {"coordinates": [121.507813, 31.328138], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "hywangk@vip.sina.com", "contactPhone": "+86 13801955367", "dateEnrollment": "2020-02-10", "description": "Study for immune cell subsets in convalescent patients with novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030690", "primaryOutcome": "Lymphocyte grouping;", "study_type": "Basic Science", "time": "2020-03-10", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50261"}, "type": "Feature"}, {"geometry": {"coordinates": [115.19204, 31.44533], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "b5477@163.com", "contactPhone": "+86 15907190882", "dateEnrollment": "2020-02-01", "description": "Novel coronavirus pneumonia (COVID-19) associated kidney injury in children", "name": "ChiCTR2000030687", "primaryOutcome": "temperature;heart rate;respiratory rate;blood pressure;Urine volume;blood routine;C-reactive protein;erythrocyte sedimentation rat;pulmonary CT;liver function;coagulation function;renal function;immunoglobulin;complement;T cell subsets;electrolytes;Urine analysis;microalbuminuria;COVID-19 nucleic acid;COVID-19 antibody;renal ultrasound;24-hour urine protein;Tc-DTPA renal dynamic imaging;eGFR;", "study_type": "Basic Science", "time": "2020-03-09", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50572"}, "type": "Feature"}, {"geometry": {"coordinates": [116.415921, 39.875082], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "caobaoshan0711@aliyun.com", "contactPhone": "+86 15611963362", "dateEnrollment": "2020-03-03", "description": "The effects of prevention and control measures on treatment and psychological status of cancer patients during the novel coronavirus pneumonia (COVID-19) outbreak", "name": "ChiCTR2000030686", "primaryOutcome": "impact on the treatment of tumor patients;", "study_type": "Observational study", "time": "2020-03-09", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50714"}, "type": "Feature"}, {"geometry": {"coordinates": [113.395087, 23.038714], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "chenlei0nan@163.com", "contactPhone": "+86 13570236595", "dateEnrollment": "2020-03-09", "description": "The prediction value of prognosis of novel coronavirus pneumonia (COVID-19) in elderly patients by modified early warning score (MEWS): a medical records based retrospective observational study", "name": "ChiCTR2000030683", "primaryOutcome": "In-hospital mortality;ACC, SEN, SPE, ROC;", "study_type": "Diagnostic test", "time": "2020-03-09", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50633"}, "type": "Feature"}, {"geometry": {"coordinates": [115.995513, 36.458172], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "ly29.love@163.com", "contactPhone": "+86 18263511977", "dateEnrollment": "2020-03-16", "description": "An anaesthesia procedure and extubation strategy for reducing patient agitation and cough after extubation that can be used to prevent the spread of Novel Coronavirus Pneumonia (COVID-19) and other infectious viruses in the operating Room", "name": "ChiCTR2000030681", "primaryOutcome": "cough;agitation;", "study_type": "Interventional study", "time": "2020-03-09", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50763"}, "type": "Feature"}, {"geometry": {"coordinates": [115.176595, 31.461766], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "liuzsc@126.com", "contactPhone": "+86 027-82433145", "dateEnrollment": "2020-01-28", "description": "Cohort study of Novel Coronavirus Infected Diseases (COVID-19) in children", "name": "ChiCTR2000030679", "primaryOutcome": "Clinical characteristics;Clinical outcomes;", "study_type": "Observational study", "time": "2020-03-09", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50730"}, "type": "Feature"}, {"geometry": {"coordinates": [117.361135, 32.948089], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "sir_shi@126.com", "contactPhone": "+86 13855288331", "dateEnrollment": "2020-02-01", "description": "A medical records based real world study for the characteristics and correlation mechanism of traditional Chinese medicine combined with western medicine in the treatment of patients with novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030619", "primaryOutcome": "treatment effect;", "study_type": "Observational study", "time": "2020-03-08", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50656"}, "type": "Feature"}, {"geometry": {"coordinates": [116.286405, 39.996002], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "miaoqing55@sina.com", "contactPhone": "+86 13910812309", "dateEnrollment": "2020-03-09", "description": "Medical records based study for the correlation between Chinese medicine certificate and lung image of novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030606", "primaryOutcome": "Imaging;", "study_type": "Observational study", "time": "2020-03-08", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50713"}, "type": "Feature"}, {"geometry": {"coordinates": [116.286405, 39.996002], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "miaoqing55@sina.com", "contactPhone": "+86 13910812309", "dateEnrollment": "2020-03-09", "description": "Medical records based study for the correlation between Chinese medicine certificate and lung image of novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030597", "primaryOutcome": "Disease Severity;Imaging;Syndrome Features of TCM;", "study_type": "Observational study", "time": "2020-03-08", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50702"}, "type": "Feature"}, {"geometry": {"coordinates": [121.501404, 31.270678], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "maggie_zhangmin@163.com", "contactPhone": "+86 18121288279", "dateEnrollment": "2020-02-01", "description": "Efficacy and safety of tozumab combined with adamumab(Qletli) in severe and critical patients with novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030580", "primaryOutcome": "chest computerized tomography;Nucleic acid detection of novel coronavirus;TNF-alpha;IL-6;IL-10;", "study_type": "Interventional study", "time": "2020-03-08", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50693"}, "type": "Feature"}, {"geometry": {"coordinates": [113.395373, 23.005948], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "docterwei@sina.com", "contactPhone": "+86 18922238906", "dateEnrollment": "2020-03-07", "description": "Cancelled by the investigator             Epidemiological research of novel coronavirus pneumonia (COVID-19) suspected cases based on virus nucleic acid test combined with low-dose chest CT screening in primary hospital", "name": "ChiCTR2000030558", "primaryOutcome": "CT image features;Fever;Throat swab virus nucleic acid tes;lymphocyte;", "study_type": "Epidemilogical research", "time": "2020-03-07", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50678"}, "type": "Feature"}, {"geometry": {"coordinates": [114.402108, 30.573136], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "153267742@qq.com", "contactPhone": "+86 18971163518", "dateEnrollment": "2020-02-04", "description": "Efficacy and safety of honeysuckle oral liquid in the treatment of novel coronavirus pneumonia (COVID-19): a multicenter, randomized, controlled, open clinical trial", "name": "ChiCTR2000030545", "primaryOutcome": "Recovery time;Pneumonia psi score;", "study_type": "Interventional study", "time": "2020-03-06", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50126"}, "type": "Feature"}, {"geometry": {"coordinates": [113.237215, 23.136749], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "lmzmay@163.com", "contactPhone": "+86 18922108136", "dateEnrollment": "2020-03-06", "description": "Application of TCM Nursing Scheme in Patients with Novel Coronavirus Pneumonia (COVID-19)", "name": "ChiCTR2000030528", "primaryOutcome": "GAD-7;", "study_type": "Observational study", "time": "2020-03-06", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50641"}, "type": "Feature"}, {"geometry": {"coordinates": [126.748501, 45.652573], "type": "Point"}, "properties": {"classification": "Advanced therapy medicinal products", "contactEmail": "drkaijiang@163.com", "contactPhone": "+86 0451-53602290", "dateEnrollment": "2020-03-13", "description": "Cancelled by the investigator           Clinical Study of NK Cells in the Treatment of Novel Coronavirus Pneumonia (COVID-19)", "name": "ChiCTR2000030509", "primaryOutcome": "Time and rate of novel coronavirus become negative.;", "study_type": "Interventional study", "time": "2020-03-05", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49956"}, "type": "Feature"}, {"geometry": {"coordinates": [113.36585, 23.080767], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "sakeonel@126.com", "contactPhone": "+86 13760661654", "dateEnrollment": "2020-03-01", "description": "Cancelled by the investigator         A multicentre, randomized, controlled trial for the Ba-Duan-Jin in the adjunctive treatment of patients with common type novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030483", "primaryOutcome": "", "study_type": "Interventional study", "time": "2020-03-03", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50495"}, "type": "Feature"}, {"geometry": {"coordinates": [118.864715, 31.950883], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "nhb_2002@126.com", "contactPhone": "+86 15312019183", "dateEnrollment": "2020-02-26", "description": "Cancelled by the investigator                                    Study for the Effectiveness and Safety of Compound Yuxingcao Mixture in the Treatment of the Novel Coronavirus Pneumonia (COVID-19)", "name": "ChiCTR2000030478", "primaryOutcome": "lasting time of fever;lasting time of novel coronavirus pneumonia virus nucleic acid detected by RT-PCR and negative result rate of the novel coronavirus disease nucleic acid;", "study_type": "Interventional study", "time": "2020-03-03", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50460"}, "type": "Feature"}, {"geometry": {"coordinates": [121.414884, 31.203951], "type": "Point"}, "properties": {"classification": "Other", "contactEmail": "ljjia@shutcm.edu.cn", "contactPhone": "+86 13585779708", "dateEnrollment": "2020-03-03", "description": "Study for meditation assists for the rehabilitation of patients with novel coronaviruse pneumonia (COVID-19)", "name": "ChiCTR2000030476", "primaryOutcome": "Self-rating depression scale;self-rating anxiety scale;Athens Insomnia Scale;", "study_type": "Interventional study", "time": "2020-03-03", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50455"}, "type": "Feature"}, {"geometry": {"coordinates": [105.89392, 29.35376], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "164738059@qq.com", "contactPhone": "+86 13668077090", "dateEnrollment": "2020-02-26", "description": "Cancelled due to lack of patients                                       Investigation on Mental Health Status and Psychological Intervention of Hospitalized Patients with Novel Coronavirus Pneumonia (COVID-19)", "name": "ChiCTR2000030466", "primaryOutcome": "Comprehensive psychological assessment;Mental toughness;Solution;", "study_type": "Observational study", "time": "2020-03-02", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50387"}, "type": "Feature"}, {"geometry": {"coordinates": [126.646602, 45.751374], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "18604501911@163.com", "contactPhone": "+86 18604501911", "dateEnrollment": "2020-03-01", "description": "Cancelled by the investigator                               Efficacy and safety of chloroquine phosphate inhalation combined with standard therapy in the treatment of novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030417", "primaryOutcome": "Temperature returns to normal for more than 3 days;Respiratory symptoms improved significantly;Pulmonary imaging showed that acute exudative lesions were significantly improved;Negative for two consecutive tests of respiratory pathogenic nucleic acid (sampling interval at least 1 day);", "study_type": "Interventional study", "time": "2020-03-01", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50279"}, "type": "Feature"}, {"geometry": {"coordinates": [112.351289, 30.196701], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "99xw@sina.com", "contactPhone": "+86 071 68494565", "dateEnrollment": "2020-02-18", "description": "Efficacy and safety of Xue-Bi-Jing injection in the treatment of severe cases of novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030388", "primaryOutcome": "The percentage of patients who convert to moderate one;The rate of shock;Endotracheal intubation ratio;Time spent on the ventilator;mortality;Time of virus nucleic acid test turning negative;", "study_type": "Interventional study", "time": "2020-03-01", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50306"}, "type": "Feature"}, {"geometry": {"coordinates": [114.450454, 30.495464], "type": "Point"}, "properties": {"classification": "Advanced therapy medicinal products", "contactEmail": "liubende99@outlook.com", "contactPhone": "+86 13907191851", "dateEnrollment": "2020-02-29", "description": "Cancelled by investigator           A randomized, open-label, controlled and single-center trial to evaluate the efficacy and safety of anti-SARS-CoV-2 inactivated convalescent plasma in the treatment of novel coronavirus pneumonia (COVID-19) patient", "name": "ChiCTR2000030381", "primaryOutcome": "Clinical symptom improvement rate: improvement rate of clinical symptoms = number of cases with clinical symptom improvement /number of enrolling cases * 100%;", "study_type": "Interventional study", "time": "2020-02-29", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50290"}, "type": "Feature"}, {"geometry": {"coordinates": [109.08186, 34.31829], "type": "Point"}, "properties": {"classification": "Advanced therapy medicinal products", "contactEmail": "13816012151@163.com", "contactPhone": "+86 13816012151", "dateEnrollment": "2020-03-05", "description": "Cancelled by the investigator                          Clinical trial for umbilical cord blood CIK and NK cells in the treatment of mild and general patients infected with novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030329", "primaryOutcome": "Status of immune function;The time of nucleic acid turns to negative;Length of stay in-hospital;", "study_type": "Interventional study", "time": "2020-02-28", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49779"}, "type": "Feature"}, {"geometry": {"coordinates": [114.369829, 22.612371], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "524712958@qq.com", "contactPhone": "+86 15618795225", "dateEnrollment": "2020-03-19", "description": "Cancelled by the investigator                               Mechanism of novel coronavirus pneumonia (COVID-19) virus with silent latent immune system induced by envelope protein and vaccine development", "name": "ChiCTR2000030306", "primaryOutcome": "Time to disease recovery;Time and rate of coronavirus become negative;", "study_type": "Observational study", "time": "2020-02-28", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50222"}, "type": "Feature"}, {"geometry": {"coordinates": [113.398184, 23.038707], "type": "Point"}, "properties": {"classification": "Impact on helpers", "contactEmail": "zhb-ck@163.com", "contactPhone": "+86 13826041759", "dateEnrollment": "2020-01-31", "description": "Cancelled by the investigator               Study for sleep status of medical staffs of hospitals administrating suspected cases of Novel Coronavirus Pneumonia (COVID-19)", "name": "ChiCTR2000030221", "primaryOutcome": "sleep status and related factors of insomnia;", "study_type": "Health services reaserch", "time": "2020-02-25", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50071"}, "type": "Feature"}, {"geometry": {"coordinates": [112.335844, 30.213137], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "99xw@sina.com", "contactPhone": "+86 18972161798", "dateEnrollment": "2020-02-25", "description": "Clinical study for Lopinavir and Ritonavir in the treatment of novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030187", "primaryOutcome": "Endotracheal intubation rate;mortality;Ratio of virus nucleic acid detection to negative;", "study_type": "Interventional study", "time": "2020-02-24", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50057"}, "type": "Feature"}, {"geometry": {"coordinates": [109.051263, 34.2348], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "gaomedic@163.com", "contactPhone": "+86 15091544672", "dateEnrollment": "2020-02-25", "description": "Cancelled by the investigator                  A randomized controlled trial for high-dose Vitamin C in the treatment of severe and critical novel coronavirus pneumonia (COVID-19) patients", "name": "ChiCTR2000030135", "primaryOutcome": "Ventilation-free days;mortality;", "study_type": "Interventional study", "time": "2020-02-24", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50002"}, "type": "Feature"}, {"geometry": {"coordinates": [116.470636, 39.819566], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "fxzhu72@163.com", "contactPhone": "+86 13911005275", "dateEnrollment": "2020-02-24", "description": "Lung ultrasound in the diagnosis, treatment and prognosis of pulmonary lesions of novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030114", "primaryOutcome": "Lung ultrasound;Chest computed tomography (CT);Respiratory and oxygenation indicators;Prognostic indicators (length of stay, mortality);", "study_type": "Diagnostic test", "time": "2020-02-23", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49987"}, "type": "Feature"}, {"geometry": {"coordinates": [107.047757, 27.706621], "type": "Point"}, "properties": {"classification": "Diagnosis", "contactEmail": "188116999@qq.com", "contactPhone": "+86 15208660008", "dateEnrollment": "2020-02-22", "description": "Cancelled by the investigator               Study for the false positive rate of IgM / IgG antibody test kit for novel coronavirus pneumonia (COVID-19) in different inpatients", "name": "ChiCTR2000030085", "primaryOutcome": "Positive/Negtive;False positive of rate  ;", "study_type": "Diagnostic test", "time": "2020-02-22", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49948"}, "type": "Feature"}, {"geometry": {"coordinates": [115.344755, 27.731736], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "ht2000@vip.sina.com", "contactPhone": "+86 13803535961", "dateEnrollment": "2020-02-23", "description": "Cancelled by the investigator             Randomized controlled trial for the efficacy of dihydroartemisinine piperaquine in the treatment of mild/common novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030082", "primaryOutcome": "The time when the nucleic acid of the novel coronavirus turns negative;Conversion to heavy/critical type;", "study_type": "Interventional study", "time": "2020-02-22", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49915"}, "type": "Feature"}, {"geometry": {"coordinates": [113.397887, 23.035742], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "zqling68@hotmail.com", "contactPhone": "+86 13609068871", "dateEnrollment": "2020-02-10", "description": "Multicenter study for the treatment of Dipyridamole with novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030055", "primaryOutcome": "Complete Blood Count;CRP;blood coagulation;D-dimer;Virological examination of pharyngeal swab;Pulmonary imaging;", "study_type": "Prognosis study", "time": "2020-02-22", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49864"}, "type": "Feature"}, {"geometry": {"coordinates": [113.054973, 23.679754], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "surewin001@126.com", "contactPhone": "+86 13500296796", "dateEnrollment": "2020-02-20", "description": "Cancelled by the investigator                              A randomized, double-blind, parallel, controlled trial for comparison of phosphoric chloroquine combined with standard therapy and standard therapy in mild/common patients with novel coronavirus pneumonia (COV", "name": "ChiCTR2000030031", "primaryOutcome": "Time of conversion to be negative of novel coronavirus nucleic acid;", "study_type": "Interventional study", "time": "2020-02-21", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49806"}, "type": "Feature"}, {"geometry": {"coordinates": [114.436641, 30.464912], "type": "Point"}, "properties": {"classification": "Diagnosis", "contactEmail": "majingzhi2002@163.com", "contactPhone": "+86 13871257728", "dateEnrollment": "2020-02-21", "description": "Nucleic acid analysis of novel coronavirus pneumonia (COVID-19) in morning sputum samples and pharyngeal swabs-a prospectively diagnostic test", "name": "ChiCTR2000030005", "primaryOutcome": "detection of SARS-Cov-2 nucleic acid;SEN, ACC;", "study_type": "Diagnostic test", "time": "2020-02-19", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49669"}, "type": "Feature"}, {"geometry": {"coordinates": [113.397802, 23.129947], "type": "Point"}, "properties": {"classification": "Advanced therapy medicinal products", "contactEmail": "wwei@chinacord.org", "contactPhone": "+86 13729856651", "dateEnrollment": "2020-03-01", "description": "Cancelled by the investigator              Study on the effect of human placenta biological preparation on the defense of immune function against novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000029984", "primaryOutcome": "IFN-gama;TNF-alpha;Blood routine index;Time and rate of coronavirus become negative;immunoglobulin;Exacerbation (transfer to RICU) time;Clearance rate and time of main symptoms (fever, fatigue, cough);", "study_type": "Interventional study", "time": "2020-02-18", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49712"}, "type": "Feature"}, {"geometry": {"coordinates": [109.035818, 34.251237], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "gaomedic@163.com", "contactPhone": "+86 15091544672", "dateEnrollment": "2020-02-24", "description": "Cancelled by the investigator                         An observational study of high-dose Vitamin C in the treatment of severe and critical patients with novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000029957", "primaryOutcome": "Ventilation-free days;mortality;", "study_type": "Observational study", "time": "2020-02-17", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49633"}, "type": "Feature"}, {"geometry": {"coordinates": [113.398175, 23.038717], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "gz8hcwp@126.com", "contactPhone": "+86 020-83710825", "dateEnrollment": "2020-02-16", "description": "Cancelled by investigator                Single arm study for the efficacy and safety of GD31 in patients with novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000029895", "primaryOutcome": "The negative conversion rate and negative conversion time of novel coronavirus nucleic acid;", "study_type": "Interventional study", "time": "2020-02-16", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49569"}, "type": "Feature"}, {"geometry": {"coordinates": [112.262011, 30.308455], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "hbjzyyywlc@163.com", "contactPhone": "+86 071 68497225", "dateEnrollment": "2020-02-17", "description": "Cancelled by the investigator          A randomized, double-blind, parallel, controlled trial for comparison of phosphoric chloroquine combined with standard therapy and standard therapy in mild/common patients with novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000029837", "primaryOutcome": "Time of conversion to be negative of novel coronavirus  nucleic acid;", "study_type": "Interventional study", "time": "2020-02-15", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49495"}, "type": "Feature"}, {"geometry": {"coordinates": [112.246566, 30.324891], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "hbjzyyywlc@163.com", "contactPhone": "+86 071 68497225", "dateEnrollment": "2020-02-17", "description": "Cancelled by the investigator            A randomized, double-blind, parallel, controlled trial for comparison of phosphoric chloroquine combined with standard therapy and standard therapy in serious/critically ill patients with novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000029826", "primaryOutcome": "Mortality rate;", "study_type": "Interventional study", "time": "2020-02-14", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49481"}, "type": "Feature"}, {"geometry": {"coordinates": [114.176821, 30.5018], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "hkq123123@163.com", "contactPhone": "+86 15287110369", "dateEnrollment": "2020-02-01", "description": "Cancelled by investigator                                      A cox regression analysis of prognosis of novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000029820", "primaryOutcome": "DEATH;", "study_type": "Observational study", "time": "2020-02-14", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49492"}, "type": "Feature"}, {"geometry": {"coordinates": [113.397802, 23.129947], "type": "Point"}, "properties": {"classification": "Advanced therapy medicinal products", "contactEmail": "164972769@qq.com", "contactPhone": "+86 15018720816", "dateEnrollment": "2020-02-20", "description": "Cancelled by the investigator            Clinical Study for Umbilical Cord Blood Plasma in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19)", "name": "ChiCTR2000029818", "primaryOutcome": "Time to disease recovery;", "study_type": "Interventional study", "time": "2020-02-14", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49382"}, "type": "Feature"}, {"geometry": {"coordinates": [113.397802, 23.129947], "type": "Point"}, "properties": {"classification": "Advanced therapy medicinal products", "contactEmail": "164972769@qq.com", "contactPhone": "+86 15018720816", "dateEnrollment": "2020-02-20", "description": "Cancelled by the investigator                    Clinical Study of Cord Blood NK Cells Combined with Cord Blood Mesenchymal Stem Cells in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19)", "name": "ChiCTR2000029817", "primaryOutcome": "Time to disease recovery;", "study_type": "Interventional study", "time": "2020-02-14", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49384"}, "type": "Feature"}, {"geometry": {"coordinates": [113.398201, 23.038697], "type": "Point"}, "properties": {"classification": "Advanced therapy medicinal products", "contactEmail": "164972769@qq.com", "contactPhone": "+86 15018720816", "dateEnrollment": "2020-02-20", "description": "Cancelled by the investigator                      Clinical Study for Cord Blood Mesenchymal Stem Cells in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19)", "name": "ChiCTR2000029816", "primaryOutcome": "Time to disease recovery;", "study_type": "Interventional study", "time": "2020-02-14", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49389"}, "type": "Feature"}, {"geometry": {"coordinates": [113.397802, 23.129947], "type": "Point"}, "properties": {"classification": "Advanced therapy medicinal products", "contactEmail": "164972769@qq.com", "contactPhone": "+86 15018720816", "dateEnrollment": "2020-02-20", "description": "Cancelled by the investigator               Clinical Study for Umbilical Cord Blood Mononuclear Cells in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19)", "name": "ChiCTR2000029812", "primaryOutcome": "Time to disease recovery;", "study_type": "Interventional study", "time": "2020-02-14", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49374"}, "type": "Feature"}, {"geometry": {"coordinates": [114.436774, 30.464884], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "whuhjy@sina.com", "contactPhone": "+86 13554361146", "dateEnrollment": "2020-02-13", "description": "Study for epidemiology, diagnosis and treatment of novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000029770", "primaryOutcome": "Patients’ general information: epidemiological indicators such as age, gender, address, telephone, exposure history, past medical history, and BMI;Clinical symptoms;Patients' signs;blood routine examination;Urine routine test;stool routine examination;Blood biochemistry;myocardial enzyme spectrum;full set of coagulation;blood gas analysis;cytokine profile;T lymphocyte subsets;ESR;CRP;PCT;complete set of self-immunity test;Etiology related inspections;Chest X-ray;lung CT;Patients' treatment history;Patients' Prognosis;the cause of death;Others;", "study_type": "Observational study", "time": "2020-02-13", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49412"}, "type": "Feature"}, {"geometry": {"coordinates": [114.417893, 30.447842], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "xin11@hotmail.com", "contactPhone": "+86 027 85726732", "dateEnrollment": "2020-02-07", "description": "Clinical Study of Arbidol Hydrochloride Using for Post-exposure Prophylaxis of 2019-nCoV in High-risk Population Including Medical Staff", "name": "ChiCTR2000029592", "primaryOutcome": "2019-nCoV RNA;2019-nCoV antibody;Chest CT;", "study_type": "Observational study", "time": "2020-02-05", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49069"}, "type": "Feature"}, {"geometry": {"coordinates": [114.33954, 30.575135], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": ";pengzy5@hotmail.com;", "contactPhone": ";+8618672396028;", "dateEnrollment": "February 14, 2020", "description": "Vitamin C Infusion for the Treatment of Severe 2019-nCoV Infected Pneumonia", "name": "NCT04264533", "primaryOutcome": "Ventilation-free days", "study_type": "Interventional", "time": "2020-02-04", "weburl": "https://clinicaltrials.gov/show/NCT04264533"}, "type": "Feature"}, {"geometry": {"coordinates": [114.234077, 22.269599], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "", "contactPhone": "", "dateEnrollment": "February 14, 2020", "description": "Critically Ill Patients With COVID-19 in Hong Kong: a Multicentre Observational Cohort Study", "name": "NCT04285801", "primaryOutcome": "28 day mortality", "study_type": "Observational", "time": "2020-02-24", "weburl": "https://clinicaltrials.gov/show/NCT04285801"}, "type": "Feature"}, {"geometry": {"coordinates": [113.943165, 22.53607], "type": "Point"}, "properties": {"classification": "Vaccines", "contactEmail": ";c@szgimi.org;c@szgimi.org", "contactPhone": ";+86(755)8672 5195;86-755-86725195", "dateEnrollment": "February 15, 2020", "description": "Safety and Immunity of Covid-19 aAPC Vaccine", "name": "NCT04299724", "primaryOutcome": "Frequency of vaccine events;Frequency of serious vaccine events;Proportion of subjects with positive T cell response", "study_type": "Interventional", "time": "2020-03-05", "weburl": "https://clinicaltrials.gov/show/NCT04299724"}, "type": "Feature"}, {"geometry": {"coordinates": [114.299203, 30.535292], "type": "Point"}, "properties": {"classification": "Advanced therapy medicinal products", "contactEmail": ";xiaoyangzh@hotmail.com", "contactPhone": ";18986033792", "dateEnrollment": "March 5, 2020", "description": "Novel Coronavirus Induced Severe Pneumonia Treated by Dental Pulp Mesenchymal Stem Cells", "name": "NCT04302519", "primaryOutcome": "Disppear time of ground-glass shadow in the lungs", "study_type": "Interventional", "time": "2020-02-27", "weburl": "https://clinicaltrials.gov/show/NCT04302519"}, "type": "Feature"}, {"geometry": {"coordinates": [114.284091, 36.017922], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "", "contactPhone": "", "dateEnrollment": "December 10, 2019", "description": "Accurate Classification System for Patients With COVID-19 Pneumonitis", "name": "NCT04302688", "primaryOutcome": "survival status", "study_type": "Observational", "time": "2020-03-07", "weburl": "https://clinicaltrials.gov/show/NCT04302688"}, "type": "Feature"}, {"geometry": {"coordinates": [3.108477, 45.784777], "type": "Point"}, "properties": {"classification": "Other", "contactEmail": ";promo_interne_drci@chu-clermontferrand.fr;", "contactPhone": ";0473754963;0473754963", "dateEnrollment": "March 11, 2020", "description": "Influence of the COvid-19 Epidemic on STRESS", "name": "NCT04308187", "primaryOutcome": "Stress", "study_type": "Observational [Patient Registry]", "time": "2020-03-12", "weburl": "https://clinicaltrials.gov/show/NCT04308187"}, "type": "Feature"}, {"geometry": {"coordinates": [108.312789, 22.819532], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "yezi5729@163.com", "contactPhone": "+86 18978817899", "dateEnrollment": "2020-02-16", "description": "The relationship between Vitamin D andnovel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000031163", "primaryOutcome": "25(OH)D;", "study_type": "Observational study", "time": "2020-03-23", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51390"}, "type": "Feature"}, {"geometry": {"coordinates": [116.681661, 40.40781], "type": "Point"}, "properties": {"classification": "Diagnosis", "contactEmail": "linjie1992@zju.edu.cn", "contactPhone": "+86 15258871484", "dateEnrollment": "2020-04-01", "description": "Application of radiology in the prevention and control system of emergency respiratory infectious diseases", "name": "ChiCTR2000031150", "primaryOutcome": "Abnormalities on chest CT;", "study_type": "Health services reaserch", "time": "2020-03-23", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51021"}, "type": "Feature"}, {"geometry": {"coordinates": [114.171005, 30.493727], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "chenhhust@126.com", "contactPhone": "+86 13437171877", "dateEnrollment": "2020-02-01", "description": "Study for the impact on fetus and neonates of vertical transmission of 2019-nCoV", "name": "ChiCTR2000031140", "primaryOutcome": "Neonatal outcome;", "study_type": "Observational study", "time": "2020-03-22", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50605"}, "type": "Feature"}, {"geometry": {"coordinates": [114.283312, 30.667426], "type": "Point"}, "properties": {"classification": "Advanced therapy medicinal products", "contactEmail": "1813886398@qq.com", "contactPhone": "+86 13507117929", "dateEnrollment": "2020-03-20", "description": "Safety and Effectiveness of Human embryonic stem cell-derived M cells (CAStem) for Pulmonary Fibrosis Correlated with novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000031139", "primaryOutcome": "Pulmonary function evaluation;Changes in blood gas analysis;Evaluation of activity;Evaluation of dyspnea;CT changes from baseline;", "study_type": "Interventional study", "time": "2020-03-22", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51404"}, "type": "Feature"}, {"geometry": {"coordinates": [112.944648, 28.218968], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "mengjie@csu.edu.cn", "contactPhone": "+86 13607492399", "dateEnrollment": "2020-02-26", "description": "Prospective exploratory clinical research on the efficacy and safety of pirfenidone capsules in the treatment of severe novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000031138", "primaryOutcome": "HRCT score;", "study_type": "Interventional study", "time": "2020-03-22", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51416"}, "type": "Feature"}, {"geometry": {"coordinates": [118.859254, 24.858547], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "278353780@qq.com", "contactPhone": "+86 13674950311", "dateEnrollment": "2020-05-01", "description": "A medical records based study of peripheral blood T lymphocyte subsets in patients with novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000031115", "primaryOutcome": "T lymphocyte subsets;", "study_type": "Observational study", "time": "2020-03-22", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51032"}, "type": "Feature"}, {"geometry": {"coordinates": [113.557039, 22.313315], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "pangpf@mail.sysu.edu.cn", "contactPhone": "+86 18902536585", "dateEnrollment": "2020-02-05", "description": "Study for metagenomics of patients with novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000031104", "primaryOutcome": "Metagenomics Sequencing;", "study_type": "Observational study", "time": "2020-03-22", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51185"}, "type": "Feature"}, {"geometry": {"coordinates": [121.587495, 29.90426], "type": "Point"}, "properties": {"classification": "Other", "contactEmail": "yuhaihang0414@sina.com", "contactPhone": "+8613605880185", "dateEnrollment": "2020-03-23", "description": "Psychological Support for Diagnosed Patients with novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000031090", "primaryOutcome": "Pittsburgh sleep quality index;Self-rating anxiety scale;Self-rating depression scale;CD-RISC scale;", "study_type": "Interventional study", "time": "2020-03-22", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51148"}, "type": "Feature"}, {"geometry": {"coordinates": [113.280929, 23.13358], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "13533550083@163.com", "contactPhone": "+86 13533550083", "dateEnrollment": "2020-03-13", "description": "A medical records based study for Tou-Jie-Qu-Wen Granules in the Treatment of mild and moderate patients with novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000031089", "primaryOutcome": "syndrome;nucleic acid of nCoV-19;", "study_type": "Interventional study", "time": "2020-03-22", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51136"}, "type": "Feature"}, {"geometry": {"coordinates": [112.148414, 32.033771], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "xyxzyxzx@163.com", "contactPhone": "+86 18995678520", "dateEnrollment": "2020-02-09", "description": "A prognosis study of novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000031088", "primaryOutcome": "demographic information;exposure history;clinical  symptoms;Laboratory examination;radiological  findings;treatment;disease progression;", "study_type": "Observational study", "time": "2020-03-22", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51132"}, "type": "Feature"}, {"geometry": {"coordinates": [112.92197, 28.236918], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "315977705@qq.com", "contactPhone": "+86 13875985950", "dateEnrollment": "2020-03-16", "description": "Perioperative immune prediction and intervention of tumor patients undergoing surgery during the novel coronavirus pneumonia (COVID-19) outbreak period", "name": "ChiCTR2000031023", "primaryOutcome": "postoperative complication;occupancy rate of intensive care unit;2-year tumor-free survival and overall survival;", "study_type": "Interventional study", "time": "2020-03-21", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50984"}, "type": "Feature"}, {"geometry": {"coordinates": [121.388041, 29.122624], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "rengbinji@163.com", "contactPhone": "+86 13989370664", "dateEnrollment": "2020-03-19", "description": "A Study for SARS-COV-2 RNA Level in Blood and Excrement of Novel Coronavirus Pneumonia (COVID-19) Convalescent Patients", "name": "ChiCTR2000031014", "primaryOutcome": "Serum SARS-COV-2 RNA;Swallow swab SARS-COV-2 RNA;feces SARS-COV-2 RNA;Sputum SARS-COV-2 RNA;Urine SARS-COV-2 RNA;", "study_type": "Observational study", "time": "2020-03-21", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51348"}, "type": "Feature"}, {"geometry": {"coordinates": [116.286405, 39.996002], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "xyyylijing@sina.com", "contactPhone": "+86 15901203883", "dateEnrollment": "2020-03-18", "description": "Effect of Auricular point pressing on insomnia of novel coronavirus pneumonia (COVID-19) patients: a randomized controlled trial.", "name": "ChiCTR2000030996", "primaryOutcome": "insomnia;anxiety;depression;comfort;", "study_type": "Interventional study", "time": "2020-03-20", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51349"}, "type": "Feature"}, {"geometry": {"coordinates": [114.281471, 30.559088], "type": "Point"}, "properties": {"classification": "Diagnosis", "contactEmail": "wanbr2000@sina.com", "contactPhone": "+86 13554260702", "dateEnrollment": "2020-03-12", "description": "A medical records based study for the value of Upper Respiratory Tract Virus Detection in the assessment of rehabilitation of novel coronavirus pneumonia (COVID-19) patient", "name": "ChiCTR2000030993", "primaryOutcome": "PT-PCR test;SEN, SPE, ACC, AUC of ROC;", "study_type": "Diagnostic test", "time": "2020-03-20", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51342"}, "type": "Feature"}, {"geometry": {"coordinates": [121.464662, 31.233282], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "fanli0930@163.com", "contactPhone": "+86 13564684699", "dateEnrollment": "2020-03-10", "description": "A medical records based study for the diagnosis and prognosis prediction AI model of novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030992", "primaryOutcome": "SEN, SPE, ACC, AUC of ROC;", "study_type": "Diagnostic test", "time": "2020-03-20", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51338"}, "type": "Feature"}, {"geometry": {"coordinates": [116.369451, 39.962451], "type": "Point"}, "properties": {"classification": "Other", "contactEmail": "kittychen36@gmail.com", "contactPhone": "+86 15967196694", "dateEnrollment": "2020-03-20", "description": "Internet based Solution Focused Brief Therapy treating adolescent anxiety under the novel coronavirus pneumonia (COVID-19) outbreak: A randomized controlled trial", "name": "ChiCTR2000030989", "primaryOutcome": "GAD-7;STAI-Y (C);", "study_type": "Interventional study", "time": "2020-03-20", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51331"}, "type": "Feature"}, {"geometry": {"coordinates": [116.386033, 39.953701], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "tongzhaohuicy@sina.com", "contactPhone": "+86 13910930309", "dateEnrollment": "2020-03-05", "description": "A Randomized Controlled Trial for Favipiravir Tablets Combine With Chloroquine Phosphate in the Treatment of Novel Coronavirus Pneumonia (COVID-19)", "name": "ChiCTR2000030987", "primaryOutcome": "improvement or recovery of respiratory symptoms;viral nucleic acid shedding;", "study_type": "Interventional study", "time": "2020-03-20", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51329"}, "type": "Feature"}, {"geometry": {"coordinates": [114.247815, 22.739326], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "13603035264@139.com", "contactPhone": "+86 13603035264", "dateEnrollment": "2020-03-20", "description": "Correlation of T lymphocytes level and clinical severity in novel coronavirus pneumonia (COVID-19) patients: a medical records based retrospective study", "name": "ChiCTR2000030986", "primaryOutcome": "T lymphocyte count;", "study_type": "Observational study", "time": "2020-03-20", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51316"}, "type": "Feature"}, {"geometry": {"coordinates": [114.284091, 36.017922], "type": "Point"}, "properties": {"classification": "Impact on helpers", "contactEmail": "wenqin-1987@163.com", "contactPhone": "+86 13808628586", "dateEnrollment": "2020-03-04", "description": "Psychological Responses of Medical Staff during the Metaphase of novel coronavirus pneumonia (COVID-19) Outbreak in Hubei, China", "name": "ChiCTR2000030985", "primaryOutcome": "Pittsburgh sleep quality index;hospital anxiety and depression scale;", "study_type": "Observational study", "time": "2020-03-20", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51311"}, "type": "Feature"}, {"geometry": {"coordinates": [121.565991, 31.138421], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "tanghao_0921@126.com", "contactPhone": "+86 13816033045", "dateEnrollment": "2020-01-01", "description": "A Medical Records Based Retrospective Study for Clinical Characteristics, Treatments and Prognosis of Patients with Novel Coronavirus Pneumonia (COVID-19) in WuHan", "name": "ChiCTR2000030961", "primaryOutcome": "Clinical Characteristics, Treatments and Prognosis;", "study_type": "Observational study", "time": "2020-03-20", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51291"}, "type": "Feature"}, {"geometry": {"coordinates": [113.557039, 22.313315], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "chenjn@mail.sysu.edu.cn", "contactPhone": "+86 13926931713", "dateEnrollment": "2020-01-18", "description": "Myocardial injury and arrythmias in the novel coronavirus pneumonia (COVID-19) patients", "name": "ChiCTR2000030952", "primaryOutcome": "Clinical characteristics and risk factors;", "study_type": "Observational study", "time": "2020-03-19", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51278"}, "type": "Feature"}, {"geometry": {"coordinates": [114.583872, 30.596762], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "wwang@vip.126.com", "contactPhone": "+86 13871143176", "dateEnrollment": "2020-03-20", "description": "Developing and evaluating of artificial intelligence triage system for suspected novel coronavirus pneumonia (COVID-19): a retrospective study", "name": "ChiCTR2000030951", "primaryOutcome": "CT image;sensitivity;Specificity;Time efficiency;", "study_type": "Diagnostic test", "time": "2020-03-19", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51283"}, "type": "Feature"}, {"geometry": {"coordinates": [106.618374, 33.182406], "type": "Point"}, "properties": {"classification": "Vaccines", "contactEmail": "liudr@outlook.com", "contactPhone": "+86 18980606533", "dateEnrollment": "2020-02-10", "description": "Study for novel coronavirus pneumonia (COVID-19) patients etiology and immune response and guidance for vaccine design", "name": "ChiCTR2000030950", "primaryOutcome": "Nucleic acid;", "study_type": "Basic Science", "time": "2020-03-19", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51272"}, "type": "Feature"}, {"geometry": {"coordinates": [114.279872, 30.554157], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "tongzhaohuicy@sina.com", "contactPhone": "+86 13910930309", "dateEnrollment": "2020-02-11", "description": "A medical records based study for clinical application of extracorporeal membrane oxygenation in the treatment of severe respiratory failure patients with novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030947", "primaryOutcome": "hospital mortality;", "study_type": "Observational study", "time": "2020-03-19", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51267"}, "type": "Feature"}, {"geometry": {"coordinates": [113.397887, 23.035742], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "chunli@gird.cn", "contactPhone": "+86 13560158649", "dateEnrollment": "2020-02-10", "description": "Effects of different VTE prevention methods on the prognosis of hospitalized patients with novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030946", "primaryOutcome": "The biochemical indicators;", "study_type": "Interventional study", "time": "2020-03-19", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51265"}, "type": "Feature"}, {"geometry": {"coordinates": [115.893657, 28.686183], "type": "Point"}, "properties": {"classification": "Advanced therapy medicinal products", "contactEmail": "511201663@qq.com", "contactPhone": "+86 0791 86300047", "dateEnrollment": "2020-09-01", "description": "Clinical study of human NK cells and MSCs transplantation for severe novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030944", "primaryOutcome": "Changes of serum inflammatory factors;Patient death risk;Drug related adverse reactions and events;", "study_type": "Interventional study", "time": "2020-03-18", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50199"}, "type": "Feature"}, {"geometry": {"coordinates": [116.981129, 36.657482], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "docjiangshujuan@163.com", "contactPhone": "+86 15168887199", "dateEnrollment": "2020-03-31", "description": "Venous Thrombosis Risk of novel coronavirus pneumonia (COVID-19) Patients: A Prospective Study", "name": "ChiCTR2000030943", "primaryOutcome": "Venous Thrombosis;", "study_type": "Observational study", "time": "2020-03-18", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50898"}, "type": "Feature"}, {"geometry": {"coordinates": [121.530842, 31.282567], "type": "Point"}, "properties": {"classification": "Diagnosis", "contactEmail": "395956184@qq.com", "contactPhone": "+86 13761153836", "dateEnrollment": "2020-01-20", "description": "Combined diagnostic value of novel coronavirus (2019-CoV) infection detected by NLR and CRP", "name": "ChiCTR2000030942", "primaryOutcome": "Blood routine test;", "study_type": "Observational study", "time": "2020-03-18", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50981"}, "type": "Feature"}, {"geometry": {"coordinates": [114.279872, 30.554157], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "chenyinyin1212@hunnu.edu.cn", "contactPhone": "+86 13637403483", "dateEnrollment": "2020-01-28", "description": "A medical records based study for clinical features and prognosis of severe patients with novel coronavirus pneumonia (COVID-19) in Huanggan, Hubei in Huanggang.", "name": "ChiCTR2000030941", "primaryOutcome": "clincical characteristics;", "study_type": "Observational study", "time": "2020-03-18", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51000"}, "type": "Feature"}, {"geometry": {"coordinates": [116.401667, 39.88862], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "sunok301@126.com", "contactPhone": "+86 13501078679", "dateEnrollment": "2020-03-16", "description": "Preliminary evaluation of the safety and efficacy of oral LL-37 antiviral peptide (CAS001) in the treatment of novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030939", "primaryOutcome": "nuclear acid test of faeces;nuclear acid test of the upper respiratory tract;IgM;IgG;CT test of lung;glutamic oxalacetic transaminase;glutamic-pyruvic transaminase;total bilirubin;direct bilirubin;urea nitrogen;lactic dehydrogenase;creatinine;lymphocyte;C-reactive protein;procalcitonin;erythrocyte sedimentation rate;", "study_type": "Interventional study", "time": "2020-03-18", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51059"}, "type": "Feature"}, {"geometry": {"coordinates": [113.559347, 22.313636], "type": "Point"}, "properties": {"classification": "Vaccines", "contactEmail": "tianlin@mail.sysu.edu.cn", "contactPhone": "+86 0756 2528222", "dateEnrollment": "2020-03-01", "description": "A Platform for Rapid Immuno-detection and Emergency Vaccine Development of Novel Coronavirus (2019-COV)", "name": "ChiCTR2000030934", "primaryOutcome": "Immune response multiomics;", "study_type": "Observational study", "time": "2020-03-18", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51160"}, "type": "Feature"}, {"geometry": {"coordinates": [115.344755, 27.731736], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "fengzhenly@sina.com", "contactPhone": "+86 13970038111", "dateEnrollment": "2020-03-31", "description": "Effectiveness of ''Liu-Zi-Jue'' combined with respiratory muscle training for respiratory function in novel coronavirus pneumonia (COVID-19) patients: a randomized controlled trial", "name": "ChiCTR2000030933", "primaryOutcome": "Maximal inspiratory pressure;Respiratory muscle evaluation;", "study_type": "Interventional study", "time": "2020-03-18", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51184"}, "type": "Feature"}, {"geometry": {"coordinates": [117.048778, 30.506031], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "13966906638@139.com", "contactPhone": "+86 13966906638", "dateEnrollment": "2020-02-01", "description": "Correlation between virological negative conversion and clinical factors and prognosis in patients with novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030932", "primaryOutcome": "Length of hospital stay;", "study_type": "Observational study", "time": "2020-03-18", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51230"}, "type": "Feature"}, {"geometry": {"coordinates": [114.398908, 23.08296], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "393406816@qq.com", "contactPhone": "+86 13825498648", "dateEnrollment": "2020-03-23", "description": "A Medical Records Based Study for Clinical Characteristic and Outcomes of Hospitalized Patients With Novel Coronavirus Pneumonia (COVID-19)", "name": "ChiCTR2000030931", "primaryOutcome": "Time to negative conversion of severe acute respiratory syndrome coronavirus 2;", "study_type": "Observational study", "time": "2020-03-18", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51212"}, "type": "Feature"}, {"geometry": {"coordinates": [114.237851, 30.262307], "type": "Point"}, "properties": {"classification": "Advanced therapy medicinal products", "contactEmail": "zbhong6288@163.com", "contactPhone": "+86 13886009855", "dateEnrollment": "2020-03-17", "description": "A randomized, double-blind, parallel-controlled trial to evaluate the efficacy and safety of anti-SARS-CoV-2 virus inactivated plasma in the treatment of severe novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030929", "primaryOutcome": "Improvement of clinical symptoms (Clinical improvement is defined as a reduction of 2 points on the 6-point scale of the patient's admission status or discharge from the hospital);", "study_type": "Interventional study", "time": "2020-03-17", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50696"}, "type": "Feature"}, {"geometry": {"coordinates": [113.123216, 23.007746], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "FSYYN001@126.com", "contactPhone": "+86 18038860666", "dateEnrollment": "2020-02-26", "description": "Prospective, open-label, controlled, multicenter cohort study of long-acting interferon plus ribavirin in patients with novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030922", "primaryOutcome": "COVID-19 nucleic acid negative conversion rate;Causal mortality;All-cause mortality;", "study_type": "Interventional study", "time": "2020-03-17", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51141"}, "type": "Feature"}, {"geometry": {"coordinates": [121.372596, 29.13906], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "caiting@ucas.ac.cn", "contactPhone": "+86 13738498188", "dateEnrollment": "2020-02-20", "description": "Evaluation of the effect of taking tricholoma matsutake, cannabis sativa capsule and dendrobium candidum to nutrition intervention of patients with novel coronavirus pneumonia (COVID-19) during convalescence.", "name": "ChiCTR2000030920", "primaryOutcome": "Albumin;Cellular immune indicators (total lymphocyte count (TLC) and T lymphocyte subsets (CD3, CD4));", "study_type": "Interventional study", "time": "2020-03-17", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50476"}, "type": "Feature"}, {"geometry": {"coordinates": [109.782454, 35.898107], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "zln7095@163.com", "contactPhone": "+86 15874875763", "dateEnrollment": "2020-03-20", "description": "An observational study for cardiac and pulmonary ultrasound and evaluation of treatment of severe patients with novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030919", "primaryOutcome": "auto B line method;Semi-automatic manual measurement of line B;CT image score;NEWS score;hospital time;ICU time;Critical time;Hospital costs;mechanical ventilation time;prognosis of the patient;", "study_type": "Observational study", "time": "2020-03-17", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51149"}, "type": "Feature"}, {"geometry": {"coordinates": [118.767274, 32.067199], "type": "Point"}, "properties": {"classification": "Vaccines", "contactEmail": "iszfc@sina.com", "contactPhone": "+86 025 83759418", "dateEnrollment": "2020-03-10", "description": "A phase I clinical trial for recombinant novel coronavirus (2019-COV) vaccine (adenoviral vector)", "name": "ChiCTR2000030906", "primaryOutcome": "adverse reactions 7 days post injection;", "study_type": "Prevention", "time": "2020-03-17", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51154"}, "type": "Feature"}, {"geometry": {"coordinates": [112.993779, 28.186926], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "qianlu5860@gmail.com", "contactPhone": "+86 731-85295860", "dateEnrollment": "2020-03-01", "description": "Screening and identification of peripheral blood biomarkers in patients with COVID-19 infection based on multiomics studies", "name": "ChiCTR2000030771", "primaryOutcome": "RNA;DNA;", "study_type": "Diagnostic test", "time": "2020-03-14", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50961"}, "type": "Feature"}, {"geometry": {"coordinates": [106.602577, 26.660297], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "ant000999@126.com", "contactPhone": "+86 13985004689", "dateEnrollment": "2019-12-01", "description": "Cancelled by the investigator                 Clinical guidance of diagnose and treatment for novel coronavirus pneumonia (COVID-19) based on ''Shi-Du-Yi''", "name": "ChiCTR2000030765", "primaryOutcome": "prognosis;", "study_type": "Epidemilogical research", "time": "2020-03-13", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50964"}, "type": "Feature"}, {"geometry": {"coordinates": [113.394869, 23.005235], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "gz8hzf@126.com", "contactPhone": "+86 18122317900", "dateEnrollment": "2020-03-06", "description": "Study for clinical oral characteristics of patients with novel coronavirus pneumonia (COVID-19) and Effect of 3% hydrogen peroxide gargle on the Intraoral novel coronavirus", "name": "ChiCTR2000030539", "primaryOutcome": "novel coronavirus nucleic acid;", "study_type": "Interventional study", "time": "2020-03-06", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50660"}, "type": "Feature"}, {"geometry": {"coordinates": [113.379424, 23.021671], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "gz8hlc@126.com", "contactPhone": "+86 15989096626", "dateEnrollment": "2020-03-06", "description": "Study for the clinical characteristics and digestive system damage of novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030519", "primaryOutcome": "RNA of  Coronavirus;", "study_type": "Observational study", "time": "2020-03-05", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50604"}, "type": "Feature"}, {"geometry": {"coordinates": [114.11445, 30.356522], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "wangxinghuan@whu.edu.cn", "contactPhone": "+86 027 67813096", "dateEnrollment": "2020-02-20", "description": "the Efficacy and Safety of Favipiravir for novel coronavirus–infected pneumonia: A multicenter, randomized, open, positive, parallel-controlled clinical study", "name": "ChiCTR2000030254", "primaryOutcome": "Clinical recovery rate of day 7;", "study_type": "Interventional study", "time": "2020-02-26", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50137"}, "type": "Feature"}, {"geometry": {"coordinates": [114.436774, 30.464884], "type": "Point"}, "properties": {"classification": "Advanced therapy medicinal products", "contactEmail": "chengyunliu@hust.edu.cn", "contactPhone": "+86 18007117616", "dateEnrollment": "2020-02-26", "description": "Cancelled by the investigator                Clinical study of mesenchymal stem cells in treating severe novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030224", "primaryOutcome": "SP02;lesions of lung CT;temperature;Blood routine;Inflammatory biomarkers;", "study_type": "Interventional study", "time": "2020-02-26", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49968"}, "type": "Feature"}, {"geometry": {"coordinates": [118.773601, 32.044977], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "cleverwdw@126.com", "contactPhone": "+86 025-52362054", "dateEnrollment": "2020-02-29", "description": "Cancelled by the investigator                   A real world study for Compound Houttuyniae Mixture for prevention of novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030168", "primaryOutcome": "Compared with the control group, the positive rate of NCP nucleic acid test on subjects used Compound Houttuynia Mixture.;", "study_type": "Observational study", "time": "2020-02-24", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49433"}, "type": "Feature"}, {"geometry": {"coordinates": [115.344755, 27.731736], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "zhangweiliuxin@163.com", "contactPhone": "+86 13707089183", "dateEnrollment": "2020-02-23", "description": "A medical records based study for optimization and evaluation of the comprehensive diagnosis and treatment of novel coronavirus pneumonia (COVID-19) and the assessment of risk factors for severe pneumonia", "name": "ChiCTR2000030095", "primaryOutcome": "detection of virus nucleic acid;", "study_type": "Observational study", "time": "2020-02-23", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49845"}, "type": "Feature"}, {"geometry": {"coordinates": [104.17577, 30.57413], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "gykpanda@163.com", "contactPhone": "+86 18180609256", "dateEnrollment": "2020-03-01", "description": "Evaluation of myocardial injury of novel coronavirus pneumonia (COVID-19) assessed by multimodal MRI imaging", "name": "ChiCTR2000029955", "primaryOutcome": "First pass perfusion i;Delayed enhancement;T1 /T2 mapping;Extracellular volume;MRS;CEST;", "study_type": "Diagnostic test", "time": "2020-02-17", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49531"}, "type": "Feature"}, {"geometry": {"coordinates": [121.45941, 31.248953], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "shi_guochao2010@qq.com", "contactPhone": "+86 13918462035", "dateEnrollment": "2020-02-11", "description": "Hydroxychloroquine treating novel coronavirus pneumonia (COVID-19): a randomized controlled, open label, multicenter trial", "name": "ChiCTR2000029868", "primaryOutcome": "Viral nucleic acid test;", "study_type": "Interventional study", "time": "2020-02-15", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49524"}, "type": "Feature"}, {"geometry": {"coordinates": [113.557039, 22.313315], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "13926946929@163.com", "contactPhone": "+86 13926946929", "dateEnrollment": "2020-02-14", "description": "A study for the psychological status, social support, and care needs of tumor patients admitted to a general hospital during the novel coronavirus pneumonia (COVID-19) outbreak", "name": "ChiCTR2000029830", "primaryOutcome": "psychological states;", "study_type": "Observational study", "time": "2020-02-15", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49511"}, "type": "Feature"}, {"geometry": {"coordinates": [114.219355, 30.248255], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "bxlee@sohu.com", "contactPhone": "+86 13397192089", "dateEnrollment": "2020-02-10", "description": "Nasal high-fow preoxygenation assisted fibre-optic bronchoscope intubation in patients with critical novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000029658", "primaryOutcome": "the lowest SpO2 during intubation;", "study_type": "Interventional study", "time": "2020-02-09", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49074"}, "type": "Feature"}, {"geometry": {"coordinates": [121.17623, 30.179772], "type": "Point"}, "properties": {"classification": "Advanced therapy medicinal products", "contactEmail": "ljli@zju.edu.cn", "contactPhone": "+86 13906514210", "dateEnrollment": "2020-02-06", "description": "A multicenter, randomized, open, controlled clinical study to evaluate the efficacy and safety of recombinant cytokine gene-derived protein injection in combination with standard therapy in patients with novel coronavirus infection", "name": "ChiCTR2000029573", "primaryOutcome": "The time required for RNA Yin conversion of novel coronavirus in respiratory or blood specimens was compared between treatment groups The difference of;", "study_type": "Interventional study", "time": "2020-02-05", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49065"}, "type": "Feature"}, {"geometry": {"coordinates": [115.91793, 29.30149], "type": "Point"}, "properties": {"classification": "Advanced therapy medicinal products", "contactEmail": "gongguozhong@csu.edu.cn", "contactPhone": "+86 13873104819", "dateEnrollment": "2020-01-29", "description": "A randomized, open label, parallel controlled trial of evaluating the efficacy of recombinant cytokine gene-derived protein injection for clearing novel coronavirus in patients with novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000029496", "primaryOutcome": "novel coronavirus nucleic acid clearance rate;", "study_type": "Interventional study", "time": "2020-02-03", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=48809"}, "type": "Feature"}, {"geometry": {"coordinates": [5.398956, 43.289781], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "line.meddeb@ap-hm.fr", "contactPhone": "00334 13 73 23 47", "dateEnrollment": "05/03/2020", "description": "Hydroxychloroquine as a treatment for coronavirus disease COVID-19", "name": "EUCTR2020-000890-25-FR", "primaryOutcome": "Main Objective: To shorten the period of virus carrying and thus contagion;Secondary Objective: To evaluate the clinical effectiveness of treatment on time to apyrexia, normalization of respiratory rate, and average length of hospital stay and mortality.;Primary end point(s): Results of SARS-COV2 virus detection ;Timepoint(s) of evaluation of this end point: Day 1, Day 4, Day 7 and Day 14", "study_type": "Interventional clinical trial of medicinal product", "time": "2020-03-10", "weburl": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-000890-25"}, "type": "Feature"}, {"geometry": {"coordinates": [139.896109, 36.578363], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "keiliu0406@gmail.com", "contactPhone": "028-626-5500", "dateEnrollment": "2020/02/01", "description": "ExtraCorporeal Membrane Oxygenation for 2019 novel Coronavirus Acute Respiratory Disease", "name": "JPRN-UMIN000039686", "primaryOutcome": "1.\tDate of ECMO discontinuation<br>2.\tDate of invasive mechanical ventilation discontinuation<br>3.\tDate of ICU Discharge<br>4.\tDate of Hospital Discharge<br>5.\tMortality at 28 days<br>6.\tMain cause of death", "study_type": "Observational", "time": "2020-03-06", "weburl": "https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000045268"}, "type": "Feature"}, {"geometry": {"coordinates": [118.747539, 32.069231], "type": "Point"}, "properties": {"classification": "Other", "contactEmail": "", "contactPhone": "", "dateEnrollment": "February 5, 2020", "description": "Washed Microbiota Transplantation for Patients With 2019-nCoV Infection", "name": "NCT04251767", "primaryOutcome": "Number of participants with improvement from severe type to common type", "study_type": "Interventional", "time": "2020-01-30", "weburl": "https://clinicaltrials.gov/show/NCT04251767"}, "type": "Feature"}, {"geometry": {"coordinates": [114.348664, 30.539191], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "qning@vip.sina.com;qning@vip.sina.com", "contactPhone": "+8613971521450;", "dateEnrollment": "February 1, 2020", "description": "A Prospective/Retrospective,Randomized Controlled Clinical Study of Interferon Atomization in the 2019-nCoV Pneumonia", "name": "NCT04254874", "primaryOutcome": "Rate of disease remission;Time for lung recovery", "study_type": "Interventional", "time": "2020-02-02", "weburl": "https://clinicaltrials.gov/show/NCT04254874"}, "type": "Feature"}, {"geometry": {"coordinates": [114.333218, 30.555628], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "qning@vip.sina.com;qning@vip.sina.com", "contactPhone": "+8613971521450;", "dateEnrollment": "February 1, 2020", "description": "A Prospective/Retrospective,Randomized Controlled Clinical Study of Antiviral Therapy in the 2019-nCoV Pneumonia", "name": "NCT04255017", "primaryOutcome": "Rate of disease remission;Time for lung recovery", "study_type": "Interventional", "time": "2020-02-02", "weburl": "https://clinicaltrials.gov/show/NCT04255017"}, "type": "Feature"}, {"geometry": {"coordinates": [114.242864, 30.596649], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "qning@vip.sina.com;qning@vip.sina.com", "contactPhone": "+8613971521450;", "dateEnrollment": "February 1, 2020", "description": "A Randomized,Open,Controlled Clinical Study to Evaluate the Efficacy of ASC09F and Ritonavir for 2019-nCoV Pneumonia", "name": "NCT04261270", "primaryOutcome": "Rate of comprehensive adverse outcome", "study_type": "Interventional", "time": "2020-02-04", "weburl": "https://clinicaltrials.gov/show/NCT04261270"}, "type": "Feature"}, {"geometry": {"coordinates": [114.242864, 30.596649], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "qning@vip.sina.com;qning@vip.sina.com", "contactPhone": "+8613971521450;", "dateEnrollment": "February 1, 2020", "description": "The Efficacy of Different Hormone Doses in 2019-nCoV Severe Pneumonia", "name": "NCT04263402", "primaryOutcome": "Rate of disease remission;Rate and time of entering the critical stage", "study_type": "Interventional", "time": "2020-02-02", "weburl": "https://clinicaltrials.gov/show/NCT04263402"}, "type": "Feature"}, {"geometry": {"coordinates": [114.298976, 30.599041], "type": "Point"}, "properties": {"classification": "Advanced therapy medicinal products", "contactEmail": "", "contactPhone": "", "dateEnrollment": "March 17, 2020", "description": "Treatment of Acute Severe 2019-nCoV Pneumonia With Immunoglobulin From Cured Patients", "name": "NCT04264858", "primaryOutcome": "Time to Clinical Improvement (TTCI)", "study_type": "Interventional", "time": "2020-02-08", "weburl": "https://clinicaltrials.gov/show/NCT04264858"}, "type": "Feature"}, {"geometry": {"coordinates": [106.477006, 29.561082], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "", "contactPhone": "", "dateEnrollment": "January 25, 2020", "description": "Prognositc Factors in COVID-19 Patients Complicated With Hypertension", "name": "NCT04272710", "primaryOutcome": "Occupancy rate in the intensive care unit (ICU);Mechanical Ventilation;Death", "study_type": "Observational", "time": "2020-02-12", "weburl": "https://clinicaltrials.gov/show/NCT04272710"}, "type": "Feature"}, {"geometry": {"coordinates": [113.92772, 22.552506], "type": "Point"}, "properties": {"classification": "Vaccines", "contactEmail": ";c@szgimi.org;c@szgimi.org", "contactPhone": ";+86(755)8672 5195;86-755-86725195", "dateEnrollment": "March 24, 2020", "description": "Immunity and Safety of Covid-19 Synthetic Minigene Vaccine", "name": "NCT04276896", "primaryOutcome": "Clinical improvement based on the 7-point scale;Lower Murray lung injury score", "study_type": "Interventional", "time": "2020-02-17", "weburl": "https://clinicaltrials.gov/show/NCT04276896"}, "type": "Feature"}, {"geometry": {"coordinates": [114.286887, 30.576258], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "whunjy@126.com;whuhjy@126.com", "contactPhone": "13554361146;13554361146", "dateEnrollment": "February 21, 2020", "description": "Study for Novel Coronavirus Pneumonia (NCP)", "name": "NCT04283396", "primaryOutcome": "recovery", "study_type": "Observational", "time": "2020-02-13", "weburl": "https://clinicaltrials.gov/show/NCT04283396"}, "type": "Feature"}, {"geometry": {"coordinates": [113.286452, 23.100146], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "", "contactPhone": "", "dateEnrollment": "February 2020", "description": "Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19", "name": "NCT04287686", "primaryOutcome": "Time course of body temperature (fever);Viral load over time", "study_type": "Interventional", "time": "2020-02-21", "weburl": "https://clinicaltrials.gov/show/NCT04287686"}, "type": "Feature"}, {"geometry": {"coordinates": [114.242864, 30.596649], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "chenlin_tj@126.com", "contactPhone": "+8613517260864", "dateEnrollment": "April 1, 2020", "description": "The Efficacy and Safety of Huai er in the Adjuvant Treatment of COVID-19", "name": "NCT04291053", "primaryOutcome": "Mortality rate", "study_type": "Interventional", "time": "2020-02-27", "weburl": "https://clinicaltrials.gov/show/NCT04291053"}, "type": "Feature"}, {"geometry": {"coordinates": [106.461561, 29.577518], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "", "contactPhone": "", "dateEnrollment": "March 1, 2020", "description": "Prognostic Factors of Patients With COVID-19", "name": "NCT04292964", "primaryOutcome": "all-cause mortality", "study_type": "Observational", "time": "2020-03-01", "weburl": "https://clinicaltrials.gov/show/NCT04292964"}, "type": "Feature"}, {"geometry": {"coordinates": [114.407359, 30.477938], "type": "Point"}, "properties": {"classification": "Advanced therapy medicinal products", "contactEmail": "", "contactPhone": "", "dateEnrollment": "February 24, 2020", "description": "Therapy for Pneumonia Patients iInfected by 2019 Novel Coronavirus", "name": "NCT04293692", "primaryOutcome": "Size of lesion area by chest imaging;Blood oxygen saturation", "study_type": "Interventional", "time": "2020-02-24", "weburl": "https://clinicaltrials.gov/show/NCT04293692"}, "type": "Feature"}, {"geometry": {"coordinates": [114.242864, 30.596649], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "qning@vip.sina.com;qning@vip.sina.com", "contactPhone": "+8613971521450;", "dateEnrollment": "February 9, 2020", "description": "A Pilot Study of Sildenafil in COVID-19", "name": "NCT04304313", "primaryOutcome": "Rate of disease remission;Rate of entering the critical stage;Time of entering the critical stage", "study_type": "Interventional", "time": "2020-02-14", "weburl": "https://clinicaltrials.gov/show/NCT04304313"}, "type": "Feature"}, {"geometry": {"coordinates": [103.77189, 1.306708], "type": "Point"}, "properties": {"classification": "Other", "contactEmail": ";jeanliu@yale-nus.edu.sg;jeanliu@yale-nus.edu.sg", "contactPhone": ";66013694;", "dateEnrollment": "March 8, 2020", "description": "Social Media Use During COVID-19", "name": "NCT04305574", "primaryOutcome": "Assessment of COVID-19 situation;Depression, Anxiety and Stress Scale", "study_type": "Observational", "time": "2020-03-08", "weburl": "https://clinicaltrials.gov/show/NCT04305574"}, "type": "Feature"}, {"geometry": {"coordinates": [114.242864, 30.596649], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": ";yuyikai@163.com;", "contactPhone": ";+1 (484) 995-5917;+86 2783662886", "dateEnrollment": "February 20, 2020", "description": "Tocilizumab vs CRRT in Management of Cytokine Release Syndrome (CRS) in COVID-19", "name": "NCT04306705", "primaryOutcome": "Proportion of Participants With Normalization of Fever and Oxygen Saturation Through Day 14", "study_type": "Observational", "time": "2020-03-08", "weburl": "https://clinicaltrials.gov/show/NCT04306705"}, "type": "Feature"}, {"geometry": {"coordinates": [113.68892, 34.771752], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "", "contactPhone": "", "dateEnrollment": "March 5, 2020", "description": "Tetrandrine Tablets Used in the Treatment of COVID-19", "name": "NCT04308317", "primaryOutcome": "Survival rate", "study_type": "Interventional", "time": "2020-03-04", "weburl": "https://clinicaltrials.gov/show/NCT04308317"}, "type": "Feature"}, {"geometry": {"coordinates": [113.673474, 34.788189], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": ";13781919609@163.com;sykyxmbgs@163.com", "contactPhone": ";+86-13781919609;+86-13619842879", "dateEnrollment": "February 1, 2020", "description": "Sequential Oxygen Therapy Strategy for Patients With COVID-19", "name": "NCT04312100", "primaryOutcome": "Incidence of respiratory failure", "study_type": "Observational", "time": "2020-03-13", "weburl": "https://clinicaltrials.gov/show/NCT04312100"}, "type": "Feature"}, {"geometry": {"coordinates": [114.271442, 30.592694], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "", "contactPhone": "", "dateEnrollment": "January 1, 2020", "description": "Myocardial Damage in COVID-19", "name": "NCT04312464", "primaryOutcome": "The myocardial injury incidence;The risk factors analysis for the death", "study_type": "Observational", "time": "2020-03-04", "weburl": "https://clinicaltrials.gov/show/NCT04312464"}, "type": "Feature"}, {"geometry": {"coordinates": [35.902917, 31.951216], "type": "Point"}, "properties": {"classification": "Advanced therapy medicinal products", "contactEmail": "adeebalzoubi@stemcellsarabia.net;adeebalzoubi@stemcellsarabia.net", "contactPhone": "+962795337575;+962795337575", "dateEnrollment": "March 16, 2020", "description": "Treatment of COVID-19 Patients Using Wharton's Jelly-Mesenchymal Stem Cells", "name": "NCT04313322", "primaryOutcome": "Clinical outcome;CT Scan;RT-PCR results", "study_type": "Interventional", "time": "2020-03-15", "weburl": "https://clinicaltrials.gov/show/NCT04313322"}, "type": "Feature"}, {"geometry": {"coordinates": [10.994216, 59.932669], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "", "contactPhone": "", "dateEnrollment": "March 23, 2020", "description": "Mechanisms to Morbidity and Mortality for Covid-19", "name": "NCT04314232", "primaryOutcome": "Change in viral expression in association to organspecific biomarkers", "study_type": "Observational", "time": "2020-03-17", "weburl": "https://clinicaltrials.gov/show/NCT04314232"}, "type": "Feature"}, {"geometry": {"coordinates": [112.984598, 28.212018], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": ";562122649@qq.com;xyyyllwyh@126.com", "contactPhone": ";+86136673520046;", "dateEnrollment": "March 20, 2020", "description": "The Observational Study of Cardiac and Pulmonary Ultrasound and Evaluation of Treatment of Severe Patients With Novel Coronavirus Pneumonia", "name": "NCT04314271", "primaryOutcome": "characteristics of cardiopulmonary ultrasound", "study_type": "Observational [Patient Registry]", "time": "2020-03-16", "weburl": "https://clinicaltrials.gov/show/NCT04314271"}, "type": "Feature"}, {"geometry": {"coordinates": [2.350011, 48.85684], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": ";nguyen.lee@icloud.com;", "contactPhone": ";0033158414143;", "dateEnrollment": "March 17, 2020", "description": "Adverse Events Related to Treatments Used Against Coronavirus Disease 2019", "name": "NCT04314817", "primaryOutcome": "Renal failure", "study_type": "Observational", "time": "2020-03-17", "weburl": "https://clinicaltrials.gov/show/NCT04314817"}, "type": "Feature"}, {"geometry": {"coordinates": [14.257259, 40.845405], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "gabriele.saccone@unina.it", "contactPhone": "0817462202", "dateEnrollment": "January 1, 2020", "description": "Clinical Characteristics of Coronavirus Disease 2019 (COVID-19) in Pregnancy: The Italian Registry on Coronavirus in Pregnancy.", "name": "NCT04315870", "primaryOutcome": "Maternal and perinatal outcomes", "study_type": "Observational [Patient Registry]", "time": "2020-03-18", "weburl": "https://clinicaltrials.gov/show/NCT04315870"}, "type": "Feature"}, {"geometry": {"coordinates": [16.355341, 39.04667], "type": "Point"}, "properties": {"classification": "Diagnosis", "contactEmail": ";antonio.gaddi@ehealth.study;maurizio.cipolla@ehealth.study", "contactPhone": ";+393920039246;", "dateEnrollment": "March 2020", "description": "Clinical Performance of the VivaDiag ™ COVID-19 lgM / IgG Rapid Test in Early Detecting the Infection of COVID-19", "name": "NCT04316728", "primaryOutcome": "Number of patients with constant negative results;Number of patients with positive test with a positive PCR for COVID-19;Overall Number of patients positive for COVID-19;Overall Number of patients negative for COVID-19;Number of patients with contrasting results", "study_type": "Interventional", "time": "2020-03-14", "weburl": "https://clinicaltrials.gov/show/NCT04316728"}, "type": "Feature"}, {"geometry": {"coordinates": [17.638563, 59.848826], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": ";robert.frithiof@surgsci.uu.se;robert.frithiof@surgsci.uu.se", "contactPhone": ";0736563473;073-6563473", "dateEnrollment": "March 12, 2020", "description": "Mechanisms for Organ Dysfunction in Covid-19", "name": "NCT04316884", "primaryOutcome": "Acute Kidney Injury", "study_type": "Observational", "time": "2020-03-13", "weburl": "https://clinicaltrials.gov/show/NCT04316884"}, "type": "Feature"}, {"geometry": {"coordinates": [14.059851, 41.513776], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": ";dicastel@ngi.it;", "contactPhone": ";3289035621;", "dateEnrollment": "March 23, 2020", "description": "ACE Inhibitors, Angiotensin II Type-I Receptor Blockers and Severity of COVID-19", "name": "NCT04318418", "primaryOutcome": "Severe COVID-19", "study_type": "Observational", "time": "2020-03-19", "weburl": "https://clinicaltrials.gov/show/NCT04318418"}, "type": "Feature"}, {"geometry": {"coordinates": [116.274939, 39.90562], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "455957898@qq.com", "contactPhone": "+86 13716608331", "dateEnrollment": "2020-04-01", "description": "Causes of fever in outpatient outside Wuhan during novel coronavirus pneumonia pandemic: a medical records based retrospective analysis", "name": "ChiCTR2000031366", "primaryOutcome": "temperature;novel coronavirus;Influenza virus;", "study_type": "Observational study", "time": "2020-03-29", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51692"}, "type": "Feature"}, {"geometry": {"coordinates": [121.113606, 28.846021], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "chenhx@enzemed.com", "contactPhone": "+86 13706760666", "dateEnrollment": "2020-01-17", "description": "To explore the pathogenesis and course prediction of novel coronavirus pneumonia (COVID-19) severe patients", "name": "ChiCTR2000031365", "primaryOutcome": "proteomics;metabonomics;SEN, SPE, ACC, AUC of ROC;", "study_type": "Diagnostic test", "time": "2020-03-29", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51694"}, "type": "Feature"}, {"geometry": {"coordinates": [114.352784, 30.527976], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "sunnyabs1215@163.com", "contactPhone": "+86 18986161976", "dateEnrollment": "2020-03-31", "description": "Retrospective analysis of anesthesia management of emergency cesarean section in non-pneumonia hospital of Wuhan during pandemic of novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000031361", "primaryOutcome": "fever;Chest CT;cough;;Anesthesia during cesarean section;Adverse reactions;Apgar score for neonates; Intraoperative blood loss;diagnosis of COVID-19 during perioperative;the medical observations of anesthesiologists participating in anesthesia management;", "study_type": "Observational study", "time": "2020-03-28", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51385"}, "type": "Feature"}, {"geometry": {"coordinates": [114.242864, 30.596649], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "fwl@hust.edu.cn", "contactPhone": "+86 027 85726727", "dateEnrollment": "2020-04-12", "description": "Study for the changes of the brain structure and function in healed patients of novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000031356", "primaryOutcome": "brain volume;white matter;brain function;", "study_type": "Observational study", "time": "2020-03-28", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51499"}, "type": "Feature"}, {"geometry": {"coordinates": [120.399617, 36.06199], "type": "Point"}, "properties": {"classification": "Other", "contactEmail": "lilibestever@126.com", "contactPhone": "+86 15192552255", "dateEnrollment": "2020-03-18", "description": "The relationship between habits of using eyes, degree of visual fatigue and myopia progression in students during the novel coronavirus pneumonia (COVID-19) pandemic", "name": "ChiCTR2000031337", "primaryOutcome": "eye axial length;corneal diopter;Tear film rupture time;Visual acuity;Visual fatigue;habits of using eyes;Accommodative Amplitude;Adjustment sensitivity;Adjustment lag;Negative relative adjustment;Positive relative adjustment;Fusion function;", "study_type": "Observational study", "time": "2020-03-28", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51170"}, "type": "Feature"}, {"geometry": {"coordinates": [114.27561, 30.583312], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "fyang@vip.163.com", "contactPhone": "+86 027 85726309", "dateEnrollment": "2020-04-12", "description": "AI based prognostic evaluation of novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000031336", "primaryOutcome": "sensitivity;accuracy;specificity;", "study_type": "Diagnostic test", "time": "2020-03-28", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51517"}, "type": "Feature"}, {"geometry": {"coordinates": [120.384172, 36.078426], "type": "Point"}, "properties": {"classification": "Other", "contactEmail": "lilibestever@126.com", "contactPhone": "+86 15192552255", "dateEnrollment": "2020-03-18", "description": "Analysis for prevention and control effects of orthokeratology lens on myopia adolescents during the novel coronavirus pneumonia (COVID-19) pandemic situation", "name": "ChiCTR2000031330", "primaryOutcome": "Axle length;Visual acuity;corneal diopter;Tear film rupture time;Visual fatigue;habits of using eyes;Accommodative Amplitude;Adjustment sensitivity;Adjustment lag;Negative relative adjustment;Positive relative adjustment;Fusion function;", "study_type": "Observational study", "time": "2020-03-27", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51504"}, "type": "Feature"}, {"geometry": {"coordinates": [113.333522, 23.094736], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "litian-wang@163.com", "contactPhone": "+86 13710874687", "dateEnrollment": "2020-03-11", "description": "Influence of novel coronavirus pneumonia (COVID-19) on disease activity, medical and mental condition of patients with rheumatic diseases", "name": "ChiCTR2000031329", "primaryOutcome": "medication possession ratio;selfrating anxiety scale;selfrating depression scale;Disease activity score-28;Systemic lupus erythematosus disease activity index;Ankylosing spondylits disease activity score;Visual analogue scale;", "study_type": "Observational study", "time": "2020-03-27", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51667"}, "type": "Feature"}, {"geometry": {"coordinates": [117.164083, 39.11491], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "doctor.wuyh@gmail.com", "contactPhone": "+86 022 27986625", "dateEnrollment": "2020-03-13", "description": "The protective effect of sleep psychology and music therapy of novel coronavirus pneumonia (COVID-19) mild and moderate type patients", "name": "ChiCTR2000031328", "primaryOutcome": "Self-assessment of sleep quality;Efficient of sleep improvement;", "study_type": "Interventional study", "time": "2020-03-27", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51425"}, "type": "Feature"}, {"geometry": {"coordinates": [118.782807, 32.057181], "type": "Point"}, "properties": {"classification": "Impact on helpers", "contactEmail": "824647903@qq.com", "contactPhone": "+86 15850531741", "dateEnrollment": "2020-04-10", "description": "The investigation on medical adhesive-related skin injury caused by protective dressings of medical staffs during the period of novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000031324", "primaryOutcome": "Incidence of medical adhensive-related injury;", "study_type": "Observational study", "time": "2020-03-27", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51668"}, "type": "Feature"}, {"geometry": {"coordinates": [114.282665, 30.552102], "type": "Point"}, "properties": {"classification": "Advanced therapy medicinal products", "contactEmail": "20215851@qq.com", "contactPhone": "+86 027 88041919-83920", "dateEnrollment": "2020-04-01", "description": "Safety and Efficacy Study of Allogeneic Human Dental Pulp Mesenchymal Stem Cells to Treat Severe novel coronavirus pneumonia (COVID-19) patients", "name": "ChiCTR2000031319", "primaryOutcome": "TTCI;", "study_type": "Interventional study", "time": "2020-03-27", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51647"}, "type": "Feature"}, {"geometry": {"coordinates": [125.377177, 43.863241], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "sidaoyuan1984@sina.com", "contactPhone": "+86 13578949866", "dateEnrollment": "2020-02-01", "description": "A retrospective study of clinical characteristics and prognosis of novel coronavirus pneumonia (COVID-19) patients with myocardial injury", "name": "ChiCTR2000031301", "primaryOutcome": "ECG;", "study_type": "Observational study", "time": "2020-03-27", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51603"}, "type": "Feature"}, {"geometry": {"coordinates": [111.304942, 30.686468], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "13972046539@163.com", "contactPhone": "+86 13972046539", "dateEnrollment": "2020-01-14", "description": "A medical records based study for clinical features of novel coronavirus pneumonia (COVID-19) patients and risk factors of death", "name": "ChiCTR2000031296", "primaryOutcome": "clinical features of COVID-19 patients and risk factors of death;", "study_type": "Observational study", "time": "2020-03-27", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51584"}, "type": "Feature"}, {"geometry": {"coordinates": [114.242864, 30.596649], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "haoyaner@163.com", "contactPhone": "+86 13971679960, 13387522645", "dateEnrollment": "2020-03-16", "description": "Epidemiological study of novel coronavirus infection (COVID-19) in children at medium/low risk", "name": "ChiCTR2000031293", "primaryOutcome": "Epidemiological characteristics;clinical features;Treatment outcome;", "study_type": "Observational study", "time": "2020-03-27", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51629"}, "type": "Feature"}, {"geometry": {"coordinates": [121.595628, 31.238329], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "zhengxue.academic@gmail.com", "contactPhone": "+86 17717830223", "dateEnrollment": "2020-02-18", "description": "The effectiveness of mindfulness intervention in improving people's psychological and physical well-being during novel coronavirus pneumonia (COVID-19) outbreak", "name": "ChiCTR2000031272", "primaryOutcome": "Anxiety level;Sleep;", "study_type": "Interventional study", "time": "2020-03-26", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51455"}, "type": "Feature"}, {"geometry": {"coordinates": [113.325839, 23.151851], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "chenzhuanggui@126.com", "contactPhone": "+86 13600009221", "dateEnrollment": "2020-04-01", "description": "Metabolic abnormalities and rearrangement reversal treatment of patient with novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000031271", "primaryOutcome": "Hospital stay or death ratio of experimental group / death ratio of control group;", "study_type": "Interventional study", "time": "2020-03-26", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51194"}, "type": "Feature"}, {"geometry": {"coordinates": [106.503768, 29.53543], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "qshi@cqmu.edu.cn", "contactPhone": "+86 023-68485008", "dateEnrollment": "2020-02-10", "description": "Outcomes and infectivity of patients with asymptomatic novel coronavirus (COVID-19) infection", "name": "ChiCTR2000031252", "primaryOutcome": "Demographic data;Epidemiological characteristics;Routine laboratory testing;Viral nucleic acid test;Patient reports symptoms daily;", "study_type": "Observational study", "time": "2020-03-25", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51559"}, "type": "Feature"}, {"geometry": {"coordinates": [114.284091, 36.017922], "type": "Point"}, "properties": {"classification": "Impact on helpers", "contactEmail": "wchmhcmxd@163.com", "contactPhone": "+86 18980605046", "dateEnrollment": "2020-03-01", "description": "Study on the mental state of medical staff  during the epidemic period of novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000031247", "primaryOutcome": "mental state;", "study_type": "Observational study", "time": "2020-03-25", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51540"}, "type": "Feature"}, {"geometry": {"coordinates": [106.488323, 29.551866], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "tangxiaoj0726@qq.com", "contactPhone": "+86 13668023656", "dateEnrollment": "2020-02-01", "description": "Epidemiological survey of close contacts of novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000031246", "primaryOutcome": "IgG antibody;IgM antibody;Throat swab virus nucleic acid test;", "study_type": "Observational study", "time": "2020-03-25", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51535"}, "type": "Feature"}, {"geometry": {"coordinates": [114.284091, 36.017922], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "wanzimili@sina.com", "contactPhone": "+86 17762551726", "dateEnrollment": "2020-01-25", "description": "Epidemiologic and Clinical Characteristics of novel coronavirus pneumonia (COVID-19) in surgical patients: a medical records based retrospective study", "name": "ChiCTR2000031245", "primaryOutcome": "Rate of COVID-19, distribution, time of onset and outcome;", "study_type": "Observational study", "time": "2020-03-25", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51518"}, "type": "Feature"}, {"geometry": {"coordinates": [114.242864, 30.596649], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "wwang@vip.126.com", "contactPhone": "+86 13871143176", "dateEnrollment": "2020-03-25", "description": "Shedding virus and functional prognosis in patients with novel coronavirus pneumonia (COVID-19): a medical records based study", "name": "ChiCTR2000031244", "primaryOutcome": "RT-PCR test for Covid-19;CT image;Covid-19 antibody test;", "study_type": "Observational study", "time": "2020-03-25", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51486"}, "type": "Feature"}, {"geometry": {"coordinates": [114.284091, 36.017922], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "mengqt2013@hotmail.com", "contactPhone": "+86 13995569560", "dateEnrollment": "2020-03-26", "description": "Clinical features and prognosis of invasive echanicalventilation patients with novel coronavirus pneumonia (COVID-19) in Wuhan, China: a single-centered, retrospective, observational study", "name": "ChiCTR2000031227", "primaryOutcome": "Clinical features and prognosis;", "study_type": "Observational study", "time": "2020-03-25", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51473"}, "type": "Feature"}, {"geometry": {"coordinates": [121.538305, 31.260789], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "2235658154@qq.com", "contactPhone": "+86 18930132792", "dateEnrollment": "2020-03-31", "description": "Clinical study on the correlation between novel coronavirus pneumonia (COVID-19) clinical rehabilitation assessment and prognosis", "name": "ChiCTR2000031214", "primaryOutcome": "Modified dyspnea index scale;St.George's Respiratory Questionnaire;Self-Rating Depression Scale;", "study_type": "Observational study", "time": "2020-03-24", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51509"}, "type": "Feature"}, {"geometry": {"coordinates": [116.270745, 39.902217], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "jin_eagle@sina.com", "contactPhone": "+86 13901374552", "dateEnrollment": "2020-01-30", "description": "A multicenter, single-blind, randomized controlled clinical trial for chloroquine phosphate in the treatment of novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000031204", "primaryOutcome": " Clearance time of virus RNA;", "study_type": "Interventional study", "time": "2020-03-24", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49420"}, "type": "Feature"}, {"geometry": {"coordinates": [113.664195, 34.77495], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "fuliran@126.com", "contactPhone": "+86 15837117112", "dateEnrollment": "2020-03-16", "description": "Study for the effect of Moxibustion Guidance and Intervention based on internet for the discharged patients with novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000031203", "primaryOutcome": "TCM Syndrome Scale;", "study_type": "Interventional study", "time": "2020-03-24", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51030"}, "type": "Feature"}, {"geometry": {"coordinates": [119.431785, 32.383967], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "sjun1982@163.com", "contactPhone": "+86 18051061365", "dateEnrollment": "2020-04-01", "description": "A medical records based study for clinical characteristics and risk factors of novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000031198", "primaryOutcome": "mortality;", "study_type": "Observational study", "time": "2020-03-23", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51488"}, "type": "Feature"}, {"geometry": {"coordinates": [114.2839, 36.017922], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "xuzhe302@139.com", "contactPhone": "+86 15001111836", "dateEnrollment": "2020-01-10", "description": "Efficacy and optimization of antiviral therapy for novel coronavirus pneumonia (COVID-19) patients", "name": "ChiCTR2000031196", "primaryOutcome": "time till the SARS-CoV-2 clearance;", "study_type": "Interventional study", "time": "2020-03-23", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51112"}, "type": "Feature"}, {"geometry": {"coordinates": [114.362133, 30.536048], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "pluo@whu.edu.cn", "contactPhone": "+86 13507191363", "dateEnrollment": "2020-03-23", "description": "A medical records based retrospective study for novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000031187", "primaryOutcome": "PT-PCR test;", "study_type": "Epidemilogical research", "time": "2020-03-23", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51442"}, "type": "Feature"}, {"geometry": {"coordinates": [113.648825, 34.791377], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "nicole8611@163.com", "contactPhone": "+86 13837167212", "dateEnrollment": "2020-02-20", "description": "Study on home pharmaceutical care for chronic patients over the novel coronavirus pneumonia (COVID-19) epidemic", "name": "ChiCTR2000031176", "primaryOutcome": "Patient satisfaction;", "study_type": "Observational study", "time": "2020-03-23", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51443"}, "type": "Feature"}, {"geometry": {"coordinates": [113.237215, 23.136749], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "doctorzzd99@163.com", "contactPhone": "+86 13903076359", "dateEnrollment": "2020-03-23", "description": "A RCT for Hua-Shi Bai-Du granules in patients with novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030988", "primaryOutcome": "Inflammation absorption on Chest CT;", "study_type": "Interventional study", "time": "2020-03-20", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51317"}, "type": "Feature"}, {"geometry": {"coordinates": [104.03945, 30.742342], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "gaopy930@126.com", "contactPhone": "+86 18980025566", "dateEnrollment": "2020-03-01", "description": "Clinical efficacy of TCM syndrome differentiation in the treatment of severe/critical type of novel coronavirus pneumonia (COVID-19): a prospective, observational, one-arm clinical study", "name": "ChiCTR2000030962", "primaryOutcome": "fatality rate;the ratio of patients transforming from severe/critical to light;Non-invasive/invasive mechanical ventilation time;", "study_type": "Observational study", "time": "2020-03-20", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51254"}, "type": "Feature"}, {"geometry": {"coordinates": [121.414884, 31.203951], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "icuwei@163.com", "contactPhone": "+86 18917763194", "dateEnrollment": "2020-02-01", "description": "Study for ''Bai-Du Duan Fang'' application on the acupoint in the treatment of general type novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030940", "primaryOutcome": "Quantitative table of main symptom grading;Quantitative table of lung physical signs grading;", "study_type": "Interventional study", "time": "2020-03-18", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51061"}, "type": "Feature"}, {"geometry": {"coordinates": [117.292849, 39.028739], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "sunhongyuan12@163.com", "contactPhone": "+86 18222521385", "dateEnrollment": "2020-02-28", "description": "Clinical investigation and reseach on TCM syndrome of novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030938", "primaryOutcome": "traditional Chinese medicine symptom;", "study_type": "Observational study", "time": "2020-03-18", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51239"}, "type": "Feature"}, {"geometry": {"coordinates": [113.397887, 23.035742], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "lishiyue@188.com", "contactPhone": "+86 13902233925", "dateEnrollment": "2020-03-19", "description": "A randomized, open-label, controlled trial for Gu-Shen Ding-Chuan-Wan in the treatment of patients with novel coronavirus pneumonia (COVID-19) at recovery phase with Fei-Pi-Qi-Xu Zhen", "name": "ChiCTR2000030937", "primaryOutcome": "The change of TCM syndrome integral of deficiency of Fei-Pi-Qi-Xu Zhen;The results and changes of fatigue assessment scale at each time point;", "study_type": "Interventional study", "time": "2020-03-18", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51240"}, "type": "Feature"}, {"geometry": {"coordinates": [104.03945, 30.742342], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "gaopy930@126.com", "contactPhone": "+86 18980025566", "dateEnrollment": "2020-03-10", "description": "A real-world study for the Chinese medicines ''Xinguan 2'' and ''Xinguan 3'' in the treatment of novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030936", "primaryOutcome": "Body temperature returns to normal time;After the medication, the disappearance rate of TCM symptoms;", "study_type": "Treatment study", "time": "2020-03-18", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51100"}, "type": "Feature"}, {"geometry": {"coordinates": [108.737457, 34.314503], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "leigenping2006@163.com", "contactPhone": "+86 13609219205", "dateEnrollment": "2020-02-15", "description": "The treatment and diagnosis plan of integrated traditional Chinese and Western medicine for novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030923", "primaryOutcome": "Incidence of COVID-19 pneumonia;COVID-19 pneumonia rate of improvement;", "study_type": "Interventional study", "time": "2020-03-17", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51139"}, "type": "Feature"}, {"geometry": {"coordinates": [114.436774, 30.464884], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "xiemx@hust.edu.cn", "contactPhone": "+86 13607108938", "dateEnrollment": "2020-02-28", "description": "Multicenter clinical study of evaluation of multi-organ function in patients with novel coronavirus pneumonia (COVID-19) by ultrasound", "name": "ChiCTR2000030817", "primaryOutcome": "Two-dimensional ultrasound;M mode echocardiography;Doppler ultrasound;two-dimensional speckle tracking;three-dimensional echocardiography;", "study_type": "Observational study", "time": "2020-03-15", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50631"}, "type": "Feature"}, {"geometry": {"coordinates": [118.94204, 32.1387], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "huxingxing82@163.com", "contactPhone": "+86 17327006987", "dateEnrollment": "2020-02-10", "description": "Observation Of Clinical Efficacy And Safety Of Bufonis Venenum Injection In The Treatment Of Severe Novel Coronavirus Pneumonia (COVID-19)", "name": "ChiCTR2000030704", "primaryOutcome": "PO2/FiO2;ROX INDEX;", "study_type": "Interventional study", "time": "2020-03-10", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50778"}, "type": "Feature"}, {"geometry": {"coordinates": [115.518485, 30.544766], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "ahslyywm@163.com", "contactPhone": "+86 18655106697", "dateEnrollment": "2020-02-28", "description": "Cancelled by the investigator                               Clinical research of 6-minute walk training on motor function of novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030330", "primaryOutcome": "walking distance;oxygen saturation;heart rate;", "study_type": "Observational study", "time": "2020-02-28", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50274"}, "type": "Feature"}, {"geometry": {"coordinates": [116.509464, 39.838557], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "huangluqi01@126.com", "contactPhone": "+86 010-64089801", "dateEnrollment": "2020-02-27", "description": "Efficacy of Traditional Chinese Medicine in the Treatment of Novel Coronavirus Pneumonia (COVID-19): a Randomized Controlled Trial", "name": "ChiCTR2000030288", "primaryOutcome": "The time to 2019-nCoV RNA negativity in patients;", "study_type": "Interventional study", "time": "2020-02-27", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50202"}, "type": "Feature"}, {"geometry": {"coordinates": [106.669774, 29.47108], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "cgq1963@163.com", "contactPhone": "+86 023 68757780", "dateEnrollment": "2020-02-01", "description": "Epidemiological and clinical characteristics of COVID-19: a large-scale investigation in epicenter Wuhan, China", "name": "ChiCTR2000030256", "primaryOutcome": "Epidemiological and clinical characteristics;", "study_type": "Epidemilogical research", "time": "2020-02-26", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50078"}, "type": "Feature"}, {"geometry": {"coordinates": [106.618374, 33.182406], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "hxkfhcq@126.com", "contactPhone": "+86 18980601618", "dateEnrollment": "2020-02-24", "description": "Clinical research of pulmonary rehabilitation in survivors due to severe or critial novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030198", "primaryOutcome": "pulmonary function;", "study_type": "Interventional study", "time": "2020-02-25", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50066"}, "type": "Feature"}, {"geometry": {"coordinates": [106.618374, 33.182406], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "kangyan_hx@163.com", "contactPhone": "+86 18980601556", "dateEnrollment": "2020-02-24", "description": "Clinical comparative study of PD-1 mAb in the treatment of severe and critical patients with novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030028", "primaryOutcome": "Neutrophil count;Lymphocyte count;Monocyte / macrophage count;Monocyte / macrophage function test;NK cell count;DC cell count;PD-1( immunosuppressive biomarker );PD-L1(immunosuppressive biomarker );CTLA4 (immunosuppressive biomarker );CD79;Blnk;Il7r;T lymphocyte count;CD4+ T lymphocyte count;CD8+ T lymphocyte count;B lymphocyte count;NK cell count;Proportion of navie CD4+ T lymphocytes to CD4+ T lymphocytes;Proportion of memory CD4+ T lymphocyte to CD4+ T lymphocytes;Proportion of CD4+ T lymphocyte subsets to CD4+ T lymphocytes;Proportion of CD8+ CD28+ subsets to CD8 + T lymphocytes;Activation ratio of CD8+ T lymphocytes;Ratio of CD4+ T lymphocytes to CD8+ T lymphocytes;", "study_type": "Interventional study", "time": "2020-02-20", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49840"}, "type": "Feature"}, {"geometry": {"coordinates": [114.436774, 30.464884], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "whuhjy@sina.com", "contactPhone": "+86 13554361146", "dateEnrollment": "2020-03-26", "description": "Prediction of prognosis and antiviral effect of patients with neocoronavirus infected pneumonia based on Peripheral blood exosomal metabolomics analysis and radiomics in CT of lung and its mechanism", "name": "ChiCTR2000029982", "primaryOutcome": "Patients' general information: epidemiological indicators such as age, gender, address, telephone, past medical history, and BMI;Division of disease;Metabolomics;Laboratory inspection;Imaging examination;Etiological examination;The remaining observation indicators are supplemented according to clinical needs.;", "study_type": "Observational study", "time": "2020-02-18", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49724"}, "type": "Feature"}, {"geometry": {"coordinates": [7.769919, 48.574945], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "Public-Registry-MA-France@sanofi.com", "contactPhone": "", "dateEnrollment": "26/03/2020", "description": "Sarilumab COVID-19", "name": "EUCTR2020-001162-12-FR", "primaryOutcome": "Main Objective: Phase 2: To evaluate the clinical efficacy of sarilumab relative to the control arm in adult patients hospitalized with severe COVID-19<br>Phase 3: To evaluate the clinical efficacy of sarilumab relative to the control arm in adult patients hospitalized with severe or critical COVID-19  <br>;Secondary Objective: Evaluate the clinical efficacy of sarilumab compared to the control arm by clinical severity, changes in the National Early Warning Score 2, duration of predefined symptoms and signs, duration of supplemental oxygen dependency, incidence of new mechanical ventilation use, the duration of new mechanical ventilation use, need for admission into ICU, duration of hospitalization,  28-day mortality rate.<br>Secondary safety objectives are to evaluate the safety of sarilumab compared to the control arm as assessed by incidence of: SAEs, Grade 4 neutropenia (ANC<500/mm3) with concurrent severe or life-threatening bacterial, invasive fungal, or opportunistic infection, Grade =2 infusion related reactions, Grade =2 hypersensitivity reactions, Increase in ALT =3X ULN (for patients with normal baseline) or >3X ULN and at least 2-fold increase from baseline value (for patients with abnormal baseline), Invasive bacterial or fungal infections of clinical significance with confirmed diagnosis ;Primary end point(s): Phase 2: time to resolution of fever for at least 48 hours without antipyretics or until discharge, whichever is sooner<br>Phase 3: The percentage of patients reporting each severity rating on the 7-point ordinal scale;Timepoint(s) of evaluation of this end point: Baseline to Day 29", "study_type": "Interventional clinical trial of medicinal product", "time": "2020-03-20", "weburl": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001162-12"}, "type": "Feature"}, {"geometry": {"coordinates": [5.180149, 52.086749], "type": "Point"}, "properties": {"classification": "Impact on helpers", "contactEmail": "M.J.M.Bonten@umcutrecht.nl", "contactPhone": "00318875 503 50 ", "dateEnrollment": "17/03/2020", "description": "Reducing health care workers absenteeism in Coronavirus 2019 pandemic nu enhancement of the immune system through vaccination with Bacillus Calmette-Guérin", "name": "EUCTR2020-000919-69-NL", "primaryOutcome": "Main Objective: To reduce absenteeism among HCW with direct patient contacts during the epidemic phase of SARS-CoV-2.;Secondary Objective: To reduce hospital admission, ICU admission or death in HCW with direct patient contacts during the epidemic phase of SARS-CoV-2.;Primary end point(s): Number of days of unplanned absenteeism for any reason ;Timepoint(s) of evaluation of this end point: Between day 0 up to day 180 after inclusion", "study_type": "Interventional clinical trial of medicinal product", "time": "2020-03-17", "weburl": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-000919-69"}, "type": "Feature"}, {"geometry": {"coordinates": [-1.435667, 50.935308], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "jody.brookes@synairgen.com", "contactPhone": "02380512800", "dateEnrollment": "17/03/2020", "description": "a trial of an inhaled antiviral drug to treat or prevent severe respiratory difficulties in patients with COVID-19", "name": "EUCTR2020-001023-14-GB", "primaryOutcome": "Main Objective: To assess whether SNG001 is well tolerated, and can prevent or accelerate recovery of lower respiratory tract illness in patients with SARS-CoV-2 infection.;Secondary Objective: To understand more about the biology of how SNG001 affects patients and the virus infection, this will be done by assessing changes in biomarkers in blood and sputum if they are available.;Primary end point(s): Primary Endpoint:<br>Change in condition measured using the Ordinal Scale for Clinical Improvement during the dosing period.<br><br>The Ordinal Scale for Clinical Improvement is a World Health Organisation recommended scale for use in COVID-19 trials.<br>;Timepoint(s) of evaluation of this end point: The dosing period is 14 days. Changes in the ordinal scale during the dosing period will be assessed.", "study_type": "Interventional clinical trial of medicinal product", "time": "2020-03-17", "weburl": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001023-14"}, "type": "Feature"}, {"geometry": {"coordinates": [-74.008642, 40.714579], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "Drpitts@hudsonmedical.com", "contactPhone": "6465967386", "dateEnrollment": "February 25, 2020", "description": "Eculizumab (Soliris) in Covid-19 Infected Patients", "name": "NCT04288713", "primaryOutcome": "", "study_type": "Expanded Access", "time": "2020-02-27", "weburl": "https://clinicaltrials.gov/show/NCT04288713"}, "type": "Feature"}, {"geometry": {"coordinates": [108.985829, 34.27069], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": ";", "contactPhone": ";", "dateEnrollment": "March 23, 2020", "description": "Nitric Oxide Gas Inhalation for Severe Acute Respiratory Syndrome in COVID-19.", "name": "NCT04290871", "primaryOutcome": "SARS-free patients at 14 days", "study_type": "Interventional", "time": "2020-02-27", "weburl": "https://clinicaltrials.gov/show/NCT04290871"}, "type": "Feature"}, {"geometry": {"coordinates": [117.002589, 36.671875], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": ";;jiaojiaopang@126.com;jiaojiaopang@126.com", "contactPhone": ";;18560089129;+86 18560089129", "dateEnrollment": "March 17, 2020", "description": "Bevacizumab in Severe or Critically Severe Patients With COVID-19 Pneumonia-RCT", "name": "NCT04305106", "primaryOutcome": "The time from randomization to clinical improvement", "study_type": "Interventional", "time": "2020-03-09", "weburl": "https://clinicaltrials.gov/show/NCT04305106"}, "type": "Feature"}, {"geometry": {"coordinates": [114.299488, 30.624769], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "", "contactPhone": "", "dateEnrollment": "February 26, 2020", "description": "Acute Kidney Injury in Patients Hospitalized With COVID-19", "name": "NCT04316299", "primaryOutcome": "Rate of Acute Kidney Injury", "study_type": "Observational", "time": "2020-03-17", "weburl": "https://clinicaltrials.gov/show/NCT04316299"}, "type": "Feature"}, {"geometry": {"coordinates": [28.939546, 41.005129], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": ";erenavcil@gmail.com;erenavcil@gmail.com", "contactPhone": ";+9005320683378;+9005320683378", "dateEnrollment": "March 25, 2020", "description": "Effects of Social Isolation From Coronavirus; on Physical Activity, Quality of Life and Stress", "name": "NCT04319211", "primaryOutcome": "International Physical Activity Questionnaire (IPAQ);Health-Related Quality of Life SF-12 Scale;Beck Depression Scale", "study_type": "Observational", "time": "2020-03-20", "weburl": "https://clinicaltrials.gov/show/NCT04319211"}, "type": "Feature"}, {"geometry": {"coordinates": [116.452005, 39.925684], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "shuminwang7000@163.com;shuminwang7000@163.com", "contactPhone": "+86 13488760399;+86 13488760399", "dateEnrollment": "March 5, 2020", "description": "Clinical Trial of Favipiravir Tablets Combine With Chloroquine Phosphate in the Treatment of Novel Coronavirus Pneumonia", "name": "NCT04319900", "primaryOutcome": "Time of Improvement or recovery of respiratory symptoms;Number of days virus nucleic acid shedding;Frequency of Improvement or recovery of respiratory symptoms", "study_type": "Interventional", "time": "2020-03-20", "weburl": "https://clinicaltrials.gov/show/NCT04319900"}, "type": "Feature"}, {"geometry": {"coordinates": [16.578885, 38.868645], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "gallelli@unicz.it;gallelli@unicz.it", "contactPhone": "3339245656;3339245656", "dateEnrollment": "March 23, 2020", "description": "Escin in Patients With Covid-19 Infection", "name": "NCT04322344", "primaryOutcome": "Mortality rate;Clinical status evaluated in agreement with guidelines", "study_type": "Interventional", "time": "2020-03-23", "weburl": "https://clinicaltrials.gov/show/NCT04322344"}, "type": "Feature"}, {"geometry": {"coordinates": [-0.134654, 51.525121], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "", "contactPhone": "", "dateEnrollment": "January 1, 1998", "description": "The Use of Angiotensin Converting Enzyme Inhibitors and Incident Respiratory Infections, Are They Harmful or Protective?", "name": "NCT04322786", "primaryOutcome": "Incidence of influenza", "study_type": "Observational", "time": "2020-03-23", "weburl": "https://clinicaltrials.gov/show/NCT04322786"}, "type": "Feature"}, {"geometry": {"coordinates": [116.293389, 39.994373], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": ";xyhplihao1965@126.com;xyhplihao1965@126.com", "contactPhone": ";+0086-133113382093;01062835088", "dateEnrollment": "March 2020", "description": "Traditional Chinese Medicine for Severe COVID-19", "name": "NCT04323332", "primaryOutcome": "Length of hospital stay (days)", "study_type": "Interventional", "time": "2020-03-08", "weburl": "https://clinicaltrials.gov/show/NCT04323332"}, "type": "Feature"}, {"geometry": {"coordinates": [13.369741, 38.11798], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "s.corrao@tiscali.it;s.corrao@tiscali.it", "contactPhone": "+390916662717;+390916662717", "dateEnrollment": "March 13, 2020", "description": "Use of Ascorbic Acid in Patients With COVID 19", "name": "NCT04323514", "primaryOutcome": "In-hospital mortality", "study_type": "Interventional", "time": "2020-03-18", "weburl": "https://clinicaltrials.gov/show/NCT04323514"}, "type": "Feature"}, {"geometry": {"coordinates": [34.984912, 32.832992], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": ";M_paul@rambam.health.gov.il", "contactPhone": ";+972-50-2062140", "dateEnrollment": "March 2020", "description": "Hydroxychloroquine for the Treatment of Patients With Mild to Moderate COVID-19 to Prevent Progression to Severe Infection or Death", "name": "NCT04323631", "primaryOutcome": "Number patients developing severe infection or death", "study_type": "Interventional", "time": "2020-03-25", "weburl": "https://clinicaltrials.gov/show/NCT04323631"}, "type": "Feature"}, {"geometry": {"coordinates": [11.002611, 45.436355], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "paolo.gisondi@univr.it", "contactPhone": "+39 0458122547", "dateEnrollment": "April 1, 2020", "description": "Prevalence and Incidence of COVID-19 Infection in Patients With Chronic Plaque Psoriasis on Immunosuppressant Therapy", "name": "NCT04324866", "primaryOutcome": "Point prevalence of COVID-19 infection", "study_type": "Observational", "time": "2020-03-24", "weburl": "https://clinicaltrials.gov/show/NCT04324866"}, "type": "Feature"}, {"geometry": {"coordinates": [106.469483, 29.550489], "type": "Point"}, "properties": {"classification": "Advanced therapy medicinal products", "contactEmail": ";gwzxliumin@foxmail.com;gwzxliumin@foxmail.com", "contactPhone": ";13668072999;13668072999", "dateEnrollment": "March 21, 2020", "description": "A Phase I/II Study of Universal Off-the-shelf NKG2D-ACE2 CAR-NK Cells for Therapy of COVID-19", "name": "NCT04324996", "primaryOutcome": "Clinical response;Side effects in the treatment group", "study_type": "Interventional", "time": "2020-03-25", "weburl": "https://clinicaltrials.gov/show/NCT04324996"}, "type": "Feature"}, {"geometry": {"coordinates": [5.164704, 52.103186], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "f.w.asselbergs@umcutrecht.nl;m.p.m.linschoten@umcutrecht.nl", "contactPhone": "+31 (0) 88 755 5555;+31 (0)88 755 5555", "dateEnrollment": "March 23, 2020", "description": "Cardiac complicAtions in Patients With SARS Corona vIrus 2 regisTrY", "name": "NCT04325412", "primaryOutcome": "The incidence of cardiovascular complications in patients with COVID-19", "study_type": "Observational [Patient Registry]", "time": "2020-03-25", "weburl": "https://clinicaltrials.gov/show/NCT04325412"}, "type": "Feature"}, {"geometry": {"coordinates": [114.206761, 22.419625], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "paulkschan@cuhk.edu.hk;", "contactPhone": "+852 35053339;+852 35053555", "dateEnrollment": "February 24, 2020", "description": "Coronavirus Disease 2019 (COVID-19) Study of Hospitalized Patients in Hong Kong", "name": "NCT04325919", "primaryOutcome": "Clinical;Virological;Microbiological", "study_type": "Observational", "time": "2020-03-24", "weburl": "https://clinicaltrials.gov/show/NCT04325919"}, "type": "Feature"}, {"geometry": {"coordinates": [-73.852164, 40.856503], "type": "Point"}, "properties": {"classification": "Diagnosis", "contactEmail": ";", "contactPhone": "+1 (201) 212-6643;", "dateEnrollment": "March 25, 2020", "description": "Audio Data Collection for Identification and Classification of Coughing", "name": "NCT04326309", "primaryOutcome": "Dataset size", "study_type": "Observational", "time": "2020-03-26", "weburl": "https://clinicaltrials.gov/show/NCT04326309"}, "type": "Feature"}, {"geometry": {"coordinates": [-1.433112, 50.932497], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "", "contactPhone": "", "dateEnrollment": "20/03/2020", "description": "Does point-of-care testing for coronavirus in hospital improve patient care compared to laboratory testing?", "name": "ISRCTN14966673", "primaryOutcome": "Time from COVID-19 test being requested to the result being available to clinical teams in minutes and hours, recorded during hospitalisation", "study_type": "Interventional", "time": "2020-03-18", "weburl": "http://isrctn.com/ISRCTN14966673"}, "type": "Feature"}, {"geometry": {"coordinates": [116.35677, 39.981754], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "sunhq@bjmu.edu.cn", "contactPhone": "+86 10 82805960", "dateEnrollment": "2020-03-27", "description": "Effects of a single session internet-delivered cognitive behavioral therapy for Acute Insomnia during the pandemic of novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000031639", "primaryOutcome": "Sleep diary;The insomnia severity index;Sleep visual analogue scale;", "study_type": "Interventional study", "time": "2020-04-05", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51119"}, "type": "Feature"}, {"geometry": {"coordinates": [113.269205, 23.147477], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "winsonhong@126.com", "contactPhone": "+86 13729834533", "dateEnrollment": "2020-02-17", "description": "Clinical study for Celebrex in the treatment of novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000031630", "primaryOutcome": "Prostaglandin E2;", "study_type": "Interventional study", "time": "2020-04-05", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50474"}, "type": "Feature"}, {"geometry": {"coordinates": [115.808927, 32.899433], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "lxy7111@126.com", "contactPhone": "+86 13505581239", "dateEnrollment": "2020-04-20", "description": "Study for the Mechanism of the Relationship between Infection of novel coronavirus pneumonia (COVID-19) and Host Innate Immune", "name": "ChiCTR2000031627", "primaryOutcome": "CRP;SAA;IL-6;PCT;tRNA;", "study_type": "Basic Science", "time": "2020-04-05", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51865"}, "type": "Feature"}, {"geometry": {"coordinates": [114.281922, 30.552414], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "wenqin-1987@163.com", "contactPhone": "+86 27 88041911", "dateEnrollment": "2020-03-06", "description": "Investigation for the sleep quality in non-health care workers during the pandemic of novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000031589", "primaryOutcome": "PSQI;", "study_type": "Observational study", "time": "2020-04-05", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51969"}, "type": "Feature"}, {"geometry": {"coordinates": [114.583872, 30.596762], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "xmguo@tjh.tjmu.edu.cn", "contactPhone": "+86 13971518978", "dateEnrollment": "2020-01-27", "description": "A paired clinical study for novel coronavirus pneumonia (COVID-19) patients with ordinary, severe, critical, and deceased patients in Tongji Hospital", "name": "ChiCTR2000031587", "primaryOutcome": "Chest computed tomography (CT);", "study_type": "Observational study", "time": "2020-04-04", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51952"}, "type": "Feature"}, {"geometry": {"coordinates": [107.032312, 27.723057], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "jzxhl@126.com", "contactPhone": "+86 19385219073", "dateEnrollment": "2020-02-05", "description": "Study for clinical effect of rehabilitation nursing program for patients with novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000031540", "primaryOutcome": "6minu tewalkingtest,6MWT;mMRC;Rating of Perceived Exertion Scale;SAS;", "study_type": "Interventional study", "time": "2020-04-03", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51684"}, "type": "Feature"}, {"geometry": {"coordinates": [121.480433, 31.201595], "type": "Point"}, "properties": {"classification": "Impact on helpers", "contactEmail": "zyq1590@163.com", "contactPhone": "+86 13817091896", "dateEnrollment": "2020-04-03", "description": "Assessment of mental health status of first-line dental emergency medical personnel during novel coronavirus pneumonia (COVID-19) pandemic", "name": "ChiCTR2000031538", "primaryOutcome": "ASDS;PSS;PHQ;GAD;", "study_type": "Health Services Research", "time": "2020-04-03", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51938"}, "type": "Feature"}, {"geometry": {"coordinates": [116.398333, 39.929164], "type": "Point"}, "properties": {"classification": "Impact on helpers", "contactEmail": "yxzpumch@126.com", "contactPhone": "+86 13601262164", "dateEnrollment": "2020-04-10", "description": "Survey of psychological status and related factors of emergency medical staff in the country during the novel coronavirus pneumonia (COVID-19) pandemic", "name": "ChiCTR2000031533", "primaryOutcome": "The score of PHQ-9;", "study_type": "Health Services Research", "time": "2020-04-03", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51835"}, "type": "Feature"}, {"geometry": {"coordinates": [114.583872, 30.596762], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "393176736@qq.com", "contactPhone": "+86 02783665518", "dateEnrollment": "2019-12-01", "description": "A multi-center telephone follow-up study of disease management and infection in rheumatic patients during novel coronavirus pneumonia (COVID-19) pandemic in Hubei province", "name": "ChiCTR2000031504", "primaryOutcome": "Infection;", "study_type": "Observational study", "time": "2020-04-03", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51781"}, "type": "Feature"}, {"geometry": {"coordinates": [121.405196, 31.197632], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "shencx@sjtu.edu.cn", "contactPhone": "+86 18501664545", "dateEnrollment": "2020-04-01", "description": "Application of non-invasive multichannel cardiopulmonary monitoring cloud management platform in patients with Novel Coronavirus Pneumonia (COVID-19)", "name": "ChiCTR2000031503", "primaryOutcome": "Exposure time in the medical cabin;Hospitalization period;Detection rate of arrhythmia;", "study_type": "Interventional study", "time": "2020-04-03", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51911"}, "type": "Feature"}, {"geometry": {"coordinates": [118.807885, 32.040796], "type": "Point"}, "properties": {"classification": "Advanced therapy medicinal products", "contactEmail": "liweiqindr@vip.163.com", "contactPhone": "+86 13951839654", "dateEnrollment": "2020-03-17", "description": "The efficacy  of convalescent plasma in patients with critical novel coronavirus pneumonia (COVID-19): a pragmatic, prospective cohort study", "name": "ChiCTR2000031501", "primaryOutcome": "hospital mortality;", "study_type": "Interventional study", "time": "2020-04-02", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50254"}, "type": "Feature"}, {"geometry": {"coordinates": [116.376141, 39.927286], "type": "Point"}, "properties": {"classification": "Diagnosis", "contactEmail": "drlihang@126.com", "contactPhone": "+86 13693058190", "dateEnrollment": "2020-03-05", "description": "Impact of measuring distance and cold outdoor environment on the screening of novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000031500", "primaryOutcome": "body surface temperature;", "study_type": "Health Services Research", "time": "2020-04-02", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51897"}, "type": "Feature"}, {"geometry": {"coordinates": [121.511146, 31.237762], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "leetangbaba@163.com", "contactPhone": "+86 13585808910", "dateEnrollment": "2020-02-10", "description": "Sleep quality of patients with novel coronavirus pneumonia (COVID-19) treated in mobile cabin hospital: a retrospective study", "name": "ChiCTR2000031499", "primaryOutcome": "Quality of sleep;", "study_type": "Observational study", "time": "2020-04-02", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51915"}, "type": "Feature"}, {"geometry": {"coordinates": [115.09233, 30.210942], "type": "Point"}, "properties": {"classification": "Advanced therapy medicinal products", "contactEmail": "zhu1635253@163.com", "contactPhone": "+86 18951762691", "dateEnrollment": "2020-02-01", "description": "Clinical study for stem cells in the treatment of severe novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000031494", "primaryOutcome": "Chest Imaging;lung function;ADL;", "study_type": "Interventional study", "time": "2020-04-02", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51904"}, "type": "Feature"}, {"geometry": {"coordinates": [114.435008, 30.511901], "type": "Point"}, "properties": {"classification": "Diagnosis", "contactEmail": "18971327286@163.com", "contactPhone": "+86 18971327286", "dateEnrollment": "2020-03-25", "description": "Novel coronavirus (2019-nCOV) IgG detection kit (magnetic particle chemiluminescence) clinical trial", "name": "ChiCTR2000031465", "primaryOutcome": "2019-nCov IgG;", "study_type": "Diagnostic test", "time": "2020-04-02", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51538"}, "type": "Feature"}, {"geometry": {"coordinates": [113.557039, 22.313315], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "xiaof35@sysu.edu.cn", "contactPhone": "+86 13380600018", "dateEnrollment": "2020-01-25", "description": "Clinical study for prevention and treatment of digestive tract lesions caused by novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000031454", "primaryOutcome": " 2019-ncov nucleic acid yin rate;Blood 2019-ncov nucleic acid positive;Positive 2019-ncov nucleic acid in feces;Nasopharyngeal swab positive for 2019-ncov nucleic acid;", "study_type": "Interventional study", "time": "2020-04-01", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51693"}, "type": "Feature"}, {"geometry": {"coordinates": [114.583872, 30.596762], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "yuanxianglin@hust.edu.cn", "contactPhone": "+86 13667241722", "dateEnrollment": "2020-04-01", "description": "Efficacy and safety of Nintedanib esilate soft capsules in the treatment of pulmonary fibrosis in healed moderate to severe patients of novel coronavirus pneumonia (COVID-19): a single-center, randomized, placebo-controlled trial", "name": "ChiCTR2000031453", "primaryOutcome": "FVC;", "study_type": "Interventional study", "time": "2020-04-01", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51859"}, "type": "Feature"}, {"geometry": {"coordinates": [114.583872, 30.596762], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "wanli0604@163.com", "contactPhone": "+86 13638670601", "dateEnrollment": "2020-03-20", "description": "A medical records based study for novel coronavirus pneumonia (COVID-19) patients undergoing endotracheal intubation", "name": "ChiCTR2000031439", "primaryOutcome": "Success rate of intubation;Exposure classification of glottis;", "study_type": "Observational study", "time": "2020-04-01", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51837"}, "type": "Feature"}, {"geometry": {"coordinates": [105.444942, 28.888685], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "oucehua@swmu.edu.cn", "contactPhone": "+86 15608089909", "dateEnrollment": "2020-04-01", "description": "Analysis of changes in high risk factors of cervical spondylosis during novel coronavirus pneumonia (COVID-19) pandemic", "name": "ChiCTR2000031438", "primaryOutcome": "Phone time before and during the outbreak;Physical exercise time before and during the outbreak;Symptoms worsened in patients with previous cervical spondylosis since the outbreak;Symptoms in people with no previous symptoms of cervical spondylosis since the outbreak;", "study_type": "Observational study", "time": "2020-04-01", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51815"}, "type": "Feature"}, {"geometry": {"coordinates": [118.9592, 32.10905], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "cyzhang@nju.edu.cn", "contactPhone": "+86 13913994223", "dateEnrollment": "2020-05-01", "description": "A single center clinical study of evaluating the injection of microRNA2911 plasmid in healthy adults", "name": "ChiCTR2000031432", "primaryOutcome": "Safety and tolerance;", "study_type": "Basic Science", "time": "2020-03-31", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51646"}, "type": "Feature"}, {"geometry": {"coordinates": [116.271959, 39.887875], "type": "Point"}, "properties": {"classification": "Advanced therapy medicinal products", "contactEmail": "fswang302@163.com", "contactPhone": "+86 010-66933332", "dateEnrollment": "2020-03-20", "description": "Clinical study of human umbilical cord mesenchymal stem cells in the treatment of novel coronavirus pneumonia (COVID-19) induced pulmonary fibrosis", "name": "ChiCTR2000031430", "primaryOutcome": "Electrocardiogram;St George's Respiratory Questionnaire Score;High resolution CT for chest;Blood gas analysis;Percutaneous blood oxygen saturation;6 min walking distance;Pulmonary function VCmax;Blood routine;Liver and kidney function;Cytokine analysis;Immunoglobulin;Lymphocyte subsets;Coagulation;Myocardial enzymes;Serum ferritin;Procalcitonin;IL-6;Lactic acid;D-Dimer;CRP;", "study_type": "Interventional study", "time": "2020-03-31", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49254"}, "type": "Feature"}, {"geometry": {"coordinates": [114.583872, 30.596762], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "393176736@qq.com", "contactPhone": "+86 027-83665518", "dateEnrollment": "2020-04-01", "description": "The Effects of novel coronavirus pneumonia (COVID-19) Risk Factors on Dynamic Changes of  Immunological, biochemical, and Metabolic Parameters: a Retrospective Observational Study", "name": "ChiCTR2000031429", "primaryOutcome": "Blood cell number;Biochemical markers;Metabolic markers;", "study_type": "Observational study", "time": "2020-03-31", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51816"}, "type": "Feature"}, {"geometry": {"coordinates": [114.266604, 30.59955], "type": "Point"}, "properties": {"classification": "Diagnosis", "contactEmail": "zejinliu@163.com", "contactPhone": "+86 18963980043", "dateEnrollment": "2020-02-05", "description": "Clinical application value of multiple tests for novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000031428", "primaryOutcome": "SARS-CoV-2 antibody;SEN, SPE, ACC, AUC of ROC;", "study_type": "Diagnostic test", "time": "2020-03-31", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51813"}, "type": "Feature"}, {"geometry": {"coordinates": [114.435008, 30.511901], "type": "Point"}, "properties": {"classification": "Diagnosis", "contactEmail": "18971327286@163.com", "contactPhone": "+86 18971327286", "dateEnrollment": "2020-03-25", "description": "Novel coronavirus infection (COVID-19) IgM detection kit (magnetic particle chemiluminescence) clinical trial", "name": "ChiCTR2000031427", "primaryOutcome": "SPE, SEN, ACC, AUC of ROC;", "study_type": "Diagnostic test", "time": "2020-03-31", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51809"}, "type": "Feature"}, {"geometry": {"coordinates": [116.343857, 39.99832], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "liudongyang@vip.sina.com", "contactPhone": "+86 18610966092", "dateEnrollment": "2020-03-28", "description": "A medical records based study for safety and effectiveness analysis of data from novel coronavirus pneumonia (COVID-19) patients with conventional therapy", "name": "ChiCTR2000031376", "primaryOutcome": "Safety;Effectiveness;", "study_type": "Observational study", "time": "2020-03-29", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51724"}, "type": "Feature"}, {"geometry": {"coordinates": [112.985202, 28.211827], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "fanrong3463@163.com", "contactPhone": "+86 13808454319", "dateEnrollment": "2020-02-04", "description": "A Medical Records Based Retrospective Study for Clinical Characteristics of severe Novel Coronavirus Pneumonia (COVID-19)", "name": "ChiCTR2000031199", "primaryOutcome": "Cure rate;improvement rate;", "study_type": "Observational study", "time": "2020-03-23", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51478"}, "type": "Feature"}, {"geometry": {"coordinates": [-0.557018, 47.48151], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "DRCI-Promotion-Interne@chu-angers.fr", "contactPhone": "0241353342", "dateEnrollment": "31/03/2020", "description": "HYCOVID - Hydroxychloroquine versus placebo chez les patients ayant une infection COVID-19 à risque d’aggravation secondaire : étude prospective multicentrique randomisée en double aveugle", "name": "EUCTR2020-001271-33-FR", "primaryOutcome": "Main Objective: L’objectif principal est d’évaluer l’efficacité de l’hydroxychloroquine versus placebo sur le taux de décès ou de recours à une ventilation invasive chez les patients ayant une infection COVID-19 à haut risque d’aggravation.;Secondary Objective: Les objectifs secondaires sont :<br><br>1) Évaluer l’efficacité de l’hydroxychloroquine versus placebo chez les patients COVID-19 sur : <br>a- l’évolution clinique via l’échelle OSCI (Ordinal Scale for Clinical Improvement) pour COVID-19 de l’OMS<br>b- la mortalité toute cause <br>c- le portage viral <br>d- l’incidence des accidents thrombo-emboliques veineux <br><br>2) Évaluer l’efficacité de l’hydroxychloroquine versus placebo dans le sous-groupe des personnes âgées de 75 ans ou plus sur :<br>a- l’évolution clinique via l’échelle OSCI pour COVID-19 de l’OMS <br>b- la mortalité toute cause<br><br>3) Évaluer la tolérance de l’hydroxychloroquine versus placebo sur la survenue d’évènements indésirables graves<br><br>Objectifs ancillaires <br>Évaluer, dans un sous-groupe de patients COVID-19, l’impact de l’hydroxychloroquine versus placebo sur l’évolution des cytokines et des marqueurs biologiques de l’immunité, de l’inflammation et de l’hémostase<br>;Primary end point(s): Le critère de jugement principal est le décès quelle qu’en soit la cause ou le recours à une intubation et ventilation invasive dans les 14 jours (J14) suivant l’inclusion et le début du traitement (J0).;Timepoint(s) of evaluation of this end point: Le critère de jugement principal est le décès quelle qu’en soit la cause ou le recours à une intubation et ventilation invasive dans les 14 jours (J14) suivant l’inclusion et le début du traitement (J0).", "study_type": "Interventional clinical trial of medicinal product", "time": "2020-03-24", "weburl": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001271-33"}, "type": "Feature"}, {"geometry": {"coordinates": [-0.572464, 47.497946], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "carine.labruyere@chu-st-etienne.fr", "contactPhone": "33(0)477120469", "dateEnrollment": "30/03/2020", "description": "Evaluation of the concentration/viral effect relationship of hydroxychloroquine in COVID-19 patients in the intensive care unit..", "name": "EUCTR2020-001281-11-FR", "primaryOutcome": "Main Objective: to describe the pharmacokinetics of hydroxychloroquine in resuscitation patients infected with SARS-CoV-2.;Secondary Objective:  - Describe the relationship between HCQ concentration and cardiac toxicity.<br>- To describe the pharmacokinetic (concentration) and pharmacodynamic (viral load) relationship of hydroxychloroquine in resuscitation patients infected with SARS-CoV-2.<br>- To define the best modalities of administration of hydroxychloroquine in resuscitation patients infected with SARS-CoV-2  based on the PK/PD relationship.;Primary end point(s): determination of the blood concentration of hydroxychloroquine by liquid chromatography coupled with mass spectrometry.;Timepoint(s) of evaluation of this end point: daily for 10 days", "study_type": "Interventional clinical trial of medicinal product", "time": "2020-03-26", "weburl": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001281-11"}, "type": "Feature"}, {"geometry": {"coordinates": [2.379795, 48.827278], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "rqrc.siege@inserm.fr", "contactPhone": "33182533368", "dateEnrollment": "09/03/2020", "description": "Multi-centre, adaptive, randomized trial of the safety and efficacy of treatments of COVID-19 in hospitalized adults - DisCoVeRy", "name": "EUCTR2020-000936-23-FR", "primaryOutcome": "Main Objective: The overall objective of the study is to evaluate the clinical efficacy and safety of different investigational therapeutics relative to the control arm in patients hospitalized with COVID-19.<br>•\tThe primary endpoint is subject clinical status (on a 7-point ordinal scale) at day 15 <br>;Secondary Objective: Evaluate clinical efficacy of different investigational therapeutics as compared to the control arm as assessed by:<br><br>-Clinical Severity (Ordinal scale, National Early Warning Score (NEWS), Oxygenation, Mechanical Ventilation)<br>-Hospitalization : duration of hospitalization (days). <br>-Mortality<br>-Evaluate the safety of different investigational therapeutics through 28 days of follow-up as compared to the control arm<br>-Evaluate the virologic efficacy of different investigational therapeutics as compared to the control arm as assessed ;Primary end point(s): Clinical status of subject at day 15 (on a 7-point ordinal scale):<br>1.\tNot hospitalized, no limitations on activities<br>2.\tNot hospitalized, limitation on activities;<br>3.\tHospitalized, not requiring supplemental oxygen;<br>4.\tHospitalized, requiring supplemental oxygen;<br>5.\tHospitalized, on non-invasive ventilation or high flow oxygen devices;<br>6.\tHospitalized, on invasive mechanical ventilation or ECMO;<br>7.\tDeath.<br><br>;Timepoint(s) of evaluation of this end point: Day 15", "study_type": "Interventional clinical trial of medicinal product", "time": "2020-03-09", "weburl": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-000936-23"}, "type": "Feature"}, {"geometry": {"coordinates": [4.858126, 52.336224], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "j.aman@amsterdamumc.nl", "contactPhone": "+31610738910", "dateEnrollment": "31/03/2020", "description": "Countering Lung Damage in COVID-19 infection: the CounterCovid Study", "name": "EUCTR2020-001236-10-NL", "primaryOutcome": "Main Objective: To test whether treatment with oral imatinib reduce disease burden and consumption of medical resources.;Secondary Objective: The secondary objective is to evaluate the pharmacokinetics of a 10-day course of oral imatinib in patients with severe Covid19 pneumonitis.;Primary end point(s): Composite outcome of death / need for invasive ventilation / need for ECMO ;Timepoint(s) of evaluation of this end point: 28 days", "study_type": "Interventional clinical trial of medicinal product", "time": "2020-03-31", "weburl": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001236-10"}, "type": "Feature"}, {"geometry": {"coordinates": [10.976592, 59.949145], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "jan.erik.berdal@medisin.uio.no", "contactPhone": "+4767960000", "dateEnrollment": "23/03/2020", "description": "NORWEGIAN CORONAVIRUS DISEASE 2019 [NO-COVID-19] STUDY: A TRIAL TO EVALUATE THE ANTIVIRAL EFFECT OF CHLOROQUINE IN ADULT PATIENTS WITH SARS-COV-2 INFECTION", "name": "EUCTR2020-001010-38-NO", "primaryOutcome": "Main Objective: To assess whether early treatment with chloroquine in patients with established COVID-19 will significantly reduce replication rate of SARS-CoV-2.;Secondary Objective: •\tAssess the impact of early treatment with chloroquine in patients with established COVID-19 on rate of decline in SARS-CoV-2 viral load in nasopharyngeal samples as assessed by RT-PCR from baseline to 96 hours<br>•\tAssess the impact of early treatment with chloroquine in patients with established COVID-19 on changes in NEWS score<br>•\tAssess the impact of early treatment with chloroquine in patients with established COVID-19 on admission rate to ICU<br>•\tAssess the impact of early treatment with chloroquine in patients with established COVID-19 on in hospital mortality<br>;Primary end point(s): Rate of decline in SARS-CoV-2 viral load in nasopharyngeal samples as assessed by RT-PCR  in samples collected at baseline, 48 and 96 hours after randomization;Timepoint(s) of evaluation of this end point: 96 hours.", "study_type": "Interventional clinical trial of medicinal product", "time": "2020-03-16", "weburl": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001010-38"}, "type": "Feature"}, {"geometry": {"coordinates": [7.605616, 47.558062], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "global.rochegenentechtrials@roche.com", "contactPhone": "", "dateEnrollment": "27/03/2020", "description": "Efficacy of Tocilizumab - COVID-19", "name": "EUCTR2020-001386-37-IT", "primaryOutcome": "Main Objective: ;Secondary Objective: ;Primary end point(s): ", "study_type": "Interventional clinical trial of medicinal product", "time": "2020-04-02", "weburl": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001386-37"}, "type": "Feature"}, {"geometry": {"coordinates": [153.022034, -27.390527], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "", "contactPhone": "", "dateEnrollment": "05/03/2020", "description": "ExtraCorporeal Membrane Oxygenation for 2019 novel Coronavirus Acute Respiratory Disease (COVID-19)", "name": "ACTRN12620000421932", "primaryOutcome": "Mortality<br>[At hospital discharge or 28 days post intensive care unit admission, whichever comes later. ]", "study_type": "Observational", "time": "2020-03-30", "weburl": "https://anzctr.org.au/ACTRN12620000421932.aspx"}, "type": "Feature"}, {"geometry": {"coordinates": [-123.245994, 49.260605], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "", "contactPhone": "", "dateEnrollment": "October 24, 2017", "description": "Inhaled Gaseous Nitric Oxide (gNO) Antimicrobial Treatment of Difficult Bacterial and Viral Lung (COVID-19) Infections", "name": "NCT03331445", "primaryOutcome": "Measure the safety of 160ppm inhaled nitric oxide delivery in NTM subjects", "study_type": "Interventional", "time": "2020-04-14", "weburl": "https://clinicaltrials.gov/show/NCT03331445"}, "type": "Feature"}, {"geometry": {"coordinates": [117.002589, 36.671875], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": ";jiaojiaopang@126.com", "contactPhone": ";(086)0531-82166843", "dateEnrollment": "February 15, 2020", "description": "Bevacizumab in Severe or Critical Patients With COVID-19 Pneumonia", "name": "NCT04275414", "primaryOutcome": "Partial arterial oxygen pressure (PaO2) to fraction of inspiration O2 (FiO2) ratio;Partial arterial oxygen pressure (PaO2) to fraction of inspiration O2 (FiO2) ratio;Partial arterial oxygen pressure (PaO2) to fraction of inspiration O2 (FiO2) ratio", "study_type": "Interventional", "time": "2020-02-14", "weburl": "https://clinicaltrials.gov/show/NCT04275414"}, "type": "Feature"}, {"geometry": {"coordinates": [121.455483, 31.229078], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": ";ifan@ansunbiopharma.com", "contactPhone": ";+86 186 2190 9313", "dateEnrollment": "April 2020", "description": "DAS181 for Patients With Severe Hospitalized Flu and SAD-RVs (COVID-19)", "name": "NCT04298060", "primaryOutcome": "Percent of subjects who have returned to room air;Percent change of subjects return to baseline oxygen requirement", "study_type": "Interventional", "time": "2020-02-28", "weburl": "https://clinicaltrials.gov/show/NCT04298060"}, "type": "Feature"}, {"geometry": {"coordinates": [110.777737, 32.622385], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "zhongji.meng@163.com;zhongji.meng@163.com", "contactPhone": "18971905757;+86-18971905757", "dateEnrollment": "January 21, 2020", "description": "Experimental Trial of rhIFNa Nasal Drops to Prevent 2019-nCOV in Medical Staff", "name": "NCT04320238", "primaryOutcome": "new-onset COVID-19", "study_type": "Interventional", "time": "2020-03-21", "weburl": "https://clinicaltrials.gov/show/NCT04320238"}, "type": "Feature"}, {"geometry": {"coordinates": [10.716748, 59.949212], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "Arne.Vasli.Lund.Soraas@rr-research.no;Arne.Vasli.Lund.Soraas@rr-research.no", "contactPhone": "+4790652904;+4790652904", "dateEnrollment": "March 27, 2020", "description": "Risk Factors for Community- and Workplace Transmission of COVID-19", "name": "NCT04320732", "primaryOutcome": "Rate of COVID-19 infection", "study_type": "Observational", "time": "2020-03-23", "weburl": "https://clinicaltrials.gov/show/NCT04320732"}, "type": "Feature"}, {"geometry": {"coordinates": [-122.577684, 37.757617], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": ";info@beat19.org;info@beat19.org", "contactPhone": ";(415) 754-9290;", "dateEnrollment": "March 21, 2020", "description": "Behavior, Environment And Treatments for Covid-19", "name": "NCT04321811", "primaryOutcome": "Define Natural Symptom Course", "study_type": "Observational [Patient Registry]", "time": "2020-03-23", "weburl": "https://clinicaltrials.gov/show/NCT04321811"}, "type": "Feature"}, {"geometry": {"coordinates": [9.15777, 45.500016], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": ";Guido.bertolini@marionegri.it", "contactPhone": ";+39 035 4535 313", "dateEnrollment": "April 6, 2020", "description": "Early CPAP in COVID Patients With Respiratory Failure. A Prospective Cohort Study.", "name": "NCT04323878", "primaryOutcome": "Death or need of intubation", "study_type": "Observational [Patient Registry]", "time": "2020-03-25", "weburl": "https://clinicaltrials.gov/show/NCT04323878"}, "type": "Feature"}, {"geometry": {"coordinates": [2.352411, 48.810321], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "ohermine@gmail.com", "contactPhone": "603707920", "dateEnrollment": "March 27, 2020", "description": "Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients", "name": "NCT04324047", "primaryOutcome": "Survival;WHO progression scale COVID 19", "study_type": "Observational", "time": "2020-03-25", "weburl": "https://clinicaltrials.gov/show/NCT04324047"}, "type": "Feature"}, {"geometry": {"coordinates": [7.837186, 48.00503], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": ";alexander.supady@universitaets-herzzentrum.de;", "contactPhone": ";+49761270;", "dateEnrollment": "March 27, 2020", "description": "Cytokine Adsorption in Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation", "name": "NCT04324528", "primaryOutcome": "interleukin-6 (IL-6) level after 72 hours", "study_type": "Interventional", "time": "2020-03-25", "weburl": "https://clinicaltrials.gov/show/NCT04324528"}, "type": "Feature"}, {"geometry": {"coordinates": [26.10287, 44.432689], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": ";;alexandru.burlacu@umfiasi.ro", "contactPhone": ";;0040744488580", "dateEnrollment": "March 31, 2020", "description": "Integrated Distance Management Strategy for Patients With Cardiovascular Diseases in the Context of COVID-19", "name": "NCT04325867", "primaryOutcome": "Providing a special electronic platform (e-health) for remote managing cardiovascular outpatients;Number of patients included in this platform", "study_type": "Interventional", "time": "2020-03-21", "weburl": "https://clinicaltrials.gov/show/NCT04325867"}, "type": "Feature"}, {"geometry": {"coordinates": [-114.093603, 46.502975], "type": "Point"}, "properties": {"classification": "Advanced therapy medicinal products", "contactEmail": "", "contactPhone": "", "dateEnrollment": "March 25, 2020", "description": "Use of cSVF Via IV Deployment for Residual Lung Damage After Symptomatic COVID-19 Infection", "name": "NCT04326036", "primaryOutcome": "Incidence of Treatment-Emergent Adverse Events", "study_type": "Interventional", "time": "2020-03-26", "weburl": "https://clinicaltrials.gov/show/NCT04326036"}, "type": "Feature"}, {"geometry": {"coordinates": [9.142325, 45.516452], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": ";guido.bertolini@marionegri.it", "contactPhone": ";+39 035 4554 313", "dateEnrollment": "April 6, 2020", "description": "Early CPAP in COVID Patients With Respiratory Failure.", "name": "NCT04326075", "primaryOutcome": "Death or need of intubation", "study_type": "Interventional", "time": "2020-03-26", "weburl": "https://clinicaltrials.gov/show/NCT04326075"}, "type": "Feature"}, {"geometry": {"coordinates": [-110.880365, 32.252397], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "", "contactPhone": "", "dateEnrollment": "March 27, 2020", "description": "Treating COVID-19 With a Bidirectional Oxygenation Valve", "name": "NCT04326452", "primaryOutcome": "Pulse oximetry level", "study_type": "Interventional", "time": "2020-03-25", "weburl": "https://clinicaltrials.gov/show/NCT04326452"}, "type": "Feature"}, {"geometry": {"coordinates": [3.032079, 50.607156], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": ";julien.poissy@chru-lille.fr;", "contactPhone": ";0320444495;0320445962", "dateEnrollment": "March 30, 2020", "description": "PREdiction of DIagnosed Covid-19 infecTion in IUC Patients", "name": "NCT04327180", "primaryOutcome": "Correlation between nasal and deep PCR positivity for Covid-19 patients performed and all predictors for Covid-19 patients performed within 24 hours of admission to ICU", "study_type": "Observational", "time": "2020-03-25", "weburl": "https://clinicaltrials.gov/show/NCT04327180"}, "type": "Feature"}, {"geometry": {"coordinates": [53.091074, 36.733235], "type": "Point"}, "properties": {"classification": "Advanced therapy medicinal products", "contactEmail": "", "contactPhone": "", "dateEnrollment": "March 28, 2020", "description": "Investigating Effect of Convalescent Plasma on COVID-19 Patients Outcome: A Clinical Trial", "name": "NCT04327349", "primaryOutcome": "Mortality changes in day 10;Mortality changes in day 30;Changes of C-reactive protein;Changes of C-reactive protein;Changes of C-reactive protein;Changes of Interleukin 6;Changes of Interleukin 6;Changes of Interleukin 6;Changes of tumor necrosis factor-a;Changes of tumor necrosis factor-a;Changes of tumor necrosis factor-a;Changes of PaO2/FiO2 Ratio;Changes of PaO2/FiO2 Ratio;Changes of PaO2/FiO2 Ratio", "study_type": "Interventional", "time": "2020-03-24", "weburl": "https://clinicaltrials.gov/show/NCT04327349"}, "type": "Feature"}, {"geometry": {"coordinates": [10.20202, 56.168344], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": ";soeska@rm.dk", "contactPhone": ";28911869", "dateEnrollment": "March 14, 2020", "description": "The Use of Focused Lung Ultrasound in Patients Suspected of COVID-19", "name": "NCT04327674", "primaryOutcome": "FLUS findings and respiratory failure", "study_type": "Observational [Patient Registry]", "time": "2020-03-27", "weburl": "https://clinicaltrials.gov/show/NCT04327674"}, "type": "Feature"}, {"geometry": {"coordinates": [73.234635, 34.202232], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": ";dean@ayubmed.edu.pk;dean@ayubmed.edu.pk", "contactPhone": ";00923219111681;00929929311100", "dateEnrollment": "March 28, 2020", "description": "Effectiveness of Hydroxychloroquine in Covid-19 Patients", "name": "NCT04328272", "primaryOutcome": "National Early Warning Score equal to zero", "study_type": "Interventional", "time": "2020-03-25", "weburl": "https://clinicaltrials.gov/show/NCT04328272"}, "type": "Feature"}, {"geometry": {"coordinates": [121.453281, 31.271893], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "mlid163@163.com", "contactPhone": "+8613524348108", "dateEnrollment": "January 30, 2020", "description": "Clinical Characteristics and Prognostic Factors of Patients With COVID-19", "name": "NCT04328454", "primaryOutcome": "Time to negative conversion of severe acute respiratory syndrome coronavirus 2", "study_type": "Observational", "time": "2020-03-27", "weburl": "https://clinicaltrials.gov/show/NCT04328454"}, "type": "Feature"}, {"geometry": {"coordinates": [-3.213533, 55.930176], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "m.eddleston@ed.ac.uk", "contactPhone": "0131 242 3867", "dateEnrollment": "March 25, 2020", "description": "Non-invasive Detection of Pneumonia in Context of Covid-19 Using Gas Chromatography - Ion Mobility Spectrometry (GC-IMS)", "name": "NCT04329507", "primaryOutcome": "To perform a study in patients with clinical features of pneumonia/chest infection to identify a signature of Covid-19 pneumonia in patients exposed to SARS-CoV-2, compared to unexposed patients or those without.", "study_type": "Observational", "time": "2020-03-26", "weburl": "https://clinicaltrials.gov/show/NCT04329507"}, "type": "Feature"}, {"geometry": {"coordinates": [114.284091, 36.017922], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": ";;;;;;;;;;;;;;;;qixiaolong@vip.163.com", "contactPhone": ";;;;;;;;;;;;;;;;+86-18588602600", "dateEnrollment": "March 30, 2020", "description": "COVID-19 in Patients With Pre-existing Cirrhosis (COVID-Cirrhosis-CHESS2002): A Multicentre Observational Study", "name": "NCT04329559", "primaryOutcome": "All-cause mortality of COVID-19 patients with liver cirrhosis", "study_type": "Observational [Patient Registry]", "time": "2020-03-29", "weburl": "https://clinicaltrials.gov/show/NCT04329559"}, "type": "Feature"}, {"geometry": {"coordinates": [127.045944, 37.492782], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": ";imfell@yuhs.ac", "contactPhone": ";82-2-2019-3310", "dateEnrollment": "April 1, 2020", "description": "Hydroxychloroquine as Post Exposure Prophylaxis for SARS-CoV-2(HOPE Trial)", "name": "NCT04330144", "primaryOutcome": "The rate of COVID-19", "study_type": "Interventional", "time": "2020-03-30", "weburl": "https://clinicaltrials.gov/show/NCT04330144"}, "type": "Feature"}, {"geometry": {"coordinates": [-114.140695, 51.077606], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": ";stephen.freedman@ahs.ca;stephen.freedman@ahs.ca", "contactPhone": ";4039557740;4039557740", "dateEnrollment": "March 18, 2020", "description": "Clinical Characteristics and Outcomes of Pediatric COVID-19", "name": "NCT04330261", "primaryOutcome": "Clinical characteristics of children with SARS-CoV-2;Factors associated with severe COVID-19 outcomes", "study_type": "Observational", "time": "2020-03-30", "weburl": "https://clinicaltrials.gov/show/NCT04330261"}, "type": "Feature"}, {"geometry": {"coordinates": [-122.170872, 37.428033], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "", "contactPhone": "", "dateEnrollment": "April 2020", "description": "Impact of the Coronavirus (COVID-19) on Patients With Cancer", "name": "NCT04330521", "primaryOutcome": "Number of participants who fill out the survey and participate in the semi-structured interviews.", "study_type": "Observational", "time": "2020-03-30", "weburl": "https://clinicaltrials.gov/show/NCT04330521"}, "type": "Feature"}, {"geometry": {"coordinates": [126.884358, 37.492315], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "infection@korea.ac.kr", "contactPhone": "82-2-2626-3052", "dateEnrollment": "April 1, 2020", "description": "A Trial of Ciclesonide in Adults With Mild COVID-19", "name": "NCT04330586", "primaryOutcome": "Rate of SARS-CoV-2 eradication at day 14 from study enrollment", "study_type": "Interventional", "time": "2020-03-31", "weburl": "https://clinicaltrials.gov/show/NCT04330586"}, "type": "Feature"}, {"geometry": {"coordinates": [10.229447, 45.557468], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": ";;;;;;;guiaccar@unina.it;", "contactPhone": ";;;;;;;+390817464717;", "dateEnrollment": "March 10, 2020", "description": "Renin-Angiotensin System Inhibitors and COVID-19", "name": "NCT04331574", "primaryOutcome": "Numbers of COVID-19 patients enrolled that use ACE inhibitors and/or Angiotensin Receptor Blockers (ARB) as antihypertensive agents;Numbers of COVID-19 patients enrolled with no symptoms, with moderate symptoms or with severe symptoms of pneumoni based on the WHO specification for ARDS that also used ACE inhibitors and/or Angiotensin Receptor Blockers (ARB) as antihypertensive agents", "study_type": "Observational [Patient Registry]", "time": "2020-03-30", "weburl": "https://clinicaltrials.gov/show/NCT04331574"}, "type": "Feature"}, {"geometry": {"coordinates": [116.354185, 39.867294], "type": "Point"}, "properties": {"classification": "Advanced therapy medicinal products", "contactEmail": ";wangliu@ioz.ac.cn", "contactPhone": ";+86-01064807858", "dateEnrollment": "January 27, 2020", "description": "Safety and Efficacy of CAStem for Severe COVID-19 Associated With/Without ARDS", "name": "NCT04331613", "primaryOutcome": "Adverse reaction (AE) and severe adverse reaction (SAE);Changes of lung imaging examinations", "study_type": "Interventional", "time": "2020-02-06", "weburl": "https://clinicaltrials.gov/show/NCT04331613"}, "type": "Feature"}, {"geometry": {"coordinates": [-0.608382, 44.829016], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "isabelle.pellegrin@chu-bordeaux.fr;isabelle.pellegrin@chu-bordeaux.fr", "contactPhone": "05 57 82 11 50;05 57 82 11 50", "dateEnrollment": "April 2, 2020", "description": "COVID-19 Biological Samples Collection", "name": "NCT04332016", "primaryOutcome": "COVID-19 desease description;COVID-19 desease description", "study_type": "Observational", "time": "2020-03-30", "weburl": "https://clinicaltrials.gov/show/NCT04332016"}, "type": "Feature"}, {"geometry": {"coordinates": [4.264062, 50.812892], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": ";;filippo.annoni@erasme.ulb.ac.be", "contactPhone": ";;0032(0)483141483", "dateEnrollment": "March 31, 2020", "description": "Angiotensin-(1,7) Treatment in COVID-19: the ATCO Trial", "name": "NCT04332666", "primaryOutcome": "ventilator free days", "study_type": "Interventional", "time": "2020-03-27", "weburl": "https://clinicaltrials.gov/show/NCT04332666"}, "type": "Feature"}, {"geometry": {"coordinates": [-96.78669, 32.792196], "type": "Point"}, "properties": {"classification": "Advanced therapy medicinal products", "contactEmail": "", "contactPhone": "", "dateEnrollment": "April 1, 2020", "description": "Study Testing Convalescent Plasma vs Best Supportive Care", "name": "NCT04333251", "primaryOutcome": "reduction in oxygen and ventilation support", "study_type": "Interventional", "time": "2020-03-27", "weburl": "https://clinicaltrials.gov/show/NCT04333251"}, "type": "Feature"}, {"geometry": {"coordinates": [34.864678, 32.089157], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": ";Zivit@canfite.co.il", "contactPhone": ";+972-3-9241114", "dateEnrollment": "April 6, 2020", "description": "Piclidenoson for Treatment of COVID-19", "name": "NCT04333472", "primaryOutcome": "Duration of viral shedding in days;Time to clinical recovery (TTCR) in days;Treatment-emergent adverse events (AEs)", "study_type": "Interventional", "time": "2020-04-01", "weburl": "https://clinicaltrials.gov/show/NCT04333472"}, "type": "Feature"}, {"geometry": {"coordinates": [-3.674148, 40.426215], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "esannorberto@hotmail.com;esannorberto@hotmail.com", "contactPhone": "0034686754618;0034686754618", "dateEnrollment": "April 1, 2020", "description": "Outcomes of Vascular Surgery in COVID-19 Infection: National Cohort Study", "name": "NCT04333693", "primaryOutcome": "30-days mortality", "study_type": "Observational [Patient Registry]", "time": "2020-03-31", "weburl": "https://clinicaltrials.gov/show/NCT04333693"}, "type": "Feature"}, {"geometry": {"coordinates": [7.422546, 46.947268], "type": "Point"}, "properties": {"classification": "Impact on helpers", "contactEmail": ";Guido.Beldi@insel.ch;Guido.Beldi@insel.ch", "contactPhone": ";0316328275;0316328275", "dateEnrollment": "March 19, 2020", "description": "Assessment of Covid-19 Infection Rates in Healthcare Workers Using a Desynchronization Strategy", "name": "NCT04333862", "primaryOutcome": "Fraction of healthcare workers infected with SARS-CoV-2", "study_type": "Observational", "time": "2020-04-01", "weburl": "https://clinicaltrials.gov/show/NCT04333862"}, "type": "Feature"}, {"geometry": {"coordinates": [2.334949, 48.873335], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": ";mehdi.benchoufi@aphp.fr", "contactPhone": ";+33(0) 6 30 37 11 00", "dateEnrollment": "April 2020", "description": "Interest of the Use of Pulmonary Ultrasound in the Referral of Patients With or Suspected COVID-19 +", "name": "NCT04335019", "primaryOutcome": "Association of pulmonary lesions on ultrasound on D0 classified according to three stages of severity", "study_type": "Observational", "time": "2020-04-02", "weburl": "https://clinicaltrials.gov/show/NCT04335019"}, "type": "Feature"}, {"geometry": {"coordinates": [9.264955, 45.504982], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "ciceri.clinicaltrials@hsr.it", "contactPhone": "+39 02 2643", "dateEnrollment": "April 6, 2020", "description": "Defibrotide in COVID-19 Pneumonia", "name": "NCT04335201", "primaryOutcome": "to able to reduce the progression of acute respiratory failure", "study_type": "Interventional", "time": "2020-03-31", "weburl": "https://clinicaltrials.gov/show/NCT04335201"}, "type": "Feature"}, {"geometry": {"coordinates": [138.567818, -35.022019], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "", "contactPhone": "", "dateEnrollment": "01/05/2020", "description": "Home rehabilitation for people with COVID-19: Implementing telehealth approaches to care", "name": "ACTRN12620000443998", "primaryOutcome": "Integration to community as measured on the Reintegration to Normal Living Index (RNLI) -  A 11-item questionnaire-based instrument that measures the degree to which individuals achieve reintegration into normal social activities (such as recreation, movement in the community, and interaction in family or other relationships). [Baseline, <br>Three (3) months following baseline assessment. ]", "study_type": "Interventional", "time": "2020-04-06", "weburl": "https://anzctr.org.au/ACTRN12620000443998.aspx"}, "type": "Feature"}, {"geometry": {"coordinates": [115.815709, -31.980069], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "", "contactPhone": "", "dateEnrollment": "07/04/2020", "description": "COVID-19 Research Response (ISARIC/WHO Clinical Characterisation Protocol for Severe Emerging Infections COVID-19 Research Response Trial)", "name": "ACTRN12620000444987", "primaryOutcome": "Describe the clinical features of COVID-19.<br><br>(This is verbatim from submitted protocol)[Due to the nature of the evolving pandemic, there is no timeline for the assessment of primary timepoints. ];Describe the response to treatment, including supportive care and novel therapeutics, based on data linkage to medical records. (composite primary outcome)<br><br>(This is verbatim from submitted protocol)<br>[Due to the nature of the evolving pandemic, there is no timeline for the assessment of primary timepoints.]", "study_type": "Observational", "time": "2020-04-06", "weburl": "https://anzctr.org.au/ACTRN12620000444987.aspx"}, "type": "Feature"}, {"geometry": {"coordinates": [145.112263, -37.847764], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "", "contactPhone": "", "dateEnrollment": "01/06/2020", "description": "Expressive Writing To Combat Distress Associated With The COVID-19 Pandemic In People With Inflammatory Bowel Disease", "name": "ACTRN12620000448943", "primaryOutcome": "Distress measured on Kessler Psychological Distress Scale (K10)[Baseline, post-intervention (within one week since the completion of the intervention, primary endpoint), 3 months post-intervention]", "study_type": "Interventional", "time": "2020-04-06", "weburl": "https://anzctr.org.au/ACTRN12620000448943.aspx"}, "type": "Feature"}, {"geometry": {"coordinates": [153.02628, -27.446977], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "", "contactPhone": "", "dateEnrollment": "31/03/2020", "description": "Use of therapeutic drug monitoring (TDM) to optimise oral/enteral hydroxychloroquine dosing in critically ill patients with COVID-19", "name": "ACTRN12620000447954", "primaryOutcome": "Dose adjustment required to attain a steady-state target trough hydroxychloroquine concentration of 0.24mg/L using TDM (proportion of patients / magnitude of adjustments)<br><br>Dose adjustment data will be collected and maintained by the senior ICU clinical pharmacist.[Up to the point of ICU discharge, in the first 10 days after commencement of initial HCQ dose, ]", "study_type": "Interventional", "time": "2020-04-06", "weburl": "https://anzctr.org.au/ACTRN12620000447954.aspx"}, "type": "Feature"}, {"geometry": {"coordinates": [153.051504, -27.553872], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "", "contactPhone": "", "dateEnrollment": "20/04/2020", "description": "Utilizing lung ultrasound in COVID-19 patients in ICU – comparison of management strategies on survival and time on ventilation.", "name": "ACTRN12620000438954", "primaryOutcome": "Mortality[During Intensive care unit stay < 14 days];Mortality[28 day post discharge from ICU];Length of stay intensive care unit from patient medical record[Discharge from intensive care]", "study_type": "Observational", "time": "2020-04-06", "weburl": "https://anzctr.org.au/ACTRN12620000438954.aspx"}, "type": "Feature"}, {"geometry": {"coordinates": [144.952669, -37.798615], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "", "contactPhone": "", "dateEnrollment": "10/04/2020", "description": "Maternal and neonatal outcomes from women infected with SARS-COV2 (COVID-19) during pregnancy", "name": "ACTRN12620000449932", "primaryOutcome": "Maternal mortality from COVID-19[During pregnancy until 6 weeks postpartum];Perinatal mortality (stillbirth, neonatal death)[During pregnancy and until day 28 in the neonate]", "study_type": "Observational", "time": "2020-04-06", "weburl": "https://anzctr.org.au/ACTRN12620000449932.aspx"}, "type": "Feature"}, {"geometry": {"coordinates": [145.060179, -37.754791], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "", "contactPhone": "", "dateEnrollment": "09/04/2020", "description": "Can intravenous high dose zinc improve clinical outcomes in patients with COVID-19 infection?", "name": "ACTRN12620000454976", "primaryOutcome": "In non-ventilated patients- Mean change in the worst (highest) level of oxygenation (oxygen flow in litres/min). This will be assessed by the nursing documentation in the participant's electronic record of the flow rate of oxygen delivered and the delivery method (ie nasal prongs, Hudson mask, or non-breather mask). <br>In ventilated patients- Mean change in the worst (lowest) PaO2 /FiO2 ratio (in mmHg). This will be assessed by nursing documented PaO2 and FiO2 levels in the patient chart.[Worst recorded level of oxygenation during the 7 days of intervention.];Feasibility will be assesses by the following measures:<br>• The primary assessment of our ability to blind treatment of the HDIVZn in a 250-ml saline preparation<br>• Drug availability from supplier, storage and timely delivery to a patient<br>• Good clinical practice documentation of drug prescription on Cerner (an electronic medical record), delivery to ICU by project research officer, double signing by nursing staff<br>• Appropriate preparation of drug- onsite refrigeration storage, preparation with SOPs, maintenance of sterile conditions, protocol compliance, breaches, and variation, documentation processes including patient retention and follow-up rates<br>• Determine the per-patient cost to estimate subsequent pivotal trial costs<br>• Assess the process for efficient and effective data entry and analysis<br>These will be assessed by our research investigators on a regular basis and data collected in the case report forms.[During 7 days of intervention]", "study_type": "Interventional", "time": "2020-04-08", "weburl": "https://anzctr.org.au/ACTRN12620000454976.aspx"}, "type": "Feature"}, {"geometry": {"coordinates": [116.315624, 40.02412], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "ydkfedu@163.com", "contactPhone": "+86 18600819602", "dateEnrollment": "2020-04-27", "description": "Study for the exercise rehabilitation therapy for the dysfunction of cured discharged novel coronavirus pneumonia (COVID-19) patients", "name": "ChiCTR2000031860", "primaryOutcome": "cardiopulmonary function;motor function;", "study_type": "Observational study", "time": "2020-04-12", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=52198"}, "type": "Feature"}, {"geometry": {"coordinates": [112.148243, 30.354301], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "jinzhilu2015@163.com", "contactPhone": "+86 18163138632", "dateEnrollment": "2020-01-23", "description": "A Medical Records Based study for the Clinical Characteristics Of Hospitalized Novel Coronavirus Pneumonia (COVID-19) Patients With Acute Respiratory Distress Syndrome", "name": "ChiCTR2000031836", "primaryOutcome": "partial pressure of arterial oxygen;", "study_type": "Observational study", "time": "2020-04-11", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=52213"}, "type": "Feature"}, {"geometry": {"coordinates": [104.054332, 30.539366], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "lijianan@njmu.edu.cn", "contactPhone": "+86 13705161766", "dateEnrollment": "2020-04-20", "description": "A clinical study for the effect of remote monitoring exercise rehabilitation on the discharged patients with novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000031834", "primaryOutcome": "Total distances of 6 minutes walk test;", "study_type": "Interventional study", "time": "2020-04-11", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=52216"}, "type": "Feature"}, {"geometry": {"coordinates": [114.871603, 30.44887], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "41025513@qq.com", "contactPhone": "+86 15171346752", "dateEnrollment": "2020-04-08", "description": "A medical records based retrospective study for analysis clinical characteristics and risk factors of death in patients with novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000031794", "primaryOutcome": "clinical characteristics and risk factors of death;inflammatory factors;", "study_type": "Observational study", "time": "2020-04-10", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=52193"}, "type": "Feature"}, {"geometry": {"coordinates": [114.348066, 30.552523], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "dicespedes2@hotmail.com", "contactPhone": "+86 15549450300", "dateEnrollment": "2020-03-24", "description": "Investigation for Prevention Awareness against COVID-19", "name": "ChiCTR2000031783", "primaryOutcome": "attitudes toward COVID-19;Consciousness awareness toward COVID-19;", "study_type": "Observational study", "time": "2020-04-10", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51832"}, "type": "Feature"}, {"geometry": {"coordinates": [112.978358, 28.203399], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "qianlu5860@gmail.com", "contactPhone": "+86 13797097676", "dateEnrollment": "2020-04-13", "description": "A questionnaire investigation of hydroxychloroquine for its potential protective effect against novel coronavirus infection (COVID-19)", "name": "ChiCTR2000031782", "primaryOutcome": "Incidence of SARS-CoV-2 infection (including confirmed SARS-CoV-2 detection, but might asymptomatic);Incidence of COVID-19 pneumonia;", "study_type": "Observational study", "time": "2020-04-10", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51934"}, "type": "Feature"}, {"geometry": {"coordinates": [118.751829, 32.083636], "type": "Point"}, "properties": {"classification": "Vaccines", "contactEmail": "jszfc@sina.com", "contactPhone": "+86-025-83759418", "dateEnrollment": "2020-04-09", "description": "A randomized, double-blinded, placebo-controlled phase II clinical trial for Recombinant Novel Coronavirus (2019-nCOV) Vaccine (Adenovirus Vector)", "name": "ChiCTR2000031781", "primaryOutcome": "Adverse reactions 0-14 days post vaccination;Anti-S antibody IgG titer on day 28 post vaccination;Anti-SARS-CoV-2 neutralizing antibody titer on day 28 post vaccination;", "study_type": "Interventional study", "time": "2020-04-10", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=52006"}, "type": "Feature"}, {"geometry": {"coordinates": [116.965684, 36.673918], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "398139849@qq.com", "contactPhone": "+86 15153169567", "dateEnrollment": "2020-01-01", "description": "Effect of novel coronavirus pneumonia (COVID-19) upon male reproductive system", "name": "ChiCTR2000031779", "primaryOutcome": "semen;feces;blood;urine;", "study_type": "Observational study", "time": "2020-04-10", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=52051"}, "type": "Feature"}, {"geometry": {"coordinates": [119.282645, 26.095022], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "lgh19870628@126.com", "contactPhone": "18359186153", "dateEnrollment": "2020-01-10", "description": "Impact of WeChat-based parenting education for children with autism spectrum disorder and their mothers during the epidemic of Coronavirus disease 2019 (COVID-19)", "name": "ChiCTR2000031772", "primaryOutcome": "Psycho Educational Profile,PEP;Self-Rated Anxiety Scale,SAS;Self-Rated Depression Scale,SDS;Parenting Stress Index-Short Form,PSI-SF;", "study_type": "Interventional study", "time": "2020-04-09", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=52165"}, "type": "Feature"}, {"geometry": {"coordinates": [121.407535, 31.194117], "type": "Point"}, "properties": {"classification": "Impact on helpers", "contactEmail": "liuliu9027@163.com", "contactPhone": "+86 18930177147", "dateEnrollment": "2020-01-22", "description": "Experiences in nursing care for patients with suspected novel coronavirus pneumonia (COVID-19) in Shanghai", "name": "ChiCTR2000031770", "primaryOutcome": "Fever;", "study_type": "Observational study", "time": "2020-04-09", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=52148"}, "type": "Feature"}, {"geometry": {"coordinates": [118.765032, 32.049147], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "yanggang201301@163.com", "contactPhone": "+86 18601406982", "dateEnrollment": "2020-01-01", "description": "A medical records based observational study for myocardial injury and cardiac function in critically ill patients with novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000031752", "primaryOutcome": "survival;", "study_type": "Observational study", "time": "2020-04-09", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=52135"}, "type": "Feature"}, {"geometry": {"coordinates": [114.583991, 30.581262], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "happyzhupengfei@163.com", "contactPhone": "+8613720162185", "dateEnrollment": "2020-04-01", "description": "Novel coronavirus pneumonia (COVID-2019) patients' prognosis and their influence on heart and lung function", "name": "ChiCTR2000031751", "primaryOutcome": "Colour Sonography;electrocardiogram;Pulmonary function(TLC, FVC, FEV1, DLCO);", "study_type": "Observational study", "time": "2020-04-08", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=52130"}, "type": "Feature"}, {"geometry": {"coordinates": [120.090226, 30.866277], "type": "Point"}, "properties": {"classification": "Advanced therapy medicinal products", "contactEmail": "kjkceh@126.com", "contactPhone": "+86 13857281688", "dateEnrollment": "2020-03-01", "description": "Clinical study for natural killer (NK) cells from umbilical cord blood in the treatment of novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000031735", "primaryOutcome": "Monitoring of adverse events within 24 hours after infusion (including infusion related events and severe adverse reactions associated with non-primary disease);", "study_type": "Interventional study", "time": "2020-04-08", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50613"}, "type": "Feature"}, {"geometry": {"coordinates": [114.088135, 30.544789], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "docd1@sina.com", "contactPhone": "18917387623", "dateEnrollment": "2020-03-19", "description": "Evaluation Danorevir sodium tablets combined with ritonavir in the treatment of novel Coronavirus Pneumonia (COVID-19): a randomized, open-label, controlled trial", "name": "ChiCTR2000031734", "primaryOutcome": "Rate of composite advers outcomes: SpO2, PaO2/FiO2, respiratory rate;", "study_type": "Interventional study", "time": "2020-04-08", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=52103"}, "type": "Feature"}, {"geometry": {"coordinates": [121.407535, 31.194117], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "fanyingsh@126.com", "contactPhone": "+86 13918307508", "dateEnrollment": "2020-03-10", "description": "Study for early biological warning signals in patients with acute renal injury caused by novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000031705", "primaryOutcome": "NGAL;MAU;cystatin C;Beta 2-MG;", "study_type": "Observational study", "time": "2020-04-07", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51793"}, "type": "Feature"}, {"geometry": {"coordinates": [116.261014, 39.921063], "type": "Point"}, "properties": {"classification": "Diagnosis", "contactEmail": "rebrcca@126.com", "contactPhone": "+86 18810882866", "dateEnrollment": "2020-04-21", "description": "Development and clinical application of novel coronavirus pneumonia (COVID-19) antigen reagent", "name": "ChiCTR2000031700", "primaryOutcome": "new coronavirus nucleocapsid (N) antigen;SEN, SPE, ACC, AUC of ROC;", "study_type": "Diagnostic test", "time": "2020-04-07", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=52052"}, "type": "Feature"}, {"geometry": {"coordinates": [120.650968, 28.011924], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "tsh006@163.com", "contactPhone": "+86 13858825280", "dateEnrollment": "2020-02-01", "description": "Study for immune antibody and multi-group function of novel coronavirus pneumonia (COVID-19) patients", "name": "ChiCTR2000031699", "primaryOutcome": "proteomics;metabonomics;S antibody IgG;S antibody IgM;S-RBD antibody IgG;S-RBD antibody IgM;N antibody IgG;N antibody IgM;SEN, SPE, ACC, AUC of ROC;", "study_type": "Diagnostic test", "time": "2020-04-07", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51924"}, "type": "Feature"}, {"geometry": {"coordinates": [120.168101, 30.255823], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "baixiaoxia@zju.edu.cn", "contactPhone": "+86 13957152365", "dateEnrollment": "2020-04-06", "description": "A medical records based retrospective analysis of maternal and infant outcomes in Cesarean delivery in Hangzhou non pneumonia Hospital during pandemic of Novel coronovirus pneumonia(COVID-19)", "name": "ChiCTR2000031675", "primaryOutcome": "Perioperative fever;Perioperative cough;Outcome of lung CT;Operative time;Volume of Postpartum hemorrhage;postoperative hospitalization;Stay in isolation ward;Apgar score of newborn;Neonatal admission to NICU;Medical observation of personnel involved in the operation;", "study_type": "Observational study", "time": "2020-04-06", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=52037"}, "type": "Feature"}, {"geometry": {"coordinates": [116.425414, 39.971062], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "liyingshuai2013@163.com", "contactPhone": "+86 13681410020", "dateEnrollment": "2020-04-01", "description": "Development and application of TCM body regulating protection scheme for the convalescent population of novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000031672", "primaryOutcome": "Lung CT Score;", "study_type": "Interventional study", "time": "2020-04-06", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51940"}, "type": "Feature"}, {"geometry": {"coordinates": [113.25, 23.5], "type": "Point"}, "properties": {"classification": "Vaccines", "contactEmail": "zhaozl2006@163.com", "contactPhone": "+86 13828895409", "dateEnrollment": "2020-03-01", "description": "A clinical study for effectiveness and safety evaluation for recombinant chimeric COVID-19 epitope DC vaccine in the treatment of novel coronavirus pneumonia", "name": "ChiCTR2000030750", "primaryOutcome": "Shorten the duration of the disease;Antipyretic rate;Severe rate;Time of virus nucleic acid turning negative;Negative rate of viral nucleic acid;Time for improvement of lung image;PCT;CRP;IL-17;WBC;Lymphocyte subtype analysis;Blood gas analysis;", "study_type": "Interventional study", "time": "2020-03-13", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50928"}, "type": "Feature"}, {"geometry": {"coordinates": [106.739975, 33.054766], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "zengrui_0524@126.com", "contactPhone": "+86 028-85423248", "dateEnrollment": "2020-03-01", "description": "Early risk stratification of the novel coronavirus infected diseases (COVID-19): a multicenter retrospective study  (ERS-COVID-19 study)", "name": "ChiCTR2000030494", "primaryOutcome": "mortality;", "study_type": "Observational study", "time": "2020-03-05", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50077"}, "type": "Feature"}, {"geometry": {"coordinates": [115.518485, 30.544766], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "wengjp@ustc.edu.cn", "contactPhone": "+86 0551-62286223", "dateEnrollment": "2020-02-01", "description": "Construction of a Bio information platform for novel coronavirus pneumonia (COVID-19) patients follow-up in Anhui", "name": "ChiCTR2000030331", "primaryOutcome": "", "study_type": "Epidemilogical research", "time": "2020-02-28", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50271"}, "type": "Feature"}, {"geometry": {"coordinates": [114.436682, 30.464901], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "frank0130@126.com", "contactPhone": "+86 13986268403", "dateEnrollment": "2020-03-02", "description": "Cancelled by the investigator                            Clinical application of inhaled acetylcysteine solution in the treatment of novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000030328", "primaryOutcome": "Lung CT after 3 days;Lung CT after 7 days;Oxygenation parameters: SpO2, Partial arterial oxygen pressure (PaO2), PaO2/FiO2;Hospital stay;Novel coronavirus nucleic acid detection;Recurrence rate;", "study_type": "Interventional study", "time": "2020-02-28", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50241"}, "type": "Feature"}, {"geometry": {"coordinates": [2.334949, 48.873335], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "elodie.soler@aphp.fr", "contactPhone": "+3301 44 84 17 35", "dateEnrollment": "10/04/2020", "description": "Efficacy of Addition of Naproxen for COVID-19 Infection / Enacovid Study", "name": "EUCTR2020-001301-23-FR", "primaryOutcome": "Main Objective: To demonstrate the superiority of naproxen treatment addition to standard of care compared to standard of care in term of 30-day mortality;Secondary Objective: To demonstrate the effect of naproxen treatment to in-hospital mortality, morbidity, virus concentration;Primary end point(s): 30-day mortality all causes;Timepoint(s) of evaluation of this end point: 30 days", "study_type": "Interventional clinical trial of medicinal product", "time": "2020-03-26", "weburl": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001301-23"}, "type": "Feature"}, {"geometry": {"coordinates": [11.570358, 50.909731], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "korinna.pilz@inflarx.de", "contactPhone": "+4989414 1897897", "dateEnrollment": "29/03/2020", "description": "An open label phase II/III study of IFX-1 in patients with severe COVID-19 Pneumonia", "name": "EUCTR2020-001335-28-NL", "primaryOutcome": "Main Objective: The primary objective of Phase II is:<br>• To explore the effect of IFX-1 on COVID-19 related severe pneumonia (hypothesis generating)<br><br>The primary objective of Phase III is<br>• To demonstrate the efficacy of IFX-1 to improve of symptoms and outcome of severe COVID-19 pneumonia (confirmative)<br>;Secondary Objective: The secondary objectives of Phase II and Phase III are:<br>• To assess and define other parameters of efficacy<br>• To assess the safety of IFX-1<br>;Primary end point(s): Phase II: <br>The primary endpoint in Phase II is the relative change (%) from baseline (day 1 prior to study drug administration at ± 1h of randomization) in Oxygenation Index (PaO2 / FiO2) in supine position at day 3, 5, 9, and 15.<br><br>Phase III: <br>The primary, secondary, and other endpoints for Phase III are the same as those for Phase II if not adjusted according to recommendations of the expert committee.<br>;Timepoint(s) of evaluation of this end point: Day 3, 5, 9 and 15", "study_type": "Interventional clinical trial of medicinal product", "time": "2020-03-27", "weburl": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001335-28"}, "type": "Feature"}, {"geometry": {"coordinates": [4.360775, 45.482028], "type": "Point"}, "properties": {"classification": "Impact on helpers", "contactEmail": "arnauld.garcin@chu-st-etienne.fr", "contactPhone": "33(0)477120286", "dateEnrollment": "07/04/2020", "description": "Chemoprophylaxis of SARS-CoV-2 infection (COVID-19) in exposed healthcare workers: a randomized double-blind placebo-controlled clinical trial", "name": "EUCTR2020-001188-96-FR", "primaryOutcome": "Secondary Objective: 1. To evaluate the occurrence of adverse events in each arm,<br>2. To evaluate the discontinuation rates of the investigational drug in each arm,<br>3. To evaluate the adherence of participants to study drug,<br>4. To evaluate the incidence of symptomatic cases of SARS-CoV-2 infection in each arm,<br>5. To evaluate the incidence of asymptomatic cases of SARS-CoV-2 infection in each arm, at to 2,5 months after randomization,<br>6. To evaluate the incidence of severe cases of SARS-CoV-2 infection in each arm. ;Primary end point(s): The primary endpoint is the occurrence of an symptomatic or asymptomatic SARS-CoV-2 infection among healthcare workers (HCWs) <br>An infection by SARS-CoV-2 is defined by either:<br>• a positive specific RT-PCR on periodic systematic nasopharyngeal swab during follow-up<br>OR<br>• a positive specific RT-PCR on a respiratory sample in case of onset of symptoms consistent with COVID-19 during follow-up<br>OR<br>• a seroconversion to SARS-CoV-2 after randomization.;Timepoint(s) of evaluation of this end point: Day: 7, 14, 21, 28, 35, 42, 49, 57, 71 after the start of the drug;Main Objective: To explore whether a 2-month treatment with either LPV/r or hydroxychloroquine may reduce the incidence of symptomatic or asymptomatic infection by SARS-CoV-2, as compared to their placebo in healthcare workers exposed to SARS-CoV-2.", "study_type": "Interventional clinical trial of medicinal product", "time": "2020-03-24", "weburl": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001188-96"}, "type": "Feature"}, {"geometry": {"coordinates": [4.877448, 45.741335], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "julien.gautier@lyon.unicancer.fr", "contactPhone": "+33426 55 68 29", "dateEnrollment": "01/04/2020", "description": "Study comparing the efficacy of a chloroquine analog (GNS561), anti PD-1 (nivolumab) and anti-interleukine-6 receptor (tocilizumab) versus standard of care in advanced or metastatic cancer patients with SARS-CoV-2 (COVID-19) infection", "name": "EUCTR2020-001373-70-FR", "primaryOutcome": "Main Objective: The main objective is to compare versus standard of care short-term mortality rates in advanced or metastatic cancer patients who are positive for COVID-19 treated with a chloroquine analog (GNS561), an anti-PD1 (nivolumab) or an anti-IL-6R antibody (tocilizumab).;Secondary Objective: The secondary objectives will be to describe in each arm of the study:<br>• Time to clinical improvement<br>• Clinical status at days 7, 14 and 28<br>• Mean change in clinical status from baseline to days 7, 14 and 28 <br>• Overall survival <br>• Length of stay in Intensive Care Unit and in Resuscitation Unit<br>• Duration of mechanical ventilation or high flow oxygen devices<br>• Duration of hospitalization<br>• Rate of throat swab negativation at days 7, 14 and 28<br>• Quantitative SARS-CoV-2 virus in throat swab at days 7, 14 and 28<br>• Quantitative SARS-CoV-2 virus in blood at days 7, 14 and 28<br>• Rate of secondary infection by other documented pathogens (bacteria, fungi)<br>• Biological parameters (hematological parameters and markers of inflammation)<br>• Safety of experimental treatments.<br>And to perform Cost-Effectiveness Analyses (CEA) with Incremental Cost-Effectiveness Ratios (ICERs) expressed in cost per Life Year Gained.<br>;Primary end point(s): The primary endpoint will be the 28-day survival rate, defined by the proportion of patients still alive 28 days after randomization. <br>;Timepoint(s) of evaluation of this end point: 28-day", "study_type": "Interventional clinical trial of medicinal product", "time": "2020-03-29", "weburl": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001373-70"}, "type": "Feature"}, {"geometry": {"coordinates": [2.334949, 48.873335], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "carla.vandenabele@aphp.fr", "contactPhone": "+33140 27 57 27", "dateEnrollment": "08/04/2020", "description": "COVID-19 - ACORES-2 study: ACE inhibitors or ARBs discontinuation for Clinical Outcome Risk reduction in patients hospitalized for the Endemic Severe acute respiratory syndrome coronavirus (SARS-CoV-2) infection", "name": "EUCTR2020-001381-11-FR", "primaryOutcome": "Main Objective: To compare the effect of discontinuation versus continuation of RAS blockers on the clinical course of patients with confirmed COVID-19 infection leading to hospitalization;Secondary Objective: 1.\tEvaluate the cardiovascular safety of RAS blockers discontinuation in patients hospitalized for COVID-19 by a composite endpoint of MACE.<br>2.\tEvaluate the efficacy of RAS blockers discontinuation in patients hospitalized for COVID-19 by the secondary efficacy endpoints.<br>;Primary end point(s): Primary endpoint: <br>Time to clinical improvement from day 0 to day 28.<br>Clinical improvement is defined as an improvement of two points  on a seven-category ordinal scale, or live discharge from the hospital, whichever comes first,  as recommended by the WHO R&D Blueprint expert group (3).<br><br>The seven-category ordinal scale consisted of the following categories: <br>1.\tnot hospitalized with resumption of normal activities <br>2.\tnot hospitalized, but unable to resume normal activities<br>3.\thospitalized, not requiring supplemental oxygen <br>4.\thospitalized, requiring supplemental oxygen<br>5.\thospitalized, requiring nasal high-flow oxygen therapy, noninvasive mechanical ventilation, or both<br>6.\thospitalized, requiring ECMO, invasive mechanical ventilation, or both<br>7. death. ;Timepoint(s) of evaluation of this end point: 28 days", "study_type": "Interventional clinical trial of medicinal product", "time": "2020-03-29", "weburl": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001381-11"}, "type": "Feature"}, {"geometry": {"coordinates": [2.34626, 48.794259], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "", "contactPhone": "", "dateEnrollment": "03/04/2020", "description": "COVID-19 - Epidemiology of SARS-CoV-2 and Mortality to Covid19 Disease upon Hydroxychloroquine and Azithromycin Therapy in French Cancer patients", "name": "EUCTR2020-001250-21-FR", "primaryOutcome": "Main Objective: To determine the prevalence and the 3-months incidence of SARS-CoV-2 in cancer patients (Part A).<br>To evaluate the Covid-19 disease mortality rate in cancer patients treated by hydroxychloroquine and azithromycin (Part B).<br>;Secondary Objective: To evaluate the safety, Covid-19 disease severity, response to cancer treatment, Progression-free survival (PFS), cancer mortality, and Overall Survival (OS) of cancer patients infected by SARS-Cov2.<br>To follow the evolution of SARS-CoV-2 infection and viral load in different compartments (nasal epithelia, blood and urine) during the course of therapy.<br>To evaluate the impact of mutation shifts in SARS-CoV-2 genotype (in sever cases only).<br>To follow the humoral and cellular immune responses to the virus, to cancer and control antigens during infection with SARS-CoV-2.<br>To deconvolute SARS-CoV-2-specific MHC class I and II binding epitopes to follow T cell responses with tetramers and Elispot assays, as well as cancer antigens (NY-ESO-1, MAGEn, preprocalcitonin, actinin...)-specific responses.<br>;Primary end point(s): The primary endpoints of the study are for the: <br>o\tPart A: prevalence at first visit and 12 weeks cumulative incidence (in a competing risk model with mortality) of SARS-CoV-2 positive subjects (RT-PCR)<br>o\tPart B: Covid-19 disease specific mortality;Timepoint(s) of evaluation of this end point: 12 weeks and 12 month (mortality)", "study_type": "Interventional clinical trial of medicinal product", "time": "2020-03-24", "weburl": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001250-21"}, "type": "Feature"}, {"geometry": {"coordinates": [-0.623827, 44.845452], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "patrick.cassai@chu-bordeaux.fr", "contactPhone": "+33057820334", "dateEnrollment": "10/04/2020", "description": "Home treatment of elderly patients with symptomatic SARS-CoV-2 infection (COVID-19) : a multiarm, multi-stage (MAMS) randomized trial to assess the efficacy and safety\nof several experimental treatments to reduce the risk of hospitalization or death\n(COVERAGE trial)", "name": "EUCTR2020-001435-27-FR", "primaryOutcome": "Main Objective: The main objective of this trial is To estimate the efficacy of several specific experimental treatments, compared to standard care, to prevent hospitalization or death at D14 in adults over 65 years of age, with documented SARS-CoV-2 infection, with symptoms lasting less than 72 hours and not meeting any hospitalization criteria.;Secondary Objective: To estimate :<br>- the effectiveness of experimental treatments against SARS-CoV-2, to prevent death on D28<br>- the effectiveness of experimental treatments against SARS-CoV-2, to prevent hospitalization on D28<br>- the effectiveness of experimental treatments against SARS-CoV-2, compared to standard care, to prevent hospitalization in intensive care on D28<br>- the effectiveness of experimental treatments against SARS-CoV-2 to suppress nasopharyngeal viral carriage, compared to standard care<br>- the effectiveness of experimental treatments against SARS-CoV-2, compared to standard care, to prevent a loss of autonomy on D14 and D28<br>- the tolerance of experimental treatments against SARS-CoV-2<br>- Study the factors associated with the worsening of the disease<br>- Evaluate the feasibility and acceptability of the trial and the care model implemented<br>- Assess the relationship between the concentration of each drug and the effectiveness of each treatment;Primary end point(s): Proportion of participants with an occurrence of hospitalization and/or death between D0 and D14 in each arm;Timepoint(s) of evaluation of this end point: day 14 after inclusion", "study_type": "Interventional clinical trial of medicinal product", "time": "2020-04-01", "weburl": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001435-27"}, "type": "Feature"}, {"geometry": {"coordinates": [-3.72178, 40.440426], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "fibucicec.hcsc@salud.madrid.org", "contactPhone": "+349133030007360", "dateEnrollment": "27/03/2020", "description": "An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care", "name": "EUCTR2020-001366-11-ES", "primaryOutcome": "Main Objective: The aim of this core protocol is to compare the effects on major outcomes in hospital of the local standard of care alone versus the local standard of care plus one of four alternative anti-viral agents. <br><br>The primary objective of this large international randomised trial is to provide reliable estimates on any effects of these anti-viral treatments on in-hospital mortality in moderate and in severe COVID;Secondary Objective: The secondary objectives are to assess any effects of these anti-viral treatments on hospital duration and receipt of ventilation or intensive care, and to identify any serious adverse reactions.;Primary end point(s): The primary outcome is all-cause mortality, subdivided by severity of disease at the time of randomisation.;Timepoint(s) of evaluation of this end point: At discharge or death.", "study_type": "Interventional clinical trial of medicinal product", "time": "2020-03-26", "weburl": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001366-11"}, "type": "Feature"}, {"geometry": {"coordinates": [2.33393, 48.873155], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "fadila.amerali@aphp.fr", "contactPhone": "", "dateEnrollment": "10/04/2020", "description": "Dexamethasone and oxygen support strategies in ICU patients with Covid-19 pneumonia", "name": "EUCTR2020-001457-43-FR", "primaryOutcome": "Main Objective: The main objective is to assess the impact of dexamethasone on overall mortality at day-60 after randomization in patients admitted in ICU for severe COVID-19 infection.<br>In non mechanical ventilation (MV) patients, the additional objective is to assess whether oxygen support based on either HFNO or CPAP modality in COVID-19 related AHRF reduces the need for mechanical ventilation at day-28.<br>;Secondary Objective: For the study of the effect of corticosteroids, secondary objectives include: <br>1.To compare the evolution of the viral load in the respiratory tract <br>2.To compare the occurrence of healthcare-associated infections <br>3.To compare the exposition to mechanical ventilation <br>4.To compare the evolution of SOFA score <br>5.To compare the exposition to renal replacement therapy <br>6.To compare the lengths of ICU and hospital-stay<br><br>For the study of the effect of oxygen support modalities, secondary objectives are, to compare each of oxygen support group to the control group in terms of: <br>1.overall survival<br>2.occurrence of healthcare-associated infections <br>3.length of ICU and hospital-stay<br>;Primary end point(s): , the primary endpoint is the time-to-death from all causes within the first 60 days after randomization.and the  time to need for mechanical ventilation (MV);Timepoint(s) of evaluation of this end point: october 2020", "study_type": "Interventional clinical trial of medicinal product", "time": "2020-04-02", "weburl": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001457-43"}, "type": "Feature"}, {"geometry": {"coordinates": [2.103769, 41.344626], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "xsolanich@bellvitgehospital.cat", "contactPhone": "0034932602324", "dateEnrollment": "31/03/2020", "description": "CLINICAL TRIAL TO EVALUATE METHYLPREDNISOLONE PULSES AND TACROLIMUS IN HOSPITALIZED PATIENTS WITH SEVERE PNEUMONIA SECONDARY TO COVID-19 (TACROVID)", "name": "EUCTR2020-001445-39-ES", "primaryOutcome": "Main Objective: Main objective: <br>- To study the time (days) to reach clinical stability after randomization in hospitalized patients with severe pneumonia secondary  to COVID-19, and elevated inflammatory parameters.;Secondary Objective: Clinical <br>-time to reach an afebrile state during 48 hours. <br>-time to reach PaO2/FiO2 >400 and/or SatO2/FiO2 >400 <br>-time until you reach a FR = 24 rpm for 48 hours <br>-time to D-dimer normalization (<250 ug/L) <br>-time until PCR is normalized (<5mg/L). <br>-time to normalisation of ferritin (<400ug/L). <br>-impact of immunosuppressive treatment on viral dynamics using quantitative PCR. <br>-duration of treatment with tacrolimus. <br>-duration of the inpatient stay. <br>-Percentage of patients requiring artificial respiratory support<br>-duration of artificial respiratory support needs to be maintained. <br>-mortality Incidence COVID at 28 and 56 days<br>-mortality incidence all-cause at 28 and 56 days <br>-relapses of COVID-19 pneumonia at 28 and 56 days<br>-Analysis of expanded cytokine profile (day 0 and every 7 days)<br>Safety<br>-side effects according to the severity attributed to tacrolimus during its administration. <br>-side effects according to the severity attributed to other treatments administered;Primary end point(s): Primary endpoint  (for the main objective of effectiveness): <br>- Time (days) to clinical stability after initiation of trial treatment in hospitalised patients with severe pneumonia secondary to COVID-19 and elevated inflammatory parameters;Timepoint(s) of evaluation of this end point: Throughout the study until clinical stability", "study_type": "Interventional clinical trial of medicinal product", "time": "2020-04-03", "weburl": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001445-39"}, "type": "Feature"}, {"geometry": {"coordinates": [2.175436, 41.415069], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "epenag@santpau.cat", "contactPhone": "34935537636", "dateEnrollment": "02/04/2020", "description": "Clinical trial of combined use of hydroxychloroquine, azithromycin, and tocilizumab for the treatment of COVID-19", "name": "EUCTR2020-001442-19-ES", "primaryOutcome": "Main Objective: To evaluate in-hospital mortality or mechanical ventilation in the Intensive Care Unit (ICU), or need for a rescue dose of tocilizumab in patients with confirmed infection by COVID-19 in treatment with hydroxychloroquine and azithromycin combined or non-tocilizumab.;Secondary Objective: To assess the clinical efficacy of tocilizumab in COVID-19 infection compared to the control arm by:<br><br>Clinical severity:<br>Patient score according to the WHO 7-point ordinal scale<br>National Early Warning Score (NEWS)<br>Oxygen therapy<br>Mechanic ventilation<br>Hospitalization<br>Mortality at 15, 30 and 90 days<br><br>To assess the safety of the intervention 30 days after treatment compared to the control arm.<br><br>To assess the safety of the intervention at 90 days of treatment compared to the control arm.<br>- Cumulative incidence of serious adverse effects (SAEs).<br>- Cumulative incidence of grade 3 and 4 adverse effects (AEs).<br>- Discontinuation or suspension of treatment for any reason.<br>- Changes in the white blood cell count, hemoglobin, platelets, creatinine, glucose, total bilirubin, AST, ALT, GGT, LDH, C-reactive protein, D-dimer, troponin, ferritin, fibrinogen, KL-6 during follow-up.;Primary end point(s): In-hospital mortality or need for mechanical ventilation in the Intensive Care Unit.;Timepoint(s) of evaluation of this end point: During hospitalization", "study_type": "Interventional clinical trial of medicinal product", "time": "2020-04-03", "weburl": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001442-19"}, "type": "Feature"}, {"geometry": {"coordinates": [-3.694319, 40.413748], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "", "contactPhone": "+34912948910", "dateEnrollment": "28/03/2020", "description": "EPICOS - Experimental clinical trial for PreventIon or COronavirus in health Care professionalS", "name": "EUCTR2020-001385-11-ES", "primaryOutcome": "Main Objective: To assess the efficacy of a daily single dose of TDF (300 mg)/FTC (200 mg), a daily single dose of HC (200 mg), daily single dose of TDF (300 mg)/FTC (200 mg) plus HC (200 mg) or placebo, during 12 weeks in: (1) reducing the incidence of symptomatic disease and (2) reducing the clinical severity of the coronavirus infection (COVID-19) among hospital healthcare workers aged 18 to 65 years who are exposed to coronavirus infection (COVID-19) in Spain.;Secondary Objective: not applicable;Primary end point(s): number of symptomatic confirmed infections by SARS-CoV-2 (COVID-19);Timepoint(s) of evaluation of this end point: 12 weeks treatment + 4 weeks F/U", "study_type": "Interventional clinical trial of medicinal product", "time": "2020-04-03", "weburl": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001385-11"}, "type": "Feature"}, {"geometry": {"coordinates": [-1.120497, 37.983672], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "lola.serna@carm.es", "contactPhone": "", "dateEnrollment": "01/04/2020", "description": "DEFIBROTIDE AS PREVENTION AND TREATMENT OF RESPIRATORY DISTRESS AND CYTOKINE RELEASE SYNDROME OF COVID-19", "name": "EUCTR2020-001409-21-ES", "primaryOutcome": "Main Objective: To determine the efficacy of the intravenous infusion of Defibrotide (Defitelio) to reduce mortality in patients with SARS-CoV-2 infection with clinical status grade 4, 5 or 6 according to the WHO classification.;Secondary Objective: To assess the safety of intravenous Defibrotide (Defitelio) infusion in patients with SARS-CoV-2 infection with clinical status grade 4, 5 or 6 according to the WHO classification.<br>? To analyze the effects of the intravenous infusion of Defibrotide (Defitelio) on the clinical state of patients with SARS-CoV-2 infection with clinical status grade 4, 5 or 6 according to the WHO classification.<br>? Assess the capacity of intravenous infusion of Defibrotide (Defitelio) to improve the radiological response of patients with SARS-CoV-2 infection with clinical status grade 4, 5 or 6 according to the WHO classification.<br>? Study the action of Defibrotide (Defitelio) on risk biomarkers in patients with SARS-CoV-2 infection with grade 4, 5 or 6 clinical status according to the WHO classification.;Primary end point(s): Mortality rate 30 days after starting treatment.;Timepoint(s) of evaluation of this end point: 15, 30 ,60 days", "study_type": "Interventional clinical trial of medicinal product", "time": "2020-04-03", "weburl": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001409-21"}, "type": "Feature"}, {"geometry": {"coordinates": [2.308143, 48.829771], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "l.lamrani@hml.fr", "contactPhone": "0033140942554", "dateEnrollment": "09/04/2020", "description": "Dexamethasone associated with hydroxychloroquine vs. hydroxychloroquine alone for the early treatment of severe ARDS caused by COVID-19 : a randomized controlled trial", "name": "EUCTR2020-001333-13-FR", "primaryOutcome": "Main Objective: Assess, in patients with ARDS caused by COVID-19, the efficacy of dexamethasone (DXM) associated with hydroxychloroquine (HCQ) compared to HCQ alone on mortality at 28 days;Secondary Objective: Assess, in patients with ARDS causedd by COVID-19, the efficacy of DXM associated with HCQ compared to HCQ alone on :<br>- the ventilator-free days<br>- mortality in intensive care unit<br>- mortality on D60<br>- the occurrence of infectious complications ;Primary end point(s): Mortality on D28<br>;Timepoint(s) of evaluation of this end point: the 28th day after the start of treatment<br>", "study_type": "Interventional clinical trial of medicinal product", "time": "2020-04-02", "weburl": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001333-13"}, "type": "Feature"}, {"geometry": {"coordinates": [2.376574, 48.87848], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "pvachey@for.paris", "contactPhone": "33148036433", "dateEnrollment": "10/04/2020", "description": "Interest in the administration of Dornase alpha aerosol in Acute Respiratory Distress Syndrome secondary to respiratory infection by the coronavirus SRASCoV-2 / COVID-19", "name": "EUCTR2020-001492-33-FR", "primaryOutcome": "Main Objective: To evaluate the efficacy of intratracheal administration of dornase alfa (Pulmozyme) on the evolution of ventilatory parameters at D7;Secondary Objective: 1) all-cause mortality at D28<br>2) the clinical evolution at D28 ;<br>3) the duration of mechanical ventilation;<br>4) the number of days without mechanical ventilation at D28;<br>5) the length of stay in intensive care ;<br>6) the concentrations of blood markers of inflammation over time;<br>7) NET concentrations in bronchial secretions over time<br>8) the occurrence of adverse events;Primary end point(s): Comparison between the two treatment arms of the evolution of the PaO2/FiO2 ratio between D0 (inclusion) and D7;Timepoint(s) of evaluation of this end point: D7", "study_type": "Interventional clinical trial of medicinal product", "time": "2020-04-01", "weburl": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001492-33"}, "type": "Feature"}, {"geometry": {"coordinates": [-0.4358, 38.389938], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "gutierrez_fel@gva.es", "contactPhone": "34966616234", "dateEnrollment": "30/03/2020", "description": "Pilot study to evaluate the efficacy and safety of mefloquine as prophylaxis in people exposed to the disease caused by the new SARS-CoV-2 coronavirus (COVID-19)", "name": "EUCTR2020-001194-69-ES", "primaryOutcome": "Main Objective: To determine the protective efficacy of mefloquine prophylaxis against placebo in close contacts of people with COVID-19.;Secondary Objective: -Establish if the preventive administration of mefloquine attenuates the clinical manifestations of COVID-19 in people who become infected.<br>-Evaluate the safety of prophylactic mefloquine in this setting.;Primary end point(s): COVID-19 infection.;Timepoint(s) of evaluation of this end point: The patient will be evaluated weekly for 30 days from enrollment in the study to rule out / confirm COVID-19 infection.", "study_type": "Interventional clinical trial of medicinal product", "time": "2020-04-07", "weburl": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001194-69"}, "type": "Feature"}, {"geometry": {"coordinates": [2.153073, 41.390072], "type": "Point"}, "properties": {"classification": "Impact on helpers", "contactEmail": "jose.munoz@isglobal.org", "contactPhone": "+349322754001825", "dateEnrollment": "03/04/2020", "description": "Prevention of novel Coronavirus infection with hydroxychloroquine", "name": "EUCTR2020-001565-37-ES", "primaryOutcome": "Main Objective: To compare the efficacy of the use of PrEP with hydroxychloroquine against placebo in healthcare workers with high risk of SARS-CoV-2 infection in reducing their risk of COVID-19 disease during an epidemic period.;Secondary Objective: 1) To assess the efficacy of the use of PrEP with hydroxychloroquine against placebo in healthcare workers with high risk of SARS-CoV-2 infection in reducing their risk of exposure to SARS-CoV-2 (defined by seroconversion) during an epidemic period.<br><br>2) To evaluate the safety of PrEP with hydroxychloroquine in adults.<br><br>3) To describe the incidence of SARS-CoV-2 infection among healthcare workers at high risk of SARS-CoV-2 infection.<br><br>4) To identify clinical, analytical and microbiological predictors of COVID-19 among healthcare workers at high risk of SARS-CoV-2 infection.<br><br>5) To set up a repository (biobank) of serum samples obtained from healthcare workers at high risk of SARS-CoV-2 infection for future research on blood markers to predict SARS-CoV-2 infection.;Primary end point(s): Confirmed cases of a COVID-19 (defined by symptoms compatible with COVID-19 and/or a positive PCR for SARS-CoV-2) in the PrEP group compared to the placebo group at any time during the 6 months of the follow-up in healthcare workers with negative PCR for SARS-CoV-2 at day 0.;Timepoint(s) of evaluation of this end point: 6 months", "study_type": "Interventional clinical trial of medicinal product", "time": "2020-04-07", "weburl": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001565-37"}, "type": "Feature"}, {"geometry": {"coordinates": [-3.687617, 40.426022], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "secretaria@delosclinical.com", "contactPhone": "", "dateEnrollment": "06/04/2020", "description": "Clinical trial for evaluation of efficacy and safety of hydroxychloroquine chemoprophylaxis against SARS-CoV-2 (COVID-19) infection in healthcare professionals.", "name": "EUCTR2020-001421-31-ES", "primaryOutcome": "Main Objective: To assess the efficacy of hydroxychloroquine as chemoprophylaxis against SARS-CoV-2 (COVID-19) infection in healthcare professionals by negative PCR.;Secondary Objective: To assess the safety of hydroxychloroquine as chemoprophylaxis against SARS-CoV-2 (COVID-19) infection in healthcare professionals.<br><br>To assess the efficacy of personal protective equipment against SARS-CoV-2 (COVID-19) infection in healthcare professionals;Primary end point(s): Diagnosis of SARS-CoV-2 COVID-19 infection;Timepoint(s) of evaluation of this end point: - At the end of prophylaxis treatment<br>- Fourteen days after the last dose of treatment", "study_type": "Interventional clinical trial of medicinal product", "time": "2020-04-07", "weburl": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001421-31"}, "type": "Feature"}, {"geometry": {"coordinates": [-2.984568, 43.283505], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "eunate.aranaarri@osakidetza.eus", "contactPhone": "0034946182646", "dateEnrollment": "07/04/2020", "description": "Randomized clinical trial to evaluate the efficacy of hydroxychloroquine associated or not with azithromycin as a treatment for COVID-19 infection", "name": "EUCTR2020-001606-33-ES", "primaryOutcome": "Main Objective: Demonstrate the therapeutic effectiveness of Hydroxychloroquine associated with Azithromycin treatment for symptom control and negative viral load, in patients with comorbidities without pneumonia and COVID-19 infection.;Secondary Objective: - Evaluate the safety of the treatment<br>- Assess tolerance of treatment;Primary end point(s): Proportion of patients with negative viral load by CODV-19 [SARS-CoV-2 (PCR)] at 6 days after the start of treatment;Timepoint(s) of evaluation of this end point: 30 DAYS", "study_type": "Interventional clinical trial of medicinal product", "time": "2020-04-07", "weburl": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001606-33"}, "type": "Feature"}, {"geometry": {"coordinates": [-3.688277, 40.482034], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "anabelsanchez.hrc@gmail.com", "contactPhone": "+34913368825", "dateEnrollment": "01/04/2020", "description": "Efficacy and Safety of corticoids in patients with adult respiratory distress syndrome (ARDS) secondary to coronavirus infection.", "name": "EUCTR2020-001307-16-ES", "primaryOutcome": "Main Objective: To evaluate the efficacy of methylprednisolone treatment, added to the standard treatment, in patients with ARDS secondary tp SARS-CoV-2 .;Secondary Objective: To evaluate the safety of methylprednisolone treatment, added to the standard treatment, in patients with ARDS secondary to SARS-CoV-2.;Primary end point(s): The primary end point of efficacy will be death for any cause in the first 28 days after randomization.;Timepoint(s) of evaluation of this end point: The first 28 days after randomization.", "study_type": "Interventional clinical trial of medicinal product", "time": "2020-04-08", "weburl": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001307-16"}, "type": "Feature"}, {"geometry": {"coordinates": [23.756084, 37.980298], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "insepsis@otenet.gr", "contactPhone": "302107480662", "dateEnrollment": "01/04/2020", "description": "MANAGEMENT OF NOVEL SARS CORONAVIRUS", "name": "EUCTR2020-001039-29-GR", "primaryOutcome": "Main Objective: Our aim is to conduct one trial of personalized immunotherapy in patients with SARS-CoV-2 associated with organ dysfunction and with laboratory findings of macrophage activation syndrome or immune dysregulation. These patients will be selected by the use of a panel of biomarkers and laboratory findings and they will be allocated to immunotherapy treatment according to their needs.  ;Secondary Objective: Not applicable;Primary end point(s): The study primary endpoint is composite and contains the achievement of at least one of the following goals or both goals after 7 days (study visit of day 8):<br>• At least 25% decrease of baseline total SOFA score or increase of the pO2/FiO2 ratio by at least 50%<br>• Clinical improvement of lung involvement<br>Patients discharged from hospital alive before study visit of day 8 are considered achieving the primary endpoint. Patients dying before study visit of day 8 are considered non-achieving the primary endpoint.;Timepoint(s) of evaluation of this end point: Visit study day 8", "study_type": "Interventional clinical trial of medicinal product", "time": "2020-03-31", "weburl": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001039-29"}, "type": "Feature"}, {"geometry": {"coordinates": [-71.870148, 45.448589], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": ";;marie-helene.masse3@usherbrooke.ca;marie-helene.masse3@usherbrooke.ca", "contactPhone": ";;819-346-1110;819-346-1110", "dateEnrollment": "November 8, 2018", "description": "Lessening Organ Dysfunction With VITamin C", "name": "NCT03680274", "primaryOutcome": "Number of deceased participants or with persistent organ dysfunction", "study_type": "Interventional", "time": "2020-04-20", "weburl": "https://clinicaltrials.gov/show/NCT03680274"}, "type": "Feature"}, {"geometry": {"coordinates": [116.52379, 40.023361], "type": "Point"}, "properties": {"classification": "Diagnosis", "contactEmail": ";xieyao00120184@sina.com;xieyao00120184@sina.com", "contactPhone": ";8610-84322200;8610-84322200", "dateEnrollment": "January 1, 2020", "description": "Development of a Simple, Fast and Portable Recombinase Aided Amplification Assay for 2019-nCoV", "name": "NCT04245631", "primaryOutcome": "Detection sensitivity is greater than 95%;Detection specificity is greater than 95%", "study_type": "Observational", "time": "2020-01-26", "weburl": "https://clinicaltrials.gov/show/NCT04245631"}, "type": "Feature"}, {"geometry": {"coordinates": [121.325934, 30.808185], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "luhongzhou@fudan.edu.cn", "contactPhone": "+86-021-37990333", "dateEnrollment": "January 30, 2020", "description": "Efficacy and Safety of Darunavir and Cobicistat for Treatment of COVID-19", "name": "NCT04252274", "primaryOutcome": "The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 7", "study_type": "Interventional", "time": "2020-01-29", "weburl": "https://clinicaltrials.gov/show/NCT04252274"}, "type": "Feature"}, {"geometry": {"coordinates": [121.325934, 30.808185], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "", "contactPhone": "", "dateEnrollment": "February 6, 2020", "description": "Efficacy and Safety of Hydroxychloroquine for Treatment of COVID-19", "name": "NCT04261517", "primaryOutcome": "The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 3;The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 5;The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 7;The mortality rate of subjects at weeks 2", "study_type": "Interventional", "time": "2020-02-06", "weburl": "https://clinicaltrials.gov/show/NCT04261517"}, "type": "Feature"}, {"geometry": {"coordinates": [116.343857, 39.99832], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "", "contactPhone": "", "dateEnrollment": "February 19, 2020", "description": "Identifying Critically-ill Patients With COVID-19 Who Will Benefit Most From Nutrition Support Therapy: Validation of the NUTRIC Nutritional Risk Assessment Tool", "name": "NCT04274322", "primaryOutcome": "28-day all cause mortality", "study_type": "Observational", "time": "2020-02-16", "weburl": "https://clinicaltrials.gov/show/NCT04274322"}, "type": "Feature"}, {"geometry": {"coordinates": [4.831482, 45.760865], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": ";philippe.vanhems@chu-lyon.fr", "contactPhone": ";04 72 11 07 20", "dateEnrollment": "March 9, 2020", "description": "COVID-19 - Multicenter Study on Nosocomial Transmission of SARS-CoV-2 Virus", "name": "NCT04290780", "primaryOutcome": "nosocomial infection", "study_type": "Observational", "time": "2020-02-27", "weburl": "https://clinicaltrials.gov/show/NCT04290780"}, "type": "Feature"}, {"geometry": {"coordinates": [115.926134, 28.668621], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "", "contactPhone": "", "dateEnrollment": "February 17, 2020", "description": "Evaluation of Ganovo (Danoprevir ) Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection", "name": "NCT04291729", "primaryOutcome": "Rate of composite adverse outcomes", "study_type": "Interventional", "time": "2020-02-27", "weburl": "https://clinicaltrials.gov/show/NCT04291729"}, "type": "Feature"}, {"geometry": {"coordinates": [-77.427273, 39.435398], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "sandi.k.parriott.mil@mail.mil", "contactPhone": "301-619-6824", "dateEnrollment": "April 2020", "description": "Expanded Access Remdesivir (RDV; GS-5734™)", "name": "NCT04302766", "primaryOutcome": "", "study_type": "Expanded Access", "time": "2020-03-02", "weburl": "https://clinicaltrials.gov/show/NCT04302766"}, "type": "Feature"}, {"geometry": {"coordinates": [113.375707, 23.141785], "type": "Point"}, "properties": {"classification": "Other", "contactEmail": "", "contactPhone": "", "dateEnrollment": "March 13, 2020", "description": "Blood Donor Recruitment During Epidemic of COVID-19", "name": "NCT04306055", "primaryOutcome": "Differences of attitude about blood donation towards different questionnaires", "study_type": "Interventional", "time": "2020-03-08", "weburl": "https://clinicaltrials.gov/show/NCT04306055"}, "type": "Feature"}, {"geometry": {"coordinates": [116.364683, 39.948169], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": ";john131212@sina.com", "contactPhone": ";13911405123", "dateEnrollment": "March 8, 2020", "description": "Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019", "name": "NCT04310228", "primaryOutcome": "Clinical cure rate", "study_type": "Interventional", "time": "2020-03-09", "weburl": "https://clinicaltrials.gov/show/NCT04310228"}, "type": "Feature"}, {"geometry": {"coordinates": [12.908712, 43.920387], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "", "contactPhone": "", "dateEnrollment": "March 12, 2020", "description": "Tocilizumab for SARS-CoV2 (COVID-19) Severe Pneumonitis", "name": "NCT04315480", "primaryOutcome": "arrest in deterioration of pulmonary function;improving in pulmonary function", "study_type": "Interventional", "time": "2020-03-14", "weburl": "https://clinicaltrials.gov/show/NCT04315480"}, "type": "Feature"}, {"geometry": {"coordinates": [14.222266, 40.862549], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": ";f.perrone@istitutotumori.na.it", "contactPhone": ";+390815903571", "dateEnrollment": "March 19, 2020", "description": "Tocilizumab in COVID-19 Pneumonia (TOCIVID-19)", "name": "NCT04317092", "primaryOutcome": "One-month mortality rate", "study_type": "Interventional", "time": "2020-03-19", "weburl": "https://clinicaltrials.gov/show/NCT04317092"}, "type": "Feature"}, {"geometry": {"coordinates": [31.165291, 27.186031], "type": "Point"}, "properties": {"classification": "Impact on helpers", "contactEmail": ";aliaehussein@aun.edu.eg;aliaehussein@aun.edu.eg", "contactPhone": ";01222302352;01222302352", "dateEnrollment": "March 11, 2020", "description": "Social Media Effect on Knowledge Dissemination During COVID-19 Virus Outbreak", "name": "NCT04319315", "primaryOutcome": "Number of physicians affected by social media measured by online survey designed to measure the influence of social media on medical practice", "study_type": "Observational", "time": "2020-03-16", "weburl": "https://clinicaltrials.gov/show/NCT04319315"}, "type": "Feature"}, {"geometry": {"coordinates": [6.786666, 51.198707], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "contact@vipstudy.org", "contactPhone": "+2118118800", "dateEnrollment": "March 19, 2020", "description": "Outcomes and Prognostic Factors in COVID-19", "name": "NCT04321265", "primaryOutcome": "Survival", "study_type": "Observational", "time": "2020-03-19", "weburl": "https://clinicaltrials.gov/show/NCT04321265"}, "type": "Feature"}, {"geometry": {"coordinates": [-122.345313, 47.754814], "type": "Point"}, "properties": {"classification": "Diagnosis", "contactEmail": "", "contactPhone": "", "dateEnrollment": "March 9, 2020", "description": "Impact of Swab Site and Sample Collector on Testing Sensitivity for COVID-19 Virus in Symptomatic Individuals", "name": "NCT04321369", "primaryOutcome": "Accuracy of patient administered tests", "study_type": "Observational", "time": "2020-03-23", "weburl": "https://clinicaltrials.gov/show/NCT04321369"}, "type": "Feature"}, {"geometry": {"coordinates": [12.52129, 55.68428], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": ";lars.erik.kristensen@regionh.dk", "contactPhone": ";0045 38164157", "dateEnrollment": "April 5, 2020", "description": "Anti-il6 Treatment of Serious COVID-19 Disease With Threatening Respiratory Failure", "name": "NCT04322773", "primaryOutcome": "Time to independence from supplementary oxygen therapy", "study_type": "Interventional", "time": "2020-03-24", "weburl": "https://clinicaltrials.gov/show/NCT04322773"}, "type": "Feature"}, {"geometry": {"coordinates": [10.214491, 45.57333], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": ";sobi.immuno@sobi.com", "contactPhone": ";+46 8 697 20 00", "dateEnrollment": "April 2, 2020", "description": "Efficacy and Safety of Emapalumab and Anakinra in Reducing Hyperinflammation and Respiratory Distress in Patients With COVID-19 Infection.", "name": "NCT04324021", "primaryOutcome": "Treatment success", "study_type": "Interventional", "time": "2020-03-25", "weburl": "https://clinicaltrials.gov/show/NCT04324021"}, "type": "Feature"}, {"geometry": {"coordinates": [-92.46816, 44.022787], "type": "Point"}, "properties": {"classification": "Advanced therapy medicinal products", "contactEmail": "", "contactPhone": "", "dateEnrollment": "April 1, 2020", "description": "Convalescent Plasma to Limit Coronavirus Associated Complications", "name": "NCT04325672", "primaryOutcome": "RNA in SARS-CoV-2;ICU Admissions;Hospital Mortality;Hospital Length of Stay (LOS)", "study_type": "Interventional", "time": "2020-03-26", "weburl": "https://clinicaltrials.gov/show/NCT04325672"}, "type": "Feature"}, {"geometry": {"coordinates": [28.930353, 41.016461], "type": "Point"}, "properties": {"classification": "Impact on helpers", "contactEmail": "ozmenmm@gmail.com;mahir.ozmen@istinye.edu.tr", "contactPhone": "+905324246838;+905324246838", "dateEnrollment": "March 20, 2020", "description": "Proflaxis Using Hydroxychloroquine Plus Vitamins-Zinc During COVID-19 Pandemia", "name": "NCT04326725", "primaryOutcome": "Protection against COVID-19", "study_type": "Observational", "time": "2020-03-26", "weburl": "https://clinicaltrials.gov/show/NCT04326725"}, "type": "Feature"}, {"geometry": {"coordinates": [-74.925772, 42.695694], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": ";jennifer.victory@bassett.org;kristin.pullyblank@bassett.org", "contactPhone": ";6075476965;607-547-6711", "dateEnrollment": "April 6, 2020", "description": "COVID MED Trial - Comparison Of Therapeutics for Hospitalized Patients Infected With SARS-CoV-2", "name": "NCT04328012", "primaryOutcome": "National Institute of Allergy and Infectious Diseases COVID-19 Ordinal Severity Scale (NCOSS)", "study_type": "Interventional", "time": "2020-03-27", "weburl": "https://clinicaltrials.gov/show/NCT04328012"}, "type": "Feature"}, {"geometry": {"coordinates": [6.14686, 46.193315], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": ";claire-anne.siegrist@unige.ch;", "contactPhone": ";+41795533396;+4179 553 4676", "dateEnrollment": "March 27, 2020", "description": "Understanding COVID-19", "name": "NCT04329546", "primaryOutcome": "Immunogenicity primary outcome: Geometric mean antibody concentration of total IgG antibodies to SARS-CoV-2 assessed by ELISA at 28 days;Virologic primary outcome: Peak viral load in the 56 days following diagnosis/suspected diagnosis", "study_type": "Observational", "time": "2020-03-29", "weburl": "https://clinicaltrials.gov/show/NCT04329546"}, "type": "Feature"}, {"geometry": {"coordinates": [-9.067775, 53.276519], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": ";johnwilliam.mcevoy@nuigalway.ie;johnwilliam.mcevoy@nuigalway.ie", "contactPhone": ";+353 9 154 4331;+353 9 154 4331", "dateEnrollment": "March 30, 2020", "description": "Coronavirus (COVID-19) ACEi/ARB Investigation", "name": "NCT04330300", "primaryOutcome": "Number of Covid-19 positive participants who die, require intubation in ICU, or require hospitalization for non-invasive ventilation (NIV)", "study_type": "Interventional", "time": "2020-03-30", "weburl": "https://clinicaltrials.gov/show/NCT04330300"}, "type": "Feature"}, {"geometry": {"coordinates": [-3.833871, 43.458196], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "javiercrespo1991@gmail.com", "contactPhone": "942202520", "dateEnrollment": "April 6, 2020", "description": "Randomized, Controlled, Double-blind Clinical Trial Comparing the Efficacy and Safety of Chemoprophylaxis With Hydroxychloroquine in Patients Under Biological Treatment and / or JAK Inhibitors in the Prevention of SARS-CoV-2 Infection", "name": "NCT04330495", "primaryOutcome": "Incidence rate of new COVID-19 cases in both arms;Prevalence of COVID-19 cases in both arms;Mortality rate secondary to COVID-19 cases in both groups;Intensive Care Unit (CU) admission rate secondary to COVID-19 cases in both groups", "study_type": "Interventional", "time": "2020-03-31", "weburl": "https://clinicaltrials.gov/show/NCT04330495"}, "type": "Feature"}, {"geometry": {"coordinates": [13.374044, 52.526356], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": ";;antonia.bendau@charite.de;corona-angst@charite.de", "contactPhone": ";;+4930450517274;+49 30 450 517 285", "dateEnrollment": "March 27, 2020", "description": "Survey of the Anxiety Associated With the COVID-19 Pandemic", "name": "NCT04331106", "primaryOutcome": "COVID-19-related anxiety symptoms;Characteristics of COVID-19-related anxiety", "study_type": "Observational", "time": "2020-03-27", "weburl": "https://clinicaltrials.gov/show/NCT04331106"}, "type": "Feature"}, {"geometry": {"coordinates": [53.631453, 28.929775], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": ";Dr.afazeli@gmail.com;info@fums.ac.ir", "contactPhone": ";+989121392982;+987153314026", "dateEnrollment": "April 4, 2020", "description": "Evaluation of Efficacy of Levamisole and Formoterol+Budesonide in Treatment of COVID-19", "name": "NCT04331470", "primaryOutcome": "Clear chest CT-scan;PCR test", "study_type": "Interventional", "time": "2020-03-30", "weburl": "https://clinicaltrials.gov/show/NCT04331470"}, "type": "Feature"}, {"geometry": {"coordinates": [-0.118186, 51.511486], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": ";victoria.vazquez@kcl.ac.uk", "contactPhone": ";02071886765", "dateEnrollment": "March 23, 2020", "description": "COVID-19 Symptom Tracker", "name": "NCT04331509", "primaryOutcome": "Physical health symptoms;Lack of physical health symptoms", "study_type": "Observational", "time": "2020-03-31", "weburl": "https://clinicaltrials.gov/show/NCT04331509"}, "type": "Feature"}, {"geometry": {"coordinates": [-79.39188, 43.658157], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": ";;steven.chan@uhn.ca;steven.chan@uhn.ca", "contactPhone": ";;416-946-2000;", "dateEnrollment": "April 20, 2020", "description": "Study of the Efficacy and Safety of Ruxolitinib to Treat COVID-19 Pneumonia", "name": "NCT04331665", "primaryOutcome": "Proportion of patients with COVID-19 pneumonia who become critically ill (defined as requiring mechanical ventilation and/or FiO2 of 60% of more);Number of adverse events", "study_type": "Interventional", "time": "2020-04-01", "weburl": "https://clinicaltrials.gov/show/NCT04331665"}, "type": "Feature"}, {"geometry": {"coordinates": [2.137628, 41.406509], "type": "Point"}, "properties": {"classification": "Impact on helpers", "contactEmail": ";jose.munoz@isglobal.org", "contactPhone": ";608774071", "dateEnrollment": "April 3, 2020", "description": "Pre-Exposure Prophylaxis With Hydroxychloroquine for High-Risk Healthcare Workers During the COVID-19 Pandemic", "name": "NCT04331834", "primaryOutcome": "Confirmed cases of a COVID-19", "study_type": "Interventional", "time": "2020-04-01", "weburl": "https://clinicaltrials.gov/show/NCT04331834"}, "type": "Feature"}, {"geometry": {"coordinates": [2.173659, 41.413458], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "pdomingo@santpau.cat;pdomingo@santpau.cat", "contactPhone": ";", "dateEnrollment": "April 2, 2020", "description": "Clinical Trial of Combined Use of Hydroxychloroquine, Azithromycin, and Tocilizumab for the Treatment of COVID-19", "name": "NCT04332094", "primaryOutcome": "In-hospital mortality;Need for mechanical ventilation in the Intensive Care Unit", "study_type": "Interventional", "time": "2020-03-31", "weburl": "https://clinicaltrials.gov/show/NCT04332094"}, "type": "Feature"}, {"geometry": {"coordinates": [13.39511, 42.35143], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "roberto.giacomelli@univaq.it;roberto.giacomelli@univaq.it", "contactPhone": "0039 0862 434742;0862434742", "dateEnrollment": "April 1, 2020", "description": "Efficacy and Safety of Tocilizumab in the Treatment of SARS-Cov-2 Related Pneumonia", "name": "NCT04332913", "primaryOutcome": "Percentage of patients with complete recovery defined as fever disappearance and return to normal peripheral oxygen saturation values (SpO2) after 14 days from the end of treatment with tocilizumab.", "study_type": "Observational", "time": "2020-03-26", "weburl": "https://clinicaltrials.gov/show/NCT04332913"}, "type": "Feature"}, {"geometry": {"coordinates": [-0.222946, 51.487027], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": ";alena.marynina@nhs.net;alena.marynina@nhs.net", "contactPhone": ";07776 224520;07776 224520", "dateEnrollment": "April 3, 2020", "description": "Preventing Cardiac Complication of COVID-19 Disease With Early Acute Coronary Syndrome Therapy: A Randomised Controlled Trial.", "name": "NCT04333407", "primaryOutcome": "All-cause mortality at 30 days after admission", "study_type": "Interventional", "time": "2020-04-01", "weburl": "https://clinicaltrials.gov/show/NCT04333407"}, "type": "Feature"}, {"geometry": {"coordinates": [-0.572464, 47.497946], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "ceannweiler@chu-angers.fr", "contactPhone": "(+33)241354725", "dateEnrollment": "March 27, 2020", "description": "Telephony Or Videophony for Isolated elDerly in Maine-Et-Loire 49 During COVID-19", "name": "NCT04333849", "primaryOutcome": "Preferred means of communication for elderly people in isolation, hospitalized in the acute care geriatric unit or residing at St Nicolas nursing home (Angers UH).", "study_type": "Observational", "time": "2020-04-01", "weburl": "https://clinicaltrials.gov/show/NCT04333849"}, "type": "Feature"}, {"geometry": {"coordinates": [-92.328928, 38.940387], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "dandachid@health.missouri.edu", "contactPhone": "573-884-8728", "dateEnrollment": "April 1, 2020", "description": "COVID-19 in Patients With HIV", "name": "NCT04333953", "primaryOutcome": "Mortality", "study_type": "Observational [Patient Registry]", "time": "2020-03-31", "weburl": "https://clinicaltrials.gov/show/NCT04333953"}, "type": "Feature"}, {"geometry": {"coordinates": [-3.601835, 37.184486], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": ";mcgarzon@ugr.es", "contactPhone": ";+34 649440850", "dateEnrollment": "April 10, 2020", "description": "Vitamin D on Prevention and Treatment of COVID-19", "name": "NCT04334005", "primaryOutcome": "Composite of cumulative death (i.e. mortality) for all causes and for specific causes.", "study_type": "Interventional", "time": "2020-03-29", "weburl": "https://clinicaltrials.gov/show/NCT04334005"}, "type": "Feature"}, {"geometry": {"coordinates": [-111.89293, 40.659009], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": ";Valerie.Aston@imail.org", "contactPhone": ";8015074606", "dateEnrollment": "April 2, 2020", "description": "Hydroxychloroquine vs. Azithromycin for Outpatients in Utah With COVID-19", "name": "NCT04334382", "primaryOutcome": "Hospitalization within 14 days of enrollment", "study_type": "Interventional", "time": "2020-04-02", "weburl": "https://clinicaltrials.gov/show/NCT04334382"}, "type": "Feature"}, {"geometry": {"coordinates": [8.423318, 49.490881], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": ";gitta@klilu.de;gitta@klilu.de", "contactPhone": ";+49 621 5032944;0621 - 5032944", "dateEnrollment": "April 6, 2020", "description": "COVID-19 Registry Rhineland-Palatinate (Germany)", "name": "NCT04335188", "primaryOutcome": "Lab parameters;Intra-hospital complications;Vital status at discharge;Therapeutic strategies;Medication;Supportive care - ventilation;Supportive care - oxygen therapy;Supportive care - ICU;Chest CT;Chest x-ray", "study_type": "Observational", "time": "2020-03-31", "weburl": "https://clinicaltrials.gov/show/NCT04335188"}, "type": "Feature"}, {"geometry": {"coordinates": [-95.397326, 29.713986], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "Efstratios.Koutroumpakis@uth.tmc.edu;Efstratios.Koutroumpakis@uth.tmc.edu", "contactPhone": "4123203161;412-320-3161", "dateEnrollment": "March 30, 2020", "description": "Cardiovascular Manifestations of COVID-19", "name": "NCT04335630", "primaryOutcome": "Prevalence of cardiomyopathy, myocardial infarction, heart failure, clinically significant arrhythmias, cardiogenic shock or cardiac arrest.", "study_type": "Observational", "time": "2020-04-02", "weburl": "https://clinicaltrials.gov/show/NCT04335630"}, "type": "Feature"}, {"geometry": {"coordinates": [114.281922, 30.552414], "type": "Point"}, "properties": {"classification": "Advanced therapy medicinal products", "contactEmail": ";qingsongye@foxmail.com;", "contactPhone": ";+8615858242516;+86 027 88041919", "dateEnrollment": "April 6, 2020", "description": "Safety and Efficacy Study of Allogeneic Human Dental Pulp Mesenchymal Stem Cells to Treat Severe COVID-19 Patients", "name": "NCT04336254", "primaryOutcome": "TTCI", "study_type": "Interventional", "time": "2020-03-28", "weburl": "https://clinicaltrials.gov/show/NCT04336254"}, "type": "Feature"}, {"geometry": {"coordinates": [113.261582, 23.112072], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "zheng862080@139.com;zheng862080@139.com", "contactPhone": "18928868242;86-20-83062843", "dateEnrollment": "February 15, 2020", "description": "Hydrogen-Oxygen Generator With Nebulizer in the Improvement of Symptoms in Patients Infected With COVID-19", "name": "NCT04336462", "primaryOutcome": "Recovery time", "study_type": "Interventional", "time": "2020-03-25", "weburl": "https://clinicaltrials.gov/show/NCT04336462"}, "type": "Feature"}, {"geometry": {"coordinates": [31.150961, 27.205352], "type": "Point"}, "properties": {"classification": "Other", "contactEmail": "aliaehussein@aun.edu.eg;aliaehussein@gmail.com", "contactPhone": "01222302352;+201222302352", "dateEnrollment": "April 2020", "description": "Corona-Like Illness: Did we Got it Before WHO Announcement of the Disease?", "name": "NCT04336657", "primaryOutcome": "Measure frequency of people suffered from unusual flu-like symptoms before December 2019", "study_type": "Observational", "time": "2020-04-03", "weburl": "https://clinicaltrials.gov/show/NCT04336657"}, "type": "Feature"}, {"geometry": {"coordinates": [28.829947, 40.991293], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "azengin@istanbul.edu.tr;", "contactPhone": "(212) 866 37 00 43144;", "dateEnrollment": "April 12, 2020", "description": "Physical Activity Level, Stress Level, Sleep Quality in Pregnant Women During Covid-19 Quarantine", "name": "NCT04336787", "primaryOutcome": "International Physical Activity Questionnaire;Pittsburgh Sleep Quality Index;Perceived Stress Scale;Numerical Pain Rating Scale", "study_type": "Observational", "time": "2020-04-03", "weburl": "https://clinicaltrials.gov/show/NCT04336787"}, "type": "Feature"}, {"geometry": {"coordinates": [9.218851, 45.484822], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "", "contactPhone": "", "dateEnrollment": "March 25, 2020", "description": "Clinical Study To Evaluate The Performance And Safety Of Favipiravir in COVID-19", "name": "NCT04336904", "primaryOutcome": "Time from randomization to clinical recovery", "study_type": "Interventional", "time": "2020-04-03", "weburl": "https://clinicaltrials.gov/show/NCT04336904"}, "type": "Feature"}, {"geometry": {"coordinates": [-0.31287, 51.631622], "type": "Point"}, "properties": {"classification": "Other", "contactEmail": "harry.hothi@nhs.net", "contactPhone": "+44 (0) 20 8909 5847?", "dateEnrollment": "April 2020", "description": "Blood Titanium Analysis of Patients With MAGEC Spine Rods in the COVID-19 Environment", "name": "NCT04337151", "primaryOutcome": "Titanium level", "study_type": "Observational", "time": "2020-04-03", "weburl": "https://clinicaltrials.gov/show/NCT04337151"}, "type": "Feature"}, {"geometry": {"coordinates": [-0.572464, 47.497946], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": ";piasfar@chu-angers.fr;julien.demiselle@chu-angers.fr", "contactPhone": ";+33241355865;33 (0)241355865", "dateEnrollment": "April 3, 2020", "description": "Impact of Angiotensin II Receptor Blockers Treatment in Patients With COVID 19 (COVID-ARA2)", "name": "NCT04337190", "primaryOutcome": "ACE2 level change over time", "study_type": "Observational", "time": "2020-04-03", "weburl": "https://clinicaltrials.gov/show/NCT04337190"}, "type": "Feature"}, {"geometry": {"coordinates": [-0.177066, 51.4988], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": ";f.iqbal@imperial.ac.uk", "contactPhone": ";07588550244", "dateEnrollment": "April 1, 2020", "description": "Remote Monitoring Use In Cases Of Suspected COVID-19 (Coronavirus)", "name": "NCT04337489", "primaryOutcome": "Deterioration resulting in healthcare review", "study_type": "Observational", "time": "2020-04-01", "weburl": "https://clinicaltrials.gov/show/NCT04337489"}, "type": "Feature"}, {"geometry": {"coordinates": [114.262514, 30.627769], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "", "contactPhone": "", "dateEnrollment": "December 23, 2019", "description": "Clinical and Radiomic Model of COVID-19", "name": "NCT04337502", "primaryOutcome": "Predictive performance", "study_type": "Observational", "time": "2020-04-06", "weburl": "https://clinicaltrials.gov/show/NCT04337502"}, "type": "Feature"}, {"geometry": {"coordinates": [12.564599, 55.696084], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": ";;;;henning.bundgaard@regionh.dk;henning.bundgaard@regionh.dk", "contactPhone": ";;;;+4526112290;+4526112290", "dateEnrollment": "April 2, 2020", "description": "Reduction in COVID-19 Infection Using Surgical Facial Masks Outside the Healthcare System", "name": "NCT04337541", "primaryOutcome": "Reduction in COVID-19 infection frequency", "study_type": "Interventional", "time": "2020-04-02", "weburl": "https://clinicaltrials.gov/show/NCT04337541"}, "type": "Feature"}, {"geometry": {"coordinates": [-87.774498, 41.603044], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "rjager@beatcovidtrial.com", "contactPhone": "(708) 620-4608", "dateEnrollment": "April 6, 2020", "description": "Beat COVID-19 - Observational Trial", "name": "NCT04337762", "primaryOutcome": "Health Outcomes", "study_type": "Observational", "time": "2020-04-06", "weburl": "https://clinicaltrials.gov/show/NCT04337762"}, "type": "Feature"}, {"geometry": {"coordinates": [2.336519, 48.826825], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "xavier.monnet@aphp.fr", "contactPhone": "+33 01 45 21 35 39", "dateEnrollment": "April 15, 2020", "description": "Hemodynamic Characteristics of Patients With SARS-CoV-2", "name": "NCT04337983", "primaryOutcome": "Body temperature;Blood pressure;Pulse (heart rate);Respiratory rate;Data provided by transpulmonary thermodilution-CI;Data provided by transpulmonary thermodilution-GEDV;Data provided by transpulmonary thermodilution-EVLW;Data provided by transpulmonary thermodilution-PVPI;Incidence of abnormal laboratory test results", "study_type": "Observational", "time": "2020-03-30", "weburl": "https://clinicaltrials.gov/show/NCT04337983"}, "type": "Feature"}, {"geometry": {"coordinates": [-0.572464, 47.497946], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": ";;;;;;;;;Francois.Morin@chu-angers.fr", "contactPhone": ";;;;;;;;;33 (0)2 41 35 00 81", "dateEnrollment": "April 6, 2020", "description": "Point Of Care UltraSonography for Risk-stratification of COVID-19 Patients", "name": "NCT04338100", "primaryOutcome": "Risk of unfavourable outcome at D14", "study_type": "Observational", "time": "2020-03-31", "weburl": "https://clinicaltrials.gov/show/NCT04338100"}, "type": "Feature"}, {"geometry": {"coordinates": [-81.447334, 30.262648], "type": "Point"}, "properties": {"classification": "Other", "contactEmail": ";USCOVIDplasma@mayo.edu", "contactPhone": ";507-255-4288", "dateEnrollment": "January 10, 2019", "description": "Expanded Access to Convalescent Plasma for the Treatment of Patients With COVID-19", "name": "NCT04338360", "primaryOutcome": "", "study_type": "Expanded Access", "time": "2020-04-03", "weburl": "https://clinicaltrials.gov/show/NCT04338360"}, "type": "Feature"}, {"geometry": {"coordinates": [74.30762, 31.506777], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": ";shehnoor.azhar@gmail.com", "contactPhone": ";+92 321 4090221", "dateEnrollment": "April 7, 2020", "description": "Hydroxychloroquine, Oseltamivir and Azithromycin for the Treatment of COVID-19 Infection: An RCT", "name": "NCT04338698", "primaryOutcome": "Laboratory Result;Clinical Outcome", "study_type": "Interventional", "time": "2020-04-04", "weburl": "https://clinicaltrials.gov/show/NCT04338698"}, "type": "Feature"}, {"geometry": {"coordinates": [114.242864, 30.596649], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "Huilanz_76@163.com", "contactPhone": "15391532171", "dateEnrollment": "April 2, 2020", "description": "Efficacy and Safety of Nintedanib in the Treatment of Pulmonary Fibrosis in Patients With Moderate to Severe COVID -19", "name": "NCT04338802", "primaryOutcome": "Changes in forced vital capacity (FVC)", "study_type": "Interventional", "time": "2020-04-01", "weburl": "https://clinicaltrials.gov/show/NCT04338802"}, "type": "Feature"}, {"geometry": {"coordinates": [6.791901, 51.19134], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "", "contactPhone": "", "dateEnrollment": "June 1, 2020", "description": "Combination Therapy With Camostat Mesilate + Hydroxychloroquine for COVID-19", "name": "NCT04338906", "primaryOutcome": "Not hospitalized", "study_type": "Interventional", "time": "2020-04-03", "weburl": "https://clinicaltrials.gov/show/NCT04338906"}, "type": "Feature"}, {"geometry": {"coordinates": [31.150961, 27.205352], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "", "contactPhone": "", "dateEnrollment": "May 1, 2020", "description": "Characteristics and Outcome of Coronavirus Disease 2019 (COVID-19) in Egypt", "name": "NCT04339322", "primaryOutcome": "Demographics of Coronavirus Disease 2019 (COVID-19) in the cohort group;Clinical manifestations of Coronavirus Disease 2019 (COVID-19);Laboratory data of included Coronavirus Disease 2019 (COVID-19) cohort;Radiological features of Coronavirus Disease 2019 (COVID-19) cohort", "study_type": "Observational", "time": "2020-04-07", "weburl": "https://clinicaltrials.gov/show/NCT04339322"}, "type": "Feature"}, {"geometry": {"coordinates": [-71.10762, 42.336156], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "dmlevine@bwh.harvard.edu;dmlevine@bwh.harvard.edu", "contactPhone": "617-732-7063;617-732-7063", "dateEnrollment": "March 1, 2020", "description": "COVID-19 Risk Stratification", "name": "NCT04339387", "primaryOutcome": "Suitable for discharge", "study_type": "Observational", "time": "2020-04-06", "weburl": "https://clinicaltrials.gov/show/NCT04339387"}, "type": "Feature"}, {"geometry": {"coordinates": [77.211611, 28.52755], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": ";sujeet.jha@maxhealthcare.com;samreensiddiqui@maxhealthcare.com", "contactPhone": ";+919910609000;+919582865898", "dateEnrollment": "April 2, 2020", "description": "Max COVID19- Study", "name": "NCT04339608", "primaryOutcome": "COVID-19 positive case", "study_type": "Observational", "time": "2020-04-07", "weburl": "https://clinicaltrials.gov/show/NCT04339608"}, "type": "Feature"}, {"geometry": {"coordinates": [114.391914, 30.494375], "type": "Point"}, "properties": {"classification": "Advanced therapy medicinal products", "contactEmail": "447822853@qq.com;447822853@qq.com", "contactPhone": "+8613387517458;+8613387517458", "dateEnrollment": "February 1, 2020", "description": "Clinical Research of Human Mesenchymal Stem Cells in the Treatment of COVID-19 Pneumonia", "name": "NCT04339660", "primaryOutcome": "The immune function (TNF-a ?IL-1ß?IL-6?TGF-ß?IL-8?PCT?CRP);Blood oxygen saturation", "study_type": "Interventional", "time": "2020-04-02", "weburl": "https://clinicaltrials.gov/show/NCT04339660"}, "type": "Feature"}, {"geometry": {"coordinates": [-81.46278, 30.279084], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": ";brannock.robert@mayo.edu;brannock.robert@mayo.edu", "contactPhone": ";904-953-2000;904-953-2000", "dateEnrollment": "September 10, 2019", "description": "Breath Analysis Based Disease Biomarkers of COVID-19 and Other Diseases", "name": "NCT04341012", "primaryOutcome": "Breath volatile organic compound profiles;Utility of breath profiles for disease diagnosis or prognosis", "study_type": "Observational", "time": "2020-04-07", "weburl": "https://clinicaltrials.gov/show/NCT04341012"}, "type": "Feature"}, {"geometry": {"coordinates": [2.088324, 41.361062], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": ";xsolanich@bellvitgehospital.cat;xsolanich@bellvitgehospital.cat", "contactPhone": ";0034 932607500;0034 932607500", "dateEnrollment": "April 1, 2020", "description": "Clinical Trial to Evaluate Methylprednisolone Pulses and Tacrolimus in Patients With COVID-19 Lung Injury", "name": "NCT04341038", "primaryOutcome": "Time to reach clinical stability", "study_type": "Interventional", "time": "2020-04-07", "weburl": "https://clinicaltrials.gov/show/NCT04341038"}, "type": "Feature"}, {"geometry": {"coordinates": [-122.400062, 37.666434], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "aburns@caredx.com", "contactPhone": "415.287.2420", "dateEnrollment": "April 1, 2020", "description": "AlloSure Guided Immuno-Optimization for COVID-19: An Early Experience", "name": "NCT04341103", "primaryOutcome": "Assessing the utility of AlloSure dd-cfDNA to guide clinical immune-optimization for transplant patients with COVID-19", "study_type": "Observational", "time": "2020-03-16", "weburl": "https://clinicaltrials.gov/show/NCT04341103"}, "type": "Feature"}, {"geometry": {"coordinates": [2.330814, 48.810695], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "lisa.derosa@gustaveroussy.fr;lisa.derosa@gustaveroussy.fr", "contactPhone": "0142114211;0142114211", "dateEnrollment": "April 3, 2020", "description": "Epidemiology of SARS-CoV-2 and Mortality to Covid19 Disease in French Cancer Patients", "name": "NCT04341207", "primaryOutcome": "Prevalence and the 3-months incidence of SARS-CoV-2 in cancer patients;Covid-19 disease-specific mortality rate in cancer patients treated by hydroxychloroquine and azithromycin", "study_type": "Interventional", "time": "2020-04-08", "weburl": "https://clinicaltrials.gov/show/NCT04341207"}, "type": "Feature"}, {"geometry": {"coordinates": [114.242864, 30.596649], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "qingleigao@hotmail.com;qingleigao@hotmail.com", "contactPhone": "+86-13871127473;+86-13871127473", "dateEnrollment": "April 10, 2020", "description": "The Safety of Chemotherapy for Patients With Gynecological Malignancy in High-risk Region of COVID-19", "name": "NCT04341480", "primaryOutcome": "SARS-CoV-2 infection", "study_type": "Observational", "time": "2020-04-07", "weburl": "https://clinicaltrials.gov/show/NCT04341480"}, "type": "Feature"}, {"geometry": {"coordinates": [-88.158911, 41.804386], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "andrew.gostine@nm.org", "contactPhone": "(312) 695-0061", "dateEnrollment": "April 15, 2020", "description": "Non-contact ECG Sensor System for COVID19", "name": "NCT04341506", "primaryOutcome": "ECG changes associated with COVID-19", "study_type": "Observational", "time": "2020-04-07", "weburl": "https://clinicaltrials.gov/show/NCT04341506"}, "type": "Feature"}, {"geometry": {"coordinates": [2.367581, 48.873407], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": ";nancy.kentish@aphp.fr;nancy.kentish@aphp.fr", "contactPhone": ";142499995;142499995", "dateEnrollment": "April 9, 2020", "description": "Psychological Burden in ICU Survivors of Severe COVID-19 Pneumonia, Their Relatives and Their Healthcare Providers", "name": "NCT04341519", "primaryOutcome": "PTSD Family members sup 22", "study_type": "Observational", "time": "2020-04-07", "weburl": "https://clinicaltrials.gov/show/NCT04341519"}, "type": "Feature"}, {"geometry": {"coordinates": [3.019009, 50.627336], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": ";Delphine.garrigue@chru-lille.fr", "contactPhone": ";03 20 44 67 97", "dateEnrollment": "April 2020", "description": "Predictive Biomarkers of Secondary Aggravation in Covid-19 Suspect Patient", "name": "NCT04341792", "primaryOutcome": "Rate of secondary aggravation", "study_type": "Observational", "time": "2020-04-07", "weburl": "https://clinicaltrials.gov/show/NCT04341792"}, "type": "Feature"}, {"geometry": {"coordinates": [-1.131719, 37.994793], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": ";;miguelguia7@gmail.com;antmesquinas@gmail.com", "contactPhone": ";;00351915774975;0034609321966", "dateEnrollment": "April 1, 2020", "description": "NIV and CPAP Failure Predictors in COVID-19 Associated Respiratory Failure", "name": "NCT04342104", "primaryOutcome": "HACOR score efficacy;HACOR score addaptation", "study_type": "Observational", "time": "2020-04-08", "weburl": "https://clinicaltrials.gov/show/NCT04342104"}, "type": "Feature"}, {"geometry": {"coordinates": [28.94027, 41.004918], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "azengin@istanbul.edu.tr", "contactPhone": "+905526830479", "dateEnrollment": "April 10, 2020", "description": "Evaluate the Working Environments of Individuals Working From Home During Covid-19 Outbreak", "name": "NCT04342208", "primaryOutcome": "The Rapid Office Strain Assessment (ROSA)", "study_type": "Observational", "time": "2020-04-07", "weburl": "https://clinicaltrials.gov/show/NCT04342208"}, "type": "Feature"}, {"geometry": {"coordinates": [9.06195, 48.527348], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": ";diane.egger-adam@uni-tuebingen.de;diane.egger-adam@uni-tuebingen.de", "contactPhone": ";+4970712982191;+4970712982191", "dateEnrollment": "March 29, 2020", "description": "Hydroxychloroquine for COVID-19", "name": "NCT04342221", "primaryOutcome": "Effect of HCQ on in vivo viral clearance", "study_type": "Interventional", "time": "2020-04-08", "weburl": "https://clinicaltrials.gov/show/NCT04342221"}, "type": "Feature"}, {"geometry": {"coordinates": [7.742826, 48.576278], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": ";pierre-emmanuel.falcoz@chru-strasbourg.fr;pierre-emmanuel.falcoz@chru-strasbourg.fr", "contactPhone": ";33 3 69 55 11 34;33 3 69 55 11 34", "dateEnrollment": "April 1, 2020", "description": "PLACE OF VENOVENOUS ECMO IN THE MANAGEMENT OF SEVERE REFRACTORY ARDS ASSOCIATED WITH SARS-COV-2", "name": "NCT04343404", "primaryOutcome": "Retrospective description of COVID-19 patients receiving respiratory ECMO-VV supplementation and what happens to them", "study_type": "Observational", "time": "2020-04-08", "weburl": "https://clinicaltrials.gov/show/NCT04343404"}, "type": "Feature"}, {"geometry": {"coordinates": [-77.056605, 38.871843], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": ";;;;usaf.pentagon.11-mdg.mbx.flight-med-clinic@mail.mil;usaf.pentagon.11-mdg.mbx.flight-med-clinic@mail.mil", "contactPhone": ";;;;703-697-3255;703-697-3255", "dateEnrollment": "April 2020", "description": "Military COVID-19 Hydroxychloroquine Pre-exposure and Post-exposure Prophylaxis Study", "name": "NCT04343677", "primaryOutcome": "Incidence", "study_type": "Interventional", "time": "2020-04-09", "weburl": "https://clinicaltrials.gov/show/NCT04343677"}, "type": "Feature"}, {"geometry": {"coordinates": [9.972344, 53.590812], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": ";d.jarczak@uke.de;d.jarczak@uke.de", "contactPhone": ";+49 40 741035315;+49 40 741035315", "dateEnrollment": "April 1, 2020", "description": "Effect of CytoSorb Adsorber on Hemodynamic and Immunological Parameters in Critical Ill Patients With COVID-19", "name": "NCT04344080", "primaryOutcome": "Percentage of patients with a significant stabilization of hemodynamics for at least 24 hours", "study_type": "Interventional", "time": "2020-04-09", "weburl": "https://clinicaltrials.gov/show/NCT04344080"}, "type": "Feature"}, {"geometry": {"coordinates": [12.628883, 41.858332], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "", "contactPhone": "", "dateEnrollment": "April 2, 2020", "description": "Surgery During Covid-19: The Role of Asymptomatic Patients, a Survey", "name": "NCT04344197", "primaryOutcome": "overview of surgical management on preventive measures of hospital infection spread during covid 19", "study_type": "Observational", "time": "2020-04-09", "weburl": "https://clinicaltrials.gov/show/NCT04344197"}, "type": "Feature"}, {"geometry": {"coordinates": [151.22966, -33.918092], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "", "contactPhone": "", "dateEnrollment": "20/04/2020", "description": "Effect of a Brief Problem Management Intervention on Covid 19-Related Anxiety and Depression", "name": "ACTRN12620000468921", "primaryOutcome": "Anxiety and depression represent a composite primary outcome, as measured by the Hospital Anxiety and Depression scale.[Pretreatment (week 1), posttreatment (week 7), primary follow-up (week 15). ]", "study_type": "Interventional", "time": "2020-04-14", "weburl": "https://anzctr.org.au/ACTRN12620000468921.aspx"}, "type": "Feature"}, {"geometry": {"coordinates": [115.842631, -32.067928], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "", "contactPhone": "", "dateEnrollment": "20/04/2020", "description": "The design of an updated iron lung ventilator which can be easily built and used by people with minimal training in situations such as COVID-19 where skilled doctors or normal ventilators are unavailable.", "name": "ACTRN12620000477921", "primaryOutcome": "Recorded tidal volumes whilst continuously using the pandemic cuirass ventilator for 60 minutes. Tidal volumes will be recorded using a face mask connected to an existing GE Anaesthetic Machine.[Tidal volumes will be assessed every 15 minutes. Total sedation time will be 60 minutes.]", "study_type": "Interventional", "time": "2020-04-16", "weburl": "https://anzctr.org.au/ACTRN12620000477921.aspx"}, "type": "Feature"}, {"geometry": {"coordinates": [145.122677, -37.920207], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "", "contactPhone": "", "dateEnrollment": "27/04/2020", "description": "Adapting the Decathlon Group Easybreathe® snorkelling face mask for the safer administration of oxygen and/or continuous positive airway pressure and in the intra/interhospital transportation of patients with proven or suspected COVID 19 infection.", "name": "ACTRN12620000472976", "primaryOutcome": "Patient comfort and tolerability as assessed by a 6 point question item originally developed for CPAP use.  We will use a modified version of the 6 point scale developed by Balachandran et al JCSM 2013.  It is a 6 point Likert scale.[At 24 hours after initiation of therapy and every subsequent 24 hours of use of the mask until disposition from hospital.]", "study_type": "Interventional", "time": "2020-04-15", "weburl": "https://anzctr.org.au/ACTRN12620000472976.aspx"}, "type": "Feature"}, {"geometry": {"coordinates": [151.185494, -33.891512], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "", "contactPhone": "", "dateEnrollment": "01/05/2020", "description": "Mental health and wellbeing on general population during the COVID-19 outbreak", "name": "ACTRN12620000479909", "primaryOutcome": "the prevalence of depression which will be assessed by the 9-item Patient Health Questionnaire[Assessed at baseline];the prevalence of anxiety, which will be assessed by the 7-item Generalized Anxiety Disorder scale[Assessed at baseline];the prevalence of insomnia, which will be assessed by the 7-item Insomnia Severity Index. [Assessed at baseline]", "study_type": "Observational", "time": "2020-04-16", "weburl": "https://anzctr.org.au/ACTRN12620000479909.aspx"}, "type": "Feature"}, {"geometry": {"coordinates": [115.771556, -31.742131], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "", "contactPhone": "", "dateEnrollment": "20/04/2020", "description": "Virucidal pilot study of Nasodine® Antiseptic Nasal Spray (povidone-iodine 0.5%) in people with COVID-19 and confirmed nasal shedding of SARS-CoV-2 virus.", "name": "ACTRN12620000470998", "primaryOutcome": "Impact of Nasodine on the reduction in virus in the nasal passages of subjects who are shedding the virus.  Virus concentration is  measured by PCR analysis of cell culture medium 96 hours after inoculation with a post-treatment nasal swab and compared to an equivalent culture inoculated with swab collected prior to treatment.[Endpoint is swab taken 5 minutes after dosing and compared against a swab taken 5 minutes prior to dosing.]", "study_type": "Interventional", "time": "2020-04-14", "weburl": "https://anzctr.org.au/ACTRN12620000470998.aspx"}, "type": "Feature"}, {"geometry": {"coordinates": [153.023562, -27.484392], "type": "Point"}, "properties": {"classification": "Impact on helpers", "contactEmail": "", "contactPhone": "", "dateEnrollment": "01/06/2020", "description": "Reducing acute severe respiratory events in health care workers during the Covid-19 pandemic with OM85", "name": "ACTRN12620000473965", "primaryOutcome": "Proportion of health care workers (HCW) contracting an lower respiratory illness necessitating workforce removal, assessed from workforce information including rosters and medical records.[Assessed at the end of month 3, prior to the wait-list control (WLC) commencing treatment.]", "study_type": "Interventional", "time": "2020-04-15", "weburl": "https://anzctr.org.au/ACTRN12620000473965.aspx"}, "type": "Feature"}, {"geometry": {"coordinates": [115.814544, -31.967477], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "", "contactPhone": "", "dateEnrollment": "27/04/2020", "description": "Airway Pressure Release Ventilation for mechanically ventilated patients with COVID-19 in Western Australian Intensive Care Units: an observational study", "name": "ACTRN12620000474954", "primaryOutcome": "Ventilation free survival days  as assessed by reviewing medical records[At 90 days after initiation of mechanical ventilation]", "study_type": "Observational", "time": "2020-04-15", "weburl": "https://anzctr.org.au/ACTRN12620000474954.aspx"}, "type": "Feature"}, {"geometry": {"coordinates": [145.107232, -37.903771], "type": "Point"}, "properties": {"classification": "Advanced therapy medicinal products", "contactEmail": "", "contactPhone": "", "dateEnrollment": "01/06/2020", "description": "Cord Blood Therapy to prevent progression of COVID-19 related pneumonia", "name": "ACTRN12620000478910", "primaryOutcome": "Safety and tolerability of UCB cell administration (absence of immediate and short-term side effects, including allergic reactions, line related effects, infection)<br>This will be assessed based on partipant rports, and hospital charts and monitoring[24 hrs (collection of hourly vital monitoring data, examination at 24 hrs)];Clinical improvement, as documented by change of patient status on a seven-category ordinal scale (to be completed by hospital staff or researcher)<br>Seven-category ordinal scale:<br>1, not hospitalised with resumption of normal activities; 2, not hospitalised, but unable to resume normal activities; 3, hospitalised, not requiring supplemental oxygen; 4, hospitalised, requiring supplemental oxygen; 5, hospitalised, requiring humidified nasal high-flow oxygen therapy, non-invasive mechanical ventilation, or both; 6,hospitalised, requiring ECMO, invasive mechanical ventilation, ECMO or both; and 7, death.[ Assessed every day until resolution of symptoms or death]", "study_type": "Interventional", "time": "2020-04-16", "weburl": "https://anzctr.org.au/ACTRN12620000478910.aspx"}, "type": "Feature"}, {"geometry": {"coordinates": [174.767365, -36.861702], "type": "Point"}, "properties": {"classification": "Impact on helpers", "contactEmail": "", "contactPhone": "", "dateEnrollment": "01/06/2020", "description": "Stress-reduction Using Probiotics to Promote Ongoing Resilience Throughout COVID-19 for Healthcare Workers (SUPPORT COVID-19 Healthcare Workers)", "name": "ACTRN12620000480987", "primaryOutcome": "Scores on the Perceived Stress Scale.  The PSS is a widely used measure of the appraisal of how stressful events over the previous month are.  Scores range from 0 to 40 with higher scores representing higher levels of stress. [Perceived Stress Scale scores will be measured at baseline and following a 12 week intervention period, with the primary time point of interest being scores post the 12 week intervention period.]", "study_type": "Interventional", "time": "2020-04-16", "weburl": "https://anzctr.org.au/ACTRN12620000480987.aspx"}, "type": "Feature"}, {"geometry": {"coordinates": [114.418087, 30.513004], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "yangshenglan@126.com", "contactPhone": "+86 13995641276", "dateEnrollment": "2020-01-20", "description": "Danggui Shaoyao Powder in the synergistic treatment of novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000032098", "primaryOutcome": "Blood routine;Blood biochemistry;C-reactive protein;chest CT;2019-ncov-RNA;TCM symptom;", "study_type": "Interventional study", "time": "2020-04-19", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=52477"}, "type": "Feature"}, {"geometry": {"coordinates": [113.325395, 23.15182], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "naturestyle@163.com", "contactPhone": "+86 18922103768", "dateEnrollment": "2020-03-18", "description": "Study for Healthy Behavior, Psychological Analysis and Psychological Reconstruction Strategies of Students Population Keeping in Home Under the Pandemic of Novel Coronavirus Pneumonia (COVID-19)", "name": "ChiCTR2000032095", "primaryOutcome": "Changes in anxiety and depression scale scores;difference between two interventions;", "study_type": "Observational study", "time": "2020-04-19", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=52565"}, "type": "Feature"}, {"geometry": {"coordinates": [110.403296, 21.198277], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "zhangyuanly@126.com", "contactPhone": "+86 13828223316", "dateEnrollment": "2020-04-01", "description": "A medical records based study for the curative effect of combined traditional Chinese and western medicine in the treatment of severe novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000032040", "primaryOutcome": "28-day mortality;", "study_type": "Observational study", "time": "2020-04-18", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=52529"}, "type": "Feature"}, {"geometry": {"coordinates": [116.301229, 39.923876], "type": "Point"}, "properties": {"classification": "Impact on helpers", "contactEmail": "shenchuanan@126.com", "contactPhone": "+86 010 66848772", "dateEnrollment": "2020-02-02", "description": "The prevention and treatment strategy of the protective respirator related facial pressure injuries among healthcare professionals fighting novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000032013", "primaryOutcome": "temperature;area of facial indents;gray level of facial indents;pain;", "study_type": "Interventional study", "time": "2020-04-17", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=52483"}, "type": "Feature"}, {"geometry": {"coordinates": [116.275465, 39.920569], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "psy9992011@163.com", "contactPhone": "+86 18600310183", "dateEnrollment": "2020-04-17", "description": "Effecacy and Safety of Hyperbaric Oxygen Therapy to patients with novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000032011", "primaryOutcome": "Oxygenation index;", "study_type": "Interventional study", "time": "2020-04-17", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=52142"}, "type": "Feature"}, {"geometry": {"coordinates": [114.257837, 30.600222], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "fyang@vip.163.com", "contactPhone": "+86 027 85726309", "dateEnrollment": "2020-05-01", "description": "Novel coronavirus pneumonia (COVID-19) Intelligent Assistant Analysis System:A Multi-center Clinical Research", "name": "ChiCTR2000032010", "primaryOutcome": "sensitivity;specificity;accuracy;", "study_type": "Diagnostic test", "time": "2020-04-17", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=52479"}, "type": "Feature"}, {"geometry": {"coordinates": [121.48404, 31.233698], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "maxiongmd@163.com", "contactPhone": "+86 13636354001", "dateEnrollment": "2020-02-08", "description": "Clinical characteristics and risk factors of novel coronavirus pneumonia (COVID-19) patients with chronic liver disease", "name": "ChiCTR2000032009", "primaryOutcome": "Critical event rate;Critical event rate;", "study_type": "Observational study", "time": "2020-04-17", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=52490"}, "type": "Feature"}, {"geometry": {"coordinates": [113.24213, 23.275155], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "huangmx5@mail.sysu.edu.cn", "contactPhone": "+86 15989778816", "dateEnrollment": "2020-04-01", "description": "Clinical observation for the effect of Ke-Gan-Li-Yan oral liquid on the relief of laryngeal symptoms of novel coronavirus pneumonia (COVID-19) convalescence and suspected patients and other susceptible people", "name": "ChiCTR2000031982", "primaryOutcome": "Relief time and rate of symptoms of laryngeal discomfort, sore throat, dry and hot pharynx, and pharyngeal mucosal congestion;New fever, cough, muscle soreness, headache, the time it takes for symptoms to disappear or to subside;Symptom scores;Occurrence of adverse events/reactions;", "study_type": "Observational study", "time": "2020-04-16", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=52341"}, "type": "Feature"}, {"geometry": {"coordinates": [116.41064, 39.987702], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "Lilingru912@163.com", "contactPhone": "+86 13426096071", "dateEnrollment": "2020-04-01", "description": "Study for prevention of novel coronavirus pneumonia (COVID-19) in high risk population by Chinese medicine", "name": "ChiCTR2000031955", "primaryOutcome": "SARS-CoV-2;IgM;IgG;", "study_type": "Interventional study", "time": "2020-04-16", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=52364"}, "type": "Feature"}, {"geometry": {"coordinates": [121.438818, 31.196042], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "huanghefg@sjtu.edu.cn", "contactPhone": "+86 021 64070434", "dateEnrollment": "2020-04-15", "description": "Medical Records Based Study for Maternal and Perinatal Outcomes of Women with novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000031954", "primaryOutcome": "pregnancy maternal complications;labor complications;mode of delivery;birth weight;Neonatal disease;Apgar score;neonatal infection;NICU admitting rate;neonates with COVID-19;", "study_type": "Observational study", "time": "2020-04-16", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=52365"}, "type": "Feature"}, {"geometry": {"coordinates": [116.426396, 39.939041], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "lv_cheng0816@163.com", "contactPhone": "+86 010-64093264", "dateEnrollment": "2020-04-16", "description": "Efficacy of Chinese Herbal Tea in the Prevention of Novel Coronavirus Pneumonia (COVID-19): a Randomized Controlled Trial", "name": "ChiCTR2000031944", "primaryOutcome": "the rate of 2019-nCoV RNA positive;", "study_type": "Interventional study", "time": "2020-04-15", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=52414"}, "type": "Feature"}, {"geometry": {"coordinates": [106.945991, 27.706111], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "764590955@qq.com", "contactPhone": "+86 13595248166", "dateEnrollment": "2020-01-31", "description": "Analysis of clinical characteristics and therapeutic effect of 9 cases of novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000031930", "primaryOutcome": "Blood routine tests;Liver function;Renal function;CK-MB;B-BNP;myoglobin;Hypersensitive troponin;Interleukin - 6;Tumor necrotizing factor-alpha;Interleukin - 10;", "study_type": "Observational study", "time": "2020-04-15", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51602"}, "type": "Feature"}, {"geometry": {"coordinates": [114.204961, 22.419579], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "paulkschan@cuhk.edu.hk", "contactPhone": "+852 35053333", "dateEnrollment": "2020-06-01", "description": "Delineate the prevalence, risk factors, temporal distribution and epidemiological characteristics of hidden novel coronavirus (2019-nCoV) infection in the community", "name": "ChiCTR2000031928", "primaryOutcome": "Delineate the true prevalence of SARS-CoV-2 infection in Hong Kong;Estimate the size of outbreak at different periods;Understand the epidemiology and characteristics of asymptomatic and mild infections;", "study_type": "Observational study", "time": "2020-04-14", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=52353"}, "type": "Feature"}, {"geometry": {"coordinates": [113.270894, 23.147581], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "13533550083@163.com", "contactPhone": "+86 13533550083", "dateEnrollment": "2020-02-11", "description": "A medical records based study for ''Guangdong Pneumonia NO.1'' in the Treatment of Novel Coronavirus Pneumonia (COVID-19)", "name": "ChiCTR2000031888", "primaryOutcome": "syndrome;nucleic acid of nCoV-19;blood count;liver and kidney function;cardiac enzymes;lung CT;", "study_type": "Interventional study", "time": "2020-04-13", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=52106"}, "type": "Feature"}, {"geometry": {"coordinates": [114.191315, 22.436061], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "chris.kclai@cuhk.edu.hk", "contactPhone": "+852 55696828", "dateEnrollment": "2020-04-01", "description": "Study for investigation of contamination by novel coronavirus pneumonia (COVID-19) in the clinical environment", "name": "ChiCTR2000031712", "primaryOutcome": "Environment viral load;", "study_type": "Observational study", "time": "2020-04-07", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51650"}, "type": "Feature"}, {"geometry": {"coordinates": [116.537564, 33.839175], "type": "Point"}, "properties": {"classification": "Advanced therapy medicinal products", "contactEmail": "hcm200702@163.com", "contactPhone": "+86 13584010516", "dateEnrollment": "2020-02-20", "description": "Cancelled by the investigator             Umbilical cord mesenchymal stem cells (hucMSCs) in the treatment of high risk novel coronavirus pneumonia (COVID-19) patients", "name": "ChiCTR2000030300", "primaryOutcome": "Time to disease recovery;Exacerbation (transfer to RICU) time;", "study_type": "Interventional study", "time": "2020-02-28", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=50022"}, "type": "Feature"}, {"geometry": {"coordinates": [121.819671, 31.067954], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "shanclhappy@163.com", "contactPhone": "+86 18616974986", "dateEnrollment": "2020-02-18", "description": "The effect of Gymnastic Qigong Yangfeifang on functional recovery and quality of life in patients with mild novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000029976", "primaryOutcome": "cough;Degree of expiratory dyspnoea;", "study_type": "Interventional study", "time": "2020-02-18", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=49631"}, "type": "Feature"}, {"geometry": {"coordinates": [114.447438, 38.019008], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "jiactm@163.com", "contactPhone": "+86 0311 83855881", "dateEnrollment": "2020-02-01", "description": "A randomized, open-label, blank-controlled trial for Lian-Hua Qing-Wen Capsule /Granule in the treatment of novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000029434", "primaryOutcome": "Clinical symptoms (fever, weakness, cough) recovery rate and recovery time;", "study_type": "Interventional study", "time": "2020-02-01", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=48889"}, "type": "Feature"}, {"geometry": {"coordinates": [114.462525, 38.035365], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "jiactm@163.com", "contactPhone": "+86 0311-83855881", "dateEnrollment": "2020-02-01", "description": "A randomized, open-label, blank-controlled trial for Lian-Hua Qing-Wen Capsule/Granule in the treatment of suspected novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000029433", "primaryOutcome": "Clinical symptoms (fever, weakness, cough) recovery rate and recovery time;", "study_type": "Interventional study", "time": "2020-02-01", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=48898"}, "type": "Feature"}, {"geometry": {"coordinates": [2.334565, 48.873277], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "aurelie.zindjirdjian@aphp.fr", "contactPhone": "+33144841764", "dateEnrollment": "09/04/2020", "description": "Use of a respiratory multiplex PCR and procalcitonin to reduce antibiotic exposure in patients with severe confirmed COVID-19 pneumonia", "name": "EUCTR2020-001324-33-FR", "primaryOutcome": "Main Objective: To assess the efficacy of a management strategy combining a broad panel respiratory mPCR and an algorithm of early antibiotic de-escalation and discontinuation based on both the mPCR results and the procalcitonin, on antibiotics exposure, as compared with a conventional strategy, in severe confirmed COVID-19 pneumonia.;Secondary Objective: Mortality rates at 28 (D28) and 90 days (D90); <br>- Overall antibiotics use, including broad- and narrow-spectrum antibiotics;<br>- Total exposure to antibiotics at D28;<br>- Number of organ-failure free days at D28;<br>- Incidence rates of bacterial super-infections and colonization/infection with resistant pathogens at D28;<br>- ICU and hospital lengths of stay;<br> - Quality of life at D90.;Primary end point(s): The primary assessment criterion is the number of antibiotic free days at D28, which corresponds to the number of days alive without any antibiotic at Day 28. The D28 time point is usual in studies assessing antibiotic use in ICU patients.;Timepoint(s) of evaluation of this end point: D28", "study_type": "Interventional clinical trial of medicinal product", "time": "2020-03-29", "weburl": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001324-33"}, "type": "Feature"}, {"geometry": {"coordinates": [5.858993, 51.823573], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "", "contactPhone": "+31621137538", "dateEnrollment": "10/04/2020", "description": "A clinicial trial to investigate te effect of valsartan compared to placebo on acute respiratory failure in hospitalized SARS-CoV-2-infected patients", "name": "EUCTR2020-001320-34-NL", "primaryOutcome": "Main Objective: To investigate the effect of the ARB valsartan in comparison to placebo on the occurrence of one of the following items, within 14 days of randomization:1) ICU admission; 2) Mechanical ventilation; 3) Mortality.;Secondary Objective: •\tDeath within 14 days, 30 days, 90 days and at 1 year, defined as all-cause mortality.<br>•\tMechanical ventilation and ICU admission within 14 days.<br>•\tTime to ICU admission, mechanical ventilation and death.<br>•\tOccurrence of acute kidney injury within 14 days defined as a 50% decline in estimated glomerular filtration rate relative to baseline, or decrease of >30 ml/min/1.73m2 and to a value below 60 ml/min/1.73m2.<br>;Primary end point(s): The primary study endpoint is the occurrence within 14 days of randomization of either: 1) ICU admission; 2) Mechanical ventilation; 3) Death.  ;Timepoint(s) of evaluation of this end point: The occurrence of the main study endpoint will be assessed on a daily basis.", "study_type": "Interventional clinical trial of medicinal product", "time": "2020-03-30", "weburl": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001320-34"}, "type": "Feature"}, {"geometry": {"coordinates": [7.748754, 48.577253], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "dpidrci@chru-strasbourg.fr", "contactPhone": "0033388115266", "dateEnrollment": "11/04/2020", "description": "Efficacy of Hydroxychloroquine, Telmisartan and Azithromycin on Survival in Elderly Hospitalized Patients with VIDOC-19 : A Randomized, Multi-Centre, Adaptive, Blinded Study", "name": "EUCTR2020-001303-16-FR", "primaryOutcome": "Main Objective: The main objective of this study is to evaluate the survival interest of Hydroxychloroquine 400 mg, Telmisartan 80 mg, Azithromycin 500 mg and Curcumin 800 mg daily on the survival of elderly patients with VIDOC-19 at 2 weeks from the start of treatment.;Secondary Objective: To evaluate adverse events, and particulary serious adverse avent.<br>ToEvaluate the effectiveness of different treatments on :<br>- SARS-Cov-2<br>- Survival to 4 weeks<br>- Inflammation<br>- The confusion <br>- Walking<br>- Functional capabilities<br>- Breathing rate<br>-Oxygen therapy<br>- Pulse rate<br>- Systolic and diastolic blood pressure <br>- Temperature<br>- Pneumonia<br>- Discharge<br>- Transfer to a convalescent hospital (SSR or equivalent)<br>- Necessity of add-on coritcosteroids or other immunomodulator or immunosuppressor<br>- Oxygen therapy<br>- The impulse rate<br>- Systolic and diastolic blood pressure<br>- The temperature<br>- Pneumonia<br>- The return home<br>- Disclaimer<br>- Transfer to a convalescent hospital (RHS or equivalent)<br>- The need for treatment with complementary, immonumodulating or immunosuppressive corticosteroids.;Primary end point(s): The primary endpoint will be two-weeks survival rate.;Timepoint(s) of evaluation of this end point: 14 days", "study_type": "Interventional clinical trial of medicinal product", "time": "2020-03-29", "weburl": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001303-16"}, "type": "Feature"}, {"geometry": {"coordinates": [-3.705716, 40.499053], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "a.borobia@gmail.com", "contactPhone": "+34912071466", "dateEnrollment": "27/03/2020", "description": "Efficacy of different treatments in patients infected with COVID-19", "name": "EUCTR2020-001156-18-ES", "primaryOutcome": "Secondary Objective: The secondary objectives are to evaluate the effects of these antiviral treatments on the length of the hospital stay and on the reception of ventilation or intensive care.;Main Objective: Provide reliable estimates of the effects of these antiviral treatments on hospital mortality.;Timepoint(s) of evaluation of this end point: The main result is all-cause mortality, subdivided by disease severity at the time of randomization.;Primary end point(s): Discharge from the patient or death", "study_type": "Interventional clinical trial of medicinal product", "time": "2020-04-03", "weburl": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001156-18"}, "type": "Feature"}, {"geometry": {"coordinates": [2.187366, 41.403394], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "regulatory@medsir.org", "contactPhone": "34932214135", "dateEnrollment": "09/04/2020", "description": "Tocilizumab plus Pembrolizumab in COVID-19", "name": "EUCTR2020-001160-28-ES", "primaryOutcome": "Timepoint(s) of evaluation of this end point: through day 14 after study treatment initiation.;Primary end point(s): Percentage of patients with normalization of SpO2 =96% through day 14 after study treatment initiation;Secondary Objective: To assess the efficacy –as determined by:<br> the proportion of patients with normalization of fever– of study drugs in this population.<br>• the proportion of discharged patients– of study drugs in this population.<br>• the duration of hospitalization– of study drugs in this population.<br>• the Sequential Organ Failure Assessment (SOFA)– of study drugs in this population.<br>• the mortality rate– of study drugs in this population.<br>• the remission of respiratory symptoms– of study drugs in this population in terms of:<br>      -Time to invasive mechanical ventilation;<br>      -Time to independence from oxygen therapy.<br>• the radiological response– of study drugs in this population.<br>• the severe acute respiratory syndrome (SARS)-coronavirus (CoV)-2 negativization– of study drugs in this population.<br>•the change in laboratory parameters– of study drugs in this population.<br>•To evaluate the safety and tolerability of study drugs in this population.;Main Objective: To assess the efficacy –as determined by the proportion of patients with normalization of SpO2 =96%– of continued standard care together with tocilizumab plus pembrolizumab (MK-3475) in patients with COVID-19 pneumonia who are nonresponsive to frontline therapy within 48 hours from treatment initiation.", "study_type": "Interventional clinical trial of medicinal product", "time": "2020-04-13", "weburl": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001160-28"}, "type": "Feature"}, {"geometry": {"coordinates": [-3.736683, 40.455432], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "mireia.arcas@fjd.es", "contactPhone": "+00349155048003214", "dateEnrollment": "09/04/2020", "description": "Clinical trial to assess the efficacy and safety of cyclosporin A treatment associated with standard treatment versus standard treatment only in hospitalized patients with confirmed coronavirus infection", "name": "EUCTR2020-001262-11-ES", "primaryOutcome": "Main Objective: To assess the efficacy of the association of CsA with standard treatment in reducing the severity of COVID19-confirmed infection in hospitalized patients.;Secondary Objective: -To assess the efficacy of CsA in combination with standard treatment in reducing mortality, days in hospital, days in ICU beds, and FiO2.<br>- Compare the evolution of BP, plasma creatinine, lymphocyte count, lymphocyte activation markers and CD4 between both groups.<br>- To evaluate the safety of the association of CsA with the standard treatment of hospitalized patients with confirmed infection by COVID19.<br>- To study the possible differences in the modification in the viral load and the seroconversion parameters (IgM and IgG to the virus) throughout the process in both groups.<br>-To assess the incidence of the use of CsA in combination with standard treatment in the reduction of ferritin, LDH and PCR levels from admission, in the CPK and D-dimer peak, in the KL6 peak and in IL6 levels at the same time. throughout evolution.<br>- Evaluate the relationship between CsA doses (mean in mg / kg / day and accumulated) and improvement parameters.;Primary end point(s): Proportion of patients in a non-serious category at 12 days of treatment;Timepoint(s) of evaluation of this end point: At 12 days of treatment", "study_type": "Interventional clinical trial of medicinal product", "time": "2020-04-13", "weburl": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001262-11"}, "type": "Feature"}, {"geometry": {"coordinates": [2.218156, 41.412768], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "aaldea@imim.es", "contactPhone": "+34933160490", "dateEnrollment": "11/04/2020", "description": "Efficacy and safety of sarilumab in the early treament of hospitalized patients with mild-moderate neumonia and COVID19 infection versus standard of care", "name": "EUCTR2020-001290-74-ES", "primaryOutcome": "Main Objective: To assess the efficacy and safety of early treatment of sarilumab, added to standard treatment, in patients hospitalized for mild-moderate COVID-19 pneumonia, with criteria of a CURB 65 less than or equal to 1, oxygen saturation equal to or greater than 90%, MEWS less than 3 and with IL6 greater than 20 pg / mL.;Secondary Objective: To evaluate:<br>-Clinical status of patients on days 7 and 14 later than the treatment initiation.<br>-Proportion of patients discharged on day 14<br>-28-day mortality rate<br>-Proportion of patients who required mechanical ventilation and days of duration<br>-Days of hospital stay of patients who have survived to 28 days<br>-Time since start of treatment to death of the patient<br>-Possible serious adverse events related to sarilumab and possible causes of discontinuation of sarilumab treatment<br>to analyze:<br>-type of medications received during admission and days since onset of symptoms to starting glucocorticoids<br>-the evolution of prognostic factors: IL6, D-dimer, ferritin, calprotectin;Timepoint(s) of evaluation of this end point: 28 days;Primary end point(s): Time to clinical improvement, defined as the time from randomization to a two-point improvement (from randomization status) on an ordinal scale of seven categories or hospital discharge, whichever occurs first.<br><br>The seven-category ordinal scale consisted of the following categories: 1, not hospitalized with resumption of normal activities; 2, not hospitalized, but unable to resume normal activities; 3, hospitalized, not requiring supplemental oxygen; 4, hospitalized, requiring supplemental oxygen; 5, hospitalized, requiring nasal high-flow oxygen therapy, noninvasive mechanical ventilation, or both; 6, hospitalized, requiring ECMO, invasive mechanical ventilation, or both; and 7, death.", "study_type": "Interventional clinical trial of medicinal product", "time": "2020-04-13", "weburl": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001290-74"}, "type": "Feature"}, {"geometry": {"coordinates": [3.84948, 43.630201], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "depotAC@chu-montpellier.fr", "contactPhone": "00330608492834", "dateEnrollment": "07/04/2020", "description": "efficacy and safety of a bitherapy by hydroxychloroquine + azythromycin vs monotherapy by hydroxychoroquine in adult patients with documentated infection by covid19", "name": "EUCTR2020-001406-27-FR", "primaryOutcome": "Timepoint(s) of evaluation of this end point: D11;Primary end point(s): At least 1 level improvement in clinical status assessed by a level ordinal scale (at least 1 level) between D1 and D11 :<br>1. Not hospitalized, no limitation of activities<br>2. Not hospitalized, limitation of activities;<br>3. Hospitalized, not requiring oxygen supplementation<br>4. Hospitalized, requiring oxygen supplementation<br>5. Hospitalized, non-invasive ventilation or high flow oxygen device<br>6. Hospitalized, under invasive mechanical ventilation or ECMO (extracorporeal membrane oxygenation)<br>7. Death;Secondary Objective: - Evaluation of the safety  of  a bitherapy  by hydroxychloroquine + azythromycin vs  monotherapy by hydroxychoroquine<br>- Need of oxygenotherapy<br>- virological, and pharmacokinetic assessment of each treatment<br>-PAtient transfer in ICU.<br>- hospitalization duration<br>Vital status<br>Adverses event;Main Objective: Evaluation of efficacy of a bitherapy  by hydroxychloroquine + azythromycin vs  monotherapy by hydroxychoroquine administered for 10 days, on patient infected with SarS COV 2 with either a moderate clinical form (level 3), or a severe non-resuscitative clinical form (level 4)", "study_type": "Interventional clinical trial of medicinal product", "time": "2020-04-03", "weburl": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001406-27"}, "type": "Feature"}, {"geometry": {"coordinates": [4.816037, 45.777302], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "drci_promo@chu-lyon.fr", "contactPhone": "472406829+33", "dateEnrollment": "13/04/2020", "description": "Corticoïdes au cours de la pneumonie virale Covid-19 liée à l’infection par le SARS-Cov-2", "name": "EUCTR2020-001553-48-FR", "primaryOutcome": "Main Objective: Réduire le nombre de patients présentant une indication théorique de transfert en réanimation d’indication respiratoire, évaluée par une SpO2 < 90% stabilisée au repos et sous un débit d’oxygène ne dépassant pas 5 L/min d’oxygène au masque à moyenne concentration à J7 de la randomisation (soit J14 des symptômes ±5 jours). Ce critère permet de déterminer objectivement la gravité de l’état respiratoire du patient.;Secondary Objective: Evalués à la visite 3, J7 de la randomisation (soit J14 des symptômes ±2jours) : <br>-\tRéduire la gravité sur une échelle ordinale à 7 niveaux <br>-\tRéduire les besoins en oxygénothérapie<br>-\tRéduire les signes radiologiques visibles sur l’imagerie thoracique<br><br>Evalués à la visite 4, J21 de la randomisation (soit J28 des symptômes ±2jours) : <br>-\tRéduire le nombre de patients transférés en réanimation ou soins intensifs<br>-\tRéduire le nombre de patients nécessitant un recours à la ventilation invasive<br>-\tRéduire la durée de l’oxygénothérapie<br>-\tRéduire la durée d’hospitalisation à partir de la randomisation<br>-\tEvaluer la tolérance de la corticothérapie et la fréquence des complications induites par la corticothérapie<br>-\tEvaluer la fréquence des infections autres que SARS-CoV-2<br>-\tEvaluer la mortalité globale à J21 (J28 des symptômes)<br>;Primary end point(s): Nombre de patients à J7 de la randomisation (soit J14 des symptômes ±5 jours), présentant une indication théorique de transfert en réanimation d’indication respiratoire évaluée par une SpO2 < 90% stabilisée au repos et sous 5 L/min d’oxygène au masque à moyenne concentration mesurée deux fois à 5-15 min d’intervalle. La valeur moyenne des deux mesures sera retenue.;Timepoint(s) of evaluation of this end point: J14 des symptômes ±5 jours", "study_type": "Interventional clinical trial of medicinal product", "time": "2020-04-03", "weburl": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001553-48"}, "type": "Feature"}, {"geometry": {"coordinates": [-0.572464, 47.497946], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "justine.gonsard@chu-angers.fr", "contactPhone": "0241356329", "dateEnrollment": "10/04/2020", "description": "COvid-19 and Vitamin D supplementation: a multicenter randomized controlled Trial of high dose versus standard dose vitamin D3 in high-risk COVID-19 patients", "name": "EUCTR2020-001602-34-FR", "primaryOutcome": "Main Objective: Evaluer l’efficacité d’une forte dose de cholecalciferol 400 000 UI per os en une fois versus une dose standard de 50 000 UI per os en une fois sur le taux de décès à 14 jours (J14) chez les patients âgés ayant ;Secondary Objective: 1) Evaluer l’efficacité de la forte dose de cholecalciferol versus la dose standard sur : <br>2) Evaluer la tolérance de la forte dose de cholecalciferol versus la dose standard sur la survenue d’évènements indésirables graves<br>3) Evaluer l’efficacité de la forte dose de cholecalciferol versus la dose standard dans le sous-groupe des participants ayant une hypovitaminose D sévère à l’inclusion, c’est-à-dire ayant une concentration sérique de 25-OHD <25 nmol/L à J1<br>4) Evaluer l’impact de la concentration sérique de 25-hydroxyvitamine D à J7 (< 75 nmol/L versus = 75 nmol/L) sur le taux de décès à J14 et J28 et l’évolution clinique (échelle OSCI) à J14 et J28 <br>5) Dans le sous-groupe des participants présentant une hypovitaminose D sévère initiale (25-OHD <25 nmol/L à J1), comparer le taux de décès et l’évolution clinique (échelle OSCI) à J14 et J28 en fonction de la concentration sérique de 25-OHD atteinte à J7 (< 75 nmol/L versus = 75 nmol/L).<br>;Primary end point(s): Le critère d’évaluation principal est la survenue d’un décès quelle qu’en soit la cause dans les 14 jours (J14) suivant l’inclusion et le début du traitement (J1).;Timepoint(s) of evaluation of this end point: Le critère d’évaluation principal est la survenue d’un décès quelle qu’en soit la cause dans les 14 jours (J14) suivant l’inclusion et le début du traitement (J1).", "study_type": "Interventional clinical trial of medicinal product", "time": "2020-04-03", "weburl": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001602-34"}, "type": "Feature"}, {"geometry": {"coordinates": [-3.817975, 40.287084], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "fernando.bermejo@salud.madrid.org", "contactPhone": "34916006000", "dateEnrollment": "11/04/2020", "description": "Clinical trial phase II to evaluate the efficacy of  3 types of treatment in patients with pneumonia by COVID-19", "name": "EUCTR2020-001321-31-ES", "primaryOutcome": "Timepoint(s) of evaluation of this end point: Baseline, 7 days during treatment, day 14, day 35+/-5 and day 70+/-5;Primary end point(s): 8.1 Demographics<br>Age<br>Sex<br>Tobacco<br>Alcohol<br>Significant comorbidity<br>- HTA<br>- Cardiovascular disease<br>- DM<br>- COPD<br>- Cancer<br>- Chronic liver disease<br>- I kidney<br>- Known immunosuppression<br><br>8.2 Laboratory parameters<br>COVID BIOMARKERS<br>- PCR<br>- Procalcitonin<br>- LDH<br>- Dimero D<br>-\tFerritin<br>- IL6<br>BIOCHEMICAL PARAMETERS<br>- Enzymatic creatinine<br>- ALT<br>- AST<br>- Bilirubin<br>- GGT<br>- F Alkaline<br>- Albumine<br>- Venous lactate<br>- Ultrasensitive Troponin I<br>- Creatin Kinasa (CK)<br><br>HEMATOLOGICAL PARAMETERS<br>- White Series<br>- Leukocytes (in absolute value)<br>- Neutrophils (in absolute value)<br>- Lymphocytes (in absolute value)<br>- Neutrophil / lymphocyte ratio<br>- Platelet / lymphocyte ratio<br>- Red Series<br>- erythrocytes<br>- Hb<br>- Platelets<br>- Coagulation<br>- Fibrinogen<br>- Coagulation Study<br><br>MICROBIOLOGICAL PARAMETERS<br>- SARS-Cov2 PCR in nasopharyngeal exudate<br><br>8.3 Radiodiagnosis<br>- Unilateral, unilobar, bilobar pneumonia ...<br>- Bilateral pneumonia<br>- Resolution infiltrators<br>- Infiltration resolution days<br>- Stabilization<br>- Radiological progression<br><br>8.4 Clinical variables<br>- Symptom onset days<br>- Days resolution symptoms<br>- Fever days<br>- Respiratory improvement (days)<br>- Temperature (<38.4 / 38.4-39.4 /> 39.4) * From The The Hscore11<br>- Organomegaly (No, liver or spleen, both) * From The Hscore11<br>-\tFever<br>-\tDry cough<br>- productive cough<br>- Hemoptysis<br>- dyspnea<br>- Asthenia<br>- Myalgia<br>- headache<br>- nausea<br>Vomiting<br>-\tDiarrhea<br>- Abdominal discomfort<br>- ARDS<br>- I cardiac<br>- FRA<br>- SHOCK<br>- death<br>- Secondary infection<br>- O2 saturation levels.<br>- Need O2, nasal goggles, liters VM non-invasive reservoir Intubation<br><br>8.5 Clinical management variables<br>-\tHospital stay<br>- ICU admission<br>- No. of registrations;Secondary Objective: To assess the safety (serious adverse effects, premature discontinuation of treatment), tolerability and secondary efficacy parameters of the 3 treatment guidelines, understood as: absence of progression to respiratory failure, absence of increased O2 requirements; need for mechanical ventilation; reduction of analytical parameters associated with poor prognosis; radiological progression of the disease on day + 7 of starting treatment; average hospital stay, intensification treatments, such as steroid boluses and tocilizumab, ICU admission,% mortality at the end of follow-up.<br>In addition, in those patients who consent and participate in an additional sub-study, possible biomarkers and genetic markers of susceptibility to SARS-CoV-2 will be evaluated using high-performance techniques with serum DNA from the participants.;Main Objective: To compare and evaluate the efficacy of 3 treatment regimens (Hydroxychloroquine in combination with baricitinib, imatinib or lopinavir / ritonavir) in SARS-CoV-2 patients with severe pneumonia requiring admission, considering primary efficacy as time to clinical improvement.", "study_type": "Interventional clinical trial of medicinal product", "time": "2020-04-13", "weburl": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001321-31"}, "type": "Feature"}, {"geometry": {"coordinates": [2.134866, 41.404801], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "fgarcia@clinic.cat", "contactPhone": "+349322754002884", "dateEnrollment": "07/04/2020", "description": "Efficacy and safety of siltuximab vs. corticosteroids in hospitalized patients with COVID-19 pneumonia", "name": "EUCTR2020-001413-20-ES", "primaryOutcome": "Main Objective: To assess the efficacy of siltuximab vs corticosteroids in hospitalized patients with COVID19 pneumonia by evaluating the number of admissions in the unit intensive care (ICU);Secondary Objective: -Stay in the ICU<br>-Time to resolution of fever for at least 48 hours, without administration of antipyretics<br>-Incidence of worsening in the oxygen therapy requirement <br>-Duration of supplemental oxygen dependence<br>-Incidence of the use of mechanical ventilation <br>-Duration of the use of mechanical ventilation <br>-Time to start of mechanical ventilation, non-invasive ventilation<br>or use of high flow nasal cannula<br>-Days of hospitalization <br>-Mortality rate at 29 days<br>-Incidence of SAEs <br>-Incidence of invasive bacterial or fungal infections or opportunistic with grade 4 neutropenia<br>-Incidence of invasive bacterial or fungal infections or opportunistic <br>-Incidence of hypersensitivity reactions or reactions grade 2 related to the infusion<br>-Incidence of GI perforations <br>-Incidence of new serious secondary infections or worsening of existing infections <br>-Changes in leukocytes, Hb, platelets, creatinine, bilirubin, ALT<br>-Changes in inflammatory biomarkers<br>-Changes in chest X-ray;Timepoint(s) of evaluation of this end point: 29 days;Primary end point(s): Proportion of patients requiring ICU admission at any time within the study period.", "study_type": "Interventional clinical trial of medicinal product", "time": "2020-04-13", "weburl": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001413-20"}, "type": "Feature"}, {"geometry": {"coordinates": [2.136829, 41.429156], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "", "contactPhone": "0034934893000", "dateEnrollment": "09/04/2020", "description": "Random, controlled, open, one-site clinical trial in adult patients with COVID-19 severe pneumonia treated with immunomodulatory drugs", "name": "EUCTR2020-001437-12-ES", "primaryOutcome": "Main Objective: To assess the mortality impact at 28 days of an immunomodulatory strategy with 2 treatment regimens stratified according to IL-6 plasma levels, administered in addition to standard treatment, in adult patients with severe COVID-19 pneumonia.;Secondary Objective: To assess the impact of this strategy on the following variables: premature mortality (48 hours, 7 days and at hospital), mortality at intensive care unit, days of mechanical ventilation, virus clearance (viral clearance / viral shedding), time to normalization of oxygen saturation , time to defervescence, improvement of inflammatory reaction, days of hospitalization, days of intubation, safety and tolerability of the intervention;Primary end point(s): Mortality at day 28 after treatment initiation  (proportion of patient died that day);Timepoint(s) of evaluation of this end point: Day 28 after treatment initiation", "study_type": "Interventional clinical trial of medicinal product", "time": "2020-04-13", "weburl": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001437-12"}, "type": "Feature"}, {"geometry": {"coordinates": [-3.705716, 40.499053], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "alberto.borobia@salud.madrid.org", "contactPhone": "34912071466", "dateEnrollment": "09/04/2020", "description": "Clinical trial to avoid infection by SARS-CoV-2 in high-risk population. COVID-19", "name": "EUCTR2020-001530-35-ES", "primaryOutcome": "Timepoint(s) of evaluation of this end point: 16 weeks;Primary end point(s): Number of symptomatic infections confirmed by SARS-CoV-2 (COVID-19);Secondary Objective: o Evaluate the efficacy of melatonin in the prevention of asymptomatic SARS-CoV-2 infections (COVID-19).<br>o To evaluate the efficacy of melatonin in preventing the development of severe COVID-19 in participants who acquire the infection during the development of the study.<br>o Assess the duration of symptoms of COVID-19 infection in participants receiving melatonin.<br>o Assess IgM / IgG seroconversion from symptom detection;Main Objective: The main objective is to evaluate the efficacy of melatonin in the prevention of SARS-CoV-2 infection in healthcare personnel with high-risk contacts.", "study_type": "Interventional clinical trial of medicinal product", "time": "2020-04-13", "weburl": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001530-35"}, "type": "Feature"}, {"geometry": {"coordinates": [2.137043, 41.406346], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "clara.menendez@isglobal.org", "contactPhone": "", "dateEnrollment": "08/04/2020", "description": "Preventing SARS-CoV-2 virus infection and severity of COVID-19 diseases during pregnancy with hydroxychloroquine", "name": "EUCTR2020-001587-29-ES", "primaryOutcome": "Timepoint(s) of evaluation of this end point: Day 14 after treatment initiation;Primary end point(s): - The mean reduction in viral load at day 14 after recruitment among those women infected by SARS-CoV-2, in the ITT and ATP cohorts, adjusted by age, gravidity, region(municipality) and other variables associated with the prevalence and viral load of SARS-CoV-2 infection. <br>- The comparison of the proportion of pregnant women who were close contacts of confirmed cases of SARS-CoV-2 infection, with a positive PCR for the infection at day 14, in the ITT and ATP cohorts, adjusted by adjusted by age, gravidity, region(municipality) and other variables associated with the prevalence of SARS-CoV-2 infection.;Secondary Objective: 1.\tTo determine the impact of HCQ on the clinical course and duration of the COVID-19 disease <br>2.\tTo evaluate the effect of HCQ in avoiding the development of the COVID-19 disease in asymptomatic-infected women<br>3.\tTo determine the safety and tolerability of HCQ in pregnant women <br>4.\tTo describe the clinical presentation of SARS-CoV-2 and the effects on pregnancy outcomes <br>5.\tTo determine the risk of vertical transmission (intra-utero and intra-partum) of SARS-CoV-2;Main Objective: 1.\tTo assess the effect of HCQ in reducing maternal viral load  <br>2.\tTo asses the efficacy of HCQ to prevent incident SARS-CoV-2 infection", "study_type": "Interventional clinical trial of medicinal product", "time": "2020-04-13", "weburl": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001587-29"}, "type": "Feature"}, {"geometry": {"coordinates": [-3.677925, 40.434081], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "mariadelrosario.garcia@salud.madrid.org", "contactPhone": "0034915202473", "dateEnrollment": "09/04/2020", "description": "Randomized open pilot study to evaluate the efficacy of subcutaneous sarilumab in patients with moderate-severe COVID-19 infection.", "name": "EUCTR2020-001634-36-ES", "primaryOutcome": "Main Objective: -To evaluate the efficacy of the early administration of sarilumab subcutaneously in patients with moderate-severe COVID-19 infection in early stages compared to the current treatment standard.<br>-To compare the baseline clinical and biological parameters, including serum IL-6, of the intervention population against historical controls, to search for possible markers that identify candidates for treatment with subcutaneous IL-6 inhibitors and attempt an approximation to the time frame of “window of opportunity”.;Secondary Objective: Not applicable;Primary end point(s): - Time to become afebrile for a minimum period of 48 hours, without antipyretics<br>- Average change in the ordinal scale of 7 points from the inclusion in the study until day 7 (after randomization):<br>1. Death<br>2. Hospitalized, with mechanical ventilation or extracorporeal membrane oxygenation (ECMO).<br>3. Hospitalized, with non-invasive mechanical ventilation, a mask with a reservoir or oxygen with high flow nasal goggles.<br>4. Hospitalized with oxygen supplement<br>5. Hospitalized, without oxygen supplement, but in need of continued medical care (related or not with COVID)<br>6. Hospitalized, without oxygen supplement and without the need for continued medical care<br>7. Not hospitalized<br>- Duration of hospitalization (days)<br>- Death<br>;Timepoint(s) of evaluation of this end point: The expected duration of subject participation in the trial is until resolution of the COVID-19 infection pattern, approximately 1 month. The overall duration of the study is estimated to be about 2 months, from the recruitment of the first patient to the end of the follow-up of the last patient included. The duration can be shortened if the current rate of income is maintained for at least one month.", "study_type": "Interventional clinical trial of medicinal product", "time": "2020-04-13", "weburl": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001634-36"}, "type": "Feature"}, {"geometry": {"coordinates": [-73.580168, 45.573731], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "alberto.borobia@salud.madrid.org", "contactPhone": "34912071466", "dateEnrollment": "11/04/2020", "description": "COLCHICINA TEST IN THE SARS-COV2 CORONAVIRUS (COLCORONA-COVID-19)", "name": "EUCTR2020-001689-12-ES", "primaryOutcome": "Main Objective: The main objective of this study is to determine if short-term treatment with colchicine reduces the mortality rate and lung complications related to COVID-19.;Secondary Objective: The secondary objective is to determine the safety of colchicine treatment in this patient population.;Primary end point(s): The primary endpoint will be a composite endpoint of death or need for hospitalization from COVID-19 infection within 30 days of randomization.;Timepoint(s) of evaluation of this end point: 30 days", "study_type": "Interventional clinical trial of medicinal product", "time": "2020-04-13", "weburl": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001689-12"}, "type": "Feature"}, {"geometry": {"coordinates": [2.148484, 41.400399], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "mgarciamartin@iconcologia.net", "contactPhone": "0034932607331", "dateEnrollment": "11/04/2020", "description": "Pragmatic clinical trial of hydroxychloroquine in the treatment of oncohematological patients and health professionals with COVID-19 infection without radiological alteration.", "name": "EUCTR2020-001765-37-ES", "primaryOutcome": "Main Objective: To determine the efficacy of hydroxychloroquine in the treatment of SARS-COV2 infection in oncohaematological patients without radiological alteration and SARS-COV2 positive professionals without radiological alteration.;Secondary Objective: Evaluate the toxicity profile of the treatment.;Primary end point(s): Percentage of patients (cohort A) and professionals (cohort B) who achieve control of the disease without symptoms in 14 days, assessed by chest radiography without pneumonia.;Timepoint(s) of evaluation of this end point: 14 days after treatment initiation", "study_type": "Interventional clinical trial of medicinal product", "time": "2020-04-13", "weburl": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001765-37"}, "type": "Feature"}, {"geometry": {"coordinates": [0.138539, 52.175101], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "ccturegulatory@addenbrookes.nhs.uk", "contactPhone": "01223348158", "dateEnrollment": "14/04/2020", "description": "Preventative Drug Treatment for COVID-19 Infectious Disease", "name": "EUCTR2020-001331-26-GB", "primaryOutcome": "Timepoint(s) of evaluation of this end point: Weekly over approximately 90 days;Primary end point(s): Time to positive COVID-19 disease <br>;Secondary Objective: •\tTo determine whether giving hydroxychloroquine daily versus weekly decreases time to COVID-19 disease in healthy frontline healthcare workers<br>•\tTo compare the number of confirmed COVID-19 cases between each group on the basis of different testing methods<br>•\tTo compare disease severity in each group<br>•\tTo compare recovery time in each group;Main Objective: The principle research objective is to determine whether giving the drug Hydroxychloroquine increases time to COVID-19 disease in healthy frontline healthcare workers compared to giving a placebo.", "study_type": "Interventional clinical trial of medicinal product", "time": "2020-04-14", "weburl": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001331-26"}, "type": "Feature"}, {"geometry": {"coordinates": [23.740018, 37.996919], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "insepsis@otenet.gr", "contactPhone": "+302107480662", "dateEnrollment": "15/04/2020", "description": "Prevention of severe respiratory failure in Covid-19", "name": "EUCTR2020-001466-11-GR", "primaryOutcome": "Timepoint(s) of evaluation of this end point: Day 14;Primary end point(s): This is defined on day 14 as the percentage of patients who will not experience SAIs (as defined in Annex V). Patients who die before the day 14 visit are considered to have failed at the primary endpoint.;Secondary Objective: Not applicable;Main Objective: Recent data coming from the Hellenic Sepsis Study Group reveal that suPAR levels =6 ng/ml are early found among patients who will eventually develop severe respiratory failure (SRF) by Covid-19 with positive predictive value more than 80%. This signifies that an early pro-inflammatory reaction has been started in the lung. It is postulated that early anakinra treatment in these patients may halt this reaction and prevent development of SRF.  In the SAVE study patients with sars-cov-2 infection with SARS-CoV-2 virus at high risk for progression to MSDs will be detected using the suPAR biomarker. They will begin early treatment with anakinra in the effort to prevent progression in SAA. ", "study_type": "Interventional clinical trial of medicinal product", "time": "2020-04-14", "weburl": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001466-11"}, "type": "Feature"}, {"geometry": {"coordinates": [-0.36422, 39.479535], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "gestioncientifica@incliva.es", "contactPhone": "0034961973536", "dateEnrollment": "14/04/2020", "description": "Sedation with sevoflurane versus propofol in patients with Acute Respiratory Distress Syndrome caused by COVID-19 infection", "name": "EUCTR2020-001379-34-ES", "primaryOutcome": "Timepoint(s) of evaluation of this end point: 2 days -\tPaO2/FiO2 and TNF, IL-1b, IL-6 e IL-8 día 2.;Primary end point(s): Efficacy will be assessed according to the defined objectives of oxygenation, reduction of inflammatory markers;Secondary Objective: - to quantify the effects of sevoflurane on pro-inflammatory cytokine levels during ARDS-CoVid19 <br>- evaluate the 30-day mortality.;Main Objective: To evaluate the effect of 48-hour treatment with inhaled sevoflurane on arterial oxygenation, assessed by PaO2/FiO2 on day two, in patients with ARDS-CoVid19", "study_type": "Interventional clinical trial of medicinal product", "time": "2020-04-14", "weburl": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001379-34"}, "type": "Feature"}, {"geometry": {"coordinates": [-4.70708, 41.663978], "type": "Point"}, "properties": {"classification": "Advanced therapy medicinal products", "contactEmail": "enrique.conde@efficeresearch.com", "contactPhone": "+34912948910", "dateEnrollment": "13/04/2020", "description": "Treatment of COVID-19 with allogeneic mesenchymal cells (MSV®).", "name": "EUCTR2020-001682-36-ES", "primaryOutcome": "Main Objective: Assessing the safety and efficacy of MSV-allo® in obtaining recovery from respiratory failure in patients with pneumonia due to severe / critical COVID-19 infection.;Secondary Objective: 1. Time to recover from the symptoms and clinical signs after the MSV-allo® administration<br>2. Time to reach the normalization of imaging tests, chest radiography and/or lung CT<br>3. Modification in the inflammatory response in terms of blood levels of cytokines and chemokines.<br>4. Modification in the number of leukocytes and lymphocyte populations.<br>5. Safety, tolerability and immunogenicity profiles of MSV-allo® in patients with severe COVID-19;Primary end point(s): 1. Proportion of patients in whom removal of invasive mechanical ventilation has been achieved in less than 7 days after IMP administration.<br>2. Proportion of patients surviving on day 28 from diagnosis;Timepoint(s) of evaluation of this end point: 7 days from treatment and 28 days from diagnosis", "study_type": "Interventional clinical trial of medicinal product", "time": "2020-04-14", "weburl": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001682-36"}, "type": "Feature"}, {"geometry": {"coordinates": [-1.137646, 38.000062], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "Lola.serna@carm.es", "contactPhone": "34968359763", "dateEnrollment": "14/04/2020", "description": "Randomized open-blind controlled trial to study the benefit of Colchicine in Patients with COVID-19", "name": "EUCTR2020-001511-25-ES", "primaryOutcome": "Timepoint(s) of evaluation of this end point: END OF STUDY;Primary end point(s): 1. Ordinal 7-point clinical evaluation scale (WHO R&D Blueprint expert group (31).<br>2. IL-6 concentrations, which together with the rest of the laboratory result variables will be measured together at the end of the study.;Secondary Objective: 1. Improvement of clinical status defined as time to reduction of at least 2 points on the WHO 7-point ordinal scale.<br>2. Changes in the Sequential Organ Failure Scale (SOFA,) during hospitalization and time to 50% reduction with respect to randomization.<br>3. Changes in NEWS severity scale score (33) during hospitalization and time to NEWS score =2 or 50% reduction from randomization.<br>4. Number of days in invasive mechanical ventilation or ECMO<br>5. Number of days with oxygen at high flow.<br>6. Changes of other inflammatory markers: C-reactive protein, TNF-alpha, GDF-15, IL-1ß up to 28 days with respect to randomization.<br>7. Changes in severity markers: D-dimer, leukocytes, lymphocytes, platelets, LDH and ferritin up to 28 days with respect to randomization.<br>8. Changes in markers of myocardial damage: hsTnT and NT-proBNP up to 28 days with respect to randomization.<br>9. Time to viral negative by RT-PCR<br>10. Duration in days of hospital stay<br>11. ICU income<br>12. Mortality from causes;Main Objective: To study whether the administration of colchicine, compared to a control group, improves the clinical evolution of patients and prevents the inflammatory response.<br>1. Changes in the clinical status of patients on the 7-point ordinal scale (WHO R&D Blueprint expert group) (34) at 7, 14 and 28 days:<br>2. Change in IL-6 concentrations up to 28 days.", "study_type": "Interventional clinical trial of medicinal product", "time": "2020-04-15", "weburl": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001511-25"}, "type": "Feature"}, {"geometry": {"coordinates": [-3.736683, 40.455432], "type": "Point"}, "properties": {"classification": "Advanced therapy medicinal products", "contactEmail": "mireia.arcas@fjd.es", "contactPhone": "0034915 50 48 003214", "dateEnrollment": "16/04/2020", "description": "Clinical trial of administration of MSC to patients with respiratory distress type COVID-19", "name": "EUCTR2020-001266-11-ES", "primaryOutcome": "Timepoint(s) of evaluation of this end point: Day 1, Day 3, Day 7, day 10, Third Month, Sixth Month;Primary end point(s): ?% survival at 28 days after treatment<br>? Days from the patient enters the study until the temperature normalizes: measured on Day 1, Day 3, Day 7, Day 10, 3rd month and 6th month.<br>o Normalization of the temperature defined as: reaching a body temperature between 35ºC and 37ºC<br>? Days until patient was extuted: defined as<br>(Total days with mechanical ventilation) - (Total days without mechanical ventilation) Measured on Day 1, Day 3, Day 7, Day 10, 3rd month and 6th month.<br>? Number of patients who abandoned mechanical ventilation, defined as: (Total of patients with mechanical ventilation at the time of inclusion) - (Total of patients who abandoned mechanical ventilation)<br>Measured on Day 1, Day 3, Day 7, Day 10, 3rd month and 6th month.<br>? Number of patients that go from Mechanical Ventilation to oxygen therapy: measured on Day 1, Day 3, Day 7, Day 10, 3rd month and 6th month.<br>? Duration of oxygen therapy (days), defined as: (Total days in the study) - (Total days of need for oxygen therapy). Measured on Day 1, Day 3, Day 7, Day 10, 3rd month and 6th month.<br>? Days of stay in the Intensive Care Unit: defined as (Total days in the study) - (Total days in the Intensive Care Unit).<br>? Duration of hospitalization (days): defined as (Total days in the study) - (Total days hospitalized)<br>? Oxygen saturation: measurement on Day 1, Day 3, Day 7, Day 10, 3rd month and 6th month<br>Pa PaO2 / FiO2 ratio: measurement on Day 1, Day 3, Day 7, Day 10, 3rd month, and 6th month.<br>Radi Radiological pattern on Chest Radiography: decrease in interstitial alveolar infiltrates: yes / no. Measurement on Day 1, Day 3, Day 7, Day 10, 3rd month and 6th month.<br>FA SOFA score: measured on Day 1, Day 3, Day 7, Day 10, 3rd month and 6th month.<br>? Murray score: measured on Day 1, Day 3, Day 7, Day 10, 3rd month and 6th month<br>? Analytical parameters: measured on Day 1, Day 3, Day 7, Day 10, 3rd month and 6th month<br>o Hties, Hb, Hto, VCM, Leukocytes with leukocyte formula, platelets. procalcitonin<br>o Glucose, Glycosylated Hb, urea, uric acid, creatinine, total bilirubin, direct bilirubin, sodium, potassium, calcium, chlorine, total protein, C-reactive protein, AST, ALT, GGT, Cl Cr and FG.<br>o Coagulation: prothrombin time (TP), activated partial thromboplastin time (APTT), thrombin time (TT), Fibrinogen, INR.<br>o IL-6, IL-2, DD, lactate dehydrogenase, CK (Creatin Kinase), Alkaline Phosphatase<br>o Lymphocyte population: CD4 +, CD8 + T lymphocytes, B lymphocytes, NK cells<br>or C3, C4, IgG, IgA, IgM.<br>;Secondary Objective: -To evaluate the safety of the administration of expanded allogeneic adipose tissue mesenchymal stem cells, in patients infected with SARS-COV-2 with complications like COVID-19.<br>-To evaluate preclincial variables;Main Objective: The main objective of this project is to evaluate the efficacy of the administration of expanded allogeneic adipose tissue mesenchymal stem cells, in patients infected with SARS-COV-2 with complications like COVID-19.", "study_type": "Interventional clinical trial of medicinal product", "time": "2020-04-16", "weburl": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001266-11"}, "type": "Feature"}, {"geometry": {"coordinates": [-1.931222, 52.450817], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "d.smith.6@bham.ac.uk", "contactPhone": "", "dateEnrollment": "15/04/2020", "description": "Preventing Pulmonary Complications in Surgical Patients at Risk of COVID-19", "name": "EUCTR2020-001448-24-GB", "primaryOutcome": "Timepoint(s) of evaluation of this end point: Up to 30 days following surgery;Primary end point(s): Trial outcomes will only be based on routinely available data. Patients will not undergo any additional investigations for trial purposes.<br><br>Primary outcome measure<br>The primary outcome is any one of the following COVID-19 specific, inpatient, postoperative pulmonary complications  (definitions are given in an Appendix in the protocol and through brief online training):<br>•\tPneumonia<br>•\tAcute respiratory distress syndrome (ARDS)<br>•\tDeath<br><br>Definitions for each outcome are provided in the protocol. The components of the composite outcome have all been internationally validated. The feasibility of collecting these endpoints within routine care pathways has been demonstrated by our RECON cohort (11,500 patients, 4 countries).<br><br>;Secondary Objective: To assess the effects of study treatments on:<br>-Post-operative proven COVID-19 pulmonary complications<br>-Overall SARS-CoV-2 infected rate<br>-Duration of intensive care and total hospital stay<br>-Pulmonary function in keeping with WHO Solidarity Trial outcome scale <br>-Safety and tolerability of study treatments<br><br>;Main Objective: Primary Objective<br><br>To provide reliable estimates of the effect of study treatments on postoperative pulmonary complications during the COVID-19 pandemic. ", "study_type": "Interventional clinical trial of medicinal product", "time": "2020-04-17", "weburl": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001448-24"}, "type": "Feature"}, {"geometry": {"coordinates": [3.725977, 51.025759], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "hiruz.ctu@uzgent.be", "contactPhone": "+3293320500", "dateEnrollment": "24/03/2020", "description": "Sargramostim in patients with acute hypoxic respiratory failure due to COVID-19", "name": "EUCTR2020-001254-22-BE", "primaryOutcome": "Timepoint(s) of evaluation of this end point: day 5;Primary end point(s): To measure the effectiveness of sargramostim on restoring lung homeostasis, the primary endpoint of this intervention is measuring oxygenation after 5 DAYS of inhaled (and intravenous) treatment through assessment of pretreatment (day 0) and post-treatment (day 5) ratio of PaO2/FiO2 and through measurement of the P(A-a)O2 gradient, which can easily be performed in the setting of clinical observation of patients admitted to the COVID -19 ward or ICU COVID-19 unit. Preferentially, this measurement should be done in the upright position, while breathing room air for a minimum of 3 minutes.. If this is impossible due to need for supplemental oxygen, FiO2 and oxygen supplementation method should be recorded in patient record, so that A-a gradient can be normalized for age expected normal A-a gradient while on supplemental oxygen use.<br>During the 5 day treatment period, we will perform daily measurements of oxygen saturation (pulse oximetry) in relation to FiO2, and the slope of alterations in this parameters could also be an indicator that our hypothesis is correct.<br>If the patient leaves hospital prior to the day 6 analysis point, oxygenation at day of discharge will be used as value for measuring primary endpoint.<br>;Secondary Objective: - to study if early intervention with sargramostim is safe (number of AEs/SAEs)<br>- to study if early intervention with inhaled sargramostim affects clinical outcome defined by<br>duration of hospital stay, 6-point ordinal scale, clinical sign score, SOFA score, NEWS2 score<br>- to study if early intervention with sargramostim affects the rate of nosocomial infection<br>- to study if early intervention with inhaled sargramostim affects progression to mechanical ventilation and/or ARDS<br>- to study if treatment with sargramostim affects all-cause mortality rate at 4 and 20 weeks post inclusion<br>-to study if treatment with sargramostim affects features of secondary haemophagocytic lymphohistiocytosis, defined by HS score<br>- to study if treatment with sargramostim has a favourable effect on long term 10-20 week follow up<br>;Main Objective: The primary objective is to investigate whether the administration of inhaled sargramostim (Leukine®) at a dose of 250 mcg daily during 5 days improves oxygenation in COVID-19 patients with acute hypoxic respiratory failure .", "study_type": "Interventional clinical trial of medicinal product", "time": "2020-03-24", "weburl": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001254-22"}, "type": "Feature"}, {"geometry": {"coordinates": [48.648156, 31.297338], "type": "Point"}, "properties": {"classification": "Advanced therapy medicinal products", "contactEmail": "parastoomoradi40@yahoo.com", "contactPhone": "+98 61 3373 8283", "dateEnrollment": "2641-06-14", "description": "Comparison of The Therapeutic Effect of Convalescent Plasma and Plasma-derived Immunoglobulin-enriched solution on COVID-19 Patients", "name": "IRCT20200310046736N1", "primaryOutcome": "Primary outcome: complete remission of clinical signs of disease. Timepoint: About one week after starting the treatment. Method of measurement: Clinical and laboratory questionnaire.;Negative result for COVID-19 RT-PCR test. Timepoint: About 7-14 days after starting the treatment. Method of measurement: Results of qRT-PCR test.;Normal CT Scan. Timepoint: About 7-14 days after starting the treatment. Method of measurement: Result of CT scan.", "study_type": "interventional", "time": "2020-04-01", "weburl": "http://en.irct.ir/trial/46424"}, "type": "Feature"}, {"geometry": {"coordinates": [51.390784, 35.705271], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "bahreinimaryam@gmail.com", "contactPhone": "+98 21 6312 1413", "dateEnrollment": "2020-04-05", "description": "Clinical Trial of renin-angiotensin-aldosterone system inhibitors with halting their administration and the effect on clinical outcomes of patients with corona virus disease-2019 (COVID-19) referring to Sina Hospital in 2020", "name": "IRCT20151113025025N3", "primaryOutcome": "Death. Timepoint: 3 months. Method of measurement: Number of deceased patients.", "study_type": "interventional", "time": "2020-03-29", "weburl": "http://en.irct.ir/trial/46531"}, "type": "Feature"}, {"geometry": {"coordinates": [51.375546, 35.721778], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "khalilih@tums.ac.ir", "contactPhone": "+98 21 6695 4715", "dateEnrollment": "2020-03-15", "description": "Combination therapy in COVID 19", "name": "IRCT20100228003449N30", "primaryOutcome": "Clinical response. Timepoint: Every other day. Method of measurement: Evaluation of clinical signs and symptoms.;Paraclinical response. Timepoint: Every other day. Method of measurement: Laboratory and radiological findings.;Adverse drug reactions. Timepoint: Every other day. Method of measurement: Interview and laboratory data.", "study_type": "interventional", "time": "2020-03-22", "weburl": "http://en.irct.ir/trial/46536"}, "type": "Feature"}, {"geometry": {"coordinates": [51.375546, 35.721778], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "khalilih@tums.ac.ir", "contactPhone": "0098216654715", "dateEnrollment": "2020-03-15", "description": "Interferon in treatment of COVID-19", "name": "IRCT20100228003449N28", "primaryOutcome": "Response to the treatment. Timepoint: Daily. Method of measurement: According the clinical, paraclinical and laboratory findings.;Complications of the treatment. Timepoint: Daily. Method of measurement: Interview and patient's record.", "study_type": "interventional", "time": "2020-03-19", "weburl": "http://en.irct.ir/trial/46538"}, "type": "Feature"}, {"geometry": {"coordinates": [51.375546, 35.721778], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "khalilih@tums.ac.ir", "contactPhone": "+98 21 6695 4715", "dateEnrollment": "2020-03-15", "description": "Interferon ß in treatment  of COVID-19", "name": "IRCT20100228003449N27", "primaryOutcome": "Response to the treatment. Timepoint: Daily. Method of measurement: According the clinical, paraclinical and laboratory findings.;Complications of the treatment. Timepoint: Daily. Method of measurement: Interview and patient's record.", "study_type": "interventional", "time": "2020-03-16", "weburl": "http://en.irct.ir/trial/46545"}, "type": "Feature"}, {"geometry": {"coordinates": [51.379645, 35.748989], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "jamshidi.ah@iums.ac.ir", "contactPhone": "+98 21 5563 9666", "dateEnrollment": "2020-03-16", "description": "Effect of herbal syrup and solution in treatment of COVID-19", "name": "IRCT20200316046792N1", "primaryOutcome": "Response to the treatment (Significant clinical improvement). Timepoint: At baseline and on the third, fifth, seventh, and tenth days after starting the treatment. Method of measurement: According to the clinical, paraclinical and laboratory findings. Clinical improvement: normalization of the body temperature (=37.2 ° C), respiratory rate (=24 breaths per minute), oxygen saturation (> 94% at room temperature) and cough (zero or mild) that persist for at least 24 hours. Cough will measure on a qualitative scale based on the patient's report . Other outcome variables will measure during clinical examination.;Complications of the treatment. Timepoint: Daily, until the tenth day. Method of measurement: Interview and patient's record.", "study_type": "interventional", "time": "2020-03-17", "weburl": "http://en.irct.ir/trial/46554"}, "type": "Feature"}, {"geometry": {"coordinates": [51.49655, 35.815456], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "f_dastan@sbmu.ac.ir", "contactPhone": "+98 21 2610 9490", "dateEnrollment": "2020-03-03", "description": "Evaluting the therapeutic and adverse effects of Interferon beta 1-a in patients with novel Coronavirus(COVID-19)", "name": "IRCT20151227025726N12", "primaryOutcome": "Clinical response to therapy. Timepoint: Daily. Method of measurement: Clinical symptoms.", "study_type": "interventional", "time": "2020-03-23", "weburl": "http://en.irct.ir/trial/46561"}, "type": "Feature"}, {"geometry": {"coordinates": [46.325164, 38.057393], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "znikniaz@hotmail.com", "contactPhone": "+98 41 3335 1688", "dateEnrollment": "2020-04-03", "description": "Effect of vitamin A in patients with COVID19", "name": "IRCT20170117032004N3", "primaryOutcome": "Hospitalization duration. Timepoint: until discharge from hospital. Method of measurement: Questionnaire.", "study_type": "interventional", "time": "2020-03-29", "weburl": "http://en.irct.ir/trial/46564"}, "type": "Feature"}, {"geometry": {"coordinates": [51.375546, 35.721778], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "khalilih@tums.ac.ir", "contactPhone": "+98 21 6695 4715", "dateEnrollment": "2020-03-18", "description": "?Effect of sofosbuvir/ ledipasvir on COVID-19", "name": "IRCT20100228003449N29", "primaryOutcome": "Response to the treatment (improvement of patients' chief complaint, abnormal paraclinic and radiologic findings). Timepoint: Daily. Method of measurement: According the clinical, paraclinical and laboratory findings.;Gastrointestinal complications. Timepoint: Daily. Method of measurement: Interview and patient's record.;Cutaneous complications. Timepoint: Daily. Method of measurement: Interview and patient's record.;Neurological complications. Timepoint: Daily. Method of measurement: Interview and patient's record.;Renal complications. Timepoint: Daily. Method of measurement: Interview and patient's record.;Hematological complications. Timepoint: Daily. Method of measurement: Interview and patient's record.", "study_type": "interventional", "time": "2020-03-19", "weburl": "http://en.irct.ir/trial/46567"}, "type": "Feature"}, {"geometry": {"coordinates": [46.321685, 38.05496], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "dr.ansarin@gmail.com", "contactPhone": "+98 41 3335 2898", "dateEnrollment": "2020-04-08", "description": "Effect of Camostate mesylate on the outcome of Coronavirus (COVID-19)-induced pneumonia", "name": "IRCT20200317046797N1", "primaryOutcome": "Lung symptoms. Timepoint: At baseline (before intervention) and after drug administration. Method of measurement: Lung CT scan.;Hospitalization period. Timepoint: At baseline and discharge time. Method of measurement: Counting the day.;Mortality rate. Timepoint: At baseline and discharge time. Method of measurement: Observation.;Need for intubation. Timepoint: At baseline and discharge time. Method of measurement: Observation.", "study_type": "interventional", "time": "2020-04-03", "weburl": "http://en.irct.ir/trial/46573"}, "type": "Feature"}, {"geometry": {"coordinates": [49.987709, 36.28003], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "en.aali@gmail.com", "contactPhone": "+98 28 3333 6001", "dateEnrollment": "2020-03-19", "description": "The effect of Noscapine  on clinical and pulmonary manifestations of COVID-19 patients", "name": "IRCT20160625028622N1", "primaryOutcome": "Cough. Timepoint: Daily. Method of measurement: Clinical finding.;O2 Saturation. Timepoint: daily. Method of measurement: Pulse Oximeter.;Radiographic features Findings. Timepoint: Before/After. Method of measurement: Radiography- CT SCAN.", "study_type": "interventional", "time": "2020-03-22", "weburl": "http://en.irct.ir/trial/46576"}, "type": "Feature"}, {"geometry": {"coordinates": [51.377445, 35.721913], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "pirjani@razi.tums.ac.ir", "contactPhone": "+98 21 7788 3288", "dateEnrollment": "2020-03-29", "description": "Effect of hydroxychloroquine on prevention of covid-19 virus", "name": "IRCT20120826010664N6", "primaryOutcome": "Covid-19 infection. Timepoint: One, two and three months after starting the drug. Method of measurement: Covid-19 PCR test and clinical symptoms.", "study_type": "interventional", "time": "2020-04-05", "weburl": "http://en.irct.ir/trial/46603"}, "type": "Feature"}, {"geometry": {"coordinates": [57.620933, 36.209726], "type": "Point"}, "properties": {"classification": "Impact on helpers", "contactEmail": "nheshmatifar@yahoo.com", "contactPhone": "+98 51 4401 1000", "dateEnrollment": "2020-02-28", "description": "Effect of Benson Relaxation on Quality of Life and job stress  in nurses", "name": "IRCT20131113015393N6", "primaryOutcome": "Job stress. Timepoint: Before the intervention, one month after intervention. Method of measurement: Job Stress Questionnaire Osipow.;Quality of working life. Timepoint: Before the intervention,  one month after intervention. Method of measurement: Work-Related Quality of Life questionnaire.", "study_type": "interventional", "time": "2020-03-30", "weburl": "http://en.irct.ir/trial/46609"}, "type": "Feature"}, {"geometry": {"coordinates": [51.362513, 35.764911], "type": "Point"}, "properties": {"classification": "Advanced therapy medicinal products", "contactEmail": "tavakoli.n@iums.ac.ir", "contactPhone": "+98 21 6653 9260", "dateEnrollment": "2020-03-24", "description": "The effect of stem cell transplantation in the treatment of COVID-19", "name": "IRCT20140528017891N8", "primaryOutcome": "Death. Timepoint: Up to 28 days after starting the study. Method of measurement: Patient observation and evaluation of vital signs.", "study_type": "interventional", "time": "2020-03-28", "weburl": "http://en.irct.ir/trial/46623"}, "type": "Feature"}, {"geometry": {"coordinates": [51.78173, 32.643143], "type": "Point"}, "properties": {"classification": "Other", "contactEmail": "mahdi_khozaei@yahoo.com", "contactPhone": "+98 31 3267 3139", "dateEnrollment": "2020-03-22", "description": "Remedy of human coroviruse infection with genetic nanocomposit drug", "name": "IRCT20200321046828N1", "primaryOutcome": "The treatment of patients with corona infection. In healthy subjects the CT image of the lungs signs an improvement of the corona contamination. Timepoint: At the beginning of the test, positive people are determined based on who tests and then the severity of disease is classified through fever and CT-pulmonary image. Then, after 8-10, the initial cases including fever and CT lungs, as well as general individuals, were analyzed. Method of measurement: CT scan.;Fever. Timepoint: At the beginning of the test, then 8 - 10 days after taking the new drug and ensuring efficacy. Method of measurement: Thermometers.", "study_type": "interventional", "time": "2020-03-26", "weburl": "http://en.irct.ir/trial/46624"}, "type": "Feature"}, {"geometry": {"coordinates": [53.075629, 36.749672], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "lotfdavoodi@yahoo.com", "contactPhone": "+98 11 3336 1700", "dateEnrollment": "2020-03-16", "description": "?Effect of febuxostat against coronavirus", "name": "IRCT20190727044343N1", "primaryOutcome": "CT-scan findings. Timepoint: Before the intervention and 2 weeks after the intervention. Method of measurement: CT-scan.", "study_type": "interventional", "time": "2020-04-05", "weburl": "http://en.irct.ir/trial/46629"}, "type": "Feature"}, {"geometry": {"coordinates": [46.309719, 38.07383], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "hojjatpourfathi@yahoo.com", "contactPhone": "+98 41 3336 4672", "dateEnrollment": "2020-04-03", "description": "Persian Medicine Products in Covid-19", "name": "IRCT20140617018126N2", "primaryOutcome": "Oxygen saturation. Timepoint: Clinical examination and Pulse Oximetry before starting medication and regularly during treatment. Method of measurement: Pulse Oximeter.;Respiratory Rate. Timepoint: Clinical examination before starting medication and regularly during treatment. Method of measurement: respiratory Count.", "study_type": "interventional", "time": "2020-03-29", "weburl": "http://en.irct.ir/trial/46637"}, "type": "Feature"}, {"geometry": {"coordinates": [51.377445, 35.721913], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "p-payandemehr@sina.tums.ac.ir", "contactPhone": "+98 21 6312 1413", "dateEnrollment": "2020-03-27", "description": "ReciGen for treatment of Covid-19", "name": "IRCT20150914024017N1", "primaryOutcome": "Need for intubation. Timepoint: discharge date. Method of measurement: check list based on treating clinicians judgment.;Need for ICU admission. Timepoint: discharge date. Method of measurement: check list based on treating clinicians judgment.;Hospital stay. Timepoint: discharge date. Method of measurement: checklist.", "study_type": "interventional", "time": "2020-04-03", "weburl": "http://en.irct.ir/trial/46665"}, "type": "Feature"}, {"geometry": {"coordinates": [57.104833, 30.243877], "type": "Point"}, "properties": {"classification": "Advanced therapy medicinal products", "contactEmail": "afarsinejad@kmu.ac.ir", "contactPhone": "+98 34 3132 5374", "dateEnrollment": "2020-04-04", "description": "The effect of dental pulp mesenchymal stem cells in treatment of  corona disease", "name": "IRCT20140911019125N6", "primaryOutcome": "Pulmonary Condition. Timepoint: Before intervention and 14, 28 days after intervention. Method of measurement: CT scan.;Expression of nucleic acid of virus. Timepoint: Before intervention and 14 and 28 days after intervention. Method of measurement: real time PCR.;Lymphocytes count. Timepoint: Before intervention and 14 and 28 days after intervention. Method of measurement: Flowcytometry.;Patients clinical signs. Timepoint: before intervention and 14 and 28 days after intervention. Method of measurement: Observation.", "study_type": "interventional", "time": "2020-04-04", "weburl": "http://en.irct.ir/trial/46668"}, "type": "Feature"}, {"geometry": {"coordinates": [51.378076, 35.717894], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "dr.saeed.meigooni@gmail.com", "contactPhone": "+98 21 4414 4939", "dateEnrollment": "2020-03-23", "description": "Effect of Licorice in COVID-19", "name": "IRCT20160316027081N1", "primaryOutcome": "Patient discharge. Timepoint: Daily. Method of measurement: Yes or no.;Increase or decrease of respiratory rates more than 25% of primary respiratory rate. Timepoint: Daily. Method of measurement: Respiratory rate in minute.;Myocardial Infarction or unstable angina. Timepoint: Daily. Method of measurement: Yes or no.;Rising of creatinine more than 25% primary creatinine. Timepoint: Daily. Method of measurement: milligram in deciliter.;Patient death. Timepoint: Daily. Method of measurement: Yes or no.", "study_type": "interventional", "time": "2020-03-31", "weburl": "http://en.irct.ir/trial/46678"}, "type": "Feature"}, {"geometry": {"coordinates": [51.431496, 35.806297], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "f_dastan@sbmu.ac.ir", "contactPhone": "+98 21 8820 0118", "dateEnrollment": "2020-03-11", "description": "Evaluation the Efficacy and Safety of Tocilizumab in COVID-19", "name": "IRCT20151227025726N13", "primaryOutcome": "Fever. Timepoint: Daily. Method of measurement: Thermometer.;Cough. Timepoint: Daily. Method of measurement: Observation.;Dyspnea. Timepoint: Daily. Method of measurement: Observation.", "study_type": "interventional", "time": "2020-03-26", "weburl": "http://en.irct.ir/trial/46681"}, "type": "Feature"}, {"geometry": {"coordinates": [46.309719, 38.07383], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "ghaffarys@tbzmed.ac.ir", "contactPhone": "+41 33365010", "dateEnrollment": "2020-03-20", "description": "Effect of metformin in COVID-19  symptom improvement and death", "name": "IRCT20160310026998N11", "primaryOutcome": "Decreased hospitalization period. Timepoint: at baseline and discharge time. Method of measurement: counting the day.;Mortality rate. Timepoint: at baseline and discharge time. Method of measurement: observation.;Decreased need for intubation. Timepoint: at baseline and discharge time. Method of measurement: observation.", "study_type": "interventional", "time": "2020-03-27", "weburl": "http://en.irct.ir/trial/46690"}, "type": "Feature"}, {"geometry": {"coordinates": [46.309719, 38.07383], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "ghaffarys@tbzmed.ac.ir", "contactPhone": "+98 33266042", "dateEnrollment": "2020-03-20", "description": "Study of the metformin effect on the survival and recovery rate of patients with COVID-19", "name": "IRCT20160310026998N10", "primaryOutcome": "Decreased need to hospitalization. Timepoint: 2 weeks. Method of measurement: obsevation.;Decreased mortality. Timepoint: 2 weeks. Method of measurement: observation.", "study_type": "interventional", "time": "2020-03-26", "weburl": "http://en.irct.ir/trial/46693"}, "type": "Feature"}, {"geometry": {"coordinates": [49.638961, 34.085441], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "seiedalatifi@yahoo.com", "contactPhone": "+98 86 3417 3601", "dateEnrollment": "2020-04-08", "description": "The effect of Trachyspermum copticum syrup on clinical manifestations of patients with COVID-19", "name": "IRCT20180610040049N3", "primaryOutcome": "Level of CRP in serum. Timepoint: One day before the intervention and one day after the intervention is measured. Method of measurement: Using the ELISA technique.;The rate of lung inflammation. Timepoint: One day before the intervention and one day after the intervention is measured. Method of measurement: CT SCAN.", "study_type": "interventional", "time": "2020-03-29", "weburl": "http://en.irct.ir/trial/46697"}, "type": "Feature"}, {"geometry": {"coordinates": [53.616008, 28.946211], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "dr.afazeli@gmail.com", "contactPhone": "+98 21 6647 5335", "dateEnrollment": "2020-04-01", "description": "Comparison of efficacy of oral Levamisole and  Formoterol+Budesonide inhaler with standard treatment of Corona infection.", "name": "IRCT20200324046852N1", "primaryOutcome": "Response to treatment in Lymphocytes count. Timepoint: Daily. Method of measurement: By apparatus in diagnostic lab.;Response to treatment for  COVID-19 specific PCR test. Timepoint: Days 0-3-7. Method of measurement: Using PCR apparatus.;Response to treatment in  O2 level and  CO2 level in ABG or VBG test. Timepoint: Daily. Method of measurement: By apparatus in diagnostic lab.;Chest CT-Scan response to treatment including dispersion size of Ground Glass area,  bronchitis and consolidation. Timepoint: Days 0-3-7. Method of measurement: CT scan apparatus.", "study_type": "interventional", "time": "2020-04-05", "weburl": "http://en.irct.ir/trial/46706"}, "type": "Feature"}, {"geometry": {"coordinates": [51.377445, 35.721913], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "hrkk1@uswr.ac.ir", "contactPhone": "+98 21 2218 0138", "dateEnrollment": "2020-03-28", "description": "Treatment of patients with Corona virus infection", "name": "IRCT20200324046847N1", "primaryOutcome": "Number of admission days. Timepoint: every day. Method of measurement: Number of days.;The mortality rate in COVID-19 patients. Timepoint: Everyday. Method of measurement: Number of death.;Assessment of potential side effects. Timepoint: Every day. Method of measurement: Inspection for potential side effects.", "study_type": "interventional", "time": "2020-03-31", "weburl": "http://en.irct.ir/trial/46720"}, "type": "Feature"}, {"geometry": {"coordinates": [51.364199, 35.765425], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "farbod.chitsaz@gmail.com", "contactPhone": "+98 21 8413 0001", "dateEnrollment": "2020-04-03", "description": "Evaluation of the effectiveness of Ipecac homeopathic remedy  in control of Clinical manifestations of COVID-19", "name": "IRCT20140907019073N4", "primaryOutcome": "Serum CRP. Timepoint: The first day, the second day, the third day. Method of measurement: Blood test.;Number of lymphocytes. Timepoint: The first day, the second day, the third day. Method of measurement: Blood test.;O2 arterial blood saturation. Timepoint: The first day, the second day, the third day. Method of measurement: Pulse Oximeter Report.;Myalgia. Timepoint: The first day, the second day, the third day. Method of measurement: Patient Report.;Chills. Timepoint: The first day, the second day, the third day. Method of measurement: Patient Report.;Shortness of breath. Timepoint: The first day, the second day, the third day. Method of measurement: Patient Report.;Cough. Timepoint: The first day, the second day, the third day. Method of measurement: Physician report.;Fever. Timepoint: The first day, the second day, the third day. Method of measurement: Check body temperature with thermometer.", "study_type": "interventional", "time": "2020-03-29", "weburl": "http://en.irct.ir/trial/46736"}, "type": "Feature"}, {"geometry": {"coordinates": [48.221615, 30.362829], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "S.mobarak@abadanums.ac.ir", "contactPhone": "+98 61 5326 7800", "dateEnrollment": "2020-04-19", "description": "Study of the effect of vitamin C in patients with Covid-19", "name": "IRCT20200324046850N5", "primaryOutcome": "Number of hospital days. Timepoint: Daily since hospitalization time. Method of measurement: Based on patient's file.", "study_type": "interventional", "time": "2020-04-04", "weburl": "http://en.irct.ir/trial/46751"}, "type": "Feature"}, {"geometry": {"coordinates": [51.390855, 35.753108], "type": "Point"}, "properties": {"classification": "Advanced therapy medicinal products", "contactEmail": "h.abolghasemi.ha@gmail.com", "contactPhone": "+98 21 81261", "dateEnrollment": "2020-03-15", "description": "Convalescent Plasma therapy for COVID-19 Patients", "name": "IRCT20200325046860N1", "primaryOutcome": "Improving Respiratory function of patients. Timepoint: Every 24 hours. Method of measurement: Clinical and, Para-clinical.", "study_type": "interventional", "time": "2020-03-30", "weburl": "http://en.irct.ir/trial/46759"}, "type": "Feature"}, {"geometry": {"coordinates": [57.089387, 30.260313], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "drhalehtajadini@gmail.com", "contactPhone": "+98 34 3243 5539", "dateEnrollment": "2020-03-24", "description": "Evaluation of  the effect of traditional  Iranian medicine product on improvement of clinical menifestation of COVID -19", "name": "IRCT20101219005416N2", "primaryOutcome": "Response to the treatment (Significant clinical improvement). Timepoint: At baseline and daily. Method of measurement: According to the clinical, paraclinical and laboratory findings. Clinical improvement: normalization of the body temperature (=37.2 ° C), respiratory rate (=24 breaths per minute), oxygen saturation (> 94% at room temperature) and cough  ; dyspnea ; headche and dirrhea that will measure on a qualitative scale based on the patient's report . Other outcome variables will measure during clinical examination.", "study_type": "interventional", "time": "2020-04-03", "weburl": "http://en.irct.ir/trial/46775"}, "type": "Feature"}, {"geometry": {"coordinates": [46.309719, 38.07383], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "dr.ansarin@gmail.com", "contactPhone": "+98 41 3335 2898", "dateEnrollment": "2020-04-08", "description": "Effect of Fingolimod for treatment of COVID-19-induced cytokine storm", "name": "IRCT20200317046797N2", "primaryOutcome": "Improvement of the symptoms of lung, pulmonary  infiltrates. Timepoint: At baseline (before intervention) and 2 day after drug administration. Method of measurement: Lung CT scan.;Decreased hospitalization period. Timepoint: At baseline and discharge time. Method of measurement: counting the hospitalization days.;Mortality rate. Timepoint: At baseline and discharge time. Method of measurement: observation.;Need for intubation. Timepoint: period of hospitalization. Method of measurement: observation or reading of  hospitalized documents.", "study_type": "interventional", "time": "2020-04-03", "weburl": "http://en.irct.ir/trial/46786"}, "type": "Feature"}, {"geometry": {"coordinates": [51.375409, 35.769544], "type": "Point"}, "properties": {"classification": "Advanced therapy medicinal products", "contactEmail": "h.abolghasemi.ha@gmail.com", "contactPhone": "+98 21 8126 3799", "dateEnrollment": "2020-03-28", "description": "Mesenchymal Stem Cell therapy in COVID19", "name": "IRCT20200325046860N2", "primaryOutcome": "Respiratory function of patients. Timepoint: Every 24 hours after MSC infusion. Method of measurement: Clinical, lab test , CT scan.", "study_type": "interventional", "time": "2020-04-01", "weburl": "http://en.irct.ir/trial/46789"}, "type": "Feature"}, {"geometry": {"coordinates": [57.089387, 30.260313], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "a.ahmadi@kmu.ac.ir", "contactPhone": "+98 34 3132 5700", "dateEnrollment": "2020-03-30", "description": "Investigating the effectiveness of psychological interventions on mental health", "name": "IRCT20170611034452N11", "primaryOutcome": "Anxiety,. Timepoint: Before the intervention, immediately after the intervention. Method of measurement: Health Anxiety Assessment Questionnaire.;Depression. Timepoint: Before the intervention, immediately after the intervention. Method of measurement: Hospital Anxiety-Depression Index Questionnaire.", "study_type": "interventional", "time": "2020-03-31", "weburl": "http://en.irct.ir/trial/46803"}, "type": "Feature"}, {"geometry": {"coordinates": [51.377007, 35.721684], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "kourosh.sadeghi@gmail.com", "contactPhone": "+98 21 8889 6696", "dateEnrollment": "2020-04-03", "description": "Effects of High-dose Vitamin C on COVID-19", "name": "IRCT20190917044805N2", "primaryOutcome": "Time to clinical improvement (TTIC). Timepoint: day 0, 5, at discharge. Method of measurement: assessing respiratory rate, blood oxygen saturation, fever.;Time to clinical improvement (TTIC) of NEWS2 (National Early Warning Score 2) of 0 maintained for 24 hours. Timepoint: day 0, 5, at discharge. Method of measurement: NEWS2 (National Early Warning Score 2) questionaire.", "study_type": "interventional", "time": "2020-03-31", "weburl": "http://en.irct.ir/trial/46804"}, "type": "Feature"}, {"geometry": {"coordinates": [54.353067, 36.837513], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "n_abdolahi2002@yahoo.com", "contactPhone": "+98 17 3225 1910", "dateEnrollment": "2020-04-18", "description": "Efficacy of dexamethasone, IV-IG and Interferone beta for treatment of patients with severe COVID-19", "name": "IRCT20120225009124N4", "primaryOutcome": "Improvement in SpO2 (increasing in level of SpO2 to levels higher than 90%). Timepoint: After finishing the intervetion. Method of measurement: By Pulse oximeter.", "study_type": "interventional", "time": "2020-04-02", "weburl": "http://en.irct.ir/trial/46810"}, "type": "Feature"}, {"geometry": {"coordinates": [46.309719, 38.07383], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "arm.sad@gmail.com", "contactPhone": "+98 41 3335 7311", "dateEnrollment": "2020-03-31", "description": "Evaluation of the effects of Losartan in patients with corona virus disease 2019", "name": "IRCT20180802040678N4", "primaryOutcome": "Mortality. Timepoint: 28 days. Method of measurement: Number of death.;Performance of patients. Timepoint: Primary and 14 days after. Method of measurement: Sequential Organ Failure Assessment (SOFA) Respiratory Score.;Length of hospitalization. Timepoint: 28 days. Method of measurement: Days between admission to discharge.;Laboratory Findings. Timepoint: Primary and 14 days after. Method of measurement: Laboratory methods.", "study_type": "interventional", "time": "2020-04-01", "weburl": "http://en.irct.ir/trial/46824"}, "type": "Feature"}, {"geometry": {"coordinates": [52.675876, 36.531184], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "masi9932002@yahoo.com", "contactPhone": "+98 11 3219 7667", "dateEnrollment": "2020-03-24", "description": "Hemoperfusion in patients with COVID-19", "name": "IRCT20150704023055N2", "primaryOutcome": "Improving the general condition of the patient. Timepoint: Before intervention and one week after the third session of hemoperfusion. Method of measurement: No need to receive any intensive respiratory care in the patient.", "study_type": "interventional", "time": "2020-04-03", "weburl": "http://en.irct.ir/trial/46837"}, "type": "Feature"}, {"geometry": {"coordinates": [51.377007, 35.721684], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "Bitarafans@gmail.com", "contactPhone": "+98 21 6694 8899", "dateEnrollment": "2020-04-02", "description": "supplementation in COVID-19", "name": "IRCT20200319046819N1", "primaryOutcome": "WBC, CRP, IL6,TNF-a, IFN-G ? ESR. Timepoint: Before and after intervention. Method of measurement: Laboratory blood test.;Intensity of pulmonary involvement. Timepoint: Before and after intervention. Method of measurement: CT scan.;Mortality. Timepoint: Before and after intervention. Method of measurement: Observation.", "study_type": "interventional", "time": "2020-04-04", "weburl": "http://en.irct.ir/trial/46838"}, "type": "Feature"}, {"geometry": {"coordinates": [139.734336, 35.601855], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "https://www.fujifilm.co.jp/form/fftc/ja/general/input.php?id=FFTCClinicalEn", "contactPhone": "", "dateEnrollment": "31/3/2020", "description": "Phase 3 Clinical Study of Favipiravir in Patients with COVID-19 Non-Severe Pneumonia", "name": "JPRN-JapicCTI-205238", "primaryOutcome": "efficacy<br>Time to alleviation of body temperature, SpO2, and chest image findings, and time to SARS-CoV-2 RT-PCR negativity.", "study_type": "INTERVENTIONAL", "time": "2020-03-27", "weburl": "https://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-205238"}, "type": "Feature"}, {"geometry": {"coordinates": [139.063592, 36.408272], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "nakamurt@gunma-u.ac.jp", "contactPhone": "+81-27-220-8740", "dateEnrollment": "14/03/2020", "description": "Favipiravir in patients infected with COVID-19", "name": "JPRN-jRCTs031190226", "primaryOutcome": "expected value and 95% CI of ratio of C-reactive protein before versus after the treatment", "study_type": "Interventional", "time": "2020-02-27", "weburl": "https://jrct.niph.go.jp/latest-detail/jRCTs031190226"}, "type": "Feature"}, {"geometry": {"coordinates": [139.615778, 35.333358], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "horitano@yokohama-cu.ac.jp", "contactPhone": "0457872800", "dateEnrollment": "2020/03/28", "description": "Risk factors of death from coronavirus disease 2019", "name": "JPRN-UMIN000039986", "primaryOutcome": "Odds ratio for death", "study_type": "Others,meta-analysis etc", "time": "2020-03-31", "weburl": "https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000045582"}, "type": "Feature"}, {"geometry": {"coordinates": [139.716235, 35.68257], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "nobuhitotaniki@keio.jp", "contactPhone": "+81-3-3353-1211", "dateEnrollment": "2020/04/17", "description": "Multicenter prospective cohort study evaluating outcome of COVID-19 in patients with hepatobiliary-pancreatic disease", "name": "JPRN-UMIN000040185", "primaryOutcome": "mortality rate", "study_type": "Observational", "time": "2020-04-17", "weburl": "https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000045820"}, "type": "Feature"}, {"geometry": {"coordinates": [139.600332, 35.349794], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "horitano@yokohama-cu.ac.jp", "contactPhone": "0457872800", "dateEnrollment": "2020/04/17", "description": "Chloroquine and hydroxychloroquine for treatment of COVID-19: systematic review of randomized and non-randomized controlled trial", "name": "JPRN-UMIN000040188", "primaryOutcome": "All cause death (odds ratio). Viral clearance on day 7", "study_type": "Others,meta-analysis etc", "time": "2020-04-17", "weburl": "https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000045825"}, "type": "Feature"}, {"geometry": {"coordinates": [32.493076, 37.990754], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "", "contactPhone": "", "dateEnrollment": "October 23, 2019", "description": "'' The Abdominal Crunch Position for COVID-19 Patients ''", "name": "NCT04092478", "primaryOutcome": "Inter spinal distance", "study_type": "Observational [Patient Registry]", "time": "2020-04-27", "weburl": "https://clinicaltrials.gov/show/NCT04092478"}, "type": "Feature"}, {"geometry": {"coordinates": [116.27643, 39.884375], "type": "Point"}, "properties": {"classification": "Advanced therapy medicinal products", "contactEmail": "shilei302@126.com;shilei302@126.com", "contactPhone": "86-10-66933333;86-10-66933333", "dateEnrollment": "January 27, 2020", "description": "Mesenchymal Stem Cell Treatment for Pneumonia Patients Infected With COVID-19", "name": "NCT04252118", "primaryOutcome": "Size of lesion area by chest radiograph or CT;Side effects in the MSCs treatment group", "study_type": "Interventional", "time": "2020-01-27", "weburl": "https://clinicaltrials.gov/show/NCT04252118"}, "type": "Feature"}, {"geometry": {"coordinates": [116.411459, 39.99044], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "", "contactPhone": "", "dateEnrollment": "February 12, 2020", "description": "A Trial of Remdesivir in Adults With Mild and Moderate COVID-19", "name": "NCT04252664", "primaryOutcome": "Time to Clinical recoveryTime to Clinical Recovery (TTCR)", "study_type": "Interventional", "time": "2020-01-31", "weburl": "https://clinicaltrials.gov/show/NCT04252664"}, "type": "Feature"}, {"geometry": {"coordinates": [116.411459, 39.99044], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "", "contactPhone": "", "dateEnrollment": "February 6, 2020", "description": "A Trial of Remdesivir in Adults With Severe COVID-19", "name": "NCT04257656", "primaryOutcome": "Time to Clinical Improvement (TTCI) [Censored at Day 28]", "study_type": "Interventional", "time": "2020-01-31", "weburl": "https://clinicaltrials.gov/show/NCT04257656"}, "type": "Feature"}, {"geometry": {"coordinates": [114.260138, 30.599908], "type": "Point"}, "properties": {"classification": "Advanced therapy medicinal products", "contactEmail": "whuhjy@sina.com", "contactPhone": "+8613554361146", "dateEnrollment": "April 20, 2020", "description": "Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Severe COVID-19", "name": "NCT04273646", "primaryOutcome": "Pneumonia severity index;Oxygenation index (PaO2/FiO2)", "study_type": "Interventional", "time": "2020-02-14", "weburl": "https://clinicaltrials.gov/show/NCT04273646"}, "type": "Feature"}, {"geometry": {"coordinates": [114.131256, 22.270108], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "", "contactPhone": "", "dateEnrollment": "February 10, 2020", "description": "Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment", "name": "NCT04276688", "primaryOutcome": "Time to negative NPS", "study_type": "Interventional", "time": "2020-02-11", "weburl": "https://clinicaltrials.gov/show/NCT04276688"}, "type": "Feature"}, {"geometry": {"coordinates": [113.933763, 35.291488], "type": "Point"}, "properties": {"classification": "Advanced therapy medicinal products", "contactEmail": "wulingzhu@xxmu.edu.cn;guomh@163.com", "contactPhone": "00863733029089;00863734402517", "dateEnrollment": "February 15, 2020", "description": "NK Cells Treatment for COVID-19", "name": "NCT04280224", "primaryOutcome": "Improvement of clinical symptoms including duration of fever;Improvement of clinical symptoms including respiratory frequency;Number of participants with treatment-related adverse events evaluated with CTCAE,version 4.0", "study_type": "Interventional", "time": "2020-02-13", "weburl": "https://clinicaltrials.gov/show/NCT04280224"}, "type": "Feature"}, {"geometry": {"coordinates": [117.214244, 36.662306], "type": "Point"}, "properties": {"classification": "Advanced therapy medicinal products", "contactEmail": ";info@TianheCell.com", "contactPhone": ";6308496657", "dateEnrollment": "May 10, 2020", "description": "Stem Cell Educator Therapy Treat the Viral Inflammation in COVID-19", "name": "NCT04299152", "primaryOutcome": "Determine the number of Covid-19 patients who were unable to complete SCE Therapy", "study_type": "Interventional", "time": "2020-02-28", "weburl": "https://clinicaltrials.gov/show/NCT04299152"}, "type": "Feature"}, {"geometry": {"coordinates": [2.334949, 48.873335], "type": "Point"}, "properties": {"classification": "Impact on helpers", "contactEmail": "pierre.hausfater@aphp.fr", "contactPhone": "33142177240", "dateEnrollment": "March 16, 2020", "description": "COVID-19 Seroconversion Among Front Line Medical and Paramedical Staff in Emergency, Intensive Care Units and Infectious Disease Departments During the 2020 Epidemic", "name": "NCT04304690", "primaryOutcome": "Quantify the proportion of patients with documented Sars-CoV2 infection among medical and paramedical staff", "study_type": "Interventional", "time": "2020-03-09", "weburl": "https://clinicaltrials.gov/show/NCT04304690"}, "type": "Feature"}, {"geometry": {"coordinates": [-99.159258, 19.292036], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": ";;;;;;;cmhcar@hotmail.com;iner.hydra@gmail.com", "contactPhone": ";;;;;;;54871700;+52 5532 590125", "dateEnrollment": "April 14, 2020", "description": "Hydroxychloroquine Treatment for Severe COVID-19 Pulmonary Infection (HYDRA Trial)", "name": "NCT04315896", "primaryOutcome": "All-cause hospital mortality", "study_type": "Interventional", "time": "2020-03-18", "weburl": "https://clinicaltrials.gov/show/NCT04315896"}, "type": "Feature"}, {"geometry": {"coordinates": [-99.17508, 19.308576], "type": "Point"}, "properties": {"classification": "Impact on helpers", "contactEmail": ";;;;;;;;lfjcamacho@comunidad.unam.mx;iner.hydra@gmail.com", "contactPhone": ";;;;;;;;+52 55871700;+52 5532 590125", "dateEnrollment": "April 14, 2020", "description": "Hydroxychloroquine Chemoprophylaxis in Healthcare Personnel in Contact With COVID-19 Patients (PHYDRA Trial)", "name": "NCT04318015", "primaryOutcome": "Symptomatic COVID-19 infection rate", "study_type": "Interventional", "time": "2020-03-19", "weburl": "https://clinicaltrials.gov/show/NCT04318015"}, "type": "Feature"}, {"geometry": {"coordinates": [11.054941, 43.890749], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": ";fbrzcantini@gmail.com;fbrzcantini@gmail.com", "contactPhone": ";+393408075607;+39 3408075607", "dateEnrollment": "May 16, 2020", "description": "Baricitinib in Symptomatic Patients Infected by COVID-19: an Open-label, Pilot Study.", "name": "NCT04320277", "primaryOutcome": "The percentage of patients requiring transfer to ICU as compared with the rate of transfers observed in controls.", "study_type": "Interventional", "time": "2020-03-20", "weburl": "https://clinicaltrials.gov/show/NCT04320277"}, "type": "Feature"}, {"geometry": {"coordinates": [121.508582, 31.325312], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "", "contactPhone": "", "dateEnrollment": "March 16, 2020", "description": "Non-contact Endoscopy at Covid-19 Outbreak", "name": "NCT04320953", "primaryOutcome": "Technical success", "study_type": "Interventional", "time": "2020-03-21", "weburl": "https://clinicaltrials.gov/show/NCT04320953"}, "type": "Feature"}, {"geometry": {"coordinates": [-79.375393, 43.722025], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": ";Attia.Qamar@unityhealth.to", "contactPhone": ";416-864-6060", "dateEnrollment": "April 17, 2020", "description": "COVID-19 Ring-based Prevention Trial With Lopinavir/Ritonavir", "name": "NCT04321174", "primaryOutcome": "Microbiologic evidence of infection", "study_type": "Interventional", "time": "2020-03-18", "weburl": "https://clinicaltrials.gov/show/NCT04321174"}, "type": "Feature"}, {"geometry": {"coordinates": [10.701302, 59.965648], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": ";;;;;;;paukrust@ous-hf.no;andreas.barrattdue@gmail.com", "contactPhone": ";;;;;;;0047 46778374;+47 98209974", "dateEnrollment": "March 28, 2020", "description": "The Efficacy of Different Anti-viral Drugs in COVID 19 Infected Patients", "name": "NCT04321616", "primaryOutcome": "In-hospital mortality", "study_type": "Interventional", "time": "2020-03-23", "weburl": "https://clinicaltrials.gov/show/NCT04321616"}, "type": "Feature"}, {"geometry": {"coordinates": [9.176549, 45.461988], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": ";;;;libertario.demi@unitn.it", "contactPhone": ";;;;00390461283942", "dateEnrollment": "April 8, 2020", "description": "Simple, Safe, Same: Lung Ultrasound for COVID-19", "name": "NCT04322487", "primaryOutcome": "Lung ultrasound grading system for COVID-19 pneumonia", "study_type": "Observational", "time": "2020-03-23", "weburl": "https://clinicaltrials.gov/show/NCT04322487"}, "type": "Feature"}, {"geometry": {"coordinates": [30.965896, 29.995509], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": ";drmtantawy@yahoo.com", "contactPhone": ";+201221865587", "dateEnrollment": "April 15, 2020", "description": "Efficacy of Natural Honey Treatment in Patients With Novel Coronavirus", "name": "NCT04323345", "primaryOutcome": "Rate of recovery from positive to negative swaps;Fever to normal temperature in days;Resolution of lung inflammation in CT or X ray", "study_type": "Interventional", "time": "2020-03-23", "weburl": "https://clinicaltrials.gov/show/NCT04323345"}, "type": "Feature"}, {"geometry": {"coordinates": [-0.147014, 51.519005], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "", "contactPhone": "", "dateEnrollment": "March 30, 2020", "description": "Viral Infection and Respiratory Illness Universal Study[VIRUS]: COVID-19 Registry", "name": "NCT04323787", "primaryOutcome": "ICU and hospital mortality of COVID-19 patients", "study_type": "Observational", "time": "2020-03-24", "weburl": "https://clinicaltrials.gov/show/NCT04323787"}, "type": "Feature"}, {"geometry": {"coordinates": [2.33598, 48.826894], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "", "contactPhone": "", "dateEnrollment": "March 27, 2020", "description": "Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - Sarilumab Trial - CORIMUNO-19 - SARI", "name": "NCT04324073", "primaryOutcome": "Survival without needs of ventilator utilization at day 14.;WHO progression scale <=5 at day 4;Cumulative incidence of successful tracheal extubation (defined as duration extubation > 48h) at day 14;WHO progression scale at day 4", "study_type": "Interventional", "time": "2020-03-25", "weburl": "https://clinicaltrials.gov/show/NCT04324073"}, "type": "Feature"}, {"geometry": {"coordinates": [13.407745, 52.537147], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "gunther.meinlschmidt@ipu-berlin.de;contact@selfapy.com", "contactPhone": "+49 30 300117;+49 (0) 30 - 3982031", "dateEnrollment": "April 8, 2020", "description": "DIgital Online SuPport for COVID-19 StrEss", "name": "NCT04324190", "primaryOutcome": "Change in Short-Form-36 (SF-36) Health Survey - Mental Health Component Summary score", "study_type": "Interventional", "time": "2020-03-26", "weburl": "https://clinicaltrials.gov/show/NCT04324190"}, "type": "Feature"}, {"geometry": {"coordinates": [-1.559599, 47.209842], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "bertrand.cariou@univ-nantes.fr;bertrand.cariou@univ-nantes.fr", "contactPhone": "02 53 48 27 06;0253482706", "dateEnrollment": "March 10, 2020", "description": "\"COVID-19 and Diabetes Outcomes\"", "name": "NCT04324736", "primaryOutcome": "Assess the prevalence of severe forms among hospitalized patients with diabètes and COVID-19", "study_type": "Observational", "time": "2020-03-25", "weburl": "https://clinicaltrials.gov/show/NCT04324736"}, "type": "Feature"}, {"geometry": {"coordinates": [34.857512, 32.022533], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": ";miri@cordio-med.com", "contactPhone": ";97235467159", "dateEnrollment": "April 2020", "description": "Clinical Evaluation of Cordio Application in Adult COVID-19 Virus Positive Patients", "name": "NCT04325048", "primaryOutcome": "Voice anaysis", "study_type": "Observational [Patient Registry]", "time": "2020-03-25", "weburl": "https://clinicaltrials.gov/show/NCT04325048"}, "type": "Feature"}, {"geometry": {"coordinates": [-15.445011, 28.119677], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": ";jesus.villar54@gmail.com", "contactPhone": ";+34606860027", "dateEnrollment": "April 3, 2020", "description": "Efficacy of Dexamethasone Treatment for Patients With ARDS Caused by COVID-19", "name": "NCT04325061", "primaryOutcome": "60-day mortality", "study_type": "Interventional", "time": "2020-03-25", "weburl": "https://clinicaltrials.gov/show/NCT04325061"}, "type": "Feature"}, {"geometry": {"coordinates": [2.334949, 48.873335], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": ";frederic.adnet@aphp.fr", "contactPhone": ";+33 1-48-96-44-08", "dateEnrollment": "April 13, 2020", "description": "Efficacy of Addition of Naproxen in the Treatment of Critically Ill Patients Hospitalized for COVID-19 Infection", "name": "NCT04325633", "primaryOutcome": "Mortality all causes at day30", "study_type": "Interventional", "time": "2020-03-26", "weburl": "https://clinicaltrials.gov/show/NCT04325633"}, "type": "Feature"}, {"geometry": {"coordinates": [-77.049725, 38.901465], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "", "contactPhone": "", "dateEnrollment": "April 13, 2020", "description": "ODYSSEY: A Study to Investigate the Efficacy of Tradipitant in Treating Severe or Critical COVID-19 Infection", "name": "NCT04326426", "primaryOutcome": "Time to improvement on a 7-point ordinal scale as compared to baseline", "study_type": "Interventional", "time": "2020-03-26", "weburl": "https://clinicaltrials.gov/show/NCT04326426"}, "type": "Feature"}, {"geometry": {"coordinates": [-122.360758, 47.77125], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": ";;ethan.berke@uhg.com;", "contactPhone": ";;603/286-0376;", "dateEnrollment": "March 25, 2020", "description": "A Longitudinal Study of COVID-19 Positive Patients Testing Nasal Swabs and Collecting Blood Samples for Research", "name": "NCT04327804", "primaryOutcome": "Detection of SARS-CoV-2 virus", "study_type": "Observational", "time": "2020-03-26", "weburl": "https://clinicaltrials.gov/show/NCT04327804"}, "type": "Feature"}, {"geometry": {"coordinates": [2.134678, 41.40588], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": ";fgarcia@clinic.cat", "contactPhone": ";+34932275400", "dateEnrollment": "April 15, 2020", "description": "Efficacy and Safety of Siltuximab vs. Corticosteroids in Hospitalized Patients With COVID-19 Pneumonia", "name": "NCT04329650", "primaryOutcome": "Proportion of patients requiring ICU admission at any time within the study period.", "study_type": "Interventional", "time": "2020-03-31", "weburl": "https://clinicaltrials.gov/show/NCT04329650"}, "type": "Feature"}, {"geometry": {"coordinates": [2.331709, 48.898845], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": ";camille.taille@aphp.fr;camille.taille@aphp.fr", "contactPhone": ";+33 1 40 25 68 63;+33 1 40 25 68 63", "dateEnrollment": "April 13, 2020", "description": "Protective Role of Inhaled Steroids for Covid-19 Infection", "name": "NCT04331054", "primaryOutcome": "Time (in days) to clinical improvement within 30 days after randomization", "study_type": "Interventional", "time": "2020-03-29", "weburl": "https://clinicaltrials.gov/show/NCT04331054"}, "type": "Feature"}, {"geometry": {"coordinates": [2.311152, 48.840308], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": ";f.denis@cjb72.org;", "contactPhone": ";241682940;", "dateEnrollment": "March 17, 2020", "description": "Epidemiological Observation From a Smartphone Self-monitoring Application for Suspected COVID-19 Patients' Triage", "name": "NCT04331171", "primaryOutcome": "To assess of the evolution of the number of calls to Emergency service within 12 days after the launch of the application https://www.maladiecoronavirus.fr/;To assess of the evolution of the proportion of relevant calls to Emergency service within 12 days after the launch of the application https://www.maladiecoronavirus.fr/", "study_type": "Observational [Patient Registry]", "time": "2020-03-30", "weburl": "https://clinicaltrials.gov/show/NCT04331171"}, "type": "Feature"}, {"geometry": {"coordinates": [11.554912, 50.926168], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": ";korinna.pilz@inflarx.de", "contactPhone": ";+49 89 4141 89 78", "dateEnrollment": "March 31, 2020", "description": "Open-label, Randomized Study of IFX-1 in Patients With Severe COVID-19 Pneumonia", "name": "NCT04333420", "primaryOutcome": "Change in PaO2/FiO2", "study_type": "Interventional", "time": "2020-04-01", "weburl": "https://clinicaltrials.gov/show/NCT04333420"}, "type": "Feature"}, {"geometry": {"coordinates": [35.314408, 32.621076], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": ";goldstein_le@clalit.org.il", "contactPhone": ";972-4-6494143", "dateEnrollment": "April 2020", "description": "Chloroquine for Mild Symptomatic and Asymptomatic COVID-19", "name": "NCT04333628", "primaryOutcome": "change in virus duration (viral shedding);change in the number of patients going from asymptomatic to moderately disease", "study_type": "Interventional", "time": "2020-04-01", "weburl": "https://clinicaltrials.gov/show/NCT04333628"}, "type": "Feature"}, {"geometry": {"coordinates": [-99.282021, 19.394606], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "ovillarob@gmail.com", "contactPhone": "(55)5246-5000", "dateEnrollment": "April 15, 2020", "description": "Treatment of SARS Caused by COVID-19 With Ruxolitinib", "name": "NCT04334044", "primaryOutcome": "Recovery of Pneumonia", "study_type": "Interventional", "time": "2020-04-01", "weburl": "https://clinicaltrials.gov/show/NCT04334044"}, "type": "Feature"}, {"geometry": {"coordinates": [28.723342, 40.990125], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "azengin@istanbul.edu.tr;azengin@istanbul.edu.tr", "contactPhone": "+902128663700;+902128663700", "dateEnrollment": "April 20, 2020", "description": "Telerehabilitation in Individuals Over 65 Years of Age Having Social Isolation Due to Coronavirus (Covid-19)", "name": "NCT04334434", "primaryOutcome": "Physical Activity Scale for the Elderly;Nottingham Health Profile;Loneliness Scale for the Elderly", "study_type": "Interventional", "time": "2020-04-02", "weburl": "https://clinicaltrials.gov/show/NCT04334434"}, "type": "Feature"}, {"geometry": {"coordinates": [10.976592, 59.949145], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "chris.inchley@gmail.com;lisebeierommen@gmail.com", "contactPhone": "90069276;", "dateEnrollment": "April 3, 2020", "description": "COVID-19 in Hospitalised Norwegian Children - Risk Factors, Outcomes and Immunology", "name": "NCT04335773", "primaryOutcome": "Risk Factors for severe infection;Immunulogical mechanisms;Long term outcome", "study_type": "Observational [Patient Registry]", "time": "2020-04-03", "weburl": "https://clinicaltrials.gov/show/NCT04335773"}, "type": "Feature"}, {"geometry": {"coordinates": [-74.45232, 40.495212], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": ";;jeffrey.carson@rutgers.edu", "contactPhone": ";;732-235-7122", "dateEnrollment": "April 7, 2020", "description": "Rutgers COVID-19 Cohort Study", "name": "NCT04336215", "primaryOutcome": "Prevalence;Incidence", "study_type": "Observational", "time": "2020-04-02", "weburl": "https://clinicaltrials.gov/show/NCT04336215"}, "type": "Feature"}, {"geometry": {"coordinates": [3.834035, 43.646637], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": ";p-amedro@chu-montpellier.fr;p-amedro@chu-montpellier.fr", "contactPhone": ";04 67 33 66 43;467336643", "dateEnrollment": "March 1, 2020", "description": "Impact of Covid-19 in Congenital Heart Disease", "name": "NCT04336384", "primaryOutcome": "Prevalence of Covid-19 infection in the overall CHD population", "study_type": "Observational", "time": "2020-03-30", "weburl": "https://clinicaltrials.gov/show/NCT04336384"}, "type": "Feature"}, {"geometry": {"coordinates": [5.515715, 50.957107], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": ";michiel.thomeer@zol.be;michiel.thomeer@zol.be", "contactPhone": ";+3289327171;+3289327171", "dateEnrollment": "April 13, 2020", "description": "Screening COVID-19 by Point-of-care Lung Ultrasound: a Validation Study", "name": "NCT04338568", "primaryOutcome": "Accuracy of the diagnosis of interstitial syndrome by lung ultrasound;Inter-observer variability", "study_type": "Interventional", "time": "2020-04-04", "weburl": "https://clinicaltrials.gov/show/NCT04338568"}, "type": "Feature"}, {"geometry": {"coordinates": [34.842634, 32.04671], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "roi.anteby@sheba.health.gov.il;roi.anteby@sheba.health.gov.il", "contactPhone": "19293011120;+972545882207", "dateEnrollment": "April 5, 2020", "description": "The Impact of the Covid-19 Outbreak on Emergency Room Attendances of Surgical Patients", "name": "NCT04338672", "primaryOutcome": "Rates of emergency visits needing surgical consult;The ratio of severe presentations to non-severe presentations", "study_type": "Observational", "time": "2020-04-04", "weburl": "https://clinicaltrials.gov/show/NCT04338672"}, "type": "Feature"}, {"geometry": {"coordinates": [-81.282072, 28.371051], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "", "contactPhone": "", "dateEnrollment": "April 7, 2020", "description": "Simulation of Risk of Adverse Drug Events Associated With the Initiation of Drugs Repurposed for the Treatment of COVID-19 in Frail Elderly Adults With Polypharmacy", "name": "NCT04339634", "primaryOutcome": "To assess and compare the effects of various repurposed drugs for COVID-19 on each of the 5 factors computed by algorithms to derive the Medication Risk Score.;To compare the impact on Medication Risk Score before and after the addition of repurposed drugs for COVID-19.;To simulate the Medication Risk Score following the addition of different repurposed drugs against COVID-19 to their current drug regimen.;To determine the Medication Risk Score of de-identified PACE's participants using their current drug regimen.", "study_type": "Observational", "time": "2020-04-07", "weburl": "https://clinicaltrials.gov/show/NCT04339634"}, "type": "Feature"}, {"geometry": {"coordinates": [4.321195, 43.823436], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": ";claire.roger@chu-nimes.fr;claire.roger@chu-nimes.fr", "contactPhone": ";0033466683050;+33466683331", "dateEnrollment": "April 3, 2020", "description": "French Multicentre Observational Study on SARS-Cov-2 Infections (COVID-19) ICU Management Study", "name": "NCT04340466", "primaryOutcome": "Mortality at day 28", "study_type": "Observational [Patient Registry]", "time": "2020-04-07", "weburl": "https://clinicaltrials.gov/show/NCT04340466"}, "type": "Feature"}, {"geometry": {"coordinates": [6.914875, 50.923482], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": ";;robert.koerner@uk-koeln.de;robert.koerner@uk-koeln.de", "contactPhone": ";;+49 221 478;+49221478", "dateEnrollment": "April 2020", "description": "Clinical and Immunological Characterisation of COVID-19 in Children, Adolescents and Adults", "name": "NCT04341168", "primaryOutcome": "Clinical course of COVID-19;Analysis of development of antibodies to SARS-CoV-2;Estimation of viral load;Detection of viral coinfections;Measurement of cytokine and chemokine response;Characterisation of virus-host-interaction;Identification of disease patterns in proteome;Analysis of change in lymphocyte subtypes;Analysis of histological changes in severe lung disease;Detection of bacterial coinfections", "study_type": "Observational", "time": "2020-04-03", "weburl": "https://clinicaltrials.gov/show/NCT04341168"}, "type": "Feature"}, {"geometry": {"coordinates": [9.039166, 48.529888], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": ";peter.rosenberger@med.uni-tuebingen.de", "contactPhone": ";+49707129", "dateEnrollment": "June 1, 2020", "description": "Early Versus Late ECMO Therapy in COVID-19 Induced ARDS (ECMO-VID)", "name": "NCT04341285", "primaryOutcome": "28 day all cause mortality", "study_type": "Interventional", "time": "2020-03-30", "weburl": "https://clinicaltrials.gov/show/NCT04341285"}, "type": "Feature"}, {"geometry": {"coordinates": [2.334949, 48.873335], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": ";xavier.mariette@aphp.fr", "contactPhone": ";145213751", "dateEnrollment": "April 2020", "description": "CORIMUNO-ANA: Trial Evaluating Efficacy Of Anakinra In Patients With Covid-19 Infection", "name": "NCT04341584", "primaryOutcome": "Survival without needs of ventilator utilization at day 14;WHO progression scale = 5;Cumulative incidence of successful tracheal extubation (defined as duration extubation > 48h) or withdrawal of NIV or high flow (for > 48h), at day 14;Decrease of at least one point in WHO progression scale score", "study_type": "Interventional", "time": "2020-04-07", "weburl": "https://clinicaltrials.gov/show/NCT04341584"}, "type": "Feature"}, {"geometry": {"coordinates": [103.843645, 1.321389], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": ";rupesh_agrawal@ttsh.com.sg", "contactPhone": ";6357100", "dateEnrollment": "April 2020", "description": "Safety And Efficacy Of Hydroxychloroquine For At Risk Population (SHARP) Against COVID-19", "name": "NCT04342156", "primaryOutcome": "positive serology or reverse transcriptase (RT-PCR) for COVID-19 up until day 28.", "study_type": "Interventional", "time": "2020-04-08", "weburl": "https://clinicaltrials.gov/show/NCT04342156"}, "type": "Feature"}, {"geometry": {"coordinates": [-111.843425, 40.764691], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": ";christina.pacchia@hsc.utah.edu;christina.pacchia@hsc.utah.edu", "contactPhone": ";8012138735;801-213-8735", "dateEnrollment": "April 14, 2020", "description": "University of Utah COVID-19 Hydrochloroquine Trial", "name": "NCT04342169", "primaryOutcome": "Duration of viral shedding", "study_type": "Interventional", "time": "2020-04-07", "weburl": "https://clinicaltrials.gov/show/NCT04342169"}, "type": "Feature"}, {"geometry": {"coordinates": [-73.94109, 40.841184], "type": "Point"}, "properties": {"classification": "Advanced therapy medicinal products", "contactEmail": ";yl4459@cumc.columbia.edu;", "contactPhone": ";2123046205;", "dateEnrollment": "March 25, 2020", "description": "Acquiring Convalescent Specimens for COVID-19 Antibodies", "name": "NCT04342195", "primaryOutcome": "Number of antibodies against coronaviruses isolated and identified from patient samples", "study_type": "Observational", "time": "2020-04-08", "weburl": "https://clinicaltrials.gov/show/NCT04342195"}, "type": "Feature"}, {"geometry": {"coordinates": [-60.032062, -2.997893], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "marcuslacerda.br@gmail.com;", "contactPhone": "+55 92 99114 7633;+5592981519122", "dateEnrollment": "April 8, 2020", "description": "Chloroquine Diphosphate in the Prevention of SARS in Covid-19 Infection", "name": "NCT04342650", "primaryOutcome": "Proportion of patients with onset of severe acute respiratory syndrome (SARS)", "study_type": "Interventional", "time": "2020-04-04", "weburl": "https://clinicaltrials.gov/show/NCT04342650"}, "type": "Feature"}, {"geometry": {"coordinates": [3.872148, 7.356942], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": ";;haleema.shakur-still@lshtm.ac.uk", "contactPhone": ";;+44 207 958 8113", "dateEnrollment": "April 2020", "description": "Coronavirus Response - Active Support for Hospitalised Covid-19 Patients", "name": "NCT04343001", "primaryOutcome": "Death", "study_type": "Interventional", "time": "2020-04-08", "weburl": "https://clinicaltrials.gov/show/NCT04343001"}, "type": "Feature"}, {"geometry": {"coordinates": [2.334949, 48.873335], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "jacques.cadranel@aphp.fr;jacques.cadranel@aphp.fr", "contactPhone": "1 56 01 66 73;01 56 01 66 73", "dateEnrollment": "April 15, 2020", "description": "Trial Evaluating Efficacy and Safety of Nivolumab (Optivo®) in Patients With COVID-19 Infection, Nested in the Corimmuno-19 Cohort.", "name": "NCT04343144", "primaryOutcome": "Time to clinical improvement", "study_type": "Interventional", "time": "2020-04-09", "weburl": "https://clinicaltrials.gov/show/NCT04343144"}, "type": "Feature"}, {"geometry": {"coordinates": [-90.147098, 29.961762], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": ";englemd94@gmail.com", "contactPhone": ";985-768-8918", "dateEnrollment": "April 2020", "description": "Hyperbaric Oxygen Therapy (HBOT) as a Treatment for COVID-19 (COVID-19) Infection", "name": "NCT04343183", "primaryOutcome": "Decrease incidence of intubation by 30% or greater", "study_type": "Interventional", "time": "2020-04-07", "weburl": "https://clinicaltrials.gov/show/NCT04343183"}, "type": "Feature"}, {"geometry": {"coordinates": [3.834035, 43.646637], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": ";h-donnadieu_rigole@chu-montpellier.fr;h-donnadieu_rigole@chu-montpellier.fr", "contactPhone": ";0467337020;0467337020", "dateEnrollment": "April 8, 2020", "description": "Evolution of Psychoactive Substances Consumption in Connection With COVID-19 Containment", "name": "NCT04343339", "primaryOutcome": "Evolution of consumption;Evolution of consumption", "study_type": "Observational", "time": "2020-04-08", "weburl": "https://clinicaltrials.gov/show/NCT04343339"}, "type": "Feature"}, {"geometry": {"coordinates": [106.844681, -6.19718], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": ";;twiga00@yahoo.com", "contactPhone": ";;+628129005599", "dateEnrollment": "April 12, 2020", "description": "Mental Health Assessment Among Community Member During the Covid-19 Pandemic in Indonesia", "name": "NCT04343664", "primaryOutcome": "Depression;Anxiety symptoms;Stress related problems;Behavior and emotional problem among children and adolescents", "study_type": "Observational [Patient Registry]", "time": "2020-04-09", "weburl": "https://clinicaltrials.gov/show/NCT04343664"}, "type": "Feature"}, {"geometry": {"coordinates": [114.2839, 36.017922], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": ";;erika.ratcliffe@duke.edu;erika.ratcliffe@duke.edu", "contactPhone": ";;919-681-5006;919-681-5006", "dateEnrollment": "April 13, 2020", "description": "COPING With COVID-19( CWC-19)", "name": "NCT04343690", "primaryOutcome": "Change in stress level as measured by survey", "study_type": "Interventional", "time": "2020-04-09", "weburl": "https://clinicaltrials.gov/show/NCT04343690"}, "type": "Feature"}, {"geometry": {"coordinates": [-74.05873, 40.884034], "type": "Point"}, "properties": {"classification": "Advanced therapy medicinal products", "contactEmail": ";Mariefel.Vendivil@HackensackMeridian.org;Mariefel.Vendivil@HackensackMeridian.org", "contactPhone": ";551-996-5828;551-996-5828", "dateEnrollment": "April 9, 2020", "description": "Convalescent Plasma as Treatment for Hospitalized Subjects With COVID-19 Infection", "name": "NCT04343755", "primaryOutcome": "For patients hospitalized for COVID-19 but not intubated;Primary objective for patients with COVID-19 already intubated", "study_type": "Interventional", "time": "2020-04-08", "weburl": "https://clinicaltrials.gov/show/NCT04343755"}, "type": "Feature"}, {"geometry": {"coordinates": [114.113622, 22.286544], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": ";cwdsiu@hku.hk;cwdsiu@hku.hk", "contactPhone": ";22554694;22554649", "dateEnrollment": "April 1, 2020", "description": "Using Biovitals® Sentinel to Monitor Disease Progression in Subjects Quarantined for Suspected COVID-19", "name": "NCT04343794", "primaryOutcome": "Time to diagnosis of COVID-19 by RT-PCR in subjects", "study_type": "Interventional", "time": "2020-02-20", "weburl": "https://clinicaltrials.gov/show/NCT04343794"}, "type": "Feature"}, {"geometry": {"coordinates": [-99.173032, 19.30559], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": ";sergio.valdesf@incmnsz.mx;sergio.valdesf@incmnsz.mx", "contactPhone": ";+525554870900;+52(55)5487-0900", "dateEnrollment": "April 4, 2020", "description": "Pyridostigmine in Severe SARS-CoV-2 Infection", "name": "NCT04343963", "primaryOutcome": "IL-6;Critical condition or death", "study_type": "Interventional", "time": "2020-04-09", "weburl": "https://clinicaltrials.gov/show/NCT04343963"}, "type": "Feature"}, {"geometry": {"coordinates": [5.497466, 43.693868], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": ";;;;;;;;rechercheclinique@ch-aix.fr;rechercheclinique@ch-aix.fr", "contactPhone": ";;;;;;;;0442335650;0442335650", "dateEnrollment": "April 1, 2020", "description": "Prone Positioning in Spontaneously Breathing Nonintubated Covid-19 Patient: a Pilot Study", "name": "NCT04344106", "primaryOutcome": "Proportion of \"responder\" patients to prone position", "study_type": "Interventional", "time": "2020-04-08", "weburl": "https://clinicaltrials.gov/show/NCT04344106"}, "type": "Feature"}, {"geometry": {"coordinates": [12.01481, 47.865789], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": ";;j.ferencz@clardata.com", "contactPhone": ";;+4917687607223", "dateEnrollment": "March 30, 2020", "description": "CovidDB: The Covid-19 Inpatient Database", "name": "NCT04344171", "primaryOutcome": "Outcome comparison between different antiviral therapies;Outcome comparisons between ventilation types;Identification of risk factors;Number of days in hospital vs. clinical classification", "study_type": "Observational", "time": "2020-04-10", "weburl": "https://clinicaltrials.gov/show/NCT04344171"}, "type": "Feature"}, {"geometry": {"coordinates": [-51.208815, -30.038611], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "", "contactPhone": "", "dateEnrollment": "April 17, 2020", "description": "Impact of Tele-interventions During the COVID-19 Pandemic in Patients With Diabetes Mellitus", "name": "NCT04344210", "primaryOutcome": "Variation in HbA1c levels", "study_type": "Interventional", "time": "2020-04-07", "weburl": "https://clinicaltrials.gov/show/NCT04344210"}, "type": "Feature"}, {"geometry": {"coordinates": [-73.974081, 40.742045], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": ";scott.rickert@nyulangone.org;scott.rickert@nyulangone.org", "contactPhone": ";646-501-7890;", "dateEnrollment": "April 9, 2020", "description": "Gargling and Nasal Rinses to Reduce Oro- and Nasopharyngeal Viral Load in Patients With COVID-19", "name": "NCT04344236", "primaryOutcome": "Viral load (and/or cycle time to PCR as a proxy for quantitative viral load) in the nasopharynx and oropharynx", "study_type": "Interventional", "time": "2020-04-08", "weburl": "https://clinicaltrials.gov/show/NCT04344236"}, "type": "Feature"}, {"geometry": {"coordinates": [-90.083655, 29.960568], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": ";jeannine.ascani@lcmchealth.org;jeannine.ascani@lcmchealth.org", "contactPhone": ";5047023141;504-702-3141", "dateEnrollment": "April 10, 2020", "description": "Treatment in Patients With Suspected or Confirmed COVID-19 With Early Moderate or Severe Disease", "name": "NCT04344444", "primaryOutcome": "Most severe outcome", "study_type": "Interventional", "time": "2020-04-10", "weburl": "https://clinicaltrials.gov/show/NCT04344444"}, "type": "Feature"}, {"geometry": {"coordinates": [-73.116976, 40.908825], "type": "Point"}, "properties": {"classification": "Advanced therapy medicinal products", "contactEmail": "", "contactPhone": "", "dateEnrollment": "April 8, 2020", "description": "Convalescent Plasma vs. Standard Plasma for COVID-19", "name": "NCT04344535", "primaryOutcome": "28 day ventilator free days", "study_type": "Interventional", "time": "2020-04-10", "weburl": "https://clinicaltrials.gov/show/NCT04344535"}, "type": "Feature"}, {"geometry": {"coordinates": [-74.096357, 4.648323], "type": "Point"}, "properties": {"classification": "Advanced therapy medicinal products", "contactEmail": "dbernal.investigacion@saluddelosandes.com;dbernal.investigacion@saluddelosandes.com", "contactPhone": "3105638254;3105638254", "dateEnrollment": "April 13, 2020", "description": "Phase I / II Clinical Study of Immunotherapy Based on Adoptive Cell Transfer as a Therapeutic Alternative for Patients With COVID-19 in Colombia", "name": "NCT04344548", "primaryOutcome": "Adverse effects and Safety", "study_type": "Interventional", "time": "2020-04-10", "weburl": "https://clinicaltrials.gov/show/NCT04344548"}, "type": "Feature"}, {"geometry": {"coordinates": [2.334949, 48.873335], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": ";jean-françois.timsit@aphp.fr;", "contactPhone": ";1 40 25 77 03;", "dateEnrollment": "April 10, 2020", "description": "Dexamethasone and Oxygen Support Strategies in ICU Patients With Covid-19 Pneumonia", "name": "NCT04344730", "primaryOutcome": "The time-to-death from all causes;The time to need for mechanical ventilation (MV)", "study_type": "Interventional", "time": "2020-04-09", "weburl": "https://clinicaltrials.gov/show/NCT04344730"}, "type": "Feature"}, {"geometry": {"coordinates": [2.234062, 48.924629], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "tristan.mirault@aphp.fr", "contactPhone": "1 56 09 50 41", "dateEnrollment": "April 20, 2020", "description": "Trial Evaluating Efficacy and Safety of Anticoagulation in Patients With COVID-19 Infection, Nested in the Corimmuno-19 Cohort", "name": "NCT04344756", "primaryOutcome": "Survival without ventilation (VNI or mechanical ventilation);ventilator free survival", "study_type": "Interventional", "time": "2020-04-09", "weburl": "https://clinicaltrials.gov/show/NCT04344756"}, "type": "Feature"}, {"geometry": {"coordinates": [2.334949, 48.873335], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "jacques.cadranel@aphp.fr", "contactPhone": "1 56 01 66 73", "dateEnrollment": "April 15, 2020", "description": "Trial Evaluating Efficacy and Safety of Bevacizumab (Avastin®/Zeribev®) in Patients With COVID-19 Infection, Nested in the Corimmuno-19 Cohort", "name": "NCT04344782", "primaryOutcome": "Proportion of surviving patients without need for intubation for respiratory support", "study_type": "Interventional", "time": "2020-04-09", "weburl": "https://clinicaltrials.gov/show/NCT04344782"}, "type": "Feature"}, {"geometry": {"coordinates": [31.149845, 27.202467], "type": "Point"}, "properties": {"classification": "Impact on helpers", "contactEmail": "", "contactPhone": "", "dateEnrollment": "May 2020", "description": "Impact of Covid-19 on Egyptian Health Care Workers and General Population Mental Health", "name": "NCT04344834", "primaryOutcome": "Depression;Anxiety;Obsessive compulsive disorder", "study_type": "Observational", "time": "2020-04-11", "weburl": "https://clinicaltrials.gov/show/NCT04344834"}, "type": "Feature"}, {"geometry": {"coordinates": [31.149845, 27.202467], "type": "Point"}, "properties": {"classification": "Impact on helpers", "contactEmail": "", "contactPhone": "", "dateEnrollment": "April 2020", "description": "Covid 19 Pandemic. Emerging Legal and Ehical Disputes Over Patient Confidentiality", "name": "NCT04344938", "primaryOutcome": "Evaluate the ethical requirement of controlled disrupts of patients In case of infectious disease pandemic", "study_type": "Observational", "time": "2020-04-10", "weburl": "https://clinicaltrials.gov/show/NCT04344938"}, "type": "Feature"}, {"geometry": {"coordinates": [-97.681425, 30.336897], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": ";leo.zorronchengtaopu@austin.org.au", "contactPhone": ";03 9496 3688", "dateEnrollment": "April 15, 2020", "description": "Endoscopy-related Phone Consultation During the COVID-19 Outbreak", "name": "NCT04344964", "primaryOutcome": "Failed to attend patients", "study_type": "Observational", "time": "2020-04-10", "weburl": "https://clinicaltrials.gov/show/NCT04344964"}, "type": "Feature"}, {"geometry": {"coordinates": [12.218868, 44.195367], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": ";giovanni.martinelli@irst.emr.it;giovanni.martinelli@irst.emr.it", "contactPhone": ";+39 0543 739100;", "dateEnrollment": "March 27, 2020", "description": "Correlative Study on Cancer Patients and Healthcare Professionals Exposed to Infection by Severe Acute Respiratory Syndrome-Corona Virus-2 (SARS-Cov-2), COVID-19 Causative Agent.", "name": "NCT04345315", "primaryOutcome": "epidemiology", "study_type": "Observational", "time": "2020-04-10", "weburl": "https://clinicaltrials.gov/show/NCT04345315"}, "type": "Feature"}, {"geometry": {"coordinates": [30.992925, 30.801502], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": ";sheriefabdelsalam@yahoo.com", "contactPhone": ";+201147773440", "dateEnrollment": "April 15, 2020", "description": "Angiotensin Converting Enzyme Inhibitors in Treatment of Covid 19", "name": "NCT04345406", "primaryOutcome": "number of patients with virological cure", "study_type": "Interventional", "time": "2020-04-11", "weburl": "https://clinicaltrials.gov/show/NCT04345406"}, "type": "Feature"}, {"geometry": {"coordinates": [101.650731, 3.113706], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "adeeba@um.edu.my;reena@um.edu.my", "contactPhone": "+603-79492050;", "dateEnrollment": "April 15, 2020", "description": "Study to Evaluate the Efficacy and Safety of Tocilizumab Versus Corticosteroids in Hospitalised COVID-19 Patients With High Risk of Progression", "name": "NCT04345445", "primaryOutcome": "The proportion of patients requiring mechanical ventilation;Mean days of ventilation", "study_type": "Interventional", "time": "2020-04-08", "weburl": "https://clinicaltrials.gov/show/NCT04345445"}, "type": "Feature"}, {"geometry": {"coordinates": [8.670772, 49.414414], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "", "contactPhone": "", "dateEnrollment": "April 20, 2020", "description": "Testing for COVID-19 Infection in Asymptomatic Persons", "name": "NCT04345510", "primaryOutcome": "COVID-19 infection", "study_type": "Observational", "time": "2020-04-12", "weburl": "https://clinicaltrials.gov/show/NCT04345510"}, "type": "Feature"}, {"geometry": {"coordinates": [-0.905557, 41.643417], "type": "Point"}, "properties": {"classification": "Advanced therapy medicinal products", "contactEmail": ";;;;;cavendano@salud.madrid.org", "contactPhone": ";;;;;+34 91 191 64 79", "dateEnrollment": "April 3, 2020", "description": "Convalescent Plasma Therapy vs. SOC for the Treatment of COVID19 in Hospitalized Patients", "name": "NCT04345523", "primaryOutcome": "Category Changes in Ordinal Scale", "study_type": "Interventional", "time": "2020-04-02", "weburl": "https://clinicaltrials.gov/show/NCT04345523"}, "type": "Feature"}, {"geometry": {"coordinates": [10.701302, 59.965648], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": ";aleksander.holten@gmail.com;", "contactPhone": ";+4799275784;", "dateEnrollment": "March 15, 2020", "description": "Prospective Quality Register of Patients With Confirmed Covid-19 at Oslo University Hospital", "name": "NCT04345536", "primaryOutcome": "Mortality;Severe disease", "study_type": "Observational [Patient Registry]", "time": "2020-04-05", "weburl": "https://clinicaltrials.gov/show/NCT04345536"}, "type": "Feature"}, {"geometry": {"coordinates": [-1.122283, 52.657991], "type": "Point"}, "properties": {"classification": "Other", "contactEmail": ";", "contactPhone": ";", "dateEnrollment": "February 26, 2020", "description": "Ayurveda Self-Management for Flu Like Symptoms During the Covid-19 Outbreak", "name": "NCT04345549", "primaryOutcome": "Time to achieve afebrile", "study_type": "Interventional", "time": "2020-04-10", "weburl": "https://clinicaltrials.gov/show/NCT04345549"}, "type": "Feature"}, {"geometry": {"coordinates": [77.163951, 28.506639], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": ";doctor.ashokchoudhury@gmail.com;doctor.ashokchoudhury@gmail.com", "contactPhone": ";01146300000;01146300000", "dateEnrollment": "April 14, 2020", "description": "The Spectrum and Profile of COVID-19 Infection and Its Impact on Liver.", "name": "NCT04345640", "primaryOutcome": "Spontaneous recovery or death in both groups", "study_type": "Observational", "time": "2020-04-10", "weburl": "https://clinicaltrials.gov/show/NCT04345640"}, "type": "Feature"}, {"geometry": {"coordinates": [28.705349, 41.008192], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": ";olcaydilken@gmail.com;olcaydilken@gmail.com", "contactPhone": ";+905547378709;+905547378709", "dateEnrollment": "April 21, 2020", "description": "Spironolactone in Covid-19 Induced ARDS", "name": "NCT04345887", "primaryOutcome": "p/f ratio", "study_type": "Interventional", "time": "2020-04-10", "weburl": "https://clinicaltrials.gov/show/NCT04345887"}, "type": "Feature"}, {"geometry": {"coordinates": [4.329302, 50.887437], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "francis.corazza@chu-brugmann.be;francis.corazza@chu-brugmann.be", "contactPhone": "024772506;32 2 477 25 06", "dateEnrollment": "March 20, 2020", "description": "Evaluation of Interleukine 6 (and Other Cytokines and Inflammatory Markers) in COVID-19 Patients With a Systemic Inflammatory Response Syndrome", "name": "NCT04346017", "primaryOutcome": "IL6 concentration;IL6 concentration change from baseline value;Complement parameters;Complement parameters change from baseline values;Inflammatory cytokines baseline concentrations;Inflammatory cytokines change from baseline values", "study_type": "Interventional", "time": "2020-04-13", "weburl": "https://clinicaltrials.gov/show/NCT04346017"}, "type": "Feature"}, {"geometry": {"coordinates": [31.28045, 30.075995], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "dr.fatma_ebeid@yahoo.com;dr.fatma_ebeid@yahoo.com", "contactPhone": "01095569596;01095569596", "dateEnrollment": "April 20, 2020", "description": "To Access the Egyptian COVID-19 Whole Genome by NGS and Compare to the International Worldwide Database", "name": "NCT04346043", "primaryOutcome": "Dominant viral genome strain", "study_type": "Observational", "time": "2020-04-13", "weburl": "https://clinicaltrials.gov/show/NCT04346043"}, "type": "Feature"}, {"geometry": {"coordinates": [31.26348, 30.092431], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": ";sarakariem@gmail.com", "contactPhone": ";01223431070", "dateEnrollment": "April 14, 2020", "description": "Retrospective Study on Severe Respiratory Illness to Access the Presence of COVID-19", "name": "NCT04346056", "primaryOutcome": "Exploring the presence of COVID-19", "study_type": "Observational", "time": "2020-04-13", "weburl": "https://clinicaltrials.gov/show/NCT04346056"}, "type": "Feature"}, {"geometry": {"coordinates": [20.148837, 46.246967], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": ";m.lanzini@unich.it", "contactPhone": ";+393703005156", "dateEnrollment": "April 14, 2020", "description": "A Study to Assess the Virus RNA, and miRNA Levels Related to Viral Infection, and Inflammatory Response in Tears of Patients Affected by COVID-19 Disease", "name": "NCT04346160", "primaryOutcome": "virus molecular analysis;host molecular analysis", "study_type": "Observational", "time": "2020-04-10", "weburl": "https://clinicaltrials.gov/show/NCT04346160"}, "type": "Feature"}, {"geometry": {"coordinates": [12.441151, 55.731226], "type": "Point"}, "properties": {"classification": "Impact on helpers", "contactEmail": ";;;;;;;;;;rasmus.bo.hasselbalch@regionh.dk", "contactPhone": ";;;;;;;;;;+4538686405", "dateEnrollment": "April 15, 2020", "description": "COVID-19: Investigation of Transmission and Immunisation Among Hospital Staff", "name": "NCT04346186", "primaryOutcome": "Positive IgM/IgG tests;Positive IgM/IgG tests;Positive IgM/IgG tests;Comparison of the point of care test and Elisa;Comparison of the point of care test and Elisa;Comparison of the point of care test and Elisa;Re-infection rate;Re-infection rate;IgM/IgG positive participants on follow-up test;IgM/IgG positive participants on follow-up test", "study_type": "Observational", "time": "2020-04-11", "weburl": "https://clinicaltrials.gov/show/NCT04346186"}, "type": "Feature"}, {"geometry": {"coordinates": [15.469102, 47.08024], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "", "contactPhone": "", "dateEnrollment": "April 27, 2020", "description": "CoVid-19 - Infection and Antibody Formation in the Viennese Population", "name": "NCT04346264", "primaryOutcome": "Prevalence of SARS-CoV-2 antibody titres", "study_type": "Observational", "time": "2020-04-13", "weburl": "https://clinicaltrials.gov/show/NCT04346264"}, "type": "Feature"}, {"geometry": {"coordinates": [9.249509, 45.521418], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "dagna.lorenzo@unisr.it", "contactPhone": "+39-02-26434683", "dateEnrollment": "April 27, 2020", "description": "Compassionate Use Open-Label Anti-CD14 Treatment in Patients With SARS-CoV-2 (COVID-19)", "name": "NCT04346277", "primaryOutcome": "", "study_type": "Expanded Access", "time": "2020-04-13", "weburl": "https://clinicaltrials.gov/show/NCT04346277"}, "type": "Feature"}, {"geometry": {"coordinates": [-74.084601, 4.636005], "type": "Point"}, "properties": {"classification": "Impact on helpers", "contactEmail": "", "contactPhone": "", "dateEnrollment": "April 20, 2020", "description": "Immune Monitoring of Prophylactic Effect of Hydroxychloroquine in Healthcare Providers Highly Exposed to COVID-19", "name": "NCT04346329", "primaryOutcome": "Adverse effects", "study_type": "Interventional", "time": "2020-04-10", "weburl": "https://clinicaltrials.gov/show/NCT04346329"}, "type": "Feature"}, {"geometry": {"coordinates": [4.957021, 52.293896], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": ";;;;;;m.botta@amsterdamumc.nl;m.botta@amsterdamumc.nl", "contactPhone": ";;;;;;+31-20-5664432;", "dateEnrollment": "March 6, 2020", "description": "PRactice of VENTilation in COVID-19 Patients (PRoVENT-COVID)", "name": "NCT04346342", "primaryOutcome": "Ventilation Mode;Tidal volume set;Expiratory tidal volume;Positive end-expiratory pressure;Maximum airway pressure or plateau pressure (Pplateau) or peak pressure (Ppeak) (cm H2O);;Level of pressure support above PEEP;Inspired fraction of oxygen;Set and measured respiratory rate;Inspiration to expiration ratio", "study_type": "Observational", "time": "2020-04-09", "weburl": "https://clinicaltrials.gov/show/NCT04346342"}, "type": "Feature"}, {"geometry": {"coordinates": [113.246406, 23.12866], "type": "Point"}, "properties": {"classification": "Advanced therapy medicinal products", "contactEmail": "lishiyue@188.com;lishiyue@188.com", "contactPhone": "86-20-83062885;86-20-83062885", "dateEnrollment": "April 2020", "description": "Bone Marrow-Derived Mesenchymal Stem Cell Treatment for Severe Patients With Coronavirus Disease 2019 (COVID-19)", "name": "NCT04346368", "primaryOutcome": "Changes of oxygenation index (PaO2/FiO2);Side effects in the BM-MSCs treatment group", "study_type": "Interventional", "time": "2020-03-23", "weburl": "https://clinicaltrials.gov/show/NCT04346368"}, "type": "Feature"}, {"geometry": {"coordinates": [2.168476, 48.838714], "type": "Point"}, "properties": {"classification": "Impact on helpers", "contactEmail": "hakim.harkouk@aphp.fr", "contactPhone": "0033149095422", "dateEnrollment": "April 15, 2020", "description": "Burnout Among Caregivers Facing COVID-19 Health Crisis at a Non-conventional Intensive Care Unit Compared to a Conventional Intensive Care Unit", "name": "NCT04346810", "primaryOutcome": "Stress in a recovery room transformed into an intensive care unit versus a conventional intensive care unit", "study_type": "Observational", "time": "2020-04-08", "weburl": "https://clinicaltrials.gov/show/NCT04346810"}, "type": "Feature"}, {"geometry": {"coordinates": [28.902855, 41.014532], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "", "contactPhone": "", "dateEnrollment": "April 10, 2020", "description": "Telerehabilitation for Patients Diagnosed With Coronavirus", "name": "NCT04346927", "primaryOutcome": "Visual Analogue Scale;Modified Borg Scale;Leicester Cough Questionnaire;Timed Up and Go;30 Second Chair Stand Test;The Beck Depression Inventory;The Beck Anxiety Inventory", "study_type": "Interventional", "time": "2020-04-13", "weburl": "https://clinicaltrials.gov/show/NCT04346927"}, "type": "Feature"}, {"geometry": {"coordinates": [28.88741, 41.030968], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "", "contactPhone": "", "dateEnrollment": "April 20, 2020", "description": "Video-Based Exercise for Individuals With Social Isolation Due to Coronavirus (COVID-19)", "name": "NCT04346953", "primaryOutcome": "International Physical Activity Questionnaire - Short Form;Nottingham Health Profile;Beck Depression Inventory;Beck Anxiety Inventory;Pittsburgh Sleep Quality Index;Timed Get Up and Go Test;Flamingo Balance Test", "study_type": "Interventional", "time": "2020-04-13", "weburl": "https://clinicaltrials.gov/show/NCT04346953"}, "type": "Feature"}, {"geometry": {"coordinates": [3.834035, 43.646637], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": ";r-martinezalejos@chu-montpellier.fr;r-martinezalejos@chu-montpellier.fr", "contactPhone": ";677952556;", "dateEnrollment": "April 1, 2017", "description": "Implementation of Physiotherapy on COVID-19 Patients in ICU", "name": "NCT04347070", "primaryOutcome": "Time of physiotherapy;Time of physiotherapy;Time of physiotherapy", "study_type": "Observational", "time": "2020-04-10", "weburl": "https://clinicaltrials.gov/show/NCT04347070"}, "type": "Feature"}, {"geometry": {"coordinates": [106.437961, 29.522796], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "sunjg09@aliyun.com;sunjg09@aliyun.com", "contactPhone": "023-68774490;", "dateEnrollment": "January 17, 2020", "description": "A Retrospective Study of Neural Network Model to Dynamically Quantificate the Severity in COVID-19 Disease", "name": "NCT04347369", "primaryOutcome": "discrimination;Calibration;Net benefit", "study_type": "Observational", "time": "2020-03-18", "weburl": "https://clinicaltrials.gov/show/NCT04347369"}, "type": "Feature"}, {"geometry": {"coordinates": [11.599705, 48.137598], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": ";christoph.schmaderer@mri.tum.de;christoph.schmaderer@mri.tum.de", "contactPhone": ";0049-89-4140;0049-89-4140", "dateEnrollment": "March 27, 2020", "description": "Establishing a COVID-19 Prospective Cohort for Identification of Secondary HLH", "name": "NCT04347460", "primaryOutcome": "Presence of sHLH as determined by expert chart review by two independent reviewers;Determine the incidence of patients fulfilling HLH criteria in Covid 19 viral infection;Determine the incidence of patients fulfilling modified 2004 HLH diagnostic criteria (Ferritin > 10000 µg/L) in Covid 19 viral infection;Characterization and incidence of the hyper-inflammatory state in COVID-19", "study_type": "Observational", "time": "2020-04-08", "weburl": "https://clinicaltrials.gov/show/NCT04347460"}, "type": "Feature"}, {"geometry": {"coordinates": [3.834035, 43.646637], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": ";e-tuaillon@chu-montpellier.fr;e-tuaillon@chu-montpellier.fr", "contactPhone": ";467 338 469;467 338 469", "dateEnrollment": "February 1, 2020", "description": "A Cohort of Patients With Possible or Confirmed SARS-CoV-2 (COVID-19)", "name": "NCT04347850", "primaryOutcome": "Number of confirmed COVID-19", "study_type": "Observational", "time": "2020-04-09", "weburl": "https://clinicaltrials.gov/show/NCT04347850"}, "type": "Feature"}, {"geometry": {"coordinates": [31.149845, 27.202467], "type": "Point"}, "properties": {"classification": "Other", "contactEmail": "aliaehussein@gmail.com", "contactPhone": "+201222302352", "dateEnrollment": "April 11, 2020", "description": "Outcome of COVID-19 Cases Based on Tuberculin Test: Can Previous BCG Alter the Prognosis?", "name": "NCT04347876", "primaryOutcome": "Pneumonia severity index;Need for ICU admission", "study_type": "Observational", "time": "2020-04-14", "weburl": "https://clinicaltrials.gov/show/NCT04347876"}, "type": "Feature"}, {"geometry": {"coordinates": [-73.132421, 40.925261], "type": "Point"}, "properties": {"classification": "Impact on helpers", "contactEmail": "", "contactPhone": "", "dateEnrollment": "April 20, 2020", "description": "Preventing COVID-19 in Healthcare Workers With HCQ: A RCT", "name": "NCT04347889", "primaryOutcome": "COVID-19 Seroconversion rate", "study_type": "Interventional", "time": "2020-04-13", "weburl": "https://clinicaltrials.gov/show/NCT04347889"}, "type": "Feature"}, {"geometry": {"coordinates": [-9.08322, 53.292955], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "bairbre.nimhaille@hse.ie", "contactPhone": "353838624777", "dateEnrollment": "April 11, 2020", "description": "Awake Prone Positioning to Reduce Invasive VEntilation in COVID-19 Induced Acute Respiratory failurE", "name": "NCT04347941", "primaryOutcome": "The effect of prone positioning on requirement for invasive mechanical ventilation in patients with COVID 19 induced respiratory failure.", "study_type": "Interventional", "time": "2020-04-08", "weburl": "https://clinicaltrials.gov/show/NCT04347941"}, "type": "Feature"}, {"geometry": {"coordinates": [2.273011, 48.784291], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": ";f.stephan@hml.fr;f.stephan@hml.fr", "contactPhone": ";33140948580;0140948580", "dateEnrollment": "April 2020", "description": "Dexamethasone Treatment for Severe Acute Respiratory Distress Syndrome Induced by COVID-19", "name": "NCT04347980", "primaryOutcome": "Day-28 mortality", "study_type": "Interventional", "time": "2020-04-09", "weburl": "https://clinicaltrials.gov/show/NCT04347980"}, "type": "Feature"}, {"geometry": {"coordinates": [10.831577, 35.770332], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "", "contactPhone": "", "dateEnrollment": "January 1, 2019", "description": "How COVID-19 Virus Outbreak Affects Antimicrobial Resistance in a Low-middle-income Country's ICU?", "name": "NCT04348227", "primaryOutcome": "MDR pathogens in endotracheal aspirates", "study_type": "Observational [Patient Registry]", "time": "2020-04-10", "weburl": "https://clinicaltrials.gov/show/NCT04348227"}, "type": "Feature"}, {"geometry": {"coordinates": [-1.164716, 37.932657], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "jmoraled@um.es", "contactPhone": "+34 968369532", "dateEnrollment": "April 8, 2020", "description": "Defibrotide as Prevention and Treatment of Respiratory Distress and Cytokine Release Syndrome of Covid 19.", "name": "NCT04348383", "primaryOutcome": "1. Mortality rate", "study_type": "Interventional", "time": "2020-04-08", "weburl": "https://clinicaltrials.gov/show/NCT04348383"}, "type": "Feature"}, {"geometry": {"coordinates": [13.510233, 43.623364], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "s.bustacchini@inrca.it;a.cherubini@inrca.it", "contactPhone": "00390718004613;00390718003537", "dateEnrollment": "April 2020", "description": "Clinical and Biological Predictors of COVID-19 Disease in Older Patients", "name": "NCT04348396", "primaryOutcome": "Descriptive-epidemiological analysis of health conditions", "study_type": "Observational", "time": "2020-04-10", "weburl": "https://clinicaltrials.gov/show/NCT04348396"}, "type": "Feature"}, {"geometry": {"coordinates": [34.837229, 31.966053], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": ";efratishai@outlook.com", "contactPhone": ";972549212866", "dateEnrollment": "April 20, 2020", "description": "Evaluating the Immune Response for COVID-19", "name": "NCT04348422", "primaryOutcome": "Proportion of symptomatic patients with immune response (IgM/IgG/IgA);Proportion of Asymptomatic patients with immune response (IgM/IgG/IgA)", "study_type": "Observational", "time": "2020-04-13", "weburl": "https://clinicaltrials.gov/show/NCT04348422"}, "type": "Feature"}, {"geometry": {"coordinates": [12.579014, 44.040462], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "", "contactPhone": "", "dateEnrollment": "April 2020", "description": "Observational Study, Use of Canakinumab Administered Subcutaneously in the Treatment COVID-19 Pneumonia", "name": "NCT04348448", "primaryOutcome": "intensive care treatment", "study_type": "Observational", "time": "2020-04-13", "weburl": "https://clinicaltrials.gov/show/NCT04348448"}, "type": "Feature"}, {"geometry": {"coordinates": [-3.736683, 40.455432], "type": "Point"}, "properties": {"classification": "Advanced therapy medicinal products", "contactEmail": "barbara.soria@quironsalud.es", "contactPhone": "0034 915 50 48 00", "dateEnrollment": "April 6, 2020", "description": "BAttLe Against COVID-19 Using MesenchYmal Stromal Cells", "name": "NCT04348461", "primaryOutcome": "Efficacy of the administration of allogeneic mesenchymal stem cells derived from adipose tissue assessed by Survival Rate);Safety of the administration of allogeneic mesenchymal stem cells derived from adipose tissue assessed by Adverse Event Rate", "study_type": "Interventional", "time": "2020-04-10", "weburl": "https://clinicaltrials.gov/show/NCT04348461"}, "type": "Feature"}, {"geometry": {"coordinates": [-3.666938, 40.490158], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "jgarciadonas@gmail.com;jgarciadonas@gmail.com", "contactPhone": "+34 666383649;+34 666383649", "dateEnrollment": "April 12, 2020", "description": "Study of Ruxolitinib Plus Simvastatin in the Prevention and Treatment of Respiratory Failure of COVID-19.", "name": "NCT04348695", "primaryOutcome": "Percentage of patients who develop severe respiratory failure.", "study_type": "Interventional", "time": "2020-04-13", "weburl": "https://clinicaltrials.gov/show/NCT04348695"}, "type": "Feature"}, {"geometry": {"coordinates": [-104.991138, 39.880929], "type": "Point"}, "properties": {"classification": "Diagnosis", "contactEmail": ";COVID19study@protonmail.com;covid19study@protonmail.com", "contactPhone": ";7204313495;720-431-3495", "dateEnrollment": "April 16, 2020", "description": "COVID-19 Antibody Self-testing Using Virtual Point-of-care", "name": "NCT04348864", "primaryOutcome": "Clinical accuracy of the antibody-based rapid tests compared to PCR-based test result;Clinical accuracy of the rapid tests based on Clinical diagnosis;Self-test interpretation of result vs expert clinical image interpretation of result", "study_type": "Interventional", "time": "2020-04-13", "weburl": "https://clinicaltrials.gov/show/NCT04348864"}, "type": "Feature"}, {"geometry": {"coordinates": [31.267473, 30.093454], "type": "Point"}, "properties": {"classification": "Advanced therapy medicinal products", "contactEmail": "", "contactPhone": "", "dateEnrollment": "April 20, 2020", "description": "Plasma Rich Antibodies From Recovered Patients From COVID19", "name": "NCT04348877", "primaryOutcome": "viral COVID-19 clearance", "study_type": "Interventional", "time": "2020-04-13", "weburl": "https://clinicaltrials.gov/show/NCT04348877"}, "type": "Feature"}, {"geometry": {"coordinates": [31.265005, 30.092431], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": ";drhdabbous@gmail.com;dr.fatma_ebeid@yahoo.com", "contactPhone": ";01001798313;01095569596", "dateEnrollment": "April 20, 2020", "description": "Efficacy and Safety of Favipiravir in Management of COVID-19", "name": "NCT04349241", "primaryOutcome": "Viral clearance;Clinical improvement", "study_type": "Interventional", "time": "2020-04-13", "weburl": "https://clinicaltrials.gov/show/NCT04349241"}, "type": "Feature"}, {"geometry": {"coordinates": [-73.956535, 40.85762], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": ";ada20@cumc.columbia.edu;ada20@cumc.columbia.edu", "contactPhone": ";212-305-0856;212-305-0856", "dateEnrollment": "April 2020", "description": "Saved From COVID-19", "name": "NCT04349371", "primaryOutcome": "Number of symptomatic illness in at risk healthcare workers;Number of healthcare workers with symptomatic COVID infections;Number of severe illness in at risk healthcare workers", "study_type": "Interventional", "time": "2020-04-12", "weburl": "https://clinicaltrials.gov/show/NCT04349371"}, "type": "Feature"}, {"geometry": {"coordinates": [-73.967637, 40.766366], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "", "contactPhone": "", "dateEnrollment": "April 11, 2020", "description": "The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol", "name": "NCT04349410", "primaryOutcome": "Improvement in FMTVDM Measurement with nuclear imaging.", "study_type": "Interventional", "time": "2020-04-11", "weburl": "https://clinicaltrials.gov/show/NCT04349410"}, "type": "Feature"}, {"geometry": {"coordinates": [3.08924, 45.7592], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "j-christophe.richard@chu-lyon.fr", "contactPhone": "04 26 10 92 72", "dateEnrollment": "April 14, 2020", "description": "Ultraprotective Ventilation Without Extracorporeal Circulation During COVID 19 Pneumonia", "name": "NCT04349618", "primaryOutcome": "A composite score based on all-cause mortality and the number of ventilator free-days (VFD)", "study_type": "Interventional", "time": "2020-04-08", "weburl": "https://clinicaltrials.gov/show/NCT04349618"}, "type": "Feature"}, {"geometry": {"coordinates": [15.464377, 47.079741], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "martin.rief@medunigraz.at;", "contactPhone": "(+43)0316-385;", "dateEnrollment": "April 8, 2020", "description": "ICU Trial in Critical Ill COVID-19 Patients", "name": "NCT04349982", "primaryOutcome": "ICU CV risk and Biomarker (e.g. Troponin)", "study_type": "Observational [Patient Registry]", "time": "2020-04-10", "weburl": "https://clinicaltrials.gov/show/NCT04349982"}, "type": "Feature"}, {"geometry": {"coordinates": [1.233524, 45.812311], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "Paul-Antoine.QUESNEL@chu-limoges.fr;Paul-Antoine.QUESNEL@chu-limoges.fr", "contactPhone": "+33 (0) 555 056 613;+33 (0) 555 056 613", "dateEnrollment": "April 20, 2020", "description": "Use of Dexmedetomidine in Light to Moderate Sedation in the Patient in the Palliative Situation of a Sars-cov-2 / COVID-19 Infection", "name": "NCT04350086", "primaryOutcome": "Efficacy of mild to moderate palliative sedation induced by Dexmedetomidine.", "study_type": "Interventional", "time": "2020-04-13", "weburl": "https://clinicaltrials.gov/show/NCT04350086"}, "type": "Feature"}, {"geometry": {"coordinates": [1.239059, 45.815309], "type": "Point"}, "properties": {"classification": "Impact on helpers", "contactEmail": "alfauchais@orange.fr", "contactPhone": "0555051640", "dateEnrollment": "April 15, 2020", "description": "Emotional Burden of Healthcare Professionals and Covid Infection 19", "name": "NCT04350099", "primaryOutcome": "anxiety;anxiety;anxiety;anxiety", "study_type": "Observational", "time": "2020-04-11", "weburl": "https://clinicaltrials.gov/show/NCT04350099"}, "type": "Feature"}, {"geometry": {"coordinates": [114.113622, 22.286544], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": ";ivanhung@hku.hk;ivanhung@hku.hk", "contactPhone": ";22554049;22554049", "dateEnrollment": "April 9, 2020", "description": "Double Therapy With IFN-beta 1b and Hydroxychloroquine", "name": "NCT04350281", "primaryOutcome": "Time to negative NPS viral load", "study_type": "Interventional", "time": "2020-04-13", "weburl": "https://clinicaltrials.gov/show/NCT04350281"}, "type": "Feature"}, {"geometry": {"coordinates": [51.416051, 35.822734], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": ";;;;", "contactPhone": ";;;;", "dateEnrollment": "April 15, 2020", "description": "Interferon Beta 1a in Hospitalized COVID-19 Patients", "name": "NCT04350671", "primaryOutcome": "Time to clinical improvement", "study_type": "Interventional", "time": "2020-04-14", "weburl": "https://clinicaltrials.gov/show/NCT04350671"}, "type": "Feature"}, {"geometry": {"coordinates": [51.416051, 35.822734], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": ";;;;;;;", "contactPhone": ";;;;;;;", "dateEnrollment": "April 15, 2020", "description": "Umifenovir in Hospitalized COVID-19 Patients", "name": "NCT04350684", "primaryOutcome": "Time to clinical improvement", "study_type": "Interventional", "time": "2020-04-14", "weburl": "https://clinicaltrials.gov/show/NCT04350684"}, "type": "Feature"}, {"geometry": {"coordinates": [31.267473, 30.093454], "type": "Point"}, "properties": {"classification": "Impact on helpers", "contactEmail": "dr.imangalal@gmail.com;dr.fatma_ebeid@yahoo.com", "contactPhone": "01001502179;01095569596", "dateEnrollment": "April 20, 2020", "description": "Application of BCG Vaccine for Immune-prophylaxis Among Egyptian Healthcare Workers During the Pandemic of COVID-19", "name": "NCT04350931", "primaryOutcome": "incidence of confirmed COVID-19;Effectiveness of BCG vaccine", "study_type": "Interventional", "time": "2020-04-13", "weburl": "https://clinicaltrials.gov/show/NCT04350931"}, "type": "Feature"}, {"geometry": {"coordinates": [30.999118, 30.801502], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": ";sheriefabdelsalam@yahoo.com", "contactPhone": ";00201147773440", "dateEnrollment": "April 17, 2020", "description": "Efficacy of Faviprevir in COVID-19 Treatment", "name": "NCT04351295", "primaryOutcome": "Number of patients with viral cure", "study_type": "Interventional", "time": "2020-04-15", "weburl": "https://clinicaltrials.gov/show/NCT04351295"}, "type": "Feature"}, {"geometry": {"coordinates": [3.019009, 50.627336], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": ";david.seguy@chru-lille.fr", "contactPhone": ";0320444850", "dateEnrollment": "April 2020", "description": "Impact of Zinc and Vitamin D3 Supplementation on the Survival of Aged Patients Infected With COVID-19", "name": "NCT04351490", "primaryOutcome": "Survival rate in asymptomatic subjects at inclusion", "study_type": "Interventional", "time": "2020-04-14", "weburl": "https://clinicaltrials.gov/show/NCT04351490"}, "type": "Feature"}, {"geometry": {"coordinates": [13.029146, 47.809267], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": ";d.wolkersdorfer@agmt.at;", "contactPhone": ";+43 662 6404411;", "dateEnrollment": "April 1, 2020", "description": "Austrian COVID-19 Registry", "name": "NCT04351529", "primaryOutcome": "Documentation of natural course and the therapeutic landscape of patients with COVID-19.", "study_type": "Observational [Patient Registry]", "time": "2020-04-16", "weburl": "https://clinicaltrials.gov/show/NCT04351529"}, "type": "Feature"}, {"geometry": {"coordinates": [-1.139956, 52.674324], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": ";", "contactPhone": ";", "dateEnrollment": "March 6, 2020", "description": "Ayurveda for Flu Like Illness During Covid-19 Outbreak", "name": "NCT04351542", "primaryOutcome": "Time to achieve afebrile;Severity of symptom score", "study_type": "Interventional", "time": "2020-04-14", "weburl": "https://clinicaltrials.gov/show/NCT04351542"}, "type": "Feature"}, {"geometry": {"coordinates": [-87.598713, 41.788797], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": ";rjan@medicine.bsd.uchicago.edu;rjan@medicine.bsd.uchicago.edu", "contactPhone": ";734-972-7953;734-972-7953", "dateEnrollment": "April 2020", "description": "High-dose Hydroxychloroquine for the Treatment of Ambulatory Patients With Mild COVID-19", "name": "NCT04351620", "primaryOutcome": "Tolerability of high dose HCQ as measured by HCQ dose modification;Tolerability of high dose HCQ as measured by discontinuation of HCQ;Tolerability of High Dose HCQ as measured by Adverse Events", "study_type": "Interventional", "time": "2020-04-14", "weburl": "https://clinicaltrials.gov/show/NCT04351620"}, "type": "Feature"}, {"geometry": {"coordinates": [-0.176469, 51.426314], "type": "Point"}, "properties": {"classification": "Diagnosis", "contactEmail": "tim.planche@nhs.net;tim.planche@nhs.net", "contactPhone": "02087252683;02087252683", "dateEnrollment": "April 15, 2020", "description": "Diagnostics of COVID-19/DARTS (Development and Assessment of Rapid Testing for SARS-CoV-2 Outbreak)", "name": "NCT04351646", "primaryOutcome": "Antibody titres to SARS-CoV-2;Antibody titres to SARS-CoV-2;Antibody titres to SARS-CoV-2;Antibody titres to SARS-CoV-2;Antibody titres to SARS-CoV-2;Antibody titres to SARS-CoV-2;Antibody titres to SARS-CoV-2", "study_type": "Observational", "time": "2020-04-07", "weburl": "https://clinicaltrials.gov/show/NCT04351646"}, "type": "Feature"}, {"geometry": {"coordinates": [103.780987, 1.293728], "type": "Point"}, "properties": {"classification": "Advanced therapy medicinal products", "contactEmail": ";childhoodcancer@kkh.com.sg", "contactPhone": ";82487085", "dateEnrollment": "April 2020", "description": "Novel Adoptive Cellular Therapy With SARS-CoV-2 Specific T Cells in Patients With Severe COVID-19", "name": "NCT04351659", "primaryOutcome": "Success rate in production of SARS-CoV-2 specific T cells from convalescent donor", "study_type": "Observational", "time": "2020-04-16", "weburl": "https://clinicaltrials.gov/show/NCT04351659"}, "type": "Feature"}, {"geometry": {"coordinates": [4.304149, 43.839389], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": ";pierre.corbeau@chu-nimes.fr;drc@chu-nimes.fr", "contactPhone": ";06.07.23.16.35;04.66.68.42.36", "dateEnrollment": "April 2020", "description": "Immunological Profiling of Patients With COVID-19 in Respiratory Distress", "name": "NCT04351711", "primaryOutcome": "Membrane expression of Human Leukocyte Antigen -DR isotype compared to normal values (based on 150 healthy volunteers previously sampled);Membrane expression of cluster of differentiation 38 compared to normal values (based on 150 healthy volunteers previously sampled);Membrane expression of Programmed cell death 1 protein compared to normal values (based on 150 healthy volunteers previously sampled);Membrane expression of cluster of differentiation 45RA compared to normal values (based on 150 healthy volunteers previously sampled);Membrane expression of cluster of differentiation 27 (naïve/central memory/effector memory) compared to normal values (based on 150 healthy volunteers previously sampled);Membrane expression of CD57 on T CD4+ and T CD8+ cells compared to normal values (based on 150 healthy volunteers previously sampled);Membrane expression of cluster of differentiation 27 on T CD4+ and T CD8+ cells compared to normal values (based on 150 healthy volunteers previously sampled);Membrane expression of cluster of differentiation 28 on T CD4+ and T CD8+ cells compared to normal values (based on 150 healthy volunteers previously sampled);Membrane expression of Human Leukocyte Antigen -DR isotype on Naturel Killer cells compared to normal values (based on 150 healthy volunteers previously sampled);Membrane expression of cluster of differentiation 69 on Naturel Killer cells compared to normal values (based on 150 healthy volunteers previously sampled);Membrane expression of cluster of differentiation 56 on Naturel Killer cells compared to normal values (based on 150 healthy volunteers previously sampled);Membrane expression of cluster of differentiation 57 on Naturel Killer cells compared to normal values (based on 150 healthy volunteers previously sampled);Membrane expression of cluster of differentiation 14 on Naturel Killer cells compared to normal values (based on 150 healthy volunteers previously sampled);Membrane expression of cluster of differentiation 16 on Naturel Killer cells compared to normal values (based on 150 healthy volunteers previously sampled);Number of regulatory T cells (CD4+CD25hiCD127loFoxP3+).;Percentage of regulatory T cells (CD4+CD25hiCD127loFoxP3+).;Rate of circulating Immunoglobulin A compared to normal values (based on 150 healthy volunteers previously sampled);Rate of circulating Immunoglobulin G compared to normal values (based on 150 healthy volunteers previously sampled);Rate of circulating Immunoglobulin M compared to normal values (based on 150 healthy volunteers previously sampled);Rate of circulating Soluble cluster of differentiation 14 compared to normal values (based on 150 healthy volunteers previously sampled);Rate of circulating Soluble cluster of differentiation 163 compared to normal values (based on 150 healthy volunteers previously sampled);Rate of circulating Ultrasensitive C-Reactive Protein compared to normal values (based on 150 healthy volunteers previously sampled);Rate of circulating Soluble tumor necrosis factor alpha receptor type I compared to normal values (based on 150 healthy volunteers previously sampled);Rate of circulating E-selectin (cluster of differentiation 62E) compared to normal values (based on 150 healthy volunteers previously sampled);Rate of circulating Granulocyte Macrophage Colony-Stimulating Factor compared to normal values (based on 150 healthy volunteers previously sampled);Rate of circulating InterCellular Adhesion Molecule-1 compared to normal values (based on 150 healthy volunteers previously sampled);Rate of circulating Interferon alpha compared to normal values (based on 150 healthy volunteers previously sampled);Rate of circulating Interferon beta compared to normal values (based on 150 healthy volunteers previously sampled);Rate of circulating Interferon gamma compared to normal values (based on 150 healthy volunteers previously sampled);Rate of circulating Interleukin-1 alpha compared to normal values (based on 150 healthy volunteers previously sampled);Rate of circulating Interleukin-1 beta compared to normal values (based on 150 healthy volunteers previously sampled);Rate of circulating Interleukin-4 compared to normal values (based on 150 healthy volunteers previously sampled);Rate of circulating Interleukin-6 compared to normal values (based on 150 healthy volunteers previously sampled);Rate of circulating Interleukin-8 compared to normal values (based on 150 healthy volunteers previously sampled);Rate of circulating Interleukin-10 compared to normal values (based on 150 healthy volunteers previously sampled);Rate of circulating Interleukin-12p70 compared to normal values (based on 150 healthy volunteers previously sampled);Rate of circulating Interleukin-13 compared to normal values (based on 150 healthy volunteers previously sampled);Rate of circulating Interleukin-17A compared to normal values (based on 150 healthy volunteers previously sampled);Rate of circulating Induced Protein 10 (C-X-C motif chemokine 10) compared to normal values (based on 150 healthy volunteers previously sampled);Rate of circulating Monocyte Chemoattractant Protein-1 (C-C Motif Chemokine Ligand 2) compared to normal values (based on 150 healthy volunteers previously sampled);Rate of circulating Macrophage inflammatory protein-1 alpha (C-C Motif Chemokine Ligand 3) compared to normal values (based on 150 healthy volunteers previously sampled);Rate of circulating Macrophage inflammatory protein-1 beta (C-C Motif Chemokine Ligand 4) compared to normal values (based on 150 healthy volunteers previously sampled);Rate of circulating P-selectin compared to normal values (based on 150 healthy volunteers previously sampled);Rate of tumor necrosis factor alpha compared to normal values (based on 150 healthy volunteers previously sampled);Rate of tissue plasminogen activator compared to normal values (based on 150 healthy volunteers previously sampled);Rate of soluble form of endothelial protein C receptor compared to normal values (based on 150 healthy volunteers previously sampled);Rate of D-Dimers compared to normal values (based on 150 healthy volunteers previously sampled)", "study_type": "Observational", "time": "2020-04-10", "weburl": "https://clinicaltrials.gov/show/NCT04351711"}, "type": "Feature"}, {"geometry": {"coordinates": [18.569011, 53.019519], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "elianonavarese@gmail.com;jwkubica@gmail.com", "contactPhone": "+48 885 101 728;", "dateEnrollment": "April 27, 2020", "description": "Amiodarone or Verapamil in COVID-19 Hospitalized Patients With Symptoms", "name": "NCT04351763", "primaryOutcome": "Clinical improvement", "study_type": "Interventional", "time": "2020-04-14", "weburl": "https://clinicaltrials.gov/show/NCT04351763"}, "type": "Feature"}, {"geometry": {"coordinates": [12.466867, 55.649142], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": ";nina.weis@regionh.dk", "contactPhone": ";+45 3862 3514", "dateEnrollment": "April 2020", "description": "Impact of a Minimal Psychoeducational Intervention on Anxiety Among Hospitalized COVID-19 Patients in Denmark", "name": "NCT04351789", "primaryOutcome": "Anxiety 1 month", "study_type": "Interventional", "time": "2020-04-11", "weburl": "https://clinicaltrials.gov/show/NCT04351789"}, "type": "Feature"}, {"geometry": {"coordinates": [-4.114201, 50.416945], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": ";plh-tr.RD-Office@nhs.net", "contactPhone": ";+44 (0)1752 432842", "dateEnrollment": "April 20, 2020", "description": "CORonavirus (COVID-19) Diagnostic Lung UltraSound Study", "name": "NCT04351802", "primaryOutcome": "Diagnosis of COVID-19 on lung ultrasound;Difference in diagnosis of COVID-19 on lung ultrasound vs. chest x-ray", "study_type": "Observational", "time": "2020-04-16", "weburl": "https://clinicaltrials.gov/show/NCT04351802"}, "type": "Feature"}, {"geometry": {"coordinates": [11.887432, 45.403388], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": ";gianpaolo.rossi@unipd.it", "contactPhone": ";00390498217821", "dateEnrollment": "April 2020", "description": "Efficacy of Nafamostat in Covid-19 Patients (RACONA Study)", "name": "NCT04352400", "primaryOutcome": "Time-to-clinical improvement", "study_type": "Interventional", "time": "2020-04-03", "weburl": "https://clinicaltrials.gov/show/NCT04352400"}, "type": "Feature"}, {"geometry": {"coordinates": [-47.854166, -21.16368], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": ";albacc@unex.es", "contactPhone": ";+34 927 25 78 94", "dateEnrollment": "March 16, 2020", "description": "Influence Physical Activity Psychological Responses COVID-19 Pandemic", "name": "NCT04352517", "primaryOutcome": "Impact of International Physical Activity Questionnaire-score (high, moderate, low level;higher scores mean a better outcome) on avoidance impact of COVID-19 through IES-R;Impact of International Physical Activity Questionnaire-score (high, moderate, low level;higher scores mean a better outcome) on intrusion impact of COVID-19 through IES-R;Impact of International Physical Activity Questionnaire-score (high, moderate, low level;higher scores mean a better outcome) on hyperarousal impact of COVID-19 through IES-R;Impact of International Physical Activity Questionnaire-score (high, moderate, low level;higher scores mean a better outcome) on depression health status through DASS-21;IImpact of International Physical Activity Questionnaire-score (high, moderate, low level;higher scores mean a better outcome) on anxiety health status through DASS-21;Impact of International Physical Activity Questionnaire-score (high, moderate, low level;higher scores mean a better outcome) on stress health status through DASS-21", "study_type": "Observational", "time": "2020-04-10", "weburl": "https://clinicaltrials.gov/show/NCT04352517"}, "type": "Feature"}, {"geometry": {"coordinates": [6.131415, 46.209751], "type": "Point"}, "properties": {"classification": "Other", "contactEmail": ";geraldine.blanchardrohner@hcuge.ch;geraldine.blanchardrohner@hcuge.ch", "contactPhone": ";0041795534482;", "dateEnrollment": "April 14, 2020", "description": "COVID-19 and Vaccination Attitudes", "name": "NCT04352582", "primaryOutcome": "How vaccination and other attitudes are affected by COVID", "study_type": "Observational", "time": "2020-04-13", "weburl": "https://clinicaltrials.gov/show/NCT04352582"}, "type": "Feature"}, {"geometry": {"coordinates": [-71.339488, 41.967429], "type": "Point"}, "properties": {"classification": "Advanced therapy medicinal products", "contactEmail": "r.welter@regenerismedical.com", "contactPhone": "(508) 576-8325", "dateEnrollment": "April 2020", "description": "Adipose Mesenchymal Cells for Abatement of SARS-CoV-2 Respiratory Compromise in COVID-19 Disease", "name": "NCT04352803", "primaryOutcome": "Safety - Incidence of unexpected adverse events;Efficacy - Frequency of progression to mechanical ventilation;Efficacy - Changes in length of mechanical ventilation;Efficacy - Changes in length of weaning of mechanical ventilation;Efficacy - Changes in length of hospital stay;Efficacy - Changes in mortality rate", "study_type": "Interventional", "time": "2020-04-16", "weburl": "https://clinicaltrials.gov/show/NCT04352803"}, "type": "Feature"}, {"geometry": {"coordinates": [4.865379, 45.757709], "type": "Point"}, "properties": {"classification": "Diagnosis", "contactEmail": "", "contactPhone": "", "dateEnrollment": "April 27, 2020", "description": "COVID-19: Nasal and Salivary Detection of the SARS-CoV-2 Virus After Antiviral Mouthrinses", "name": "NCT04352959", "primaryOutcome": "Change from Baseline amount of SARS-CoV-2 in salivary samples at 7 days", "study_type": "Interventional", "time": "2020-04-15", "weburl": "https://clinicaltrials.gov/show/NCT04352959"}, "type": "Feature"}, {"geometry": {"coordinates": [-75.72287, 45.394161], "type": "Point"}, "properties": {"classification": "Diagnosis", "contactEmail": "dso@ottawaheart.ca", "contactPhone": "613-696-7000", "dateEnrollment": "April 15, 2020", "description": "The RAPID COVID TRIAGE Algorithm", "name": "NCT04353154", "primaryOutcome": "Sensitivity", "study_type": "Observational", "time": "2020-04-15", "weburl": "https://clinicaltrials.gov/show/NCT04353154"}, "type": "Feature"}, {"geometry": {"coordinates": [30.983672, 30.817938], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": ";sheriefabdelsalam@yahoo.com", "contactPhone": ";00201147773440", "dateEnrollment": "April 17, 2020", "description": "Efficacay of Chloroquine in COVID-19 Treatment", "name": "NCT04353336", "primaryOutcome": "Number of patients with virological cure", "study_type": "Interventional", "time": "2020-04-15", "weburl": "https://clinicaltrials.gov/show/NCT04353336"}, "type": "Feature"}, {"geometry": {"coordinates": [-82.642798, 27.764992], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "Frances.Hamblin@jhmi.edu;", "contactPhone": "7277672460;", "dateEnrollment": "May 15, 2020", "description": "COVID-19 Anticoagulation in Children - Thromboprophlaxis (COVAC-TP) Trial", "name": "NCT04354155", "primaryOutcome": "Safety of in-hospital thromboprophylaxis", "study_type": "Interventional", "time": "2020-04-13", "weburl": "https://clinicaltrials.gov/show/NCT04354155"}, "type": "Feature"}, {"geometry": {"coordinates": [2.334565, 48.873277], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "yves.boucher@aphp.fr", "contactPhone": "01 42 16 14 51", "dateEnrollment": "April 13, 2020", "description": "Evaluation of Dental Emergency Treatments During COVID19 Crisis", "name": "NCT04354272", "primaryOutcome": "Pain score evolution measured by a 0-10 numeric scale (NS) where 0 is no pain and 10 the worst pain imaginable", "study_type": "Observational", "time": "2020-04-10", "weburl": "https://clinicaltrials.gov/show/NCT04354272"}, "type": "Feature"}, {"geometry": {"coordinates": [-73.632527, 45.496893], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "andrea.spence@ladydavis.ca", "contactPhone": "514-340-8222", "dateEnrollment": "May 2020", "description": "Effect of Hydroxychloroquine in COVID-19 Positive Pregnant Women", "name": "NCT04354441", "primaryOutcome": "COVID-19-related hospital admissions", "study_type": "Interventional", "time": "2020-04-14", "weburl": "https://clinicaltrials.gov/show/NCT04354441"}, "type": "Feature"}, {"geometry": {"coordinates": [2.254455, 49.875191], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": ";abouarab.osama@chu-amiens.fr", "contactPhone": ";(33)3 22 08 78 36", "dateEnrollment": "April 2020", "description": "French Single Centre Experience of Critically Ill Patients With Covid 19", "name": "NCT04354558", "primaryOutcome": "Variation of age between critically ill patients with SARS Cov2 admitted in ICU with non critically ill patients with SARS Cov2 admitted in ICU;Variation of medical history between critically ill patients with SARS Cov2 admitted in ICU with non critically ill patients with SARS Cov2 admitted in ICU;Variation of chronic drug used between critically ill patients with SARS Cov2 admitted in ICU with non critically ill patients with SARS Cov2 admitted in ICU;Variation of chest CT scan at admission, between critically ill patients with SARS Cov2 admitted in ICU with non critically ill patients with SARS Cov2 admitted in ICU;Variation of respiratory support at ICU admission, between critically ill patients with SARS Cov2 admitted in ICU with non critically ill patients with SARS Cov2 admitted in ICU", "study_type": "Observational", "time": "2020-04-06", "weburl": "https://clinicaltrials.gov/show/NCT04354558"}, "type": "Feature"}, {"geometry": {"coordinates": [12.454233, 55.665133], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": ";ronni.thermann.reitz.plovsing.01@regionh.dk;ronni.thermann.reitz.plovsing.01@regionh.dk", "contactPhone": ";+45 38 62 07 21;+45 38 62 07 21", "dateEnrollment": "April 6, 2020", "description": "Compartmental Inflammation in Mechanically Ventilated Patients With COVID-19", "name": "NCT04354584", "primaryOutcome": "White blood cell counts;White blood cell counts;Lymphocyte populations;Lymphocyte populations", "study_type": "Observational", "time": "2020-04-13", "weburl": "https://clinicaltrials.gov/show/NCT04354584"}, "type": "Feature"}, {"geometry": {"coordinates": [-1.137728, 52.674427], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "", "contactPhone": "", "dateEnrollment": "March 28, 2020", "description": "AiM COVID for Covid 19 Tracking and Prediction", "name": "NCT04354753", "primaryOutcome": "Physical symptoms;Contact History;Travel History", "study_type": "Observational", "time": "2020-04-17", "weburl": "https://clinicaltrials.gov/show/NCT04354753"}, "type": "Feature"}, {"geometry": {"coordinates": [4.304149, 43.839389], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": ";benjamin.lallemant@chu-nimes.fr;drc@chu-nimes.fr", "contactPhone": ";04.66.68.32.73;04.66.68.42.36", "dateEnrollment": "March 27, 2020", "description": "Qualitative and Quantitative Evaluation of Anosmia Over Time in Clinically Symptomatic Patients Tested for COVID-19 Infection", "name": "NCT04354857", "primaryOutcome": "SARS-CoV-2 infection status;Olfactory and gustatory loss", "study_type": "Observational", "time": "2020-04-17", "weburl": "https://clinicaltrials.gov/show/NCT04354857"}, "type": "Feature"}, {"geometry": {"coordinates": [15.259252, 46.232805], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "meznar.miha@gmail.com;meznar.miha@gmail.com", "contactPhone": "+386 3 4233419;+386 3 4233419", "dateEnrollment": "April 10, 2020", "description": "Use of Bromhexine and Hydroxychloroquine for Treatment of COVID-19 Pneumonia", "name": "NCT04355026", "primaryOutcome": "Duration of hospitalization;Duration of disease", "study_type": "Interventional", "time": "2020-04-15", "weburl": "https://clinicaltrials.gov/show/NCT04355026"}, "type": "Feature"}, {"geometry": {"coordinates": [-66.074394, 18.39473], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": ";cabanillasmd@gmail.com", "contactPhone": ";787-758-2000", "dateEnrollment": "April 14, 2020", "description": "Prophylactic Corticosteroid to Prevent COVID-19 Cytokine Storm", "name": "NCT04355247", "primaryOutcome": "Clinical complete response criteria;Clinical Partial Response criteria", "study_type": "Interventional", "time": "2020-04-17", "weburl": "https://clinicaltrials.gov/show/NCT04355247"}, "type": "Feature"}, {"geometry": {"coordinates": [2.451258, 48.797902], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "clinicaltrials@alexion.com", "contactPhone": "1-855-752-2356", "dateEnrollment": "April 17, 2020", "description": "SOLIRIS® (Eculizumab) Treatment of Participants With COVID-19", "name": "NCT04355494", "primaryOutcome": "", "study_type": "Expanded Access", "time": "2020-04-17", "weburl": "https://clinicaltrials.gov/show/NCT04355494"}, "type": "Feature"}, {"geometry": {"coordinates": [-71.200366, 42.29195], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": ";jshah@karyopharm.com", "contactPhone": ";(617) 658-0600", "dateEnrollment": "April 30, 2020", "description": "Evaluation of Activity and Safety of Two Regimens of Low Dose Oral Selinexor in Participants With Moderate or Severe COVID-19", "name": "NCT04355676", "primaryOutcome": "Percentage of Participants with at Least a 2 Point Improvement in the Ordinal Scale", "study_type": "Interventional", "time": "2020-04-17", "weburl": "https://clinicaltrials.gov/show/NCT04355676"}, "type": "Feature"}, {"geometry": {"coordinates": [-9.168897, 38.705632], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": ";;;;;ccalhau@nms.unl.pt", "contactPhone": ";;;;;00351 218803035", "dateEnrollment": "April 2020", "description": "Gut Microbiota, \"Spark and Flame\" of COVID-19 Disease", "name": "NCT04355741", "primaryOutcome": "Differences in gut microbiota composition between COVID-19 patients with different degrees of disease severity.", "study_type": "Observational", "time": "2020-04-15", "weburl": "https://clinicaltrials.gov/show/NCT04355741"}, "type": "Feature"}, {"geometry": {"coordinates": [2.436149, 48.81448], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": ";emilie.sbidian@aphp.fr;emilie.sbidian@aphp.fr", "contactPhone": ";+33 6 83 31 66 96;+33 6 83 31 66 96", "dateEnrollment": "April 2020", "description": "Long-term Use of Drugs That Could Prevent the Risk of Serious COVID-19 Infections or Make it Worse", "name": "NCT04356417", "primaryOutcome": "Identification of serious COVID-19 infections", "study_type": "Observational", "time": "2020-04-17", "weburl": "https://clinicaltrials.gov/show/NCT04356417"}, "type": "Feature"}, {"geometry": {"coordinates": [-71.068188, 42.362611], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "ohyder@partners.org;ohyder@partners.org", "contactPhone": "617-724-0151;617-724-0151", "dateEnrollment": "April 15, 2020", "description": "Non-Invasive Monitoring of Respiratory Function in Spontaneously Breathing Patients With COVID-19 Infection", "name": "NCT04356443", "primaryOutcome": "Endotracheal intubation during present hospitalization, recorded through chart review", "study_type": "Observational", "time": "2020-04-16", "weburl": "https://clinicaltrials.gov/show/NCT04356443"}, "type": "Feature"}, {"geometry": {"coordinates": [114.113622, 22.286544], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": ";gggjerry@gmail.com", "contactPhone": ";+852-22553111", "dateEnrollment": "April 14, 2020", "description": "COVID-19: A Pilot Study of Adaptive Immunity and Anti-PD1", "name": "NCT04356508", "primaryOutcome": "Viral clearance kinetics", "study_type": "Interventional", "time": "2020-04-10", "weburl": "https://clinicaltrials.gov/show/NCT04356508"}, "type": "Feature"}, {"geometry": {"coordinates": [8.546989, 47.376616], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": ";;;;;;matthias.hilty@usz.ch;", "contactPhone": ";;;;;;+41 44 255 11 11;", "dateEnrollment": "March 13, 2020", "description": "The RIsk Stratification in COVID-19 Patients in the ICU Registry", "name": "NCT04357275", "primaryOutcome": "ICU mortality", "study_type": "Observational [Patient Registry]", "time": "2020-04-15", "weburl": "https://clinicaltrials.gov/show/NCT04357275"}, "type": "Feature"}, {"geometry": {"coordinates": [14.2401, 40.861844], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "felice.iasevoli@unina.it", "contactPhone": "+390817462647", "dateEnrollment": "April 10, 2020", "description": "COVID-19 Pandemic Burden in Severe Mental Disease Patients", "name": "NCT04357769", "primaryOutcome": "Perceived Stress Scale (PSS) outcome", "study_type": "Observational", "time": "2020-04-16", "weburl": "https://clinicaltrials.gov/show/NCT04357769"}, "type": "Feature"}, {"geometry": {"coordinates": [1.106913, 49.440538], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "emmanuel.besnier@chu-rouen.fr;emmanuel.besnier@chu-rouen.fr", "contactPhone": "+33 2 32 88 82 83;+33 2 32 88 82 83", "dateEnrollment": "April 9, 2020", "description": "Assessment of Endothelial and Haemostatic Changes During Severe SARS-CoV-2 Infection", "name": "NCT04357847", "primaryOutcome": "Association of InterCellular Adhesion Molecule-1 plasma level with 28 days mortality", "study_type": "Observational", "time": "2020-04-09", "weburl": "https://clinicaltrials.gov/show/NCT04357847"}, "type": "Feature"}, {"geometry": {"coordinates": [145.037466, -37.821222], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "", "contactPhone": "", "dateEnrollment": "30/03/2020", "description": "Chloroquine Chemorophylaxis Countermeasure against COVID-19", "name": "ACTRN12620000417987", "primaryOutcome": "Number of sick days (SDS) during the study period: The number of sick days will be obtained from participants medical records as defined as the number of days deemed 'not fit for duty/work' by their reviewing medical professional, and will be compared between participants randomised to chloroquine and vitamin C.[12 weeks post-commencement of the IMP. Study to commence Apr 2020.]", "study_type": "Interventional", "time": "2020-03-30", "weburl": "https://anzctr.org.au/ACTRN12620000417987.aspx"}, "type": "Feature"}, {"geometry": {"coordinates": [151.187921, -33.82459], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "", "contactPhone": "", "dateEnrollment": "20/04/2020", "description": "AUSTRALIAN CARDIOVASCULAR COVID-19 REGISTRY (AUS-COVID) \r\n", "name": "ACTRN12620000486921", "primaryOutcome": "Incidence of in-hospital cardiac complications. This data will be collected from hospital medical records.[Discharge from hospital]", "study_type": "Observational", "time": "2020-04-17", "weburl": "https://anzctr.org.au/ACTRN12620000486921.aspx"}, "type": "Feature"}, {"geometry": {"coordinates": [174.777288, -41.273122], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "", "contactPhone": "", "dateEnrollment": "14/04/2020", "description": "Hydroxychloroquine for the Community-Based Treatment of COVID-19", "name": "ACTRN12620000457943", "primaryOutcome": "Efficacy of Hydroxychloroquine in the community-based management of COVID-19 assessed by the mean daily InFLUenza Patient-Reported Outcome (FLU-PRO) illness severity score[Day 5 of treatment administration]", "study_type": "Interventional", "time": "2020-04-08", "weburl": "https://anzctr.org.au/ACTRN12620000457943.aspx"}, "type": "Feature"}, {"geometry": {"coordinates": [151.213634, -33.900911], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "", "contactPhone": "", "dateEnrollment": "01/05/2020", "description": "A Facebook delivered physical activity focused group lifestyle intervention for older adults during the COVID-19 pandemic", "name": "ACTRN12620000492954", "primaryOutcome": "Feasibility. Measured by:<br>1. Participant retention (in program and completion of questionnaires).<br>2. Usage of the Facebook group (manual calculation of the sum of comments & likes)<br>3. Feasibility and acceptability questionnaire (modified version of Naslund et al's (2016) Feasibility and Acceptability questionnaire) [Post intervention (week 6)];SIDAS- Suicidal Ideation Attributes Scale[Post intervention (week 6)]", "study_type": "Interventional", "time": "2020-04-20", "weburl": "https://anzctr.org.au/ACTRN12620000492954.aspx"}, "type": "Feature"}, {"geometry": {"coordinates": [-7.007485, 38.883451], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "", "contactPhone": "", "dateEnrollment": "17/03/2020", "description": "Impact of high intensity interval training and aerobic training on stress, depression symptoms, anxiety and resilience in self-isolated people during the COVID-19 health emergency in Spain", "name": "ACTRN12620000482965", "primaryOutcome": "Anxiety assessed by the State-Trait Anxiety Inventory (STAI)[Baseline (after the first exercise session), after three weeks of exercise intervention and after the self-isolation period (approximately 6 weeks after intervention commencement).];Depression symptoms by the the Beck Depression Inventory (BDI-13)[Baseline (after the first exercise session), after three weeks of exercise intervention and after the self-isolation period (approximately 6 weeks after intervention commencement)..];Stress by the Perceived Stress Scale (PPS-10)[Baseline (after the first exercise session), after three weeks of exercise intervention and after the self-isolation period (approximately 6 weeks after intervention commencement)..]", "study_type": "Interventional", "time": "2020-04-17", "weburl": "https://anzctr.org.au/ACTRN12620000482965.aspx"}, "type": "Feature"}, {"geometry": {"coordinates": [2.398921, 48.865802], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "", "contactPhone": "", "dateEnrollment": "22/04/2020", "description": "Retrospective Study on surgical outcomes among surgical patients during the COVID-19 (SARS-CoV-2) Pandemic", "name": "ACTRN12620000498998", "primaryOutcome": "Incidence of Sars-COV-2 infection during hospital stay :<br>- positive rt-PCR or high clinical suspicion with typical parenchymal lesion[From day of surgery until 2 weeks post operative. If hospital stay exceeds 2 weeks, it'll be assess at hospital discharge]", "study_type": "Observational", "time": "2020-04-20", "weburl": "https://anzctr.org.au/ACTRN12620000498998.aspx"}, "type": "Feature"}, {"geometry": {"coordinates": [146.937337, -36.078327], "type": "Point"}, "properties": {"classification": "Impact on helpers", "contactEmail": "", "contactPhone": "", "dateEnrollment": "07/04/2020", "description": "Study evaluating Front-line health care workers serial blood COVID-19 antibody results in relation to symptom presentation", "name": "ACTRN12620000493943", "primaryOutcome": "To determine the rate of front-line healthcare workers at Albury Wodonga Health who demonstrate SARS-CoV-2 antibody seroconversion [Monthly for six months following enrollment or until presentation of Coronavirus symptoms]", "study_type": "Observational", "time": "2020-04-20", "weburl": "https://anzctr.org.au/ACTRN12620000493943.aspx"}, "type": "Feature"}, {"geometry": {"coordinates": [114.957052, 25.840738], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "luhongzhou@fudan.edu.cn", "contactPhone": "+86 21-37990333", "dateEnrollment": "2020-05-15", "description": "A medical records based retrospective study for the effectiveness and safety of Xi-Yan-Ping injection combined with conventional protocol in the treatment of common type novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000032412", "primaryOutcome": "Clinical recovery time ;", "study_type": "Observational study", "time": "2020-04-27", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=52988"}, "type": "Feature"}, {"geometry": {"coordinates": [121.451806, 31.227026], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "maoeq@yeah.net", "contactPhone": "+86 13501747906", "dateEnrollment": "2020-01-01", "description": "the efficacy and safety of high dose intravenous vitamin C in the treatment of novel coronavirus pneumonia (COVID-19): a prospective, randomize, controlled trial", "name": "ChiCTR2000032400", "primaryOutcome": "C-reactive protein;ESR;existence of SIRS;", "study_type": "Interventional study", "time": "2020-04-27", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=52958"}, "type": "Feature"}, {"geometry": {"coordinates": [113.919897, 30.916882], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "1365431567@qq.com", "contactPhone": "+86 15335748899", "dateEnrollment": "2020-04-20", "description": "A multicenter, randomized, double-blind, placebo-controlled trial for Xiaoyao capsule in the improvement of sleep mood disorder of convalescence patients of novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000032399", "primaryOutcome": "N/A;", "study_type": "Interventional study", "time": "2020-04-27", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=52942"}, "type": "Feature"}, {"geometry": {"coordinates": [116.411327, 39.990275], "type": "Point"}, "properties": {"classification": "Impact on helpers", "contactEmail": "jade_yl@126.com", "contactPhone": "+86 010 84205706", "dateEnrollment": "2020-04-15", "description": "Investigation on the mental health status and intervention of the medical staff of the national rescue medical team in hubei province during the pandemic of novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000032368", "primaryOutcome": "Acute stress disorder;Anxiety;Depression;Perception of stress;The need for spiritual care;Social support;Sleep disorders;", "study_type": "Health Services Research", "time": "2020-04-26", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=52933"}, "type": "Feature"}, {"geometry": {"coordinates": [121.520701, 31.275946], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "fangmin19650510@163.com", "contactPhone": "+86 18930568005", "dateEnrollment": "2020-02-19", "description": "Efficacy of Liu-zi-jue in Patients with 2019 Novel Coronavirus Pneumonia (COVID-19):  a randomized controlled trial", "name": "ChiCTR2000032367", "primaryOutcome": "Hospital stay;Modify Borg Dyspnea Score;", "study_type": "Interventional study", "time": "2020-04-26", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=52972"}, "type": "Feature"}, {"geometry": {"coordinates": [113.246137, 23.128508], "type": "Point"}, "properties": {"classification": "Other", "contactEmail": "tcmlin-801@163.com", "contactPhone": "+86 13609021435", "dateEnrollment": "2020-04-21", "description": "Lingnan Fire-Needle Therapy Improves the Quality of Life in General Population Under the Pandemic of novel coronavirus pneumonia (COVID-19): A Prospective, Randomized Controlled Trial", "name": "ChiCTR2000032346", "primaryOutcome": "Quality of life score;", "study_type": "Interventional study", "time": "2020-04-26", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=52692"}, "type": "Feature"}, {"geometry": {"coordinates": [104.046741, 30.659776], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "luofengming@hotmail.com", "contactPhone": "+86 18980601355", "dateEnrollment": "2020-03-01", "description": "A randomized clinical trial for the efficacy and safety of Aliskiren and Nifedipine in novel coronavirus pneumonia (COVID-19) patients with hypertension", "name": "ChiCTR2000032314", "primaryOutcome": "Improvement rate and time required for improvement (hours);Clinical status decrease by two levels;Pulmonary-related mortality;All-cause mortality;", "study_type": "Interventional study", "time": "2020-04-25", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=52867"}, "type": "Feature"}, {"geometry": {"coordinates": [116.408856, 39.978302], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "hshcui@sina.com", "contactPhone": "+86 13901101359", "dateEnrollment": "2020-05-01", "description": "Study for efficacy and safety of Jie-Xing-Jun-Zi granules in the Treatment of convalescent patients of novel coronavious pneumonia (COVID-19)", "name": "ChiCTR2000032313", "primaryOutcome": "TCM syndrome curative effect;", "study_type": "Interventional study", "time": "2020-04-25", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=52916"}, "type": "Feature"}, {"geometry": {"coordinates": [126.650058, 45.764143], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "drkaijiang@163.com", "contactPhone": "+86 13303608899", "dateEnrollment": "2020-04-24", "description": "A multicenter, randomized, open, controlled trial for the efficacy and safety of oral kolimycin in the treatment of patients with new coronavirus pneumonia (CoVID-19)", "name": "ChiCTR2000032242", "primaryOutcome": "Virus negative time;Medication 3, 5, 7, 9, 11, 13, 15 days mouthwash (pharyngeal swab) 2019-nCOVRNA negative rate (%);", "study_type": "Interventional study", "time": "2020-04-24", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=52824"}, "type": "Feature"}, {"geometry": {"coordinates": [119.458527, 32.403675], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "353071331@qq.com", "contactPhone": "+86 15952568717", "dateEnrollment": "2020-01-29", "description": "A medical records based study for epidemiological characteristics of 88 patients with new coronavirus pneumonia (COVID-19) and its impact on severe disease", "name": "ChiCTR2000032239", "primaryOutcome": "Hospital stay;", "study_type": "Observational study", "time": "2020-04-23", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=52507"}, "type": "Feature"}, {"geometry": {"coordinates": [114.887022, 30.399136], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "372861095@qq.com", "contactPhone": "+86 18071178279", "dateEnrollment": "2020-04-01", "description": "A multicenter, randomized, double-blind, placebo-controlled trial for Xiang-Sha-Liu-Jun Pill in the treatment of novel coronavirus pneumonia (COVID-19) decline in digestive function during convalescence", "name": "ChiCTR2000032237", "primaryOutcome": "Clinical symptoms include fatigue, poor appetite, abdominal distension, loose stool and so on.;", "study_type": "Interventional study", "time": "2020-04-23", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=52699"}, "type": "Feature"}, {"geometry": {"coordinates": [121.45484, 31.228687], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "jianglaimz@sina.com", "contactPhone": "+86 13651695976", "dateEnrollment": "2020-04-23", "description": "Clinical study for the potential impact of novel coronavirus pneumonia (COVID-19) on endocrine system", "name": "ChiCTR2000032233", "primaryOutcome": "serum thyroid levels;cortisol levels;ACE2;", "study_type": "Observational study", "time": "2020-04-23", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=52796"}, "type": "Feature"}, {"geometry": {"coordinates": [114.407556, 30.521041], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "1723426138@qq.com", "contactPhone": "+86 13871013338", "dateEnrollment": "2020-05-01", "description": "Screening of proprietary Chinese medicines in convalescent rehabilitation of novel coronavirus pneumonia (COVID-19) convalescent patients", "name": "ChiCTR2000032214", "primaryOutcome": "Visual analog score of symptoms;", "study_type": "Interventional study", "time": "2020-04-23", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=52781"}, "type": "Feature"}, {"geometry": {"coordinates": [106.51165, 29.530505], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "ms89011068@163.com", "contactPhone": "+86 13508302749", "dateEnrollment": "2020-04-23", "description": "A medical records based study for the impact of wearing medical masks on oxygen saturation in adult surgical patients after general anaesthesia during novel coronavirus pneumonia (COVID-19) pandemic", "name": "ChiCTR2000032213", "primaryOutcome": "oxygen saturation;", "study_type": "Observational study", "time": "2020-04-23", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=52788"}, "type": "Feature"}, {"geometry": {"coordinates": [114.271768, 30.571976], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "xiapingfm@126.com", "contactPhone": "+86 027-85332028", "dateEnrollment": "2020-04-15", "description": "A multicenter randomized, double-blind, placebo-controlled trial for Sheng-Mai-Yin for improvement of the pulmonary heart function related symptoms of convalescence patients of new coronavirus pneumonia", "name": "ChiCTR2000032205", "primaryOutcome": "VAS;", "study_type": "Interventional study", "time": "2020-04-23", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=52662"}, "type": "Feature"}, {"geometry": {"coordinates": [114.392111, 30.537478], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "309452513@qq.com", "contactPhone": "+86 18908640865", "dateEnrollment": "2020-04-25", "description": "A multicenter, randomized, double-blind, parallel-controlled trial for Qi-Mai-Fei-Luo-Ping Mixture in the improvement of lung function of novel coronavirus pneumonia (COVID-19) in the convalescent period", "name": "ChiCTR2000032165", "primaryOutcome": "Six-minute Walk Test;", "study_type": "Interventional study", "time": "2020-04-21", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=52679"}, "type": "Feature"}, {"geometry": {"coordinates": [106.554374, 29.555283], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "zhichunfeng81@163.com", "contactPhone": "+86 17710717187", "dateEnrollment": "2020-04-22", "description": "A medical records based study for ECMO in the rescue therapy of extremely critical novel coronavirus pneumonia (COVID-19) patients", "name": "ChiCTR2000032162", "primaryOutcome": "in-hospital mortality;", "study_type": "Observational study", "time": "2020-04-21", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=52694"}, "type": "Feature"}, {"geometry": {"coordinates": [114.242864, 30.596649], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "qingleigao@hotmail.com", "contactPhone": "+86 13871127473", "dateEnrollment": "2020-02-01", "description": "A retrospective study for evolution and clinical outcomes study of novel coronavirus pneumonia (COVID-19) patients", "name": "ChiCTR2000032161", "primaryOutcome": "Clinical outcomes;", "study_type": "Observational study", "time": "2020-04-21", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=52561"}, "type": "Feature"}, {"geometry": {"coordinates": [-4.719847, 41.654737], "type": "Point"}, "properties": {"classification": "Impact on helpers", "contactEmail": "", "contactPhone": "", "dateEnrollment": "16/04/2020", "description": "Occupational health and safety among health care personnel in a COVID-19 pandemic", "name": "ISRCTN18348009", "primaryOutcome": "<br>                1. Respiratory rate, assessed by clinical observation at baseline and at the end of the 4-hour workday<br>                2. Oxygen saturation, assessed using a Physio LifePAK® 15 monitor at baseline and at the end of the 4-hour workday<br>                3. Heart rate, assessed using a Physio LifePAK® 15 monitor at baseline and at the end of the 4-hour workday<br>                4. Blood pressure, assessed using a Physio LifePAK® 15 monitor at the start of the study and at the end of the 4-hour workday<br>                5. Tympanic temperature evaluated using a Braun ThermoScan® PRO 6000 model at baseline and at the end of the 4-hour workday<br>                6. Weight, with the TANITA BC 545-N scale at baseline<br>                8. Size, with the SECA 206 tape measure at baseline<br>                9. Analytical biomarkers: pH, pCO2, pO2, cHCO3-, BE (ecf), cSO2, Na +, K +, Ca ++, Cl-, TCO2, Agap, AGapK, Hct, Hb, BE (b), Glu , Lac, BUN, Urea and Crea, evaluated using COPD Siemens Healthcare at baseline and at the end of the 4-hour workday<br>                10. Medical history of interest, through a structured questionnaire at baseline<br>                11. Level of physical activity using the IPAQ questionnaire at baseline<br>            ", "study_type": "Observational", "time": "2020-04-15", "weburl": "http://isrctn.com/ISRCTN18348009"}, "type": "Feature"}, {"geometry": {"coordinates": [-79.855307, 43.262243], "type": "Point"}, "properties": {"classification": "Diagnosis", "contactEmail": "lorenz.risch@risch.ch", "contactPhone": "+41 585233000", "dateEnrollment": "14/04/2020", "description": "Can the Ava fertility tracker device detect early signs of COVID-19?", "name": "ISRCTN51255782", "primaryOutcome": "Occurrence of COVID-19 infection, as assessed by clinical signs, serology and/or RT-PCR testing. Date of occurrence, clinical symptoms and laboratory results will be collected. The endpoints will be collected by periodic monthly reports obtained on questioning the study participants. Participants and the treating healthcare institutions will be contacted to obtain respective information.   ", "study_type": "Observational", "time": "2020-04-14", "weburl": "http://isrctn.com/ISRCTN51255782"}, "type": "Feature"}, {"geometry": {"coordinates": [-79.406293, 43.676366], "type": "Point"}, "properties": {"classification": "Impact on helpers", "contactEmail": "julie.wright@one-mail.on.ca", "contactPhone": "+1 (0)416 340 4800", "dateEnrollment": "13/04/2020", "description": "Does taking hydroxychloroquine before and during exposure to patients protect frontline healthcare workers from coronavirus?", "name": "ISRCTN14326006", "primaryOutcome": "Microbiologically confirmed COVID-19 (i.e. SARS-CoV-2 infection). This is a composite endpoint which includes any validated SARS-CoV-2 diagnostic assay, including detection of viral RNA and seroconversion, performed on participant viral detection samples throughout the study period or venous samples for serologic testing collected at day 0, 30, 60, 90 and 120.", "study_type": "Interventional", "time": "2020-04-14", "weburl": "http://isrctn.com/ISRCTN14326006"}, "type": "Feature"}, {"geometry": {"coordinates": [-1.181806, 52.65501], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "vern.arterial.disease@gmail.com;vern.arterial.disease@gmail.com", "contactPhone": "+44 (0)121 4143344;+44 (0)191 2336161", "dateEnrollment": "09/04/2020", "description": "The impact of the COVID-19 pandemic on the provision, practice, and outcomes of vascular surgery (COVER study)", "name": "ISRCTN80453162", "primaryOutcome": "<br>                1. Structure and processes within the vascular service measured using a novel online questionnaire weekly until the end of data collection<br>                2. Document all vascular surgery and interventional procedures performed using an online purpose-built data collection tool (per centre/patient) at baseline, time/date of surgery, date of discharge from hospital, three, six, and twelve months:<br>                2.1. Type of procedure performed<br>                2.2. Time taken from presentation to the surgical team to intervention<br>                2.3. Mode of referral (primary vs. secondary care)<br>                2.4. Site of surgery – hub or spoke hospital<br>                2.5. Imaging modalities used and timings<br>                2.6. Emergency classification i.e. urgent/emergency/elective<br>                2.7. Operative technique(s) and device(s) used<br>                2.8. Mode(s) of anaesthesia (local, regional, general, locoregional, other)<br>                2.9. Whether suspected or confirmed COVID-19 positive (+ve) at time of surgery, COVID-19 +ve after surgery, or COVID-19 negative (-ve)<br>                2.10. Documentation of changes to usual practice for this specific procedure as per surgeon’s standard protocol (type of procedure, type of anaesthetic, post-procedural destination)<br>                3. Management of all referred urgent vascular cases using the online survey, focusing on:<br>                3.1.  Chronic Limb Threatening Ischaemia (CLTI):<br>                3.1.1. Decision to discharge/admit/refer to a \"hot\"/emergency clinic<br>                3.1.2. Decision for endovascular or open surgery first<br>                3.1.3. Decision for best medical therapy or palliation or primary amputation<br>                3.2. Carotid disease:<br>                3.2.1. Number of patients managed with best medical therapy (BMT)<br>                3.2.2. Modifications to the indication and decision for carotid endarterectomy (CEA)<br>                3.2.3. Delays to treatment due to lack of theatre/bed availability<br>                3.3. Abdominal Aortic Aneurysm (AAA)<br>                3.3.1. Increasing use of Endovascular repair (if applicable)<br>                3.3.2. Changes to criteria for intervention<br>                3.3.3. Decisions for palliation, i.e. ‘turn down’<br>                3.4. Acute Aortic syndrome (AAS)<br>                3.4.1. Decision to manage in non-critical care beds<br>                3.4.2. Changes to imaging protocol at unit level<br>                3.4.3. Decision to defer surgery<br>            ", "study_type": "Observational", "time": "2020-04-14", "weburl": "http://isrctn.com/ISRCTN80453162"}, "type": "Feature"}, {"geometry": {"coordinates": [-1.55281, 52.374769], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "k.couper@warwick.ac.uk", "contactPhone": "+442476151179", "dateEnrollment": "06/04/2020", "description": "RECOVERY Respiratory Support: Respiratory Strategies in patients with coronavirus COVID-19 – CPAP, high-flow nasal oxygen, and standard care", "name": "ISRCTN16912075", "primaryOutcome": "Composite outcome comprising tracheal intubation or mortality within 30 days. Mortality will be reported from hospital records up until discharge and tracked after discharge. Intubation will be obtained from hospital data.", "study_type": "Interventional", "time": "2020-04-06", "weburl": "http://isrctn.com/ISRCTN16912075"}, "type": "Feature"}, {"geometry": {"coordinates": [7.40374, 46.961635], "type": "Point"}, "properties": {"classification": "Impact on helpers", "contactEmail": "", "contactPhone": "", "dateEnrollment": "02/04/2020", "description": "Distress and resilience of healthcare professionals during the COVID-19 (coronavirus) pandemic", "name": "ISRCTN13694948", "primaryOutcome": "COVID-19 Anxiety (adapted SARS-Anxiety-Scale) at 3 time periods of 2 weeks over 6 months", "study_type": "Observational", "time": "2020-04-01", "weburl": "http://isrctn.com/ISRCTN13694948"}, "type": "Feature"}, {"geometry": {"coordinates": [-6.262189, 53.339001], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "mandyjackson@Rcsi.ie", "contactPhone": "+353852147569", "dateEnrollment": "24/04/2020", "description": "A randomized double-blind placebo-controlled trial of intravenous plasma-purified alpha-1 antitrypsin for severe COVID-19 illness.", "name": "EUCTR2020-001391-15-IE", "primaryOutcome": "Main Objective: The aim of the study is to conduct a clinical trial of IV AAT as a prospective anti-inflammatory therapy for severely ill COVID-19 patients with ARDS requiring ICU admission.<br><br>The primary objective is to demonstrate a biological effect of IV Prolastin administered weekly at 120mg per kilogram of ideal body weight in patients with severe COVID-19 illness requiring intubation and mechanical ventilation for ARDS by reducing circulating levels of IL-6 as measured by plasma ELISA. The study sample size is sufficient to demonstrate a significant difference in patients receiving Prolastin versus patients receiving placebo.;Secondary Objective: determine the safety and tolerability of [IV Prolastin administered once at 120mg/kg of ideal body weight] and [IV Prolastin administered weekly at 120mg/kg of ideal body weight for 4 weeks], as assessed by the number of AEs and SAEs and determine the effects of [IV Prolastin administered once at 120mg per kilogram of ideal body weight] and [IV Prolastin administered weekly at 120mg per kilogram of ideal body weight for 4 weeks] on: <br>Physiological indices of respiratory dysfunction reflecting severity of ARDS, as measured by oxygenation index (OI), respiratory compliance<br>Sequential organ failure assessment (SOFA) score<br>Mortality<br>Time on ventilator in days<br>Circulating alpha-1 antitrypsin (AAT) levels<br>Circulating levels of IL-1ß, IL-8, IL-10, soluble TNF receptor 1<br>Development of shock<br>Acute kidney injury<br>Need for renal replacement therapy<br>Clinical relapse<br>Length of ICU stay in days;Primary end point(s): The primary effectiveness outcome measure, a continuous variable, is IL-6 in plasma as measured by ELISA.;Timepoint(s) of evaluation of this end point: day 2 , day 7, day 14, day 21 and day 28", "study_type": "Interventional clinical trial of medicinal product", "time": "2020-03-31", "weburl": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001391-15"}, "type": "Feature"}, {"geometry": {"coordinates": [-71.083633, 42.379047], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "", "contactPhone": "0016177269252", "dateEnrollment": "09/04/2020", "description": "Therapy with Inhaled Nitric Oxide for Patients Infected with Coronavirus Suffering form Lung Failure", "name": "EUCTR2020-001329-30-AT", "primaryOutcome": "Main Objective: To assess the rate of change in oxygenation <br><br>;Secondary Objective: To assess an improvement in survival, organ damage and weaning from mechanical ventilation in SARS-CoV-2 patients. This would indicate an effect that cannot be addressed only the amelioration of V/Q mismatching in the course of a disease characterized by pneumonia and, in most severe cases, multiorgan failure.<br><br>To assess the time at which a patient is negative for SARS-CoV2, reflective of a possible antiviral effect.;Primary end point(s): Difference in oxygenation between the two groups;Timepoint(s) of evaluation of this end point: 48 hours", "study_type": "Interventional clinical trial of medicinal product", "time": "2020-04-03", "weburl": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001329-30"}, "type": "Feature"}, {"geometry": {"coordinates": [4.468115, 51.911253], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "j.aerts@erasmusmc.nl", "contactPhone": "00310107040704", "dateEnrollment": "21/04/2020", "description": "COVID-19: addition of azithromycin to chloroquine treatment", "name": "EUCTR2020-001527-14-NL", "primaryOutcome": "Main Objective: Does addition of azithromycin to standard chloroquine treatment result in a higher clinical cure rate at day 7 than treatment with chloroquine alone in patients with COVID-19.<br><br>Cure is considered when 4 criteria are present:<br>(1) O2 sat > 94% with room air<br>(2) 24 hours without fever (=38°C) <br>(3) Breathing frequency < 24/min<br>;Secondary Objective: Does addition of azithromycin to standard chloroquine treatment result in a higher viral clearance rate at day 7 confirmed by a negative COVID-19 PCR than treatment with chloroquine alone in patients with COVID-19.;Primary end point(s): The initial response to treatment will be evaluated during admission. <br>Cure is considered when 3 criteria are present:<br>(1) O2 sat > 94% with room air<br>(2) 24 hours without fever (=38°C) <br>(3) Breathing frequency < 24/min<br><br>The percentage of patients with clinical cure at day 7 will be calculated<br>;Timepoint(s) of evaluation of this end point: days of admission to day of discharge<br>primary endpoint will be determined at day 7", "study_type": "Interventional clinical trial of medicinal product", "time": "2020-04-06", "weburl": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001527-14"}, "type": "Feature"}, {"geometry": {"coordinates": [17.06688, 51.109595], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "ewa.jankowska@umed.wroc.pl", "contactPhone": "0048608553169", "dateEnrollment": "08/04/2020", "description": "A multicenter, open, randomized, non-commercial study to evaluate the efficacy and safety of chloroquine phosphate in the outpatient treatment of COVID-19 in combination with telemedicine care for patients with SARS-CoV-2 infection with the risk of developing complications to reduce the risk of COVID-19-related hospitalization and death.", "name": "EUCTR2020-001469-35-PL", "primaryOutcome": "Main Objective: The study that chlorchine phosphate used outpatient and standard symptomatic treatment in combination with telemedical care in patients with SARS-CoV-2 infection with a higher risk of complications in the COVID-19 treatment, not requiring hospitalization - compared to standard symptomatic treatment used under isolation (during home quarantine or in isolation) in combination with telemedical care - prevents COVID-19 hospitalization and death of any cause in 15-day observation.;Secondary Objective: Not applicable;Primary end point(s): Hospitalisation due to COVID-19 or death for any cause in 15-day observation (up to and including the 15th study);Timepoint(s) of evaluation of this end point: Day 15 (the day after the 14-day treatment cycle)", "study_type": "Interventional clinical trial of medicinal product", "time": "2020-04-08", "weburl": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001469-35"}, "type": "Feature"}, {"geometry": {"coordinates": [-3.73462, 40.456863], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "evelina.tacconelli@univr.it", "contactPhone": "0458128243", "dateEnrollment": "09/04/2020", "description": "An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care", "name": "EUCTR2020-001366-11-IT", "primaryOutcome": "Main Objective: The aim of this core protocol is to compare the effects on major outcomes in hospital of the local standard of care alone versus the local standard of care plus one of four alternative anti-viral agents. <br><br>The primary objective of this large international randomised trial is to provide reliable estimates on any effects of these anti-viral treatments on in-hospital mortality in moderate and in severe COVID;Secondary Objective: The secondary objectives are to assess any effects of these anti-viral treatments on hospital duration and receipt of ventilation or intensive care, and to identify any serious adverse reactions.;Primary end point(s): The primary outcome is all-cause mortality, subdivided by severity of disease at the time of randomisation.;Timepoint(s) of evaluation of this end point: At discharge or death.", "study_type": "Interventional clinical trial of medicinal product", "time": "2020-04-20", "weburl": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001366-11"}, "type": "Feature"}, {"geometry": {"coordinates": [-1.663677, 42.805448], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "ucicec@unav.es", "contactPhone": "34948255 4002723", "dateEnrollment": "16/04/2020", "description": "Sarilumab Treatment In cytoKinE storm caused by infection with COVID-19.", "name": "EUCTR2020-001255-40-ES", "primaryOutcome": "Main Objective: Evaluate the impact of sarilumab on the progression of COVID 19-associated respiratory failure as measured by the change in a severity rating on a 7-point severity index.;Secondary Objective: 1.\tAssess the impact of sarilumab on markers of systemic inflammation and the coagulation cascade in the context of COVID-19.<br>2.\tAssess the impact of sarilumab on mortality caused by COVID-19.<br><br>3.\tAssess the impact of sarilumab on oxygenation.<br>4.\tEvaluate the safety of sarilumab in patients with severe pneumonia caused by COVID 19.;Primary end point(s): -\tChange in a severity rating on a 7-point ordinal scale<br><br>7-point Ordinal Scale:<br>1.\tDeath<br>2.\tHospitalized, on invasive mechanical ventilation or ECMO<br>3.\tHospitalized, on non-invasive ventilation or high flow oxygen devices<br>4.\tHospitalized, requiring supplemental oxygen<br>5.\tHospitalized, not requiring supplemental oxygen – requiring ongoing medical care (COVID-19 related or otherwise)<br>6.\tHospitalized, not requiring supplemental oxygen – no longer requires ongoing medical care <br>7.\tNot hospitalized;Timepoint(s) of evaluation of this end point: Time Frame: day 15", "study_type": "Interventional clinical trial of medicinal product", "time": "2020-04-20", "weburl": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001255-40"}, "type": "Feature"}, {"geometry": {"coordinates": [-4.796089, 37.868053], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "uicec@imibic.org", "contactPhone": "0034671596070", "dateEnrollment": "18/04/2020", "description": "Study of antithrombin as prophylaxis of acute respiratory disease in patients with COVID-19", "name": "EUCTR2020-001659-42-ES", "primaryOutcome": "Main Objective: Decrease the risk of developing ARDS and death in high-risk COVID-19 patients;Secondary Objective: - To evaluate the improvement in oxygenation at 12, 24, 48, 72 and 96 hours.<br>- To evaluate the improvement in analytical risk parameters for ARDS at 24, 48 and 72 hours.<br>- To evaluate the radiological improvement.<br>- To evaluate the rate of need for non-invasive and invasive mechanical ventilation.<br>- To evaluate the time of use of mechanical ventilation.<br>- To evaluate the mortality rate in hospital and one month after the pharmacological intervention.<br>- To reviews the safety profile of the established treatment.<br>- To Deepen in the anti-inflammatory mechanisms of AT.;Primary end point(s): Combined variable: mortality or worsening rate with need for non-invasive mechanical ventilation or with need for invasive mechanical ventilation.;Timepoint(s) of evaluation of this end point: Daily.", "study_type": "Interventional clinical trial of medicinal product", "time": "2020-04-20", "weburl": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001659-42"}, "type": "Feature"}, {"geometry": {"coordinates": [-4.811534, 37.884489], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "uicec@imibic.org", "contactPhone": "0034671596070", "dateEnrollment": "18/04/2020", "description": "Clinical trial of Sarilumab in adults hospitalized with COVID-19", "name": "EUCTR2020-001531-27-ES", "primaryOutcome": "Main Objective: Decrease cases of ARDS in adults requiring HFNO or either non-invasive or invasive mechanical ventilation;Secondary Objective: To reduce crude mortality at 28 days<br>To reduce the time (in days) to clinical improvement<br>To reduce the time (in days) until improvement in oxygenation for at least 48 hours<br>To reduce the proportion of patients who require invasive mechanical ventilation<br>To study the effect of the drug on the negativization of the PCR to COVID-19<br>To study the effect of the drug on the profile of cytokines<br>To study the safety of the experimental drug;Primary end point(s): Proportion of patients requiring or time (in days) until required:<br>- High flow nasal oxygenation (HFNO)<br>- Non-invasive mechanical ventilation type BiPAP<br>- Non-invasive mechanical ventilation type CPAP<br>- Invasive mechanical ventilation;Timepoint(s) of evaluation of this end point: At day 28 or when the subject is discharged (whichever occurs first)", "study_type": "Interventional clinical trial of medicinal product", "time": "2020-04-20", "weburl": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001531-27"}, "type": "Feature"}, {"geometry": {"coordinates": [-3.710586, 42.338891], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "mjcoma@hubu.es", "contactPhone": "0034610620180", "dateEnrollment": "19/04/2020", "description": "OUTPATIENT TREATMENT OF COVID-19 WITH EARLY PULMONARY CORTICOSTEROIDS AS AN OPPORTUNITY TO MODIFY THE COURSE OF THE DISEASE", "name": "EUCTR2020-001622-64-ES", "primaryOutcome": "Main Objective: The aim of this study is to explore the effectiveness and safety of oral corticosteroids (prednisone) in the treatment of early stage SARS-Cov-2 pneumonia in patients who do not yet meet hospital admission criteria.;Secondary Objective: Not applicable;Primary end point(s): referral from a Primary Care health professional, will be evaluated when they present symptoms of low respiratory tract, persistent cough, dyspnea, tightness in the chest, or for reappearance of fever, worsening or lack of improvement, after several days of previous clinic (general malaise, fever, upper tract symptoms, diarrhoea...).   <br>In the Emergency Department, the established triage and action procedure will be performed, which includes confirmation of the infection by PCR or determination of Ag (as established by the health authorities). Patients with a confirmed diagnosis of infection in previous days, and who have not received other treatment that is not symptomatic, will also be included.<br>Variables to be determined include: auscultation, O2 saturation and/or blood gas and Chest x-ray, CBC, including inflammation markers and blood biometrics, ECG. <br>Depending on the results:<br>If the patient is an admission subsidiary, he is not included in the study.<br>If the patient can be managed on an outpatient basis, meets all the criteria for inclusion and none for exclusion, data will be taken from the data collection sheet by the person responsible, verbal informed consent will be requested in front of witnesses and recorded in the medical record, and treatment will be assigned according to 1:1 randomization (established by order of inclusion). <br>Group 1. Symptomatic treatment (paracetamol 1 g on demand) + Hydroxychloroquine + Azithromycin x 5 days  <br>Group 2. Symptomatic treatment + Hydroxychloroquine + Azithromycin + Prednisone  <br>The main result is admission after 30 days. Secondary outcomes are 30-day ICU admission and hospital stay. The safety variable will be the occurrence of outbreaks of steroid-related psychosis. All analyses will be by intention to treat.;Timepoint(s) of evaluation of this end point: Telephone follow-up for 2 weeks according to the protocol established in Primary Care. If favourable evolution, 14 days later auscultation and sat O2. Throughout the follow-up, decisions will be made to refer the patient to the Emergency Department or to modify the action, at the discretion of the physician in charge.  If the evolution is favorable, a chest X-ray will be performed per month.", "study_type": "Interventional clinical trial of medicinal product", "time": "2020-04-20", "weburl": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001622-64"}, "type": "Feature"}, {"geometry": {"coordinates": [-5.979633, 37.363036], "type": "Point"}, "properties": {"classification": "Impact on helpers", "contactEmail": "claram.rosso.sspa@juntadeandalucia.es", "contactPhone": "+34670949617", "dateEnrollment": "19/04/2020", "description": "Study for the prevention of COVID-19 infection in healthcare personnel", "name": "EUCTR2020-001440-26-ES", "primaryOutcome": "Main Objective: To assess the efficacy of hydroxychloroquine preventive administration in healthcare personnel with risk of exposure to COVID-19 infected patients.;Secondary Objective: To assess the safety and tolerability of preventive use of hydroxychloroquine in healthcare personnel.;Primary end point(s): - Decrease of the contagion rate measured by RT-PCR of healthcare personnel who attends SARS-CoV-2 infected patients from 9% in control group to 3% in experimental group.<br>- Decrease of the incidence of coronavirus disease (COVID-19) in the healthcare personnel who attends SARS-CoV-2 infected patients from 9% in control group to 3% in experimental group.;Timepoint(s) of evaluation of this end point: At the end of treatment (day 60)", "study_type": "Interventional clinical trial of medicinal product", "time": "2020-04-20", "weburl": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001440-26"}, "type": "Feature"}, {"geometry": {"coordinates": [16.349333, 48.219699], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "mattias.preusser@meduniwien.ac.at", "contactPhone": "+4314040044450", "dateEnrollment": "14/04/2020", "description": "A SINGLE-BLINDED RANDOMIZED, PLACEBO-CONTROLLED PHASE II TRIAL OF PROPHYLACTIC TREATMENT WITH ORAL AZITHROMYCIN VERSUS PLACEBO IN CANCER PATIENTS UNDERGOING ANTINEOPLASTIC TREATMENT DURING THE COVID-19 PANDEMIC", "name": "EUCTR2020-001327-13-AT", "primaryOutcome": "Main Objective: Cumulative number of SARS-COV-2 infections as verified by PCR from routine nasal swabs performed every 28 days (symptomatic or asymptomatic) at week 12 after<br>initiation of therapy;Secondary Objective: - To evaluate the capacity of azithromycin to prevent severe COVID-19 infections, defined as a combined endpoint of hospitalization and death in cancer patients undergoing active treatment with chemotherapy<br>- Severity of COVID-19 cases (see grading as defined by the WHO)<br>- All-cause mortality<br>- Safety and tolerability of IMP (clinical and laboratory, CTCAE criteria)<br>-\tOccurrence of viral or bacterial infections other than COVID-19<br>-\tDevelopment of azithromycin-resistant bacterial strains as assessed by nasal swabs<br>;Primary end point(s): Number of SARS-COV-2 infections (symptomatic or asymptomatic): detected by routine SARS-COV-2 tests in all patients treated at the Division of Oncology, Medical University of Vienna. During the SARSCOV-2 pandemic, the routine approach to patients undergoing<br>chemotherapy at our institution is PCR from nasal swabs taken every 28 days. The cumulative number of infections detected (symptomatic or asymptomatic) at week 8 after initiation of therapy in both treatment arms serves as the primary endpoint.;Timepoint(s) of evaluation of this end point: after 12 weeks", "study_type": "Interventional clinical trial of medicinal product", "time": "2020-03-30", "weburl": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001327-13"}, "type": "Feature"}, {"geometry": {"coordinates": [12.165361, 55.477638], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "hans.hasselbalch@gmail.com", "contactPhone": "4526223678", "dateEnrollment": "22/04/2020", "description": "Ruxolitinib Treatment in Patients with Severe COVID-19 Infection. A Danish Safety and Efficacy Study.\n", "name": "EUCTR2020-001459-42-DK", "primaryOutcome": "Main Objective: Efficacy of therapy with ruxolitinib (Jakavi®) in patients with severe COVID-19 infection in respirator;Secondary Objective: 1. Safety of therapy with ruxolitinib in patients severely afflicted by the COVID-19 infection <br>2. Efficacy of therapy with ruxolitinib in patients with the COVID-19 infections in terms of a reduction in the number of patients who need respirator support by starting treatment before the patient is deemed to urgent need for respirator support<br>3. To demonstrate that ruxolitinib treatment is associated with a rapid decline in inflammatory cytokines, and improvement in aberrant numbers of circulating immune cells (dendritic cells, T-cells, NK-cells, B cells) and their functionality <br>4. To describe the genomic (as assessed by whole blood gene expression profiling and miRNA) and proteomic changes in COVID-19 infected patients during treatment with ruxolitinib.<br>5. To describe the microbiome before and during treatment with ruxolitinib.  ;Primary end point(s): 30-days mortality;Timepoint(s) of evaluation of this end point: 30 days", "study_type": "Interventional clinical trial of medicinal product", "time": "2020-04-14", "weburl": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001459-42"}, "type": "Feature"}, {"geometry": {"coordinates": [4.398125, 51.212181], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "yvanherrewege@itg.be", "contactPhone": "", "dateEnrollment": "12/04/2020", "description": "An open label single center randomized controlled trial to evaluate the effect of hydroxychloroquine on viral shedding in mild COVID-19", "name": "EUCTR2020-001417-21-BE", "primaryOutcome": "Main Objective: To assess if 10 doses of HC, each taken 12 hours apart, increase the proportion of COVID-19 patients who have a negative nasopharyngeal RT-PCR for SARS-CoV-2 by day 7 post diagnosis in the HC arm compared to the no-HC arm.;Secondary Objective: Secondary objective 1: To assess the safety of HC in COVID-19 patients treated in the ambulatory setting<br>Secondary objective 2: To assess the clinical efficacy of HC in COVID-19 patients<br>Secondary endpoint 3:To assess if 10 doses of HC, each taken 12 hours apart, increase the proportion of COVID-19 patients who have a negative COVIDAM, Protocol version 3.0, dated 16/April/2020 9/49<br>nasopharyngeal RT-PCR for SARS-CoV-2 by day 7 post onset of symptoms (POS) in the HC arm compared to the no-HC arm.<br>Secondary Objective 4: To assess if 10 doses of HC, each taken 12 hours apart, increase the proportion of COVID-19 patients who have a negative nasal AND salivary RT-PCR for SARS-CoV-2 by day 7 post diagnosis in the HC arm compared to the no-HC arm.;Primary end point(s): proportion of participants with a negative nasopharyngeal sample* by day 7 post diagnosis<br>* defined by a negative RT-PCR on a nasopharyngeal swab of two subsequent study visits. The date of the first negative sample will then be taken as the date of negativity<br>;Timepoint(s) of evaluation of this end point: Day  7 post diagnosis ", "study_type": "Interventional clinical trial of medicinal product", "time": "2020-04-01", "weburl": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001417-21"}, "type": "Feature"}, {"geometry": {"coordinates": [3.710532, 51.042195], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "hiruz.ctu@uzgent.be", "contactPhone": "+3293320500", "dateEnrollment": "03/04/2020", "description": "Treatment of COVID-19 patients with anti-interleukin drugs", "name": "EUCTR2020-001500-41-BE", "primaryOutcome": "Secondary Objective: -to investigate whether treatment with either tocilizumab, siltuximab, anakinra or combinations thereof<br>-improves oxygenation<br>-causes defervescence, measured as time to first fever-free 48h period<br>-improves features of secondary haemophagocytic lymphohistiocytosis<br>-improves features of secondary haemophagocytic lymphohistiocytosis in relation to serum IL-6 and IL-1<br>-affects clinical outcome in relation to IL-6 and IL-1 levels<br>-affects the rate of nosocomial infection<br>-affects progression to mechanical ventilation, high oxygen delivery device, and/or ARDS in non-ventilated patients<br>-affects length of dependency of ventilation in ventilated patients<br>-affects all-cause mortality rate at 4 and 20 weeks post inclusion<br>-affects long term 10-20 week follow up clinical status and lung function<br>-is safe (number of AEs/SAEs)<br>-When there is a significant association between IL-6 blockade and time to clinical improvement, tocilizumab and siltuximab will be compared versus usual care ;Primary end point(s): Time to clinical improvement (defined as the time from randomization to either an improvement of two points on a six-category ordinal scale measured daily till day 28 or discharge from the hospital or death)<br>1. Death<br>2. Hospitalized, on invasive mechanical ventilation or ECMO;<br>3. Hospitalized, on non-invasive ventilation or high flow oxygen devices;<br>4. Hospitalized, requiring supplemental oxygen<br>5. Hospitalized, not requiring supplemental oxygen<br>6. Not hospitalized;Main Objective: Study if blockade of IL-6 +/- IL-1 to block the cytokine storm and acute lung injury in comparison with usual care reduces time to clinical improvement as defined by an increase of more than 2 on the 6 point ordinal scale or discharge from the hospital;Timepoint(s) of evaluation of this end point: 28 days", "study_type": "Interventional clinical trial of medicinal product", "time": "2020-04-04", "weburl": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001500-41"}, "type": "Feature"}, {"geometry": {"coordinates": [27.58483, 47.168222], "type": "Point"}, "properties": {"classification": "Diagnosis", "contactEmail": ";;alexandru.burlacu@umfiasi.ro", "contactPhone": ";;0040744488580", "dateEnrollment": "March 18, 2020", "description": "Artificial Intelligence Algorithms for Discriminating Between COVID-19 and Influenza Pneumonitis Using Chest X-Rays", "name": "NCT04313946", "primaryOutcome": "COVID-19 positive X-Rays;COVID-19 negative X-Rays", "study_type": "Observational", "time": "2020-03-17", "weburl": "https://clinicaltrials.gov/show/NCT04313946"}, "type": "Feature"}, {"geometry": {"coordinates": [-73.957081, 40.857574], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": ";jtg2122@cumc.columbia.edu;jtg2122@cumc.columbia.edu", "contactPhone": ";212-305-2447;212-305-2447", "dateEnrollment": "March 29, 2020", "description": "Hydroxychloroquine Post Exposure Prophylaxis for Coronavirus Disease (COVID-19)", "name": "NCT04318444", "primaryOutcome": "Number of participants with symptomatic, lab-confirmed COVID-19.", "study_type": "Interventional", "time": "2020-03-20", "weburl": "https://clinicaltrials.gov/show/NCT04318444"}, "type": "Feature"}, {"geometry": {"coordinates": [14.241841, 40.861939], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "gabriele.saccone@libero.it", "contactPhone": "3394685179", "dateEnrollment": "January 1, 2020", "description": "Clinical Characteristics of Coronavirus Disease 2019 (COVID-19) in Pregnancy", "name": "NCT04319016", "primaryOutcome": "Maternal and perinatal outcomes", "study_type": "Observational [Patient Registry]", "time": "2020-03-20", "weburl": "https://clinicaltrials.gov/show/NCT04319016"}, "type": "Feature"}, {"geometry": {"coordinates": [-80.277867, 36.134174], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": ";WFBH_Mindfulness@wakehealth.edu;WFBH_Mindfulness@wakehealth.edu", "contactPhone": ";336-716-2357;", "dateEnrollment": "March 22, 2020", "description": "Mindfulness During COVID-19", "name": "NCT04319445", "primaryOutcome": "Helpfulness of the session;Platform effectiveness", "study_type": "Interventional", "time": "2020-03-20", "weburl": "https://clinicaltrials.gov/show/NCT04319445"}, "type": "Feature"}, {"geometry": {"coordinates": [2.362854, 48.837079], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "joe-elie.salem@aphp.fr;joe-elie.salem@aphp.fr", "contactPhone": "01 42 17 85 31;01 42 17 85 31", "dateEnrollment": "March 20, 2020", "description": "Joint Use of Electrocardiogram and Transthoracic Echocardiography With Other Clinico-biological Parameters in an Observational Study to Monitor Cardio-vascular Events and Predict Outcomes in Patients Diagnosed With COVID-19", "name": "NCT04320017", "primaryOutcome": "Incidence of acute myocardial events in COVID-19 population at baseline and during hospital stay", "study_type": "Observational", "time": "2020-03-20", "weburl": "https://clinicaltrials.gov/show/NCT04320017"}, "type": "Feature"}, {"geometry": {"coordinates": [-71.273777, 46.781408], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": ";francois.lellouche@criucpq.ulaval.ca;pierre-alexandre.bouchard@criucpq.ulaval.ca", "contactPhone": ";418-656-8711;418-656-8711", "dateEnrollment": "April 20, 2020", "description": "Closed-Loop Oxygen to Verify That Healthcare Workers Interventions Decrease During SARS-CoV-2 Pneumonia (COVID-19)", "name": "NCT04320056", "primaryOutcome": "The number of interventions;Duration of interventions", "study_type": "Interventional", "time": "2020-03-19", "weburl": "https://clinicaltrials.gov/show/NCT04320056"}, "type": "Feature"}, {"geometry": {"coordinates": [114.2839, 36.017922], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": ";mark.sendak@duke.edu", "contactPhone": ";919-684-3234", "dateEnrollment": "April 3, 2020", "description": "COVID-19 Pandemic Response Network", "name": "NCT04320862", "primaryOutcome": "Number of participants who experience inpatient admission", "study_type": "Observational", "time": "2020-03-23", "weburl": "https://clinicaltrials.gov/show/NCT04320862"}, "type": "Feature"}, {"geometry": {"coordinates": [-122.405225, 37.78548], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": ";PRIORITYCOVID19@ucsf.edu;PRIORITYCOVID19@ucsf.edu", "contactPhone": ";(415) 754-3749;415-754-3749", "dateEnrollment": "March 20, 2020", "description": "COVID-19 PRIORITY (Pregnancy CoRonavIrus Outcomes RegIsTrY)", "name": "NCT04323839", "primaryOutcome": "Clinical presentation;Disease prognosis outcomes;Pregnancy outcomes;Obstetric outcomes;Neonatal outcomes;Modes of transmission of COVID-19", "study_type": "Observational [Patient Registry]", "time": "2020-03-24", "weburl": "https://clinicaltrials.gov/show/NCT04323839"}, "type": "Feature"}, {"geometry": {"coordinates": [3.693435, 51.017868], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": ";anja.delporte@uzgent.be", "contactPhone": ";+32-9-3320228", "dateEnrollment": "March 24, 2020", "description": "Sargramostim in Patients With Acute Hypoxic Respiratory Failure Due to COVID-19 (SARPAC)", "name": "NCT04326920", "primaryOutcome": "Improvement in oxygenation at a dose of 250 mcg daily during 5 days improves oxygenation in COVID-19 patients with acute hypoxic respiratory failure", "study_type": "Interventional", "time": "2020-03-24", "weburl": "https://clinicaltrials.gov/show/NCT04326920"}, "type": "Feature"}, {"geometry": {"coordinates": [6.984803, 51.435941], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": ";matthias.totzeck@uk-essen.de;amir-abbas.mahabadi@uk-essen.de", "contactPhone": ";+49201723;+49201723", "dateEnrollment": "March 26, 2020", "description": "Characterization of Cardiovascular Diseases and Risk Factors in Patients With Suspected SARS-CoV2/Covid-19 Infection", "name": "NCT04327479", "primaryOutcome": "All-cause mortality", "study_type": "Observational [Patient Registry]", "time": "2020-03-26", "weburl": "https://clinicaltrials.gov/show/NCT04327479"}, "type": "Feature"}, {"geometry": {"coordinates": [-47.004042, -22.969861], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "", "contactPhone": "", "dateEnrollment": "April 23, 2020", "description": "Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Hospitalized Patients With Moderate to Severe COVID-19", "name": "NCT04329572", "primaryOutcome": "Evolution of acute respiratory syndrome, oxygen saturation hemodynamic stability", "study_type": "Interventional", "time": "2020-03-29", "weburl": "https://clinicaltrials.gov/show/NCT04329572"}, "type": "Feature"}, {"geometry": {"coordinates": [-0.042563, 51.524067], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "a.martineau@qmul.ac.uk", "contactPhone": "+442078822551", "dateEnrollment": "May 5, 2020", "description": "Longitudinal Population-based Observational Study of COVID-19 in the UK Population", "name": "NCT04330599", "primaryOutcome": "Incidence of confirmed COVID-19", "study_type": "Observational", "time": "2020-03-31", "weburl": "https://clinicaltrials.gov/show/NCT04330599"}, "type": "Feature"}, {"geometry": {"coordinates": [3.710532, 51.042195], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": ";anja.delporte@uzgent.be", "contactPhone": ";+32-9-3320228", "dateEnrollment": "April 2020", "description": "Treatment of COVID-19 Patients With Anti-interleukin Drugs", "name": "NCT04330638", "primaryOutcome": "Time to Clinical Improvement", "study_type": "Interventional", "time": "2020-03-31", "weburl": "https://clinicaltrials.gov/show/NCT04330638"}, "type": "Feature"}, {"geometry": {"coordinates": [2.334949, 48.873335], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "", "contactPhone": "", "dateEnrollment": "March 30, 2020", "description": "CORIMUNO-19 - Tocilizumab Trial - TOCI (CORIMUNO-TOCI)", "name": "NCT04331808", "primaryOutcome": "Survival without needs of ventilator utilization at day 14. Group 1;WHO progression scale <=5 at day 4. Group 1.;Cumulative incidence of successful tracheal extubation (defined as duration extubation > 48h) at day 14. Group 2.;WHO progression scale at day 4. Group 2.", "study_type": "Interventional", "time": "2020-03-31", "weburl": "https://clinicaltrials.gov/show/NCT04331808"}, "type": "Feature"}, {"geometry": {"coordinates": [-74.073839, 4.599982], "type": "Point"}, "properties": {"classification": "Advanced therapy medicinal products", "contactEmail": ";anayajm@gmail.com;gustavo.quintero@urosario.edu.co", "contactPhone": ";+57 321 233 9828;+57 318 3606458", "dateEnrollment": "May 1, 2020", "description": "Convalescent Plasma for Patients With COVID-19: A Pilot Study", "name": "NCT04332380", "primaryOutcome": "Change in Viral Load;Change in Immunoglobulin M COVID-19 antibodies Titers;Change in Immunoglobulin G COVID-19 antibodies Titers", "study_type": "Interventional", "time": "2020-03-30", "weburl": "https://clinicaltrials.gov/show/NCT04332380"}, "type": "Feature"}, {"geometry": {"coordinates": [-74.089284, 4.616419], "type": "Point"}, "properties": {"classification": "Advanced therapy medicinal products", "contactEmail": ";anayajm@gmail.com;gustavo.quintero@urosario.edu.co", "contactPhone": ";+57 321 233 9828;+57 318 3606458", "dateEnrollment": "May 1, 2020", "description": "Convalescent Plasma for Patients With COVID-19: A Randomized, Open Label, Parallel, Controlled Clinical Study", "name": "NCT04332835", "primaryOutcome": "Change in Viral Load;Change in Immunoglobulin M COVID-19 Titers;Change in Immunoglobulin G COVID-19 Titers", "study_type": "Interventional", "time": "2020-03-31", "weburl": "https://clinicaltrials.gov/show/NCT04332835"}, "type": "Feature"}, {"geometry": {"coordinates": [116.364683, 39.948169], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": ";john131212@sina.com", "contactPhone": ";13911405123", "dateEnrollment": "April 1, 2020", "description": "Corona Virus Disease 2019 Patients Whose Nucleic Acids Changed From Negative to Positive", "name": "NCT04333589", "primaryOutcome": "Viral nucleic acid test negative conversion rate", "study_type": "Interventional", "time": "2020-04-01", "weburl": "https://clinicaltrials.gov/show/NCT04333589"}, "type": "Feature"}, {"geometry": {"coordinates": [115.792858, 32.915946], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": ";john131212@sina.com", "contactPhone": ";13911405123", "dateEnrollment": "April 1, 2020", "description": "Efficacy and Safety of Anluohuaxian in the Treatment of Rehabilitation Patients With Corona Virus Disease 2019", "name": "NCT04334265", "primaryOutcome": "Changes in high-resolution computer tomography of the lung;Change in 6-minute walking distance", "study_type": "Interventional", "time": "2020-04-01", "weburl": "https://clinicaltrials.gov/show/NCT04334265"}, "type": "Feature"}, {"geometry": {"coordinates": [-3.737393, 40.457137], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "ibnsky@yahoo.es;ibnsky@yahoo.es", "contactPhone": "0034 913303002;913303002", "dateEnrollment": "March 23, 2020", "description": "International COVID19 Clinical Evaluation Registry,", "name": "NCT04334291", "primaryOutcome": "Death", "study_type": "Observational [Patient Registry]", "time": "2020-04-01", "weburl": "https://clinicaltrials.gov/show/NCT04334291"}, "type": "Feature"}, {"geometry": {"coordinates": [-123.129227, 49.246006], "type": "Point"}, "properties": {"classification": "Vaccines", "contactEmail": ";;;bd@symvivo.com", "contactPhone": ";;;(604) 428-7474", "dateEnrollment": "April 30, 2020", "description": "Evaluating the Safety, Tolerability and Immunogenicity of bacTRL-Spike Vaccine for Prevention of COVID-19", "name": "NCT04334980", "primaryOutcome": "Frequency of Adverse Events", "study_type": "Interventional", "time": "2020-03-31", "weburl": "https://clinicaltrials.gov/show/NCT04334980"}, "type": "Feature"}, {"geometry": {"coordinates": [7.731734, 47.485834], "type": "Point"}, "properties": {"classification": "Other", "contactEmail": "jslagel@slapharma.com", "contactPhone": "01923681001", "dateEnrollment": "April 13, 2020", "description": "EPA-FFA to Treat Hospitalised Patients With COVID-19 (SARS-CoV-2)", "name": "NCT04335032", "primaryOutcome": "Evaluation of EPA-FFA efficacy compared to standard of care", "study_type": "Interventional", "time": "2020-04-01", "weburl": "https://clinicaltrials.gov/show/NCT04335032"}, "type": "Feature"}, {"geometry": {"coordinates": [-94.613587, 39.05635], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": ";msalathe@kumc.edu;msalathe@kumc.edu", "contactPhone": ";9135886000;913-588-6000", "dateEnrollment": "March 25, 2020", "description": "Study of Open Label Losartan in COVID-19", "name": "NCT04335123", "primaryOutcome": "Number of participants with treatment-related adverse events as assessed by protocol definition of AE", "study_type": "Interventional", "time": "2020-03-31", "weburl": "https://clinicaltrials.gov/show/NCT04335123"}, "type": "Feature"}, {"geometry": {"coordinates": [5.391673, 43.291008], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": ";francois.silhol@ap-hm.fr;francois.silhol@ap-hm.fr", "contactPhone": ";;", "dateEnrollment": "April 3, 2020", "description": "Renin Angiotensin System - CoronaVirus", "name": "NCT04337008", "primaryOutcome": "overactivity of the renin / aldosterone system", "study_type": "Interventional", "time": "2020-04-03", "weburl": "https://clinicaltrials.gov/show/NCT04337008"}, "type": "Feature"}, {"geometry": {"coordinates": [-75.195402, 39.952219], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "", "contactPhone": "", "dateEnrollment": "March 31, 2020", "description": "Elimination or Prolongation of ACE Inhibitors and ARB in Coronavirus Disease 2019", "name": "NCT04338009", "primaryOutcome": "Hierarchical composite endpoint", "study_type": "Interventional", "time": "2020-04-01", "weburl": "https://clinicaltrials.gov/show/NCT04338009"}, "type": "Feature"}, {"geometry": {"coordinates": [23.776498, 37.968196], "type": "Point"}, "properties": {"classification": "Advanced therapy medicinal products", "contactEmail": ";egiamarel@med.uoa.gr", "contactPhone": ";+302107480662", "dateEnrollment": "April 2, 2020", "description": "Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction", "name": "NCT04339712", "primaryOutcome": "Change of baseline total sequential organ failure assessment (SOFA) score;Improvement of lung involvement measurements;Increase of pO2/FiO2 ratio", "study_type": "Interventional", "time": "2020-04-01", "weburl": "https://clinicaltrials.gov/show/NCT04339712"}, "type": "Feature"}, {"geometry": {"coordinates": [-99.659171, 19.272361], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": ";;drmendietaz@yahoo.com", "contactPhone": ";;+52-722-276-5540", "dateEnrollment": "April 6, 2020", "description": "Hydroxychloroquine vs Nitazoxanide in Patients With COVID-19", "name": "NCT04341493", "primaryOutcome": "Mechanical ventilation requirement", "study_type": "Interventional", "time": "2020-04-07", "weburl": "https://clinicaltrials.gov/show/NCT04341493"}, "type": "Feature"}, {"geometry": {"coordinates": [-71.083633, 42.379047], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": ";JLGustafson@mgh.harvard.edu;Chung.Raymond@mgh.harvard.edu", "contactPhone": ";6177243836;", "dateEnrollment": "May 15, 2020", "description": "Pegylated Interferon Lambda Treatment for COVID-19", "name": "NCT04343976", "primaryOutcome": "Undetectable COVID PCR at day 7", "study_type": "Interventional", "time": "2020-04-09", "weburl": "https://clinicaltrials.gov/show/NCT04343976"}, "type": "Feature"}, {"geometry": {"coordinates": [-77.468949, 37.498042], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": ";;mkashiouris@vcu.edu;brian.davis1@vcuhealth.org", "contactPhone": ";;804-305-7187;", "dateEnrollment": "June 2020", "description": "Early Infusion of Vitamin C for Treatment of Novel COVID-19 Acute Lung Injury (EVICT-CORONA-ALI)", "name": "NCT04344184", "primaryOutcome": "Number of ventilator-free days", "study_type": "Interventional", "time": "2020-04-09", "weburl": "https://clinicaltrials.gov/show/NCT04344184"}, "type": "Feature"}, {"geometry": {"coordinates": [3.017069, 50.627336], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": ";", "contactPhone": ";", "dateEnrollment": "April 10, 2020", "description": "Early Risk Stratification of Patient Hospitalized for SARS-CoV2 Infection: Critical COVID-19 France CCF", "name": "NCT04344327", "primaryOutcome": "Death rate;Transfer to intensive care unit;Ventilation analysis", "study_type": "Observational", "time": "2020-04-09", "weburl": "https://clinicaltrials.gov/show/NCT04344327"}, "type": "Feature"}, {"geometry": {"coordinates": [5.927543, 43.133736], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": ";jean-eric.blatteau@intradef.gouv.fr;jean-eric.blatteau@intradef.gouv.fr", "contactPhone": ";483162189;483162189", "dateEnrollment": "April 14, 2020", "description": "Management by Hyperbaric Oxygen Therapy of Patients With Hypoxaemic Pneumonia With SARS-CoV-2 (COVID-19)", "name": "NCT04344431", "primaryOutcome": "Time to normalize the oxygen requirement (oxygeno-dependence)", "study_type": "Interventional", "time": "2020-04-09", "weburl": "https://clinicaltrials.gov/show/NCT04344431"}, "type": "Feature"}, {"geometry": {"coordinates": [-95.418597, 29.726315], "type": "Point"}, "properties": {"classification": "Advanced therapy medicinal products", "contactEmail": ";LaQuisa.Hill@bcm.edu;LaQuisa.Hill@bcm.edu", "contactPhone": ";(713) 441-1450;713-441-1450", "dateEnrollment": "May 2020", "description": "Mesenchymal Stromal Cells for the Treatment of SARS-CoV-2 Induced Acute Respiratory Failure (COVID-19 Disease)", "name": "NCT04345601", "primaryOutcome": "Incidence of unexpected adverse events;Improved oxygen saturations =93%", "study_type": "Interventional", "time": "2020-04-10", "weburl": "https://clinicaltrials.gov/show/NCT04345601"}, "type": "Feature"}, {"geometry": {"coordinates": [19.065286, 47.487241], "type": "Point"}, "properties": {"classification": "Advanced therapy medicinal products", "contactEmail": ";eszter.fodor@orthosera.com", "contactPhone": ";+36306640494", "dateEnrollment": "April 14, 2020", "description": "Anti COVID-19 Convalescent Plasma Therapy", "name": "NCT04345679", "primaryOutcome": "Changing of viral load of SARS-CoV2", "study_type": "Interventional", "time": "2020-04-11", "weburl": "https://clinicaltrials.gov/show/NCT04345679"}, "type": "Feature"}, {"geometry": {"coordinates": [2.427583, 41.556113], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": ";pere.clave@ciberehd.org;pere.clave@ciberehd.org", "contactPhone": ";+34937417700;+34937417700", "dateEnrollment": "April 14, 2020", "description": "Oropharyngeal Dysphagia in Patients With COVID-19", "name": "NCT04346212", "primaryOutcome": "Prevalence of oropharyngeal dysphagia", "study_type": "Observational", "time": "2020-04-10", "weburl": "https://clinicaltrials.gov/show/NCT04346212"}, "type": "Feature"}, {"geometry": {"coordinates": [2.334949, 48.873335], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "regis.peffaultdelatour@aphp.fr", "contactPhone": "1 42 49 96 39", "dateEnrollment": "April 16, 2020", "description": "CORIMUNO19-ECU: Trial Evaluating Efficacy and Safety of Eculizumab (Soliris) in Patients With COVID-19 Infection, Nested in the CORIMUNO-19 Cohort", "name": "NCT04346797", "primaryOutcome": "Survival without needs of intubation at day 14;Change in organ failure at day 3", "study_type": "Interventional", "time": "2020-04-06", "weburl": "https://clinicaltrials.gov/show/NCT04346797"}, "type": "Feature"}, {"geometry": {"coordinates": [16.333888, 48.236135], "type": "Point"}, "properties": {"classification": "Impact on helpers", "contactEmail": ";thomas.reiter@meduniwien.ac.at;thomas.reiter@meduniwien.ac.at", "contactPhone": ";+43140400;", "dateEnrollment": "April 11, 2020", "description": "Study to Determine the Immunization Status Among Nephrological Health Care Personnel Against SARS-CoV-2 in a Single Center Over the Course of 12 Months During the Worldwide COVID-19 Pandemic.", "name": "NCT04347694", "primaryOutcome": "Status of Immunization", "study_type": "Observational", "time": "2020-04-12", "weburl": "https://clinicaltrials.gov/show/NCT04347694"}, "type": "Feature"}, {"geometry": {"coordinates": [-74.352661, 40.556358], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": ";Brittany.Sinclaire@HackensackMeridian.org;Brittany.Sinclaire@HackensackMeridian.org", "contactPhone": ";551-996-8073;551-996-8073", "dateEnrollment": "March 27, 2020", "description": "A Prospective \"Universal\" Observational Database for COVID-19", "name": "NCT04347993", "primaryOutcome": "Need for hospitalization;Duration of hospitalization;Need for ICU/Ventilator Support;Duration of ICU/Ventilator Support;Overall Survival", "study_type": "Observational [Patient Registry]", "time": "2020-04-13", "weburl": "https://clinicaltrials.gov/show/NCT04347993"}, "type": "Feature"}, {"geometry": {"coordinates": [-47.019488, -22.953424], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "", "contactPhone": "", "dateEnrollment": "April 20, 2020", "description": "Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Ambulatory Patients With Mild COVID-19", "name": "NCT04348474", "primaryOutcome": "Change in Clinical Condition", "study_type": "Interventional", "time": "2020-04-13", "weburl": "https://clinicaltrials.gov/show/NCT04348474"}, "type": "Feature"}, {"geometry": {"coordinates": [6.190994, 48.685023], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": ";c.bertholdt@chru-nancy.fr;c.bertholdt@chru-nancy.fr", "contactPhone": ";+3383344312;", "dateEnrollment": "April 16, 2020", "description": "Birth Experience During COVID-19 Confinement", "name": "NCT04348929", "primaryOutcome": "\"Labor Agentry Scale questionnaire\" score in immediate post-partum (duration of hospital stay)", "study_type": "Interventional", "time": "2020-04-10", "weburl": "https://clinicaltrials.gov/show/NCT04348929"}, "type": "Feature"}, {"geometry": {"coordinates": [-83.194813, 42.514539], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": ";Maureen.Cooney@beaumont.org;Maureen.Cooney@beaumont.org", "contactPhone": ";248-551-0099;248-551-0099", "dateEnrollment": "April 10, 2020", "description": "Beaumont Health Large-scale Automated Serologic Testing for COVID-19", "name": "NCT04349202", "primaryOutcome": "Prevalence COVID antibodies in employees of Beaumont Health", "study_type": "Observational", "time": "2020-04-13", "weburl": "https://clinicaltrials.gov/show/NCT04349202"}, "type": "Feature"}, {"geometry": {"coordinates": [2.337993, 48.830233], "type": "Point"}, "properties": {"classification": "Advanced therapy medicinal products", "contactEmail": ";;a.mazeraud@ghu-paris.fr;", "contactPhone": ";;0145658902;", "dateEnrollment": "April 11, 2020", "description": "Polyvalent Immunoglobulin in COVID-19 Related ARds", "name": "NCT04350580", "primaryOutcome": "Ventilator-free days", "study_type": "Interventional", "time": "2020-04-08", "weburl": "https://clinicaltrials.gov/show/NCT04350580"}, "type": "Feature"}, {"geometry": {"coordinates": [11.38226, 47.262729], "type": "Point"}, "properties": {"classification": "Other", "contactEmail": ";klin-pharmakologie@meduniwien.ac.at", "contactPhone": ";+4314040029810", "dateEnrollment": "April 16, 2020", "description": "Austrian CoronaVirus Adaptive Clinical Trial (COVID-19)", "name": "NCT04351724", "primaryOutcome": "sustained improvement (>48h) of one point on the WHO Scale", "study_type": "Interventional", "time": "2020-04-10", "weburl": "https://clinicaltrials.gov/show/NCT04351724"}, "type": "Feature"}, {"geometry": {"coordinates": [6.915045, 50.923825], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "volker.burst@uk-koeln.de;volker.burst@uk-koeln.de", "contactPhone": "+4922147897222;+49(0)221 478 86285", "dateEnrollment": "April 20, 2020", "description": "Registry for Clinical Presentation and Management of Patients With COVID-19 in the Emergency Room", "name": "NCT04351854", "primaryOutcome": "Identification of risk factors present at the earliest stage of hospital care (i.e. in the ED) that warrant hospital admission.", "study_type": "Observational", "time": "2020-04-16", "weburl": "https://clinicaltrials.gov/show/NCT04351854"}, "type": "Feature"}, {"geometry": {"coordinates": [118.816211, 32.107639], "type": "Point"}, "properties": {"classification": "Vaccines", "contactEmail": ";jszfc@vip.sina.com;413659915@qq.com", "contactPhone": ";86-18118996996;86-18751728180", "dateEnrollment": "April 16, 2020", "description": "Safety and Immunogenicity Study of Inactivated Vaccine for Prophylaxis of SARS CoV-2 Infection (COVID-19)", "name": "NCT04352608", "primaryOutcome": "Safety indexes of adverse reactions;Immunogenicity indexes of neutralizing-antibody seroconversion rates for the emergency vaccination schedule (day 0,14);Immunogenicity indexes of neutralizing-antibody seroconversion rates for the routine vaccination schedule (day 0,28)", "study_type": "Interventional", "time": "2020-04-14", "weburl": "https://clinicaltrials.gov/show/NCT04352608"}, "type": "Feature"}, {"geometry": {"coordinates": [-97.726592, 30.289482], "type": "Point"}, "properties": {"classification": "Diagnosis", "contactEmail": "dr.natale@gmail.com;dr.natale@gmail.com", "contactPhone": "512-544-8186;", "dateEnrollment": "March 27, 2020", "description": "ANTIBODY BASED TESTS FOR SARSCoV-2 COVID-19) - Evaluation of Patients and Healthcare Providers in the Confines of Healthcare Settings", "name": "NCT04352764", "primaryOutcome": "prevalence of COVID-19 exposure", "study_type": "Observational [Patient Registry]", "time": "2020-04-16", "weburl": "https://clinicaltrials.gov/show/NCT04352764"}, "type": "Feature"}, {"geometry": {"coordinates": [-73.973365, 40.759889], "type": "Point"}, "properties": {"classification": "Impact on helpers", "contactEmail": ";bconnor1@gmail.com;bconnor1@gmail.com", "contactPhone": ";9172138998;212-988-2800", "dateEnrollment": "April 24, 2020", "description": "HEalth Care Worker pROphylaxis Against COVID-19: The HERO Trial", "name": "NCT04352946", "primaryOutcome": "Cumulative Incidence of COVID-19 Infection", "study_type": "Interventional", "time": "2020-04-16", "weburl": "https://clinicaltrials.gov/show/NCT04352946"}, "type": "Feature"}, {"geometry": {"coordinates": [-73.691975, 40.759295], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": ";phs@prohealth-care.com;", "contactPhone": ";516-656-6500;516-656-6500", "dateEnrollment": "April 7, 2020", "description": "PATCH 2&3:Prevention & Treatment of COVID-19 (Severe Acute Respiratory Syndrome Coronavirus 2) With Hydroxychloroquine", "name": "NCT04353037", "primaryOutcome": "Sub Study 1: Patients;Sub Study 2: Health Care Workers", "study_type": "Interventional", "time": "2020-04-09", "weburl": "https://clinicaltrials.gov/show/NCT04353037"}, "type": "Feature"}, {"geometry": {"coordinates": [72.458626, 22.869808], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "anil.avhad@cadilapharma.co.in", "contactPhone": "919833454044", "dateEnrollment": "April 30, 2020", "description": "Clinical Trial to Evaluate Mycobacterium w in Preventing COVID-19 in Subjects at Risk of Getting Infected With COVID-19", "name": "NCT04353518", "primaryOutcome": "Number of subject acquiring COVID-19 infection", "study_type": "Interventional", "time": "2020-04-16", "weburl": "https://clinicaltrials.gov/show/NCT04353518"}, "type": "Feature"}, {"geometry": {"coordinates": [3.017116, 50.628088], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": ";covid19.fai2r@chru-lille.fr;", "contactPhone": ";320445962;0320445962", "dateEnrollment": "April 18, 2020", "description": "Covid-19 in Patients With Chronic Inflammatory Rheumatism, Auto-immune or Auto-inflammatory Rare and Non-rare Diseases", "name": "NCT04353609", "primaryOutcome": "Proportion of patients presenting a severe form of covid-19 requiring an intensive care unit admission or leading to death", "study_type": "Observational", "time": "2020-04-15", "weburl": "https://clinicaltrials.gov/show/NCT04353609"}, "type": "Feature"}, {"geometry": {"coordinates": [-73.989526, 40.758481], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": ";emily.beato@nyulangone.org;", "contactPhone": ";+1 212 263 6411;", "dateEnrollment": "April 3, 2020", "description": "COVID-19 PrEP HCW HCQ Study", "name": "NCT04354870", "primaryOutcome": "Frequency of seroconversion to SARS-CoV-2", "study_type": "Interventional", "time": "2020-04-16", "weburl": "https://clinicaltrials.gov/show/NCT04354870"}, "type": "Feature"}, {"geometry": {"coordinates": [34.827189, 32.063146], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "", "contactPhone": "", "dateEnrollment": "April 11, 2020", "description": "Open Label Study to Compare Efficacy, Safety and Tolerability of Hydroxychloroquine Combined With Azithromycin Compared to Hydroxychloroquine Combined With Camostat Mesylate and to \"no Treatment\" in SARS CoV 2 Virus", "name": "NCT04355052", "primaryOutcome": "clinical state as reflected by NEWS scoring;positive PCR", "study_type": "Interventional", "time": "2020-04-16", "weburl": "https://clinicaltrials.gov/show/NCT04355052"}, "type": "Feature"}, {"geometry": {"coordinates": [2.334565, 48.873277], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": ";christelle.vauloup-fellous@aphp.fr", "contactPhone": ";01 45 59 33 14", "dateEnrollment": "April 24, 2020", "description": "Prevalence and Impact of COVID-19 Infection in Pregnant Women, Fetuses and Newborns", "name": "NCT04355234", "primaryOutcome": "Seroprevalence or Number of women who are positive for SARS-CoV-2 in parturient woman", "study_type": "Interventional", "time": "2020-04-17", "weburl": "https://clinicaltrials.gov/show/NCT04355234"}, "type": "Feature"}, {"geometry": {"coordinates": [-46.720965, -23.567754], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": ";ricardo.palacios@butantan.gov.br", "contactPhone": ";+55(11)26279300", "dateEnrollment": "May 15, 2020", "description": "Assessment of Incidence of SARS-CoV-2 Infection and COVID-19 in Brazil (AVISA)", "name": "NCT04355338", "primaryOutcome": "Incidence of SARS-CoV-2 infection;Incidence of COVID-19", "study_type": "Observational", "time": "2020-04-17", "weburl": "https://clinicaltrials.gov/show/NCT04355338"}, "type": "Feature"}, {"geometry": {"coordinates": [2.334949, 48.873335], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": ";mohammed.rahaoui@aphp.fr", "contactPhone": ";+33 1 48 95 59 77", "dateEnrollment": "May 5, 2020", "description": "Efficacy of Captopril in Covid-19 Patients With Severe Acute Respiratory Syndrome (SARS) CoV-2 Pneumonia (CAPTOCOVID)", "name": "NCT04355429", "primaryOutcome": "Efficacy of captopril nebulization addition to standard of care compared to standard of care.", "study_type": "Interventional", "time": "2020-04-17", "weburl": "https://clinicaltrials.gov/show/NCT04355429"}, "type": "Feature"}, {"geometry": {"coordinates": [2.334949, 48.873335], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": ";yacine.tandjaoui-lambiotte@aphp.fr", "contactPhone": ";06 64 17 19 36", "dateEnrollment": "April 17, 2020", "description": "Dissemination of SARS-COV-2 (COVID-19) in the Environment of Infected Patients Admitted to Intensive Care Unit", "name": "NCT04355481", "primaryOutcome": "Estimate the proportion of patients hospitalized in intensive care for a SARS-Cov-2 viral lung infection and contaminating their environment at 1 meter.", "study_type": "Observational", "time": "2020-04-17", "weburl": "https://clinicaltrials.gov/show/NCT04355481"}, "type": "Feature"}, {"geometry": {"coordinates": [76.287294, 9.964794], "type": "Point"}, "properties": {"classification": "Diagnosis", "contactEmail": ";marie-pierre.revel@aphp.fr;marie.pierre@aphp.fr", "contactPhone": ";+33 1 42 34 79 10;+33 1 42 34 79 10", "dateEnrollment": "April 2020", "description": "Computed Tomography for COVID-19 Diagnosis", "name": "NCT04355507", "primaryOutcome": "Predictive values of CT criteria", "study_type": "Observational", "time": "2020-04-17", "weburl": "https://clinicaltrials.gov/show/NCT04355507"}, "type": "Feature"}, {"geometry": {"coordinates": [3.834035, 43.646637], "type": "Point"}, "properties": {"classification": "Diagnosis", "contactEmail": "", "contactPhone": "", "dateEnrollment": "April 1, 2019", "description": "Combination of Chest Scanography and Nasal Viral Detection Test to Detect COVID-19 Positive Patients Before Surgical Intervention in a University Hospital During Coronavirus Pandemia", "name": "NCT04355715", "primaryOutcome": "Confirmed diagnosis of COVID-19 infection", "study_type": "Observational", "time": "2020-04-17", "weburl": "https://clinicaltrials.gov/show/NCT04355715"}, "type": "Feature"}, {"geometry": {"coordinates": [18.627208, 54.366312], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": ";r.owczuk@gumed.edu.pl;magwuj@gumed.edu.pl", "contactPhone": ";+48583493270;+48583493357", "dateEnrollment": "April 15, 2020", "description": "Ventil Device Usefulness in Mechanically Ventilated ICU Patients", "name": "NCT04355754", "primaryOutcome": "Number of cases in which it was necessary to stop using Ventil and to step- back to ventilation without this flow divider", "study_type": "Interventional", "time": "2020-04-16", "weburl": "https://clinicaltrials.gov/show/NCT04355754"}, "type": "Feature"}, {"geometry": {"coordinates": [-75.553896, 39.762566], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "medinfo@incyte.com", "contactPhone": "1.855.463.3463", "dateEnrollment": "April 15, 2020", "description": "Expanded Access Program of Ruxolitinib for the Emergency Treatment of Cytokine Storm From COVID-19 Infection", "name": "NCT04355793", "primaryOutcome": "", "study_type": "Expanded Access", "time": "2020-04-18", "weburl": "https://clinicaltrials.gov/show/NCT04355793"}, "type": "Feature"}, {"geometry": {"coordinates": [114.113622, 22.286544], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "cwdsiu@hku.hk", "contactPhone": "852-2255-4694", "dateEnrollment": "April 20, 2020", "description": "Opportunistic Screening for Asymptomatic Left Ventricular Dysfunction in Coronavirus Disease 2019 (COVID19) Survivors", "name": "NCT04355884", "primaryOutcome": "New-onset cardiac arrhythmia;Elevation of NT-proBNP;Left ventricular dysfunction", "study_type": "Observational", "time": "2020-04-19", "weburl": "https://clinicaltrials.gov/show/NCT04355884"}, "type": "Feature"}, {"geometry": {"coordinates": [8.53365, 47.393038], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": ";martin.schlaepfer@usz.ch;martin.schlaepfer@usz.ch", "contactPhone": ";+41442554690;+41442554690", "dateEnrollment": "April 23, 2020", "description": "Sevoflurane in COVID-19 ARDS (SevCov)", "name": "NCT04355962", "primaryOutcome": "Composite outcome of death rate (rate of patients that did not survive) and organ failure rate (rate of patients surviving with persistent organ dysfunction) at day 28", "study_type": "Interventional", "time": "2020-03-26", "weburl": "https://clinicaltrials.gov/show/NCT04355962"}, "type": "Feature"}, {"geometry": {"coordinates": [10.719561, 59.939959], "type": "Point"}, "properties": {"classification": "Other", "contactEmail": ";;", "contactPhone": ";;", "dateEnrollment": "March 31, 2020", "description": "The Mental Health Status of the General Population During the COVID-19 Pandemic and Its Association With Adherence to Government-initiated Non-pharmacological Epidemiological Interventions (NPI's)", "name": "NCT04356365", "primaryOutcome": "Patient Health Questionnaire 9;Generalized Anxiety Disorder 7;Measures of adherence", "study_type": "Observational", "time": "2020-04-21", "weburl": "https://clinicaltrials.gov/show/NCT04356365"}, "type": "Feature"}, {"geometry": {"coordinates": [12.549154, 55.71252], "type": "Point"}, "properties": {"classification": "Impact on helpers", "contactEmail": ";;", "contactPhone": ";;", "dateEnrollment": "March 23, 2020", "description": "COVID-19 Surveillance of Patients and Healthcare Workers in a Hospital Department", "name": "NCT04356560", "primaryOutcome": "Incidence of healthcare workers with SARS-CoV-2;Incidence of ENT patients with SARS-CoV-2;Development of SARS-CoV-2 antibodies among healthcare workers", "study_type": "Observational", "time": "2020-04-13", "weburl": "https://clinicaltrials.gov/show/NCT04356560"}, "type": "Feature"}, {"geometry": {"coordinates": [4.37973, 50.82422], "type": "Point"}, "properties": {"classification": "Impact on helpers", "contactEmail": "", "contactPhone": "", "dateEnrollment": "April 30, 2020", "description": "Immune Response to Covid-19 in 300 Health Care Workers With Mild Symptoms", "name": "NCT04356586", "primaryOutcome": "Percentage of serological positive healthcare workers;Percentage of HCW with positive Saliva-sabs", "study_type": "Observational [Patient Registry]", "time": "2020-04-17", "weburl": "https://clinicaltrials.gov/show/NCT04356586"}, "type": "Feature"}, {"geometry": {"coordinates": [-74.628486, 40.587826], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": ";Alexandre.Brkovic@bauschhealth.com", "contactPhone": ";1 514-904-4863", "dateEnrollment": "April 2020", "description": "Study to Evaluate the Safety and Efficacy of VIRAZOLE® in Hospitalized Adult Participants With Respiratory Distress Due to COVID-19", "name": "NCT04356677", "primaryOutcome": "Change in the clinical status severity (CSS) rating from the first dose date up to the completion of treatment", "study_type": "Interventional", "time": "2020-04-20", "weburl": "https://clinicaltrials.gov/show/NCT04356677"}, "type": "Feature"}, {"geometry": {"coordinates": [-98.200927, 19.026329], "type": "Point"}, "properties": {"classification": "Advanced therapy medicinal products", "contactEmail": "jolivares@hsctmexico.com;jolivares@hsctmexico.com", "contactPhone": "2222438100;2222438100", "dateEnrollment": "April 13, 2020", "description": "COPLA Study: Treatment of Severe Forms of COronavirus Infection With Convalescent PLAsma", "name": "NCT04357106", "primaryOutcome": "Lung injury;Overall survival", "study_type": "Interventional", "time": "2020-04-14", "weburl": "https://clinicaltrials.gov/show/NCT04357106"}, "type": "Feature"}, {"geometry": {"coordinates": [8.837584, 45.807865], "type": "Point"}, "properties": {"classification": "Diagnosis", "contactEmail": ";l.azzi@uninsubria.it;l.azzi@uninsubria.it", "contactPhone": ";+393476766856;+39-3476766856", "dateEnrollment": "April 16, 2020", "description": "Rapid Salivary Test to Detect SARS-CoV-2 (COVID-19)", "name": "NCT04357327", "primaryOutcome": "Sensibility;Specificity", "study_type": "Interventional", "time": "2020-04-15", "weburl": "https://clinicaltrials.gov/show/NCT04357327"}, "type": "Feature"}, {"geometry": {"coordinates": [23.827994, 38.046348], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": ";egiamarel@med.uoa.gr", "contactPhone": ";+302107480662", "dateEnrollment": "April 15, 2020", "description": "suPAR-guided Anakinra Treatment for Validation of the Risk and Management of Respiratory Failure by COVID-19 (SAVE)", "name": "NCT04357366", "primaryOutcome": "The ratio of patients who will not develop serious respiratory failure (SRF)", "study_type": "Interventional", "time": "2020-04-20", "weburl": "https://clinicaltrials.gov/show/NCT04357366"}, "type": "Feature"}, {"geometry": {"coordinates": [2.526649, 48.882153], "type": "Point"}, "properties": {"classification": "Impact on helpers", "contactEmail": ";", "contactPhone": ";", "dateEnrollment": "April 1, 2020", "description": "Psychological Outcome of COVID-19 Lockdown on Psychiatric Hospital Staff and Close Relatives", "name": "NCT04357418", "primaryOutcome": "State Anxiety assessed by the State-Trait Anxiety Inventory (STAI);State Anxiety assessed by the State-Trait Anxiety Inventory (STAI)", "study_type": "Observational", "time": "2020-04-16", "weburl": "https://clinicaltrials.gov/show/NCT04357418"}, "type": "Feature"}, {"geometry": {"coordinates": [12.145696, 54.09242], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": ";Volha.Skrahina@centogene.com", "contactPhone": ";+49 (0)38180113594", "dateEnrollment": "April 20, 2020", "description": "COVID-19 Epidemic Response Study", "name": "NCT04357496", "primaryOutcome": "Identification of prognostic parameters for SARS-CoV-2 infected participants.", "study_type": "Observational", "time": "2020-04-20", "weburl": "https://clinicaltrials.gov/show/NCT04357496"}, "type": "Feature"}, {"geometry": {"coordinates": [114.2839, 36.017922], "type": "Point"}, "properties": {"classification": "Other", "contactEmail": "", "contactPhone": "", "dateEnrollment": "April 14, 2020", "description": "Assessing the System for High-Intensity Evaluation During Radiotherapy During Changes in Response to COVID-19", "name": "NCT04357574", "primaryOutcome": "Radiation Oncology providers perception of of telehealth for on treatment patients in lieu of in person on treatment visits during COVID-19", "study_type": "Observational", "time": "2020-04-20", "weburl": "https://clinicaltrials.gov/show/NCT04357574"}, "type": "Feature"}, {"geometry": {"coordinates": [-0.621876, 44.845358], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": ";lmorisset@ch-versailles.fr", "contactPhone": ";+33139239785", "dateEnrollment": "May 1, 2020", "description": "IMATINIB IN COVID-19 DISEASE IN AGED PATIENTS.", "name": "NCT04357613", "primaryOutcome": "To evaluate the benefit of early imatinib therapy to prevent severe COVID-19 disease in hospitalized aged patients.", "study_type": "Interventional", "time": "2020-04-20", "weburl": "https://clinicaltrials.gov/show/NCT04357613"}, "type": "Feature"}, {"geometry": {"coordinates": [-77.484395, 37.514478], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": ";Brian.Davis5@va.gov;Brian.Davis5@va.gov", "contactPhone": ";804-675-5000;", "dateEnrollment": "April 16, 2020", "description": "Administration of Intravenous Vitamin C in Novel Coronavirus Infection (COVID-19) and Decreased Oxygenation", "name": "NCT04357782", "primaryOutcome": "Incidence of adverse events;Incidence of serious adverse reactions;Incidence of adverse reactions", "study_type": "Interventional", "time": "2020-04-17", "weburl": "https://clinicaltrials.gov/show/NCT04357782"}, "type": "Feature"}, {"geometry": {"coordinates": [-3.693371, 40.450517], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": ";mariadelrosario.garcia@salud.madrid.org;mariadelrosario.garcia@salud.madid.org", "contactPhone": ";+34 91 5202473;+34915202438", "dateEnrollment": "April 13, 2020", "description": "Efficacy of Subcutaneous Sarilumab in Hospitalised Patients With Moderate-severe COVID-19 Infection (SARCOVID)", "name": "NCT04357808", "primaryOutcome": "Mean change in clinical status assessment using the 7-point ordinal scale at day 7 after randomisation;Duration of hospitalisation (days);Death", "study_type": "Interventional", "time": "2020-04-14", "weburl": "https://clinicaltrials.gov/show/NCT04357808"}, "type": "Feature"}, {"geometry": {"coordinates": [7.408581, 46.963672], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": ";davidshiva.srivastava@insel.ch;davidshiva.srivastava@insel.ch", "contactPhone": ";+41 31 632 45 87;+41316324587", "dateEnrollment": "May 1, 2020", "description": "WAVE. Wearable-based COVID-19 Markers for Prediction of Clinical Trajectories", "name": "NCT04357834", "primaryOutcome": "Diagnostic accuracy of smartwatch data in predicting ICU requirement in COVID-19 contracted inpatients quantified as the area under the receiver operator characteristics curve (AUC ROC > 0.85).", "study_type": "Observational", "time": "2020-04-17", "weburl": "https://clinicaltrials.gov/show/NCT04357834"}, "type": "Feature"}, {"geometry": {"coordinates": [-4.815434, 37.884196], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": ";uicec@imibic.org;", "contactPhone": ";0034671596070;", "dateEnrollment": "April 27, 2020", "description": "Clinical Trial of Sarilumab in Adults With COVID-19", "name": "NCT04357860", "primaryOutcome": "Ventilation requirements", "study_type": "Interventional", "time": "2020-04-20", "weburl": "https://clinicaltrials.gov/show/NCT04357860"}, "type": "Feature"}, {"geometry": {"coordinates": [28.924825, 41.021355], "type": "Point"}, "properties": {"classification": "Other", "contactEmail": ";salihagurdal@hotmail.com;salihagurdal@hotmail.com", "contactPhone": ";+905555925304;+905555925304", "dateEnrollment": "May 2020", "description": "Comparison of New Coronavirus (COVID-19) Awareness in Individuals of Different Age Groups: Analysis of Turkey", "name": "NCT04357886", "primaryOutcome": "COVID-19 Awareness Survey", "study_type": "Observational", "time": "2020-04-20", "weburl": "https://clinicaltrials.gov/show/NCT04357886"}, "type": "Feature"}, {"geometry": {"coordinates": [-1.537251, 47.196103], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "marie.bronnec@chu-nantes.fr", "contactPhone": "02.40.84.76.20", "dateEnrollment": "April 25, 2020", "description": "PSYCHIATRIC Disorders and Covid-19", "name": "NCT04358042", "primaryOutcome": "impact of the COVID-19 pandemic on psychiatric symptomatology", "study_type": "Observational [Patient Registry]", "time": "2020-04-08", "weburl": "https://clinicaltrials.gov/show/NCT04358042"}, "type": "Feature"}, {"geometry": {"coordinates": [-90.093517, 29.972081], "type": "Point"}, "properties": {"classification": "Advanced therapy medicinal products", "contactEmail": "nsaba@tulane.edu;nsaba@tulane.edu", "contactPhone": "504-988-5263;504-988-5263", "dateEnrollment": "May 1, 2020", "description": "Expanded Access to Convalescent Plasma to Treat and Prevent Pulmonary Complications Associated With COVID-19", "name": "NCT04358211", "primaryOutcome": "", "study_type": "Expanded Access", "time": "2020-04-17", "weburl": "https://clinicaltrials.gov/show/NCT04358211"}, "type": "Feature"}, {"geometry": {"coordinates": [-58.861264, -34.455733], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "", "contactPhone": "", "dateEnrollment": "April 15, 2020", "description": "Liver Injury in Patients With COVID-19", "name": "NCT04358380", "primaryOutcome": "Liver injury in patients with COVID-19", "study_type": "Observational", "time": "2020-04-18", "weburl": "https://clinicaltrials.gov/show/NCT04358380"}, "type": "Feature"}, {"geometry": {"coordinates": [-74.448659, 40.467475], "type": "Point"}, "properties": {"classification": "Advanced therapy medicinal products", "contactEmail": "mdinubile@bioaegistx.com", "contactPhone": "609-706-5866", "dateEnrollment": "June 2020", "description": "Rhu-pGSN for Severe Covid-19 Pneumonia", "name": "NCT04358406", "primaryOutcome": "Efficacy: Proportion of subjects alive not on vasopressors, mechanical ventilator, and dialysis;Safety and Tolerability: Proportion of subjects with serious adverse events (SAEs)", "study_type": "Interventional", "time": "2020-04-16", "weburl": "https://clinicaltrials.gov/show/NCT04358406"}, "type": "Feature"}, {"geometry": {"coordinates": [-122.272872, 37.803543], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "", "contactPhone": "", "dateEnrollment": "April 1, 2020", "description": "COVID-19 Mortality Prediction Model", "name": "NCT04358510", "primaryOutcome": "Mortality outcome in COVID-19 ICU patients;Mortality outcome in mechanically ventilated ICU patients;Mortality outcome in pneumonia ICU patients", "study_type": "Observational", "time": "2020-04-20", "weburl": "https://clinicaltrials.gov/show/NCT04358510"}, "type": "Feature"}, {"geometry": {"coordinates": [-122.288317, 37.819979], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "", "contactPhone": "", "dateEnrollment": "April 1, 2020", "description": "Classification of COVID-19 Infection in Posteroanterior Chest X-rays", "name": "NCT04358536", "primaryOutcome": "Identification of COVID-19", "study_type": "Observational", "time": "2020-04-20", "weburl": "https://clinicaltrials.gov/show/NCT04358536"}, "type": "Feature"}, {"geometry": {"coordinates": [11.079984, 43.855125], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "", "contactPhone": "", "dateEnrollment": "March 16, 2020", "description": "Baricitinib Therapy in COVID-19", "name": "NCT04358614", "primaryOutcome": "To assess the safety of baricitinib combined with antiviral (lopinavir-ritonavir) in terms of serious or non-serious adverse events incidence rate.", "study_type": "Interventional", "time": "2020-04-19", "weburl": "https://clinicaltrials.gov/show/NCT04358614"}, "type": "Feature"}, {"geometry": {"coordinates": [2.136741, 41.405884], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "plgambus@clinic.cat", "contactPhone": "+34687075332", "dateEnrollment": "April 15, 2020", "description": "Dexmedetomidine to Improve Outcomes of ARDS in Critical Care COVID-19 Patients", "name": "NCT04358627", "primaryOutcome": "Mechanical ventilation", "study_type": "Observational", "time": "2020-04-15", "weburl": "https://clinicaltrials.gov/show/NCT04358627"}, "type": "Feature"}, {"geometry": {"coordinates": [4.304149, 43.839389], "type": "Point"}, "properties": {"classification": "Impact on helpers", "contactEmail": "jean.yves.lefrant@chu-nimes.fr;jean.yves.lefrant@chu-nimes.fr", "contactPhone": "+33466683331;+33466683331", "dateEnrollment": "April 9, 2020", "description": "Anxiety and Work Resilience Among Tertiary University Hospital Workers During the COVID-19 Outbreak: An Online Survey", "name": "NCT04358640", "primaryOutcome": "Anxiety", "study_type": "Observational", "time": "2020-04-21", "weburl": "https://clinicaltrials.gov/show/NCT04358640"}, "type": "Feature"}, {"geometry": {"coordinates": [72.443181, 22.886244], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "anil.avhad@cadilapharma.co.in", "contactPhone": "919833454044", "dateEnrollment": "April 30, 2020", "description": "Clinical Trial of Mycobacterium w in COVID-19 Positive Patients, Hospitalized But Not Critically Ill", "name": "NCT04358809", "primaryOutcome": "Number of patients with increased disease severity", "study_type": "Interventional", "time": "2020-04-21", "weburl": "https://clinicaltrials.gov/show/NCT04358809"}, "type": "Feature"}, {"geometry": {"coordinates": [-75.283383, 2.932135], "type": "Point"}, "properties": {"classification": "Other", "contactEmail": ";hggaitand@unal.edu.co", "contactPhone": ";(+57)-1-316500", "dateEnrollment": "May 11, 2020", "description": "Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia", "name": "NCT04359095", "primaryOutcome": "Mortality;Number of Participants with Treatment Related Severe Adverse Events as Assessed by the NCORP Guidance for Collection of Adverse Events Related to COVID-19 Infection", "study_type": "Interventional", "time": "2020-04-15", "weburl": "https://clinicaltrials.gov/show/NCT04359095"}, "type": "Feature"}, {"geometry": {"coordinates": [118.776612, 32.071115], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "", "contactPhone": "", "dateEnrollment": "March 5, 2020", "description": "Different PEEP Settings of COVID-19 Induced ARDS", "name": "NCT04359251", "primaryOutcome": "Respiratory system compliance improvement", "study_type": "Interventional", "time": "2020-04-13", "weburl": "https://clinicaltrials.gov/show/NCT04359251"}, "type": "Feature"}, {"geometry": {"coordinates": [8.782232, 50.817461], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": ";neubauer@staff.uni-marburg.de", "contactPhone": ";+49 6421 58 66273", "dateEnrollment": "May 2020", "description": "Ruxolitinib for Treatment of Covid-19 Induced Lung Injury ARDS", "name": "NCT04359290", "primaryOutcome": "Overall survival", "study_type": "Interventional", "time": "2020-04-15", "weburl": "https://clinicaltrials.gov/show/NCT04359290"}, "type": "Feature"}, {"geometry": {"coordinates": [51.3699, 35.787418], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": ";;;;;;;sina.irvani@gmail.com", "contactPhone": ";;;;;;;09141182825", "dateEnrollment": "April 20, 2020", "description": "Azithromycin in Hospitalized COVID-19 Patients", "name": "NCT04359316", "primaryOutcome": "Time to clinical improvement", "study_type": "Interventional", "time": "2020-04-18", "weburl": "https://clinicaltrials.gov/show/NCT04359316"}, "type": "Feature"}, {"geometry": {"coordinates": [-73.132421, 40.925261], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": ";PatchStudy@stonybrookmedicine.edu;PatchStudy@stonybrookmedicine.edu", "contactPhone": ";631-371-3309;631-371-3309", "dateEnrollment": "April 20, 2020", "description": "Estrogen Patch for COVID-19 Symptoms", "name": "NCT04359329", "primaryOutcome": "Rate of Hospitalization;Rate of Transfer to Intensive Care Unit;Rate of Intubation;Rate of Death", "study_type": "Interventional", "time": "2020-04-21", "weburl": "https://clinicaltrials.gov/show/NCT04359329"}, "type": "Feature"}, {"geometry": {"coordinates": [6.577026, 53.220974], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": ";;m.van.den.berge@umcg.nl", "contactPhone": ";;+31503615260", "dateEnrollment": "June 2020", "description": "Nasal Epithelial Genetic and Single Cell RNA COVID-19 Study", "name": "NCT04359459", "primaryOutcome": "Nasal epithelial transcriptional response to SARS-CoV2", "study_type": "Observational", "time": "2020-04-20", "weburl": "https://clinicaltrials.gov/show/NCT04359459"}, "type": "Feature"}, {"geometry": {"coordinates": [51.354455, 35.803854], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": ";;;;;;;sina.irvani@gmail.com;", "contactPhone": ";;;;;;;+989141182825;", "dateEnrollment": "April 20, 2020", "description": "Favipiravir in Hospitalized COVID-19 Patients", "name": "NCT04359615", "primaryOutcome": "Time to clinical improvement", "study_type": "Interventional", "time": "2020-04-18", "weburl": "https://clinicaltrials.gov/show/NCT04359615"}, "type": "Feature"}, {"geometry": {"coordinates": [-119.223249, 34.256628], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": ";drsabinehazan@progenabiome.com;sabinehazan@aim.com", "contactPhone": ";805-339-0549;805-339-0549", "dateEnrollment": "April 16, 2020", "description": "A Study to Explore the Role of Gut Flora in COVID-19 Infection", "name": "NCT04359836", "primaryOutcome": "Correlation of Microbiome to Disease via Relative Abundance Found in Microbiome Sequencing", "study_type": "Observational", "time": "2020-04-20", "weburl": "https://clinicaltrials.gov/show/NCT04359836"}, "type": "Feature"}, {"geometry": {"coordinates": [-1.07227, 50.849983], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "samuel.robson@port.ac.uk;", "contactPhone": "+44 (0) 23 9284 2144;", "dateEnrollment": "May 2020", "description": "Sequencing and Tracking of Phylogeny in COVID-19 Study", "name": "NCT04359849", "primaryOutcome": "To produce whole genome sequences for the SARS-CoV-2 virus from viral RNA samples", "study_type": "Observational", "time": "2020-04-20", "weburl": "https://clinicaltrials.gov/show/NCT04359849"}, "type": "Feature"}, {"geometry": {"coordinates": [0.701966, 47.404897], "type": "Point"}, "properties": {"classification": "Other", "contactEmail": "clarisse.dibao-dina@univ-tours.fr;clarisse.dibao-dina@univ-tours.fr", "contactPhone": "2 47 57 74 22;(0)2 47 36 60 19", "dateEnrollment": "April 2020", "description": "A Phone-call With a Student/General Practitioner Team to Impact Morbidity of Chronic Patients During COVID-19 Containment", "name": "NCT04359875", "primaryOutcome": "Hospitalization(s) at 1 month", "study_type": "Interventional", "time": "2020-04-18", "weburl": "https://clinicaltrials.gov/show/NCT04359875"}, "type": "Feature"}, {"geometry": {"coordinates": [12.102365, 54.085595], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": ";johannes.ehler@med.uni-rostock.de;johannes.ehler@med.uni-rostock.de", "contactPhone": ";+49381494146467;+49381494146467", "dateEnrollment": "April 15, 2020", "description": "Neurocognitive Impairment in Patients With COVID-19", "name": "NCT04359914", "primaryOutcome": "Incidence of delirium/neurocognitive impairment in adult and pediatric patients with COVID-19 compared to patients without COVID-19;Change in neuroaxonal injury biomarker levels in patients with COVID-19 compared to patients without COVID-19;Neurocognitive 3-months outcome in patients with COVID-19 compared to patients without COVID-19;Neurocognitive 3-months outcome in patients with COVID-19 compared to patients without COVID-19", "study_type": "Observational", "time": "2020-04-19", "weburl": "https://clinicaltrials.gov/show/NCT04359914"}, "type": "Feature"}, {"geometry": {"coordinates": [7.733309, 48.59369], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": ";frederic.blanc@chru-strasbourg.fr;frederic.blanc@chru-strasbourg.fr", "contactPhone": ";03 88 11 58 58;03 88 11 58 58", "dateEnrollment": "April 24, 2020", "description": "Efficacy of Hydroxychloroquine, Telmisartan and Azithromycin on the Survival of Hospitalized Elderly Patients With COVID-19", "name": "NCT04359953", "primaryOutcome": "Two-weeks survival rate", "study_type": "Interventional", "time": "2020-04-17", "weburl": "https://clinicaltrials.gov/show/NCT04359953"}, "type": "Feature"}, {"geometry": {"coordinates": [7.733309, 48.59369], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "charlesambroise.tacquard@chru-strasbourg.fr", "contactPhone": "369551608", "dateEnrollment": "April 17, 2020", "description": "Study of Hemostasis in Case of Severe COVID-19", "name": "NCT04359992", "primaryOutcome": "Platelet activation intensity with the occurrence of clinical thrombotic complications", "study_type": "Observational", "time": "2020-04-16", "weburl": "https://clinicaltrials.gov/show/NCT04359992"}, "type": "Feature"}, {"geometry": {"coordinates": [-75.548858, 43.722415], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": ";rbesthof@neurorxpharma.com", "contactPhone": ";+48425461134", "dateEnrollment": "June 1, 2020", "description": "Inhaled Aviptadil for the Treatment of Non-Acute Lung Injury in COVID-19", "name": "NCT04360096", "primaryOutcome": "Progression to ARDS", "study_type": "Interventional", "time": "2020-04-21", "weburl": "https://clinicaltrials.gov/show/NCT04360096"}, "type": "Feature"}, {"geometry": {"coordinates": [30.97748, 30.817938], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": ";vp_research@unv.tanta.edu.eg", "contactPhone": ";+201004706770", "dateEnrollment": "May 2020", "description": "Ivermectin and Nitazoxanide Combination Therapy for COVID-19", "name": "NCT04360356", "primaryOutcome": "Number of Patients with COVID-19-negative PCR", "study_type": "Interventional", "time": "2020-04-19", "weburl": "https://clinicaltrials.gov/show/NCT04360356"}, "type": "Feature"}, {"geometry": {"coordinates": [-77.442719, 39.451835], "type": "Point"}, "properties": {"classification": "Advanced therapy medicinal products", "contactEmail": "andrew.p.cap.mil@mail.mil", "contactPhone": "210-539-4858", "dateEnrollment": "June 2020", "description": "Treatment Of CORONAVIRUS DISEASE 2019 (COVID-19) With Anti-Sars-CoV-2 Convalescent Plasma (ASCoV2CP)", "name": "NCT04360486", "primaryOutcome": "", "study_type": "Expanded Access", "time": "2020-04-20", "weburl": "https://clinicaltrials.gov/show/NCT04360486"}, "type": "Feature"}, {"geometry": {"coordinates": [-87.614159, 41.805233], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "bpatel@medicine.bsd.uchicago.edu;bpatel@medicine.bsd.uchicago.edu", "contactPhone": "773-702-6800;773-702-6800", "dateEnrollment": "April 8, 2020", "description": "Long Term Outcomes of Patients With COVID-19", "name": "NCT04360538", "primaryOutcome": "Quality of Life score", "study_type": "Observational", "time": "2020-04-16", "weburl": "https://clinicaltrials.gov/show/NCT04360538"}, "type": "Feature"}, {"geometry": {"coordinates": [-157.865587, 21.296152], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": ";shikuma@hawaii.edu", "contactPhone": ";808 692-1328", "dateEnrollment": "July 1, 2020", "description": "Pilot Clinical Trial of the Safety and Efficacy of Telmisartan for the Mitigation of Pulmonary and Cardiac Complications in COVID-19 Patients", "name": "NCT04360551", "primaryOutcome": "Maximum clinical severity of disease", "study_type": "Interventional", "time": "2020-04-21", "weburl": "https://clinicaltrials.gov/show/NCT04360551"}, "type": "Feature"}, {"geometry": {"coordinates": [7.100888, 50.701482], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "christian.bode@ukbonn.de;christian.bode@ukb.uni-bonn.de", "contactPhone": "+49228287;+4922828714119", "dateEnrollment": "April 20, 2020", "description": "Precision Immunology to Determine the Immune Response in Patients With COVID-19", "name": "NCT04360733", "primaryOutcome": "Immune response", "study_type": "Observational", "time": "2020-04-22", "weburl": "https://clinicaltrials.gov/show/NCT04360733"}, "type": "Feature"}, {"geometry": {"coordinates": [18.6742, -34.050834], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": ";;mpumi.maxebengula@uct.ac.za", "contactPhone": ";;+27727633386", "dateEnrollment": "May 1, 2020", "description": "Chloroquine Outpatient Treatment Evaluation for HIV-Covid-19", "name": "NCT04360759", "primaryOutcome": "Event-free survival at 28 days post-randomization between experimental group and standard of care group", "study_type": "Interventional", "time": "2020-04-22", "weburl": "https://clinicaltrials.gov/show/NCT04360759"}, "type": "Feature"}, {"geometry": {"coordinates": [1.436456, 43.599546], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": ";dubucs.c@chu-toulouse.fr;dubucs.c@chu-toulouse.fr", "contactPhone": ";05 31 15 61 93;05 31 15 61 93", "dateEnrollment": "April 17, 2020", "description": "Assessment of Obstetric, Fetal and Neonatal Risks and Vertical SARS-CoV-2 Transmission During COVID-19 Pandemic", "name": "NCT04360811", "primaryOutcome": "number of positive COVID-19 women", "study_type": "Interventional", "time": "2020-04-22", "weburl": "https://clinicaltrials.gov/show/NCT04360811"}, "type": "Feature"}, {"geometry": {"coordinates": [-122.305709, 47.932856], "type": "Point"}, "properties": {"classification": "Other", "contactEmail": ";hunthoff9@gmail.com;hunthoff9@gmail.com", "contactPhone": ";206-601-5090;", "dateEnrollment": "April 24, 2020", "description": "Use of Telehealth Technology by Mental Health Care Professionals in Times of COVID-19 Pandemic", "name": "NCT04360850", "primaryOutcome": "responses to the survey questions", "study_type": "Observational", "time": "2020-04-21", "weburl": "https://clinicaltrials.gov/show/NCT04360850"}, "type": "Feature"}, {"geometry": {"coordinates": [114.134896, 22.282999], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "william3@hku.hk;william3@hku.hk", "contactPhone": "+85239176634;39176634", "dateEnrollment": "April 24, 2020", "description": "The Impact of COVID-19 Pandemic on the Smoking Behaviour of Young Smokers and the Youth Quitline Service in Hong Kong", "name": "NCT04360863", "primaryOutcome": "Smoking behaviors;Knowledge;Readiness to quit", "study_type": "Observational", "time": "2020-04-22", "weburl": "https://clinicaltrials.gov/show/NCT04360863"}, "type": "Feature"}, {"geometry": {"coordinates": [-105.004531, 39.74636], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "", "contactPhone": "", "dateEnrollment": "May 1, 2020", "description": "Targeted Steroids for ARDS Due to COVID-19 Pneumonia: A Pilot Randomized Clinical Trial", "name": "NCT04360876", "primaryOutcome": "Ventilator Free Days (VFD) at Day 28", "study_type": "Interventional", "time": "2020-04-22", "weburl": "https://clinicaltrials.gov/show/NCT04360876"}, "type": "Feature"}, {"geometry": {"coordinates": [-90.265118, 38.636753], "type": "Point"}, "properties": {"classification": "Diagnosis", "contactEmail": "gary.j.weil@wustl.edu;gary.j.weil@wustl.edu", "contactPhone": "314-747-5198;314-276-3139", "dateEnrollment": "April 27, 2020", "description": "Evaluation of Antibody Tests for COVID-19", "name": "NCT04360954", "primaryOutcome": "Test Sensitivity;Test Specificity", "study_type": "Observational", "time": "2020-04-20", "weburl": "https://clinicaltrials.gov/show/NCT04360954"}, "type": "Feature"}, {"geometry": {"coordinates": [51.416051, 35.822734], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": ";nooshindalili4@gmail.com", "contactPhone": ";00989122404331", "dateEnrollment": "March 20, 2020", "description": "The Effects of Standard Protocol With or Without Colchicine in Covid-19 Infection", "name": "NCT04360980", "primaryOutcome": "CRPxN/R ratio change;Clinical deterioration by the WHO definition;PCR Viral Load;CT severity involvement index", "study_type": "Interventional", "time": "2020-04-22", "weburl": "https://clinicaltrials.gov/show/NCT04360980"}, "type": "Feature"}, {"geometry": {"coordinates": [-2.972795, 43.331406], "type": "Point"}, "properties": {"classification": "Other", "contactEmail": ";jon.irazusta@ehu.eus;jon.irazusta@ehu.eus", "contactPhone": ";34-946012837;00-34-946012837", "dateEnrollment": "April 16, 2020", "description": "Physical Activity in University Students Around COVID-19 Confinement", "name": "NCT04361019", "primaryOutcome": ": International Physical Activity Questionnaire - Short Form;: International Physical Activity Questionnaire - Short Form;: International Physical Activity Questionnaire - Short Form", "study_type": "Observational", "time": "2020-04-22", "weburl": "https://clinicaltrials.gov/show/NCT04361019"}, "type": "Feature"}, {"geometry": {"coordinates": [30.97748, 30.817938], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": ";vp_research@unv.tanta.edu.eg", "contactPhone": ";+201004706770", "dateEnrollment": "May 2020", "description": "Hydroxychloroquine and Nitazoxanide Combination Therapy for COVID-19", "name": "NCT04361318", "primaryOutcome": "Number of patients with COVID-19-negative PCR", "study_type": "Interventional", "time": "2020-04-18", "weburl": "https://clinicaltrials.gov/show/NCT04361318"}, "type": "Feature"}, {"geometry": {"coordinates": [30.97748, 30.817938], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "", "contactPhone": "", "dateEnrollment": "April 21, 2020", "description": "Isotretinoin in Treatment of COVID-19", "name": "NCT04361422", "primaryOutcome": "Clinical clearance", "study_type": "Interventional", "time": "2020-04-21", "weburl": "https://clinicaltrials.gov/show/NCT04361422"}, "type": "Feature"}, {"geometry": {"coordinates": [-73.641608, 45.51969], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": ";salysalti@hotmail.com", "contactPhone": ";+1-514-345-4927", "dateEnrollment": "May 1, 2020", "description": "Lung Recruitment Device for COVID-19", "name": "NCT04361435", "primaryOutcome": "SpO2/FIO2 Ratio", "study_type": "Interventional", "time": "2020-04-12", "weburl": "https://clinicaltrials.gov/show/NCT04361435"}, "type": "Feature"}, {"geometry": {"coordinates": [5.342958, 50.910637], "type": "Point"}, "properties": {"classification": "Diagnosis", "contactEmail": ";reinoud.cartuyvels@jessazh.be", "contactPhone": ";+3211338200", "dateEnrollment": "April 20, 2020", "description": "Performance of 3 Sampling Methods for the Detection of SARS-CoV-2 (COVID-19) With Real-time Reverse Transcriptase PCR", "name": "NCT04361448", "primaryOutcome": "sensitivity", "study_type": "Interventional", "time": "2020-04-20", "weburl": "https://clinicaltrials.gov/show/NCT04361448"}, "type": "Feature"}, {"geometry": {"coordinates": [-46.712623, -23.647787], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "fernanda.martinez@apsen.com.br", "contactPhone": "+ 55 11 5644-8200", "dateEnrollment": "May 4, 2020", "description": "Use of Hydroxychloroquine Alone or Associated for Inpatients With SARS-CoV2 Virus (COVID-19)", "name": "NCT04361461", "primaryOutcome": "Individual response rate", "study_type": "Interventional", "time": "2020-04-22", "weburl": "https://clinicaltrials.gov/show/NCT04361461"}, "type": "Feature"}, {"geometry": {"coordinates": [10.542602, 52.235303], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "schmidt.julius@mh-hannover.de", "contactPhone": "+495115326319", "dateEnrollment": "April 15, 2020", "description": "Registry of COVID-19 Patients Treated With the Seraph 100 Microbind Affinity Blood Filter", "name": "NCT04361500", "primaryOutcome": "Survival", "study_type": "Observational [Patient Registry]", "time": "2020-04-22", "weburl": "https://clinicaltrials.gov/show/NCT04361500"}, "type": "Feature"}, {"geometry": {"coordinates": [2.134678, 41.40588], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": ";mcaste@clinic.cat;mcaste@clinic.cat", "contactPhone": ";+34932275515;+34932275515", "dateEnrollment": "April 17, 2020", "description": "Pilot Study on Cytokine Filtration in COVID-19 ARDS", "name": "NCT04361526", "primaryOutcome": "Mechanical ventilation-free days", "study_type": "Interventional", "time": "2020-04-21", "weburl": "https://clinicaltrials.gov/show/NCT04361526"}, "type": "Feature"}, {"geometry": {"coordinates": [2.136741, 41.405884], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": ";jcolme@clinic.cat;", "contactPhone": ";+932275753", "dateEnrollment": "March 1, 2020", "description": "COVID-19 in Liver Transplant Recipients", "name": "NCT04361591", "primaryOutcome": "Incidence of COVID19 in LT recipients;Clinical characteristics of COVID19 in LT recipients;Survival and Mechanical ventilation / respiratory support;Observed treatments and immunosuppression management", "study_type": "Observational [Patient Registry]", "time": "2020-04-22", "weburl": "https://clinicaltrials.gov/show/NCT04361591"}, "type": "Feature"}, {"geometry": {"coordinates": [2.334949, 48.873335], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "antoine.cheret@aphp.fr", "contactPhone": "0145212586", "dateEnrollment": "April 2020", "description": "Clinical Characterisation Protocol for COVID-19 in People Living With HIV", "name": "NCT04361604", "primaryOutcome": "Describe the course of COVID-19 disease in patients infected with HIV,", "study_type": "Observational", "time": "2020-04-20", "weburl": "https://clinicaltrials.gov/show/NCT04361604"}, "type": "Feature"}, {"geometry": {"coordinates": [3.834035, 43.646637], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": ";d-bessis@chu-montpellier.fr;lp-secco@chu-montpellier.fr", "contactPhone": ";467336906;632069859", "dateEnrollment": "April 1, 2020", "description": "Acral Cutaneous Thrombotic Vasculopathy and Covid-19 Infection", "name": "NCT04361786", "primaryOutcome": "Biological acquired thrombophilia", "study_type": "Observational", "time": "2020-04-17", "weburl": "https://clinicaltrials.gov/show/NCT04361786"}, "type": "Feature"}, {"geometry": {"coordinates": [10.436785, 43.762873], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": ";enrico.capochiani@uslnordovest.toscana.it", "contactPhone": ";00393473527340", "dateEnrollment": "April 25, 2020", "description": "Ruxolitinib for the Treatment of Acute Respiratory Distress Syndrome in Patients With COVID-19 Infection", "name": "NCT04361903", "primaryOutcome": "Number of patients who avoid mechanical assisted ventilation in acute respiratory distress syndrome in patients with SARS-CoV-2 COVID-19", "study_type": "Observational", "time": "2020-04-14", "weburl": "https://clinicaltrials.gov/show/NCT04361903"}, "type": "Feature"}, {"geometry": {"coordinates": [9.142325, 45.516452], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": ";chiara.gerardi@marionegri.it;", "contactPhone": ";+39 03901;", "dateEnrollment": "April 21, 2020", "description": "Home Care for Patients With COVID-19: Active Monitoring in Two Italian Health Units (Casale Monferrato and Torino)", "name": "NCT04361916", "primaryOutcome": "SpO2", "study_type": "Interventional", "time": "2020-04-14", "weburl": "https://clinicaltrials.gov/show/NCT04361916"}, "type": "Feature"}, {"geometry": {"coordinates": [-3.689367, 40.442626], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": ";deharojoaquin@yahoo.es;deharojoaquin@yahoo.es", "contactPhone": ";+34 626022977;+34 626022977", "dateEnrollment": "April 2020", "description": "Influence of COVID-19 Infection in Thromboembolic Venous Disease: National Cohort Study", "name": "NCT04361981", "primaryOutcome": "Deep Venous Disease Incidence", "study_type": "Observational [Patient Registry]", "time": "2020-04-23", "weburl": "https://clinicaltrials.gov/show/NCT04361981"}, "type": "Feature"}, {"geometry": {"coordinates": [-86.808632, 33.501989], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": ";wchatham@uabmc.edu", "contactPhone": ";800-822-6478", "dateEnrollment": "May 2020", "description": "Early Identification and Treatment of Cytokine Storm Syndrome in Covid-19", "name": "NCT04362111", "primaryOutcome": "No increase in oxygen requirement and no increase in respiratory support measures", "study_type": "Interventional", "time": "2020-04-21", "weburl": "https://clinicaltrials.gov/show/NCT04362111"}, "type": "Feature"}, {"geometry": {"coordinates": [-75.568988, 6.267744], "type": "Point"}, "properties": {"classification": "Other", "contactEmail": ";kataju@hotmail.com", "contactPhone": ";314-617-5507", "dateEnrollment": "April 2020", "description": "Performance Evaluation of BCG Vaccination in Healthcare Personnel to Reduce the Severity of SARS-COV-2 Infection", "name": "NCT04362124", "primaryOutcome": "Primary outcome", "study_type": "Interventional", "time": "2020-04-21", "weburl": "https://clinicaltrials.gov/show/NCT04362124"}, "type": "Feature"}, {"geometry": {"coordinates": [7.78681, 48.6029], "type": "Point"}, "properties": {"classification": "Impact on helpers", "contactEmail": "luisa.weiner@chru-strasbourg.fr", "contactPhone": "03 88 11 65 11", "dateEnrollment": "May 1, 2020", "description": "Online Cognitive Behavioral Therapy (CBT) for Stress Disorders in Health Workers Involved in the Care of Patients During the Covid-19 Epidemic", "name": "NCT04362358", "primaryOutcome": "Significant score reduction at the Perceived Stress Scale;Significant score reduction at the Perceived Stress Scale;Significant score reduction at the Perceived Stress Scale;Significant score reduction at the Perceived Stress Scale", "study_type": "Interventional", "time": "2020-04-21", "weburl": "https://clinicaltrials.gov/show/NCT04362358"}, "type": "Feature"}, {"geometry": {"coordinates": [-1.848493, 38.985401], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": ";pabizanda@sescam.jccm.es;pabizanda@sescam.jccm.es", "contactPhone": ";+34636557437;+34967597684", "dateEnrollment": "April 20, 2020", "description": "Clinical-epidemiological Characterization of COVID-19 Disease in Hospitalized Older Adults", "name": "NCT04362943", "primaryOutcome": "Mortality", "study_type": "Observational", "time": "2020-04-22", "weburl": "https://clinicaltrials.gov/show/NCT04362943"}, "type": "Feature"}, {"geometry": {"coordinates": [-58.462647, -34.626881], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "gofman@infant.org.ar", "contactPhone": "01154911-4078-1550", "dateEnrollment": "May 1, 2020", "description": "Clinical and Immunologic Impact of Perinatal SARS-CoV-2 (COVID-19) Infection", "name": "NCT04362956", "primaryOutcome": "Vertical transmission;Neonatal protection due to maternal antibodies", "study_type": "Observational", "time": "2020-04-21", "weburl": "https://clinicaltrials.gov/show/NCT04362956"}, "type": "Feature"}, {"geometry": {"coordinates": [2.475821, 49.264417], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "svetlane.dimi@sfr.fr;", "contactPhone": "+33650002085;", "dateEnrollment": "March 1, 2020", "description": "Multicentre Observational Study on Management COVID 19 Positive Outpatients in a French Cluster.", "name": "NCT04363099", "primaryOutcome": "clinical description of covid 19 ambulatory cases.", "study_type": "Observational", "time": "2020-04-23", "weburl": "https://clinicaltrials.gov/show/NCT04363099"}, "type": "Feature"}, {"geometry": {"coordinates": [-122.161517, 37.448585], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": ";reem.yunis@medable.com;reem.yunis@medable.com", "contactPhone": ";1-877-820-6259;877-820-6259", "dateEnrollment": "April 20, 2020", "description": "ACCESS A Master Digital Surveillance Protocol for COVID-19", "name": "NCT04363268", "primaryOutcome": "Development of population-based models of disease risk;Relation between disease burden and geolocation;Effect of medications on symptoms of COVID19;Effect of medications on disease severity of COVID19", "study_type": "Observational", "time": "2020-04-23", "weburl": "https://clinicaltrials.gov/show/NCT04363268"}, "type": "Feature"}, {"geometry": {"coordinates": [-1.548305, 53.797484], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": ";clinicaltrials@4dpharmaplc.com", "contactPhone": ";+441138950130", "dateEnrollment": "May 2020", "description": "A Study for Efficacy and Safety of Live Biotherapeutic MRx4DP0004 to Treat COVID-19", "name": "NCT04363372", "primaryOutcome": "Change in mean clinical status score in each treatment arm", "study_type": "Interventional", "time": "2020-04-24", "weburl": "https://clinicaltrials.gov/show/NCT04363372"}, "type": "Feature"}, {"geometry": {"coordinates": [1.918505, 47.836164], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": ";aurelie.despujols@chr-orleans.fr", "contactPhone": ";+33238744071", "dateEnrollment": "May 2020", "description": "Impact of Prone Position in Patients Under Spontaneous Breathing on Intubation or Non-invasive Ventilation or Death Incidence During COVID-19 Acute Respiratory Distress", "name": "NCT04363463", "primaryOutcome": "Percent age of patients who will have endotracheal intubation or non-invasive ventilation at two pressure levels and/or die, in each of the 2 randomization groups.", "study_type": "Interventional", "time": "2020-04-22", "weburl": "https://clinicaltrials.gov/show/NCT04363463"}, "type": "Feature"}, {"geometry": {"coordinates": [-0.133631, 51.527923], "type": "Point"}, "properties": {"classification": "Impact on helpers", "contactEmail": ";;;dina.radenkovic@kcl.ac.uk", "contactPhone": ";;;020 7188 7188", "dateEnrollment": "April 27, 2020", "description": "The CEDiD Study (COVID-19 Early Diagnosis in Doctors)", "name": "NCT04363489", "primaryOutcome": "COVID-19", "study_type": "Observational", "time": "2020-04-23", "weburl": "https://clinicaltrials.gov/show/NCT04363489"}, "type": "Feature"}, {"geometry": {"coordinates": [2.12538, 48.831221], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "amaurizot@ch-versailles.fr", "contactPhone": "01.39.63.87.93", "dateEnrollment": "April 27, 2020", "description": "Incidence of Deep Vein Thrombosis at Doppler Echo in Covid-19 Patients With SARS-Cov-2 Pneumopathy Hospitalized in ICU", "name": "NCT04363528", "primaryOutcome": "Incidence of Deep Vein Thrombosis at Doppler Echo in Patients With SARS-Cov-2 Pneumopathy Hospitalized in ICU;Incidence of Deep Vein Thrombosis at Doppler Echo in Patients With SARS-Cov-2 Pneumopathy Hospitalized in ICU", "study_type": "Interventional", "time": "2020-04-23", "weburl": "https://clinicaltrials.gov/show/NCT04363528"}, "type": "Feature"}, {"geometry": {"coordinates": [-99.208033, 19.422941], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "ngalindosevilla@gmail.com", "contactPhone": "+525539968217", "dateEnrollment": "April 2020", "description": "Local Thermotherapy for Patients With Moderate Symptoms of COVID-19", "name": "NCT04363541", "primaryOutcome": "Hospitalization time;Patients needing intensive care", "study_type": "Interventional", "time": "2020-04-23", "weburl": "https://clinicaltrials.gov/show/NCT04363541"}, "type": "Feature"}, {"geometry": {"coordinates": [2.334949, 48.873335], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": ";emilie.carretier@aphp.fr", "contactPhone": ";+33 (0)158412814", "dateEnrollment": "May 2020", "description": "Adolescents and Health Professionals Faced With the Necessity for Changing to Remote Care During the COVID-19 Outbreak Quarantine (AdoPro-Cov19)", "name": "NCT04363671", "primaryOutcome": "Exploration of themes emerging from analysis of the content of the interview with the adolescents and therapists", "study_type": "Observational", "time": "2020-04-21", "weburl": "https://clinicaltrials.gov/show/NCT04363671"}, "type": "Feature"}, {"geometry": {"coordinates": [2.334949, 48.873335], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "thomas.similowski@aphp.fr", "contactPhone": "01 42 16 77 52", "dateEnrollment": "April 27, 2020", "description": "COVID-19 Infection: Exploration of Respiratory Control Center Abnormalities", "name": "NCT04363749", "primaryOutcome": "Intensity of the emotional response to hypoxic exposure (14.3 et 12.7% FIO2)", "study_type": "Interventional", "time": "2020-04-20", "weburl": "https://clinicaltrials.gov/show/NCT04363749"}, "type": "Feature"}, {"geometry": {"coordinates": [21.013498, 52.177682], "type": "Point"}, "properties": {"classification": "Impact on helpers", "contactEmail": "", "contactPhone": "", "dateEnrollment": "February 28, 2020", "description": "Needle Stick Injuries in Emergency Medical Service Practice", "name": "NCT04363788", "primaryOutcome": "Number of visible puncture", "study_type": "Observational", "time": "2020-04-23", "weburl": "https://clinicaltrials.gov/show/NCT04363788"}, "type": "Feature"}, {"geometry": {"coordinates": [-90.085451, 29.957296], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": ";flau@lsuhsc.edu", "contactPhone": ";504 412 1240", "dateEnrollment": "May 2020", "description": "The LEAD COVID-19 Trial: Low-risk, Early Aspirin and Vitamin D to Reduce COVID-19 Hospitalizations", "name": "NCT04363840", "primaryOutcome": "Hospitalization", "study_type": "Interventional", "time": "2020-04-24", "weburl": "https://clinicaltrials.gov/show/NCT04363840"}, "type": "Feature"}, {"geometry": {"coordinates": [-122.691315, 45.496313], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": ";rodgerbr@ohsu.edu;rodgerbr@ohsu.edu", "contactPhone": ";503-494-0076;503-494-0076", "dateEnrollment": "May 2020", "description": "A Pilot Study to Assess Hydroxychloroquine in Patients With SARS-CoV-2 (COVID-19)", "name": "NCT04363866", "primaryOutcome": "Clinical Status at Day 5 Assessed by a 6-Point Ordinal Scale", "study_type": "Interventional", "time": "2020-04-24", "weburl": "https://clinicaltrials.gov/show/NCT04363866"}, "type": "Feature"}, {"geometry": {"coordinates": [7.580869, 47.56218], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": ";;alexandra.calmy@hcuge.ch;", "contactPhone": ";;223729811;", "dateEnrollment": "April 2020", "description": "Efficacy of Pragmatic Same-day COVID-19 Ring Prophylaxis for Adult Individuals Exposed to SARS-CoV-2 in Switzerland", "name": "NCT04364022", "primaryOutcome": "21-day incidence of COVID-19 in individuals exposed to SARS-CoV- 2 who are asymptomatic at baseline (intent-to-treat (ITT) analysis).", "study_type": "Interventional", "time": "2020-04-23", "weburl": "https://clinicaltrials.gov/show/NCT04364022"}, "type": "Feature"}, {"geometry": {"coordinates": [5.177724, 52.336224], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "", "contactPhone": "", "dateEnrollment": "May 1, 2020", "description": "EuRopean Study of MAjor Infectious Disease Syndromes Related to COVID-19", "name": "NCT04364711", "primaryOutcome": "Pneumonia Severity indexes;Need for supplemental oxygen; non-invasive or invasive mechanical ventilation; extra-corporeal life support;Hospital - and ICU/HCU length of stay;In-hospital mortality;Activities of daily life, quality of life, variations in home living status and employment status;Proportion of SARS-CoV2 positive patients", "study_type": "Observational", "time": "2020-04-20", "weburl": "https://clinicaltrials.gov/show/NCT04364711"}, "type": "Feature"}, {"geometry": {"coordinates": [-43.194463, -22.958523], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": ";renato.lopes@duke.edu;", "contactPhone": ";55 11 5904 7339;", "dateEnrollment": "April 6, 2020", "description": "Angiotensin Receptor Blockers and Angiotensin-converting Enzyme Inhibitors and Adverse Outcomes in Patients With COVID19", "name": "NCT04364893", "primaryOutcome": "Median days alive and out of the hospital", "study_type": "Interventional", "time": "2020-04-07", "weburl": "https://clinicaltrials.gov/show/NCT04364893"}, "type": "Feature"}, {"geometry": {"coordinates": [30.447241, 50.469434], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "ivanovdd@i.kiev.ua", "contactPhone": "0504448788", "dateEnrollment": "April 1, 2020", "description": "ARB, ACEi, DRi in COVID-19", "name": "NCT04364984", "primaryOutcome": "BP (hypertensive efficacy)", "study_type": "Observational [Patient Registry]", "time": "2020-04-23", "weburl": "https://clinicaltrials.gov/show/NCT04364984"}, "type": "Feature"}, {"geometry": {"coordinates": [-118.38125, 34.075071], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": ";Vanessa.Vasco@csmns.org;", "contactPhone": ";3109677451;310-423-5000", "dateEnrollment": "April 27, 2020", "description": "Progesterone for the Treatment of COVID-19 in Hospitalized Men", "name": "NCT04365127", "primaryOutcome": "Change in clinical status of subjects at Day 15 based on the following 7-point ordinal scale", "study_type": "Interventional", "time": "2020-04-24", "weburl": "https://clinicaltrials.gov/show/NCT04365127"}, "type": "Feature"}, {"geometry": {"coordinates": [8.953022, 46.018408], "type": "Point"}, "properties": {"classification": "Advanced therapy medicinal products", "contactEmail": ";enos.bernasconi@eoc.ch", "contactPhone": ";+41 91 811 60 22", "dateEnrollment": "April 27, 2020", "description": "Convalescent Plasma for COVID-19", "name": "NCT04365439", "primaryOutcome": "Titers of anti-SARS-CoV-2 antibodies in the plasma derived from convalescent donors;Change in titers of anti-SARS-CoV-2 antibodies in patients' plasma;Change in inflammatory cytokines concentration (e.g. IL-6, HMGB1);Viral load decay in the recipient after plasma transfusion with semiquantitative assessment of nasopharyngeal swabs", "study_type": "Interventional", "time": "2020-04-18", "weburl": "https://clinicaltrials.gov/show/NCT04365439"}, "type": "Feature"}, {"geometry": {"coordinates": [114.242864, 30.596649], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "", "contactPhone": "", "dateEnrollment": "February 2, 2020", "description": "A Single-center Retrospective Study to Find Prediction Factors Related to Mortality of COVID-19 Patients.", "name": "NCT04365634", "primaryOutcome": "Find the prediction factors associated with hospitalized death of patients with COVID-19 by univariate and multivariate analysis", "study_type": "Observational", "time": "2020-04-25", "weburl": "https://clinicaltrials.gov/show/NCT04365634"}, "type": "Feature"}, {"geometry": {"coordinates": [-73.989526, 40.758481], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": ";Stuart.katz@nyulangone.org;", "contactPhone": ";212-263-3946;", "dateEnrollment": "April 8, 2020", "description": "Cardiovascular Effects of COVID-19", "name": "NCT04365699", "primaryOutcome": "Proportion of subjects with decreased left ventricular ejection fraction =10% from baseline at time of hospitalization;Incidence of Adverse Events for patients receiving AT-001", "study_type": "Interventional", "time": "2020-04-25", "weburl": "https://clinicaltrials.gov/show/NCT04365699"}, "type": "Feature"}, {"geometry": {"coordinates": [28.943672, 41.0668], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "", "contactPhone": "", "dateEnrollment": "March 11, 2020", "description": "Pulmonary Rehabilitation in Post-Acute Period of COVID-19 Infection", "name": "NCT04365738", "primaryOutcome": "Dyspnea", "study_type": "Interventional", "time": "2020-04-26", "weburl": "https://clinicaltrials.gov/show/NCT04365738"}, "type": "Feature"}, {"geometry": {"coordinates": [10.704116, 59.956395], "type": "Point"}, "properties": {"classification": "Other", "contactEmail": ";;", "contactPhone": ";;", "dateEnrollment": "March 31, 2020", "description": "Loneliness During the NPIs for the COVID-19 Pandemic in Norway: Risk Factors and Associations With Psychopathology", "name": "NCT04365881", "primaryOutcome": "UCLA Loneliness Scale-8 (ULS-8);Patient Health Questionnaire-9 (PHQ-9);Generalized Anxiety Disorder-7 (GAD-7)", "study_type": "Observational", "time": "2020-04-26", "weburl": "https://clinicaltrials.gov/show/NCT04365881"}, "type": "Feature"}, {"geometry": {"coordinates": [9.210917, 45.518446], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "", "contactPhone": "", "dateEnrollment": "March 20, 2020", "description": "The Prone Position in Covid-19 Affected Patients", "name": "NCT04365959", "primaryOutcome": "Number of patients in whom the prone position caused an increase in oxygenation", "study_type": "Observational", "time": "2020-04-21", "weburl": "https://clinicaltrials.gov/show/NCT04365959"}, "type": "Feature"}, {"geometry": {"coordinates": [-117.236202, 32.88006], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "llazaro@health.ucsd.edu", "contactPhone": "858-822-2661", "dateEnrollment": "April 2020", "description": "Ramipril for the Treatment of COVID-19", "name": "NCT04366050", "primaryOutcome": "Composite of mortality or need for ICU admission or ventilator use", "study_type": "Interventional", "time": "2020-04-24", "weburl": "https://clinicaltrials.gov/show/NCT04366050"}, "type": "Feature"}, {"geometry": {"coordinates": [-73.953754, 40.789413], "type": "Point"}, "properties": {"classification": "Advanced therapy medicinal products", "contactEmail": "", "contactPhone": "", "dateEnrollment": "April 2020", "description": "Intermediate-size Expanded Access Program (EAP), Mesenchymal Stromal Cells (MSC) for Acute Respiratory Distress Syndrome (ARDS) Due to COVID-19 Infection", "name": "NCT04366830", "primaryOutcome": "", "study_type": "Expanded Access", "time": "2020-04-24", "weburl": "https://clinicaltrials.gov/show/NCT04366830"}, "type": "Feature"}, {"geometry": {"coordinates": [153.380147, -27.959226], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "", "contactPhone": "", "dateEnrollment": "29/04/2020", "description": "SARS-CoV2 in children presenting to hospital: A repeating point prevalence study during the COVID-19 pandemic in South East Queensland", "name": "ACTRN12620000512921", "primaryOutcome": "The primary outcome of this study is the proportion of children who test positive for SARS-CoV2 infection by PCR testing of upper airway swabs when presenting to an Emergency Department or admitted to hospital for any reason. [This is a repeating point prevalence study. The point prevalence will be calculated for each screening day and changes analysed over the duration of the 3 month study]", "study_type": "Observational", "time": "2020-04-27", "weburl": "https://anzctr.org.au/ACTRN12620000512921.aspx"}, "type": "Feature"}, {"geometry": {"coordinates": [174.753263, -36.841788], "type": "Point"}, "properties": {"classification": "Other", "contactEmail": "", "contactPhone": "", "dateEnrollment": "02/06/2020", "description": "Testing a wellbeing app to support wellbeing during the Covid-19 pandemic", "name": "ACTRN12620000516987", "primaryOutcome": "Emotional wellbeing: assessed via the World Health Organization Five Well-Being Index (WHO-5)(Bech, Olsen, Kjoller, & Rasmussen, 2003).  [Baseline, 4 weeks after baseline and 3 months after baseline];Mental Well-being: assessed by the Short Warwick-Edinburgh Mental Well-being Scale (WEMWBS)(Fat, Scholes, Boniface, Mindell, & Stewart-Brown, 2017; Tennant et al., 2007). [Baseline, 4 weeks after baseline and 3 months after baseline]", "study_type": "Interventional", "time": "2020-04-27", "weburl": "https://anzctr.org.au/ACTRN12620000516987.aspx"}, "type": "Feature"}, {"geometry": {"coordinates": [144.972848, -37.807357], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "", "contactPhone": "", "dateEnrollment": "21/05/2020", "description": "COVID-19: Can Nebulised HepArin Reduce Time to Extubation in SARS-CoV-2 patients requiring mechanical ventilation (CHARTER Study)", "name": "ACTRN12620000517976", "primaryOutcome": "Time to separation from invasive ventilation, censored at Day 28, with non-survivors treated as though never separated from the ventilator. This will be assessed from review of the medical records. [Day 28]", "study_type": "Interventional", "time": "2020-04-27", "weburl": "https://anzctr.org.au/ACTRN12620000517976.aspx"}, "type": "Feature"}, {"geometry": {"coordinates": [151.236041, -33.917128], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "", "contactPhone": "", "dateEnrollment": "01/05/2020", "description": "Neonatal CoVID-19 Study to evaluate the population health impacts of COVID-19 in mothers and their newborn infants cared for in tertiary and non-tertiary hospitals in Australia.", "name": "ACTRN12620000527965", "primaryOutcome": "Need for resuscitation - collected from hospital records[At birth];Type of respiratory support required after birth - collected from hospital records[First week of life];Mortality - collected from hospital records[Discharge]", "study_type": "Observational", "time": "2020-04-29", "weburl": "https://anzctr.org.au/ACTRN12620000527965.aspx"}, "type": "Feature"}, {"geometry": {"coordinates": [80.274457, 13.081268], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "", "contactPhone": "", "dateEnrollment": "30/04/2020", "description": "START (Siddha Treatment Accelerating Recovery from SARS-CoV-2 Test) trial of Siddha treatment for patients with novel coronavirus infectious disease (COVID-19)", "name": "ISRCTN13311119", "primaryOutcome": "Proportion of patients confirmed as negative for COVID-19 in 2 consecutive throat/nasal swabs (taken 24 hours apart) at 15 and 16 days", "study_type": "Interventional", "time": "2020-04-24", "weburl": "http://isrctn.com/ISRCTN13311119"}, "type": "Feature"}, {"geometry": {"coordinates": [20.457302, 44.818406], "type": "Point"}, "properties": {"classification": "Other", "contactEmail": "", "contactPhone": "", "dateEnrollment": "07/04/2020", "description": "Expressive writing for the reduction of psychological difficulties during the COVID-19 pandemic", "name": "ISRCTN17898730", "primaryOutcome": "Severity of psychological difficulties assessed by DASS 21 - depression, anxiety and stress scale, short version at pre-test and post-test (2 weeks)", "study_type": "Interventional", "time": "2020-04-23", "weburl": "http://isrctn.com/ISRCTN17898730"}, "type": "Feature"}, {"geometry": {"coordinates": [6.134079, 46.23251], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "", "contactPhone": "", "dateEnrollment": "26/03/2020", "description": "Public health emergency SOLIDARITY trial of treatments for COVID-19 infection in hospitalized patients", "name": "ISRCTN83971151", "primaryOutcome": "All-cause mortality, subdivided by the severity of disease at the time of randomization, measured using patient records throughout the study", "study_type": "Interventional", "time": "2020-03-25", "weburl": "http://isrctn.com/ISRCTN83971151"}, "type": "Feature"}, {"geometry": {"coordinates": [87.583784, 43.838818], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "fuzhenyan316@126.com", "contactPhone": "+86 13639903192", "dateEnrollment": "2020-03-20", "description": "The influence of COVID-19 pandemic on cardiovascular patients", "name": "ChiCTR2000032632", "primaryOutcome": "LDL-C;HDL-C;Exercise;", "study_type": "Interventional study", "time": "2020-05-04", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=53190"}, "type": "Feature"}, {"geometry": {"coordinates": [114.935345, 25.863947], "type": "Point"}, "properties": {"classification": "Diagnosis", "contactEmail": "zhangweiwei.120@163.com", "contactPhone": "+86 15970064556", "dateEnrollment": "2020-01-01", "description": "Diagnostic value of chest CT in outpatient for novel coronavirus pneumonia (COVID-19) compared to RT-PCR", "name": "ChiCTR2000032574", "primaryOutcome": "chest CT;RT-PCR;SEN, SPE, ACC, AUC of ROC;", "study_type": "Diagnostic test", "time": "2020-05-03", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=53122"}, "type": "Feature"}, {"geometry": {"coordinates": [113.246137, 23.128508], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "jiw037@ucsd.edu", "contactPhone": "+86 020 37103055", "dateEnrollment": "2020-05-02", "description": "A randomized, double-blind, controlled trial for Bu-Fei-Huo-Xue Capsule in the treatment of novel coronavirus pneumonia (COVID-19) convalescence patient with ''Fei-Pi-Qi-Xu zhen''", "name": "ChiCTR2000032573", "primaryOutcome": "St George's respiratory questionnaire score;Fatigue assessment scale;Six minute walking experiment;", "study_type": "Interventional study", "time": "2020-05-03", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=53225"}, "type": "Feature"}, {"geometry": {"coordinates": [114.244796, 30.597217], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "shushengli16@sina.com", "contactPhone": "+86 13971086498", "dateEnrollment": "2020-05-01", "description": "Developing and validating of clinical prediction model for novel coronavirus pneumonia (COVID-19) patients progressing to critical type, acute respiratory distress syndrome and death: a medical records based study", "name": "ChiCTR2000032527", "primaryOutcome": "In hospital mortality;", "study_type": "Observational study", "time": "2020-05-01", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=53196"}, "type": "Feature"}, {"geometry": {"coordinates": [114.338158, 30.569351], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "wb002554@whu.edu.cn", "contactPhone": "+86 18971525805", "dateEnrollment": "2020-05-05", "description": "Direct evidence of rectal cancer patient infected with novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000032514", "primaryOutcome": "the virus particles by electron microscopy;2019-nCoV antigens  expressions in rectum;", "study_type": "Basic Science", "time": "2020-05-01", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=53181"}, "type": "Feature"}, {"geometry": {"coordinates": [121.326097, 30.808236], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "lushuihua@shphc.org.cn", "contactPhone": "+86 18930811818", "dateEnrollment": "2020-03-26", "description": "Study for using sulfate in the prevention and control of novel coronavirus pneumonia (COVID-19) in high and low prevalence communities", "name": "ChiCTR2000032487", "primaryOutcome": "Detection of nucleic acid and antibody of new coronavirus ;", "study_type": "Interventional study", "time": "2020-04-29", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=52394"}, "type": "Feature"}, {"geometry": {"coordinates": [116.411044, 39.955616], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "liuby5505@139.com", "contactPhone": "+86 010-64089669", "dateEnrollment": "2020-04-29", "description": "Study on data management and diagnosis-treatment mode of TCM intervention for novel coronavirus pneumonia (COVID-19)  convalescence", "name": "ChiCTR2000032480", "primaryOutcome": "syndrome scale;Record of Disease;Record of Medication;", "study_type": "Observational study", "time": "2020-04-29", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=52698"}, "type": "Feature"}, {"geometry": {"coordinates": [116.411044, 39.955616], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "xiaolintong66@sina.com", "contactPhone": "+86 010-88001260", "dateEnrollment": "2020-02-03", "description": "TCM Intervention study for novel coronavirus pneumonia (COVID-19) patient during home/designate-unit isolation based on community prevention and control", "name": "ChiCTR2000032478", "primaryOutcome": "COVID symptom;Intervention record of TCM treatment;Intervention record of anti-virus treatment;", "study_type": "Observational study", "time": "2020-04-29", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=52777"}, "type": "Feature"}, {"geometry": {"coordinates": [112.970385, 28.228146], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "pinhuapan668@126.com", "contactPhone": "+86 13574810968", "dateEnrollment": "2020-03-23", "description": "Analysis of clinical features of novel coronavirus  pneumonia (COVID-19): a medical records based study", "name": "ChiCTR2000032476", "primaryOutcome": "Treatment outcome;", "study_type": "Observational study", "time": "2020-04-29", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=53094"}, "type": "Feature"}, {"geometry": {"coordinates": [103.809645, 30.687265], "type": "Point"}, "properties": {"classification": "Complementary and alternative medicine", "contactEmail": "xcg718@aliyun.com", "contactPhone": "+86 18980880132", "dateEnrollment": "2020-05-06", "description": "A medical records based retrospective study for effect of applying individualized Chinese herbal medicine in treatment of patients with novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000032461", "primaryOutcome": "conversion rate among mild, common, severe and critical symptoms;", "study_type": "Observational study", "time": "2020-04-29", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=52482"}, "type": "Feature"}, {"geometry": {"coordinates": [117.278401, 31.821994], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "wtl9911002@163.com", "contactPhone": "+86 13866683842", "dateEnrollment": "2020-01-20", "description": "Early warning model and new biomarker of severe novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000032460", "primaryOutcome": "CRP, Cys, SAA, IL-6, ESR, PCT;myoglobin, troponin, lactate dehydrogenase, urea nitrogen, total bilirubin, aspartate aminotransaminase, alanine aminotransaminase;APTT, PT, fibrinogen, D-D, albumin, glucose, uric acid;white blood cell count, neutrophil count, lymphocyte count, monocyte count, platelet count, mean platelet volume;", "study_type": "Diagnostic test", "time": "2020-04-29", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=52875"}, "type": "Feature"}, {"geometry": {"coordinates": [116.534159, 39.799839], "type": "Point"}, "properties": {"classification": "Vaccines", "contactEmail": "wangyanxia99@163.com", "contactPhone": "+86 13613816598", "dateEnrollment": "2020-04-29", "description": "A phase I/II clinical trial for inactivated novel coronavirus (2019-CoV) vaccine (Vero cells)", "name": "ChiCTR2000032459", "primaryOutcome": "Incidence of adverse reactions/events;", "study_type": "Interventional study", "time": "2020-04-29", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=53003"}, "type": "Feature"}, {"geometry": {"coordinates": [106.930546, 27.722547], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "350210481@qq.com", "contactPhone": "+86 18982262419", "dateEnrollment": "2020-02-29", "description": "A medical records based retrospective study: Leukopenia is more common in asymptomatic patients less than 18 years old with novel coronavirus pneumonia (COVID-19) in convalescence", "name": "ChiCTR2000032458", "primaryOutcome": "WBC account;Plt;", "study_type": "Observational study", "time": "2020-04-29", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=52779"}, "type": "Feature"}, {"geometry": {"coordinates": [116.434834, 39.943255], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "zsn0928@163.com", "contactPhone": "+86 13971445469", "dateEnrollment": "2020-05-01", "description": "Application of pulmonary rehabilitation exercise in the treatment of novel coronavirus pneumonia (COVID-19) patients during convalescence period.", "name": "ChiCTR2000032457", "primaryOutcome": "ADL score;MMRC score;", "study_type": "Observational study", "time": "2020-04-29", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=52925"}, "type": "Feature"}, {"geometry": {"coordinates": [121.326097, 30.808236], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "tubercle@shphc.org", "contactPhone": "+86 021-37990333", "dateEnrollment": "2020-03-01", "description": "A Randomized Controlled Trial for the Effects of Low-Oxygen Consumption Instruction on the Prognosis of Patients with Novel Coronavirus Pneumonia (COVID-19)", "name": "ChiCTR2000032456", "primaryOutcome": "Improvement of anxiety, depression;CAP symptoms improvement;", "study_type": "Interventional study", "time": "2020-04-29", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=53048"}, "type": "Feature"}, {"geometry": {"coordinates": [106.338309, 38.107772], "type": "Point"}, "properties": {"classification": "Impact on helpers", "contactEmail": "nxwsyzc@163.com", "contactPhone": "+86 13309598299", "dateEnrollment": "2020-04-28", "description": "A study for the mental health status of novel coronavirus pneumonia (COVID-19) convalescent patients and first-line medical staff and Isolate residents and Hospital staffand the intervention strategy of psychological crisis in Ningxia", "name": "ChiCTR2000032455", "primaryOutcome": "Mental health status;sleep;emotion;", "study_type": "Interventional study", "time": "2020-04-29", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=53050"}, "type": "Feature"}, {"geometry": {"coordinates": [121.326097, 30.808236], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "luhongzhou@fudan.edu.cn", "contactPhone": "+86 21 37990333", "dateEnrollment": "2020-04-22", "description": "Efficacy and Safety of ulinastatin in the Treatment of novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000032135", "primaryOutcome": "mild cases: the critical illness rate of subjects at weeks 2;Severe or critical cases: the Changes of PaO2/FiO2 from baseline to day 1, 3, 5 and 24 hours later after the last administration;Safety data of COVID-19 patients treated with ulinastatin were collected;", "study_type": "Interventional study", "time": "2020-04-20", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=52506"}, "type": "Feature"}, {"geometry": {"coordinates": [119.290539, 26.103964], "type": "Point"}, "properties": {"classification": "Impact on helpers", "contactEmail": "miaoxing126@126.com", "contactPhone": "+86 13763810443", "dateEnrollment": "2020-02-05", "description": "Study for the influence of novel coronavirus pneumonia (COVID-19) on mental health of Chinese public hospital stuffs", "name": "ChiCTR2000031896", "primaryOutcome": "Mental health index;", "study_type": "Observational study", "time": "2020-04-14", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=52332"}, "type": "Feature"}, {"geometry": {"coordinates": [114.242864, 30.596649], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "tjqiuhong@163.com", "contactPhone": "+86 13986296106", "dateEnrollment": "2020-04-01", "description": "Clinical characteristics and death risk factors in severe novel coronavirus pneumonia (COVID-19) patients: a single-center respective analysis based on medical records", "name": "ChiCTR2000031327", "primaryOutcome": "Time of death;The hospitalization time;", "study_type": "Observational study", "time": "2020-03-27", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51669"}, "type": "Feature"}, {"geometry": {"coordinates": [121.325934, 30.808185], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "tuberculosis@shphc.org.cn", "contactPhone": "+86 18930811818", "dateEnrollment": "2020-03-23", "description": "Effectiveness and safety of hydroxychloroquine sulfate in the preventive treatment of novel coronavirus pneumonia (COVID-19)", "name": "ChiCTR2000031174", "primaryOutcome": "COVID-19 Nucleic acid;", "study_type": "Interventional study", "time": "2020-03-23", "weburl": "http://www.chictr.org.cn/showproj.aspx?proj=51437"}, "type": "Feature"}, {"geometry": {"coordinates": [2.292697, 48.846207], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "nbennasr@hpsj.fr", "contactPhone": "0033144127084", "dateEnrollment": "17/04/2020", "description": "A randomized trial of efficacy and safety of an early OUTpatient treatment of COVID-19 in patients with risk factor for poor outcome : a strategy to prevent hospitalization : OUTCOV Study", "name": "EUCTR2020-001723-13-FR", "primaryOutcome": "Main Objective: The primary objective of the study is to evaluate the effect of treatment on the reduction of hospitalization rate among COVID19 patients with risk factors of poor prognosis. ;Secondary Objective: To evaluate the effect of treatment on <br>1.\tDeath<br>2.\tDeath due to COVID <br>3.\tNeed for ICU stay<br>4.\tDuration of ICU stay<br>5.\tNeed of mechanical ventilation<br>6.\tDuration of mechanical ventilation<br>7.\tTime to hospitalization<br>8.\tDuration of Hospital stay<br>9.\tDuration of symptoms<br>To evaluate the safety of the different arms <br>To evaluate the respiratory impairment;Primary end point(s): Hospital admission rate between D0 and Day 20 ;Timepoint(s) of evaluation of this end point: DAY 20", "study_type": "Interventional clinical trial of medicinal product", "time": "2020-04-08", "weburl": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001723-13"}, "type": "Feature"}, {"geometry": {"coordinates": [-1.509734, 53.66544], "type": "Point"}, "properties": {"classification": "Therapeutic strategies", "contactEmail": "jens.ulrik.jensen@regionh.dk", "contactPhone": "4528938168", "dateEnrollment": "03/04/2020", "description": "Early Treatment to Patients with Coronavirus (COVID)", "name": "EUCTR2020-001198-55-DK", "primaryOutcome": "Main Objective: In patients  who are admitted urgently to hospital with coronavirus infection (COVID-19) and symptoms, treatment with virus-modifying agent Hydroxyhloroquine as well as virus-immunomodulatory and antibacterial drug Azithromycin can lead to a shorter hospitalization.;Secondary Objective: The secondary objectives are to clarify whether the patients riscs of non-invasive ventilation, intensive care unit admittance and death can be reduced by hydroxychloroquine and azithromycine treatment. ;Primary end point(s): Days alive and discharged from hospital within 14 days ;Timepoint(s) of evaluation of this end point: 15 days", "study_type": "Interventional clinical trial of medicinal product", "time": "2020-03-21", "weburl": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001198-55"}, "type": "Feature"}, {"geometry": {"coordinates": [5.376227, 43.307444], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "promotion.interne@ap-hm.fr", "contactPhone": "04 91 38 27 47", "dateEnrollment": "23/04/2020", "description": "A double-blind, randomized study versus placebo of avdoralimab (IPH5401), an anti-C5aR antibody, in patients with COVID-19 induced pneumonia", "name": "EUCTR2020-001686-36-FR", "primaryOutcome": "Main Objective: -Early evaluation criteria: Short-term improvement at Day7 of respiratory functions through Pa02 improvement in ambient air   (cohort 1: COVID-19 severe pneumonia patients who don't require hospitalization in  intensive care unit)  or PaO2/FiO2 improvement at Day7 (cohort 2: COVID-19 related Acute Respiratory Distress Syndrome (ARDS) Patients hospitalized in  intensive care unit )<br>-Late evaluation criteria: number of days living without mechanical ventilation at D28 (Ventilator-free days or VFD28) (cohorts 1 and 2);Secondary Objective: -Reduce the number of patients transferred to intensive care unit<br>-Decrease the duration of hospital stay <br>-Decrease the duration of stay in intensive care units<br>-Decrease mortality at D28<br>-Improve the SOFA (organ failure) score of patients at D7 <br>-Do not increase the occurrence of infectious complications (bacterial or fungal infections) under treatment with avdoralimab.;Primary end point(s): - Early evaluation endpoint: Short-term improvement in respiratory function assessed by a 30% improvement in Pa02 in ambient air at D7 (Cohort 1: Patients with severe COVID-19 pneumonia not requiring management in intensive care unit) and a 15% improvement in the PaO2/FiO2 ratio at D7 (Cohort 2: Patients with COVID-19 ARDS hospitalized in intensive care unit) in the experimental arm. <br>- Late evaluation endpoint: 3 days improvement in  ventilator-free days à D28 (VFD28) in the experimental arm (cohorts 1 and 2)<br>;Timepoint(s) of evaluation of this end point: -Early evaluation criteria: Day7<br>-Late evaluation criteria:  Day28", "study_type": "Interventional clinical trial of medicinal product", "time": "2020-04-14", "weburl": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001686-36"}, "type": "Feature"}, {"geometry": {"coordinates": [4.345329, 45.498464], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "carine.labruyere@chu-st-etienne.fr", "contactPhone": "33(0)477120469", "dateEnrollment": "28/04/2020", "description": "Evaluation of the concentration-effect relationship of enoxaparin for thromboembolic prevention in COVID-19 resuscitation patients. COV-ENOX study", "name": "EUCTR2020-001823-15-FR", "primaryOutcome": "Main Objective: To describe the pharmacokinetics of enoxaparin in resuscitation patients infected with CoV-2-SARS.;Secondary Objective: - To describe the relationship between enoxaparin concentration and bleeding risk in resuscitation patients with CoV-2-SARS.<br><br>- To describe the relationship between enoxaparin concentration and thrombotic risk in resuscitation patients with CoV-2-SARS.<br><br>- To propose optimal enoxaparin administration regimens tailored to individual patient characteristics.;Primary end point(s): Measurement of the anti-Xa activity of enoxaparin by chromogenic method.;Timepoint(s) of evaluation of this end point: daily for 30 days or until the complete decrease of drug ", "study_type": "Interventional clinical trial of medicinal product", "time": "2020-04-15", "weburl": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001823-15"}, "type": "Feature"}, {"geometry": {"coordinates": [2.334565, 48.873277], "type": "Point"}, "properties": {"classification": "Impact on helpers", "contactEmail": "moufida.dabbech@aphp.fr", "contactPhone": "3301 44 84 17 37", "dateEnrollment": "28/04/2020", "description": "Randomized controlled trial evaluating the efficacy of vaccination with Bacillus Calmette and Guérin (BCG) in the Prevention of COVID-19 via the strengthening of innate immunity in Health Care Workers.”\r\nCOVID-BCG", "name": "EUCTR2020-001678-31-FR", "primaryOutcome": "Main Objective: To evaluate among health care workers exposed to SARS CoV2 protection mediated by BCG against documented COVID-19.;Secondary Objective: - To evaluate protection mediated by BCG revaccination against :<br>a.\tSevere forms of COVID-19<br>b.\tAsymptomatic forms of SARS CoV2 infection<br>c.\tRespiratory infections<br>d.\tAbsenteeism. <br>- To evaluate safety of BCG revaccination among health care workers.<br>- To evaluate the impact of COVID-19 on innate immunity in the context of BCG revaccination versus controls.<br>;Primary end point(s): Documented COVID-19, i.e. <br>-  symptomatic COVID-19 confirmed by either positive nasopharyngeal tests for SARS CoV2 and/or by thoracic tomodensitometry compatible with the diagnosis. <br>- and/or SARS CoV2 seroconversion during the study period of 6 months.   <br>;Timepoint(s) of evaluation of this end point: 6 months", "study_type": "Interventional clinical trial of medicinal product", "time": "2020-04-17", "weburl": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001678-31"}, "type": "Feature"}, {"geometry": {"coordinates": [-6.010859, 37.405246], "type": "Point"}, "properties": {"classification": "Advanced therapy medicinal products", "contactEmail": "fabiola.lora@juntadeandalucia.es", "contactPhone": "+34671 533 802NA", "dateEnrollment": "20/04/2020", "description": "Study with stem cells from allogenic adipose tissue, in patients with coronavirus severe pneumonia", "name": "EUCTR2020-001364-29-ES", "primaryOutcome": "Main Objective: To evaluate the safety and efficacy of the administration of two doses of Allogeneic Adipose Tissue-derived Mesenchymal Stem Cells in severe or critical pneumonia caused by COVID-19 infection;Secondary Objective: To assess the immunomodulatory effects of MSC against the control group through changes in immune markers, using flow cytometry, collecting samples on days 1, 3, 6, and 15 days after administration of the investigational therapy.<br><br>To study the expression of coronavirus receptors in mesenchymal cells through the analysis of gene expression of the angiotensin convertase-2 enzyme (ACE-2 or ACE2) and the TMPRSS2 protease used by SARS-CoV-2 as a gateway to the alveolar cell;Primary end point(s): Safety endpoints:<br>Incidence of Adverse Events and Serious Adverse Events, related to the investigational drug or the administration procedure, graduated according to the common toxicity criteria scale (CTCAE).<br>Efficacy endpoints:<br>Reduction of the SARS-CoV-2 viral load by PCR on days 6 and 15.<br>Mortality at day 15.<br>Mortality at day 28.<br>Proportion of patients in categories 5, 6 or 7 of the ordinal scale of 7 points on days 15 and 28 days<br>Proportion of patients needing rescue therapy (Tocilizumab, corticosteroids, or therapies under investigation in clinical trials)<br>Time to get an improvement in a category since admission to the ordinal scale.;Timepoint(s) of evaluation of this end point: For safety: 12 months post-infusión<br>For efficacy: At baseline and at 1, 3, 6, 9, 15, 21 and 28 days after infusion, acording to the visits and assessments schedule of the trial protocol.", "study_type": "Interventional clinical trial of medicinal product", "time": "2020-04-27", "weburl": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001364-29"}, "type": "Feature"}, {"geometry": {"coordinates": [-4.811534, 37.884489], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "acruceta@clinic.cat", "contactPhone": "00349322754004380", "dateEnrollment": "23/04/2020", "description": "Plasma turnover in patients with COVID-19 disease and invasive mechanical ventilation", "name": "EUCTR2020-001722-66-ES", "primaryOutcome": "Timepoint(s) of evaluation of this end point: Impact of plasma exchange on the rate and probability of survival 28 days after inclusion.;Primary end point(s): Impact of plasma exchange on the rate and probability of survival 28 days after inclusion.;Secondary Objective: 1– Evaluate survival variables<br>2– Time in which mechanical ventilation, vasoactive support and renal support have been necessary.<br>3- Days of ICU stay, days of hospitalization.<br>4- Evaluation of the degree of organic failure (s) by daily calculation of SOFA and APACHE score during the intervention period (from day 1 to day 7), at discharge from the ICU and from the hospital.<br>5- Measure the basic systemic inflammatory response.<br>6- Measure the inflammatory response of advanced inflammatory serum mediators.<br>7. Evaluate which blood components and molecular pathways are altered and the impact of plasma turnover.<br>8- Safety variables and adverse events related or not to treatment during its administration period.;Main Objective: To assess the impact of plasma exchange on mortality at 28 days in patients with covid-19 disease and invasive mechanical ventilation.", "study_type": "Interventional clinical trial of medicinal product", "time": "2020-04-27", "weburl": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001722-66"}, "type": "Feature"}, {"geometry": {"coordinates": [2.208253, 41.40051], "type": "Point"}, "properties": {"classification": "Advanced therapy medicinal products", "contactEmail": "rucoll@bst.cat", "contactPhone": "349355735006707", "dateEnrollment": "23/04/2020", "description": "Efficacy and safety evaluation of umbilical cord mesenchymal stem cells for the treatment of patients with respiratory failure due to coronavirus (COVID-19)", "name": "EUCTR2020-001505-22-ES", "primaryOutcome": "Main Objective: All-cause mortality at day 28;Secondary Objective: 1-\tTo assess the safety and feasibility of WJ-MSC administration compared to placebo in the treatment of patients with SARS-CoV-2 infection and ARDS<br>2-\tNeed for treatment with rescue medication<br>3-\tNeed and duration of mechanical ventilation<br>4-\tVentilator free days<br>5-\tEvolution of PaO2 / FiO2 ratio at 3, 5, 7, 14, 21 and 28 days after starting treatment<br>6-\tEvolution of the SOFA index at 3, 5, 7, 14, 21 and 28 days after starting treatment<br>7-\tEvolution of the APACHE II score at 3, 5, 7, 14, 21 and 28 days after starting treatment<br>8-\tDuration of hospitalization <br>9-\tEvolution of disease biomarkers: RT-PCR, LDH, D-dimer and Ferritin at 3, 5, 7, 14, 21 y 28 after starting treatment<br>10-\tEvolution of markers of immune response (leucocyte count, neutrophils) at 3, 5, 7, 14, 21 y 28 days after starting treatment;Primary end point(s): Number of patients who died on day +28, by treatment group;Timepoint(s) of evaluation of this end point: Day 28", "study_type": "Interventional clinical trial of medicinal product", "time": "2020-04-27", "weburl": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001505-22"}, "type": "Feature"}, {"geometry": {"coordinates": [-4.811534, 37.884489], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "uicec@imibic.org", "contactPhone": "0034671596070", "dateEnrollment": "20/04/2020", "description": "Prevention and treatment with Calcifediol of respiratory problems caused by COVID-19", "name": "EUCTR2020-001717-20-ES", "primaryOutcome": "Timepoint(s) of evaluation of this end point: Daily throughout the subject duration in the trial.;Primary end point(s): 1) Admission to the Intensive Care Unit or<br>2) Death;Secondary Objective: - To assess if the treatment in newly hospitalized patients with non-invasive ventilation will decrease the time at discharge<br>- To evaluate in patients who require invasive ventilation and ICU admission during the process, if the treatment will decrease the number of days until the withdrawal of invasive ventilation and if it will decrease the time (in days) upon discharge from the ICU<br>- To assess if the treatment improves the clinical evolution<br>- To evaluate if the treatment improves the evolution of hematimetry & biochemistry parameters<br>- To assess if the treatment decreases the markers of inflammation<br>- To confirm that low serum 25OHD levels have a role in the negative evolution of patients to SARS<br>- To evaluate improvement in the O2/FiO2 Saturation ratio, improvement in the degree of dyspnea according to the Borg analog scale, improvement of radiological findings by simple radiology, improvement in transcutaneous O2 saturation and potential side effects of treatment;Main Objective: To demonstrate that in patients =18 and <90 years, positive for coronavirus, newly hospitalized with or without oxygen respiratory support, conventional or non-invasive ventilation (BIPAP type), treatment with Calcifediol will decrease the need for ventilation invasive and admissions to the Intensive Care Unit and deaths", "study_type": "Interventional clinical trial of medicinal product", "time": "2020-04-27", "weburl": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001717-20"}, "type": "Feature"}, {"geometry": {"coordinates": [2.134866, 41.404801], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "uicec@imibic.org", "contactPhone": "0034671596070", "dateEnrollment": "24/04/2020", "description": "Pilot study of bevacizumab as a treatment for respiratory distress in patients with COVID-19", "name": "EUCTR2020-001541-39-ES", "primaryOutcome": "Timepoint(s) of evaluation of this end point: 28 days after the inclusion of the patient.;Primary end point(s): 1. Crude mortality at 28 days.;Secondary Objective: - To evaluate the improvement in the PaO2 / FiO2 ratio at 24 hours, at 72 hours, at 7 days, 14 days and 28 days.<br>- To evaluate the improvement in the degree of dyspnea at 72 hours and at 7 days according to the Likert scale (-3 to +3).<br>- To evaluate the improvement of the radiological findings by (simple radiology) at 72 hours and at 7 days.<br>- To evaluate the improvement in transcutaneous O2 saturation at 24 hours, at 72 hours and at 7 days.<br>- To evaluate the improvement in PaO2.<br>- To measure the decrease in mortality (crude rate per month).<br>- To evaluate the toxicity of the established strategy.;Main Objective: - To evaluate the crude mortality rate at 28 days.", "study_type": "Interventional clinical trial of medicinal product", "time": "2020-04-27", "weburl": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001541-39"}, "type": "Feature"}, {"geometry": {"coordinates": [2.086778, 41.348289], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "sgutierrez@oryzon.com", "contactPhone": "+34 647 796 923", "dateEnrollment": "24/04/2020", "description": "Study to evaluate the efficacy and tolerability of treatment with vafidemstat in combination with standard of care treatment to prevent Acute Respiratory Distress Syndrome in adult severely ill patients with COVID-19.", "name": "EUCTR2020-001618-39-ES", "primaryOutcome": "Secondary Objective: To evaluate the tolerability of vafidemstat, in combination with standard of care treatment (e.g., chloroquine, lopinavir/ritonavir, azithromycin, or any other being applied by the Hospitals according to the current guides), to prevent Acute Respiratory Distress Syndrome (ARDS) in adult severely ill patients with CoVID-19.;Primary end point(s): • Reduction in the incidence of patients (%) requiring mechanical ventilation and referral to ICU within the period from Day 1 (i.e.: first study drug administration) to Day 14  <br><br>• Decrease in global mortality and mortality associated to CoVID-19 pneumonias within the period from Day 1 (i.e.: first study drug administration) to Day 14;Timepoint(s) of evaluation of this end point: 14 days;Main Objective: To investigate the efficacy of vafidemstat, in combination with standard of care treatment (e.g., hidroxihidroxichloroquine, lopinavir/ritonavir, azithromycin, or any other being applied by the Hospitals according to the current guides) to prevent Acute Respiratory Distress Syndrome (ARDS) in adult severely ill patients with CoVID-19.", "study_type": "Interventional clinical trial of medicinal product", "time": "2020-04-27", "weburl": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001618-39"}, "type": "Feature"}, {"geometry": {"coordinates": [9.955974, 53.606266], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "sonja.hoeller@apeiron-biologics.com", "contactPhone": "", "dateEnrollment": "03/04/2020", "description": "Recombinant human angiotensin-converting enzyme 2 (rhACE2) as a treat-ment for patients with COVID-19", "name": "EUCTR2020-001172-15-DK", "primaryOutcome": "Main Objective: To assess clinical efficacy of APN01 using a composite outcome of all cause-death or need of invasive mechanical ventilation up to 28 days;Secondary Objective: To assess efficacy of APN01 using log transformed levels of Lactate dehydrogenase (LDH) as a surrogate marker for organ damage.<br>To evaluate the safety of APN01 in patients with severe COVID-19<br>To monitor other biomarker changes (e.g. IL-6, AngII) in patient with severe COVID-19 treated with APN01<br><br>;Primary end point(s): The primary endpoint is a composite endpoint of all cause-death or invasive mechanical ventilation up to 28 days or hospital discharge.;Timepoint(s) of evaluation of this end point: Continioulsy over the duration of the trial", "study_type": "Interventional clinical trial of medicinal product", "time": "2020-03-23", "weburl": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001172-15"}, "type": "Feature"}, {"geometry": {"coordinates": [7.834176, 48.006071], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "tobias.wengenmayer@uniklinik-freiburg.de", "contactPhone": "+4976127034010", "dateEnrollment": "21/04/2020", "description": "Evaluation of efficacy and safety of an tocilizumab treatment in patients with severe COVID-19 pneumonia", "name": "EUCTR2020-001408-41-DE", "primaryOutcome": "Timepoint(s) of evaluation of this end point: 28 days after randomisation;Primary end point(s): •\tVentilator free days (d) (VFD) in the first 28 days after randomisation <br>o\tNIV, IMV and ECMO are defined as ventilator days<br>o\tVFD=0, if the patient dies in the first 28 days after randomisation<br>;Secondary Objective: Not applicable;Main Objective: Evaluation of the efficacy and safety of a treatment with Tocilizumab in patients with severe COVID-19 pneumonia", "study_type": "Interventional clinical trial of medicinal product", "time": "2020-04-07", "weburl": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001408-41"}, "type": "Feature"}, {"geometry": {"coordinates": [23.789059, 38.085744], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "soumelas@uni-pharma.gr", "contactPhone": "3021080725121374", "dateEnrollment": "02/04/2020", "description": "CHROLOQUINE PHOSPHATE AGAINST INFECTION BY THE NOVEL CORONAVIRUS", "name": "EUCTR2020-001345-38-GR", "primaryOutcome": "Timepoint(s) of evaluation of this end point: Days 1, 2-7, 8;Primary end point(s): • Recording of co-administered drugs, vital signs, absolute blood cell count (if any), biochemical markers (if any), microbiological tests and antibiotics (if any)<br>• Pneumonia symptoms ratings for patients with lower respiratory infection (Appendix V)<br>• Recording of adverse reactions (AEs) or serious adverse reactions (SAEs);Secondary Objective: • Comparison of the primary endpoint with respective patients not receiving the treatment<br>• Serious respiratory failure until day 14. This will be compared with respective patients not receiving the treatment<br>• Frequency of AEs and SAEs;Main Objective: Achieving one of two goals on day 8 visit from study initiation:<br>• 50% reduction in symptom score for patients with lower respiratory tract infection<br>• Lack of progression to lower respiratory tract infection in patients enrolled in the study due to upper respiratory tract infection<br><br>Patients leaving the hospital alive before day 8 visit are considered to have reached the primary endpoint. Patients who die before the day 8 visit are considered to have failed at the primary endpoint.", "study_type": "Interventional clinical trial of medicinal product", "time": "2020-03-31", "weburl": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001345-38"}, "type": "Feature"}, {"geometry": {"coordinates": [10.701302, 59.965648], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "andreas.barrattdue@gmail.com", "contactPhone": "+4723071916", "dateEnrollment": "26/03/2020", "description": "A clinical study to evaluate the efficacy of different anti-viral drugs in SARS-CoV-2 infected patients (COVID-19).", "name": "EUCTR2020-000982-18-NO", "primaryOutcome": "Timepoint(s) of evaluation of this end point: During hospitalisation.;Primary end point(s):  All-cause in-hospital mortality. ;Secondary Objective: - To assess the effect of Remdesivir and Hydroxychloroquine treatment on hospital duration, receipt of ventilation or intensive care, and to identify any serious adverse reactions.<br>- To assess the effect of Remdesivir and  Hydroxychloroquine treatment on 28 days mortality, viral clearance, kidney and myocardial failure, co-infections, organ dysfunction, health-related Quality of Life and biomarkers.<br>- To assess safety of Remdesivir and Hydroxychloroquine on severe, life-threatening and/or serious adverse events;Main Objective: To investigate the effect of Remdesivir and Hydroxychloroquine on all-cause in-hospital mortality in moderate and in severe COVID 19.<br><br>", "study_type": "Interventional clinical trial of medicinal product", "time": "2020-03-24", "weburl": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-000982-18"}, "type": "Feature"}, {"geometry": {"coordinates": [10.167892, 56.192089], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "charlotte.kastberg.levin.01@regionh.dk", "contactPhone": "+4538622941", "dateEnrollment": "14/04/2020", "description": "Efficacy and safety of novel treatment options for adults with COVID-19 pneumonia", "name": "EUCTR2020-001367-88-DK", "primaryOutcome": "Timepoint(s) of evaluation of this end point: Day 28;Primary end point(s): The primary outcome is a composite endpoint: All-cause mortality or need of invasive mechanical ventilation up to 28 days.;Secondary Objective: Not applicable;Main Objective: The aim of this study is to evaluate the efficacy and safety of convalescent anti-SARS-CoV-2 plasma, hydroxychloroquine, sarilumab and baricitinib compared with placebo in combination with standard of care (SOC) for the treatment of moderate-to-severe COVID-19 pneumonia on the basis of the composite endpoint: All-cause mortality or need of invasive mechanical ventilation up to 28 days.", "study_type": "Interventional clinical trial of medicinal product", "time": "2020-04-01", "weburl": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001367-88"}, "type": "Feature"}, {"geometry": {"coordinates": [120.670061, 28.006211], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": "", "contactPhone": "", "dateEnrollment": "February 16, 2020", "description": "Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment/ Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneumonia (COVID-19)", "name": "NCT04273763", "primaryOutcome": "Time to clinical recovery after treatment;Rate of aggravation", "study_type": "Interventional", "time": "2020-02-14", "weburl": "https://clinicaltrials.gov/show/NCT04273763"}, "type": "Feature"}, {"geometry": {"coordinates": [-93.227728, 44.97399], "type": "Point"}, "properties": {"classification": "Drugs", "contactEmail": ";covid19@umn.edu", "contactPhone": ";6126249996", "dateEnrollment": "March 17, 2020", "description": "Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2", "name": "NCT04308668", "primaryOutcome": "Incidence of COVID19 Disease among those who are asymptomatic at baseline;Overall change in disease severity over 14 days among those who are symptomatic at baseline", "study_type": "Interventional", "time": "2020-03-11", "weburl": "https://clinicaltrials.gov/show/NCT04308668"}, "type": "Feature"}, {"geometry": {"coordinates": [114.294601, 30.622945], "type": "Point"}, "properties": {"classification": "Disease understanding", "contactEmail": "", "contactPhone": "", "dateEnrollment": "March 21, 2020", "description": "Hypertension in Patients Hospitalized With COVID-19", "name": "NCT04318301", "primaryOutcome": "Rate of Death", "study_type": "Observational", "time": "2020-03-20", "weburl": "https://clinicaltrials.gov/show/NCT04318301"}, "type": "Feature"}, {"geometry": {"coordinates": [10.152447, 56.